12549952
D002231_D056486 CID carbimazole_36/NN (r_pobj) with_35/IN (r_prep) treatment_34/NN (r_pobj) on_32/IN (r_prep) resulted_21/VBN (r_relcl) case_15/NN (r_attr) is_12/VBZ (l_advcl) increasing_3/VBG (l_dobj) evidence_4/NN (l_prep) of_5/IN (l_pobj) hepatotoxicity_6/NN
D011433_D006980 NONE propranolol_17/NN (r_conj) treated_13/VBN (l_nsubjpass) man_5/NN (l_prep) with_6/IN (l_pobj) history_8/NN (l_prep) of_9/IN (l_pobj) hyperthyroidism_10/NN
D002231_D017093 NONE carbimazole_16/NN (r_conj) bupropion_14/NN (r_pobj) of_13/IN (r_prep) use_12/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) failure_7/NN
D016642_D017114 CID bupropion_5/NN (r_pobj) with_3/IN (r_prep) failure_2/NN
D016642_D017114 CID bupropion_9/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) evidence_4/NN (r_dobj) increasing_3/VBG (r_advcl) is_12/VBZ (l_attr) case_15/NN (l_relcl) resulted_21/VBN (l_prep) from_22/IN (l_pobj) failure_25/NN
D016642_D017114 CID bupropion_30/NN (r_dobj) receiving_29/VBG (r_acl) patient_28/JJ (r_pobj) in_26/IN (r_prep) failure_25/NN
D016642_D017114 CID bupropion_13/NN (r_pobj) by_12/IN (r_agent) induced_11/VBN (r_acl) insult_10/NN
D002231_D006980 NONE carbimazole_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (l_nsubjpass) man_5/NN (l_prep) with_6/IN (l_pobj) history_8/NN (l_prep) of_9/IN (l_pobj) hyperthyroidism_10/NN
D002231_D017114 CID carbimazole_7/NN (r_compound) therapy_8/NN (r_conj) bupropion_5/NN (r_pobj) with_3/IN (r_prep) failure_2/NN
D002231_D017114 CID carbimazole_36/NN (r_pobj) with_35/IN (r_prep) treatment_34/NN (r_pobj) on_32/IN (r_prep) resulted_21/VBN (l_prep) from_22/IN (l_pobj) failure_25/NN
D016642_D056486 CID bupropion_3/NN (r_nsubj) induced_4/VBD (l_dobj) hepatotoxicity_5/NN
D016642_D056486 CID bupropion_9/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) evidence_4/NN (l_prep) of_5/IN (l_pobj) hepatotoxicity_6/NN
D016642_D056486 CID bupropion_30/NN (r_dobj) receiving_29/VBG (r_acl) patient_28/JJ (r_pobj) in_26/IN (r_prep) failure_25/NN (r_pobj) from_22/IN (r_prep) resulted_21/VBN (r_relcl) case_15/NN (r_attr) is_12/VBZ (l_advcl) increasing_3/VBG (l_dobj) evidence_4/NN (l_prep) of_5/IN (l_pobj) hepatotoxicity_6/NN
D016642_D056486 CID bupropion_13/NN (l_acl) given_14/VBN (l_prep) with_16/IN (l_pobj) drugs_19/NNS (l_amod) hepatotoxic_18/JJ
D016642_D017093 NONE bupropion_14/NN (r_pobj) of_13/IN (r_prep) use_12/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) failure_7/NN
2220369
C015173_D020246 CID epinephrine_6/NN (r_conj) thrombosis_2/NN
C015173_D020246 CID epinephrine_28/NN (r_pobj) with_26/IN (r_prep) started_23/VBN (r_pcomp) after_21/IN (r_prep) acquired_11/VBD (l_dobj) thrombosis_14/NN
C015173_D005901 NONE epinephrine_28/NN (l_prep) for_29/IN (l_pobj) glaucoma_31/NN
14742097
D004809_D020018 NONE ephedrine_10/NN (r_pobj) of_9/IN (r_prep) study_8/NN (l_prep) for_11/IN (l_pobj) dysfunction_17/NN
D004809_D020018 NONE ephedrine_9/NN (r_nsubj) has_28/VBZ (l_dobj) effects_30/NNS (l_prep) in_31/IN (l_pcomp) reversing_32/VBG (l_dobj) dysfunction_37/NN
D004809_D020018 NONE ephedrine_35/NN (r_pobj) of_34/IN (r_prep) effects_33/NNS (r_pobj) of_31/IN (r_prep) study_30/NN (r_pobj) in_13/IN (r_prep) participated_12/VBD (l_nsubj) women_3/NNS (l_amod) dysfunctional_2/JJ
D020280_D020018 CID sertraline_8/NN (r_conj) fluoxetine_6/NN (r_dobj) receiving_4/VBG (r_acl) women_3/NNS (l_amod) dysfunctional_2/JJ
D017374_D020018 CID paroxetine_11/NN (r_conj) sertraline_8/NN (r_conj) fluoxetine_6/NN (r_dobj) receiving_4/VBG (r_acl) women_3/NNS (l_amod) dysfunctional_2/JJ
D005473_D020018 CID fluoxetine_6/NN (r_dobj) receiving_4/VBG (r_acl) women_3/NNS (l_amod) dysfunctional_2/JJ
14736955
D004317_D007674 NONE Doxorubicin_0/NNP (r_nsubj) induces_1/VBZ (l_dobj) nephropathy_6/NN
D004317_D007674 NONE Doxorubicin_0/NNP (r_nsubj) induces_1/VBZ (l_dobj) nephropathy_6/NN (l_acl) characterized_7/VBN (l_agent) by_8/IN (l_pobj) lesions_16/NNS
D004317_D007674 NONE doxorubicin_27/RB (r_npadvmod) induced_29/VBN (r_amod) lesions_31/NNS
C102006_D007674 NONE citrate_32/NN (r_compound) synthase_33/NN (r_compound) activity_34/NN (r_conj) activities_15/NNS (r_appos) lesions_12/NNS
D004317_D009401 CID doxorubicin_10/NN (r_compound) nephrosis_11/NN
D013481_D007674 NONE superoxide_41/JJ (r_amod) production_42/NN (r_pobj) with_40/IN (r_prep) correlated_39/VBN (r_conj) correlated_10/VBN (l_prep) Among_0/IN (l_pobj) injury_7/NN
D013481_D007674 NONE superoxide_25/NN (l_prep) in_26/IN (l_pobj) lesions_31/NNS
14648024
D014212_D015473 NONE acid_4/NN (r_npadvmod) induced_6/VBN (r_amod) erythema_7/NN (r_compound) nodosum_8/NN (l_prep) in_9/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) leukemia_14/NN
D014212_D015473 NONE acid_8/NN (r_pobj) with_3/IN (r_prep) associated_2/VBD (l_prep) for_12/IN (l_pobj) leukemia_15/NN
D014212_D015473 NONE acid_8/NN (r_pobj) with_3/IN (r_prep) associated_2/VBD (l_prep) for_12/IN (l_pobj) leukemia_15/NN (l_appos) APL_17/NNP
D014212_D015473 NONE ATRA_10/NNP (r_appos) acid_8/NN (r_pobj) with_3/IN (r_prep) associated_2/VBD (l_prep) for_12/IN (l_pobj) leukemia_15/NN
D014212_D015473 NONE ATRA_10/NNP (r_appos) acid_8/NN (r_pobj) with_3/IN (r_prep) associated_2/VBD (l_prep) for_12/IN (l_pobj) leukemia_15/NN (l_appos) APL_17/NNP
D014212_D015473 NONE ATRA_12/NNP (r_compound) therapy_13/NN (r_pobj) during_11/IN (r_prep) developed_8/VBD (r_relcl) APL_6/NNP
D013256_D004893 NONE steroid_5/NN (r_pobj) of_4/IN (r_prep) use_3/NN (r_nsubj) is_6/VBZ (l_prep) in_9/IN (l_pobj) nodosum_14/NN
D014212_D005334 CID ATRA_23/NNP (r_compound) therapy_24/NN (r_pobj) after_22/IN (r_prep) nodules_6/NNS (r_conj) Fever_0/NN
D014212_D010146 NONE ATRA_23/NNP (r_compound) therapy_24/NN (r_pobj) after_22/IN (r_prep) nodules_6/NNS (l_amod) painful_4/JJ
D014212_D004893 CID acid_4/NN (r_npadvmod) induced_6/VBN (r_amod) erythema_7/NN (r_compound) nodosum_8/NN
D014212_D004893 CID acid_8/NN (r_pobj) with_3/IN (r_prep) associated_2/VBD (r_acl) nodosum_1/NN
D014212_D004893 CID ATRA_10/NNP (r_appos) acid_8/NN (r_pobj) with_3/IN (r_prep) associated_2/VBD (r_acl) nodosum_1/NN
D014212_D004893 CID ATRA_12/NNP (r_compound) therapy_13/NN (r_pobj) during_11/IN (r_prep) developed_8/VBD (l_dobj) nodosum_10/NN
D014212_D004893 CID ATRA_23/NNP (r_compound) therapy_24/NN (r_pobj) after_22/IN (r_prep) nodules_6/NNS
D014212_D004893 CID ATRA_0/NNP (r_nsubj) seemed_1/VBD (l_xcomp) be_3/VB (l_attr) etiology_7/NN (l_prep) of_8/IN (l_pobj) nodosum_10/NN
D014212_D004893 CID ATRA_10/NNP (r_npadvmod) induced_12/VBN (r_amod) nodosum_14/NN
9105126
D013256_D018658 CID steroid_9/NN (r_compound) therapy_10/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) defect_3/NN
D013256_D018658 CID steroid_13/NN (r_compound) therapy_14/NN (r_pobj) on_9/IN (r_prep) patients_8/NNS (r_pobj) in_7/IN (r_prep) rupture_6/NN
D013256_D018658 CID steroid_4/NN (r_compound) therapy_5/NN (l_conj) rupture_10/NN
18177388
D000661_D054549 CID amphetamine_21/NN (r_compound) use_22/NN (r_pobj) of_20/IN (r_prep) setting_19/NN (r_pobj) in_17/IN (r_prep) woman_16/NN (r_pobj) in_13/IN (r_prep) left_3/VBN (l_dobj) syndrome_7/NN
D000661_D054549 CID amphetamine_21/NN (r_compound) use_22/NN (r_pobj) of_20/IN (r_prep) setting_19/NN (r_pobj) in_17/IN (r_prep) woman_16/NN (r_pobj) in_13/IN (r_prep) left_3/VBN (l_oprd) cardiomyopathy_11/NN
D000661_D054549 CID amphetamine_26/NN (r_compound) use_27/NN (r_pobj) after_25/IN (r_prep) occurring_24/VBG (r_acl) type_18/NN (l_prep) of_19/IN (l_pobj) syndrome_23/NN
12911170
D002939_D000744 NONE Ciprofloxacin_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) nephritis_5/NN (l_conj) anemia_9/NN
D002939_D000744 NONE ciprofloxacin_9/NNS (r_npadvmod) induced_11/VBN (r_amod) nephritis_13/NN (l_conj) anemia_17/NN
D002939_D009395 CID Ciprofloxacin_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) nephritis_5/NN
D002939_D009395 CID Ciprofloxacin_0/NNP (r_nsubjpass) associated_3/VBN (l_prep) with_4/IN (l_pobj) effects_7/NNS (l_prep) including_8/VBG (l_pobj) nephritis_10/NN
D002939_D009395 CID ciprofloxacin_9/NNS (r_npadvmod) induced_11/VBN (r_amod) nephritis_13/NN
D002939_D000743 CID Ciprofloxacin_0/NNP (r_nsubjpass) associated_3/VBN (l_prep) with_4/IN (l_pobj) effects_7/NNS (l_prep) including_8/VBG (l_pobj) nephritis_10/NN (l_conj) anemia_13/NN
D013256_D000743 NONE steroid_10/NN (r_compound) therapy_11/NN (r_pobj) of_9/IN (r_prep) initiation_8/NN (r_conj) drug_6/NN (r_dobj) stopping_4/VBG (r_pcomp) after_3/IN (r_prep) improved_2/VBD (l_nsubj) anemia_1/NN
10074612
D008775_D006323 CID methylprednisolone_11/NN (r_pobj) after_6/IN (r_prep) asystole_5/NN
D008775_D006323 CID methylprednisolone_18/NN (r_pobj) of_14/IN (r_prep) administration_13/NN (r_pobj) after_11/IN (r_prep) asystole_10/NN
D008775_D003645 NONE methylprednisolone_16/NN (r_pobj) of_14/IN (r_prep) dose_13/NN (r_pobj) after_10/IN (r_prep) reviews_2/VBZ (l_dobj) mechanisms_6/NNS (l_prep) of_7/IN (l_pobj) death_9/NN
D008775_D003645 NONE IVMP_18/NN (r_appos) methylprednisolone_16/NN (r_pobj) of_14/IN (r_prep) dose_13/NN (r_pobj) after_10/IN (r_prep) reviews_2/VBZ (l_dobj) mechanisms_6/NNS (l_prep) of_7/IN (l_pobj) death_9/NN
D008775_D007022 CID methylprednisolone_11/NN (r_pobj) after_6/IN (r_prep) asystole_5/NN (r_conj) bradycardia_2/NNP (r_conj) Hypotension_0/NN
D008775_D007022 CID methylprednisolone_18/NN (r_pobj) of_14/IN (r_prep) administration_13/NN (r_pobj) after_11/IN (r_prep) asystole_10/NN (r_conj) bradycardia_7/NNP (r_conj) hypotension_5/NN
D008775_D001919 CID methylprednisolone_11/NN (r_pobj) after_6/IN (r_prep) asystole_5/NN (r_conj) bradycardia_2/NNP
D008775_D001919 CID methylprednisolone_18/NN (r_pobj) of_14/IN (r_prep) administration_13/NN (r_pobj) after_11/IN (r_prep) asystole_10/NN (r_conj) bradycardia_7/NNP
1899352
D015080_D006417 NONE Mesna_22/NNP (r_dobj) adding_21/VBG (r_advcl) is_18/VBZ (r_conj) are_6/VBP (l_nsubj) frequency_1/NN (l_conj) predictability_3/NN (l_prep) of_4/IN (l_pobj) hematuria_5/NN
D015080_D006417 NONE Mesna_22/NNP (r_dobj) adding_21/VBG (l_prep) to_23/IN (l_pobj) infusate_25/NN (l_prep) in_26/IN (l_pobj) patients_27/NNS (l_prep) with_28/IN (l_pobj) hematuria_30/NN
19944736
D018021_D001930 CID LiCl_4/NNP (r_pobj) in_3/IN (r_prep) administered_2/VBN (r_acl) Tacrine_0/NNP (r_nsubj) induces_10/VBZ (l_conj) delayed_14/VBD (l_dobj) damage_16/NN
D008094_D004827 NONE lithium_24/NN (r_compound) model_25/NN (l_prep) of_26/IN (l_pobj) epilepsy_27/NN
D013619_D012640 CID Tacrine_0/NNP (r_nsubj) induces_10/VBZ (l_dobj) seizures_12/NNS
D013619_D001930 CID Tacrine_0/NNP (r_nsubj) induces_10/VBZ (l_conj) delayed_14/VBD (l_dobj) damage_16/NN
D013619_D001930 CID tacrine_3/NN (r_npadvmod) loaded_5/VBN (r_amod) administration_7/NN (r_nsubj) induced_8/VBD (l_dobj) damage_9/NN (l_prep) of_10/IN (l_pobj) cells_12/NNS
D013619_D001930 CID tacrine_29/NN (r_pobj) of_28/IN (r_prep) solution_27/NN (r_advcl) induced_8/VBD (l_dobj) damage_9/NN (l_prep) of_10/IN (l_pobj) cells_12/NNS
D018021_D012640 CID LiCl_4/NNP (r_pobj) in_3/IN (r_prep) administered_2/VBN (r_acl) Tacrine_0/NNP (r_nsubj) induces_10/VBZ (l_dobj) seizures_12/NNS
D013619_D004827 NONE tacrine_5/NN (r_npadvmod) loaded_7/VBN (r_amod) nanoparticles_8/NNS (r_pobj) with_4/IN (r_prep) treated_3/VBN (r_csubj) showed_9/VBD (l_dobj) outcome_12/NN (l_prep) of_13/IN (l_pobj) symptoms_16/NNS (l_appos) onset_20/NN (l_amod) epileptic_19/JJ
D013619_D004827 NONE tacrine_22/NN (r_compound) lithium_24/NN (r_compound) model_25/NN (l_prep) of_26/IN (l_pobj) epilepsy_27/NN
1445986
D002511_D000743 NONE cephalosporins_22/NNS (r_conj) penicillins_17/NNS (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) in_14/IN (r_prep) described_12/VBN (l_nsubjpass) anemia_2/NN
D010406_D000743 NONE penicillins_17/NNS (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) in_14/IN (r_prep) described_12/VBN (l_nsubjpass) anemia_2/NN
D015313_D000740 NONE cefotetan_10/NN (r_dobj) receiving_8/VBG (r_advcl) developed_5/VBD (l_dobj) anemia_6/NN
D015313_D000743 CID Cefotetan_0/NNP (r_npadvmod) induced_2/VBN (r_amod) anemia_5/NN
9799166
D003042_D020521 CID cocaine_2/NN (r_conj) Stroke_0/NN
D003042_D020521 CID cocaine_3/NN (r_pobj) of_2/IN (r_prep) association_1/NN (l_prep) with_7/IN (l_pobj) stroke_11/NN
D003042_D020521 CID cocaine_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_conj) stroke_7/NN
D003042_D020521 CID cocaine_13/NN (r_dobj) using_12/VBG (r_pcomp) to_11/IN (r_prep) admitted_10/VBD (r_relcl) stroke_6/NN
D003042_D020521 CID cocaine_3/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) is_6/VBZ (l_attr) factor_10/NN (l_prep) for_11/IN (l_pobj) stroke_12/NN
D000661_D020521 CID amphetamine_4/NN (r_conj) cocaine_2/NN (r_conj) Stroke_0/NN
D000661_D020521 CID amphetamine_5/NN (r_compound) use_6/NN (r_conj) cocaine_3/NN (r_pobj) of_2/IN (r_prep) association_1/NN (l_prep) with_7/IN (l_pobj) stroke_11/NN
D000661_D020521 CID amphetamine_13/NN (r_conj) cocaine_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_conj) stroke_7/NN
D000661_D020521 CID amphetamine_15/NN (r_conj) cocaine_13/NN (r_dobj) using_12/VBG (r_pcomp) to_11/IN (r_prep) admitted_10/VBD (r_relcl) stroke_6/NN
D000661_D020521 CID amphetamine_5/NN (r_conj) cocaine_3/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) is_6/VBZ (l_attr) factor_10/NN (l_prep) for_11/IN (l_pobj) stroke_12/NN
D003042_D007511 NONE cocaine_3/NN (r_pobj) of_2/IN (r_prep) association_1/NN (l_prep) with_7/IN (l_pobj) stroke_11/NN (l_amod) hemorrhagic_8/JJ (l_conj) ischemic_10/JJ
D000661_D007511 NONE amphetamine_5/NN (r_compound) use_6/NN (r_conj) cocaine_3/NN (r_pobj) of_2/IN (r_prep) association_1/NN (l_prep) with_7/IN (l_pobj) stroke_11/NN (l_amod) hemorrhagic_8/JJ (l_conj) ischemic_10/JJ
3535719
D009428_D006311 CID netilmicin_10/NNS (r_pobj) of_8/IN (r_prep) %_6/NN (r_pobj) in_2/IN (r_prep) occurred_1/VBD (l_nsubj) Ototoxicity_0/NN
D009428_D006311 CID netilmicin_15/NNS (r_pobj) with_14/IN (r_prep) reversible_13/JJ (r_conj) severe_9/JJ (r_acomp) was_7/VBD (l_nsubj) ototoxicity_6/NN
D009428_D007674 CID netilmicin_10/NNS (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) patients_7/NNS (r_pobj) in_6/IN (r_prep) proportion_5/NN (r_pobj) in_2/IN (r_prep) occurred_1/VBD (l_nsubj) Nephrotoxicity_0/NN
D009428_D064420 NONE netilmicin_5/NNS (r_pobj) of_4/IN (r_prep) toxicity_3/NN
D014031_D007674 CID tobramycin_12/JJ (r_conj) netilmicin_10/NNS (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) patients_7/NNS (r_pobj) in_6/IN (r_prep) proportion_5/NN (r_pobj) in_2/IN (r_prep) occurred_1/VBD (l_nsubj) Nephrotoxicity_0/NN
D010878_D007239 NONE sodium_17/NN (r_pobj) with_15/IN (r_prep) conjunction_14/NN (l_prep) in_18/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) infections_25/NNS
D014031_D006311 CID tobramycin_22/NNS (r_pobj) of_20/IN (r_prep) %_18/NN (r_pobj) in_14/IN (r_conj) in_2/IN (r_prep) occurred_1/VBD (l_nsubj) Ototoxicity_0/NN
D014031_D006311 CID tobramycin_18/NNS (r_pobj) with_17/IN (r_prep) than_16/IN (r_prep) reversible_13/JJ (r_conj) severe_9/JJ (r_acomp) was_7/VBD (l_nsubj) ototoxicity_6/NN
D000617_D006311 NONE aminoglycoside_3/NN (r_npadvmod) associated_5/VBN (r_amod) ototoxicity_6/NN
D010878_D006311 CID piperacillin_12/VB (r_conj) netilmicin_10/NNS (r_pobj) of_8/IN (r_prep) %_6/NN (r_pobj) in_2/IN (r_prep) occurred_1/VBD (l_nsubj) Ototoxicity_0/NN
D010878_D006311 CID piperacillin_24/NN (r_npadvmod) treated_26/VBN (r_amod) patients_27/NNS (r_conj) tobramycin_22/NNS (r_pobj) of_20/IN (r_prep) %_18/NN (r_pobj) in_14/IN (r_conj) in_2/IN (r_prep) occurred_1/VBD (l_nsubj) Ototoxicity_0/NN
D014031_D064420 NONE tobramycin_7/JJ (l_nsubj) efficacy_1/NN (l_conj) toxicity_3/NN
D014031_D007239 NONE sulfate_12/NN (r_conj) sulfate_9/NN (r_pobj) of_7/IN (r_prep) efficacy_4/NN (r_dobj) compared_2/VBD (l_prep) in_13/IN (l_pobj) conjunction_14/NN (l_prep) in_18/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) infections_25/NNS
D009428_D007239 NONE sulfate_9/NN (r_pobj) of_7/IN (r_prep) efficacy_4/NN (r_dobj) compared_2/VBD (l_prep) in_13/IN (l_pobj) conjunction_14/NN (l_prep) in_18/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) infections_25/NNS
2569282
D020927_D009123 NONE dexmedetomidine_7/NN (r_nsubj) is_13/VBZ (l_acomp) capable_14/JJ (l_prep) of_15/IN (l_pcomp) inducing_16/VBG (l_dobj) flaccidity_18/NN
D020927_D009123 NONE MED_11/NNP (r_appos) dexmedetomidine_7/NN (r_nsubj) is_13/VBZ (l_acomp) capable_14/JJ (l_prep) of_15/IN (l_pcomp) inducing_16/VBG (l_dobj) flaccidity_18/NN
D020927_D018476 NONE MED_6/NNP (r_compound) animals_7/NNS (r_nsubj) were_8/VBD (l_acomp) flaccid_9/JJ (l_conj) akinetic_11/JJ
D015760_D009127 CID alfentanil_23/NN (r_compound) anesthesia_24/NN (r_pobj) by_19/IN (r_agent) caused_18/VBN (r_acl) rigidity_17/NN
D015760_D009127 CID alfentanil_7/NN (r_npadvmod) induced_9/VBN (r_amod) rigidity_11/NN
D020927_D012021 NONE MED_6/NNP (r_compound) animals_7/NNS (r_nsubj) were_8/VBD (l_conj) lacked_14/VBD (l_dobj) response_17/NN (l_compound) startle_16/JJ
D020927_D009127 NONE Dexmedetomidine_0/NNP (r_nsubj) prevents_8/VBZ (l_dobj) rigidity_13/NN
D020927_D009127 NONE MED_13/NNP (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_nsubj) prevents_14/VBZ (l_dobj) rigidity_17/NN
D020927_D009127 NONE MED_5/NNP (r_nsubj) prevented_6/VBD (l_dobj) rigidity_11/NN
18808529
D010100_D007022 NONE oxygen_15/NN (r_compound) supply_16/NN (r_pobj) of_14/IN (r_prep) mismatch_13/NN (l_prep) vs._17/IN (l_pobj) demand_18/NN (l_prep) following_19/VBG (l_pobj) hyperactivity_24/NN (l_nmod) hypotension_21/NN
D007545_D009202 CID Isoproterenol_0/NN (r_nsubj) induces_1/VBZ (l_dobj) correlation_10/NN (l_prep) with_11/IN (l_pobj) injury_13/NN
D007545_D009202 CID isoproterenol_3/NN (r_npadvmod) induced_5/VBN (r_amod) damage_7/NN
D007545_D009202 CID isoproterenol_3/NN (r_npadvmod) induced_5/VBN (r_amod) damage_7/NN (r_pobj) of_2/IN (r_prep) mechanism_1/NN (r_nsubj) is_8/VBZ (l_conj) is_25/VBZ (l_nsubj) mismatch_13/NN (l_prep) vs._17/IN (l_pobj) demand_18/NN (l_prep) following_19/VBG (l_pobj) hyperactivity_24/NN
D010100_D009202 NONE oxygen_15/NN (r_compound) supply_16/NN (r_pobj) of_14/IN (r_prep) mismatch_13/NN (r_nsubj) is_25/VBZ (r_conj) is_8/VBZ (l_nsubj) mechanism_1/NN (l_prep) of_2/IN (l_pobj) damage_7/NN
D010100_D009202 NONE oxygen_15/NN (r_compound) supply_16/NN (r_pobj) of_14/IN (r_prep) mismatch_13/NN (l_prep) vs._17/IN (l_pobj) demand_18/NN (l_prep) following_19/VBG (l_pobj) hyperactivity_24/NN
D007545_D007022 NONE isoproterenol_3/NN (r_npadvmod) induced_5/VBN (r_amod) damage_7/NN (r_pobj) of_2/IN (r_prep) mechanism_1/NN (r_nsubj) is_8/VBZ (l_conj) is_25/VBZ (l_nsubj) mismatch_13/NN (l_prep) vs._17/IN (l_pobj) demand_18/NN (l_prep) following_19/VBG (l_pobj) hyperactivity_24/NN (l_nmod) hypotension_21/NN
D007545_D007511 CID isoproterenol_29/NN (r_pobj) by_28/IN (r_agent) induced_27/VBN (r_acl) alterations_11/NNS (r_dobj) explain_8/VBP (l_nsubj) changes_1/NNS (l_acl) related_3/VBN (l_prep) to_4/IN (l_pobj) injury_6/NN
3088349
D016627_D009069 NONE 6-OHDA_2/CD (r_pobj) Following_0/VBG (r_prep) induced_3/VBN (r_ccomp) reported_15/VBN (l_nsubjpass) period_9/NN (l_prep) of_10/IN (l_pobj) rotation_12/NN
D016627_D009069 NONE 6-OHDA_2/CD (r_pobj) Following_0/VBG (r_prep) induced_3/VBN (r_ccomp) reported_15/VBN (l_xcomp) precede_17/VB (l_dobj) circling_21/NN
D000661_-1 NONE amphetamine_17/NN (r_pobj) by_16/IN (r_prep) exhaustion_15/NN (r_pobj) to_14/TO (r_prep) reflects_8/VBZ (l_nsubj) rotation_2/NN (l_prep) following_3/VBG (l_pobj) lesion_7/NN
D000661_D009069 CID amphetamine_17/NN (r_pobj) by_16/IN (r_prep) exhaustion_15/NN (r_pobj) to_14/TO (r_prep) reflects_8/VBZ (l_nsubj) rotation_2/NN
D000661_D009069 CID amphetamine_26/NN (r_npadvmod) induced_28/VBN (r_amod) behavior_30/NN (r_pobj) on_25/IN (r_prep) examined_12/VBD (l_prep) In_0/IN (l_pobj) order_1/NN (l_acl) clarify_3/VB (l_dobj) nature_5/NN (l_prep) of_6/IN (l_pobj) rotation_10/NN
D000661_D009069 CID amphetamine_26/NN (r_npadvmod) induced_28/VBN (r_amod) behavior_30/NN
D000661_D009069 CID amphetamine_10/NN (r_nsubjpass) administered_12/VBN (r_advcl) was_6/VBD (l_advcl) indicating_22/VBG (l_dobj) involvement_23/NN (l_prep) of_24/IN (l_pobj) cells_26/NNS (l_prep) in_27/IN (l_pobj) rotation_30/NN
D000661_D009069 CID amphetamine_16/NN (r_compound) dose_17/NN (r_conj) volume_14/NN (r_pobj) of_11/IN (r_prep) irrespective_10/RB (r_conj) duration_5/NN (r_pobj) of_3/IN (r_prep) regardless_2/RB (r_advmod) tended_31/VBD (l_nsubj) rotation_30/NN
D000661_D009069 CID amphetamine_27/NN (r_npadvmod) induced_29/VBN (r_amod) rotation_30/NN
D000661_D009069 CID amphetamine_55/NN (r_compound) injections_56/NNS (r_pobj) to_53/IN (r_prep) response_52/NN (r_pobj) in_51/IN (r_prep) circled_46/VBD (r_conj) tended_31/VBD (l_nsubj) rotation_30/NN
D000661_D009069 CID amphetamine_4/NN (r_nsubj) has_5/VBZ (l_dobj) effect_8/NN (l_prep) on_9/IN (l_pobj) pool_15/NN (l_acl) contributing_16/VBG (l_prep) to_17/IN (l_pobj) rotation_19/NN
D016627_-1 NONE 6-OHDA_2/CD (r_pobj) Following_0/VBG (r_prep) induced_3/VBN (l_dobj) lesion_5/NN
15266362
D004280_D002312 NONE dobutamine_22/NN (r_compound) infusion_23/NN (r_pobj) with_21/IN (r_prep) managed_19/VBD (r_conj) admitted_14/VBN (l_nsubjpass) patient_5/NN (l_acl) known_7/VBN (l_xcomp) have_9/VB (l_dobj) cardiomyopathy_11/NN
D004280_D009205 CID dobutamine_13/NN (r_xcomp) related_11/VBN (l_nsubjpass) hypersensitivity_5/NN (l_amod) myocarditis_9/NN
D004280_D004802 CID dobutamine_13/NN (r_xcomp) related_11/VBN (l_nsubjpass) hypersensitivity_5/NN (l_amod) eosinophilic_7/JJ
D004280_D018754 NONE dobutamine_22/NN (r_compound) infusion_23/NN (r_pobj) with_21/IN (r_prep) managed_19/VBD (r_conj) admitted_14/VBN (l_prep) with_15/IN (l_pobj) failure_17/NN
D004280_D004342 CID dobutamine_13/NN (r_xcomp) related_11/VBN (l_nsubjpass) hypersensitivity_5/NN
7007443
D000082_D017114 CID paracetamol_26/JJ (r_compound) overdose_27/NN (r_pobj) after_25/IN (r_prep) survived_21/VBD (l_dobj) failure_24/NN
D000082_D017114 CID paracetamol_26/JJ (r_compound) overdose_27/NN (r_pobj) after_25/IN (r_prep) survived_21/VBD (r_relcl) those_19/DT (r_pobj) in_18/IN (r_prep) fourfold_17/RB (r_conj) died_14/VBD (r_relcl) patients_12/NNS (r_pobj) in_11/IN (r_prep) increased_8/VBN (l_advcl) increased_32/VBN (l_prep) in_34/IN (l_pobj) patients_35/NNS (l_prep) with_36/IN (l_pobj) failure_39/NN
D000082_D006525 NONE paracetamol_26/JJ (r_compound) overdose_27/NN (r_pobj) after_25/IN (r_prep) survived_21/VBD (r_relcl) those_19/DT (r_pobj) in_18/IN (r_prep) fourfold_17/RB (r_conj) died_14/VBD (r_relcl) patients_12/NNS (r_pobj) in_11/IN (r_prep) increased_8/VBN (l_advcl) increased_32/VBN (l_prep) in_34/IN (l_pobj) patients_35/NNS (l_prep) with_36/IN (l_pobj) failure_39/NN (l_amod) due_40/IN (l_pcomp) to_41/IN (l_pobj) hepatitis_43/NN
D000082_D062787 NONE paracetamol_26/JJ (r_compound) overdose_27/NN
6153967
D004737_D004827 NONE enflurane_6/NN (r_pobj) by_5/IN (r_agent) activated_4/VBN (r_conj) delineated_2/VBN (l_nsubj) foci_1/NN (l_amod) Epileptic_0/JJ
D004737_D004827 NONE enflurane_5/NN (r_nsubj) prove_7/VB (l_xcomp) be_9/VB (l_attr) activator_14/NN (l_prep) of_15/IN (l_pobj) foci_17/VBD (l_amod) epileptic_16/JJ
D004737_D012640 CID enflurane_4/NN (r_nsubj) resulted_10/VBD (l_prep) in_11/IN (l_pobj) seizures_15/NNS
D004737_D012640 CID enflurane_6/NN (r_pobj) by_5/IN (r_agent) activated_4/VBN (r_conj) delineated_2/VBN (l_conj) are_13/VBP (l_acomp) free_17/JJ (l_npadvmod) seizure_15/NN
18405372
D012460_D001168 NONE sulfasalazine_3/NN (l_prep) in_4/IN (l_pobj) arthritis_6/NN
D012460_D056486 CID sulfasalazine_3/NN (r_pobj) with_2/IN (r_prep) associated_1/VBN (r_acl) Hepatotoxicity_0/NN
D012460_D056486 CID sulfasalazine_7/NN (r_pobj) on_6/IN (r_prep) had_4/VBD (l_dobj) hepatotoxicity_5/NN
D012460_D056486 CID sulfasalazine_6/NN (r_pobj) with_5/IN (r_prep) hepatotoxicity_4/NN
D012460_D056486 CID sulfasalazine_7/NN (r_pobj) with_6/IN (r_prep) hepatotoxicity_5/NN
D012460_D056486 CID sulfasalazine_4/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) hepatotoxicity_1/NN
1732442
D019797_D009202 NONE iodine-125-metaiodobenzylguanidine_13/NNP (r_pcomp) with_12/IN (r_prep) cardiomyopathy_11/NN
D019797_D009202 NONE MIBG_24/NNP (r_compound) scintigraphy_25/NN (r_nsubj) be_27/VB (r_ccomp) indicates_22/VBZ (l_nsubj) appearance_1/NN (l_prep) of_2/IN (l_pobj) activity_7/NN (l_prep) in_8/IN (l_pobj) presence_10/NN (l_prep) of_11/IN (l_pobj) impairment_14/NN
D019797_D009202 NONE MIBG_24/NNP (r_compound) scintigraphy_25/NN (r_nsubj) be_27/VB (l_attr) method_30/NN (l_prep) for_31/IN (l_pobj) detection_32/NN (l_prep) of_33/IN (l_pobj) cardiomyopathy_37/NN
D004317_D009202 CID adriamycin_8/NNS (r_npadvmod) induced_10/VBN (r_amod) cardiomyopathy_11/NN
D004317_D009202 CID adriamycin_5/NNS (r_amod) induced_7/VBN (r_amod) cardiomyopathy_8/NN
D004317_D009202 CID adriamycin_5/NNS (r_amod) induced_7/VBN (r_amod) cardiomyopathy_8/NN (r_pobj) of_4/IN (r_prep) model_3/NN (r_dobj) Using_0/VBG (r_advcl) tested_11/VBD (l_dobj) hypothesis_13/NN (l_acl) appear_21/VB (l_conj) exacerbated_24/VBN (l_advmod) dependently_27/RB (l_prep) in_28/IN (l_pobj) cardiomyopathy_30/NN
D004317_D009202 CID adriamycin_29/FW (r_amod) cardiomyopathy_30/NN (r_pobj) in_28/IN (r_prep) dependently_27/RB (r_advmod) exacerbated_24/VBN (r_conj) appear_21/VB (r_acl) hypothesis_13/NN (r_dobj) tested_11/VBD (l_advcl) Using_0/VBG (l_dobj) model_3/NN (l_prep) of_4/IN (l_pobj) cardiomyopathy_8/NN
D004317_D009202 CID adriamycin_29/FW (r_amod) cardiomyopathy_30/NN
D004317_D009202 CID adriamycin_34/NNS (r_amod) induced_36/VBN (r_amod) cardiomyopathy_37/NN (r_pobj) of_33/IN (r_prep) detection_32/NN (r_pobj) for_31/IN (r_prep) method_30/NN (r_attr) be_27/VB (r_ccomp) indicates_22/VBZ (l_nsubj) appearance_1/NN (l_prep) of_2/IN (l_pobj) activity_7/NN (l_prep) in_8/IN (l_pobj) presence_10/NN (l_prep) of_11/IN (l_pobj) impairment_14/NN
D004317_D009202 CID adriamycin_34/NNS (r_amod) induced_36/VBN (r_amod) cardiomyopathy_37/NN
D004317_C536522 NONE adriamycin_16/JJ (r_amod) treatment_17/NN (r_pobj) of_15/IN (r_prep) duration_14/NN (r_pobj) to_12/IN (r_prep) relation_11/NN (r_pobj) in_10/IN (r_prep) analyzed_9/VBN (l_nsubjpass) degree_1/NN (l_prep) of_2/IN (l_pobj) degeneration_4/NN (l_prep) of_5/IN (l_pobj) cells_7/NNS
D004317_C536522 NONE adriamycin_34/NNS (r_amod) induced_36/VBN (r_amod) cardiomyopathy_37/NN (r_pobj) of_33/IN (r_prep) detection_32/NN (r_pobj) for_31/IN (r_prep) method_30/NN (r_attr) be_27/VB (r_ccomp) indicates_22/VBZ (l_nsubj) appearance_1/NN (l_prep) of_2/IN (l_pobj) activity_7/NN (l_prep) in_8/IN (l_pobj) presence_10/NN (l_prep) of_11/IN (l_pobj) impairment_14/NN (l_appos) degeneration_20/NN
D019797_C536522 NONE MIBG_24/NNP (r_compound) scintigraphy_25/NN (r_nsubj) be_27/VB (r_ccomp) indicates_22/VBZ (l_nsubj) appearance_1/NN (l_prep) of_2/IN (l_pobj) activity_7/NN (l_prep) in_8/IN (l_pobj) presence_10/NN (l_prep) of_11/IN (l_pobj) impairment_14/NN (l_appos) degeneration_20/NN
14704468
C066440_D012640 NONE Loreclezole_0/NNP (r_nsubj) exerted_5/VBD (l_advcl) reducing_16/VBG (l_dobj) seizure_18/NN
11243580
D001120_D012640 NONE arginine_29/NN (r_conj) inhibitor_25/NN (r_appos) oxide_20/NN (r_appos) ester_12/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) investigated_36/VBN (l_prep) on_37/IN (l_pobj) convulsions_41/NNS
D001120_D012640 NONE arginine_6/NN (r_compound) treatment_7/NN (r_nsubj) increased_8/VBD (l_dobj) incidence_10/NN (l_appos) convulsions_18/NNS
D008012_D012640 CID lidocaine_6/NN (r_npadvmod) induced_8/VBN (r_amod) convulsion_9/NN
D008012_D012640 CID lidocaine_38/NN (r_npadvmod) induced_40/VBN (r_amod) convulsions_41/NNS
D008012_D012640 CID lidocaine_20/NN (r_pobj) of_19/IN (r_prep) incidence_18/NN (l_appos) convulsions_26/NNS
D008012_D012640 CID lidocaine_12/NN (r_pobj) of_11/IN (r_prep) incidence_10/NN (l_appos) convulsions_18/NNS
D008012_D012640 CID lidocaine_11/NN (r_npadvmod) induced_13/VBN (r_amod) convulsions_14/NNS
D019331_D012640 NONE ester_12/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) investigated_36/VBN (l_prep) on_37/IN (l_pobj) convulsions_41/NNS
D019331_D012640 NONE NAME_16/NN (r_appos) ester_12/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) investigated_36/VBN (l_prep) on_37/IN (l_pobj) convulsions_41/NNS
D019331_D012640 NONE NAME_2/NNP (r_nsubj) decreased_16/VBD (l_dobj) incidence_18/NN (l_appos) convulsions_26/NNS
D009569_D012640 NONE oxide_20/NN (r_appos) ester_12/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) investigated_36/VBN (l_prep) on_37/IN (l_pobj) convulsions_41/NNS
D009569_D012640 NONE NO_22/NNP (r_intj) inhibitor_25/NN (r_appos) oxide_20/NN (r_appos) ester_12/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) investigated_36/VBN (l_prep) on_37/IN (l_pobj) convulsions_41/NNS
D009569_D012640 NONE NO_32/JJ (r_det) precursor_33/NN (r_appos) oxide_20/NN (r_appos) ester_12/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) investigated_36/VBN (l_prep) on_37/IN (l_pobj) convulsions_41/NNS
D009569_D012640 NONE NO_5/DT (r_nsubj) is_6/VBZ (l_attr) mediator_9/NN (l_prep) in_10/IN (l_pobj) convulsions_14/NNS
D003975_D012640 NONE diazepam_10/NN (r_conj) NAME_2/NNP (r_nsubj) decreased_16/VBD (l_dobj) incidence_18/NN (l_appos) convulsions_26/NNS
2576810
D009627_D006948 CID nomifensine_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) hyperactivity_1/NN
D016666_D006948 CID fluvoxamine_4/NNP (r_pobj) with_3/IN (r_prep) treatment_2/NN (r_nsubj) potentiated_12/VBN (l_dobj) hyperactivity_25/NN
D016666_D006948 CID fluvoxamine_10/NN (r_pobj) by_9/IN (r_prep) unaffected_8/JJ (r_acomp) remained_7/VBD (l_nsubj) hyperactivity_1/NN
D000661_D006948 CID amphetamine_22/NN (r_npadvmod) induced_24/VBN (r_amod) hyperactivity_25/NN
3220106
D009538_D006948 CID nicotine_3/NN (r_npadvmod) induced_5/VBN (r_amod) hyperactivity_7/NN
D009538_D006948 CID nicotine_10/NN (r_npadvmod) treated_12/VBN (r_amod) rats_13/NNS (r_pobj) in_8/IN (r_prep) hyperactivity_7/NN
D009538_D006948 CID nicotine_5/NN (r_npadvmod) treated_7/VBN (r_amod) rats_8/NNS (r_nsubj) develop_9/VBP (l_dobj) hyperactivity_11/NN
D009538_D006948 CID nicotine_15/NN (r_pobj) to_14/IN (r_prep) response_13/NN (r_pobj) in_12/IN (r_prep) develop_9/VBP (l_dobj) hyperactivity_11/NN
D004298_D006948 NONE DA_28/NNP (r_compound) concentration_29/NN (r_conj) receptors_26/NNS (r_pobj) of_24/IN (r_prep) density_23/NN (r_pobj) of_20/IN (r_prep) increases_19/NNS (r_pobj) due_17/JJ (r_prep) develop_9/VBP (l_dobj) hyperactivity_11/NN
D004298_D006948 NONE DA_34/NNP (r_compound) supersensitivity_36/NN (r_dobj) inducing_33/VBG (r_pcomp) by_32/IN (r_agent) followed_31/VBN (r_advcl) suggest_2/VBP (l_ccomp) develop_9/VBP (l_dobj) hyperactivity_11/NN
10414674
D007660_D002532 NONE ketoprofen_1/NN (r_nsubjpass) used_3/VBN (l_prep) on_6/IN (l_pobj) aneurysms_9/NNS
D007660_D017542 NONE ketoprofen_13/JJ (r_dobj) receive_11/VB (l_parataxis) starting_52/VBG (l_prep) after_54/IN (l_pobj) diagnosis_56/NN (l_prep) of_57/IN (l_pobj) SAH_59/NNP (l_amod) aneurysmal_58/JJ
D007660_D017542 NONE ketoprofen_23/JJ (r_compound) group_24/NN (r_dobj) receive_11/VB (l_parataxis) starting_52/VBG (l_prep) after_54/IN (l_pobj) diagnosis_56/NN (l_prep) of_57/IN (l_pobj) SAH_59/NNP (l_amod) aneurysmal_58/JJ
D007660_D001791 CID ketoprofen_14/NN (r_pobj) of_13/IN (r_prep) administration_12/NN (r_pobj) after_11/IN (r_prep) decreased_10/VBD (r_conj) induced_3/VBN (l_nsubj) aggregation_2/NN
D000082_D013345 NONE acetaminophen_35/RB (r_advmod) NSAID_33/NNP (r_conj) group_24/NN (r_dobj) receive_11/VB (r_xcomp) randomized_9/VBN (l_nsubjpass) Patients_0/NNS (l_prep) with_1/IN (l_pobj) hemorrhage_4/NN
D000082_D013345 NONE acetaminophen_35/RB (r_advmod) NSAID_33/NNP (r_conj) group_24/NN (r_dobj) receive_11/VB (r_xcomp) randomized_9/VBN (l_punct) (_5/-LRB- (l_preconj) SAH_6/NNP
D000082_D013345 NONE acetaminophen_35/RB (r_advmod) NSAID_33/NNP (r_conj) group_24/NN (r_dobj) receive_11/VB (l_parataxis) starting_52/VBG (l_prep) after_54/IN (l_pobj) diagnosis_56/NN (l_prep) of_57/IN (l_pobj) SAH_59/NNP
D000082_D013345 NONE acetaminophen_45/NN (r_compound) group_46/NN (r_nsubj) starting_52/VBG (r_parataxis) receive_11/VB (r_xcomp) randomized_9/VBN (l_nsubjpass) Patients_0/NNS (l_prep) with_1/IN (l_pobj) hemorrhage_4/NN
D000082_D013345 NONE acetaminophen_45/NN (r_compound) group_46/NN (r_nsubj) starting_52/VBG (r_parataxis) receive_11/VB (r_xcomp) randomized_9/VBN (l_punct) (_5/-LRB- (l_preconj) SAH_6/NNP
D000082_D013345 NONE acetaminophen_45/NN (r_compound) group_46/NN (r_nsubj) starting_52/VBG (l_prep) after_54/IN (l_pobj) diagnosis_56/NN (l_prep) of_57/IN (l_pobj) SAH_59/NNP
D000082_D013345 NONE acetaminophen_3/RB (l_dobj) function_6/NN (l_prep) in_7/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) SAH_10/NNP
D000082_D017542 NONE acetaminophen_35/RB (r_advmod) NSAID_33/NNP (r_conj) group_24/NN (r_dobj) receive_11/VB (l_parataxis) starting_52/VBG (l_prep) after_54/IN (l_pobj) diagnosis_56/NN (l_prep) of_57/IN (l_pobj) SAH_59/NNP (l_amod) aneurysmal_58/JJ
D000082_D017542 NONE acetaminophen_45/NN (r_compound) group_46/NN (r_nsubj) starting_52/VBG (l_prep) after_54/IN (l_pobj) diagnosis_56/NN (l_prep) of_57/IN (l_pobj) SAH_59/NNP (l_amod) aneurysmal_58/JJ
D007660_D013345 NONE ketoprofen_13/JJ (r_dobj) receive_11/VB (r_xcomp) randomized_9/VBN (l_nsubjpass) Patients_0/NNS (l_prep) with_1/IN (l_pobj) hemorrhage_4/NN
D007660_D013345 NONE ketoprofen_13/JJ (r_dobj) receive_11/VB (r_xcomp) randomized_9/VBN (l_punct) (_5/-LRB- (l_preconj) SAH_6/NNP
D007660_D013345 NONE ketoprofen_13/JJ (r_dobj) receive_11/VB (l_parataxis) starting_52/VBG (l_prep) after_54/IN (l_pobj) diagnosis_56/NN (l_prep) of_57/IN (l_pobj) SAH_59/NNP
D007660_D013345 NONE ketoprofen_23/JJ (r_compound) group_24/NN (r_dobj) receive_11/VB (r_xcomp) randomized_9/VBN (l_nsubjpass) Patients_0/NNS (l_prep) with_1/IN (l_pobj) hemorrhage_4/NN
D007660_D013345 NONE ketoprofen_23/JJ (r_compound) group_24/NN (r_dobj) receive_11/VB (r_xcomp) randomized_9/VBN (l_punct) (_5/-LRB- (l_preconj) SAH_6/NNP
D007660_D013345 NONE ketoprofen_23/JJ (r_compound) group_24/NN (r_dobj) receive_11/VB (l_parataxis) starting_52/VBG (l_prep) after_54/IN (l_pobj) diagnosis_56/NN (l_prep) of_57/IN (l_pobj) SAH_59/NNP
D007660_D013345 NONE Ketoprofen_0/NNP (l_conj) acetaminophen_3/RB (l_dobj) function_6/NN (l_prep) in_7/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) SAH_10/NNP
D007660_D006406 CID ketoprofen_4/JJ (r_compound) group_5/NN (r_pobj) in_2/IN (r_prep) patient_1/NN (r_nsubj) developed_6/VBD (l_dobj) hematoma_10/NN
D000082_D001791 NONE acetaminophen_9/NN (r_compound) group_10/NN (r_pobj) in_7/IN (r_prep) increased_6/VBD (l_nsubj) aggregation_5/NN
D000082_D001791 NONE acetaminophen_9/NN (r_compound) group_10/NN (r_pobj) in_7/IN (r_prep) increased_6/VBD (l_advcl) compared_17/VBN (l_prep) with_18/IN (l_pobj) results_23/NNS (l_compound) aggregation_22/NN
D007660_D006470 NONE ketoprofen_1/NN (r_nsubjpass) used_3/VBN (r_advcl) pose_13/VB (l_dobj) factor_17/NN (l_prep) for_18/IN (l_pobj) hemorrhage_19/NN
D000244_D001791 NONE diphosphate_9/NN (r_pobj) of_7/IN (r_prep) microM_6/NNS (r_pobj) by_4/IN (r_prep) induced_3/VBN (l_nsubj) aggregation_2/NN
11868798
D013148_D006402 NONE spironolactone_21/NN (r_conj) AmB_15/VB (r_dobj) receive_12/VB (r_xcomp) randomized_10/VBN (l_nsubjpass) patients_4/NNS (l_prep) with_5/IN (l_pobj) disorders_8/NNS
D000666_D007008 CID B_12/NN (r_npadvmod) related_14/VBN (r_amod) hypokalemia_15/NN
D000666_D007008 CID AmB_22/JJ (r_compound) treatment_23/NN (r_pobj) on_21/IN (r_prep) patients_20/NNS (r_pobj) in_18/IN (r_prep) hypokalemia_17/NN
D000666_D007008 CID AmB_21/JJ (r_compound) treatment_22/NN (r_pobj) on_20/IN (r_prep) patients_19/NNS (r_pobj) in_17/IN (r_prep) loss_16/NN (r_dobj) reducing_13/VBG (r_pcomp) by_12/IN (r_prep) prevent_10/VBP (l_dobj) hypokalemia_11/NN
D011188_D009503 NONE potassium_12/NN (r_compound) requirements_13/NNS (r_dobj) reduce_11/VB (l_conj) prevent_16/VB (l_dobj) hypokalemia_17/NN (l_prep) in_18/IN (l_pobj) patients_20/NNS (l_amod) neutropenic_19/JJ
D011188_D009503 NONE potassium_7/NN (r_compound) requirements_8/NNS (r_dobj) reduce_6/VB (l_conj) prevent_10/VBP (l_prep) by_12/IN (l_pcomp) reducing_13/VBG (l_dobj) loss_16/NN (l_prep) in_17/IN (l_pobj) patients_19/NNS (l_amod) neutropenic_18/JJ
D011188_D009503 NONE potassium_15/NN (r_compound) loss_16/NN (l_prep) in_17/IN (l_pobj) patients_19/NNS (l_amod) neutropenic_18/JJ
D011188_D007008 NONE potassium_12/NN (r_compound) requirements_13/NNS (r_dobj) reduce_11/VB (l_conj) prevent_16/VB (l_dobj) hypokalemia_17/NN
D011188_D007008 NONE potassium_7/NN (r_compound) requirements_8/NNS (r_dobj) reduce_6/VB (l_conj) prevent_10/VBP (l_dobj) hypokalemia_11/NN
D011188_D007008 NONE potassium_15/NN (r_compound) loss_16/NN (r_dobj) reducing_13/VBG (r_pcomp) by_12/IN (r_prep) prevent_10/VBP (l_dobj) hypokalemia_11/NN
D000666_D009369 NONE B_12/NN (r_npadvmod) related_14/VBN (r_amod) hypokalemia_15/NN (l_prep) in_16/IN (l_pobj) patients_18/NNS (l_compound) cancer_17/NN
D013148_D007008 NONE Spironolactone_0/NNP (r_npadvmod) is_2/VBZ (l_attr) drug_6/NN (l_prep) for_7/IN (l_pobj) prevention_9/NN (l_prep) of_10/IN (l_pobj) hypokalemia_15/NN
D013148_D007008 NONE spironolactone_9/NN (r_pobj) of_8/IN (r_prep) ability_7/NN (l_acl) reduce_11/VB (l_conj) prevent_16/VB (l_dobj) hypokalemia_17/NN
D013148_D007008 NONE spironolactone_4/NN (r_nsubj) reduce_6/VB (l_conj) prevent_10/VBP (l_dobj) hypokalemia_11/NN
D000666_D006402 NONE AmB_15/VB (r_dobj) receive_12/VB (r_xcomp) randomized_10/VBN (l_nsubjpass) patients_4/NNS (l_prep) with_5/IN (l_pobj) disorders_8/NNS
D000666_D006402 NONE AmB_18/JJ (r_conj) AmB_15/VB (r_dobj) receive_12/VB (r_xcomp) randomized_10/VBN (l_nsubjpass) patients_4/NNS (l_prep) with_5/IN (l_pobj) disorders_8/NNS
D011188_D064420 NONE potassium_12/NN (r_compound) wasting_13/VBG (r_pobj) for_9/IN (r_prep) responsible_8/JJ (r_acomp) be_7/VB (r_xcomp) seems_5/VBZ (l_nsubj) toxicity_4/NN
D011188_D064420 NONE potassium_12/NN (r_compound) wasting_13/VBG (r_pobj) for_9/IN (r_prep) responsible_8/JJ (r_acomp) be_7/VB (r_xcomp) seems_5/VBZ (l_conj) potentiates_28/VBZ (l_dobj) toxicity_31/NN
D011188_D064420 NONE Potassium_25/NN (r_compound) depletion_26/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) of_21/IN (r_prep) effect_20/NN (r_attr) is_15/VBZ (r_relcl) wasting_13/VBG (r_pobj) for_9/IN (r_prep) responsible_8/JJ (r_acomp) be_7/VB (r_xcomp) seems_5/VBZ (l_nsubj) toxicity_4/NN
D011188_D064420 NONE Potassium_25/NN (r_compound) depletion_26/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) of_21/IN (r_prep) effect_20/NN (r_attr) is_15/VBZ (r_relcl) wasting_13/VBG (r_pobj) for_9/IN (r_prep) responsible_8/JJ (r_acomp) be_7/VB (r_xcomp) seems_5/VBZ (l_conj) potentiates_28/VBZ (l_dobj) toxicity_31/NN
D013148_D009181 NONE spironolactone_21/NN (r_conj) AmB_15/VB (r_dobj) receive_12/VB (l_advcl) developing_27/VBG (l_dobj) infection_33/NN
D000666_D009181 NONE AmB_15/VB (r_dobj) receive_12/VB (l_advcl) developing_27/VBG (l_dobj) infection_33/NN
D000666_D009181 NONE AmB_18/JJ (r_conj) AmB_15/VB (r_dobj) receive_12/VB (l_advcl) developing_27/VBG (l_dobj) infection_33/NN
D000666_D009503 NONE AmB_22/JJ (r_compound) treatment_23/NN (r_pobj) on_21/IN (r_prep) patients_20/NNS (l_amod) neutropenic_19/JJ
D000666_D009503 NONE AmB_21/JJ (r_compound) treatment_22/NN (r_pobj) on_20/IN (r_prep) patients_19/NNS (l_amod) neutropenic_18/JJ
D000666_D007674 NONE B_9/NNP (r_pobj) of_7/IN (r_prep) effect_6/NN (r_attr) is_2/VBZ (l_nsubj) Nephrotoxicity_1/NN
D000666_D007674 NONE AmB_11/NNP (r_appos) B_9/NNP (r_pobj) of_7/IN (r_prep) effect_6/NN (r_attr) is_2/VBZ (l_nsubj) Nephrotoxicity_1/NN
D000666_D064420 NONE AmB._24/NNP (r_compound) Potassium_25/NN (r_compound) depletion_26/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) of_21/IN (r_prep) effect_20/NN (r_attr) is_15/VBZ (r_relcl) wasting_13/VBG (r_pobj) for_9/IN (r_prep) responsible_8/JJ (r_acomp) be_7/VB (r_xcomp) seems_5/VBZ (l_nsubj) toxicity_4/NN
D000666_D064420 NONE AmB._24/NNP (r_compound) Potassium_25/NN (r_compound) depletion_26/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) of_21/IN (r_prep) effect_20/NN (r_attr) is_15/VBZ (r_relcl) wasting_13/VBG (r_pobj) for_9/IN (r_prep) responsible_8/JJ (r_acomp) be_7/VB (r_xcomp) seems_5/VBZ (l_conj) potentiates_28/VBZ (l_dobj) toxicity_31/NN
D000666_D064420 NONE AmB._33/NN (r_pobj) of_32/IN (r_prep) toxicity_31/NN (r_dobj) potentiates_28/VBZ (r_conj) seems_5/VBZ (l_nsubj) toxicity_4/NN
D000666_D064420 NONE AmB._33/NN (r_pobj) of_32/IN (r_prep) toxicity_31/NN
D013148_D009503 NONE spironolactone_9/NN (r_pobj) of_8/IN (r_prep) ability_7/NN (l_acl) reduce_11/VB (l_conj) prevent_16/VB (l_dobj) hypokalemia_17/NN (l_prep) in_18/IN (l_pobj) patients_20/NNS (l_amod) neutropenic_19/JJ
D013148_D009503 NONE spironolactone_4/NN (r_nsubj) reduce_6/VB (l_conj) prevent_10/VBP (l_prep) by_12/IN (l_pcomp) reducing_13/VBG (l_dobj) loss_16/NN (l_prep) in_17/IN (l_pobj) patients_19/NNS (l_amod) neutropenic_18/JJ
D013148_D009369 NONE Spironolactone_0/NNP (r_npadvmod) is_2/VBZ (l_attr) drug_6/NN (l_prep) for_7/IN (l_pobj) prevention_9/NN (l_prep) of_10/IN (l_pobj) hypokalemia_15/NN (l_prep) in_16/IN (l_pobj) patients_18/NNS (l_compound) cancer_17/NN
20164825
D008687_D014652 NONE metformin_3/NN (r_nsubj) diminish_5/VB (l_conj) prevent_15/VB (l_dobj) dysfunction_17/NN
D005839_D064420 NONE gentamicin_14/NN (r_amod) toxicity_15/NN
D008687_D007674 NONE Metformin_0/NNP (r_nsubj) prevents_1/VBZ (l_dobj) nephropathy_6/NN
D008687_D007674 NONE metformin_11/NN (r_pobj) by_10/IN (r_prep) correction_9/NN (r_conj) markers_3/NNS (l_prep) of_4/IN (l_pobj) dysfunction_6/NN
D008687_D007674 NONE metformin_9/NN (r_pobj) of_8/IN (r_prep) effects_7/NNS (r_nsubj) lessen_11/VB (l_dobj) nephrotoxicity_13/NN
D008687_D058186 NONE Metformin_0/NNP (r_compound) treatment_1/NN (r_nsubj) blocked_3/VBD (l_dobj) failure_9/NN
D005839_D007674 NONE gentamicin_3/NN (r_npadvmod) induced_5/VBN (r_amod) nephropathy_6/NN
D005839_D007674 NONE gentamicin_12/NN (r_amod) nephrotoxicity_13/NN
D005839_D058186 CID gentamicin_4/NN (r_npadvmod) mediated_6/VBN (r_amod) failure_9/NN
2466960
D005472_D009369 NONE 5-FU_11/CD (r_compound) infusion_12/NN (l_prep) for_13/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) tumors_17/NNS
D005472_D066126 NONE fluorouracil_11/NN (r_nmod) therapy_15/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) toxicity_8/NN
D005472_D066126 NONE 5-FU_13/CD (r_nmod) therapy_15/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) toxicity_8/NN
D005472_D000787 CID 5-FU_12/CD (r_nummod) infusion_13/NN (r_pobj) during_11/IN (r_prep) had_8/VBD (l_ccomp) were_2/VBD (l_nsubj) episodes_1/NNS (l_compound) Anginal_0/JJ
D005472_D000787 CID 5-FU_12/CD (r_nummod) infusion_13/NN (r_pobj) during_11/IN (r_prep) had_8/VBD (l_dobj) angina_9/NN
D005472_D003324 NONE 5-FU_3/CD (r_compound) infusion_4/NN (r_nsubjpass) associated_6/VBN (l_prep) with_7/IN (l_pobj) increase_10/NN (l_prep) among_21/IN (l_pobj) patients_22/NNS (l_prep) with_23/IN (l_pobj) disease_26/NN
D005472_D007511 CID 5-FU_11/CD (r_compound) infusion_12/NN (r_dobj) undergoing_10/VBG (r_acl) patients_9/NNS (r_pobj) on_7/IN (r_prep) monitoring_6/NN (r_dobj) performed_2/VBD (l_prep) in_18/IN (l_pobj) order_19/NN (l_acl) assess_21/VB (l_dobj) incidence_23/NN (l_prep) of_24/IN (l_pobj) changes_27/NNS (l_compound) ST_26/NNP (l_amod) ischemic_25/JJ
D005472_D007511 CID 5-FU_15/CD (r_nummod) infusion_16/NN (r_pobj) to_14/IN (r_prep) prior_13/RB (r_advmod) was_9/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) episodes_4/NNS (l_amod) ischemic_3/JJ
D005472_D007511 CID 5-FU_22/CD (r_nummod) infusion_23/NN (r_pobj) during_21/IN (r_prep) infusion_16/NN (r_pobj) to_14/IN (r_prep) prior_13/RB (r_advmod) was_9/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) episodes_4/NNS (l_amod) ischemic_3/JJ
D005472_D007511 CID 5-FU_46/CD (r_pobj) before_45/IN (r_prep) was_36/VBD (l_ccomp) was_9/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) episodes_4/NNS (l_amod) ischemic_3/JJ
D005472_D007511 CID 5-FU_57/CD (r_pobj) during_56/IN (r_prep) was_36/VBD (l_ccomp) was_9/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) episodes_4/NNS (l_amod) ischemic_3/JJ
D005472_D007511 CID 5-FU_3/CD (r_compound) infusion_4/NN (r_nsubjpass) associated_6/VBN (l_prep) with_7/IN (l_pobj) increase_10/NN (l_prep) in_11/IN (l_pobj) deviation_15/NN (l_amod) suggestive_16/JJ (l_prep) of_17/IN (l_pobj) ischemia_18/NN
3057041
C020976_D006970 CID azelastine_16/NN (r_compound) group_17/NN (r_pobj) in_11/IN (r_prep) increased_6/VBN (l_nsubjpass) Drowsiness_0/VB
C020976_D006255 NONE azelastine_18/NN (r_pobj) of_17/IN (r_prep) trial_16/NN (r_conj) efficacy_13/NN (l_prep) in_24/IN (l_pobj) treatment_26/NN (l_prep) of_27/IN (l_pobj) rhinitis_30/NN
C020976_D006255 NONE Azelastine_0/NNP (r_nsubjpass) compared_8/VBN (l_prep) with_9/IN (l_pobj) maleate_11/NN (l_prep) for_14/IN (l_pobj) efficacy_15/NN (l_prep) in_18/IN (l_pobj) treatment_20/NN (l_prep) of_21/IN (l_pobj) rhinitis_24/NN
C020976_D006255 NONE Azelastine_0/NNP (r_nsubj) appears_1/VBZ (l_xcomp) be_3/VB (l_attr) medication_8/NN (l_prep) for_9/IN (l_pobj) rhinitis_12/NN
D002744_D006255 NONE chlorpheniramine_20/NN (r_conj) azelastine_18/NN (r_pobj) of_17/IN (r_prep) trial_16/NN (r_conj) efficacy_13/NN (l_prep) in_24/IN (l_pobj) treatment_26/NN (l_prep) of_27/IN (l_pobj) rhinitis_30/NN
D002744_D006255 NONE maleate_11/NN (l_prep) for_14/IN (l_pobj) efficacy_15/NN (l_prep) in_18/IN (l_pobj) treatment_20/NN (l_prep) of_21/IN (l_pobj) rhinitis_24/NN
C020976_D013651 CID azelastine_16/NN (r_compound) group_17/NN (r_pobj) in_11/IN (r_prep) increased_6/VBN (l_nsubjpass) Drowsiness_0/VB (l_conj) perception_4/NN
9875685
D014031_D064420 NONE tobramicyn_17/NN (l_prep) on_18/IN (l_pobj) concentrations_23/NNS (l_conj) toxicity_25/NN
D003404_D007674 NONE creatinine_2/NN (r_nsubjpass) observed_4/VBN (l_prep) without_20/IN (l_pobj) evidence_21/NN (l_prep) of_22/IN (l_pobj) nephrotoxicity_23/NN
16006300
C097949_D000471 NONE D_27/JJ (r_compound) concentrations_28/NNS (r_conj) peptide_23/NN (r_conj) hormone_15/NN (r_conj) alkalosis_10/NN
D002118_D006996 NONE calcium_7/NN (r_compound) concentrations_8/NNS (r_pobj) with_3/IN (r_prep) patients_2/NNS (r_nsubj) pamidronate_10/JJ (l_relcl) caused_22/VBD (l_dobj) hypocalcemia_24/NN
D002119_D006934 CID carbonate_1/NN (r_compound) toxicity_2/NN (l_appos) syndrome_9/NN
D002119_D006934 CID carbonate_6/NN (r_npadvmod) induced_8/VBN (r_amod) hypercalcemia_9/NN
D002119_D006934 CID carbonate_6/NN (r_npadvmod) induced_8/VBN (r_amod) hypercalcemia_9/NN (r_pobj) with_4/IN (r_prep) patients_3/NNS (r_dobj) describe_1/VB (l_conj) gain_11/VB (l_dobj) insights_12/NNS (l_prep) into_13/IN (l_pobj) cause_15/NN (l_prep) of_18/IN (l_pobj) syndrome_23/NN
D002119_D006934 CID carbonate_23/NN (r_pobj) of_19/IN (r_prep) amounts_18/NNS (r_pobj) by_16/IN (r_agent) precipitated_15/VBN (r_conj) be_5/VB (l_nsubj) syndrome_3/NN
D002119_D006934 CID carbonate_23/NN (r_pobj) of_19/IN (r_prep) amounts_18/NNS (r_pobj) by_16/IN (r_agent) precipitated_15/VBN (r_conj) be_5/VB (l_attr) cause_8/NN (l_prep) of_9/IN (l_pobj) hypercalcemia_11/NN
C019248_D006934 NONE Pamidronate_0/JJ (r_compound) treatment_1/NN (r_nsubjpass) associated_3/VBN (l_prep) in_11/IN (l_pobj) cases_12/NNS (l_prep) of_13/IN (l_pobj) hypercalcemia_16/NN
D002119_D064420 NONE carbonate_1/NN (r_compound) toxicity_2/NN
D002118_D006934 NONE calcium_18/NN (r_dobj) corrected_16/VBN (r_parataxis) report_1/VBP (l_dobj) data_6/NNS (l_prep) in_7/IN (l_pobj) patients_9/NNS (l_relcl) presented_11/VBD (l_prep) with_12/IN (l_pobj) hypercalcemia_14/NN
D002118_D006934 NONE calcium_18/NN (r_dobj) corrected_16/VBN (l_conj) review_28/VB (l_dobj) literature_31/NN (l_prep) on_32/IN (l_pobj) syndrome_36/NN
C019248_D006996 CID pamidronate_10/JJ (l_relcl) caused_22/VBD (l_dobj) hypocalcemia_24/NN
C019248_D006996 CID Pamidronate_0/JJ (r_compound) treatment_1/NN (r_nsubjpass) associated_3/VBN (l_prep) with_4/IN (l_pobj) risk_6/NN (l_prep) for_7/IN (l_pobj) hypocalcemia_8/NN
C097949_D058186 NONE D_27/JJ (r_compound) concentrations_28/NNS (r_conj) peptide_23/NN (r_conj) hormone_15/NN (r_conj) alkalosis_10/NN (r_conj) insufficiency_6/NN
1700207
D010042_D001145 CID ouabain_21/NN (r_pobj) of_20/IN (r_prep) injection_19/NN (r_appos) intravenous_15/JJ (r_pobj) by_13/IN (r_agent) induced_12/VBN (l_nsubjpass) arrhythmia_1/NN
C032151_D001145 NONE cibenzoline_6/NN (l_prep) on_7/IN (l_pobj) arrhythmias_10/NNS
C032151_D001145 NONE -cibenzoline_6/: (r_conj) of_2/IN (r_prep) effects_1/NNS (l_conj) examined_11/VBN (l_advcl) using_12/VBG (l_dobj) models_17/NNS (l_compound) arrhythmia_16/NN
C032151_D001145 NONE -)-cibenzoline_9/: (r_nsubjpass) examined_11/VBN (l_advcl) using_12/VBG (l_dobj) models_17/NNS (l_compound) arrhythmia_16/NN
C032151_D001145 NONE -cibenzoline_8/, (r_punct) suppressed_9/VBN (r_amod) arrhythmias_15/NNS
C032151_D001145 NONE -cibenzoline_9/: (r_punct) for_10/IN (l_pobj) arrhythmias_16/NNS
C032151_D001145 NONE -)-cibenzoline_9/NNP (r_nsubj) suppressed_10/VBD (l_dobj) arrhythmia_15/NN
C032151_D001145 NONE -)-cibenzoline_9/NNP (r_nsubj) suppressed_10/VBD (r_pcomp) of_7/IN (r_prep) i.v._6/NN (r_appos) dose_2/NN (r_nsubjpass) needed_22/VBN (l_advcl) suppress_24/VB (l_dobj) arrhythmias_28/NNS
C032151_D001145 NONE -)-cibenzoline_7/: (l_prep) for_8/IN (l_pobj) arrhythmia_14/NN
D010424_D001145 NONE pentobarbital_23/NN (r_npadvmod) anesthetized_25/VBN (r_amod) dogs_26/NNS (r_pobj) in_22/IN (r_prep) injection_19/NN (r_appos) intravenous_15/JJ (r_pobj) by_13/IN (r_agent) induced_12/VBN (l_nsubjpass) arrhythmia_1/NN
D012964_D001145 NONE Na_7/NNP (r_compound) blockers_9/NNS (r_pobj) by_6/IN (r_agent) suppressed_5/VBN (r_relcl) arrhythmia_1/NN
D006221_D001145 NONE halothane_17/NN (r_npadvmod) anesthetized_19/VBN (r_amod) dogs_20/NNS (r_pobj) in_16/IN (r_prep) infusion_15/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (l_nsubjpass) arrhythmia_1/NN
D004837_D001145 CID adrenaline_14/NN (r_amod) infusion_15/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (l_nsubjpass) arrhythmia_1/NN
D004837_D001145 CID adrenaline_12/NN (r_npadvmod) induced_14/VBN (r_conj) digitalis-_10/NN (r_amod) arrhythmias_15/NNS
D004837_D001145 CID adrenaline_13/NN (r_npadvmod) induced_15/VBN (r_conj) digitalis-_11/NN (r_amod) arrhythmias_16/NNS
D004837_D001145 CID adrenaline_25/NN (r_npadvmod) induced_27/VBN (r_amod) arrhythmias_28/NNS (r_dobj) suppress_24/VB (r_advcl) needed_22/VBN (l_nsubjpass) dose_2/NN (l_appos) i.v._6/NN (l_prep) of_7/IN (l_pcomp) suppressed_10/VBD (l_dobj) arrhythmia_15/NN
D004837_D001145 CID adrenaline_25/NN (r_npadvmod) induced_27/VBN (r_amod) arrhythmias_28/NNS
D004837_D001145 CID adrenaline_11/NN (r_npadvmod) induced_13/VBN (r_conj) digitalis-_9/NN (r_amod) arrhythmia_14/NN
D004070_D001145 NONE Digitalis_0/NNP (r_compound) arrhythmia_1/NN
D004070_D001145 NONE digitalis-_10/NN (r_amod) arrhythmias_15/NNS
D004070_D001145 NONE digitalis-_11/NN (r_amod) arrhythmias_16/NNS
D004070_D001145 NONE digitalis_12/NN (r_npadvmod) induced_14/VBN (r_amod) arrhythmia_15/NN
D004070_D001145 NONE digitalis_12/NN (r_npadvmod) induced_14/VBN (r_amod) arrhythmia_15/NN (r_dobj) suppressed_10/VBD (r_pcomp) of_7/IN (r_prep) i.v._6/NN (r_appos) dose_2/NN (r_nsubjpass) needed_22/VBN (l_advcl) suppress_24/VB (l_dobj) arrhythmias_28/NNS
D004070_D001145 NONE digitalis-_9/NN (r_amod) arrhythmia_14/NN
D002118_D001145 NONE Ca_7/NNP (r_aux) channel_8/NN (r_compound) blockers_9/NNS (r_pobj) by_6/IN (r_agent) suppressed_5/VBN (r_relcl) arrhythmia_1/NN
19944333
C471405_D003329 CID Sorafenib_0/NNP (r_npadvmod) induced_2/VBN (l_prep) due_6/IN (l_pobj) spasm_10/NN
C471405_D003329 CID sorafenib_6/NN (r_npadvmod) induced_8/VBN (r_amod) spasm_11/NN
C471405_D009203 NONE Sorafenib_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) infarction_5/NN
D020108_D060050 NONE nicorandil_3/NN (r_pobj) of_1/IN (r_prep) Addition_0/NN (r_nsubj) reduced_4/VBD (l_conj) maintained_8/VBD (l_dobj) status_11/NN (l_compound) angina_10/NN
1687392
C534628_D002375 CID 23390_7/CD (r_nummod) SCH_6/NNP (r_appos) fluphenazine_2/NN (r_nsubj) induced_12/VBD (l_dobj) catalepsy_13/NN
C534628_D002375 CID 23390_3/CD (r_nummod) SCH_2/NNP (r_pobj) of_1/IN (r_prep) Combination_0/NN (r_nsubj) induce_8/VB (l_dobj) potentiation_10/NN (l_compound) catalepsy_9/NN
C534628_D002375 CID 23390_18/CD (r_nummod) SCH_17/NNP (r_appos) fluphenazine_15/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) catalepsy_12/NN
D004298_D002375 NONE dopamine_6/NN (r_compound) receptors_7/NNS (r_pobj) of_1/IN (r_prep) Blockade_0/NN (r_nsubj) induce_9/VB (l_dobj) catalepsy_10/NN
D004298_D002375 NONE dopamine_4/NN (r_compound) antagonists_5/NNS (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) catalepsy_1/NN
D004298_D002375 NONE dopamine_4/NN (r_compound) antagonists_5/NNS (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) catalepsy_1/NN (r_nsubjpass) tested_8/VBN (l_conj) determined_18/VBN (l_nsubjpass) subtypes_13/NNS (l_acl) involved_14/VBN (l_prep) in_15/IN (l_pobj) catalepsy_16/NN
D004298_D002375 NONE dopamine_12/NN (r_compound) subtypes_13/NNS (r_nsubjpass) determined_18/VBN (r_conj) tested_8/VBN (l_nsubjpass) catalepsy_1/NN
D004298_D002375 NONE dopamine_12/NN (r_compound) subtypes_13/NNS (l_acl) involved_14/VBN (l_prep) in_15/IN (l_pobj) catalepsy_16/NN
D004298_D002375 NONE Dopamine_0/NN (r_compound) fluphenazine_2/NN (r_nsubj) induced_12/VBD (l_dobj) catalepsy_13/NN
D004298_D002375 NONE dopamine_16/NN (r_compound) antagonists_17/NNS (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_acl) effect_11/NN (l_prep) on_12/IN (l_pobj) catalepsy_13/NN
D013469_D002375 CID sulpiride_11/NN (r_npadvmod) induced_12/VBD (l_dobj) catalepsy_13/NN
D013469_D002375 CID sulpiride_5/NN (r_pobj) with_4/IN (r_prep) Combination_0/NN (r_nsubj) induce_8/VB (l_dobj) potentiation_10/NN (l_compound) catalepsy_9/NN
D013469_D002375 CID sulpiride_20/NN (r_conj) SCH_17/NNP (r_appos) fluphenazine_15/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) catalepsy_12/NN
D015647_D002375 NONE 38393_5/CD (r_nummod) SKF_4/NNP (r_nmod) quinpirole_9/NN (r_nsubj) decreased_10/VBD (l_dobj) catalepsy_12/NN
D015647_D002375 NONE 38393_3/CD (r_nummod) SKF_2/NNP (r_pobj) of_1/IN (r_prep) Combination_0/NN (r_nsubj) cause_8/VB (l_ccomp) potentiated_9/VBN (l_dobj) effect_11/NN (l_prep) on_12/IN (l_pobj) catalepsy_13/NN
D005476_D002375 CID fluphenazine_2/NN (r_nsubj) induced_12/VBD (l_dobj) catalepsy_13/NN
D005476_D002375 CID fluphenazine_15/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) catalepsy_12/NN
D019257_D002375 NONE quinpirole_9/NN (r_nsubj) decreased_10/VBD (l_dobj) catalepsy_12/NN
D019257_D002375 NONE quinpirole_5/NN (r_pobj) with_4/IN (r_prep) Combination_0/NN (r_nsubj) cause_8/VB (l_ccomp) potentiated_9/VBN (l_dobj) effect_11/NN (l_prep) on_12/IN (l_pobj) catalepsy_13/NN
3108839
D016685_D006463 CID C_1/NNP (r_nsubj) associated_2/VBD (l_dobj) syndrome_5/NN
D016685_D006463 CID C_1/NNP (r_nsubj) associated_2/VBD (l_dobj) Syndrome_5/NNP
D016685_D006463 CID C_1/NNP (r_nsubj) associated_2/VBD (l_dobj) Syndrome_5/NNP (l_appos) HUS_7/NNP
D016685_D051437 CID C_15/NN (r_compound) treatment_16/NN (r_pobj) with_13/IN (r_prep) associated_12/VBN (r_acl) failure_11/NN
D016685_D051437 CID C_14/NN (r_compound) treatment_15/NN (r_pobj) of_12/IN (r_prep) start_11/NN (r_pobj) after_10/IN (r_prep) develops_4/VBZ (l_nsubj) failure_2/NN
D016685_D051437 CID C_14/NN (r_compound) treatment_15/NN (r_pobj) of_12/IN (r_prep) start_11/NN (r_pobj) after_10/IN (r_prep) develops_4/VBZ (l_conj) is_19/VBZ (l_attr) %_22/NN (l_prep) from_23/IN (l_pobj) failure_25/NN
D016685_D051437 CID C_29/NN (r_pobj) with_27/IN (r_prep) treatment_26/NN (r_pobj) on_25/IN (r_advcl) describe_1/VBP (l_prep) in_8/IN (l_pobj) man_14/NN (l_relcl) developed_19/VBD (l_dobj) failure_21/NN
D016685_D000743 NONE C_15/NN (r_compound) treatment_16/NN (r_pobj) with_13/IN (r_prep) associated_12/VBN (r_acl) failure_11/NN (r_conj) thrombocytopenia_7/JJ (r_conj) anemia_5/NN
D016685_D013921 NONE C_15/NN (r_compound) treatment_16/NN (r_pobj) with_13/IN (r_prep) associated_12/VBN (r_acl) failure_11/NN (r_conj) thrombocytopenia_7/JJ
D016685_D013921 NONE C_29/NN (r_pobj) with_27/IN (r_prep) treatment_26/NN (r_pobj) on_25/IN (r_advcl) describe_1/VBP (l_prep) in_8/IN (l_pobj) man_14/NN (l_relcl) developed_19/VBD (l_conj) thrombocytopenia_23/NN
D016685_D013274 NONE C_29/NN (r_pobj) with_27/IN (r_prep) treatment_26/NN (r_pobj) on_25/IN (r_advcl) describe_1/VBP (l_prep) in_8/IN (l_pobj) man_14/NN (l_prep) with_15/IN (l_pobj) adenocarcinoma_17/NN
D016685_D011654 NONE C_14/NN (r_compound) treatment_15/NN (r_pobj) of_12/IN (r_prep) start_11/NN (r_pobj) after_10/IN (r_prep) develops_4/VBZ (l_conj) is_19/VBZ (l_attr) %_22/NN (l_prep) from_23/IN (l_pobj) failure_25/NN (l_conj) edema_28/NN
D016685_D011654 NONE C_29/NN (r_pobj) with_27/IN (r_prep) treatment_26/NN (r_pobj) on_25/IN (r_advcl) describe_1/VBP (l_conj) died_31/VBD (l_prep) in_32/IN (l_pobj) edema_34/NN
14745746
12734532
D010665_D009203 CID Dexatrim_3/NNP (l_prep) as_7/IN (l_pobj) cause_9/NN (l_prep) of_10/IN (l_pobj) infarction_12/NN
D010665_D009203 CID Phenylpropanolamine_5/NNP (r_appos) Dexatrim_3/NNP (l_prep) as_7/IN (l_pobj) cause_9/NN (l_prep) of_10/IN (l_pobj) infarction_12/NN
D010665_D009202 NONE PPA_7/NNP (r_pobj) of_6/IN (r_prep) abuse_5/NN (l_prep) with_8/IN (l_pobj) injury_10/NN
D010665_D009202 NONE Dexatrim_7/NNP (r_nmod) injury_11/NN
D010665_D009202 NONE PPA)-induced_9/VBN (r_amod) injury_11/NN
D010665_D009202 NONE PPA_10/NN (r_pobj) of_9/IN (r_prep) cases_8/NNS (l_acl) related_11/VBN (l_dobj) injury_13/NN
D010665_D062787 NONE PPA_7/NNP (r_pobj) of_6/IN (r_prep) abuse_5/NN (r_dobj) linked_3/VBN (l_advcl) involved_16/VBN (l_nsubjpass) overdose_14/NN
1848636
D013726_D007008 CID terbutaline_10/NN (r_npadvmod) induced_12/VBN (r_amod) hypokalemia_13/NN
D008790_D007008 NONE metoprolol_8/NN (l_prep) of_9/IN (l_pobj) hypokalemia_13/NN
20973483
D058915_D010300 NONE antagonist_11/NN (l_prep) in_12/IN (l_pobj) models_14/NNS (l_prep) of_15/IN (l_pobj) disease_18/NN
D058915_D010300 NONE antagonist_11/NN (l_prep) in_12/IN (l_pobj) models_15/NNS (l_prep) of_16/IN (l_pobj) disease_19/NN
D012110_D010300 NONE reserpine_61/NN (r_npadvmod) induced_63/VBN (r_compound) akinesia_64/NN (r_pobj) of_60/IN (r_prep) model_59/NN (r_appos) catalepsy_56/NN (r_pobj) of_52/IN (r_prep) models_51/NNS (r_pobj) including_47/VBG (r_prep) disease_46/NN
D016627_D004409 NONE 6-hydroxydopamine_67/NN (r_nmod) 6-OHDA_69/CD (r_nummod) model_72/NN (r_appos) catalepsy_56/NN (l_appos) model_59/NN (l_prep) of_60/IN (l_pobj) akinesia_64/NN
D016627_D004409 NONE 6-OHDA_69/CD (r_nummod) model_72/NN (r_appos) catalepsy_56/NN (l_appos) model_59/NN (l_prep) of_60/IN (l_pobj) akinesia_64/NN
D015632_D004409 NONE MPTP_80/NNP (r_npadvmod) treated_82/VBN (r_amod) model_87/NN (r_conj) across_37/IN (l_pobj) number_39/NN (l_prep) of_40/IN (l_pobj) models_42/NNS (l_prep) of_43/IN (l_pobj) disease_46/NN (l_prep) including_47/VBG (l_pobj) models_51/NNS (l_prep) of_52/IN (l_pobj) catalepsy_56/NN (l_appos) model_59/NN (l_prep) of_60/IN (l_pobj) akinesia_64/NN
D012110_D002375 NONE reserpine_61/NN (r_npadvmod) induced_63/VBN (r_compound) akinesia_64/NN (r_pobj) of_60/IN (r_prep) model_59/NN (r_appos) catalepsy_56/NN
D015632_D002375 NONE MPTP_80/NNP (r_npadvmod) treated_82/VBN (r_amod) model_87/NN (r_conj) across_37/IN (l_pobj) number_39/NN (l_prep) of_40/IN (l_pobj) models_42/NNS (l_prep) of_43/IN (l_pobj) disease_46/NN (l_prep) including_47/VBG (l_pobj) models_51/NNS (l_prep) of_52/IN (l_pobj) catalepsy_56/NN
D015632_D010300 NONE MPTP_80/NNP (r_npadvmod) treated_82/VBN (r_amod) model_87/NN (r_conj) across_37/IN (l_pobj) number_39/NN (l_prep) of_40/IN (l_pobj) models_42/NNS (l_prep) of_43/IN (l_pobj) disease_46/NN
D012110_D004409 CID reserpine_61/NN (r_npadvmod) induced_63/VBN (r_compound) akinesia_64/NN
D016627_D002375 NONE 6-hydroxydopamine_67/NN (r_nmod) 6-OHDA_69/CD (r_nummod) model_72/NN (r_appos) catalepsy_56/NN
D016627_D002375 NONE 6-OHDA_69/CD (r_nummod) model_72/NN (r_appos) catalepsy_56/NN
D006220_D004409 NONE haloperidol_53/NN (r_npadvmod) induced_55/VBN (r_amod) catalepsy_56/NN (l_appos) model_59/NN (l_prep) of_60/IN (l_pobj) akinesia_64/NN
D006220_D002375 CID haloperidol_53/NN (r_npadvmod) induced_55/VBN (r_amod) catalepsy_56/NN
D006220_D010300 NONE haloperidol_53/NN (r_npadvmod) induced_55/VBN (r_amod) catalepsy_56/NN (r_pobj) of_52/IN (r_prep) models_51/NNS (r_pobj) including_47/VBG (r_prep) disease_46/NN
D016627_D010300 NONE 6-hydroxydopamine_67/NN (r_nmod) 6-OHDA_69/CD (r_nummod) model_72/NN (r_appos) catalepsy_56/NN (r_pobj) of_52/IN (r_prep) models_51/NNS (r_pobj) including_47/VBG (r_prep) disease_46/NN
D016627_D010300 NONE 6-OHDA_69/CD (r_nummod) model_72/NN (r_appos) catalepsy_56/NN (r_pobj) of_52/IN (r_prep) models_51/NNS (r_pobj) including_47/VBG (r_prep) disease_46/NN
2598570
D000431_D006255 NONE alcohol_83/NN (r_dobj) use_82/VB (r_conj) participate_47/VB (l_ccomp) were_2/VBD (l_conj) suffer_24/VB (l_prep) from_25/IN (l_pobj) fever_27/NN
D007052_D006073 NONE ibuprofen_15/NNP (r_appos) agents_12/NNS (r_pobj) of_9/IN (r_prep) use_8/NN (r_appos) age_5/NN (l_conj) disease_20/NN (l_conj) history_29/NN (l_prep) of_30/IN (l_pobj) gout_31/NN
D007052_D007674 NONE ibuprofen_15/NNP (r_appos) agents_12/NNS (r_pobj) of_9/IN (r_prep) use_8/NN (r_appos) age_5/NN (l_conj) disease_20/NN
D013496_D021501 CID suprofen_9/NN (r_pobj) from_8/IN (r_prep) epidemiology_1/NN (l_prep) of_2/IN (l_pobj) syndrome_7/NN (l_compound) pain_6/NN
D000431_D001249 NONE alcohol_83/NN (r_dobj) use_82/VB (r_conj) participate_47/VB (l_ccomp) were_2/VBD (l_conj) suffer_24/VB (l_prep) from_25/IN (l_pobj) fever_27/NN (l_conj) asthma_29/NN
D007052_D007669 NONE ibuprofen_15/NNP (r_appos) agents_12/NNS (r_pobj) of_9/IN (r_prep) use_8/NN (r_appos) age_5/NN (l_conj) disease_20/NN (l_conj) history_23/NN (l_prep) of_24/IN (l_pobj) stones_26/NNS
8492347
D005665_D012206 CID furosemide_6/NN (r_pobj) due_3/JJ (r_prep) Tetany_0/NNP (l_conj) rhabdomyolysis_2/NN
D008274_D012206 NONE magnesium_10/NN (r_compound) supplementation_11/NN (r_pobj) of_9/IN (r_prep) importance_8/NN (r_appos) Tetany_0/NNP (l_conj) rhabdomyolysis_2/NN
D008274_D007008 NONE magnesium_27/NN (r_compound) depletion_28/NN (r_pobj) of_26/IN (r_prep) effects_25/NNS (r_nsubjpass) noted_31/VBN (r_conj) observed_19/VBN (r_conj) reported_4/VBN (l_nsubjpass) hypokalemia_1/NN
D002118_D007008 NONE calcium_25/NN (r_conj) potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_advcl) cause_4/VB (l_nsubj) hypokalemia_2/NN
D011188_D007008 NONE potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_advcl) cause_4/VB (l_nsubj) hypokalemia_2/NN
D002118_D018908 NONE calcium_25/NN (r_conj) potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_advcl) cause_4/VB (l_dobj) weakness_6/NN
D005665_D013746 CID furosemide_6/NN (r_pobj) due_3/JJ (r_prep) Tetany_0/NNP
D002118_D013035 NONE calcium_25/NN (r_conj) potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_prep) with_12/IN (l_pobj) spasms_14/NNS
D011188_C537153 NONE potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_nsubjpass) hypomagnesemia_9/NN
D002118_D013746 NONE calcium_25/NN (r_conj) potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_prep) with_12/IN (l_pobj) spasms_14/NNS (l_conj) tetany_16/NN
D011188_D013035 NONE potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_prep) with_12/IN (l_pobj) spasms_14/NNS
D008274_D013746 NONE magnesium_10/NN (r_compound) supplementation_11/NN (r_pobj) of_9/IN (r_prep) importance_8/NN (r_appos) Tetany_0/NNP
D002118_C537153 NONE calcium_25/NN (r_conj) potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_nsubjpass) hypomagnesemia_9/NN
D011188_D018908 NONE potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_advcl) cause_4/VB (l_dobj) weakness_6/NN
D011188_D013746 NONE potassium_23/NN (r_nmod) supplementation_26/NN (r_pobj) by_22/IN (r_agent) corrected_21/VBN (r_ccomp) associated_11/VBN (l_prep) with_12/IN (l_pobj) spasms_14/NNS (l_conj) tetany_16/NN
D008274_D006996 NONE magnesium_27/NN (r_compound) depletion_28/NN (r_pobj) of_26/IN (r_prep) effects_25/NNS (r_nsubjpass) noted_31/VBN (r_conj) observed_19/VBN (l_prep) in_14/IN (l_pobj) hypocalcemia_17/NN
7059267
D002747_D009901 CID Chlorpropamide_0/NN (r_npadvmod) induced_2/VBN (r_amod) neuropathy_4/NN
D002747_D009901 CID chlorpropamide_12/NN (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_csubj) had_16/VBD (l_dobj) neuropathy_20/NN
D002747_D009901 CID Diabenese_14/NNP (r_appos) chlorpropamide_12/NN (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_csubj) had_16/VBD (l_dobj) neuropathy_20/NN
D002747_D009901 CID chlorpropamide_26/NN (r_amod) therapy_27/NN (r_pobj) of_25/IN (r_prep) discontinuation_24/NN (r_pobj) with_23/IN (r_prep) resolved_22/VBD (r_relcl) neuropathy_20/NN
D002747_D003924 NONE chlorpropamide_12/NN (r_pobj) with_11/IN (r_prep) treated_10/VBN (l_nsubj) woman_4/NN (l_prep) with_5/IN (l_pobj) diabetes_9/NNS
D002747_D003924 NONE Diabenese_14/NNP (r_appos) chlorpropamide_12/NN (r_pobj) with_11/IN (r_prep) treated_10/VBN (l_nsubj) woman_4/NN (l_prep) with_5/IN (l_pobj) diabetes_9/NNS
D002747_D003924 NONE chlorpropamide_26/NN (r_amod) therapy_27/NN (r_pobj) of_25/IN (r_prep) discontinuation_24/NN (r_pobj) with_23/IN (r_prep) resolved_22/VBD (r_relcl) neuropathy_20/NN (r_dobj) had_16/VBD (l_csubj) treated_10/VBN (l_nsubj) woman_4/NN (l_prep) with_5/IN (l_pobj) diabetes_9/NNS
9209318
D015215_D000163 NONE AZT_0/NNP (r_nsubj) induced_2/VBN (l_dobj) anemia_5/NN (l_prep) in_6/IN (l_pobj) patients_8/NNS (l_compound) AIDS_7/NNP
D015215_D000163 NONE AZT_12/NNP (r_compound) therapy_13/NN (r_appos) term_11/NN (r_pobj) on_9/IN (r_prep) anemia_5/NN (l_prep) in_6/IN (l_pobj) patients_8/NNS (l_compound) AIDS_7/NNP
D015215_D009190 CID azidothymidine_5/NN (r_pcomp) with_4/IN (r_prep) treatment_1/NN (r_nsubj) produces_9/VBZ (l_dobj) myelodysplasia_10/NN
D015215_D009190 CID AZT_7/NNP (r_appos) treatment_1/NN (r_nsubj) produces_9/VBZ (l_dobj) myelodysplasia_10/NN
D015215_D009190 CID AZT_2/NNP (r_compound) incorporation_3/NN (r_nsubj) induced_6/VBN (l_dobj) hemopoiesis_9/NN (l_prep) in_10/IN (l_pobj) cells_15/NNS (l_relcl) known_19/VBN (l_xcomp) seen_22/VBN (l_prep) in_24/IN (l_pobj) syndrome_27/NN
D015215_D000748 CID AZT_0/NNP (r_nsubj) induced_2/VBN (l_dobj) anemia_5/NN
D015215_D000748 CID AZT_12/NNP (r_compound) therapy_13/NN (r_appos) term_11/NN (r_pobj) on_9/IN (r_prep) anemia_5/NN
7542793
D016572_D006984 NONE A_1/NNP (r_nsubj) caused_29/VBD (l_dobj) reduction_31/NN (l_prep) of_32/IN (l_pobj) rate_35/NN (l_appos) changes_38/NNS (l_conj) hypertrophy_45/NN
D016572_D006984 NONE CsA_3/NNP (r_appos) A_1/NNP (r_nsubj) caused_29/VBD (l_dobj) reduction_31/NN (l_prep) of_32/IN (l_pobj) rate_35/NN (l_appos) changes_38/NNS (l_conj) hypertrophy_45/NN
D018942_D006984 NONE macrolide_21/NN (r_amod) rapamycin_23/NNS (r_conj) Fujimycine_9/NNP (r_conj) mg/kg_6/NN (r_appos) A_1/NNP (r_nsubj) caused_29/VBD (l_dobj) reduction_31/NN (l_prep) of_32/IN (l_pobj) rate_35/NN (l_appos) changes_38/NNS (l_conj) hypertrophy_45/NN
D016572_D064420 NONE CsA_4/NNP (l_conj) toxicity_7/NN
D016559_D064420 NONE FK506_6/NNP (r_compound) toxicity_7/NN
D020123_D006984 NONE rapamycin_23/NNS (r_conj) Fujimycine_9/NNP (r_conj) mg/kg_6/NN (r_appos) A_1/NNP (r_nsubj) caused_29/VBD (l_dobj) reduction_31/NN (l_prep) of_32/IN (l_pobj) rate_35/NN (l_appos) changes_38/NNS (l_conj) hypertrophy_45/NN
D016572_D007674 CID A_3/NNP (r_pobj) of_1/IN (r_prep) Nephrotoxicity_0/NN
D016572_D007674 CID CsA_8/NNP (r_pobj) of_7/IN (r_prep) effects_6/NNS (l_amod) nephrotoxic_5/JJ
D016559_D006984 NONE Fujimycine_9/NNP (r_conj) mg/kg_6/NN (r_appos) A_1/NNP (r_nsubj) caused_29/VBD (l_dobj) reduction_31/NN (l_prep) of_32/IN (l_pobj) rate_35/NN (l_appos) changes_38/NNS (l_conj) hypertrophy_45/NN
D016559_D006984 NONE FK506_11/NNP (r_appos) Fujimycine_9/NNP (r_conj) mg/kg_6/NN (r_appos) A_1/NNP (r_nsubj) caused_29/VBD (l_dobj) reduction_31/NN (l_prep) of_32/IN (l_pobj) rate_35/NN (l_appos) changes_38/NNS (l_conj) hypertrophy_45/NN
D016559_D007674 CID FK506_5/NNP (r_conj) Nephrotoxicity_0/NN
D016559_D007674 CID FK506_10/NNP (r_nsubjpass) mediated_13/VBN (l_nsubjpass) effects_6/NNS (l_amod) nephrotoxic_5/JJ
1728915
D002220_D013616 CID carbamazepine_12/NN (r_compound) overdose_13/NN (r_pobj) of_9/IN (r_prep) setting_8/NN (r_pobj) in_6/IN (r_prep) developed_3/VBD (l_dobj) tachycardias_5/NNS
D002220_D001919 CID carbamazepine_11/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) patient_1/NN (l_prep) with_2/IN (l_pobj) bradycardia_4/NNP
D002220_D001919 CID carbamazepine_28/NN (r_compound) levels_30/NNS (r_pobj) with_22/IN (r_prep) associated_21/VBN (r_advcl) consisted_3/VBD (l_advmod) exclusively_5/RB (l_prep) of_6/IN (l_pobj) women_8/NNS (l_relcl) developed_10/VBD (l_dobj) bradyarrhythmias_15/NNS
D002220_D062787 NONE carbamazepine_12/NN (r_compound) overdose_13/NN
D002220_D006331 NONE Carbamazepine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dysfunction_4/NN
D002220_D006331 NONE carbamazepine_11/NN (r_npadvmod) associated_13/VBN (r_amod) dysfunction_15/NN
D002220_D001523 NONE carbamazepine_1/NN (r_nsubjpass) used_4/VBN (l_prep) in_5/IN (l_pobj) treatment_7/NN (l_prep) of_8/IN (l_pobj) conditions_13/NNS (l_amod) neurologic_10/JJ (l_conj) psychiatric_12/JJ
D002220_D054537 CID carbamazepine_11/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) patient_1/NN (l_prep) with_2/IN (l_pobj) bradycardia_4/NNP (l_conj) block_7/NN
D002220_D054537 CID carbamazepine_28/NN (r_compound) levels_30/NNS (r_pobj) with_22/IN (r_prep) associated_21/VBN (r_advcl) consisted_3/VBD (l_advmod) exclusively_5/RB (l_prep) of_6/IN (l_pobj) women_8/NNS (l_relcl) developed_10/VBD (l_dobj) bradyarrhythmias_15/NNS (l_conj) delay_19/NN
10027919
C051883_D006934 CID OCT_6/NNP (r_nsubj) prevent_10/VB (l_dobj) occurrence_12/NN (l_prep) of_13/IN (l_pobj) hypercalcemia_14/NN
D002117_D006934 CID Calcitriol_0/NNP (r_compound) therapy_1/NN (r_nsubj) suppresses_2/VBZ (l_conj) has_17/VBZ (l_dobj) drawbacks_19/NNS (l_prep) including_21/VBG (l_pobj) hypercalcemia_22/NN
C051883_D001851 NONE 22-oxacalcitriol_0/JJ (r_nsubj) suppresses_1/VBZ (l_prep) without_4/IN (l_pcomp) inducing_5/VBG (l_dobj) turnover_8/NN
C051883_D001851 NONE OCT_6/NNP (r_nsubj) prevent_10/VB (r_advcl) be_24/VB (l_advcl) induce_37/VB (l_dobj) turnover_40/NN
C051883_D001851 NONE OCT_6/NNP (r_nsubj) prevent_10/VB (r_advcl) be_24/VB (l_advcl) induce_37/VB (l_conj) increase_47/VB (l_dobj) risk_49/NN (l_prep) of_50/IN (l_pobj) disease_53/NN
C051883_-1 NONE OCT_4/NNP (r_nsubj) reversed_5/VBD (l_dobj) formation_8/NN (l_prep) as_11/IN (l_pobj) osteoid_13/NN
D002117_D051437 NONE Calcitriol_0/NNP (r_compound) therapy_1/NN (r_nsubj) suppresses_2/VBZ (l_prep) in_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) failure_15/NN
D002117_D001851 CID Calcitriol_0/NNP (r_compound) therapy_1/NN (r_nsubj) suppresses_2/VBZ (l_conj) has_17/VBZ (l_dobj) drawbacks_19/NNS (l_prep) including_21/VBG (l_pobj) hypercalcemia_22/NN (l_conj) suppression_25/NN (l_prep) of_26/IN (l_pobj) turnover_28/NN
D002117_D001851 CID Calcitriol_0/NNP (r_compound) therapy_1/NN (r_nsubj) suppresses_2/VBZ (l_conj) has_17/VBZ (l_dobj) drawbacks_19/NNS (l_prep) including_21/VBG (l_pobj) hypercalcemia_22/NN (l_conj) suppression_25/NN (l_prep) of_26/IN (l_pobj) turnover_28/NN (l_relcl) lead_32/VB (l_prep) to_33/IN (l_pobj) disease_36/NN
C051883_D005355 NONE OCT_4/NNP (r_nsubj) reversed_5/VBD (l_dobj) formation_8/NN (l_prep) as_11/IN (l_pobj) osteoid_13/NN (l_conj) fibrosis_15/NN
C051883_D007674 NONE OCT_9/NNP (r_pobj) of_8/IN (r_prep) effects_7/NNS (l_prep) on_10/IN (l_pobj) levels_13/NNS (l_conj) turnover_16/NN (l_prep) in_17/IN (l_pobj) states_18/NNS (l_prep) of_19/IN (l_pobj) function_24/NN
C051883_D006962 NONE 22-oxacalcitriol_0/JJ (r_nsubj) suppresses_1/VBZ (l_dobj) hyperparathyroidism_3/NN
C051883_D006962 NONE OCT_7/NNP (r_nsubj) stabilized_14/VBD (l_prep) In_0/IN (l_pobj) hyperparathyroidism_5/NN
C051883_D006962 NONE OCT_6/NNP (r_nsubj) prevent_10/VB (r_advcl) be_24/VB (l_prep) in_27/IN (l_pobj) management_29/NN (l_prep) of_30/IN (l_pobj) hyperparathyroidism_32/NN
C051883_D051437 NONE 22-oxacalcitriol_0/JJ (r_nsubj) suppresses_1/VBZ (l_prep) without_4/IN (l_pcomp) inducing_5/VBG (l_dobj) turnover_8/NN (l_prep) in_9/IN (l_pobj) dogs_10/NNS (l_prep) with_11/IN (l_pobj) failure_13/NN
C051883_D051437 NONE OCT_4/NNP (r_nsubj) decreased_6/VBD (l_prep) after_11/IN (l_pobj) induction_13/NN (l_prep) of_14/IN (l_pobj) insufficiency_16/NN
C051883_D051437 NONE OCT_6/NNP (r_nsubj) prevent_10/VB (l_dobj) occurrence_12/NN (l_prep) in_15/IN (l_pobj) dogs_17/NNS (l_prep) with_18/IN (l_pobj) insufficiency_20/NN
15565293
D004977_D009901 CID ethambutol_10/NN (r_advmod) induced_12/VBN (r_amod) neuropathy_14/NN
D004977_D009901 CID ethambutol_14/NN (r_advmod) induced_16/VBN (r_amod) neuropathy_18/NN
D004977_D009901 CID ethambutol_4/NN (r_pobj) of_3/IN (r_prep) complication_2/NN (r_nsubj) is_5/VBZ (l_attr) neuropathy_8/NN
D004977_D009901 CID ethambutol_6/NN (r_amod) neuropathy_10/NN
D004977_D009901 CID EMB)-induced_8/VBN (r_amod) optic_9/JJ (r_compound) neuropathy_10/NN
D004977_D009901 CID EMB_6/NNP (r_npadvmod) induced_8/VBN (r_amod) neuropathy_10/NN
D004977_D009901 CID EMB_7/NNP (r_npadvmod) induced_9/VBN (r_amod) neuropathy_11/NN
D004977_D009901 CID EMB_7/NNP (r_npadvmod) induced_9/VBN (r_amod) neuropathy_11/NN
D004977_D009901 CID ethambutol_19/NN (r_amod) dosing_20/VBG (r_dobj) manage_18/VB (r_xcomp) important_15/JJ (r_acomp) is_14/VBZ (l_prep) in_2/IN (l_pobj) terms_3/NNS (l_prep) of_4/IN (l_pobj) management_5/NN (l_prep) of_6/IN (l_pobj) neuropathy_11/NN
D004977_D014376 NONE Ethambutol_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_4/NN (l_acl) used_6/VBD (l_xcomp) treat_8/VB (l_dobj) tuberculosis_9/NN
D004977_D014786 CID ethambutol_6/NN (r_amod) neuropathy_10/NN (r_pobj) of_5/IN (r_prep) history_4/NN (r_pobj) with_2/IN (r_prep) subjects_1/NNS (r_nsubjpass) administered_23/VBN (l_nsubjpass) deficits_21/NNS
D004977_D014786 CID EMB)-induced_8/VBN (r_amod) optic_9/JJ (r_compound) neuropathy_10/NN (r_pobj) of_5/IN (r_prep) history_4/NN (r_pobj) with_2/IN (r_prep) subjects_1/NNS (r_nsubjpass) administered_23/VBN (l_nsubjpass) deficits_21/NNS
D004977_D014786 CID EMB_6/NNP (r_npadvmod) induced_8/VBN (r_amod) neuropathy_10/NN (r_pobj) of_5/IN (r_prep) history_4/NN (r_pobj) with_3/IN (r_prep) subjects_2/NNS (r_pobj) In_0/IN (r_prep) was_13/VBD (l_attr) loss_16/NN (l_prep) with_32/IN (l_pobj) recovery_34/NN (l_prep) with_48/IN (l_pobj) deficits_51/NNS
D004977_D014786 CID EMB_6/NNP (r_npadvmod) induced_8/VBN (r_amod) neuropathy_10/NN (r_pobj) of_5/IN (r_prep) history_4/NN (r_pobj) with_3/IN (r_prep) subjects_2/NNS (r_pobj) In_0/IN (r_prep) was_13/VBD (l_attr) loss_16/NN (l_conj) loss_55/NN (l_conj) C_58/NN (l_prep) with_60/IN (l_pobj) deficits_63/NNS
D004977_D051437 NONE EMB_7/NNP (r_npadvmod) induced_9/VBN (r_amod) neuropathy_11/NN (r_pobj) of_6/IN (r_prep) management_5/NN (r_pobj) of_4/IN (r_prep) terms_3/NNS (r_pobj) in_2/IN (r_prep) is_14/VBZ (l_acomp) important_15/JJ (l_xcomp) manage_18/VB (l_dobj) dosing_20/VBG (l_prep) in_21/IN (l_pobj) patients_22/NNS (l_prep) with_23/IN (l_pobj) impairment_25/NN
D004977_D051437 NONE ethambutol_19/NN (r_amod) dosing_20/VBG (l_prep) in_21/IN (l_pobj) patients_22/NNS (l_prep) with_23/IN (l_pobj) impairment_25/NN
D004977_D009410 NONE ethambutol_14/NN (r_advmod) induced_16/VBN (r_amod) neuropathy_18/NN (r_pobj) in_13/IN (r_prep) degeneration_12/NN
15266215
C406224_D001172 NONE valdecoxib_6/NNS (r_pobj) for_5/IN (r_prep) data_4/NNS (l_appos) inhibitor_11/NN (l_prep) in_12/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) osteoarthritis_17/NN (l_conj) arthritis_20/NN
C406224_D001172 NONE valdecoxib_23/NNS (r_dobj) analyzing_21/VBG (r_pcomp) by_20/IN (r_prep) determined_19/VBN (l_appos) NSAID_33/NNP (l_npadvmod) ibuprofen_40/VBD (l_conj) data_53/NNS (l_prep) from_54/IN (l_pobj) trials_61/NNS (l_compound) arthritis_60/NN
C406224_D001172 NONE valdecoxib_24/NN (r_compound) doses_25/NNS (r_conj) treatment_5/NN (r_nsubjpass) associated_28/VBN (l_prep) with_29/IN (l_pobj) incidence_32/NN (l_prep) of_33/IN (l_pobj) events_35/NNS (l_amod) relative_36/JJ (l_prep) to_37/IN (l_pobj) NSAIDs_39/NNPS (l_prep) in_42/IN (l_pobj) patients_47/NNS (l_compound) arthritis_46/NN
D009288_D013927 NONE naproxen_46/NN (r_conj) ibuprofen_40/VBD (r_npadvmod) NSAID_33/NNP (r_appos) determined_19/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) events_5/NNS (l_amod) thrombotic_4/JJ
D009288_D013927 NONE naproxen_46/NN (r_conj) ibuprofen_40/VBD (r_npadvmod) NSAID_33/NNP (r_appos) determined_19/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) events_5/NNS (l_appos) thrombotic_16/JJ
D007052_D013927 NONE ibuprofen_40/VBD (r_npadvmod) NSAID_33/NNP (r_appos) determined_19/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) events_5/NNS (l_amod) thrombotic_4/JJ
D007052_D013927 NONE ibuprofen_40/VBD (r_npadvmod) NSAID_33/NNP (r_appos) determined_19/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) events_5/NNS (l_appos) thrombotic_16/JJ
C406224_D010003 NONE valdecoxib_6/NNS (r_pobj) for_5/IN (r_prep) data_4/NNS (l_appos) inhibitor_11/NN (l_prep) in_12/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) osteoarthritis_17/NN
C406224_D010003 NONE valdecoxib_23/NNS (r_dobj) analyzing_21/VBG (r_pcomp) by_20/IN (r_prep) determined_19/VBN (l_appos) NSAID_33/NNP (l_npadvmod) ibuprofen_40/VBD (l_conj) data_53/NNS (l_prep) from_54/IN (l_pobj) trials_61/NNS (l_nmod) osteoarthritis_57/NN
C406224_D010003 NONE valdecoxib_24/NN (r_compound) doses_25/NNS (r_conj) treatment_5/NN (r_nsubjpass) associated_28/VBN (l_prep) with_29/IN (l_pobj) incidence_32/NN (l_prep) of_33/IN (l_pobj) events_35/NNS (l_amod) relative_36/JJ (l_prep) to_37/IN (l_pobj) NSAIDs_39/NNPS (l_prep) in_42/IN (l_pobj) patients_47/NNS (l_nmod) osteoarthritis_43/NN
C406224_D013927 NONE valdecoxib_6/NNS (l_prep) versus_7/IN (l_pobj) agents_10/NNS (l_conj) placebo_12/NN (l_prep) on_13/IN (l_pobj) events_16/NNS (l_amod) thrombotic_15/JJ
C406224_D013927 NONE valdecoxib_23/NNS (r_dobj) analyzing_21/VBG (r_pcomp) by_20/IN (r_prep) determined_19/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) events_5/NNS (l_amod) thrombotic_4/JJ
C406224_D013927 NONE valdecoxib_23/NNS (r_dobj) analyzing_21/VBG (r_pcomp) by_20/IN (r_prep) determined_19/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) events_5/NNS (l_appos) thrombotic_16/JJ
C406224_D013927 NONE valdecoxib_12/NNS (r_pobj) for_11/IN (r_prep) similar_10/JJ (r_acomp) were_9/VBD (l_nsubj) incidences_5/NNS (l_prep) of_6/IN (l_pobj) events_8/NNS (l_amod) thrombotic_7/JJ
C406224_D013927 NONE valdecoxib_11/NN (r_compound) dose_12/NN (r_pobj) for_9/IN (r_prep) similar_8/JJ (r_acomp) was_6/VBD (l_nsubj) risk_1/NN (l_prep) of_2/IN (l_pobj) events_5/NNS (l_amod) thrombotic_4/JJ
C406224_D013927 NONE valdecoxib_23/NN (r_conj) placebo_15/NN (r_appos) nonusers_11/NNS (r_pobj) than_10/IN (r_prep) users_9/NNS (r_pobj) of_7/IN (r_prep) users_6/NNS (r_pobj) for_5/IN (r_prep) was_2/VBD (l_nsubj) risk_1/NN (l_amod) Thrombotic_0/JJ
C406224_D013927 NONE valdecoxib_24/NN (r_compound) doses_25/NNS (r_conj) treatment_5/NN (r_nsubjpass) associated_28/VBN (l_prep) with_29/IN (l_pobj) incidence_32/NN (l_prep) of_33/IN (l_pobj) events_35/NNS (l_amod) thrombotic_34/JJ
D004008_D010003 NONE diclofenac_35/NN (r_nmod) bid_38/NN (r_appos) NSAID_33/NNP (l_npadvmod) ibuprofen_40/VBD (l_conj) data_53/NNS (l_prep) from_54/IN (l_pobj) trials_61/NNS (l_nmod) osteoarthritis_57/NN
D007052_D010003 NONE ibuprofen_40/VBD (l_conj) data_53/NNS (l_prep) from_54/IN (l_pobj) trials_61/NNS (l_nmod) osteoarthritis_57/NN
D007052_D001172 NONE ibuprofen_40/VBD (l_conj) data_53/NNS (l_prep) from_54/IN (l_pobj) trials_61/NNS (l_compound) arthritis_60/NN
D009288_D001172 NONE naproxen_46/NN (r_conj) ibuprofen_40/VBD (l_conj) data_53/NNS (l_prep) from_54/IN (l_pobj) trials_61/NNS (l_compound) arthritis_60/NN
C406224_D001168 NONE valdecoxib_6/NNS (l_prep) versus_7/IN (l_pobj) agents_10/NNS (l_conj) placebo_12/NN (l_prep) on_13/IN (l_pobj) events_16/NNS (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) arthritis_20/NN
D004008_D001172 NONE diclofenac_35/NN (r_nmod) bid_38/NN (r_appos) NSAID_33/NNP (l_npadvmod) ibuprofen_40/VBD (l_conj) data_53/NNS (l_prep) from_54/IN (l_pobj) trials_61/NNS (l_compound) arthritis_60/NN
D009288_D010003 NONE naproxen_46/NN (r_conj) ibuprofen_40/VBD (l_conj) data_53/NNS (l_prep) from_54/IN (l_pobj) trials_61/NNS (l_nmod) osteoarthritis_57/NN
D004008_D013927 NONE diclofenac_35/NN (r_nmod) bid_38/NN (r_appos) NSAID_33/NNP (r_appos) determined_19/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) events_5/NNS (l_amod) thrombotic_4/JJ
D004008_D013927 NONE diclofenac_35/NN (r_nmod) bid_38/NN (r_appos) NSAID_33/NNP (r_appos) determined_19/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) events_5/NNS (l_appos) thrombotic_16/JJ
D001241_D013927 CID aspirin_8/NN (r_compound) users_9/NNS (r_pobj) of_7/IN (r_prep) users_6/NNS (r_pobj) for_5/IN (r_prep) was_2/VBD (l_nsubj) risk_1/NN (l_amod) Thrombotic_0/JJ
D001241_D013927 CID aspirin_13/NN (r_pobj) of_12/IN (r_prep) nonusers_11/NNS (r_pobj) than_10/IN (r_prep) users_9/NNS (r_pobj) of_7/IN (r_prep) users_6/NNS (r_pobj) for_5/IN (r_prep) was_2/VBD (l_nsubj) risk_1/NN (l_amod) Thrombotic_0/JJ
6942642
D006852_C563897 NONE hydrochlorothiazide_18/NN (r_pobj) with_17/IN (r_prep) hypertension_16/NN
D006852_C563897 NONE HCTC_20/NNP (r_appos) hydrochlorothiazide_18/NN (r_pobj) with_17/IN (r_prep) hypertension_16/NN
D049971_D001145 NONE Thiazide_0/NNP (r_compound) diuretics_1/NNS (l_conj) hypokalemia_3/JJ (l_conj) arrhythmias_6/NNS
D011188_D007008 NONE potassium_13/NN (r_pobj) of_11/IN (r_prep) depletion_10/NN (r_conj) hypokalemia_8/NN
D049971_D007008 NONE Thiazide_0/NNP (r_compound) diuretics_1/NNS (l_conj) hypokalemia_3/JJ
D049971_D007008 NONE thiazide_9/NN (r_compound) therapy_10/NN (r_pobj) of_7/IN (r_prep) consequence_6/NN (r_attr) is_1/VBZ (l_nsubj) Hypokalemia_0/NNP
D049971_D007008 NONE thiazide_5/JJ (r_csubj) cause_7/VBP (l_dobj) hypokalemia_8/NN
3769769
D014282_D012559 NONE hydrochloride_12/NN (r_dobj) trihexyphenidyl_11/JJ (r_conj) treated_5/VBN (l_nsubjpass) patient_3/NN (l_amod) schizophrenic_2/JJ
D014282_D001919 CID hydrochloride_4/NN (r_pobj) due_1/JJ (r_amod) Bradycardia_0/NNS
1564236
D004176_D023921 NONE dipyridamole_1/NN (r_npadvmod) induced_3/VBN (r_amod) hyperemia_4/NN (r_pobj) During_0/IN (r_prep) had_16/VBD (l_nsubj) 12_6/CD (l_prep) of_7/IN (l_pobj) dogs_10/NNS (l_prep) with_11/IN (l_pobj) stenosis_15/NN
D004176_D006940 CID dipyridamole_1/NN (r_npadvmod) induced_3/VBN (r_amod) hyperemia_4/NN
D004176_D006940 CID dipyridamole_24/NN (r_npadvmod) induced_26/VBN (r_amod) hyperemia_27/NN
D004176_D006940 CID dipyridamole_11/NN (r_npadvmod) induced_13/VBN (r_amod) hyperemia_14/NN
D013793_D023921 NONE thallium-201_18/JJ (r_amod) tomography_23/NN (r_pobj) with_17/IN (r_prep) correlation_16/NN (r_appos) observed_4/VBN (l_prep) with_5/IN (l_pobj) contrast_7/NN (l_prep) to_9/IN (l_pobj) severity_11/NN (l_prep) of_12/IN (l_pobj) stenosis_14/NN
17574447
D010634_D056487 NONE PB_15/NNP (r_npadvmod) related_17/VBN (r_amod) dysfunction_22/NN
D010634_D004827 NONE PB_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) history_10/NN (l_prep) of_11/IN (l_pobj) epilepsy_12/NN
D010634_D006323 NONE PB_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) history_10/NN (r_pobj) with_7/IN (r_prep) report_2/VBP (l_appos) one_20/CD (l_prep) as_21/IN (l_pobj) consequence_22/NN (l_prep) of_23/IN (l_pobj) arrest_25/NN
D010634_-1 NONE phenobarbital_8/JJ (r_amod) therapy_9/NN (r_pobj) to_4/IN (r_prep) related_3/VBN (r_acl) Hepatonecrosis_0/NNP
D010634_D008107 CID Phenobarbital_0/NNP (r_nsubj) has_4/VBZ (l_conj) believed_14/VBN (l_ccomp) indicate_26/VB (l_conj) predict_28/VB (l_dobj) development_30/NN (l_prep) of_31/IN (l_pobj) disease_35/NN
D010634_D008107 CID PB_2/NNP (r_appos) Phenobarbital_0/NNP (r_nsubj) has_4/VBZ (l_conj) believed_14/VBN (l_ccomp) indicate_26/VB (l_conj) predict_28/VB (l_dobj) development_30/NN (l_prep) of_31/IN (l_pobj) disease_35/NN
D010634_D008107 CID PB_16/NNP (r_npadvmod) related_18/VBN (r_amod) increases_19/NNS (r_nsubj) indicate_26/VB (l_conj) predict_28/VB (l_dobj) development_30/NN (l_prep) of_31/IN (l_pobj) disease_35/NN
D010634_D008107 CID PB_4/NNP (r_nsubjpass) associated_7/VBN (l_prep) with_8/IN (l_pobj) damage_11/NN
D010634_D002761 CID phenobarbital_8/JJ (r_amod) therapy_9/NN (r_pobj) to_4/IN (r_prep) related_3/VBN (r_acl) Hepatonecrosis_0/NNP (l_conj) cholangitis_2/NN
D010634_D001996 NONE PB_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) history_10/NN (r_pobj) with_7/IN (r_prep) report_2/VBP (l_appos) one_20/CD (l_appos) other_28/JJ (l_prep) of_29/IN (l_pobj) bronchopneumonia_31/NN
1535072
D002997_D020018 CID clomipramine_17/NN (r_pobj) of_16/IN (r_prep) effects_15/NNS
D015016_D007172 NONE yohimbine_6/NN (r_nsubj) facilitates_7/VBZ (l_conj) be_12/VB (l_acomp) helpful_13/JJ (l_prep) in_14/IN (l_pobj) treatment_16/NN (l_prep) of_17/IN (l_pobj) impotence_19/NN
D015016_D009771 NONE yohimbine_28/NN (r_dobj) given_27/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_2/IN (l_pobj) disorder_6/NN
D015016_D014256 NONE yohimbine_28/NN (r_dobj) given_27/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_2/IN (l_pobj) disorder_6/NN (l_conj) trichotillomania_8/NN
D012701_D019964 NONE serotonin_23/NN (r_compound) blockers_25/NNS (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) after_20/IN (r_prep) suffered_16/VBD (r_relcl) disorders_14/NNS
D012701_D014256 NONE serotonin_23/NN (r_compound) blockers_25/NNS (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) after_20/IN (r_prep) suffered_16/VBD (r_relcl) disorders_14/NNS (r_conj) anxiety_10/NN (r_conj) trichotillomania_8/NN
D015016_D001008 NONE yohimbine_28/NN (r_dobj) given_27/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_2/IN (l_pobj) disorder_6/NN (l_conj) trichotillomania_8/NN (l_conj) anxiety_10/NN
D015016_D001008 NONE yohimbine_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubj) included_4/VBD (l_dobj) sweating_6/NN (l_conj) anxiety_9/NN
D015016_D020018 NONE Yohimbine_0/NNP (r_compound) treatment_1/NN (l_prep) of_2/IN (l_pobj) effects_5/NNS
D015016_D020018 NONE yohimbine_6/NN (r_nsubjpass) used_9/VBN (l_xcomp) treat_11/VB (l_dobj) effects_15/NNS
D015016_D020018 NONE yohimbine_3/NN (r_dobj) evaluated_2/VBD (l_prep) as_4/IN (l_pobj) treatment_6/NN (l_prep) for_7/IN (l_pobj) effects_11/NNS
D015016_D020018 NONE yohimbine_28/NN (r_dobj) given_27/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_2/IN (l_pobj) disorder_6/NN (l_conj) trichotillomania_8/NN (l_conj) anxiety_10/NN (l_conj) disorders_14/NNS (l_relcl) suffered_16/VBD (l_dobj) effects_19/NNS
D015016_D020018 NONE yohimbine_7/NN (r_nsubj) be_9/VB (l_attr) treatment_12/NN (l_prep) for_13/IN (l_pobj) effects_17/NNS
D012701_D020018 NONE serotonin_8/NN (r_compound) blockers_10/NNS (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) treatment_1/NN (l_prep) of_2/IN (l_pobj) effects_5/NNS
D012701_D020018 NONE serotonin_14/NN (r_compound) blockers_16/NNS (r_pobj) by_13/IN (r_agent) caused_12/VBN (r_acl) effects_11/NNS
D012701_D020018 NONE serotonin_23/NN (r_compound) blockers_25/NNS (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) after_20/IN (r_prep) suffered_16/VBD (l_dobj) effects_19/NNS
D012701_D020018 NONE serotonin_20/NN (r_compound) blockers_22/NNS (r_pobj) by_19/IN (r_agent) caused_18/VBN (r_acl) effects_17/NNS
D012701_D001008 NONE serotonin_23/NN (r_compound) blockers_25/NNS (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) after_20/IN (r_prep) suffered_16/VBD (r_relcl) disorders_14/NNS (r_conj) anxiety_10/NN
D015016_D019964 NONE yohimbine_28/NN (r_dobj) given_27/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_2/IN (l_pobj) disorder_6/NN (l_conj) trichotillomania_8/NN (l_conj) anxiety_10/NN (l_conj) disorders_14/NNS
D012701_D009771 NONE serotonin_23/NN (r_compound) blockers_25/NNS (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) after_20/IN (r_prep) suffered_16/VBD (r_relcl) disorders_14/NNS (r_conj) anxiety_10/NN (r_conj) trichotillomania_8/NN (r_conj) disorder_6/NN
11230490
D004317_D064420 NONE Myocet_26/NNP (r_nmod) M_28/NNP (r_pobj) of_25/IN (r_prep) m(2_23/NN (r_dobj) receive_18/VB (l_npadvmod) weeks_53/NNS (l_prep) until_54/IN (l_pobj) progression_56/NN (l_conj) toxicity_59/NN
D004317_D064420 NONE doxorubicin_32/NN (r_dobj) receive_18/VB (l_npadvmod) weeks_53/NNS (l_prep) until_54/IN (l_pobj) progression_56/NN (l_conj) toxicity_59/NN
D004317_D066126 NONE doxorubicin_10/NN (r_pobj) of_6/IN (r_prep) efficacy_5/NN (r_conj) cardiotoxicity_1/NN
D004317_D066126 NONE doxorubicin_16/NN (r_pobj) with_14/IN (r_prep) compared_13/VBN (r_prep) cardiotoxicity_1/NN
D004317_D066126 NONE Myocet_3/NNP (r_nmod) doxorubicin_8/NN (r_dobj) determine_1/VB (r_advcl) reduces_26/VBZ (l_dobj) cardiotoxicity_28/NN
D004317_D066126 NONE doxorubicin_8/NN (r_dobj) determine_1/VB (r_advcl) reduces_26/VBZ (l_dobj) cardiotoxicity_28/NN
D004317_D066126 NONE doxorubicin_27/NN (r_compound) cardiotoxicity_28/NN
D004317_D066126 NONE Myocet_0/NNP (r_nsubj) improves_1/VBZ (l_prep) by_7/IN (l_pcomp) reducing_9/VBG (l_dobj) cardiotoxicity_10/NN
D004317_D066126 NONE doxorubicin_6/NN (r_pobj) of_5/IN (r_prep) index_4/NN (r_dobj) improves_1/VBZ (l_prep) by_7/IN (l_pcomp) reducing_9/VBG (l_dobj) cardiotoxicity_10/NN
D003520_D001943 NONE cyclophosphamide_12/NN (r_conj) doxorubicin_10/NN (r_pobj) of_6/IN (r_prep) efficacy_5/NN (r_conj) cardiotoxicity_1/NN (l_prep) compared_13/VBN (l_prep) in_19/IN (l_pobj) trial_24/NN (l_prep) of_25/IN (l_pobj) cancer_28/NN
D003520_D001943 NONE cyclophosphamide_18/NN (r_conj) doxorubicin_16/NN (r_pobj) with_14/IN (r_prep) compared_13/VBN (l_prep) in_19/IN (l_pobj) trial_24/NN (l_prep) of_25/IN (l_pobj) cancer_28/NN
D003520_D001943 NONE cyclophosphamide_24/NN (r_pobj) with_23/IN (r_prep) combination_22/NN (r_pobj) in_21/IN (r_prep) Company_12/NNP (r_nsubj) reduces_26/VBZ (l_advcl) providing_30/VBG (l_prep) in_34/IN (l_pobj) treatment_38/NN (l_prep) of_39/IN (l_pobj) cancer_42/NN
D003520_D001943 NONE cyclophosphamide_24/NN (r_pobj) with_23/IN (r_prep) combination_22/NN (r_pobj) in_21/IN (r_prep) Company_12/NNP (r_nsubj) reduces_26/VBZ (l_advcl) providing_30/VBG (l_prep) in_34/IN (l_pobj) treatment_38/NN (l_prep) of_39/IN (l_pobj) cancer_42/NN (l_appos) MBC_44/NNP
D003520_D001943 NONE cyclophosphamide_46/NN (r_pobj) of_45/IN (r_prep) combination_38/NN (r_pobj) in_37/IN (r_prep) receive_18/VB (r_xcomp) randomized_16/VBN (l_nsubjpass) patients_5/NNS (l_prep) with_6/IN (l_pobj) MBC_7/NNP
D003520_D001943 NONE cyclophosphamide_26/NN (r_pobj) with_25/IN (r_prep) combination_24/NN (r_pobj) in_23/IN (r_prep) used_22/VBN (l_prep) as_27/IN (l_pobj) therapy_31/NN (l_prep) for_32/IN (l_pobj) MBC_33/NNP
D004317_D001943 NONE doxorubicin_10/NN (r_pobj) of_6/IN (r_prep) efficacy_5/NN (r_conj) cardiotoxicity_1/NN (l_prep) compared_13/VBN (l_prep) in_19/IN (l_pobj) trial_24/NN (l_prep) of_25/IN (l_pobj) cancer_28/NN
D004317_D001943 NONE doxorubicin_16/NN (r_pobj) with_14/IN (r_prep) compared_13/VBN (l_prep) in_19/IN (l_pobj) trial_24/NN (l_prep) of_25/IN (l_pobj) cancer_28/NN
D004317_D001943 NONE Myocet_3/NNP (r_nmod) doxorubicin_8/NN (r_dobj) determine_1/VB (r_advcl) reduces_26/VBZ (l_advcl) providing_30/VBG (l_prep) in_34/IN (l_pobj) treatment_38/NN (l_prep) of_39/IN (l_pobj) cancer_42/NN
D004317_D001943 NONE Myocet_3/NNP (r_nmod) doxorubicin_8/NN (r_dobj) determine_1/VB (r_advcl) reduces_26/VBZ (l_advcl) providing_30/VBG (l_prep) in_34/IN (l_pobj) treatment_38/NN (l_prep) of_39/IN (l_pobj) cancer_42/NN (l_appos) MBC_44/NNP
D004317_D001943 NONE doxorubicin_8/NN (r_dobj) determine_1/VB (r_advcl) reduces_26/VBZ (l_advcl) providing_30/VBG (l_prep) in_34/IN (l_pobj) treatment_38/NN (l_prep) of_39/IN (l_pobj) cancer_42/NN
D004317_D001943 NONE doxorubicin_8/NN (r_dobj) determine_1/VB (r_advcl) reduces_26/VBZ (l_advcl) providing_30/VBG (l_prep) in_34/IN (l_pobj) treatment_38/NN (l_prep) of_39/IN (l_pobj) cancer_42/NN (l_appos) MBC_44/NNP
D004317_D001943 NONE doxorubicin_27/NN (r_compound) cardiotoxicity_28/NN (r_dobj) reduces_26/VBZ (l_advcl) providing_30/VBG (l_prep) in_34/IN (l_pobj) treatment_38/NN (l_prep) of_39/IN (l_pobj) cancer_42/NN
D004317_D001943 NONE doxorubicin_27/NN (r_compound) cardiotoxicity_28/NN (r_dobj) reduces_26/VBZ (l_advcl) providing_30/VBG (l_prep) in_34/IN (l_pobj) treatment_38/NN (l_prep) of_39/IN (l_pobj) cancer_42/NN (l_appos) MBC_44/NNP
D004317_D001943 NONE Myocet_26/NNP (r_nmod) M_28/NNP (r_pobj) of_25/IN (r_prep) m(2_23/NN (r_dobj) receive_18/VB (r_xcomp) randomized_16/VBN (l_nsubjpass) patients_5/NNS (l_prep) with_6/IN (l_pobj) MBC_7/NNP
D004317_D001943 NONE doxorubicin_32/NN (r_dobj) receive_18/VB (r_xcomp) randomized_16/VBN (l_nsubjpass) patients_5/NNS (l_prep) with_6/IN (l_pobj) MBC_7/NNP
D004317_D001943 NONE Myocet_0/NNP (r_nsubj) improves_1/VBZ (l_conj) provides_16/VBZ (l_advcl) used_22/VBN (l_prep) as_27/IN (l_pobj) therapy_31/NN (l_prep) for_32/IN (l_pobj) MBC_33/NNP
D004317_D001943 NONE doxorubicin_6/NN (r_pobj) of_5/IN (r_prep) index_4/NN (r_dobj) improves_1/VBZ (l_conj) provides_16/VBZ (l_advcl) used_22/VBN (l_prep) as_27/IN (l_pobj) therapy_31/NN (l_prep) for_32/IN (l_pobj) MBC_33/NNP
D003520_D009503 CID cyclophosphamide_26/NN (r_pobj) with_25/IN (r_prep) combination_24/NN (r_pobj) in_23/IN (r_prep) used_22/VBN (r_advcl) provides_16/VBZ (r_conj) improves_1/VBZ (l_dobj) neutropenia_14/NN
D003520_D066126 NONE cyclophosphamide_12/NN (r_conj) doxorubicin_10/NN (r_pobj) of_6/IN (r_prep) efficacy_5/NN (r_conj) cardiotoxicity_1/NN
D003520_D066126 NONE cyclophosphamide_18/NN (r_conj) doxorubicin_16/NN (r_pobj) with_14/IN (r_prep) compared_13/VBN (r_prep) cardiotoxicity_1/NN
D003520_D066126 NONE cyclophosphamide_24/NN (r_pobj) with_23/IN (r_prep) combination_22/NN (r_pobj) in_21/IN (r_prep) Company_12/NNP (r_nsubj) reduces_26/VBZ (l_dobj) cardiotoxicity_28/NN
D003520_D066126 NONE cyclophosphamide_26/NN (r_pobj) with_25/IN (r_prep) combination_24/NN (r_pobj) in_23/IN (r_prep) used_22/VBN (r_advcl) provides_16/VBZ (r_conj) improves_1/VBZ (l_prep) by_7/IN (l_pcomp) reducing_9/VBG (l_dobj) cardiotoxicity_10/NN
D004317_D009503 CID Myocet_0/NNP (r_nsubj) improves_1/VBZ (l_dobj) neutropenia_14/NN
D004317_D009503 CID doxorubicin_6/NN (r_pobj) of_5/IN (r_prep) index_4/NN (r_dobj) improves_1/VBZ (l_dobj) neutropenia_14/NN
D003520_D064420 NONE cyclophosphamide_46/NN (r_pobj) of_45/IN (r_prep) combination_38/NN (r_pobj) in_37/IN (r_prep) receive_18/VB (l_npadvmod) weeks_53/NNS (l_prep) until_54/IN (l_pobj) progression_56/NN (l_conj) toxicity_59/NN
6381653
D007980_D010302 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) dyskinesia_3/NN (l_prep) in_7/IN (l_pobj) cases_9/NNS (l_prep) of_10/IN (l_pobj) Parkinsonism_11/NNP
D007980_D010302 NONE levodopa_2/NN (r_npadvmod) induced_4/VBN (r_amod) dyskinesias_5/NNS (r_pobj) of_1/IN (r_prep) Control_0/NN (l_prep) in_9/IN (l_pobj) course_11/NN (l_prep) of_12/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) Parkinsonism_16/NNP
D007980_D020821 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) dyskinesia_3/NN (l_prep) in_7/IN (l_pobj) cases_9/NNS (l_prep) of_10/IN (l_pobj) Parkinsonism_11/NNP (l_relcl) was_14/VBD (l_attr) choreic_15/JJ (l_conj) ballistic_17/JJ (l_conj) dystonic_19/JJ
D007980_D013786 NONE levodopa_2/NN (r_npadvmod) induced_4/VBN (r_amod) dyskinesias_5/NNS (l_prep) by_6/IN (l_pobj) lesions_8/NNS
D007980_D004409 CID Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesia_3/JJ
D007980_D004409 CID Levodopa_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) dyskinesia_3/NN
D007980_D004409 CID levodopa_2/NN (r_npadvmod) induced_4/VBN (r_amod) dyskinesias_5/NNS
11861791
D018943_D066126 NONE anthracycline_21/NN (r_amod) antibiotic_22/NN (r_appos) doxorubicin_12/NN (r_pobj) of_11/IN (r_prep) cardiotoxicity_10/NN
D004317_D005117 NONE DOX_16/NNP (r_compound) treatment_17/NN (r_pobj) with_14/IN (r_prep) associated_13/VBN (r_acl) complications_12/NNS
C434926_D006331 NONE PJ34_19/NNP (r_pobj) with_14/IN (r_prep) inhibition_13/NN (r_conj) deletion_10/NN (r_pobj) by_8/IN (r_prep) Using_0/VBG (r_advcl) demonstrate_23/VBP (l_dobj) role_25/NN (l_prep) in_28/IN (l_pobj) development_30/NN (l_prep) of_31/IN (l_pobj) dysfunction_33/NN
C434926_D006331 NONE PJ34_3/NNP (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubj) improved_5/VBD (l_dobj) dysfunction_7/NN
D004317_D066126 NONE doxorubicin_12/NN (r_pobj) of_11/IN (r_prep) cardiotoxicity_10/NN
D004317_D066126 NONE DOX_14/NNP (r_appos) doxorubicin_12/NN (r_pobj) of_11/IN (r_prep) cardiotoxicity_10/NN
D004317_D066126 NONE DOX_13/NNP (r_npadvmod) induced_15/VBN (r_amod) cardiotoxicity_16/NN
D004317_D066126 NONE DOX_9/NNP (r_pobj) of_8/IN (r_prep) cardiotoxicity_7/NN
D004317_D006333 CID doxorubicin_11/NN (r_npadvmod) induced_13/VBN (r_amod) failure_15/NN
D011064_D006333 NONE )_5/-RRB- (r_punct) polymerase_6/NN (r_pobj) of_1/IN (r_prep) Activation_0/NN (r_nsubj) contributes_7/VBZ (l_prep) to_8/IN (l_pobj) development_9/NN (l_prep) of_10/IN (l_pobj) failure_15/NN
D004317_D006331 NONE DOX_36/NNP (r_pobj) by_35/IN (r_agent) induced_34/VBN (r_acl) dysfunction_33/NN
9672273
D013629_D016889 NONE Tamoxifen_0/NNP (r_nsubj) is_1/VBZ (l_advcl) associated_15/VBN (l_prep) with_16/IN (l_pobj) development_18/NN (l_prep) of_19/IN (l_pobj) cancer_21/NN
D013629_D001943 NONE tamoxifen_5/NN (r_pobj) with_4/IN (r_prep) Prevention_0/NN (l_prep) of_1/IN (l_pobj) cancer_3/NN
D013629_D001943 NONE Tamoxifen_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_5/NN (l_prep) in_6/IN (l_pobj) cancer_8/NN
D013629_D001943 NONE tamoxifen_18/NN (r_pobj) of_17/IN (r_prep) trial_16/NN (l_relcl) have_29/VB (l_dobj) cancer_31/NN
D013629_D001943 NONE tamoxifen_17/NN (r_nmod) arms_21/NNS (r_conj) placebo_11/NN (r_pobj) between_9/IN (r_prep) frequency_8/NN (l_compound) cancer_7/NN
D013629_D001943 NONE tamoxifen_12/NN (r_dobj) receiving_11/VBG (r_acl) women_10/NNS (r_pobj) among_9/IN (r_prep) reduction_5/NN (l_prep) of_6/IN (l_pobj) cancer_8/NN
D013629_D001943 NONE tamoxifen_12/NN (r_dobj) receiving_11/VBG (r_acl) women_10/NNS (r_pobj) among_9/IN (r_prep) reduction_5/NN (r_attr) is_1/VBZ (r_ccomp) found_36/VBD (l_dobj) cases_38/NNS (l_prep) of_39/IN (l_pobj) cancer_41/NN
D013629_D001943 NONE tamoxifen_51/NN (r_pobj) to_50/IN (r_prep) allocated_49/VBN (r_acl) women_48/NNS (r_pobj) among_46/IN (r_prep) case_45/NN (r_pobj) with_43/IN (r_prep) compared_42/VBN (r_prep) found_36/VBD (l_ccomp) is_1/VBZ (l_attr) reduction_5/NN (l_prep) of_6/IN (l_pobj) cancer_8/NN
D013629_D001943 NONE tamoxifen_51/NN (r_pobj) to_50/IN (r_prep) allocated_49/VBN (r_acl) women_48/NNS (r_pobj) among_46/IN (r_prep) case_45/NN (r_pobj) with_43/IN (r_prep) compared_42/VBN (r_prep) found_36/VBD (l_dobj) cases_38/NNS (l_prep) of_39/IN (l_pobj) cancer_41/NN
D013629_D001943 NONE tamoxifen_29/NN (r_pobj) of_28/IN (r_prep) effects_27/NNS (r_nsubj) are_30/VBP (l_prep) in_8/IN (l_prep) at_13/IN (l_pobj) risk_19/NN (l_prep) of_20/IN (l_pobj) cancer_22/NN
D013629_D014652 CID tamoxifen_20/NN (r_pobj) on_19/IN (r_prep) women_18/NNS (r_pobj) among_17/IN (r_prep) events_14/NNS
D013629_D015228 CID tamoxifen_20/NN (r_pobj) on_19/IN (r_prep) women_18/NNS (r_pobj) among_17/IN (r_prep) events_14/NNS (l_conj) hypertriglyceridaemia_16/NN
9022662
D001569_D002819 NONE benzodiazepines_10/NNS (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_conj) decontamination_4/NN (r_dobj) received_2/VBD (l_prep) in_11/IN (l_pobj) attempt_13/NN (l_acl) control_15/VB (l_dobj) movements_18/NNS (l_compound) choreoathetoid_17/JJ
D001569_D001264 NONE benzodiazepines_10/NNS (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_conj) decontamination_4/NN (r_dobj) received_2/VBD (l_prep) in_11/IN (l_pobj) attempt_13/NN (l_acl) control_15/VB (l_dobj) movements_18/NNS (l_compound) choreoathetoid_17/JJ
D010389_D001289 NONE Pemoline_0/NNP (r_nsubj) is_1/VBZ (l_attr) derivative_4/NN (l_relcl) is_6/VBZ (l_conj) used_12/VBN (l_prep) in_13/IN (l_pobj) treatment_15/NN (l_prep) of_16/IN (l_pobj) disorder_19/NN
D010389_D062787 CID pemoline_12/NN (r_compound) overdose_13/NN
D008774_D001289 NONE methylphenidate_14/NN (r_pobj) with_13/IN (r_prep) treated_12/VBN (r_acl) disorder_10/NN
D010389_D009069 NONE Pemoline_0/NNP (r_nsubjpass) associated_5/VBN (l_prep) as_9/IN (l_pobj) cause_11/NN (l_prep) of_12/IN (l_pobj) disorders_15/NNS
D010389_D009069 NONE Pemoline_0/NN (r_nmod) disorder_3/NN
D010389_D002819 CID Pemoline_0/NNP (r_nsubj) induced_1/VBD (l_dobj) choreoathetosis_3/NN
D010389_D002819 CID pemoline_9/NN (l_relcl) experienced_11/VBD (l_dobj) choreoathetosis_13/NN
D010389_D002819 CID pemoline_12/NN (r_compound) overdose_13/NN (r_pobj) after_11/IN (r_prep) presenting_10/VBG (r_acl) patients_9/NNS (r_pobj) in_8/IN (r_prep) considered_7/VBN (l_nsubjpass) possibility_1/NN (l_prep) of_2/IN (l_pobj) movements_4/NNS (l_compound) choreoathetoid_3/JJ
C064210_D001289 NONE oxazolidine_3/JJ (r_compound) derivative_4/NN (l_relcl) is_6/VBZ (l_conj) used_12/VBN (l_prep) in_13/IN (l_pobj) treatment_15/NN (l_prep) of_16/IN (l_pobj) disorder_19/NN
D010389_D001264 CID Pemoline_0/NNP (r_nsubj) induced_1/VBD (l_dobj) choreoathetosis_3/NN
D010389_D001264 CID pemoline_9/NN (l_relcl) experienced_11/VBD (l_dobj) choreoathetosis_13/NN
D010389_D001264 CID pemoline_12/NN (r_compound) overdose_13/NN (r_pobj) after_11/IN (r_prep) presenting_10/VBG (r_acl) patients_9/NNS (r_pobj) in_8/IN (r_prep) considered_7/VBN (l_nsubjpass) possibility_1/NN (l_prep) of_2/IN (l_pobj) movements_4/NNS (l_compound) choreoathetoid_3/JJ
D000662_D001289 NONE amphetamines_10/NNS (r_pobj) from_9/IN (r_prep) different_8/JJ (r_acomp) is_6/VBZ (l_conj) used_12/VBN (l_prep) in_13/IN (l_pobj) treatment_15/NN (l_prep) of_16/IN (l_pobj) disorder_19/NN
9061311
D013481_D017114 NONE superoxide_1/NN (r_nmod) production_5/NN (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) failure_11/NN
D013481_D017114 NONE superoxide_2/NN (r_amod) production_6/NN (r_pobj) in_1/IN (r_prep) Defects_0/NNS (r_nsubjpass) implicated_9/VBN (l_prep) in_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) infections_16/NNS (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) failure_22/NN
D013481_D017114 NONE superoxide_2/NN (r_amod) production_6/NN (r_pobj) in_1/IN (r_prep) Defects_0/NNS (r_nsubjpass) implicated_9/VBN (l_prep) in_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) infections_16/NNS (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) failure_22/NN (l_appos) ALF_24/NNP
D013481_D017114 NONE Superoxide_0/NN (l_prep) by_5/IN (l_pobj) neutrophils_7/NNS (l_compound) ALF_6/NNP
D013481_D017114 NONE Superoxide_0/NN (r_nsubj) stimulated_8/VBN (l_dobj) opsonized_11/VBN (l_prep) with_12/IN (l_pobj) serum_14/NN (l_compound) ALF_13/NNP
D013481_D017114 NONE Superoxide_0/NN (l_prep) in_5/IN (l_pobj) neutrophils_6/NNS (l_acl) stimulated_7/VBN (l_prep) from_19/IN (l_pobj) patients_24/NNS (l_compound) ALF_23/NNP
D013481_D001424 NONE superoxide_2/NN (r_amod) production_6/NN (r_pobj) in_1/IN (r_prep) Defects_0/NNS (r_nsubjpass) implicated_9/VBN (l_prep) in_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) infections_16/NNS
D000082_D017114 CID paracetamol_14/JJ (r_compound) overdose_15/NN (r_pobj) due_12/IN (r_amod) production_7/NN (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) ALF_11/NNP
D000082_D017114 CID paracetamol_10/JJ (r_compound) overdose_11/NN (r_pobj) due_8/IN (r_prep) demonstrate_2/VBP (l_dobj) defect_5/NN (l_prep) in_6/IN (l_pobj) ALF_7/NNP
D010100_D062787 NONE oxygen_5/NN (r_nmod) production_7/NN (l_amod) due_12/IN (l_pobj) overdose_15/NN
D010100_D017114 NONE oxygen_5/NN (r_nmod) production_7/NN (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) ALF_11/NNP
D009240_D017114 NONE phenylalanine_15/NN (r_nmod) fMLP_17/NN (r_pobj) with_8/IN (r_prep) stimulated_7/VBN (l_prep) from_19/IN (l_pobj) patients_24/NNS (l_compound) ALF_23/NNP
D009240_D017114 NONE fMLP_17/NN (r_pobj) with_8/IN (r_prep) stimulated_7/VBN (l_prep) from_19/IN (l_pobj) patients_24/NNS (l_compound) ALF_23/NNP
D006861_D017114 NONE peroxide_4/NN (r_conj) superoxide_1/NN (r_nmod) production_5/NN (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) failure_11/NN
D006861_D017114 NONE peroxide_5/NN (r_compound) production_6/NN (r_pobj) in_1/IN (r_prep) Defects_0/NNS (r_nsubjpass) implicated_9/VBN (l_prep) in_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) infections_16/NNS (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) failure_22/NN
D006861_D017114 NONE peroxide_5/NN (r_compound) production_6/NN (r_pobj) in_1/IN (r_prep) Defects_0/NNS (r_nsubjpass) implicated_9/VBN (l_prep) in_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) infections_16/NNS (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) failure_22/NN (l_appos) ALF_24/NNP
D006861_D017114 NONE peroxide_3/NN (r_compound) production_4/NN (r_conj) Superoxide_0/NN (l_prep) by_5/IN (l_pobj) neutrophils_7/NNS (l_compound) ALF_6/NNP
D006861_D017114 NONE peroxide_3/NN (r_compound) production_4/NN (r_conj) Superoxide_0/NN (r_nsubj) stimulated_8/VBN (l_dobj) opsonized_11/VBN (l_prep) with_12/IN (l_pobj) serum_14/NN (l_compound) ALF_13/NNP
D006861_D017114 NONE peroxide_3/NN (r_compound) production_4/NN (r_conj) Superoxide_0/NN (l_prep) in_5/IN (l_pobj) neutrophils_6/NNS (l_acl) stimulated_7/VBN (l_prep) from_19/IN (l_pobj) patients_24/NNS (l_compound) ALF_23/NNP
D000082_D062787 NONE paracetamol_14/JJ (r_compound) overdose_15/NN
D000082_D062787 NONE paracetamol_10/JJ (r_compound) overdose_11/NN
D006861_D001424 NONE peroxide_5/NN (r_compound) production_6/NN (r_pobj) in_1/IN (r_prep) Defects_0/NNS (r_nsubjpass) implicated_9/VBN (l_prep) in_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) infections_16/NNS
9121607
D010862_D013226 CID pilocarpine-_4/NN (r_nmod) seizures_11/NNS (r_pobj) against_3/IN (r_prep) protect_2/VBP (l_advcl) epilepticus_14/NN
D010862_D013226 CID pilocarpine_25/NN (r_pobj) against_24/IN (r_prep) protecting_23/VBG (r_pcomp) in_22/IN (r_prep) effective_21/JJ (r_acomp) were_19/VBD (l_npadvmod) values_39/NNS (l_amod) epilepticus_36/NN
D010862_D013226 CID pilocarpine-_11/NN (r_nmod) seizures_17/NNS (r_pobj) against_10/IN (r_prep) protecting_9/VBG (r_pcomp) in_8/IN (r_prep) effective_7/JJ (r_acomp) are_5/VBP (l_advcl) epilepticus_20/NN
D010862_D013226 CID pilocarpine-_11/NN (r_nmod) seizures_17/NNS (r_pobj) against_10/IN (r_prep) protecting_9/VBG (r_pcomp) in_8/IN (r_prep) effective_7/JJ (r_acomp) are_5/VBP (l_conj) be_26/VB (l_advmod) epilepticus_37/NN
D013256_D012640 NONE steroids_1/NNS (r_nsubj) protect_2/VBP (l_prep) against_3/IN (l_pobj) seizures_11/NNS
D013256_D012640 NONE Steroids_0/NNS (r_nsubj) were_19/VBD (l_parataxis) mg/kg_28/NNS (l_conj) s.c.)-induced_30/VBN (l_dobj) seizures_33/NNS
D013256_D012640 NONE steroids_3/NNS (r_nsubj) were_4/VBD (l_acomp) potent_7/JJ (l_advcl) clonazepam_11/NN (l_prep) in_12/IN (l_pcomp) protecting_13/VBG (l_prep) against_14/IN (l_pobj) seizures_16/NNS
D013256_D012640 NONE steroids_3/NNS (r_nsubj) were_4/VBD (r_advcl) had_26/VBD (l_dobj) values_32/NNS (l_appos) TD50_34/NNP (l_acl) divided_38/VBN (l_prep) for_41/IN (l_pobj) protection_43/NN (l_compound) seizure_42/NN
D013256_D012640 NONE steroids_18/NNS (r_nsubj) had_26/VBD (l_advcl) were_4/VBD (l_acomp) potent_7/JJ (l_advcl) clonazepam_11/NN (l_prep) in_12/IN (l_pcomp) protecting_13/VBG (l_prep) against_14/IN (l_pobj) seizures_16/NNS
D013256_D012640 NONE steroids_18/NNS (r_nsubj) had_26/VBD (l_dobj) values_32/NNS (l_appos) TD50_34/NNP (l_acl) divided_38/VBN (l_prep) for_41/IN (l_pobj) protection_43/NN (l_compound) seizure_42/NN
D013256_D012640 NONE steroids_52/NNS (r_nsubj) have_54/VB (r_ccomp) indicating_48/VBG (r_advcl) had_26/VBD (l_advcl) were_4/VBD (l_acomp) potent_7/JJ (l_advcl) clonazepam_11/NN (l_prep) in_12/IN (l_pcomp) protecting_13/VBG (l_prep) against_14/IN (l_pobj) seizures_16/NNS
D013256_D012640 NONE steroids_52/NNS (r_nsubj) have_54/VB (r_ccomp) indicating_48/VBG (r_advcl) had_26/VBD (l_dobj) values_32/NNS (l_appos) TD50_34/NNP (l_acl) divided_38/VBN (l_prep) for_41/IN (l_pobj) protection_43/NN (l_compound) seizure_42/NN
D013256_D012640 NONE Steroids_0/NNS (r_nsubj) produced_13/VBD (l_dobj) delay_18/NN (l_prep) in_19/IN (l_pobj) onset_21/NN (l_prep) of_22/IN (l_pobj) seizures_24/NNS
D013256_D012640 NONE Steroids_0/NNS (r_nsubj) produced_13/VBD (l_conj) protect_40/VB (l_prep) against_41/IN (l_pobj) seizures_43/NNS
D013256_D012640 NONE steroid_8/NN (r_pobj) of_6/IN (r_prep) dose_5/NN (r_nsubjpass) administered_10/VBN (r_advcl) hr_12/NN (r_nmod) protection_19/NN (l_prep) from_20/IN (l_pobj) seizures_27/NNS
D013256_D012640 NONE steroids_1/NNS (r_nsubj) caused_3/VBD (l_conj) protect_22/VB (l_prep) against_23/IN (l_pobj) seizures_25/NNS
D013256_D012640 NONE steroids_4/NNS (r_nsubj) are_5/VBP (l_acomp) effective_7/JJ (l_prep) in_8/IN (l_pcomp) protecting_9/VBG (l_prep) against_10/IN (l_pobj) seizures_17/NNS
D010862_D012640 CID pilocarpine-_4/NN (r_nmod) seizures_11/NNS
D010862_D012640 CID pilocarpine_25/NN (r_pobj) against_24/IN (r_prep) protecting_23/VBG (r_pcomp) in_22/IN (r_prep) effective_21/JJ (r_acomp) were_19/VBD (l_parataxis) mg/kg_28/NNS (l_conj) s.c.)-induced_30/VBN (l_dobj) seizures_33/NNS
D010862_D012640 CID pilocarpine_15/NN (r_amod) seizures_16/NNS
D010862_D012640 CID pilocarpine_15/NN (r_amod) seizures_16/NNS (r_pobj) against_14/IN (r_prep) protecting_13/VBG (r_pcomp) in_12/IN (r_prep) clonazepam_11/NN (r_advcl) potent_7/JJ (r_acomp) were_4/VBD (r_advcl) had_26/VBD (l_dobj) values_32/NNS (l_appos) TD50_34/NNP (l_acl) divided_38/VBN (l_prep) for_41/IN (l_pobj) protection_43/NN (l_compound) seizure_42/NN
D010862_D012640 CID pilocarpine-_11/NN (r_nmod) seizures_17/NNS
D007608_D013226 CID acid_7/NN (r_npadvmod) induced_9/VBN (r_amod) seizures_11/NNS (r_pobj) against_3/IN (r_prep) protect_2/VBP (l_advcl) epilepticus_14/NN
D007608_D013226 CID acid_23/NN (r_npadvmod) induced_25/VBN (r_amod) seizures_27/NNS (l_conj) epilepticus_30/NN
D007608_D013226 CID acid_14/NN (r_npadvmod) induced_16/VBN (r_amod) seizures_17/NNS (r_pobj) against_10/IN (r_prep) protecting_9/VBG (r_pcomp) in_8/IN (r_prep) effective_7/JJ (r_acomp) are_5/VBP (l_advcl) epilepticus_20/NN
D007608_D013226 CID acid_14/NN (r_npadvmod) induced_16/VBN (r_amod) seizures_17/NNS (r_pobj) against_10/IN (r_prep) protecting_9/VBG (r_pcomp) in_8/IN (r_prep) effective_7/JJ (r_acomp) are_5/VBP (l_conj) be_26/VB (l_advmod) epilepticus_37/NN
D001569_D064420 NONE benzodiazepine_10/JJ (r_amod) clonazepam_11/NN (r_advcl) potent_7/JJ (r_acomp) were_4/VBD (r_advcl) had_26/VBD (l_advcl) indicating_48/VBG (l_ccomp) have_54/VB (l_dobj) toxicity_57/NN
D007608_D012640 CID acid_7/NN (r_npadvmod) induced_9/VBN (r_amod) seizures_11/NNS
D007608_D012640 CID acid_28/NN (r_pobj) by_26/IN (r_agent) induced_25/VBN (r_acl) delay_18/NN (l_prep) in_19/IN (l_pobj) onset_21/NN (l_prep) of_22/IN (l_pobj) seizures_24/NNS
D007608_D012640 CID acid_28/NN (r_pobj) by_26/IN (r_agent) induced_25/VBN (r_acl) delay_18/NN (r_dobj) produced_13/VBD (l_conj) protect_40/VB (l_prep) against_41/IN (l_pobj) seizures_43/NNS
D007608_D012640 CID acid_23/NN (r_npadvmod) induced_25/VBN (r_amod) seizures_27/NNS
D007608_D012640 CID acid_14/NN (r_npadvmod) induced_16/VBN (r_amod) seizures_17/NNS
D002998_D064420 NONE clonazepam_11/NN (r_advcl) potent_7/JJ (r_acomp) were_4/VBD (r_advcl) had_26/VBD (l_advcl) indicating_48/VBG (l_ccomp) have_54/VB (l_dobj) toxicity_57/NN
D002998_D064420 NONE clonazepam_46/NN (r_advcl) had_26/VBD (l_advcl) indicating_48/VBG (l_ccomp) have_54/VB (l_dobj) toxicity_57/NN
D013256_D064420 NONE steroids_3/NNS (r_nsubj) were_4/VBD (r_advcl) had_26/VBD (l_advcl) indicating_48/VBG (l_ccomp) have_54/VB (l_dobj) toxicity_57/NN
D013256_D064420 NONE steroids_18/NNS (r_nsubj) had_26/VBD (l_advcl) indicating_48/VBG (l_ccomp) have_54/VB (l_dobj) toxicity_57/NN
D013256_D064420 NONE steroids_52/NNS (r_nsubj) have_54/VB (l_dobj) toxicity_57/NN
D016202_D012640 NONE aspartate_6/NNP (l_appos) seizures_9/NNS
D016202_D012640 NONE NMDA)-induced_8/JJ (r_amod) seizures_9/NNS
D016202_D012640 NONE NMDA_10/NNP (r_pobj) in_9/IN (r_prep) delay_8/NN (r_dobj) caused_3/VBD (l_conj) protect_22/VB (l_prep) against_23/IN (l_pobj) seizures_25/NNS
D016202_D012640 NONE NMDA_24/NNP (r_compound) seizures_25/NNS
D010862_D064420 NONE pilocarpine_15/NN (r_amod) seizures_16/NNS (r_pobj) against_14/IN (r_prep) protecting_13/VBG (r_pcomp) in_12/IN (r_prep) clonazepam_11/NN (r_advcl) potent_7/JJ (r_acomp) were_4/VBD (r_advcl) had_26/VBD (l_advcl) indicating_48/VBG (l_ccomp) have_54/VB (l_dobj) toxicity_57/NN
D002998_D012640 NONE clonazepam_11/NN (l_prep) in_12/IN (l_pcomp) protecting_13/VBG (l_prep) against_14/IN (l_pobj) seizures_16/NNS
D002998_D012640 NONE clonazepam_11/NN (r_advcl) potent_7/JJ (r_acomp) were_4/VBD (r_advcl) had_26/VBD (l_dobj) values_32/NNS (l_appos) TD50_34/NNP (l_acl) divided_38/VBN (l_prep) for_41/IN (l_pobj) protection_43/NN (l_compound) seizure_42/NN
D002998_D012640 NONE clonazepam_46/NN (r_advcl) had_26/VBD (l_advcl) were_4/VBD (l_acomp) potent_7/JJ (l_advcl) clonazepam_11/NN (l_prep) in_12/IN (l_pcomp) protecting_13/VBG (l_prep) against_14/IN (l_pobj) seizures_16/NNS
D002998_D012640 NONE clonazepam_46/NN (r_advcl) had_26/VBD (l_dobj) values_32/NNS (l_appos) TD50_34/NNP (l_acl) divided_38/VBN (l_prep) for_41/IN (l_pobj) protection_43/NN (l_compound) seizure_42/NN
D001569_D012640 NONE benzodiazepine_10/JJ (r_amod) clonazepam_11/NN (l_prep) in_12/IN (l_pcomp) protecting_13/VBG (l_prep) against_14/IN (l_pobj) seizures_16/NNS
D001569_D012640 NONE benzodiazepine_10/JJ (r_amod) clonazepam_11/NN (r_advcl) potent_7/JJ (r_acomp) were_4/VBD (r_advcl) had_26/VBD (l_dobj) values_32/NNS (l_appos) TD50_34/NNP (l_acl) divided_38/VBN (l_prep) for_41/IN (l_pobj) protection_43/NN (l_compound) seizure_42/NN
D013256_D013226 NONE steroids_1/NNS (r_nsubj) protect_2/VBP (l_advcl) epilepticus_14/NN
D013256_D013226 NONE Steroids_0/NNS (r_nsubj) were_19/VBD (l_npadvmod) values_39/NNS (l_amod) epilepticus_36/NN
D013256_D013226 NONE steroid_8/NN (r_pobj) of_6/IN (r_prep) dose_5/NN (r_nsubjpass) administered_10/VBN (r_advcl) hr_12/NN (r_nmod) protection_19/NN (l_prep) from_20/IN (l_pobj) seizures_27/NNS (l_conj) epilepticus_30/NN
D013256_D013226 NONE steroids_4/NNS (r_nsubj) are_5/VBP (l_advcl) epilepticus_20/NN
D013256_D013226 NONE steroids_4/NNS (r_nsubj) are_5/VBP (l_conj) be_26/VB (l_advmod) epilepticus_37/NN
16586083
D016861_D020521 CID inhibitors_25/NNS (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) during_21/IN (r_prep) stroke_15/NN
D016861_D006973 CID inhibitors_25/NNS (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) during_21/IN (r_prep) stroke_15/NN (l_conj) hypertension_17/NN
C109794_D002318 NONE peptide_10/NN (r_pobj) as_3/IN (r_prep) markers_1/NNS (r_nsubj) help_25/VB (l_advcl) avoiding_36/VBG (l_dobj) occurrence_38/NN (l_prep) of_39/IN (l_pobj) toxicity_42/NN
C109794_D002318 NONE proBNP_14/NNP (r_appos) peptide_10/NN (r_pobj) as_3/IN (r_prep) markers_1/NNS (r_nsubj) help_25/VB (l_advcl) avoiding_36/VBG (l_dobj) occurrence_38/NN (l_prep) of_39/IN (l_pobj) toxicity_42/NN
D016861_D006333 CID inhibitors_25/NNS (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) during_21/IN (r_prep) stroke_15/NN (l_conj) hypertension_17/NN (l_conj) failure_20/NN
D016861_D009203 CID inhibitors_25/NNS (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) during_21/IN (r_prep) stroke_15/NN (r_conj) infarction_13/NN
8267029
D010396_D001172 NONE Penicillamine_0/NN (r_nsubj) induced_2/VBN (l_prep) in_6/IN (l_pobj) patient_8/NN (l_prep) with_9/IN (l_pobj) arthritis_11/NN
D010396_D001172 NONE penicillamine_21/NN (r_nmod) treatment_28/NN (r_pobj) of_18/IN (r_prep) months_17/NNS (r_pobj) after_15/IN (r_prep) presented_8/VBD (l_nsubj) woman_4/NN (l_prep) with_5/IN (l_pobj) arthritis_7/NN
D010396_D011507 NONE penicillamine_11/NN (r_compound) treatment_12/NN (r_pobj) of_8/IN (r_prep) course_7/NN (r_pobj) in_5/IN (r_prep) case_2/NN (r_nsubj) emphasizes_13/VBZ (l_dobj) need_15/NN (l_prep) for_16/IN (l_pobj) monitoring_18/NN (l_prep) of_19/IN (l_pobj) function_21/NN (l_conj) evaluation_23/NN (l_prep) of_24/IN (l_pobj) sediment_26/NN (l_conj) proteinuria_28/NN
D010396_D005921 CID Penicillamine_0/NN (r_nsubj) induced_2/VBN (l_dobj) glomerulonephritis_5/NN
D010396_D005921 CID penicillamine_21/NN (r_nmod) treatment_28/NN (r_pobj) of_18/IN (r_prep) months_17/NNS (r_pobj) after_15/IN (r_prep) presented_8/VBD (l_dobj) glomerulonephritis_11/NN
D010396_D005921 CID penicillamine_21/NN (r_nmod) treatment_28/NN (r_pobj) of_18/IN (r_prep) months_17/NNS (r_pobj) after_15/IN (r_prep) presented_8/VBD (l_dobj) glomerulonephritis_11/NN (l_appos) RPGN_13/NNP
D010396_D005921 CID penicillamine_11/NN (r_compound) treatment_12/NN (r_pobj) of_8/IN (r_prep) course_7/NN (r_pobj) in_5/IN (r_prep) case_2/NN (l_prep) of_3/IN (l_pobj) RPGN_4/NNP
430165
D010672_D002526 CID diphenylhydantoin_6/NN (r_nmod) overdose_10/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_pobj) Among_0/IN (r_prep) are_18/VBP (l_nsubj) those_19/DT (l_prep) of_20/IN (l_pobj) dysfunction_22/NN
D010672_D002526 CID DPH_8/NNP (r_nmod) overdose_10/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_pobj) Among_0/IN (r_prep) are_18/VBP (l_nsubj) those_19/DT (l_prep) of_20/IN (l_pobj) dysfunction_22/NN
D010672_D062787 CID diphenylhydantoin_6/NN (r_nmod) overdose_10/NN
D010672_D062787 CID DPH_8/NNP (r_nmod) overdose_10/NN
D010672_D062787 CID DPH_10/NNP (r_compound) overdose_11/NN
D010672_D001927 NONE DPH_13/NNP (r_compound) toxicity_14/NN (r_dobj) manifest_12/VB (r_xcomp) liable_10/JJ (r_acomp) are_9/VBP (l_nsubj) patients_4/NNS (l_prep) with_5/IN (l_pobj) damage_8/NN
D010672_D064420 NONE diphenylhydantoin_7/JJ (r_compound) toxicity_8/NN
D010672_D064420 NONE DPH_13/NNP (r_compound) toxicity_14/NN
D010672_D010291 CID diphenylhydantoin_7/JJ (r_compound) toxicity_8/NN (r_pobj) of_6/IN (r_prep) manifestation_5/NN (r_appos) hemiparesis_1/NN
D010672_D010291 CID DPH_10/NNP (r_compound) overdose_11/NN (r_pobj) due_8/IN (r_prep) suffered_5/VBD (l_dobj) hemiparesis_7/NN
8854309
D016578_D011681 NONE cocaine_14/NN (r_compound) abusers_15/NNS (r_pobj) of_11/IN (r_prep) group_10/NN (r_dobj) distinguish_8/VB (r_xcomp) able_5/JJ (r_acomp) were_4/VBD (l_nsubj) Measures_0/NNS (l_prep) of_1/IN (l_pobj) oscillation_3/NN
D016578_D011681 NONE crack_28/NN (r_compound) addicts_29/NNS (r_pobj) of_27/IN (r_prep) group_26/NN (r_pobj) from_24/IN (r_prep) endorsing_16/VBG (r_acl) abusers_15/NNS (r_pobj) of_11/IN (r_prep) group_10/NN (r_dobj) distinguish_8/VB (r_xcomp) able_5/JJ (r_acomp) were_4/VBD (l_nsubj) Measures_0/NNS (l_prep) of_1/IN (l_pobj) oscillation_3/NN
D016578_D010259 NONE cocaine_14/NN (r_compound) abusers_15/NNS (l_acl) endorsing_16/VBG (l_prep) past_17/IN (l_pobj) CIP_18/NNP
D016578_D010259 NONE cocaine_14/NN (r_compound) abusers_15/NNS (l_acl) endorsing_16/VBG (l_prep) from_24/IN (l_pobj) group_26/NN (l_relcl) denied_31/VBD (l_prep) past_32/IN (l_pobj) CIP_33/NNP
D016578_D010259 NONE crack_28/NN (r_compound) addicts_29/NNS (r_pobj) of_27/IN (r_prep) group_26/NN (r_pobj) from_24/IN (r_prep) endorsing_16/VBG (l_prep) past_17/IN (l_pobj) CIP_18/NNP
D016578_D010259 NONE crack_28/NN (r_compound) addicts_29/NNS (r_pobj) of_27/IN (r_prep) group_26/NN (l_relcl) denied_31/VBD (l_prep) past_32/IN (l_pobj) CIP_33/NNP
D003042_D010259 CID cocaine_9/NN (r_npadvmod) induced_11/VBN (r_amod) paranoia_12/NN
D003042_D010259 CID Cocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) paranoia_3/NN
D003042_D010259 CID Cocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) paranoia_3/NN (l_appos) CIP_5/NNP
D003042_D010259 CID Cocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) paranoia_3/NN (r_nsubj) remains_7/VBZ (l_attr) model_13/NN (l_prep) of_14/IN (l_pobj) paranoia_16/NN
D003042_D011681 CID cocaine_9/NN (r_npadvmod) induced_11/VBN (r_amod) paranoia_12/NN (r_pobj) of_8/IN (r_prep) marker_7/NN (r_pobj) as_5/IN (r_prep) measure_1/NN (l_prep) of_2/IN (l_pobj) oscillation_4/NN
2893236
D005680_D012133 NONE GABA_0/NNP (r_compound) involvement_1/NN (r_nsubj) induced_4/VBN (l_dobj) reversal_5/NN (l_prep) of_6/IN (l_pobj) paralysis_8/NN
D005680_D012133 NONE GABA_13/NNP (r_conj) glutamate_11/NN (r_conj) paralysis_9/NN
D005680_D012133 NONE GABA_12/NNP (r_dobj) involves_11/VBZ (r_conj) reverses_4/VBZ (l_dobj) paralysis_6/NN
D018698_D012133 NONE glutamate_11/NN (r_conj) paralysis_9/NN
D009270_D012133 NONE naloxone_3/NN (r_pobj) in_2/IN (r_prep) involvement_1/NN (r_nsubj) induced_4/VBN (l_dobj) reversal_5/NN (l_prep) of_6/IN (l_pobj) paralysis_8/NN
D009270_D012133 NONE naloxone_3/NN (r_nsubj) reversed_4/VBD (l_dobj) paralysis_6/NN
D009270_D012133 NONE Naloxone_0/NN (r_nsubj) reversed_7/VBD (l_dobj) paralysis_9/NN
D009270_D012133 NONE naloxone_3/NN (r_nsubj) reverses_4/VBZ (l_dobj) paralysis_6/NN
D013874_D012131 NONE thiopental_4/NN (r_npadvmod) produced_5/VBD (r_amod) arrest_7/NN
D005680_D012131 NONE GABA_12/NNP (r_pobj) in_11/IN (r_prep) increase_10/NN (r_pobj) with_8/IN (r_prep) arrest_7/NN
D013874_D012133 CID thiopental_11/NN (r_pobj) by_10/IN (r_agent) produced_9/VBN (r_acl) paralysis_8/NN
D013874_D012133 CID thiopental_9/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) paralysis_6/NN
D013874_D012133 CID thiopental_9/NN (r_pobj) by_8/IN (r_agent) produced_7/VBN (r_acl) paralysis_6/NN
D018698_D012131 NONE glutamate_16/NN (r_pobj) in_15/IN (r_prep) decrease_14/NN (r_conj) increase_10/NN (r_pobj) with_8/IN (r_prep) arrest_7/NN
D000596_D012131 NONE acids_29/NNS (r_pobj) of_26/IN (r_prep) any_25/DT (r_dobj) affecting_24/VBG (r_pcomp) without_23/IN (r_prep) stem_22/NN (l_nsubj) arrest_7/NN
6504332
D010634_D009069 NONE Phenobarbital_0/NN (r_nsubjpass) added_3/VBN (l_prep) to_4/IN (l_pobj) list_6/NN (l_prep) of_7/IN (l_pobj) drugs_9/NNS (l_relcl) cause_12/VB (l_dobj) disorders_14/NNS
D010634_D009422 NONE Phenobarbital_0/NN (r_npadvmod) induced_2/VBN (r_amod) dyskinesia_3/NN (l_prep) in_4/IN (l_pobj) child_9/NN (l_amod) impaired_8/VBN
D010634_D009422 NONE phenobarbital_15/JJ (r_amod) therapy_16/NN (r_dobj) starting_14/VBG (r_pcomp) after_13/IN (r_prep) developed_9/VBD (l_nsubj) child_4/NN (l_prep) with_5/IN (l_pobj) impairment_8/NN
D010634_D012640 NONE phenobarbital_15/JJ (r_amod) therapy_16/NN (l_prep) for_17/IN (l_pobj) seizures_18/NNS
D010634_D004409 CID Phenobarbital_0/NN (r_npadvmod) induced_2/VBN (r_amod) dyskinesia_3/NN
D010634_D004409 CID phenobarbital_15/JJ (r_amod) therapy_16/NN (r_dobj) starting_14/VBG (r_pcomp) after_13/IN (r_prep) developed_9/VBD (l_dobj) dyskinesia_11/JJ
D010634_D004409 CID phenobarbital_4/JJ (r_pobj) with_3/IN (r_prep) challenge_2/NN (r_pobj) On_0/IN (r_prep) recurred_8/VBD (l_nsubj) dyskinesia_7/NN
17975693
D009643_D001008 CID norfloxacin_7/NNS (r_npadvmod) treated_9/VBN (r_conj) ciprofloxacin-_5/JJ (r_nmod) rats_10/NNS (r_nsubj) showed_11/VBD (l_dobj) behaviour_13/NN
D002939_D001008 CID ciprofloxacin-_5/JJ (r_nmod) rats_10/NNS (r_nsubj) showed_11/VBD (l_dobj) behaviour_13/NN
6496797
D014196_D006327 CID trazodone_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (r_pobj) following_3/VBG (r_prep) block_2/NN
D014196_D006327 CID trazodone_9/NN (r_pobj) of_8/IN (r_prep) dose_7/NN (r_dobj) receiving_3/VBG (r_pcomp) after_2/IN (r_prep) developed_13/VBD (l_dobj) block_16/NN
17511042
D012254_D019698 NONE ribavirin_18/JJ (r_compound) treatment_19/NN (r_conj) alpha-2b_16/NN (r_pobj) during_13/IN (r_prep) parasitosis_6/NN (l_prep) in_7/IN (l_pobj) patient_12/NN (l_compound) C_11/NN
D012254_D019698 NONE ribavirin_10/RB (r_conj) interferon_8/NN (r_pobj) with_7/IN (r_prep) patients_6/NNS (l_compound) C_5/NNP
D012254_D063726 CID ribavirin_18/JJ (r_compound) treatment_19/NN (r_conj) alpha-2b_16/NN (r_pobj) during_13/IN (r_prep) parasitosis_6/NN
D012254_D063726 CID ribavirin_20/RB (r_conj) weekly_18/RB (r_amod) alpha-2b_17/CD (r_prep) present_1/VBP (l_dobj) woman_6/NN (l_relcl) developed_8/VBD (l_dobj) parasitosis_11/NN
C417083_D063726 CID alpha-2b_16/NN (r_pobj) during_13/IN (r_prep) parasitosis_6/NN
C417083_D063726 CID alpha-2b_17/CD (r_prep) present_1/VBP (l_dobj) woman_6/NN (l_relcl) developed_8/VBD (l_dobj) parasitosis_11/NN
C417083_D019698 NONE alpha-2b_16/NN (r_pobj) during_13/IN (r_prep) parasitosis_6/NN (l_prep) in_7/IN (l_pobj) patient_12/NN (l_compound) C_11/NN
7785794
D004280_D006327 NONE dobutamine_30/NN (r_conj) dopamine_28/NN (r_pobj) as_27/IN (r_prep) agents_25/NNS (r_pobj) of_23/IN (r_prep) doses_22/NNS (r_conj) uses_14/NNS (r_pobj) with_12/IN (r_prep) remain_4/VB (l_acomp) hypotensive_5/JJ (l_prep) with_6/IN (l_pobj) block_9/NN
D002122_D007022 NONE chloride_9/NN (l_conj) hypotension_13/NN
D014700_D012770 NONE verapamil_8/NN (r_compound) SR_9/NNP (r_pobj) after_7/IN (r_prep) shock_2/NN
D008790_D007022 CID metoprolol_32/NN (r_pobj) of_31/IN (r_prep) use_30/NN (r_pobj) with_28/IN (r_prep) dose_22/NN (r_pobj) after_19/IN (r_prep) presented_9/VBN (l_prep) with_10/IN (l_pobj) block_13/NN (l_conj) hypotension_16/NN
D002122_D006327 NONE chloride_9/NN (l_conj) hypotension_13/NN (l_conj) block_17/NN
D014700_D007022 CID verapamil_27/NN (r_pobj) of_23/IN (r_prep) dose_22/NN (r_pobj) after_19/IN (r_prep) presented_9/VBN (l_prep) with_10/IN (l_pobj) block_13/NN (l_conj) hypotension_16/NN
D001285_D006327 NONE atropine_17/NN (r_pobj) of_15/IN (r_prep) uses_14/NNS (r_pobj) with_12/IN (r_prep) remain_4/VB (l_acomp) hypotensive_5/JJ (l_prep) with_6/IN (l_pobj) block_9/NN
D004298_D007022 NONE dopamine_28/NN (r_pobj) as_27/IN (r_prep) agents_25/NNS (r_pobj) of_23/IN (r_prep) doses_22/NNS (r_conj) uses_14/NNS (r_pobj) with_12/IN (r_prep) remain_4/VB (l_acomp) hypotensive_5/JJ
D008790_D006327 CID metoprolol_11/NN (r_conj) shock_2/NN (l_conj) block_6/NN
D008790_D006327 CID metoprolol_32/NN (r_pobj) of_31/IN (r_prep) use_30/NN (r_pobj) with_28/IN (r_prep) dose_22/NN (r_pobj) after_19/IN (r_prep) presented_9/VBN (l_prep) with_10/IN (l_pobj) block_13/NN
D008790_D012770 NONE metoprolol_11/NN (r_conj) shock_2/NN
D014700_D006327 CID verapamil_8/NN (r_compound) SR_9/NNP (r_pobj) after_7/IN (r_prep) shock_2/NN (l_conj) block_6/NN
D014700_D006327 CID verapamil_27/NN (r_pobj) of_23/IN (r_prep) dose_22/NN (r_pobj) after_19/IN (r_prep) presented_9/VBN (l_prep) with_10/IN (l_pobj) block_13/NN
D004298_D006327 NONE dopamine_28/NN (r_pobj) as_27/IN (r_prep) agents_25/NNS (r_pobj) of_23/IN (r_prep) doses_22/NNS (r_conj) uses_14/NNS (r_pobj) with_12/IN (r_prep) remain_4/VB (l_acomp) hypotensive_5/JJ (l_prep) with_6/IN (l_pobj) block_9/NN
D004280_D007022 NONE dobutamine_30/NN (r_conj) dopamine_28/NN (r_pobj) as_27/IN (r_prep) agents_25/NNS (r_pobj) of_23/IN (r_prep) doses_22/NNS (r_conj) uses_14/NNS (r_pobj) with_12/IN (r_prep) remain_4/VB (l_acomp) hypotensive_5/JJ
D001285_D007022 NONE atropine_17/NN (r_pobj) of_15/IN (r_prep) uses_14/NNS (r_pobj) with_12/IN (r_prep) remain_4/VB (l_acomp) hypotensive_5/JJ
3183120
C033706_D001927 CID tiazofurin_5/NN (r_compound) usage_6/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) lesions_2/NNS
19674115
D011718_D000857 CID pyrazinamide_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (l_nsubj) dysosmia_1/NN
D011718_D000857 CID pyrazinamide_10/VB (r_xcomp) related_8/VBN (r_acl) disorder_7/NN
D011718_D000857 CID pyrazinamide_4/JJ (r_compound) withdrawal_5/NN (r_pobj) after_3/IN (r_prep) disappeared_1/VBD (l_nsubj) Dysosmia_0/NNP
D011718_D056486 NONE Pyrazinamide_0/NNP (r_nsubj) have_2/VB (l_dobj) effects_4/NNS (l_prep) as_6/IN (l_pobj) toxicity_8/NN
D011718_D033461 NONE Pyrazinamide_0/NNP (r_nsubj) have_2/VB (l_dobj) effects_4/NNS (l_prep) as_6/IN (l_pobj) toxicity_8/NN (l_conj) disorders_13/NNS (l_nmod) hyperuricemia_10/NN
7596955
D000242_D001791 NONE cAMP_19/NNS (r_pobj) of_17/IN (r_prep) determination_16/NN (r_conj) aggregation_14/NN
C045645_D005483 CID CLZ_25/NNP (r_pobj) of_24/IN (r_prep) ingestion_23/NN (r_pobj) after_22/IN (r_prep) accompanying_11/VBG (l_dobj) flush_13/NN
C045645_D006261 CID CLZ_25/NNP (r_pobj) of_24/IN (r_prep) ingestion_23/NN (r_pobj) after_22/IN (r_prep) accompanying_11/VBG (r_acl) duration_10/NN (r_pobj) of_7/IN (r_prep) headache_6/NN
C045645_D009325 CID CLZ_25/NNP (r_pobj) of_24/IN (r_prep) ingestion_23/NN (r_pobj) after_22/IN (r_prep) accompanying_11/VBG (l_dobj) flush_13/NN (l_prep) in_14/IN (l_pobj) one_15/CD (l_conj) nausea_17/NN
17042884
D008094_D001480 CID Li_10/NNP (r_nmod) DVP_12/NNP (r_conj) QTP_8/NNP (r_pobj) with_7/IN (r_prep) events_6/NNS (l_amod) related_4/VBN (l_npadvmod) EPS_2/NNP
D008094_D001480 CID Li_24/NNP (r_nmod) DVP_26/NNP (r_conj) PBO_22/NNP (r_pobj) with_21/IN (r_prep) than_20/IN (r_prep) different_19/JJ (r_acomp) were_17/VBD (l_nsubj) events_6/NNS (l_amod) related_4/VBN (l_npadvmod) EPS_2/NNP
D008094_D001480 CID lithium_28/NN (r_pobj) with_27/IN (r_prep) treated_26/VBN (r_acl) patients_25/NNS (r_pobj) of_24/IN (r_prep) %_23/NN (r_pobj) whereas_21/IN (r_prep) treated_11/VBN (r_acl) patients_10/NNS (r_pobj) of_9/IN (r_prep) %_8/NN (r_pobj) in_6/IN (r_prep) occurred_5/VBD (l_nsubj) events_1/NNS (l_acl) related_2/VBN (l_prep) to_3/IN (l_pobj) EPS_4/NNP
D006220_D014202 CID Haloperidol_0/NNP (r_nsubj) induced_1/VBD (l_npadvmod) tremor_21/NN
D008094_D014202 CID Lithium_0/NN (r_nsubjpass) associated_2/VBN (l_prep) with_3/IN (l_pobj) incidence_7/NN (l_appos) 0.05_11/CD (l_prep) of_13/IN (l_pobj) tremor_14/NN
D008094_D014202 CID Lithium_0/NN (r_nsubjpass) associated_2/VBN (r_ccomp) contributed_40/VBN (l_nsubj) tremor_27/NN
D008094_D014202 CID Lithium_0/NN (r_nsubjpass) associated_2/VBN (r_ccomp) contributed_40/VBN (l_prep) to_41/IN (l_pobj) rate_44/NN (l_prep) of_45/IN (l_pobj) tremor_46/NN
D008094_D014202 CID lithium_36/NN (r_pobj) of_35/IN (r_prep) effect_34/NN (r_attr) is_30/VBZ (r_relcl) tremor_27/NN (r_nsubj) contributed_40/VBN (l_ccomp) associated_2/VBN (l_prep) with_3/IN (l_pobj) incidence_7/NN (l_appos) 0.05_11/CD (l_prep) of_13/IN (l_pobj) tremor_14/NN
D008094_D014202 CID lithium_36/NN (r_pobj) of_35/IN (r_prep) effect_34/NN (r_attr) is_30/VBZ (r_relcl) tremor_27/NN
D008094_D014202 CID lithium_36/NN (r_pobj) of_35/IN (r_prep) effect_34/NN (r_attr) is_30/VBZ (r_relcl) tremor_27/NN (r_nsubj) contributed_40/VBN (l_prep) to_41/IN (l_pobj) rate_44/NN (l_prep) of_45/IN (l_pobj) tremor_46/NN
D008094_D014202 CID lithium_50/NN (r_compound) therapy_51/NN (r_dobj) receiving_49/VBG (r_acl) patients_48/NNS (r_pobj) in_47/IN (r_prep) rate_44/NN (r_pobj) to_41/IN (r_prep) contributed_40/VBN (l_ccomp) associated_2/VBN (l_prep) with_3/IN (l_pobj) incidence_7/NN (l_appos) 0.05_11/CD (l_prep) of_13/IN (l_pobj) tremor_14/NN
D008094_D014202 CID lithium_50/NN (r_compound) therapy_51/NN (r_dobj) receiving_49/VBG (r_acl) patients_48/NNS (r_pobj) in_47/IN (r_prep) rate_44/NN (r_pobj) to_41/IN (r_prep) contributed_40/VBN (l_nsubj) tremor_27/NN
D008094_D014202 CID lithium_50/NN (r_compound) therapy_51/NN (r_dobj) receiving_49/VBG (r_acl) patients_48/NNS (r_pobj) in_47/IN (r_prep) rate_44/NN (l_prep) of_45/IN (l_pobj) tremor_46/NN
D014635_D001480 NONE DVP_12/NNP (r_conj) QTP_8/NNP (r_pobj) with_7/IN (r_prep) events_6/NNS (l_amod) related_4/VBN (l_npadvmod) EPS_2/NNP
D014635_D001480 NONE DVP_26/NNP (r_conj) PBO_22/NNP (r_pobj) with_21/IN (r_prep) than_20/IN (r_prep) different_19/JJ (r_acomp) were_17/VBD (l_nsubj) events_6/NNS (l_amod) related_4/VBN (l_npadvmod) EPS_2/NNP
D008094_D017109 NONE Li_26/NNP (r_nmod) DVP_28/NNP (r_conj) QTP_24/NNP (r_pobj) with_23/IN (r_conj) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) akathisia_3/NN
D008094_D017109 NONE Li_36/NNP (r_compound) DVP_38/NNP (r_conj) PBO_34/NNP (r_conj) DVP_28/NNP (r_conj) QTP_24/NNP (r_pobj) with_23/IN (r_conj) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) akathisia_3/NN
C069541_D017109 NONE quetiapine_14/NN (r_pobj) with_13/IN (r_prep) including_10/VBG (l_pobj) akathisia_11/NN
C069541_D017109 NONE quetiapine_16/NN (r_amod) monotherapy_17/NN (r_pobj) with_15/IN (r_prep) different_14/JJ (r_acomp) was_12/VBD (l_nsubj) incidence_1/NN (l_prep) including_9/VBG (l_pobj) akathisia_10/NN
C069541_D017109 NONE quetiapine_9/NN (r_amod) monotherapy_10/NN (r_pobj) with_8/IN (r_prep) similar_7/JJ (r_conj) low_5/JJ (r_acomp) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) akathisia_3/NN
C069541_D017109 NONE QTP_24/NNP (r_pobj) with_23/IN (r_conj) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) akathisia_3/NN
C069541_D017109 NONE quetiapine_41/NN (r_pcomp) than_40/IN (r_prep) tremor_21/NN (r_npadvmod) induced_1/VBD (l_dobj) incidence_5/NN (l_appos) 0.001_9/CD (l_prep) of_11/IN (l_pobj) akathisia_12/NN
C069541_D017109 NONE quetiapine_13/NN (r_amod) therapy_14/NN (r_nsubj) is_15/VBZ (l_nsubj) incidence_5/NN (l_prep) including_9/VBG (l_pobj) akathisia_10/NN
C069541_D014202 NONE quetiapine_20/NN (r_pobj) than_19/IN (r_prep) incidence_7/NN (l_appos) 0.05_11/CD (l_prep) of_13/IN (l_pobj) tremor_14/NN
C069541_D014202 NONE quetiapine_20/NN (r_pobj) than_19/IN (r_prep) incidence_7/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_ccomp) contributed_40/VBN (l_nsubj) tremor_27/NN
C069541_D014202 NONE quetiapine_20/NN (r_pobj) than_19/IN (r_prep) incidence_7/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_ccomp) contributed_40/VBN (l_prep) to_41/IN (l_pobj) rate_44/NN (l_prep) of_45/IN (l_pobj) tremor_46/NN
C069541_D014202 NONE quetiapine_41/NN (r_pcomp) than_40/IN (r_prep) tremor_21/NN
C069541_D001480 NONE quetiapine_11/NN (r_pobj) with_10/IN (r_prep) incidence_3/NN (l_prep) of_4/IN (l_pobj) symptoms_6/NNS
C069541_D001480 NONE quetiapine_11/NN (r_pobj) with_10/IN (r_prep) incidence_3/NN (l_prep) of_4/IN (l_pobj) symptoms_6/NNS (l_appos) EPS_8/NNP
C069541_D001480 NONE quetiapine_14/NN (r_pobj) with_13/IN (r_prep) including_10/VBG (r_prep) evaluate_3/VB (l_dobj) symptoms_5/NNS
C069541_D001480 NONE quetiapine_14/NN (r_pobj) with_13/IN (r_prep) including_10/VBG (r_prep) evaluate_3/VB (l_dobj) symptoms_5/NNS (l_appos) EPS_7/NNP
C069541_D001480 NONE quetiapine_16/NN (r_amod) monotherapy_17/NN (r_pobj) with_15/IN (r_prep) different_14/JJ (r_acomp) was_12/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) events_7/NNS (l_amod) related_5/VBN (l_npadvmod) EPS_3/NNP
C069541_D001480 NONE QTP_8/NNP (r_pobj) with_7/IN (r_prep) events_6/NNS (l_amod) related_4/VBN (l_npadvmod) EPS_2/NNP
C069541_D001480 NONE quetiapine_41/NN (r_pcomp) than_40/IN (r_prep) tremor_21/NN (l_conj) syndrome_32/NN
C069541_D001480 NONE quetiapine_13/NN (r_amod) therapy_14/NN (r_nsubj) is_15/VBZ (l_nsubj) incidence_5/NN (l_prep) of_6/IN (l_pobj) EPS_7/NNP
D014635_D017109 NONE DVP_28/NNP (r_conj) QTP_24/NNP (r_pobj) with_23/IN (r_conj) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) akathisia_3/NN
D014635_D017109 NONE DVP_38/NNP (r_conj) PBO_34/NNP (r_conj) DVP_28/NNP (r_conj) QTP_24/NNP (r_pobj) with_23/IN (r_conj) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) akathisia_3/NN
D006220_D001480 CID haloperidol_13/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) patients_10/NNS (r_pobj) of_9/IN (r_prep) %_8/NN (r_pobj) in_6/IN (r_prep) occurred_5/VBD (l_nsubj) events_1/NNS (l_acl) related_2/VBN (l_prep) to_3/IN (l_pobj) EPS_4/NNP
D006220_D001480 CID Haloperidol_0/NNP (r_nsubj) induced_1/VBD (l_npadvmod) tremor_21/NN (l_conj) syndrome_32/NN
D006220_D017109 CID Haloperidol_0/NNP (r_nsubj) induced_1/VBD (l_dobj) incidence_5/NN (l_appos) 0.001_9/CD (l_prep) of_11/IN (l_pobj) akathisia_12/NN
C069541_D001714 NONE quetiapine_11/NN (l_prep) in_12/IN (l_pobj) studies_14/NNS (l_prep) of_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) mania_19/NN
C069541_D001714 NONE quetiapine_14/NN (l_prep) in_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) mania_19/NN
C069541_D001714 NONE quetiapine_13/NN (r_amod) therapy_14/NN (r_nsubj) is_15/VBZ (l_prep) In_0/IN (l_pobj) mania_2/NN
14633084
D003907_D006470 NONE dexamethasone_2/NN (r_pobj) of_1/IN (r_prep) Use_0/NN (l_prep) for_5/IN (l_pobj) prevention_7/NN (l_prep) of_8/IN (l_pobj) cystitis_13/NN
D003907_D006470 NONE dexamethasone_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (l_prep) for_16/IN (l_pobj) prevention_18/NN (l_prep) of_19/IN (l_pobj) HC_23/NN
D003907_D006470 NONE Dexamethasone_0/NN (r_nsubj) was_5/VBD (l_acomp) efficient_6/JJ (l_prep) in_7/IN (l_pcomp) blocking_8/VBG (l_dobj) HC_12/NN
D003907_D006470 NONE dexamethasone_19/NN (r_pobj) with_18/IN (r_prep) doses_17/NNS (r_pobj) of_14/IN (r_prep) all_13/DT (r_conj) saline_11/NN (r_pobj) with_10/IN (r_prep) doses_7/NNS (r_pobj) of_4/IN (r_prep) replacement_3/NN (r_nsubj) prevent_22/VB (l_dobj) HC_23/NN
D007069_D006470 CID ifosfamide_9/RB (r_advmod) induced_11/VBN (r_amod) cystitis_13/NN
D007069_D006470 CID ifosfamide_16/NN (r_pobj) with_15/IN (r_prep) effect_12/NN (r_attr) is_7/VBZ (l_nsubj) AIM_0/VB (l_appos) cystitis_3/NN
D007069_D006470 CID ifosfamide_16/NN (r_pobj) with_15/IN (r_prep) effect_12/NN (r_attr) is_7/VBZ (l_nsubj) AIM_0/VB (l_appos) cystitis_3/NN (l_appos) HC_5/NNP
D007069_D006470 CID IFS_18/NNP (r_appos) ifosfamide_16/NN (r_pobj) with_15/IN (r_prep) effect_12/NN (r_attr) is_7/VBZ (l_nsubj) AIM_0/VB (l_appos) cystitis_3/NN
D007069_D006470 CID IFS_18/NNP (r_appos) ifosfamide_16/NN (r_pobj) with_15/IN (r_prep) effect_12/NN (r_attr) is_7/VBZ (l_nsubj) AIM_0/VB (l_appos) cystitis_3/NN (l_appos) HC_5/NNP
D007069_D006470 CID IFS_20/NNP (r_npadvmod) induced_22/VBN (r_amod) HC_23/NN
D007069_D006470 CID IFS_9/NNP (r_npadvmod) induced_11/VBN (r_amod) HC_12/NN
D003907_D003556 NONE dexamethasone_2/NN (r_pobj) of_1/IN (r_prep) Use_0/NN (l_prep) for_5/IN (l_pobj) prevention_7/NN (l_prep) of_8/IN (l_pobj) cystitis_13/NN
D003907_D003556 NONE dexamethasone_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (l_prep) for_16/IN (l_pobj) prevention_18/NN (l_prep) of_19/IN (l_pobj) HC_23/NN
D003907_D003556 NONE Dexamethasone_0/NN (r_nsubj) was_5/VBD (l_acomp) efficient_6/JJ (l_prep) in_7/IN (l_pcomp) blocking_8/VBG (l_dobj) HC_12/NN
D003907_D003556 NONE dexamethasone_19/NN (r_pobj) with_18/IN (r_prep) doses_17/NNS (r_pobj) of_14/IN (r_prep) all_13/DT (r_conj) saline_11/NN (r_pobj) with_10/IN (r_prep) doses_7/NNS (r_pobj) of_4/IN (r_prep) replacement_3/NN (r_nsubj) prevent_22/VB (l_dobj) HC_23/NN
D015080_D003556 NONE mesna_4/NN (r_pobj) with_3/IN (r_prep) Use_0/NN (l_prep) for_5/IN (l_pobj) prevention_7/NN (l_prep) of_8/IN (l_pobj) cystitis_13/NN
D015080_D003556 NONE mesna_15/NN (r_pobj) with_14/IN (r_prep) combination_13/NN (r_pobj) in_12/IN (r_prep) use_9/NN (l_prep) for_16/IN (l_pobj) prevention_18/NN (l_prep) of_19/IN (l_pobj) HC_23/NN
D015080_D003556 NONE mesna_4/NN (r_pobj) with_3/IN (r_prep) combination_2/NN (r_pobj) in_1/IN (r_prep) Dexamethasone_0/NN (r_nsubj) was_5/VBD (l_acomp) efficient_6/JJ (l_prep) in_7/IN (l_pcomp) blocking_8/VBG (l_dobj) HC_12/NN
D015080_D003556 NONE mesna_9/NN (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_pobj) of_4/IN (r_prep) replacement_3/NN (r_nsubj) prevent_22/VB (l_dobj) HC_23/NN
D015080_D003556 NONE mesna_16/JJ (r_amod) doses_17/NNS (r_pobj) of_14/IN (r_prep) all_13/DT (r_conj) saline_11/NN (r_pobj) with_10/IN (r_prep) doses_7/NNS (r_pobj) of_4/IN (r_prep) replacement_3/NN (r_nsubj) prevent_22/VB (l_dobj) HC_23/NN
D015080_D006470 NONE mesna_4/NN (r_pobj) with_3/IN (r_prep) Use_0/NN (l_prep) for_5/IN (l_pobj) prevention_7/NN (l_prep) of_8/IN (l_pobj) cystitis_13/NN
D015080_D006470 NONE mesna_15/NN (r_pobj) with_14/IN (r_prep) combination_13/NN (r_pobj) in_12/IN (r_prep) use_9/NN (l_prep) for_16/IN (l_pobj) prevention_18/NN (l_prep) of_19/IN (l_pobj) HC_23/NN
D015080_D006470 NONE mesna_4/NN (r_pobj) with_3/IN (r_prep) combination_2/NN (r_pobj) in_1/IN (r_prep) Dexamethasone_0/NN (r_nsubj) was_5/VBD (l_acomp) efficient_6/JJ (l_prep) in_7/IN (l_pcomp) blocking_8/VBG (l_dobj) HC_12/NN
D015080_D006470 NONE mesna_9/NN (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_pobj) of_4/IN (r_prep) replacement_3/NN (r_nsubj) prevent_22/VB (l_dobj) HC_23/NN
D015080_D006470 NONE mesna_16/JJ (r_amod) doses_17/NNS (r_pobj) of_14/IN (r_prep) all_13/DT (r_conj) saline_11/NN (r_pobj) with_10/IN (r_prep) doses_7/NNS (r_pobj) of_4/IN (r_prep) replacement_3/NN (r_nsubj) prevent_22/VB (l_dobj) HC_23/NN
D007069_D003556 CID ifosfamide_9/RB (r_advmod) induced_11/VBN (r_amod) cystitis_13/NN
D007069_D003556 CID ifosfamide_16/NN (r_pobj) with_15/IN (r_prep) effect_12/NN (r_attr) is_7/VBZ (l_nsubj) AIM_0/VB (l_appos) cystitis_3/NN
D007069_D003556 CID ifosfamide_16/NN (r_pobj) with_15/IN (r_prep) effect_12/NN (r_attr) is_7/VBZ (l_nsubj) AIM_0/VB (l_appos) cystitis_3/NN (l_appos) HC_5/NNP
D007069_D003556 CID IFS_18/NNP (r_appos) ifosfamide_16/NN (r_pobj) with_15/IN (r_prep) effect_12/NN (r_attr) is_7/VBZ (l_nsubj) AIM_0/VB (l_appos) cystitis_3/NN
D007069_D003556 CID IFS_18/NNP (r_appos) ifosfamide_16/NN (r_pobj) with_15/IN (r_prep) effect_12/NN (r_attr) is_7/VBZ (l_nsubj) AIM_0/VB (l_appos) cystitis_3/NN (l_appos) HC_5/NNP
D007069_D003556 CID IFS_20/NNP (r_npadvmod) induced_22/VBN (r_amod) HC_23/NN
D007069_D003556 CID IFS_9/NNP (r_npadvmod) induced_11/VBN (r_amod) HC_12/NN
8607407
D002110_D006973 CID caffeine_5/NN (r_pobj) with_4/IN (r_prep) elevations_3/NNS (l_prep) in_6/IN (l_pobj) men_7/NNS (l_prep) with_8/IN (l_pobj) hypertension_11/NN
D002110_D006973 CID caffeine_5/NN (r_pobj) of_4/IN (r_prep) actions_3/NNS (r_nsubjpass) enhanced_7/VBN (l_prep) in_8/IN (l_pobj) persons_10/NNS (l_amod) hypertensive_9/JJ
D002110_D006973 CID caffeine_24/NN (r_compound) ingestion_25/NN (r_pobj) after_23/IN (r_prep) achieved_19/VBD (l_dobj) levels_22/NNS (l_amod) hypertensive_20/JJ
D002110_D006973 CID caffeine_10/NN (r_pobj) to_9/IN (r_prep) responses_8/NNS (r_nsubj) were_11/VBD (l_prep) in_2/IN (l_pobj) men_5/NNS (l_amod) hypertensive_4/JJ
D002110_D006973 CID caffeine_10/NN (r_pobj) to_9/IN (r_prep) responses_8/NNS (r_nsubj) were_11/VBD (l_advcl) replicated_23/VBN (l_conj) representative_29/NN (l_prep) of_30/IN (l_pobj) hypertensives_34/NNS
11063349
D003404_D007674 NONE creatinine_17/NN (r_pobj) in_15/IN (r_prep) decrease_14/NN (r_attr) was_11/VBD (l_prep) In_1/IN (l_pobj) patients_4/NNS (l_acl) switched_5/VBD (l_prep) because_6/IN (l_pobj) nephrotoxicity_9/NN
D016572_D007674 CID CsA_6/NNP (l_conj) nephrotoxicity_9/NN
D016572_D007674 CID CsA_15/NNP (r_conj) nephrotoxicity_9/NN
D016572_D064420 NONE cyclosporine_16/NN (l_appos) CsA_18/NNP (l_conj) toxicity_25/NN
D016572_D064420 NONE CsA_18/NNP (l_conj) toxicity_25/NN
D016572_D064420 NONE CsA_6/NNP (l_conj) nephrotoxicity_9/NN (l_conj) CsA_15/NNP (l_conj) toxicity_18/NN
D016572_D064420 NONE CsA_15/NNP (l_conj) toxicity_18/NN
D016559_D064420 NONE tacrolimus_21/NN (r_nmod) toxicity_25/NN
D016559_D064420 NONE Tac_23/NN (r_nmod) toxicity_25/NN
D016559_D064420 NONE Tac_8/NNP (r_compound) nephrotoxicity_9/NN (l_conj) CsA_15/NNP (l_conj) toxicity_18/NN
D016559_D064420 NONE Tac_17/NNP (r_compound) toxicity_18/NN
D020123_D013281 NONE RAPA_0/NNP (r_nsubjpass) discontinued_2/VBN (l_appos) PTLD_13/NN (l_conj) ulcers_20/NNS
D016572_D008232 NONE CsA_6/NNP (l_conj) nephrotoxicity_9/NN (l_conj) disorder_32/NN
D016572_D008232 NONE CsA_6/NNP (l_conj) nephrotoxicity_9/NN (l_conj) disorder_32/NN (l_appos) PTLD_34/NN
D016572_D008232 NONE CsA_15/NNP (r_conj) nephrotoxicity_9/NN (l_conj) disorder_32/NN
D016572_D008232 NONE CsA_15/NNP (r_conj) nephrotoxicity_9/NN (l_conj) disorder_32/NN (l_appos) PTLD_34/NN
D020123_D064420 NONE RAPA_11/NNP (r_compound) conversion_12/NN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_acl) undergoing_15/VBG (l_dobj) cyclosporine_16/NN (l_appos) CsA_18/NNP (l_conj) toxicity_25/NN
D016559_D007674 CID Tac_8/NNP (r_compound) nephrotoxicity_9/NN
D016559_D007674 CID Tac_17/NNP (r_compound) toxicity_18/NN (r_conj) CsA_15/NNP (r_conj) nephrotoxicity_9/NN
D020123_D011020 NONE RAPA_6/NNP (r_compound) levels_8/NNS (r_pobj) to_5/IN (r_prep) converting_3/VBG (r_csubjpass) monitored_11/VBN (r_advcl) given_27/VBN (l_nsubjpass) prophylaxis_24/NN (l_compound) pneumonia_23/NN
D016559_-1 NONE Tac_8/NNP (r_compound) nephrotoxicity_9/NN (l_conj) CsA_15/NNP (l_conj) dysmorphism_25/NN
D016559_-1 NONE Tac_17/NNP (r_compound) toxicity_18/NN (r_conj) CsA_15/NNP (l_conj) dysmorphism_25/NN
D016559_D056486 NONE Tac_8/NNP (r_compound) nephrotoxicity_9/NN (r_conj) CsA_6/NNP (l_conj) hepatotoxicity_43/NN
D016559_D056486 NONE Tac_17/NNP (r_compound) toxicity_18/NN (r_conj) CsA_15/NNP (r_conj) nephrotoxicity_9/NN (r_conj) CsA_6/NNP (l_conj) hepatotoxicity_43/NN
D016572_-1 NONE CsA_6/NNP (l_conj) nephrotoxicity_9/NN (l_conj) CsA_15/NNP (l_conj) dysmorphism_25/NN
D016572_-1 NONE CsA_15/NNP (l_conj) dysmorphism_25/NN
D020123_D011014 NONE RAPA_0/NNP (r_nsubjpass) discontinued_2/VBN (l_prep) because_7/IN (l_pobj) pneumonia_9/NN
D016572_D056486 NONE CsA_6/NNP (l_conj) hepatotoxicity_43/NN
D016572_D056486 NONE CsA_15/NNP (r_conj) nephrotoxicity_9/NN (r_conj) CsA_6/NNP (l_conj) hepatotoxicity_43/NN
D020123_D008232 NONE RAPA_0/NNP (r_nsubjpass) discontinued_2/VBN (l_appos) PTLD_13/NN
D016559_D008232 NONE Tac_8/NNP (r_compound) nephrotoxicity_9/NN (l_conj) disorder_32/NN
D016559_D008232 NONE Tac_8/NNP (r_compound) nephrotoxicity_9/NN (l_conj) disorder_32/NN (l_appos) PTLD_34/NN
D016559_D008232 NONE Tac_17/NNP (r_compound) toxicity_18/NN (r_conj) CsA_15/NNP (r_conj) nephrotoxicity_9/NN (l_conj) disorder_32/NN
D016559_D008232 NONE Tac_17/NNP (r_compound) toxicity_18/NN (r_conj) CsA_15/NNP (r_conj) nephrotoxicity_9/NN (l_conj) disorder_32/NN (l_appos) PTLD_34/NN
8268147
D010396_D012216 NONE penicillamine_3/NN (r_nsubjpass) used_6/VBN (l_prep) for_7/IN (l_pobj) diseases_10/NNS
D010396_D017285 CID penicillamine_15/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) cirrhosis_10/NN (r_pobj) with_7/IN (r_prep) patient_6/NN (r_pobj) in_4/IN (r_prep) case_1/NN (l_prep) of_2/IN (l_pobj) polymyositis_3/NN
D010396_D017285 CID penicillamine_14/NN (r_compound) treatment_15/NN (r_pobj) of_11/IN (r_prep) complications_10/NNS (r_pobj) of_7/IN (r_prep) one_6/CD (r_pobj) as_5/IN (r_prep) develop_4/VB (l_nsubj) dermatomyositis_2/NN (l_nmod) Polymyositis_0/NNP
D010396_D017285 CID penicillamine_16/NN (r_compound) therapy_17/NN (r_dobj) receiving_13/VBG (r_advcl) developed_10/VBD (l_dobj) polymyositis_11/NN
D010396_D017285 CID penicillamine_4/NN (r_compound) therapy_5/NN (r_dobj) receiving_1/VBG (r_acl) Patients_0/NNS (r_nsubjpass) followed_8/VBN (l_prep) for_10/IN (l_pobj) development_12/NN (l_prep) of_13/IN (l_pobj) complications_15/NNS (l_prep) like_16/IN (l_pobj) dermatomyositis_19/NN (l_nmod) polymyositis_17/NN
D010396_D064420 NONE penicillamine_3/NN (r_nsubjpass) used_6/VBN (r_advcl) limits_13/VBZ (l_nsubj) toxicity_12/NN
D010396_D008105 NONE penicillamine_15/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) cirrhosis_10/NN
D010396_D008105 NONE penicillamine_16/NN (r_compound) therapy_17/NN (r_dobj) receiving_13/VBG (r_advcl) developed_10/VBD (r_relcl) cirrhosis_7/NN
D010396_D003882 NONE penicillamine_14/NN (r_compound) treatment_15/NN (r_pobj) of_11/IN (r_prep) complications_10/NNS (r_pobj) of_7/IN (r_prep) one_6/CD (r_pobj) as_5/IN (r_prep) develop_4/VB (l_nsubj) dermatomyositis_2/NN
D010396_D003882 NONE penicillamine_4/NN (r_compound) therapy_5/NN (r_dobj) receiving_1/VBG (r_acl) Patients_0/NNS (r_nsubjpass) followed_8/VBN (l_prep) for_10/IN (l_pobj) development_12/NN (l_prep) of_13/IN (l_pobj) complications_15/NNS (l_prep) like_16/IN (l_pobj) dermatomyositis_19/NN
20195852
C038192_D007674 CID iopromide_17/JJ (r_appos) media_12/NNS (r_pobj) for_8/IN (r_prep) incidence_5/NN (l_prep) of_6/IN (l_pobj) CIN_7/NNP
D003287_D007674 CID media_8/NNS (r_dobj) contrast_7/NN (l_nsubj) Risk_0/NN (l_prep) of_1/IN (l_pobj) nephropathy_2/NN
D003287_D007674 CID media_6/NNS (r_npadvmod) induced_8/VBN (r_amod) nephropathy_9/NN
D003287_D007674 CID media_6/NNS (r_npadvmod) induced_8/VBN (r_amod) nephropathy_9/NN (l_appos) CIN_11/NNP
D003287_D007674 CID media_12/NNS (r_pobj) for_8/IN (r_prep) incidence_5/NN (l_prep) of_6/IN (l_pobj) CIN_7/NNP
D003287_D007674 CID CM_14/NNP (r_appos) media_12/NNS (r_pobj) for_8/IN (r_prep) incidence_5/NN (l_prep) of_6/IN (l_pobj) CIN_7/NNP
D003287_D007674 CID CM_43/NNP (r_pobj) of_42/IN (r_prep) type_39/NN (r_pobj) to_37/IN (r_prep) relation_36/NN (r_pobj) in_35/IN (r_prep) complication_34/NN (r_pobj) for_32/IN (r_prep) rates_31/NNS (r_dobj) compared_29/VBD (r_conj) among_21/IN (r_prep) determined_3/VBD (l_dobj) incidence_5/NN (l_prep) of_6/IN (l_pobj) CIN_7/NNP
D003287_D007674 CID CM_17/NNP (r_pobj) of_16/IN (r_prep) dosage_15/NN (r_dobj) received_12/VBD (r_relcl) those_10/DT (r_pobj) among_9/IN (r_prep) were_8/VBD (l_nsubj) %_2/NN (l_prep) of_3/IN (l_pobj) patients_5/NNS (l_prep) with_6/IN (l_pobj) CIN_7/NNP
D003287_D007674 CID CM_17/NNP (r_pobj) of_16/IN (r_prep) dosage_15/NN (r_dobj) received_12/VBD (r_relcl) those_10/DT (r_pobj) among_9/IN (r_prep) were_8/VBD (r_advcl) increased_21/VBD (l_prep) with_32/IN (l_pobj) difference_35/NN (l_prep) in_36/IN (l_pobj) incidence_38/NN (l_prep) of_39/IN (l_pobj) CIN_40/NNP
D003287_D007674 CID CM_47/NNP (r_pobj) of_46/IN (r_prep) dosages_45/NNS (r_pobj) to_42/IN (r_prep) related_41/VBN (r_acl) incidence_38/NN (r_pobj) in_36/IN (r_prep) difference_35/NN (r_pobj) with_32/IN (r_prep) increased_21/VBD (l_advcl) were_8/VBD (l_nsubj) %_2/NN (l_prep) of_3/IN (l_pobj) patients_5/NNS (l_prep) with_6/IN (l_pobj) CIN_7/NNP
D003287_D007674 CID CM_47/NNP (r_pobj) of_46/IN (r_prep) dosages_45/NNS (r_pobj) to_42/IN (r_prep) related_41/VBN (r_acl) incidence_38/NN (l_prep) of_39/IN (l_pobj) CIN_40/NNP
D003287_D007674 CID CM_13/NNP (r_pobj) of_10/IN (r_prep) type_9/NN (r_pobj) on_7/IN (r_conj) on_3/IN (r_prep) depends_2/VBZ (l_conj) needed_32/VBN (l_advcl) is_26/VBZ (l_nsubj) CIN_24/NNP
D003287_D003490 NONE media_12/NNS (r_pobj) for_8/IN (r_prep) incidence_5/NN (r_dobj) determined_3/VBD (l_prep) among_21/IN (l_conj) compared_29/VBD (l_dobj) rates_31/NNS (l_prep) for_32/IN (l_pobj) complication_34/NN (l_prep) in_35/IN (l_pobj) relation_36/NN (l_prep) to_37/IN (l_pobj) type_39/NN (l_conj) presence_46/NN (l_prep) of_47/IN (l_pobj) cyanosis_48/NN
D003287_D003490 NONE CM_14/NNP (r_appos) media_12/NNS (r_pobj) for_8/IN (r_prep) incidence_5/NN (r_dobj) determined_3/VBD (l_prep) among_21/IN (l_conj) compared_29/VBD (l_dobj) rates_31/NNS (l_prep) for_32/IN (l_pobj) complication_34/NN (l_prep) in_35/IN (l_pobj) relation_36/NN (l_prep) to_37/IN (l_pobj) type_39/NN (l_conj) presence_46/NN (l_prep) of_47/IN (l_pobj) cyanosis_48/NN
D003287_D003490 NONE CM_43/NNP (r_pobj) of_42/IN (r_prep) type_39/NN (l_conj) presence_46/NN (l_prep) of_47/IN (l_pobj) cyanosis_48/NN
D003287_D003490 NONE CM_13/NNP (r_pobj) of_10/IN (r_prep) type_9/NN (r_pobj) on_7/IN (l_conj) on_16/IN (l_pobj) presence_18/NN (l_prep) of_19/IN (l_pobj) cyanosis_20/NN
C038192_D003490 NONE iopromide_17/JJ (r_appos) media_12/NNS (r_pobj) for_8/IN (r_prep) incidence_5/NN (r_dobj) determined_3/VBD (l_prep) among_21/IN (l_conj) compared_29/VBD (l_dobj) rates_31/NNS (l_prep) for_32/IN (l_pobj) complication_34/NN (l_prep) in_35/IN (l_pobj) relation_36/NN (l_prep) to_37/IN (l_pobj) type_39/NN (l_conj) presence_46/NN (l_prep) of_47/IN (l_pobj) cyanosis_48/NN
D007472_D003490 NONE iohexol_19/NN (r_conj) iopromide_17/JJ (r_appos) media_12/NNS (r_pobj) for_8/IN (r_prep) incidence_5/NN (r_dobj) determined_3/VBD (l_prep) among_21/IN (l_conj) compared_29/VBD (l_dobj) rates_31/NNS (l_prep) for_32/IN (l_pobj) complication_34/NN (l_prep) in_35/IN (l_pobj) relation_36/NN (l_prep) to_37/IN (l_pobj) type_39/NN (l_conj) presence_46/NN (l_prep) of_47/IN (l_pobj) cyanosis_48/NN
D007472_D007674 CID iohexol_19/NN (r_conj) iopromide_17/JJ (r_appos) media_12/NNS (r_pobj) for_8/IN (r_prep) incidence_5/NN (l_prep) of_6/IN (l_pobj) CIN_7/NNP
7619765
D005047_D009203 CID Etoposide_0/RB (r_npadvmod) related_2/VBN (r_amod) infarction_4/NN
D005047_D009203 CID etoposide_11/RB (r_dobj) containing_10/VBG (r_acl) chemotherapy_9/NN (r_pobj) after_8/IN (r_prep) reported_7/VBN (l_nsubjpass) occurrence_1/NN (l_prep) of_2/IN (l_pobj) infarction_5/NN
D005047_D003327 NONE etoposide_11/RB (r_dobj) containing_10/VBG (r_acl) chemotherapy_9/NN (r_pobj) after_8/IN (r_prep) reported_7/VBN (l_prep) in_13/IN (l_pobj) man_15/NN (l_prep) with_16/IN (l_pobj) factors_19/NNS (l_prep) for_20/IN (l_pobj) disease_23/NN
6454943
D002216_D007674 NONE captopril_9/NN (r_pobj) with_8/IN (r_prep) abnormality_7/NN
D011692_D011507 CID aminonucleoside_8/RB (r_punct) -_9/HYPH (r_punct) induced_10/VBN (l_dobj) proteinuria_11/NN
D011692_D011507 CID aminonucleoside_16/NN (r_amod) puromycin_15/NNS (r_pobj) by_14/IN (r_agent) invoked_13/VBN (r_acl) proteinuria_12/NN
D002216_D011507 NONE captopril_2/NN (r_pobj) of_1/IN (r_prep) Effect_0/NN (r_nsubj) induced_10/VBN (l_dobj) proteinuria_11/NN
D002216_D011507 NONE captopril_6/NN (r_compound) treatment_7/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (r_attr) is_1/VBZ (l_nsubj) Proteinuria_0/NNP
D002216_D011507 NONE captopril_3/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) failed_10/VBD (l_xcomp) aggravate_12/VB (l_dobj) proteinuria_13/JJ
D002216_D011507 NONE captopril_2/NN (r_compound) treatment_3/NN (r_nsubj) failed_4/VBD (l_xcomp) potentiate_6/VB (l_conj) facilitate_8/VB (l_dobj) development_9/NN (l_prep) of_10/IN (l_pobj) proteinuria_12/NN
D011692_D006973 NONE aminonucleoside_8/RB (r_punct) -_9/HYPH (r_punct) induced_10/VBN (l_prep) in_12/IN (l_pobj) rats_15/NNS (l_amod) hypertensive_14/JJ
D002216_D006973 NONE captopril_2/NN (r_pobj) of_1/IN (r_prep) Effect_0/NN (r_nsubj) induced_10/VBN (l_prep) in_12/IN (l_pobj) rats_15/NNS (l_amod) hypertensive_14/JJ
D002216_D006973 NONE captopril_6/NN (r_compound) treatment_7/NN (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_amod) hypertensive_9/JJ
7724492
D003487_D007674 NONE cyanoacrylate_7/JJ (r_compound) nanoparticles_8/NNS (r_pobj) of_3/IN (r_prep) toxicity_2/NN
D004317_D007674 NONE doxorubicin_4/NN (r_nmod) nanoparticles_8/NNS (r_pobj) of_3/IN (r_prep) toxicity_2/NN
D004317_D007674 NONE adriamycin)-loaded_6/VBN (r_amod) nanoparticles_8/NNS (r_pobj) of_3/IN (r_prep) toxicity_2/NN
D004317_D007674 NONE doxorubicin_1/NN (r_npadvmod) loaded_3/VBN (r_amod) nanoparticle_4/NN (r_nmod) toxicity_9/NN
D004317_D007674 NONE DX_16/NNP (r_pobj) than_14/IN (r_prep) animals_13/NNS (r_dobj) killed_11/VBD (l_prep) despite_18/IN (l_prep) of_19/IN (l_pobj) toxicity_23/NN
D004317_D011507 CID DX_16/NNP (r_pobj) with_15/IN (r_prep) treated_14/VBN (r_acl) those_13/DT (r_pobj) in_12/IN (r_prep) than_11/IN (r_prep) treated_8/VBN (r_acl) animals_7/NNS (r_pobj) in_6/IN (r_prep) appeared_5/VBD (l_nsubj) proteinuria_4/NN
D004317_D011507 CID doxorubicin_22/NN (r_compound) treatment_23/NN (r_pobj) after_21/IN (r_prep) prolonged_20/VBN (r_conj) intense_13/JJ (r_acomp) was_7/VBD (r_conj) appeared_1/VBD (l_nsubj) Proteinuria_0/NNP
D004317_D011507 CID DX_39/NNP (r_conj) DXNP_37/NNP (r_pobj) between_36/IN (r_prep) difference_35/NN (r_pobj) without_33/IN (r_prep) was_7/VBD (r_conj) appeared_1/VBD (l_nsubj) Proteinuria_0/NNP
D004317_D005921 NONE doxorubicin_1/NN (r_npadvmod) loaded_3/VBN (r_amod) nanoparticle_4/NN (r_nmod) toxicity_9/NN (r_nsubjpass) explored_11/VBN (l_prep) in_12/IN (l_pobj) rats_15/NNS (l_conj) rats_17/NNS (l_prep) with_18/IN (l_pobj) glomerulonephritis_20/NN
D004317_D005921 NONE DX_10/NNP (r_pobj) given_9/VBN (r_prep) rats_8/NNS (r_nsubj) died_11/VBD (l_prep) In_0/IN (l_pobj) rats_1/NNS (l_prep) with_2/IN (l_pobj) glomerulonephritis_5/NN
8643973
D017239_D010051 NONE Paclitaxel_0/NNP (l_acl) combined_1/VBD (l_prep) in_4/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) cancer_13/NN
D017239_D010051 NONE paclitaxel_12/NN (r_pobj) of_11/IN (r_prep) dose_10/NN (r_dobj) determine_6/VB (l_prep) given_26/VBN (l_prep) as_27/IN (l_pobj) infusion_30/NN (l_acl) administered_35/VBN (l_prep) to_39/IN (l_pobj) women_40/NNS (l_prep) with_41/IN (l_pobj) cancer_44/NN
D017239_D010051 NONE Taxol_14/NNP (r_appos) dose_10/NN (r_dobj) determine_6/VB (l_prep) given_26/VBN (l_prep) as_27/IN (l_pobj) infusion_30/NN (l_acl) administered_35/VBN (l_prep) to_39/IN (l_pobj) women_40/NNS (l_prep) with_41/IN (l_pobj) cancer_44/NN
D017239_D010051 NONE paclitaxel_46/NN (r_compound) doses_47/NNS (r_nsubjpass) escalated_49/VBN (r_conj) study_4/VBP (l_xcomp) determine_6/VB (l_prep) given_26/VBN (l_prep) as_27/IN (l_pobj) infusion_30/NN (l_acl) administered_35/VBN (l_prep) to_39/IN (l_pobj) women_40/NNS (l_prep) with_41/IN (l_pobj) cancer_44/NN
D016190_D010051 NONE carboplatin_3/NN (r_pobj) with_2/IN (r_prep) combined_1/VBD (l_prep) in_4/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) cancer_13/NN
D016190_D010051 NONE carboplatin_34/NN (r_pobj) with_33/IN (r_prep) combination_32/NN (r_pobj) in_31/IN (r_prep) infusion_30/NN (l_acl) administered_35/VBN (l_prep) to_39/IN (l_pobj) women_40/NNS (l_prep) with_41/IN (l_pobj) cancer_44/NN
3413271
D004837_D017202 CID epinephrine_6/NN (r_pobj) by_5/IN (r_prep) induced_4/VBN (l_nsubj) Mechanisms_0/NNS (l_prep) of_1/IN (l_pobj) ischemia_3/NN
D004837_D017202 CID epinephrine_3/NN (r_pobj) of_2/IN (r_prep) role_1/NN (l_prep) in_4/IN (l_pcomp) eliciting_5/VBG (l_dobj) ischemia_7/NN
D004837_D017202 CID epinephrine_1/NN (r_nsubj) produced_4/VBD (l_dobj) ischemia_6/NN
D004837_D017202 CID epinephrine_9/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) mechanisms_3/NNS (l_prep) of_4/IN (l_pobj) ischemia_6/NN
D004837_D017202 CID epinephrine_28/NN (r_npadvmod) induced_30/VBN (r_amod) ischemia_31/NN (r_nsubjpass) characterized_33/VBN (r_advcl) marked_6/VBN (l_nsubjpass) ischemia_4/NN
D004837_D000787 NONE epinephrine_1/NN (r_nsubj) produced_4/VBD (l_advcl) evidenced_8/VBN (l_agent) by_9/IN (l_pobj) depression_12/NN (l_conj) angina_14/NN
D004837_D003324 NONE epinephrine_3/NN (r_pobj) of_2/IN (r_prep) role_1/NN (r_nsubjpass) examined_9/VBN (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) disease_15/NN
D004837_D007511 NONE epinephrine_6/NN (l_appos) comparison_8/NN (l_prep) with_9/IN (l_pobj) ischemia_13/NN
D004837_D007511 NONE epinephrine_13/NN (r_amod) infusion_14/NN (r_pobj) during_12/IN (r_prep) compared_11/VBN (l_nsubjpass) signs_1/NNS (l_prep) of_2/IN (l_pobj) ischemia_3/NN
D004837_D007511 NONE epinephrine_28/NN (r_npadvmod) induced_30/VBN (r_amod) ischemia_31/NN
D004837_D007511 NONE epinephrine_7/NN (r_pobj) by_6/IN (r_agent) produced_5/VBN (r_acl) ischemia_4/NN
D010100_D007511 NONE oxygen_8/NN (r_compound) consumption_9/NN (r_nsubjpass) compared_11/VBN (l_nsubjpass) signs_1/NNS (l_prep) of_2/IN (l_pobj) ischemia_3/NN
D004837_D003866 NONE epinephrine_1/NN (r_nsubj) produced_4/VBD (l_advcl) evidenced_8/VBN (l_agent) by_9/IN (l_pobj) depression_12/NN
2055425
D013311_D003920 CID streptozotocin_17/NNS (r_npadvmod) induced_19/VBN (r_amod) diabetes_20/NN (r_compound) mellitus_21/NN
D013311_D003920 CID streptozotocin_15/JJ (r_npadvmod) diabetic_17/JJ
D013311_D003920 CID streptozotocin_7/NNS (r_npadvmod) induced_9/VBN (r_amod) diabetes_10/NNS
D018723_D003920 NONE bethanechol_23/NN (r_conj) ATP_20/NNP (r_conj) stimulation_18/NN (r_pobj) to_16/TO (r_prep) responses_8/NNS (l_prep) from_13/IN (l_pobj) rats_15/NNS (l_amod) diabetic_14/JJ
D018723_D003920 NONE bethanechol_22/NN (r_conj) ATP_19/NNP (r_conj) stimulation_17/NN (r_pobj) to_15/TO (r_prep) responses_7/NNS (l_prep) from_12/IN (l_pobj) rats_14/NNS (l_amod) diabetic_13/JJ
D000255_D003920 NONE ATP_20/NNP (r_conj) stimulation_18/NN (r_pobj) to_16/TO (r_prep) responses_8/NNS (l_prep) from_13/IN (l_pobj) rats_15/NNS (l_amod) diabetic_14/JJ
D000255_D003920 NONE ATP_19/NNP (r_conj) stimulation_17/NN (r_pobj) to_15/TO (r_prep) responses_7/NNS (l_prep) from_12/IN (l_pobj) rats_14/NNS (l_amod) diabetic_13/JJ
12907924
D008774_D009771 CID Methylphenidate_0/NNP (r_npadvmod) induced_2/VBN (r_amod) symptoms_6/NNS
D008774_D009771 CID methylphenidate_12/NN (r_nsubjpass) replaced_14/VBN (r_advcl) diminished_7/VBN (r_conj) ensued_5/VBD (l_nsubj) behavior_4/NN
D008774_D000544 NONE methylphenidate_18/NN (r_pobj) on_17/IN (r_prep) started_16/VBN (l_nsubjpass) man_4/NN (l_prep) with_5/IN (l_pobj) depression_9/NN (l_conj) disease_14/NN
D008774_D061218 NONE methylphenidate_18/NN (r_pobj) on_17/IN (r_prep) started_16/VBN (l_nsubjpass) man_4/NN (l_prep) with_5/IN (l_pobj) depression_9/NN
D016666_D009771 NONE fluvoxamine_16/NN (r_pobj) by_15/IN (r_agent) replaced_14/VBN (r_advcl) diminished_7/VBN (r_conj) ensued_5/VBD (l_nsubj) behavior_4/NN
15673851
D009020_D020760 NONE morphine_23/NN (r_pobj) by_21/IN (r_agent) induced_20/VBN (l_prep) after_24/IN (l_pobj) interval_27/NN (l_prep) of_28/IN (l_pobj) ischemia_31/NN
D016291_D020336 NONE MK-801_8/NNP (r_punct) (_9/-LRB- (r_punct) mug_11/NN (l_prep) on_13/IN (l_pobj) changes_16/NNS (l_prep) after_21/IN (l_pobj) paraparesis_26/NN
D016291_D020336 NONE MK-801_1/NNP (r_punct) reduced_3/VBD (l_prep) after_13/IN (l_pobj) paraparesis_18/NN
D009020_D001157 NONE morphine_27/NN (r_pobj) after_25/IN (r_prep) degeneration_6/NN (l_prep) following_28/VBG (l_pobj) interval_31/NN (l_prep) of_32/IN (l_pobj) occlusion_34/NN
D016202_D020760 NONE aspartate_10/NN (r_compound) receptors_11/NNS (r_pobj) of_2/IN (r_prep) activation_1/NN (r_nsubj) contribute_13/VB (l_prep) to_14/IN (l_pobj) degeneration_15/NN (l_acl) induced_20/VBN (l_prep) after_24/IN (l_pobj) interval_27/NN (l_prep) of_28/IN (l_pobj) ischemia_31/NN
D016202_D020760 NONE NMDA_15/NNP (r_compound) activation_17/NN (r_pobj) via_14/IN (r_prep) ischemia_13/NN
D016202_D020336 NONE NMDA_21/NNP (r_compound) activation_23/NN (r_pobj) in_20/IN (r_prep) involved_19/VBN (r_relcl) glutamate_15/NN (r_pobj) in_13/IN (r_prep) increase_12/NN (r_pobj) with_9/IN (r_prep) induces_6/VBZ (l_dobj) paraparesis_8/NN
D018698_D020336 NONE glutamate_15/NN (r_pobj) in_13/IN (r_prep) increase_12/NN (r_pobj) with_9/IN (r_prep) induces_6/VBZ (l_dobj) paraparesis_8/NN
D016202_D001157 NONE aspartate_20/NNP (r_nmod) receptors_24/NNS (r_pobj) of_13/IN (r_prep) activation_12/NN (r_conj) neurons_10/NNS (r_pobj) of_7/IN (r_prep) degeneration_6/NN (l_prep) following_28/VBG (l_pobj) interval_31/NN (l_prep) of_32/IN (l_pobj) occlusion_34/NN
D016202_D001157 NONE NMDA_22/NNP (r_nmod) receptors_24/NNS (r_pobj) of_13/IN (r_prep) activation_12/NN (r_conj) neurons_10/NNS (r_pobj) of_7/IN (r_prep) degeneration_6/NN (l_prep) following_28/VBG (l_pobj) interval_31/NN (l_prep) of_32/IN (l_pobj) occlusion_34/NN
D009020_D020336 CID morphine_22/NN (r_npadvmod) induced_24/VBN (r_amod) paraparesis_26/NN
D009020_D020336 CID morphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) paraparesis_18/NN
D009020_D020336 CID morphine_5/NN (r_nsubj) induces_6/VBZ (l_dobj) paraparesis_8/NN
D016202_D020258 NONE NMDA_15/NNP (r_compound) activation_17/NN (r_pobj) via_14/IN (r_prep) ischemia_13/NN (r_pobj) of_10/IN (r_prep) setting_9/NN (r_pobj) in_7/IN (r_prep) be_5/VB (l_acomp) neurotoxic_6/JJ
11827497
D006493_D001157 CID Heparin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN (r_nsubj) presents_4/VBZ (l_prep) after_9/IN (l_pobj) exposure_11/NN (l_prep) with_13/IN (l_conj) without_15/IN (l_pobj) thromboemboli_19/NN
D006493_D001157 CID heparin_10/JJ (r_compound) exposure_11/NN (l_prep) with_13/IN (l_conj) without_15/IN (l_pobj) thromboemboli_19/NN
D006493_D013923 NONE heparin_9/NN (r_npadvmod) induced_11/VBN (r_amod) thrombocytopenia_12/NN (r_nsubj) became_13/VBD (l_prep) on_15/IN (l_pobj) presentation_17/NN (l_prep) with_18/IN (l_pobj) complications_20/NNS (l_compound) thromboembolic_19/JJ
D006493_D013923 NONE heparin_13/NN (r_npadvmod) induced_15/VBN (r_nmod) factor_17/NN (r_pobj) of_12/IN (r_prep) results_11/NNS (r_appos) counts_3/VBZ (l_appos) onset_5/NN (l_prep) of_6/IN (l_pobj) thromboembolism_9/NN
D006493_D013923 NONE heparin_9/JJ (r_compound) exposure_10/NN (r_dobj) included_8/VBN (r_relcl) hospitalizations_5/NNS (r_pobj) after_4/IN (r_prep) went_2/VBD (l_advcl) return_23/VB (l_prep) with_33/IN (l_pobj) complications_35/NNS (l_compound) thromboembolic_34/JJ
D006493_D013923 NONE heparin_8/NN (r_npadvmod) induced_10/VBN (r_amod) thrombocytopenia_11/NN (r_dobj) consider_7/VB (l_advcl) returns_17/NNS (l_prep) with_18/IN (l_pobj) thromboembolism_19/NN
D006493_D013923 NONE heparin_27/VBN (r_appos) anticoagulants_24/NNS (r_pobj) with_22/IN (r_prep) therapy_21/NN (r_nsubjpass) initiated_31/VBN (l_ccomp) consider_7/VB (l_advcl) returns_17/NNS (l_prep) with_18/IN (l_pobj) thromboembolism_19/NN
D006493_D013921 CID heparin_3/NN (r_npadvmod) induced_5/VBN (r_amod) thrombocytopenia_6/NN
D006493_D013921 CID Heparin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN
D006493_D013921 CID heparin_10/JJ (r_compound) exposure_11/NN (r_pobj) after_9/IN (r_prep) presents_4/VBZ (l_nsubj) thrombocytopenia_3/NN
D006493_D013921 CID heparin_5/NN (r_npadvmod) induced_7/VBN (r_amod) thrombocytopenia_8/NN
D006493_D013921 CID heparin_16/NN (r_npadvmod) induced_18/VBN (r_amod) thrombocytopenia_19/NN
D006493_D013921 CID heparin_9/NN (r_npadvmod) induced_11/VBN (r_amod) thrombocytopenia_12/NN
D006493_D013921 CID heparin_9/JJ (r_compound) exposure_10/NN (r_dobj) included_8/VBN (r_relcl) hospitalizations_5/NNS (r_pobj) after_4/IN (r_prep) went_2/VBD (l_prep) with_16/IN (l_pobj) thrombocytopenia_18/NN
D006493_D013921 CID heparin_3/NN (r_npadvmod) induced_5/VBN (r_amod) thrombocytopenia_6/NN
D006493_D013921 CID heparin_8/NN (r_npadvmod) induced_10/VBN (r_amod) thrombocytopenia_11/NN
D006493_D013921 CID heparin_27/VBN (r_appos) anticoagulants_24/NNS (r_pobj) with_22/IN (r_prep) therapy_21/NN (r_nsubjpass) initiated_31/VBN (l_ccomp) consider_7/VB (l_dobj) thrombocytopenia_11/NN
D006493_D054556 CID Heparin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN (r_nsubj) presents_4/VBZ (l_prep) after_9/IN (l_pobj) exposure_11/NN (l_prep) with_13/IN (l_conj) without_15/IN (l_pobj) thromboemboli_19/NN
D006493_D054556 CID heparin_10/JJ (r_compound) exposure_11/NN (l_prep) with_13/IN (l_conj) without_15/IN (l_pobj) thromboemboli_19/NN
11890511
11245434
D016190_D009369 NONE carboplatin_3/NN (r_amod) treatment_4/NN (r_pobj) after_2/IN (r_prep) implanted_16/VBN (l_nsubjpass) tumors_6/NNS
D016190_D009369 NONE carboplatin_1/NN (l_conj) influenced_5/VBN (l_dobj) rate_8/NN (l_compound) tumor_6/NN
D003520_D000740 NONE cyclophosphamide_8/NN (r_compound) cytotoxicity_9/NN (r_pobj) in_7/IN (r_prep) reduction_6/NN (l_amod) induced_5/VBN (l_npadvmod) anemia_3/NN
D003520_D000740 NONE cyclophosphamide_25/NN (r_pobj) of_24/IN (r_prep) cytotoxicity_23/NN (r_pobj) on_21/IN (r_prep) treatment_20/NN (r_pobj) by_13/IN (r_prep) impact_9/NN (l_prep) of_10/IN (l_pobj) prevention_12/NN (l_compound) anemia_11/NN
D003520_D000740 NONE cyclophosphamide_11/NN (r_pobj) of_10/IN (r_prep) cytotoxicity_9/NN (r_dobj) reduces_8/VBZ (l_nsubj) anemia_7/NN
D003520_D000740 NONE cyclophosphamide_11/NN (r_pobj) of_10/IN (r_prep) cytotoxicity_9/NN (r_dobj) reduces_8/VBZ (l_advcl) increases_26/VBZ (l_nsubj) correction_16/NN (l_prep) of_17/IN (l_pobj) anemia_18/NN
D010100_D064420 NONE oxygen_37/NN (r_compound) supply_38/NN (r_pobj) of_34/IN (r_prep) result_33/NN (r_pobj) as_31/IN (r_prep) increases_26/VBZ (r_advcl) reduces_8/VBZ (l_dobj) cytotoxicity_9/NN
D010100_D009369 NONE oxygen_37/NN (r_compound) supply_38/NN (r_pobj) of_34/IN (r_prep) result_33/NN (r_pobj) as_31/IN (r_prep) increases_26/VBZ (r_advcl) reduces_8/VBZ (l_dobj) cytotoxicity_9/NN (l_prep) in_12/IN (l_pobj) tumors_13/NNS
D010100_D009369 NONE oxygen_37/NN (r_compound) supply_38/NN (l_prep) to_39/IN (l_pobj) tissue_41/NN (l_compound) tumor_40/NN
D003520_D064420 NONE cyclophosphamide_8/NN (r_compound) cytotoxicity_9/NN
D003520_D064420 NONE cyclophosphamide_25/NN (r_pobj) of_24/IN (r_prep) cytotoxicity_23/NN
D003520_D064420 NONE cyclophosphamide_11/NN (r_pobj) of_10/IN (r_prep) cytotoxicity_9/NN
D016190_D000740 CID carboplatin_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (r_dobj) using_3/VBG (r_xcomp) induced_2/VBN (l_nsubjpass) Anemia_0/NN
D016190_D000740 CID carboplatin_29/NN (r_amod) application_30/NN (r_pobj) before_28/IN (r_prep) days_27/NNS (r_dobj) starting_25/VBG (r_advcl) administered_19/VBN (r_conj) prevented_10/VBN (l_nsubjpass) development_6/NN (l_prep) of_7/IN (l_pobj) anemia_8/NN
D010100_D000740 NONE oxygen_37/NN (r_compound) supply_38/NN (r_pobj) of_34/IN (r_prep) result_33/NN (r_pobj) as_31/IN (r_prep) increases_26/VBZ (r_advcl) reduces_8/VBZ (l_nsubj) anemia_7/NN
D010100_D000740 NONE oxygen_37/NN (r_compound) supply_38/NN (r_pobj) of_34/IN (r_prep) result_33/NN (r_pobj) as_31/IN (r_prep) increases_26/VBZ (l_nsubj) correction_16/NN (l_prep) of_17/IN (l_pobj) anemia_18/NN
D003520_D009369 NONE cyclophosphamide_8/NN (r_compound) cytotoxicity_9/NN (l_prep) in_10/IN (l_pobj) tumors_12/NNS
D003520_D009369 NONE cyclophosphamide_25/NN (r_pobj) of_24/IN (r_prep) cytotoxicity_23/NN (l_prep) in_26/IN (l_pobj) tumors_29/NNS
D003520_D009369 NONE cyclophosphamide_9/NN (r_pobj) of_8/IN (r_prep) dose_7/NN (r_pobj) with_4/IN (r_prep) treated_3/VBN (l_nsubjpass) tumors_1/NNS
D003520_D009369 NONE cyclophosphamide_9/NN (r_pobj) of_8/IN (r_prep) dose_7/NN (r_pobj) with_4/IN (r_prep) treated_3/VBN (r_advcl) observed_31/VBN (l_nsubjpass) delay_22/NN (l_prep) with_23/IN (l_pobj) regrowth_26/NN (l_prep) of_27/IN (l_pobj) tumors_29/NNS
D003520_D009369 NONE cyclophosphamide_11/NN (r_pobj) of_10/IN (r_prep) cytotoxicity_9/NN (l_prep) in_12/IN (l_pobj) tumors_13/NNS
D003520_D009369 NONE cyclophosphamide_11/NN (r_pobj) of_10/IN (r_prep) cytotoxicity_9/NN (r_dobj) reduces_8/VBZ (l_advcl) increases_26/VBZ (l_prep) as_31/IN (l_pobj) result_33/NN (l_prep) of_34/IN (l_pobj) supply_38/NN (l_prep) to_39/IN (l_pobj) tissue_41/NN (l_compound) tumor_40/NN
D016190_D012509 NONE carboplatin_3/NN (r_amod) treatment_4/NN (r_pobj) after_2/IN (r_prep) implanted_16/VBN (l_nsubjpass) tumors_6/NNS (l_appos) sarcoma_10/NN
7843916
D013256_D005901 NONE Steroid_0/NN (r_compound) treatment_1/NN (r_nsubj) resulted_2/VBD (l_prep) in_3/IN (l_pobj) changes_5/NNS (l_prep) in_6/IN (l_pobj) meshwork_9/NN (l_amod) similar_10/JJ (l_prep) to_11/IN (l_pobj) those_12/DT (l_acl) reported_13/VBN (l_prep) for_14/IN (l_pobj) glaucoma_16/NN
D013256_D005902 NONE Steroid_0/NN (r_compound) treatment_1/NN (r_nsubj) resulted_2/VBD (l_prep) in_3/IN (l_pobj) changes_5/NNS (l_prep) in_6/IN (l_pobj) meshwork_9/NN (l_amod) similar_10/JJ (l_prep) to_11/IN (l_pobj) those_12/DT (l_acl) reported_13/VBN (l_prep) for_14/IN (l_pobj) glaucoma_16/NN (l_conj) glaucoma_20/NN
D003907_D009798 CID Dexamethasone_0/NN (r_npadvmod) induced_2/VBN (l_dobj) hypertension_4/NN
D003907_D009798 CID dexamethasone_4/NN (r_npadvmod) treated_6/VBN (r_amod) eyes_8/NNS
D003907_D009798 CID Dexamethasone_0/NN (r_compound) treatment_1/NN (r_nsubj) led_10/VBD (l_prep) to_11/IN (l_pobj) generation_13/NN (l_prep) of_14/IN (l_pobj) hypertension_16/NN
D003907_D009798 CID dexamethasone_23/NN (r_npadvmod) treated_25/VBN (r_amod) eyes_26/NNS (r_pobj) of_21/IN (r_prep) %_20/NN (r_pobj) in_17/IN (r_prep) generation_13/NN (l_prep) of_14/IN (l_pobj) hypertension_16/NN
3001299
D008094_D018500 NONE lithium_22/NN (r_compound) treatment_23/NN (r_pobj) during_21/IN (r_prep) development_13/NN (l_prep) of_14/IN (l_pobj) insipidus_18/NN
D008094_D007037 CID lithium_22/NN (r_compound) treatment_23/NN (r_pobj) during_21/IN (r_prep) development_13/NN (l_prep) of_14/IN (l_pobj) insipidus_18/NN (l_conj) hypothyroidism_20/NN
D008094_D007037 CID lithium_9/NN (r_dobj) taking_8/VBG (r_advcl) developed_1/VBD (l_nsubj) Hypothyroidism_0/NN
18006530
D015742_D010146 CID propofol_9/NN (r_pobj) with_5/IN (r_prep) induction_4/NN (r_pobj) during_3/IN (r_prep) Reduction_0/NN (l_prep) of_1/IN (l_pobj) pain_2/NN
D015742_D010146 CID propofol_4/NN (r_pobj) of_3/IN (r_prep) injection_2/NN (r_pobj) on_1/IN (r_prep) Pain_0/NN
D015742_D010146 CID propofol_3/JJ (r_amod) pain_5/NN
D015742_D010146 CID propofol_15/JJ (r_amod) infusion_16/NN (r_dobj) starting_13/VBG (r_pcomp) before_12/IN (r_prep) infusing_10/VBG (r_pcomp) by_9/IN (r_prep) prevented_8/VBN (l_nsubjpass) pain_5/NN
D015742_D010146 CID propofol_15/NN (r_pobj) by_14/IN (r_agent) caused_13/VBN (r_acl) pain_12/NN
D015742_D010146 CID propofol_26/JJ (r_amod) infusion_27/NN (r_pobj) during_24/IN (r_prep) using_18/VBG (r_advcl) evaluated_17/VBN (l_nsubjpass) pain_12/NN
D015742_D010146 CID propofol_7/NN (r_pobj) of_6/IN (r_prep) anaesthesia_3/NN (r_pobj) of_2/IN (r_prep) induction_1/NN (r_pobj) During_0/IN (r_prep) achieved_19/VBN (l_nsubjpass) reduction_13/NN (l_prep) in_14/IN (l_pobj) pain_17/NN
D015742_D010146 CID propofol_15/JJ (r_amod) pain_17/NN
C071741_D010146 NONE remifentanil_11/NN (r_conj) propofol_9/NN (r_pobj) with_5/IN (r_prep) induction_4/NN (r_pobj) during_3/IN (r_prep) Reduction_0/NN (l_prep) of_1/IN (l_pobj) pain_2/NN
C071741_D010146 NONE remifentanil_11/NN (r_dobj) infusing_10/VBG (r_pcomp) by_9/IN (r_prep) prevented_8/VBN (l_nsubjpass) pain_5/NN
C071741_D010146 NONE remifentanil_26/NN (r_pobj) of_25/IN (r_prep) Ce_23/NNP (r_appos) concentration_21/NN (l_relcl) prevent_28/VB (l_dobj) pain_30/NN
C071741_D010146 NONE Remifentanil_0/NN (r_npadvmod) related_2/VBN (r_amod) complications_3/NNS (r_nsubjpass) assessed_5/VBN (l_conj) evaluated_17/VBN (l_nsubjpass) pain_12/NN
C071741_D010146 NONE remifentanil_8/NN (r_compound) infusion_9/NN (r_pobj) during_6/IN (r_prep) assessed_5/VBN (l_conj) evaluated_17/VBN (l_nsubjpass) pain_12/NN
C071741_D010146 NONE remifentanil_9/NN (r_conj) propofol_7/NN (r_pobj) of_6/IN (r_prep) anaesthesia_3/NN (r_pobj) of_2/IN (r_prep) induction_1/NN (r_pobj) During_0/IN (r_prep) achieved_19/VBN (l_nsubjpass) reduction_13/NN (l_prep) in_14/IN (l_pobj) pain_17/NN
C071741_D010146 NONE remifentanil_27/NN (r_pobj) of_26/IN (r_prep) administration_25/NN (r_pobj) by_23/IN (r_prep) complications_22/NNS (r_pobj) without_20/IN (r_prep) achieved_19/VBN (l_nsubjpass) reduction_13/NN (l_prep) in_14/IN (l_pobj) pain_17/NN
804391
D012293_D014376 NONE rifampin_8/NN (r_advmod) treated_9/VBN (r_amod) patients_10/NNS (l_prep) with_11/IN (l_pobj) tuberculosis_12/NN
D012293_D014376 NONE rifampin_13/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (l_nsubj) patients_10/NNS (l_compound) tuberculosis_9/NN
D012293_D011507 CID rifampin_8/NN (r_advmod) treated_9/VBN (r_amod) patients_10/NNS (r_pobj) in_7/IN (r_prep) proteinuria_2/NN
D012293_D011507 CID rifampin_13/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_advcl) found_4/VBN (l_nsubjpass) proteinuria_2/NN
3311455
D016572_D007674 CID cyclosporine_17/NN (r_pobj) with_16/IN (r_prep) therapy_15/NN (r_pobj) to_11/IN (r_prep) secondary_10/JJ (r_amod) nephrotoxicity_9/NN
D016572_D007674 CID cyclosporine_8/NN (r_pobj) of_7/IN (r_prep) dosages_6/NNS (r_nsubj) cause_10/VB (l_dobj) nephrotoxicity_12/NN
18441470
D008094_D013575 NONE lithium_17/NN (r_compound) therapy_18/NN (r_pobj) to_16/IN (r_prep) developed_14/VBD (l_nsubj) block_10/NN (l_prep) with_11/IN (l_pobj) attacks_13/NNS
D008094_D013575 NONE lithium_1/NN (r_compound) levels_2/NNS (r_nsubj) remained_3/VBD (l_prep) during_10/IN (l_pobj) attacks_13/NNS
D008094_D054537 CID lithium_5/NN (r_compound) therapy_6/NN (r_pobj) to_4/IN (r_prep) secondary_3/JJ (r_amod) block_2/NN
D008094_D054537 CID lithium_17/NN (r_compound) therapy_18/NN (r_pobj) to_16/IN (r_prep) developed_14/VBD (l_nsubj) block_10/NN
D008094_D012804 CID lithium_14/NN (r_pobj) of_13/IN (r_prep) effects_12/NNS (r_pobj) among_8/IN (r_prep) reported_5/VBN (l_nsubjpass) dysfunction_2/NN
6216862
D010396_D012871 NONE penicillamine_32/NN (r_pobj) with_31/IN (r_prep) treated_30/VBN (r_acl) patients_26/NNS (r_pobj) in_25/IN (r_conj) reported_11/VBN (r_relcl) serpiginosa_6/NN (r_dobj) resembled_3/VBD (l_nsubj) lesion_2/NN
D010396_D011507 CID penicillamine_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) complications_18/NNS (r_pobj) as_17/IN (r_prep) recorded_16/VBN (l_nsubjpass) rashes_1/NNS (l_conj) proteinuria_3/NN
D010396_D017285 CID penicillamine_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) complications_18/NNS (r_pobj) as_17/IN (r_prep) recorded_16/VBN (l_nsubjpass) rashes_1/NNS (l_conj) proteinuria_3/NN (l_conj) erythematosus_7/NN (l_conj) polymyositis_9/NN
D010396_D008180 CID penicillamine_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) complications_18/NNS (r_pobj) as_17/IN (r_prep) recorded_16/VBN (l_nsubjpass) rashes_1/NNS (l_conj) proteinuria_3/NN (l_conj) erythematosus_7/NN
D010396_D001172 NONE penicillamine_4/NN (r_compound) therapy_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) in_6/IN (l_pobj) patient_8/NN (l_prep) with_9/IN (l_pobj) arthritis_11/NN
D010396_D001172 NONE penicillamine_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) complications_18/NNS (l_prep) in_22/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) arthritis_26/NN
D010396_D001172 NONE penicillamine_32/NN (r_pobj) with_31/IN (r_prep) treated_30/VBN (r_acl) patients_26/NNS (l_prep) with_27/IN (l_pobj) arthritis_29/NN
D010396_D005076 CID penicillamine_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) complications_18/NNS (r_pobj) as_17/IN (r_prep) recorded_16/VBN (l_nsubjpass) rashes_1/NNS
D010396_C536202 NONE penicillamine_32/NN (r_pobj) with_31/IN (r_prep) treated_30/VBN (r_acl) patients_26/NNS (r_pobj) in_25/IN (r_conj) reported_11/VBN (r_relcl) serpiginosa_6/NN
D010396_D009157 CID penicillamine_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) complications_18/NNS (r_pobj) as_17/IN (r_prep) recorded_16/VBN (l_nsubjpass) rashes_1/NNS (l_conj) proteinuria_3/NN (l_conj) erythematosus_7/NN (l_conj) polymyositis_9/NN (l_conj) gravis_12/NN
D010396_D006527 NONE penicillamine_32/NN (r_pobj) with_31/IN (r_prep) treated_30/VBN (r_acl) patients_26/NNS (r_pobj) in_25/IN (r_conj) reported_11/VBN (l_prep) as_12/IN (l_pobj) effect_16/NN (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) disease_22/NN
7707116
D015474_D064420 NONE RA_24/NNP (r_pobj) of_21/IN (r_prep) toxicities_17/NNS
D015474_D064420 NONE RA_6/NNP (r_nsubjpass) discontinued_8/VBN (r_advcl) resolved_2/VBD (l_nsubj) toxicities_1/NNS
D015474_D006934 CID RA_13/NNP (r_compound) levels_14/NNS (r_pobj) by_9/IN (r_agent) predicted_8/VBN (r_conj) included_2/VBD (l_dobj) hypercalcemia_3/NN
D015474_D009447 NONE acid_7/NN (r_pobj) of_3/IN (r_prep) trial_2/NN (l_prep) in_8/IN (l_pobj) children_9/NNS (l_prep) with_10/IN (l_pobj) neuroblastoma_11/NN
D015474_D009447 NONE acid_11/NN (r_pobj) with_7/IN (r_prep) lines_6/NNS (l_compound) neuroblastoma_4/NN
D015474_D009447 NONE RA_15/NNP (r_appos) acid_11/NN (r_pobj) with_7/IN (r_prep) lines_6/NNS (l_compound) neuroblastoma_4/NN
D015474_D009447 NONE RA_3/NNP (r_nsubj) demonstrated_5/VBN (l_dobj) responses_7/NNS (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_compound) neuroblastoma_9/NN
D015474_D009447 NONE RA_24/NNP (r_pobj) of_21/IN (r_prep) toxicities_17/NNS (l_acl) administered_25/VBD (l_prep) on_26/IN (l_pobj) schedule_29/NN (l_prep) in_30/IN (l_pobj) children_31/NNS (l_prep) with_32/IN (l_pobj) neuroblastoma_33/NN
11079278
D008790_D017202 NONE metoprolol_3/NN (l_conj) metoprolol_6/NN (l_conj) glucagon_8/NN (l_prep) on_9/IN (l_pobj) ischemia_14/NN
D008790_D017202 NONE metoprolol_6/NN (l_conj) glucagon_8/NN (l_prep) on_9/IN (l_pobj) ischemia_14/NN
D008790_D017202 NONE metoprolol_5/FW (r_nsubj) attenuates_6/VBZ (l_conj) eliminates_8/VBZ (l_dobj) evidence_9/NN (l_prep) of_10/IN (l_pobj) ischemia_12/NN
D004280_D017202 CID dobutamine_10/NN (r_npadvmod) induced_12/VBN (r_amod) ischemia_14/NN
D004280_D017202 CID dobutamine_1/NN (r_pcomp) During_0/IN (r_prep) attenuates_6/VBZ (l_conj) eliminates_8/VBZ (l_dobj) evidence_9/NN (l_prep) of_10/IN (l_pobj) ischemia_12/NN
4038130
D008012_D009135 CID lidocaine_21/NN (r_conj) mepivacaine_19/NN (r_pobj) to_18/IN (r_prep) exposure_17/NN (r_pobj) after_16/IN (r_prep) seen_10/VBN (l_prep) In_0/IN (l_pobj) addition_1/NN (l_prep) to_2/IN (l_pobj) damage_4/NN
D008619_D009135 CID mepivacaine_19/NN (r_pobj) to_18/IN (r_prep) exposure_17/NN (r_pobj) after_16/IN (r_prep) seen_10/VBN (l_prep) In_0/IN (l_pobj) addition_1/NN (l_prep) to_2/IN (l_pobj) damage_4/NN
D004837_D009135 NONE epinephrine_23/NN (r_conj) mepivacaine_19/NN (r_pobj) to_18/IN (r_prep) exposure_17/NN (r_pobj) after_16/IN (r_prep) seen_10/VBN (l_prep) In_0/IN (l_pobj) addition_1/NN (l_prep) to_2/IN (l_pobj) damage_4/NN
2334179
D010396_D011507 CID Penicillamine_2/NN (r_nsubj) caused_3/VBD (l_prep) in_6/IN (l_pobj) patient_8/NN (l_conj) proteinuria_12/NN
D010396_D051437 NONE Penicillamine_2/NN (r_nsubj) caused_3/VBD (r_ccomp) developed_19/VBD (l_dobj) insufficiency_21/NN
D010396_D012594 NONE penicillamine_2/NN (l_prep) in_3/IN (l_pobj) treatment_5/NN (l_prep) of_6/IN (l_pobj) scleroderma_8/NN
D010396_D012594 NONE penicillamine_17/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) patients_4/NNS (l_prep) with_5/IN (l_pobj) scleroderma_10/NN
D010396_D012594 NONE penicillamine_6/NN (r_nsubj) be_8/VB (l_acomp) effective_9/JJ (l_prep) in_10/IN (l_pobj) cases_12/NNS (l_prep) of_13/IN (l_pobj) scleroderma_15/NN
D010396_D009404 CID Penicillamine_2/NN (r_nsubj) caused_3/VBD (l_dobj) syndrome_5/NN
1595783
D000638_D000542 NONE amiodarone_4/NN (r_pobj) of_3/IN (r_prep) toxicity_2/NN (r_nsubjpass) thought_6/VBN (l_xcomp) result_8/VB (l_prep) from_9/IN (l_pobj) injury_11/NN (l_acl) related_12/VBN (l_prep) to_13/IN (l_pobj) accumulation_16/NN (l_prep) of_17/IN (l_pobj) pneumonitis_25/NN
D000638_D008171 NONE Amiodarone_0/NN (r_amod) toxicity_2/NN
D000638_D008171 NONE amiodarone_4/NN (r_pobj) of_3/IN (r_prep) toxicity_2/NN
D000638_D008171 NONE amiodarone_6/NN (r_npadvmod) induced_8/VBN (r_amod) toxicity_10/NN
D000638_D004342 NONE amiodarone_4/NN (r_pobj) of_3/IN (r_prep) toxicity_2/NN (r_nsubjpass) thought_6/VBN (l_xcomp) result_8/VB (l_prep) from_9/IN (l_pobj) injury_11/NN (l_acl) related_12/VBN (l_prep) to_13/IN (l_pobj) accumulation_16/NN (l_prep) of_17/IN (l_pobj) pneumonitis_25/NN
D000638_D011014 CID Amiodarone_0/NN (r_nsubj) is_1/VBZ (l_attr) agent_5/NN (l_appos) being_19/VBG (l_attr) pneumonitis_20/NN
19058474
D014859_D010490 NONE warfarin_13/NN (r_pobj) with_12/IN (r_prep) interaction_8/NN (r_pobj) due_5/IN (r_prep) haemorrhage_4/NN (l_nmod) haemopericardium_1/NN
D014859_D006471 CID warfarin_13/NN (r_pobj) with_12/IN (r_prep) interaction_8/NN (r_pobj) due_5/IN (r_prep) haemorrhage_4/NN
D014859_D006470 NONE warfarin_26/NN (r_pobj) of_25/IN (r_prep) dosage_24/NN (r_dobj) maintaining_21/VBG (r_advcl) consumed_13/VBD (r_relcl) man_11/NN (r_pobj) in_8/IN (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) haemorrhage_7/NN
19721134
D010042_D001145 CID ouabain_24/NN (r_npadvmod) induced_26/VBN (r_amod) models_30/NNS (l_compound) arrhythmia_29/NN
D010042_D001145 CID ouabain_19/RB (r_conj) aconitine_17/NN (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) models_14/NNS (l_nmod) rat_10/NN (l_amod) arrhythmic_9/JJ
D000157_D001145 CID aconitine_19/NN (r_npadvmod) induced_21/VBN (r_amod) rat_22/NN (l_conj) models_30/NNS (l_compound) arrhythmia_29/NN
D000157_D001145 CID aconitine_17/NN (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) models_14/NNS (l_nmod) rat_10/NN (l_amod) arrhythmic_9/JJ
D010862_D001145 NONE pilocarpine_9/NN (r_pobj) of_8/IN (r_prep) effects_7/NNS (r_dobj) evaluate_5/VB (l_conj) explore_11/VB (l_conj) using_17/VBG (l_dobj) rat_22/NN (l_conj) models_30/NNS (l_compound) arrhythmia_29/NN
D010862_D001145 NONE pilocarpine_5/NN (r_amod) onset_8/NN (l_prep) of_9/IN (l_pobj) arrhythmias_10/NNS
D010862_D001145 NONE pilocarpine_5/NN (r_amod) onset_8/NN (r_dobj) showed_3/VBD (r_ccomp) decreased_12/VBD (l_npadvmod) score_24/NN (l_compound) arrhythmia_23/NN
D010862_D001145 NONE pilocarpine_5/NN (r_amod) onset_8/NN (r_dobj) showed_3/VBD (r_ccomp) decreased_12/VBD (l_npadvmod) score_24/NN (l_conj) increased_27/VBD (l_dobj) time_30/NN (l_prep) of_31/IN (l_pobj) rats_33/NNS (l_amod) arrhythmic_32/JJ
D010862_D001145 NONE pilocarpine_4/NN (r_nsubj) produced_5/VBD (l_dobj) actions_7/NNS (l_prep) on_8/IN (l_pobj) models_14/NNS (l_nmod) rat_10/NN (l_amod) arrhythmic_9/JJ
D010862_D014693 NONE pilocarpine_5/NN (r_amod) onset_8/NN (r_dobj) showed_3/VBD (r_ccomp) decreased_12/VBD (l_dobj) course_15/NN (l_prep) of_16/IN (l_pobj) tachycardia_18/NN (l_conj) fibrillation_20/NN
D010862_D017180 NONE pilocarpine_5/NN (r_amod) onset_8/NN (r_dobj) showed_3/VBD (r_ccomp) decreased_12/VBD (l_dobj) course_15/NN (l_prep) of_16/IN (l_pobj) tachycardia_18/NN (l_conj) fibrillation_20/NN
D002118_D001145 NONE Ca(2_34/NNP (r_pobj) of_33/IN (r_prep) improvement_32/NN (r_pobj) to_30/IN (r_prep) related_29/VBN (r_relcl) cardiac_23/JJ (r_dobj) stimulating_21/VBG (r_pcomp) via_20/IN (r_prep) ouabain_19/RB (r_conj) aconitine_17/NN (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) models_14/NNS (l_nmod) rat_10/NN (l_amod) arrhythmic_9/JJ
1141447
D008094_D003919 CID lithium_7/NN (r_npadvmod) induced_9/VBN (r_amod) insipidus_11/NN
D008094_D003919 CID lithium_3/NN (r_npadvmod) induced_5/VBN (r_amod) insipidus_7/NN
188339
D003276_D008113 CID contraceptives_11/NNS (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) tumors_7/NNS
D003276_D008113 CID contraceptive_18/JJ (r_amod) steroids_19/NNS (r_dobj) using_16/VBG (r_advcl) seen_12/VBN (l_nsubjpass) tumors_9/NNS
D013256_D008113 NONE steroids_19/NNS (r_dobj) using_16/VBG (r_advcl) seen_12/VBN (l_nsubjpass) tumors_9/NNS
9321531
D007980_D010300 NONE levodopa_11/RB (r_npadvmod) induced_13/VBN (r_amod) dyskinesias_14/NNS (r_dobj) reduces_10/VBZ (l_prep) In_0/IN (l_pobj) disease_6/NN
D007980_D004409 CID levodopa_11/RB (r_npadvmod) induced_13/VBN (r_amod) dyskinesias_14/NNS
17682013
D008727_D002544 NONE methotrexate_21/NN (r_pobj) of_19/IN (r_prep) recipients_18/NNS (r_pobj) in_17/IN (r_prep) described_8/VBN (l_nsubjpass) leukoencephalopathy_2/JJ (l_acl) mimicking_3/VBG (l_dobj) accident_5/NN
D008727_D007938 NONE methotrexate_21/NN (l_prep) for_22/IN (l_pobj) leukaemia_24/NN
C017367_D056784 CID carmofur_23/NN (r_conj) identified_2/VBD (l_dobj) reports_4/NNS (l_prep) of_5/IN (l_pobj) leukoencephalopathy_7/JJ
C110904_D056784 CID capecitabine_26/NN (r_conj) carmofur_23/NN (r_conj) identified_2/VBD (l_dobj) reports_4/NNS (l_prep) of_5/IN (l_pobj) leukoencephalopathy_7/JJ
D008727_D056784 CID methotrexate_21/NN (r_pobj) of_19/IN (r_prep) recipients_18/NNS (r_pobj) in_17/IN (r_prep) described_8/VBN (l_nsubjpass) leukoencephalopathy_2/JJ
D008727_D056784 CID methotrexate_12/NNP (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_acl) patients_9/NNS (r_pobj) in_8/IN (r_prep) leukoencephalopathy_7/JJ
D005472_D056784 CID 5-fluorouracil_19/CD (r_punct) identified_2/VBD (l_dobj) reports_4/NNS (l_prep) of_5/IN (l_pobj) leukoencephalopathy_7/JJ
12448656
D013792_D002292 NONE thalidomide_5/NN (r_pobj) of_4/IN (r_prep) study_3/NN (l_prep) in_6/IN (l_pobj) carcinoma_11/NN
D013792_D002292 NONE thalidomide_9/NN (r_pobj) of_8/IN (r_prep) toxicity_5/NN (r_dobj) evaluate_3/VB (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) cancer_17/NN
D013792_D002292 NONE thalidomide_11/NN (r_pobj) of_10/IN (r_prep) activity_9/NN (r_pobj) of_8/IN (r_prep) level_7/NN (l_prep) in_12/IN (l_pobj) carcinoma_15/NN
D013792_D002292 NONE thalidomide_10/NN (l_prep) for_11/IN (l_pobj) carcinoma_14/NN
D013792_D064420 NONE thalidomide_9/NN (r_pobj) of_8/IN (r_prep) toxicity_5/NN
10910842
D011239_D009468 NONE prednisolone_8/NN (r_pobj) after_7/IN (r_prep) dysfunction_6/NN
D014403_D013746 NONE tubocurarine_27/NN (r_pobj) of_24/IN (r_prep) curves_23/NNS (r_conj) fatigability_16/NN (r_conj) tensions_13/NNS (l_compound) tetanic_12/JJ
D011239_D018908 CID Prednisolone_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dysfunction_4/NN
D000109_D001284 NONE acetylcholine_13/NN (r_compound) expression_15/NN (r_pobj) by_11/IN (r_prep) than_10/IN (r_prep) atrophy_9/NN
D011239_D009133 CID prednisolone_8/NN (r_pobj) after_7/IN (r_prep) dysfunction_6/NN (r_nsubj) is_9/VBZ (l_conj) derives_15/VBZ (l_prep) from_17/IN (l_pobj) atrophy_19/NN
D011239_D001284 NONE Prednisolone_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dysfunction_4/NN (r_nsubjpass) caused_6/VBN (l_agent) by_8/IN (l_pobj) atrophy_9/NN
D000109_D009133 NONE acetylcholine_22/NN (r_compound) expression_24/NN (r_pobj) in_21/IN (r_prep) changes_20/NNS (r_pobj) from_19/IN (r_prep) less_18/JJR (r_advmod) derive_17/VB (r_conj) derive_11/VBP (l_prep) from_13/IN (l_pobj) atrophy_15/NN
D000109_D018908 NONE acetylcholine_13/NN (r_compound) expression_15/NN (r_pobj) by_11/IN (r_prep) than_10/IN (r_prep) atrophy_9/NN (r_pobj) by_8/IN (r_agent) caused_6/VBN (l_nsubjpass) dysfunction_4/NN
19719056
D019342_D010146 NONE acid_9/NN (r_dobj) using_7/VBG (r_advcl) ascertained_6/VBN (l_conj) induced_10/VBD (l_xcomp) writhing_11/VBG
D002351_D004487 CID carrageenan_17/NN (r_npadvmod) induced_19/VBN (r_amod) model_23/NN (l_compound) edema_22/NN
D019342_D004487 NONE acid_9/NN (r_dobj) using_7/VBG (r_advcl) ascertained_6/VBN (l_conj) induced_10/VBD (l_xcomp) writhing_11/VBG (l_attr) model_12/NN (l_appos) mice_14/NNS (l_conj) model_23/NN (l_compound) edema_22/NN
D002351_D010146 CID carrageenan_17/NN (r_npadvmod) induced_19/VBN (r_amod) model_23/NN (r_conj) mice_14/NNS (r_appos) model_12/NN (r_attr) writhing_11/VBG
16826348
D003561_D010523 CID arabinoside_8/NN (r_amod) treatment_9/NN (r_pobj) by_3/IN (r_agent) caused_2/VBN (r_acl) neuropathy_1/NNS
D003561_D010523 CID arabinoside_14/NN (r_nsubj) is_15/VBZ (l_advcl) are_6/VBP (l_nsubj) mechanisms_2/NNS (l_prep) of_3/IN (l_pobj) neuropathy_5/NN
D008775_D006086 NONE methylprednisolone_38/NN (r_pobj) to_37/IN (r_prep) responded_36/VBD (r_conj) worsened_19/VBD (l_prep) with_21/IN (l_pobj) development_23/NN (l_prep) of_24/IN (l_pobj) disease_30/NN
D003561_D006987 NONE arabinoside_8/NN (r_pobj) of_3/IN (r_prep) course_2/NN (r_nsubj) resulted_9/VBD (l_conj) complained_28/VBD (l_prep) of_29/IN (l_pobj) numbness_30/NN
D003561_D064420 NONE arabinoside_10/NN (r_pobj) of_5/IN (r_prep) toxicity_4/NN
D003561_D064420 NONE arabinoside_10/NN (r_pobj) of_5/IN (r_prep) toxicity_4/NN (r_nsubjpass) recognized_13/VBN (l_conj) reported_29/VBN (l_nsubjpass) toxicity_17/NN
D003561_D064420 NONE arabinoside_20/NN (r_pobj) of_18/IN (r_prep) toxicity_17/NN (r_nsubjpass) reported_29/VBN (r_conj) recognized_13/VBN (l_nsubjpass) toxicity_4/NN
D003561_D064420 NONE arabinoside_20/NN (r_pobj) of_18/IN (r_prep) toxicity_17/NN
D003561_D015470 NONE arabinoside_8/NN (r_amod) treatment_9/NN (l_prep) in_10/IN (l_pobj) patient_12/NN (l_prep) with_13/IN (l_pobj) leukemia_16/NN
D008775_D009422 NONE methylprednisolone_38/NN (r_pobj) to_37/IN (r_prep) responded_36/VBD (r_conj) worsened_19/VBD (l_ccomp) received_11/VBD (l_ccomp) resolving_4/VBG (l_nsubj) neuropathy_1/NN
3411101
C033457_D056486 CID phenylethylbarbiturate_1/NN (r_npadvmod) induced_3/VBN (l_dobj) hepatitis_5/NN
C033457_D056486 CID phenylethylbarbiturate_28/NN (r_pobj) of_26/IN (r_prep) administration_25/NN (r_pobj) after_22/IN (r_prep) affected_11/VBN (l_agent) by_12/IN (l_pobj) hepatitis_14/NN
C033457_D056486 CID phenylethylbarbiturate_3/NN (r_conj) Quinidine_0/NN (r_nsubj) be_5/VB (l_acomp) responsible_6/JJ (l_prep) for_7/IN (l_pobj) hepatitis_9/NN
D011802_D056486 NONE Quinidine_0/NN (r_nsubj) be_5/VB (l_acomp) responsible_6/JJ (l_prep) for_7/IN (l_pobj) hepatitis_9/NN
6637851
D000638_D014693 NONE amiodarone_10/NN (r_compound) therapy_11/NN (r_pobj) of_6/IN (r_prep) toxicity_5/NN (r_conj) efficacy_3/NN (l_prep) for_12/IN (l_pobj) tachycardia_14/NN (l_conj) fibrillation_17/NN
D000638_D014693 NONE amiodarone_9/NN (r_pobj) with_8/IN (r_prep) treatment_7/NN (r_dobj) continued_6/VBD (l_conj) had_11/VBD (l_dobj) recurrence_13/NN (l_prep) of_14/IN (l_pobj) VT_16/NNP (l_conj) fibrillation_19/NN
D000638_D014693 NONE amiodarone_9/NN (r_pobj) with_8/IN (r_prep) treatment_7/NN (r_dobj) continued_6/VBD (l_conj) had_11/VBD (l_dobj) recurrence_13/NN (l_prep) of_14/IN (l_pobj) VT_16/NNP (l_appos) VF_21/NNP
D000638_D014693 NONE amiodarone_4/NN (r_nsubj) is_5/VBZ (l_prep) in_8/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) VT_15/NNP (l_conj) refractory_18/NN (l_compound) VF_17/NNP
D000638_D014693 NONE amiodarone_31/NN (r_pobj) with_30/IN (r_prep) managed_29/VBN (l_nsubjpass) %_19/NN (l_prep) of_20/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) VT_23/NNP (l_conj) VF_25/NNP
D000638_D017180 NONE amiodarone_10/NN (r_compound) therapy_11/NN (r_pobj) of_6/IN (r_prep) toxicity_5/NN (r_conj) efficacy_3/NN (l_prep) for_12/IN (l_pobj) tachycardia_14/NN
D000638_D017180 NONE Amiodarone_0/NNP (r_nsubjpass) administered_2/VBN (l_prep) to_3/IN (l_pobj) patients_5/NNS (l_relcl) sustained_8/VBN (l_dobj) tachycardia_12/NN
D000638_D017180 NONE Amiodarone_0/NNP (r_nsubjpass) administered_2/VBN (l_prep) to_3/IN (l_pobj) patients_5/NNS (l_relcl) sustained_8/VBN (l_dobj) tachycardia_12/NN (l_appos) VT_14/NNP
D000638_D017180 NONE amiodarone_9/NN (r_pobj) with_8/IN (r_prep) treatment_7/NN (r_dobj) continued_6/VBD (l_conj) had_11/VBD (l_dobj) recurrence_13/NN (l_prep) of_14/IN (l_pobj) VT_16/NNP
D000638_D017180 NONE amiodarone_17/NN (r_pobj) by_15/IN (r_agent) managed_14/VBN (r_conj) had_5/VBD (l_dobj) recurrence_8/NN (l_prep) of_9/IN (l_pobj) VT_10/NNP
D000638_D017180 NONE amiodarone_4/NN (r_nsubj) is_5/VBZ (l_prep) in_8/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) VT_15/NNP
D000638_D017180 NONE amiodarone_31/NN (r_pobj) with_30/IN (r_prep) managed_29/VBN (l_nsubjpass) %_19/NN (l_prep) of_20/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) VT_23/NNP
D000638_D064420 NONE amiodarone_10/NN (r_compound) therapy_11/NN (r_pobj) of_6/IN (r_prep) toxicity_5/NN
D000638_D064420 NONE amiodarone_4/NN (r_nsubj) is_5/VBZ (r_advcl) causes_25/VBZ (l_dobj) toxicity_27/NN
D000638_D006323 NONE Amiodarone_0/NNP (r_nsubjpass) administered_2/VBN (l_prep) to_3/IN (l_pobj) patients_5/NNS (l_conj) arrest_24/NN
950631
D010396_D007674 CID penicillamine_2/NN (r_npadvmod) induced_4/VBN (r_amod) disease_6/NN
D010396_D011507 CID penicillamine_18/NN (r_pobj) with_15/IN (r_prep) treatment_14/NN (r_pobj) of_13/IN (r_prep) months_12/NNS (r_pobj) after_8/IN (r_prep) developed_5/VBD (l_dobj) proteinuria_7/NN
D010396_D001172 NONE penicillamine_18/NN (r_pobj) with_15/IN (r_prep) treatment_14/NN (r_pobj) of_13/IN (r_prep) months_12/NNS (r_pobj) after_8/IN (r_prep) developed_5/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) arthritis_4/NN
8958188
D008727_D009369 NONE methotrexate_22/NNP (r_appos) drugs_19/NNS (r_pobj) to_17/IN (r_prep) refractory_16/JJ (r_acomp) are_15/VBP (r_relcl) tumours_13/NNS
D005492_D064420 NONE acid_16/NN (r_compound) administration_17/NN (r_pobj) by_12/IN (r_agent) prevented_11/VBN (l_nsubjpass) toxicity_6/NN
D005492_D064420 NONE acid_13/NN (r_compound) supplementation_14/NN (l_relcl) confirmed_17/VBN (l_ccomp) reduced_26/VBN (l_nsubjpass) toxicity_20/NN
D005492_D064420 NONE acid_29/NN (r_compound) supplementation_30/NN (r_pobj) by_27/IN (r_agent) reduced_26/VBN (l_nsubjpass) toxicity_20/NN
D005492_D064420 NONE folate_13/JJ (r_compound) elevation_14/NN (r_pobj) of_11/IN (r_prep) extent_10/NN (r_conj) toxicity_7/NN
D005492_D064420 NONE acid_12/NN (r_compound) administration_13/NN (r_pobj) by_10/IN (r_agent) altered_9/VBN (l_advcl) indicating_14/VBG (l_ccomp) is_17/VBZ (l_acomp) unlikely_18/JJ (l_xcomp) reduce_20/VB (l_dobj) toxicity_21/NN
C045894_D009369 NONE lometrexol_9/NN (r_nsubj) has_10/VBZ (l_dobj) activity_11/NN (l_prep) against_12/IN (l_pobj) tumours_13/NNS
C045894_D064420 NONE lometrexol_7/NN (r_pobj) of_6/IN (r_prep) development_5/NN (r_nsubjpass) curtailed_9/VBN (l_prep) because_10/IN (l_pobj) toxicities_16/NNS
C045894_D064420 NONE lometrexol_8/NN (r_pobj) of_7/IN (r_prep) toxicity_6/NN
C045894_D064420 NONE lometrexol_9/NN (r_pobj) of_8/IN (r_prep) study_7/NN (l_acl) given_10/VBN (l_prep) with_11/IN (l_pobj) supplementation_14/NN (l_relcl) confirmed_17/VBN (l_ccomp) reduced_26/VBN (l_nsubjpass) toxicity_20/NN
C045894_D064420 NONE lometrexol_22/NN (r_pobj) of_21/IN (r_prep) toxicity_20/NN
C045894_D064420 NONE lometrexol_4/NN (r_compound) plasma_5/NN (r_compound) pharmacokinetics_6/NNS (r_nsubjpass) altered_9/VBN (l_advcl) indicating_14/VBG (l_ccomp) is_17/VBZ (l_acomp) unlikely_18/JJ (l_xcomp) reduce_20/VB (l_dobj) toxicity_21/NN
C045894_D064420 NONE lometrexol_24/NN (r_compound) plasma_25/NN (r_compound) clearance_26/NN (r_dobj) enhancing_23/VBG (r_pcomp) by_22/IN (r_prep) reduce_20/VB (l_dobj) toxicity_21/NN
16634859
D000431_D006130 CID alcohol_9/NN (r_npadvmod) related_11/VBN (r_amod) impairment_14/NN
D000431_D006130 CID alcohol_1/NN (r_compound) consumption_2/NN (r_compound) recognition_4/NN (r_nsubj) resulted_9/VBD (l_prep) in_10/IN (l_pobj) growth_13/NN
D000431_D006130 CID alcohol_1/NN (r_compound) consumption_2/NN (r_compound) recognition_4/NN (r_nsubj) resulted_9/VBD (l_prep) in_10/IN (l_pobj) growth_13/NN (l_conj) cranial_18/JJ (l_acl) body_20/NN (l_dobj) growth_21/NN
8599504
D004329_D004487 NONE droperidol_39/NN (r_pobj) of_38/IN (r_prep) dose_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) of_30/IN (r_prep) minutes_29/NNS (r_pobj) within_27/IN (r_prep) developed_26/VBN (l_nsubj) angioedema_19/NN (l_prep) with_20/IN (l_pobj) swelling_23/NN
D004329_D004342 NONE droperidol_39/NN (r_pobj) of_38/IN (r_prep) dose_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) of_30/IN (r_prep) minutes_29/NNS (r_pobj) within_27/IN (r_prep) developed_26/VBN (r_relcl) allergies_16/NNS
D004329_D000799 CID droperidol_3/NN (r_compound) administration_4/NN (r_pobj) with_2/IN (r_prep) associated_1/VBD (r_acl) Angioedema_0/NNP
D004329_D000799 CID droperidol_39/NN (r_pobj) of_38/IN (r_prep) dose_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) of_30/IN (r_prep) minutes_29/NNS (r_pobj) within_27/IN (r_prep) developed_26/VBN (l_nsubj) angioedema_19/NN
D004329_D014060 NONE droperidol_39/NN (r_pobj) of_38/IN (r_prep) dose_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) of_30/IN (r_prep) minutes_29/NNS (r_pobj) within_27/IN (r_prep) developed_26/VBN (l_nsubj) angioedema_19/NN (l_prep) with_20/IN (l_pobj) swelling_23/NN
6817363
D003513_D003072 NONE cycloheximide_140/NN (r_conj) chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (r_conj) protection_94/NN (r_conj) prevention_74/NN (r_conj) rats_67/NNS (r_conj) prevention_40/NN (r_appos) effects_33/NNS (r_dobj) produced_30/VBD (r_conj) studied_13/VBN (l_prep) on_14/IN (l_pobj) forms_16/NNS (l_prep) of_17/IN (l_pobj) functions_21/NNS
D003513_D003072 NONE cycloheximide_177/NN (r_pobj) by_176/IN (r_agent) induced_175/VBN (r_acl) task_174/NN (r_pobj) of_170/IN (r_prep) retention_167/NN (r_pobj) in_166/IN (r_prep) deficit_165/NN (r_pobj) of_163/IN (r_prep) reversal_149/NN (r_conj) prevention_116/NN (r_conj) protection_94/NN (r_conj) prevention_74/NN (r_conj) rats_67/NNS (r_conj) prevention_40/NN (r_appos) effects_33/NNS (r_dobj) produced_30/VBD (r_conj) studied_13/VBN (l_prep) on_14/IN (l_pobj) forms_16/NNS (l_prep) of_17/IN (l_pobj) functions_21/NNS
C036466_D008569 NONE aniracetam_5/RB (l_appos) Ro_7/NNP (l_prep) upon_12/IN (l_pobj) learning_14/NN (l_conj) memory_16/NN
C036466_D008569 NONE 5057_10/CD (r_prep) 13_8/CD (r_nummod) Ro_7/NNP (l_prep) upon_12/IN (l_pobj) learning_14/NN (l_conj) memory_16/NN
D012601_D003072 NONE scopolamine_77/NN (r_npadvmod) induced_79/VBN (r_amod) amnesia_83/NN (r_pobj) of_75/IN (r_prep) prevention_74/NN (r_conj) rats_67/NNS (r_conj) prevention_40/NN (r_appos) effects_33/NNS (r_dobj) produced_30/VBD (r_conj) studied_13/VBN (l_prep) on_14/IN (l_pobj) forms_16/NNS (l_prep) of_17/IN (l_pobj) functions_21/NNS
C036466_D000647 NONE aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_conj) rats_67/NNS (l_conj) prevention_74/NN (l_prep) of_75/IN (l_pobj) amnesia_83/NN
C036466_D000647 NONE aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_conj) rats_67/NNS (l_conj) prevention_74/NN (l_conj) protection_94/NN (l_prep) against_95/IN (l_pobj) amnesia_96/NN
C036466_D000647 NONE 5057_8/CD (r_prep) 13_6/CD (r_nummod) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_conj) rats_67/NNS (l_conj) prevention_74/NN (l_prep) of_75/IN (l_pobj) amnesia_83/NN
C036466_D000647 NONE 5057_8/CD (r_prep) 13_6/CD (r_nummod) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_conj) rats_67/NNS (l_conj) prevention_74/NN (l_conj) protection_94/NN (l_prep) against_95/IN (l_pobj) amnesia_96/NN
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10/CD (r_appos) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_conj) rats_67/NNS (l_conj) prevention_74/NN (l_prep) of_75/IN (l_pobj) amnesia_83/NN
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10/CD (r_appos) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_conj) rats_67/NNS (l_conj) prevention_74/NN (l_conj) protection_94/NN (l_prep) against_95/IN (l_pobj) amnesia_96/NN
D002701_D003072 NONE chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (r_conj) protection_94/NN (r_conj) prevention_74/NN (r_conj) rats_67/NNS (r_conj) prevention_40/NN (r_appos) effects_33/NNS (r_dobj) produced_30/VBD (r_conj) studied_13/VBN (l_prep) on_14/IN (l_pobj) forms_16/NNS (l_prep) of_17/IN (l_pobj) functions_21/NNS
C036466_D003072 NONE aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_prep) on_14/IN (l_pobj) forms_16/NNS (l_prep) of_17/IN (l_pobj) functions_21/NNS
C036466_D003072 NONE 5057_8/CD (r_prep) 13_6/CD (r_nummod) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_prep) on_14/IN (l_pobj) forms_16/NNS (l_prep) of_17/IN (l_pobj) functions_21/NNS
C036466_D003072 NONE 1-anisoyl-2-pyrrolidinone_10/CD (r_appos) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_prep) on_14/IN (l_pobj) forms_16/NNS (l_prep) of_17/IN (l_pobj) functions_21/NNS
C036466_D003072 NONE aniracetam_12/JJ (r_amod) doses_13/NNS (r_pobj) at_10/IN (r_prep) seen_9/VBN (l_nsubjpass) improvements_1/NNS (l_conj) normalizations_3/NNS (l_prep) of_4/IN (l_pobj) functions_7/NNS
C036466_D006935 NONE aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_prep) of_41/IN (l_pobj) incapacity_43/NN (l_acl) learn_45/VB (l_dobj) response_49/NN (l_prep) in_50/IN (l_pobj) rats_51/NNS (l_acl) exposed_52/VBN (l_prep) to_53/IN (l_pobj) hypercapnia_55/NN
C036466_D006935 NONE aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_conj) rats_67/NNS (l_conj) prevention_74/NN (l_conj) protection_94/NN (l_conj) prevention_116/NN (l_conj) reversal_149/NN (l_conj) prevention_186/NN (l_prep) in_190/IN (l_pobj) retrieval_192/NN (l_prep) of_193/IN (l_pobj) task_197/NN (l_acl) induced_198/VBN (l_agent) by_201/IN (l_pobj) electroshock_203/NN (l_conj) hypercapnia_205/NN
C036466_D006935 NONE 5057_8/CD (r_prep) 13_6/CD (r_nummod) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_prep) of_41/IN (l_pobj) incapacity_43/NN (l_acl) learn_45/VB (l_dobj) response_49/NN (l_prep) in_50/IN (l_pobj) rats_51/NNS (l_acl) exposed_52/VBN (l_prep) to_53/IN (l_pobj) hypercapnia_55/NN
C036466_D006935 NONE 5057_8/CD (r_prep) 13_6/CD (r_nummod) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_conj) rats_67/NNS (l_conj) prevention_74/NN (l_conj) protection_94/NN (l_conj) prevention_116/NN (l_conj) reversal_149/NN (l_conj) prevention_186/NN (l_prep) in_190/IN (l_pobj) retrieval_192/NN (l_prep) of_193/IN (l_pobj) task_197/NN (l_acl) induced_198/VBN (l_agent) by_201/IN (l_pobj) electroshock_203/NN (l_conj) hypercapnia_205/NN
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10/CD (r_appos) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_prep) of_41/IN (l_pobj) incapacity_43/NN (l_acl) learn_45/VB (l_dobj) response_49/NN (l_prep) in_50/IN (l_pobj) rats_51/NNS (l_acl) exposed_52/VBN (l_prep) to_53/IN (l_pobj) hypercapnia_55/NN
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10/CD (r_appos) Ro_5/NNP (r_appos) aniracetam_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_13/VBN (l_conj) produced_30/VBD (l_dobj) effects_33/NNS (l_appos) prevention_40/NN (l_conj) rats_67/NNS (l_conj) prevention_74/NN (l_conj) protection_94/NN (l_conj) prevention_116/NN (l_conj) reversal_149/NN (l_conj) prevention_186/NN (l_prep) in_190/IN (l_pobj) retrieval_192/NN (l_prep) of_193/IN (l_pobj) task_197/NN (l_acl) induced_198/VBN (l_agent) by_201/IN (l_pobj) electroshock_203/NN (l_conj) hypercapnia_205/NN
D002701_D000647 NONE chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (r_conj) protection_94/NN (r_conj) prevention_74/NN (l_prep) of_75/IN (l_pobj) amnesia_83/NN
D002701_D000647 NONE chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (r_conj) protection_94/NN (l_prep) against_95/IN (l_pobj) amnesia_96/NN
D003513_D006935 NONE cycloheximide_140/NN (r_conj) chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (r_conj) protection_94/NN (r_conj) prevention_74/NN (r_conj) rats_67/NNS (r_conj) prevention_40/NN (l_prep) of_41/IN (l_pobj) incapacity_43/NN (l_acl) learn_45/VB (l_dobj) response_49/NN (l_prep) in_50/IN (l_pobj) rats_51/NNS (l_acl) exposed_52/VBN (l_prep) to_53/IN (l_pobj) hypercapnia_55/NN
D003513_D006935 NONE cycloheximide_140/NN (r_conj) chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (l_conj) reversal_149/NN (l_conj) prevention_186/NN (l_prep) in_190/IN (l_pobj) retrieval_192/NN (l_prep) of_193/IN (l_pobj) task_197/NN (l_acl) induced_198/VBN (l_agent) by_201/IN (l_pobj) electroshock_203/NN (l_conj) hypercapnia_205/NN
D003513_D006935 NONE cycloheximide_177/NN (r_pobj) by_176/IN (r_agent) induced_175/VBN (r_acl) task_174/NN (r_pobj) of_170/IN (r_prep) retention_167/NN (r_pobj) in_166/IN (r_prep) deficit_165/NN (r_pobj) of_163/IN (r_prep) reversal_149/NN (r_conj) prevention_116/NN (r_conj) protection_94/NN (r_conj) prevention_74/NN (r_conj) rats_67/NNS (r_conj) prevention_40/NN (l_prep) of_41/IN (l_pobj) incapacity_43/NN (l_acl) learn_45/VB (l_dobj) response_49/NN (l_prep) in_50/IN (l_pobj) rats_51/NNS (l_acl) exposed_52/VBN (l_prep) to_53/IN (l_pobj) hypercapnia_55/NN
D003513_D006935 NONE cycloheximide_177/NN (r_pobj) by_176/IN (r_agent) induced_175/VBN (r_acl) task_174/NN (r_pobj) of_170/IN (r_prep) retention_167/NN (r_pobj) in_166/IN (r_prep) deficit_165/NN (r_pobj) of_163/IN (r_prep) reversal_149/NN (l_conj) prevention_186/NN (l_prep) in_190/IN (l_pobj) retrieval_192/NN (l_prep) of_193/IN (l_pobj) task_197/NN (l_acl) induced_198/VBN (l_agent) by_201/IN (l_pobj) electroshock_203/NN (l_conj) hypercapnia_205/NN
C036466_D007859 NONE aniracetam_5/RB (l_appos) Ro_7/NNP (l_prep) upon_12/IN (l_pobj) learning_14/NN (l_conj) memory_16/NN
C036466_D007859 NONE 5057_10/CD (r_prep) 13_8/CD (r_nummod) Ro_7/NNP (l_prep) upon_12/IN (l_pobj) learning_14/NN (l_conj) memory_16/NN
D002701_D006935 NONE chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (r_conj) protection_94/NN (r_conj) prevention_74/NN (r_conj) rats_67/NNS (r_conj) prevention_40/NN (l_prep) of_41/IN (l_pobj) incapacity_43/NN (l_acl) learn_45/VB (l_dobj) response_49/NN (l_prep) in_50/IN (l_pobj) rats_51/NNS (l_acl) exposed_52/VBN (l_prep) to_53/IN (l_pobj) hypercapnia_55/NN
D002701_D006935 NONE chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (l_conj) reversal_149/NN (l_conj) prevention_186/NN (l_prep) in_190/IN (l_pobj) retrieval_192/NN (l_prep) of_193/IN (l_pobj) task_197/NN (l_acl) induced_198/VBN (l_agent) by_201/IN (l_pobj) electroshock_203/NN (l_conj) hypercapnia_205/NN
D012601_D000647 CID scopolamine_77/NN (r_npadvmod) induced_79/VBN (r_amod) amnesia_83/NN
D012601_D000647 CID scopolamine_77/NN (r_npadvmod) induced_79/VBN (r_amod) amnesia_83/NN (r_pobj) of_75/IN (r_prep) prevention_74/NN (l_conj) protection_94/NN (l_prep) against_95/IN (l_pobj) amnesia_96/NN
D003513_D000647 NONE cycloheximide_140/NN (r_conj) chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (r_conj) protection_94/NN (r_conj) prevention_74/NN (l_prep) of_75/IN (l_pobj) amnesia_83/NN
D003513_D000647 NONE cycloheximide_140/NN (r_conj) chloramphenicol_138/NN (r_pobj) by_137/IN (r_agent) induced_132/VBN (r_acl) task_131/NN (r_pobj) for_127/IN (r_prep) prevention_116/NN (r_conj) protection_94/NN (l_prep) against_95/IN (l_pobj) amnesia_96/NN
D003513_D000647 NONE cycloheximide_177/NN (r_pobj) by_176/IN (r_agent) induced_175/VBN (r_acl) task_174/NN (r_pobj) of_170/IN (r_prep) retention_167/NN (r_pobj) in_166/IN (r_prep) deficit_165/NN (r_pobj) of_163/IN (r_prep) reversal_149/NN (r_conj) prevention_116/NN (r_conj) protection_94/NN (r_conj) prevention_74/NN (l_prep) of_75/IN (l_pobj) amnesia_83/NN
D003513_D000647 NONE cycloheximide_177/NN (r_pobj) by_176/IN (r_agent) induced_175/VBN (r_acl) task_174/NN (r_pobj) of_170/IN (r_prep) retention_167/NN (r_pobj) in_166/IN (r_prep) deficit_165/NN (r_pobj) of_163/IN (r_prep) reversal_149/NN (r_conj) prevention_116/NN (r_conj) protection_94/NN (l_prep) against_95/IN (l_pobj) amnesia_96/NN
D012601_D006935 NONE scopolamine_77/NN (r_npadvmod) induced_79/VBN (r_amod) amnesia_83/NN (r_pobj) of_75/IN (r_prep) prevention_74/NN (r_conj) rats_67/NNS (r_conj) prevention_40/NN (l_prep) of_41/IN (l_pobj) incapacity_43/NN (l_acl) learn_45/VB (l_dobj) response_49/NN (l_prep) in_50/IN (l_pobj) rats_51/NNS (l_acl) exposed_52/VBN (l_prep) to_53/IN (l_pobj) hypercapnia_55/NN
D012601_D006935 NONE scopolamine_77/NN (r_npadvmod) induced_79/VBN (r_amod) amnesia_83/NN (r_pobj) of_75/IN (r_prep) prevention_74/NN (l_conj) protection_94/NN (l_conj) prevention_116/NN (l_conj) reversal_149/NN (l_conj) prevention_186/NN (l_prep) in_190/IN (l_pobj) retrieval_192/NN (l_prep) of_193/IN (l_pobj) task_197/NN (l_acl) induced_198/VBN (l_agent) by_201/IN (l_pobj) electroshock_203/NN (l_conj) hypercapnia_205/NN
15811908
C012052_D010673 NONE amisulpride_3/NN (r_pobj) by_2/IN (r_prep) unmasked_1/VBD (l_nsubj) Pheochromocytoma_0/NNP
C012052_D010673 NONE amisulpride_11/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) patient_8/NN (r_pobj) in_6/IN (r_prep) unmasking_3/NN (l_prep) of_4/IN (l_pobj) pheochromocytoma_5/NN
C012052_D010673 NONE amisulpride-_14/JJ (r_pobj) of_13/IN (r_prep) case_12/NN (l_prep) in_21/IN (l_pobj) patient_23/NN (l_prep) with_24/IN (l_pobj) pheochromocytoma_25/NN
C012052_D006973 CID amisulpride_21/NN (r_pobj) of_20/IN (r_prep) doses_19/NNS (r_pobj) after_16/IN (r_prep) vomiting_13/NN (r_conj) developed_6/VBD (l_dobj) hypertension_8/NN
C012052_D006973 CID amisulpride_19/NN (r_conj) crisis_17/NN (l_amod) hypertensive_16/JJ
C012052_D006973 CID amisulpride-_14/JJ (l_conj) crisis_20/NN (l_amod) hypertensive_19/JJ
D063325_D006973 CID tiapride_21/NN (r_compound) therapy_22/NN (r_conj) amisulpride_19/NN (r_conj) crisis_17/NN (l_amod) hypertensive_16/JJ
D063325_D006973 CID tiapride_16/NN (r_npadvmod) induced_18/VBN (r_amod) crisis_20/NN (l_amod) hypertensive_19/JJ
C037689_D010673 NONE benzamide_14/JJ (r_amod) drugs_15/NNS (r_pobj) of_12/IN (r_prep) use_11/NN (r_pobj) with_9/IN (r_prep) associated_8/VBN (l_nsubjpass) symptoms_3/NNS (l_prep) of_4/IN (l_pobj) pheochromocytoma_5/NN
C012052_D006261 CID amisulpride_21/NN (r_pobj) of_20/IN (r_prep) doses_19/NNS (r_pobj) after_16/IN (r_prep) vomiting_13/NN (r_conj) developed_6/VBD (l_dobj) hypertension_8/NN (l_prep) with_9/IN (l_pobj) headache_11/NN
C012052_D014839 CID amisulpride_21/NN (r_pobj) of_20/IN (r_prep) doses_19/NNS (r_pobj) after_16/IN (r_prep) vomiting_13/NN
D063325_D010673 NONE tiapride_5/NN (r_conj) amisulpride_3/NN (r_pobj) by_2/IN (r_prep) unmasked_1/VBD (l_nsubj) Pheochromocytoma_0/NNP
D063325_D010673 NONE tiapride_13/NN (r_conj) amisulpride_11/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) patient_8/NN (r_pobj) in_6/IN (r_prep) unmasking_3/NN (l_prep) of_4/IN (l_pobj) pheochromocytoma_5/NN
D063325_D010673 NONE tiapride_16/NN (r_npadvmod) induced_18/VBN (r_amod) crisis_20/NN (r_conj) amisulpride-_14/JJ (r_pobj) of_13/IN (r_prep) case_12/NN (l_prep) in_21/IN (l_pobj) patient_23/NN (l_prep) with_24/IN (l_pobj) pheochromocytoma_25/NN
12013711
D008238_D012559 NONE LSD_16/NNP (r_compound) abuse_17/NN (r_pobj) of_15/IN (r_prep) history_14/NN (r_pobj) with_11/IN (r_prep) disturbances_7/NNS (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_amod) schizophrenic_9/JJ
D008238_D012559 NONE LSD_10/NNP (r_compound) abuse_11/NN (r_pobj) of_9/IN (r_prep) history_8/NN (r_dobj) had_5/VBD (r_relcl) patients_2/NNS (l_amod) schizophrenic_1/JJ
D018967_D012559 NONE Risperidone_0/NNP (r_npadvmod) associated_2/VBN (r_amod) disturbances_7/NNS (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_amod) schizophrenic_9/JJ
D018967_D012559 NONE risperidone_26/NN (r_pobj) with_25/IN (r_prep) treated_24/VBN (l_nsubjpass) patients_2/NNS (l_amod) schizophrenic_1/JJ
D018967_D001480 NONE risperidone_26/NN (r_pobj) with_25/IN (r_prep) treated_24/VBN (l_nsubjpass) patients_2/NNS (l_relcl) had_5/VBD (l_conj) developed_16/VBN (l_dobj) EPS_17/NNP
D008238_D010468 NONE LSD_16/NNP (r_compound) abuse_17/NN (r_pobj) of_15/IN (r_prep) history_14/NN (r_pobj) with_11/IN (r_prep) disturbances_7/NNS
D008238_D010468 NONE LSD_14/NNP (r_compound) consumption_15/NN (r_pobj) to_12/IN (r_prep) related_11/VBN (r_acl) flashbacks_9/NNS (r_pobj) as_7/IN (r_prep) experienced_6/VBN (r_acl) disturbances_4/NNS
D008238_D001480 NONE LSD_10/NNP (r_compound) abuse_11/NN (r_pobj) of_9/IN (r_prep) history_8/NN (r_dobj) had_5/VBD (l_conj) developed_16/VBN (l_dobj) EPS_17/NNP
D018967_D010468 CID Risperidone_0/NNP (r_npadvmod) associated_2/VBN (r_amod) disturbances_7/NNS
D018967_D010468 CID risperidone_17/NN (r_pobj) with_16/IN (r_prep) treatment_15/NN (r_dobj) starting_14/VBG (r_pcomp) after_13/IN (r_prep) appeared_11/VBD (r_relcl) disturbances_8/NNS
D018967_D010468 CID Risperidone_0/NNP (r_compound) administration_1/NN (r_nsubjpass) continued_3/VBN (l_conj) wore_9/VBD (l_nsubj) disturbances_7/NNS
3961813
D010755_D009422 NONE organophosphorus_11/NN (r_npadvmod) induced_13/VBN (r_amod) neuropathy_15/NN
D007531_D009422 CID DFP_39/NNP (r_conj) TOTP_37/NNP (r_pobj) given_35/VBN (r_acl) signs_32/NNS (r_dobj) had_14/VBD (l_dobj) effects_16/NNS (l_prep) on_17/IN (l_pobj) neuropathy_21/NN
C025541_D020258 NONE TOTP_6/NNP (r_pobj) after_5/IN (r_prep) activities_2/NNS (l_compound) esterase_1/NN (l_amod) Neurotoxic_0/JJ
C025541_D009410 CID TOTP_16/NNP (r_pobj) given_15/VBN (r_prep) were_3/VBD (l_nsubj) fibers_2/NNS
C025541_D009422 CID TOTP_18/NNP (r_npadvmod) induced_20/VBN (r_amod) neuropathy_21/NN
C025541_D009422 CID TOTP_37/NNP (r_pobj) given_35/VBN (r_acl) signs_32/NNS (r_dobj) had_14/VBD (l_dobj) effects_16/NNS (l_prep) on_17/IN (l_pobj) neuropathy_21/NN
D007531_D020258 NONE DFP_8/NNP (r_conj) TOTP_6/NNP (r_pobj) after_5/IN (r_prep) activities_2/NNS (l_compound) esterase_1/NN (l_amod) Neurotoxic_0/JJ
D010755_D020258 NONE organophosphorous_21/JJ (r_amod) compounds_22/NNS (r_dobj) given_20/VBN (r_prep) were_9/VBD (l_nsubj) activities_2/NNS (l_compound) esterase_1/NN (l_amod) Neurotoxic_0/JJ
D007531_D009410 CID DFP_18/NNP (r_conj) TOTP_16/NNP (r_pobj) given_15/VBN (r_prep) were_3/VBD (l_nsubj) fibers_2/NNS
D003345_D009422 NONE corticosterone_9/NN (l_prep) on_10/IN (l_pobj) neuropathy_15/NN
D003345_D009422 NONE corticosterone_13/NN (r_pobj) of_12/IN (r_prep) concentrations_2/NNS (r_nsubj) had_14/VBD (l_dobj) effects_16/NNS (l_prep) on_17/IN (l_pobj) neuropathy_21/NN
18483878
D003520_D001745 NONE CYP_22/NNP (r_pobj) with_21/IN (r_prep) WT_20/NNP (r_pobj) in_19/IN (r_prep) observed_18/VBD (r_advcl) increased_15/VBN (l_advcl) mice_7/NNS (l_prep) with_8/IN (l_pobj) inflammation_10/NN
D003520_D003556 CID cyclophosphamide_15/NN (r_pobj) with_14/IN (r_prep) mice_13/NNS (r_appos) knockout_9/NN (l_appos) cystitis_18/NN
D003520_D003556 CID CYP)-induced_17/VBN (r_compound) cystitis_18/NN
D003520_D003556 CID cyclophosphamide_14/NN (r_pobj) after_13/IN (r_prep) altered_4/JJ (l_dobj) cystitis_17/NN
D003520_D003556 CID CYP)-induced_16/VBN (r_amod) cystitis_17/NN
D003520_D003556 CID CYP_32/NNP (r_npadvmod) induced_34/VBN (r_amod) cystitis_35/NN
873132
D003840_D002779 NONE acid_9/NN (r_pobj) of_7/IN (r_prep) hydroxylation_6/NN (r_dobj) decreased_3/VBD (l_dobj) cholestasis_15/NN
D004997_D002779 CID estradiol_12/NN (r_npadvmod) induced_14/VBN (r_amod) cholestasis_15/NN
803783
D010121_D001523 NONE Oxytocin_0/NN (r_compound) administration_1/NN (r_nsubjpass) advocated_8/VBN (l_advcl) carried_14/VBN (l_conj) instructed_33/VBD (l_xcomp) watch_35/VB (l_conj) report_39/VB (l_dobj) signs_42/NNS (l_prep) as_46/IN (l_pobj) asthenia_47/NNP (l_conj) irritability_50/NN
D010121_D014869 CID oxytocin_4/NN (r_compound) administration_5/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) intoxication_1/NN
D010121_D014869 CID oxytocin_8/NN (r_compound) administration_9/NN (r_pobj) with_7/IN (r_prep) connection_6/NN (r_pobj) in_5/IN (r_prep) intoxication_4/NN
D010121_D014869 CID Oxytocin_0/NN (r_compound) administration_1/NN (r_nsubjpass) advocated_8/VBN (l_advcl) carried_14/VBN (l_advcl) aware_25/JJ (l_prep) of_26/IN (l_pobj) symptoms_28/NNS (l_prep) of_29/IN (l_pobj) intoxication_31/NN
D010121_D001247 NONE Oxytocin_0/NN (r_compound) administration_1/NN (r_nsubjpass) advocated_8/VBN (l_advcl) carried_14/VBN (l_conj) instructed_33/VBD (l_xcomp) watch_35/VB (l_conj) report_39/VB (l_dobj) signs_42/NNS (l_prep) as_46/IN (l_pobj) asthenia_47/NNP
D010121_D000031 NONE oxytocin_4/NN (r_compound) administration_5/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (l_prep) during_6/IN (l_pobj) abortion_10/NN
D010121_D000031 NONE oxytocin_8/NN (r_compound) administration_9/NN (r_pobj) with_7/IN (r_prep) connection_6/NN (l_prep) during_10/IN (l_pobj) abortions_14/NNS
D010121_D000031 NONE Oxytocin_0/NN (r_compound) administration_1/NN (l_prep) during_2/IN (l_pobj) abortions_6/NNS
D010121_D006261 NONE Oxytocin_0/NN (r_compound) administration_1/NN (r_nsubjpass) advocated_8/VBN (l_advcl) carried_14/VBN (l_conj) instructed_33/VBD (l_xcomp) watch_35/VB (l_conj) report_39/VB (l_dobj) signs_42/NNS (l_prep) as_46/IN (l_pobj) asthenia_47/NNP (l_conj) irritability_50/NN (l_conj) headaches_53/NNS
20103708
D013311_D058186 NONE streptozotocin_13/RB (r_npadvmod) induced_15/VBN (r_amod) damage_17/NN
D010100_D003928 NONE oxygen_20/NN (r_compound) species_21/NNS (r_pobj) of_18/IN (r_prep) production_17/NN (r_pobj) by_15/IN (r_agent) accompanied_14/VBN (r_relcl) causes_7/NNS (r_pobj) of_4/IN (r_prep) one_3/CD (r_attr) is_2/VBZ (l_nsubj) nephropathy_1/NN
D010100_D051437 NONE oxygen_20/NN (r_compound) species_21/NNS (r_pobj) of_18/IN (r_prep) production_17/NN (r_pobj) by_15/IN (r_agent) accompanied_14/VBN (r_relcl) causes_7/NNS (l_prep) of_8/IN (l_pobj) failure_10/NN
D013311_D003928 CID streptozotocin_6/JJ (r_npadvmod) induced_8/VBN (r_amod) nephropathy_10/NN
D013311_D003928 CID streptozotocin_22/RB (r_npadvmod) induced_24/VBN (r_amod) model_27/NN (l_ccomp) explore_2/VBP (l_dobj) role_5/NN (l_prep) against_8/IN (l_pobj) nephropathy_10/NN
D013311_D003928 CID streptozotocin_22/RB (r_npadvmod) induced_24/VBN (r_amod) model_27/NN (l_ccomp) explore_2/VBP (l_dobj) role_5/NN (l_prep) against_8/IN (l_pobj) nephropathy_10/NN (l_acl) using_11/VBG (l_prep) from_16/IN (l_pobj) patients_19/NNS (l_compound) nephropathy_18/NN
D013311_D003928 CID streptozotocin_22/RB (r_npadvmod) induced_24/VBN (r_amod) model_27/NN (l_compound) nephropathy_26/NN
2594614
C045856_D002318 NONE 52021_12/CD (r_nummod) BN_11/NNP (r_appos) antagonist_9/NN (l_prep) on_14/IN (l_pobj) impairments_19/NNS
C045856_D002318 NONE 52021_5/CD (r_nummod) BN_4/NNP (r_pobj) of_3/IN (r_prep) administration_2/NN (r_nsubj) alter_14/VB (r_advcl) demonstrate_29/VBP (l_dobj) action_32/NN (l_prep) against_43/IN (l_pobj) toxicity_48/NN
C045856_D002318 NONE 52021_35/CD (r_nummod) BN_34/NNP (r_pobj) of_33/IN (r_prep) action_32/NN (l_prep) against_43/IN (l_pobj) toxicity_48/NN
C045856_D001919 NONE 52021_14/CD (r_appos) antagonist_12/NN (r_appos) injection_1/NN (r_nsubj) suppressed_30/VBD (l_dobj) decrease_33/NN (l_prep) of_34/IN (l_pobj) MBP_35/NNP (l_conj) HR_37/NN
C045856_D001919 NONE 52021_2/CD (r_nummod) BN_1/NNP (r_nsubjpass) injected_9/VBN (r_advcl) observed_29/VBN (l_nsubjpass) reversion_20/NN (l_prep) of_21/IN (l_pobj) decrease_23/NN (l_prep) of_24/IN (l_pobj) MBP_25/NNP (l_conj) HR_27/NN
C045856_D007022 NONE 52021_14/CD (r_appos) antagonist_12/NN (r_appos) injection_1/NN (r_nsubj) suppressed_30/VBD (l_dobj) decrease_33/NN (l_prep) of_34/IN (l_pobj) MBP_35/NNP (l_conj) HR_37/NN
C045856_D007022 NONE 52021_2/CD (r_nummod) BN_1/NNP (r_nsubjpass) injected_9/VBN (r_advcl) observed_29/VBN (l_nsubjpass) reversion_20/NN (l_prep) of_21/IN (l_pobj) decrease_23/NN (l_prep) of_24/IN (l_pobj) MBP_25/NNP (l_conj) HR_27/NN
D002045_D007022 CID bupivacaine_5/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) elicited_16/VBD (l_dobj) decrease_19/NN (l_prep) of_20/IN (l_pobj) pressure_24/NN (l_appos) MBP_26/NNP (l_conj) rate_30/NN (l_punct) )_33/-RRB-
D002045_D007022 CID bupivacaine_23/NN (r_compound) administration_24/NN (r_pobj) before_22/IN (r_prep) min_21/NN (r_appos) injection_1/NN (r_nsubj) suppressed_30/VBD (l_dobj) decrease_33/NN (l_prep) of_34/IN (l_pobj) MBP_35/NNP (l_conj) HR_37/NN
D002045_D007022 CID bupivacaine_12/NN (r_pobj) after_11/IN (r_prep) injected_9/VBN (r_advcl) observed_29/VBN (l_nsubjpass) reversion_20/NN (l_prep) of_21/IN (l_pobj) decrease_23/NN (l_prep) of_24/IN (l_pobj) MBP_25/NNP (l_conj) HR_27/NN
D002045_D002318 NONE bupivacaine_15/NN (r_npadvmod) induced_17/VBN (r_amod) impairments_19/NNS
D002045_D002318 NONE bupivacaine_44/NN (r_npadvmod) induced_46/VBN (r_amod) toxicity_48/NN
D002045_D018376 NONE bupivacaine_16/NN (r_npadvmod) induced_18/VBN (r_amod) alterations_20/NNS
D002045_D001919 CID bupivacaine_5/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) elicited_16/VBD (l_dobj) decrease_19/NN (l_prep) of_20/IN (l_pobj) pressure_24/NN (l_appos) MBP_26/NNP (l_conj) rate_30/NN (l_punct) )_33/-RRB-
D002045_D001919 CID bupivacaine_23/NN (r_compound) administration_24/NN (r_pobj) before_22/IN (r_prep) min_21/NN (r_appos) injection_1/NN (r_nsubj) suppressed_30/VBD (l_dobj) decrease_33/NN (l_prep) of_34/IN (l_pobj) MBP_35/NNP (l_conj) HR_37/NN
D002045_D001919 CID bupivacaine_12/NN (r_pobj) after_11/IN (r_prep) injected_9/VBN (r_advcl) observed_29/VBN (l_nsubjpass) reversion_20/NN (l_prep) of_21/IN (l_pobj) decrease_23/NN (l_prep) of_24/IN (l_pobj) MBP_25/NNP (l_conj) HR_27/NN
6118280
D003975_D009207 NONE diazepam_20/NN (r_pobj) than_19/IN (r_prep) potent_18/JJ (r_acomp) be_14/VB (l_prep) in_27/IN (l_pcomp) blocking_28/VBG (l_dobj) jerks_31/NNS
C014896_D009207 NONE MK-212_8/NNP (r_punct) and_9/CC (r_punct) -)-baclofen_11/: (r_punct) in_12/IN (l_pobj) management_14/NN (l_prep) of_15/IN (l_pobj) myoclonus_17/NN
D001569_D009207 NONE benzodiazepines_3/NNS (r_conj) drugs_1/NNS (r_nsubj) induced_9/VBN (l_dobj) jerks_11/NNS
D001569_D009207 NONE benzodiazepines_2/NNS (r_pobj) Of_0/IN (r_prep) found_12/VBN (l_xcomp) be_14/VB (l_prep) in_27/IN (l_pcomp) blocking_28/VBG (l_dobj) jerks_31/NNS
D001569_D009207 NONE benzodiazepines_7/NNS (r_conj) 5-HTP_4/NN (r_nsubjpass) found_10/VBN (l_xcomp) be_12/VB (l_acomp) beneficial_13/JJ (l_prep) in_14/IN (l_pobj) management_16/NN (l_prep) of_17/IN (l_pobj) myoclonus_19/NN
D001569_D009207 NONE benzodiazepines_7/NNS (r_conj) 5-HTP_4/NN (r_nsubjpass) found_10/VBN (l_xcomp) be_12/VB (l_acomp) beneficial_13/JJ (l_prep) in_14/IN (l_pobj) management_16/NN (l_prep) of_17/IN (l_pobj) myoclonus_19/NN (l_appos) myoclonus_25/NN
D001418_D009207 NONE baclofen_5/JJ (r_compound) block_6/NN (r_conj) benzodiazepines_3/NNS (r_conj) drugs_1/NNS (r_nsubj) induced_9/VBN (l_dobj) jerks_11/NNS
D001418_D009207 NONE -)-baclofen_11/: (r_punct) in_12/IN (l_pobj) management_14/NN (l_prep) of_15/IN (l_pobj) myoclonus_17/NN
D002998_D009207 NONE clonazepam_4/NN (r_nsubjpass) found_12/VBN (l_xcomp) be_14/VB (l_prep) in_27/IN (l_pcomp) blocking_28/VBG (l_dobj) jerks_31/NNS
D006916_D009207 NONE 5-HTP_4/NN (r_nsubjpass) found_10/VBN (l_xcomp) be_12/VB (l_acomp) beneficial_13/JJ (l_prep) in_14/IN (l_pobj) management_16/NN (l_prep) of_17/IN (l_pobj) myoclonus_19/NN
D006916_D009207 NONE 5-HTP_4/NN (r_nsubjpass) found_10/VBN (l_xcomp) be_12/VB (l_acomp) beneficial_13/JJ (l_prep) in_14/IN (l_pobj) management_16/NN (l_prep) of_17/IN (l_pobj) myoclonus_19/NN (l_appos) myoclonus_25/NN
D009118_D009207 CID muscimol_7/NNS (r_npadvmod) induced_9/VBN (l_dobj) jerks_11/NNS
D009118_D009207 CID muscimol_5/NNS (r_nsubj) produced_6/VBD (l_dobj) jerks_8/NNS
D009118_D009207 CID muscimol_22/NN (r_npadvmod) induced_24/VBN (r_amod) myoclonus_25/NN (r_appos) myoclonus_19/NN
D009118_D009207 CID muscimol_22/NN (r_npadvmod) induced_24/VBN (r_amod) myoclonus_25/NN
2021202
D007530_D007022 CID isoflurane_6/RB (r_npadvmod) induced_8/VBN (r_amod) hypotension_9/NN
D007530_D007022 CID isoflurane_3/RB (r_npadvmod) induced_5/VBN (r_amod) hypotension_6/NN
D007530_D007022 CID isoflurane_11/NN (r_amod) concentration_13/NN (r_dobj) increasing_9/VBG (r_pcomp) by_8/IN (r_prep) induced_2/VBN (l_nsubjpass) Hypotension_0/NNP
D007530_D007022 CID isoflurane_9/RB (r_npadvmod) induced_11/VBN (r_amod) hypotension_12/NN
9564988
D064704_D012852 NONE levofloxacin_5/NN (r_pobj) of_4/IN (r_prep) assessment_3/NN (l_prep) for_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) sinusitis_12/NN
D064704_D012852 NONE levofloxacin_7/NN (r_pobj) of_6/IN (r_prep) efficacy_3/NN (r_dobj) evaluate_1/VB (l_prep) in_20/IN (l_pcomp) treating_21/VBG (l_prep) with_24/IN (l_pobj) sinusitis_27/NN
D064704_D012852 NONE levofloxacin_7/VBZ (r_ccomp) indicate_5/VBP (l_ccomp) is_12/VBZ (l_attr) treatment_17/NN (l_prep) for_18/IN (l_pobj) sinusitis_21/NN
12571256
D003404_D003920 NONE creatinine_9/JJ (r_compound) concentrations_10/NNS (r_pobj) with_7/IN (r_prep) diabetes_6/NNS
C044834_D007674 NONE iodixanol_29/NN (r_appos) medium_27/NN (r_pobj) of_17/IN (r_prep) effects_16/NNS (l_amod) nephrotoxic_15/JJ
C044834_D007674 NONE iodixanol_17/NN (r_nsubjpass) used_19/VBN (r_advcl) develop_10/VB (r_xcomp) likely_8/JJ (r_acomp) be_6/VB (l_csubj) induced_1/VBN (l_nsubj) Nephropathy_0/NNP
D007472_D007674 CID iohexol_45/NN (r_pobj) of_33/IN (r_prep) those_32/DT (r_pobj) with_31/IN (r_prep) effects_16/NNS (l_amod) nephrotoxic_15/JJ
8251368
D009543_D013684 CID nifedipine_1/RB (r_advmod) induced_3/VBN (r_amod) telangiectasia_5/NN
D009543_D013684 CID nifedipine_4/NN (r_dobj) starting_3/VBG (r_pcomp) after_2/IN (r_prep) developed_11/VBD (l_dobj) telangiectasia_14/NN
D009543_D013684 CID Adalat_6/NNP (r_oprd) starting_3/VBG (r_pcomp) after_2/IN (r_prep) developed_11/VBD (l_dobj) telangiectasia_14/NN
D017311_D013684 CID amlodipine_6/NN (r_dobj) commenced_1/VBD (l_prep) with_11/IN (l_pobj) recurrence_12/NN (l_prep) of_13/IN (l_pobj) telangiectasia_14/NN
16225977
C012052_D020820 NONE amisulpride_20/JJ (r_amod) treatment_21/NN (r_pobj) of_19/IN (r_prep) months_18/NNS (r_pobj) after_16/IN (r_prep) developed_9/VBD (l_dobj) movements_15/NNS
C069541_D013981 NONE quetiapine_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) during_21/IN (r_prep) occurring_20/VBG (r_xcomp) show_8/VBP (l_dobj) symptoms_12/NNS
C069541_D013981 NONE quetiapine_27/NN (r_pobj) as_26/IN (r_prep) antipsychotics_24/NNS (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) during_20/IN (r_prep) occur_15/VB (l_nsubj) symptoms_13/NNS
D003024_D013981 NONE clozapine_26/NN (r_conj) quetiapine_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) during_21/IN (r_prep) occurring_20/VBG (r_xcomp) show_8/VBP (l_dobj) symptoms_12/NNS
D003024_D013981 NONE clozapine_29/NN (r_conj) quetiapine_27/NN (r_pobj) as_26/IN (r_prep) antipsychotics_24/NNS (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) during_20/IN (r_prep) occur_15/VB (l_nsubj) symptoms_13/NNS
C092292_D013981 NONE ziprasidone_15/NN (r_conj) olanzapine_13/NN (r_conj) risperidone_11/NN (r_pobj) as_10/IN (r_prep) antipsychotics_8/NNS (r_pobj) by_6/IN (r_agent) treated_5/VBN (l_nsubjpass) disorders_1/NNS
C076029_D013981 NONE olanzapine_13/NN (r_conj) risperidone_11/NN (r_pobj) as_10/IN (r_prep) antipsychotics_8/NNS (r_pobj) by_6/IN (r_agent) treated_5/VBN (l_nsubjpass) disorders_1/NNS
D018967_D013981 NONE risperidone_11/NN (r_pobj) as_10/IN (r_prep) antipsychotics_8/NNS (r_pobj) by_6/IN (r_agent) treated_5/VBN (l_nsubjpass) disorders_1/NNS
C012052_D012559 NONE Amisulpride_0/NNP (r_amod) symptoms_5/NNS (l_prep) in_6/IN (l_pobj) schizophrenic_9/NN
C012052_D012559 NONE amisulpride_20/JJ (r_amod) treatment_21/NN (r_pobj) of_19/IN (r_prep) months_18/NNS (r_pobj) after_16/IN (r_prep) developed_9/VBD (r_relcl) schizophrenic_7/NN
C012052_D013981 CID Amisulpride_0/NNP (r_amod) symptoms_5/NNS
C012052_D013981 CID amisulpride_13/NN (r_pobj) of_12/IN (r_prep) dose_11/NN (r_dobj) reduced_9/VBD (r_advcl) resolved_5/VBN (l_nsubj) symptoms_4/NNS
C012052_D013981 CID amisulpride_32/NN (r_conj) clozapine_29/NN (r_conj) quetiapine_27/NN (r_pobj) as_26/IN (r_prep) antipsychotics_24/NNS (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) during_20/IN (r_prep) occur_15/VB (l_nsubj) symptoms_13/NNS
15764424
D002395_D006948 NONE catecholamines_12/NNS (l_conj) hyperkinesia_14/NN
D003042_D001523 NONE cocaine_29/NN (r_conj) amphetamine-_27/JJ (r_npadvmod) induced_31/VBN (r_amod) psychosis_32/NN (r_pobj) of_26/IN (r_prep) diagnosis_25/NN (r_pobj) with_23/IN (r_prep) service_22/NN (l_amod) psychiatric_20/JJ
D003042_D011605 CID cocaine_29/NN (r_conj) amphetamine-_27/JJ (r_npadvmod) induced_31/VBN (r_amod) psychosis_32/NN (r_pobj) of_26/IN (r_prep) diagnosis_25/NN (r_pobj) with_23/IN (r_prep) service_22/NN (r_pobj) in_18/IN (r_prep) patients_17/NNS (r_nsubjpass) interviewed_34/VBN (l_advcl) examine_1/VB (l_dobj) relationship_3/NN (l_prep) between_4/IN (l_pobj) levels_8/NNS (l_conj) catecholamines_10/NNS (l_conj) symptoms_14/NNS
D003042_D011605 CID cocaine_29/NN (r_conj) amphetamine-_27/JJ (r_npadvmod) induced_31/VBN (r_amod) psychosis_32/NN
D000661_D011605 CID amphetamine-_27/JJ (r_npadvmod) induced_31/VBN (r_amod) psychosis_32/NN (r_pobj) of_26/IN (r_prep) diagnosis_25/NN (r_pobj) with_23/IN (r_prep) service_22/NN (r_pobj) in_18/IN (r_prep) patients_17/NNS (r_nsubjpass) interviewed_34/VBN (l_advcl) examine_1/VB (l_dobj) relationship_3/NN (l_prep) between_4/IN (l_pobj) levels_8/NNS (l_conj) catecholamines_10/NNS (l_conj) symptoms_14/NNS
D000661_D011605 CID amphetamine-_27/JJ (r_npadvmod) induced_31/VBN (r_amod) psychosis_32/NN
D002395_D011605 NONE catecholamines_12/NNS (r_conj) severity_10/NN (r_pobj) to_8/IN (r_prep) relationship_7/NN (r_appos) levels_2/NNS (l_prep) in_3/IN (l_pobj) psychosis_5/NN
D002395_D011605 NONE catecholamines_10/NNS (l_conj) symptoms_14/NNS
D002395_D011605 NONE catecholamines_10/NNS (r_conj) levels_8/NNS (r_pobj) between_4/IN (r_prep) relationship_3/NN (r_dobj) examine_1/VB (r_advcl) interviewed_34/VBN (l_nsubjpass) patients_17/NNS (l_prep) in_18/IN (l_pobj) service_22/NN (l_prep) with_23/IN (l_pobj) diagnosis_25/NN (l_prep) of_26/IN (l_pobj) psychosis_32/NN
D002395_D011605 NONE catecholamine_49/NN (r_conj) drug_47/NN (r_nmod) levels_51/NNS (r_pobj) of_45/IN (r_prep) assays_44/NNS (r_pobj) for_42/IN (r_prep) collected_41/VBN (r_conj) interviewed_34/VBN (l_advcl) examine_1/VB (l_dobj) relationship_3/NN (l_prep) between_4/IN (l_pobj) levels_8/NNS (l_conj) catecholamines_10/NNS (l_conj) symptoms_14/NNS
D002395_D011605 NONE catecholamine_49/NN (r_conj) drug_47/NN (r_nmod) levels_51/NNS (r_pobj) of_45/IN (r_prep) assays_44/NNS (r_pobj) for_42/IN (r_prep) collected_41/VBN (r_conj) interviewed_34/VBN (l_nsubjpass) patients_17/NNS (l_prep) in_18/IN (l_pobj) service_22/NN (l_prep) with_23/IN (l_pobj) diagnosis_25/NN (l_prep) of_26/IN (l_pobj) psychosis_32/NN
D008694_D006948 CID Methamphetamine_0/NN (r_nsubjpass) related_5/VBN (l_prep) to_6/IN (l_pobj) scores_9/NNS (l_conj) rating_14/NN (l_compound) hyperkinesia_13/NN
D000661_D001523 NONE amphetamine-_27/JJ (r_npadvmod) induced_31/VBN (r_amod) psychosis_32/NN (r_pobj) of_26/IN (r_prep) diagnosis_25/NN (r_pobj) with_23/IN (r_prep) service_22/NN (l_amod) psychiatric_20/JJ
D002395_D001523 NONE catecholamines_10/NNS (r_conj) levels_8/NNS (r_pobj) between_4/IN (r_prep) relationship_3/NN (r_dobj) examine_1/VB (r_advcl) interviewed_34/VBN (l_nsubjpass) patients_17/NNS (l_prep) in_18/IN (l_pobj) service_22/NN (l_amod) psychiatric_20/JJ
D002395_D001523 NONE catecholamine_49/NN (r_conj) drug_47/NN (r_nmod) levels_51/NNS (r_pobj) of_45/IN (r_prep) assays_44/NNS (r_pobj) for_42/IN (r_prep) collected_41/VBN (r_conj) interviewed_34/VBN (l_nsubjpass) patients_17/NNS (l_prep) in_18/IN (l_pobj) service_22/NN (l_amod) psychiatric_20/JJ
D000661_D006948 CID amphetamine_2/NN (r_compound) levels_3/NNS (r_conj) Methamphetamine_0/NN (r_nsubjpass) related_5/VBN (l_prep) to_6/IN (l_pobj) scores_9/NNS (l_conj) rating_14/NN (l_compound) hyperkinesia_13/NN
1545575
D003520_D006470 CID cyclophosphamide_11/NN (r_compound) therapy_12/NN (r_pobj) of_7/IN (r_prep) complication_6/NN (r_attr) is_2/VBZ (l_nsubj) cystitis_1/NN
D003520_D006470 CID cyclophosphamide_27/NN (r_pobj) of_26/IN (r_prep) metabolite_25/NN (l_relcl) causes_29/VBZ (l_dobj) cystitis_31/NN
D015080_D006470 NONE mesna_19/NN (r_pobj) with_18/IN (r_prep) trial_15/NN (l_relcl) neutralizes_22/VBZ (l_dobj) metabolite_25/NN (l_relcl) causes_29/VBZ (l_dobj) cystitis_31/NN
D015080_D006470 NONE mesna_10/JJ (r_amod) uroprophylaxis_11/NNS (r_dobj) received_9/VBD (r_relcl) patients_7/NNS (r_nsubj) had_17/VBD (l_dobj) cystitis_20/NN
D003520_D003556 CID cyclophosphamide_11/NN (r_compound) therapy_12/NN (r_pobj) of_7/IN (r_prep) complication_6/NN (r_attr) is_2/VBZ (l_nsubj) cystitis_1/NN
D003520_D003556 CID cyclophosphamide_27/NN (r_pobj) of_26/IN (r_prep) metabolite_25/NN (l_relcl) causes_29/VBZ (l_dobj) cystitis_31/NN
D015080_D003556 NONE mesna_19/NN (r_pobj) with_18/IN (r_prep) trial_15/NN (l_relcl) neutralizes_22/VBZ (l_dobj) metabolite_25/NN (l_relcl) causes_29/VBZ (l_dobj) cystitis_31/NN
D015080_D003556 NONE mesna_10/JJ (r_amod) uroprophylaxis_11/NNS (r_dobj) received_9/VBD (r_relcl) patients_7/NNS (r_nsubj) had_17/VBD (l_dobj) cystitis_20/NN
1711760
D010656_D004487 NONE phenylephrine_4/NN (r_npadvmod) induced_6/VBN (r_amod) hypertension_7/NN (r_nsubj) instituted_8/VBD (l_advcl) aggravate_15/VB (l_dobj) edema_16/NN
D010656_D004487 NONE phenylephrine_4/NN (r_npadvmod) induced_6/VBN (r_amod) hypertension_7/NN (r_nsubj) instituted_8/VBD (l_advcl) aggravate_15/VB (l_dobj) edema_16/NN (l_acl) improves_24/VBZ (l_dobj) edema_25/NN
D010656_D020244 NONE phenylephrine_4/NN (r_npadvmod) induced_6/VBN (r_amod) hypertension_7/NN (r_nsubj) instituted_8/VBD (l_advcl) aggravate_15/VB (l_nsubj) MCAO_12/NNP
D010656_D006973 CID phenylephrine_4/NN (r_npadvmod) induced_6/VBN (r_amod) hypertension_7/NN
D010656_D007511 NONE phenylephrine_4/NN (r_npadvmod) induced_6/VBN (r_amod) hypertension_7/NN (r_nsubj) instituted_8/VBD (l_advcl) aggravate_15/VB (l_dobj) edema_16/NN (l_prep) in_17/IN (l_pobj) core_20/NN (l_amod) ischemic_19/JJ
D010656_D007511 NONE phenylephrine_4/NN (r_npadvmod) induced_6/VBN (r_amod) hypertension_7/NN (r_nsubj) instituted_8/VBD (l_advcl) aggravate_15/VB (l_dobj) edema_16/NN (l_acl) improves_24/VBZ (l_dobj) edema_25/NN (l_prep) in_26/IN (l_pobj) periphery_28/NN (l_prep) of_29/IN (l_pobj) territory_32/NN (l_amod) ischemic_31/JJ
D010656_D009410 NONE phenylephrine_4/NN (r_npadvmod) induced_6/VBN (r_amod) hypertension_7/NN (r_nsubj) instituted_8/VBD (l_advcl) aggravate_15/VB (l_dobj) edema_16/NN (l_acl) improves_24/VBZ (l_conj) reduces_37/VBZ (l_dobj) area_39/NN (l_prep) of_40/IN (l_pobj) dysfunction_43/NN
D007530_D006973 NONE isoflurane_1/JJ (r_amod) anesthesia_2/NN (r_pobj) Under_0/IN (r_prep) occluded_12/VBN (l_nsubjpass) MCA_5/NNP (l_prep) of_6/IN (l_pobj) rats_10/NNS (l_amod) hypertensive_9/JJ
C009591_D009410 NONE 2,3,5-triphenyltetrazolium_8/CD (r_nummod) staining_9/VBG (r_pobj) by_7/IN (r_agent) determined_6/VBN (l_nsubjpass) extent_1/NN (l_prep) of_2/IN (l_pobj) injury_4/NN
12600698
C005435_D015837 NONE edaravone_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (l_prep) against_4/IN (l_pobj) vestibulotoxicity_8/NN
C005435_D015837 NONE edaravone_10/NN (r_pobj) by_9/IN (r_prep) alleviation_3/NN (l_prep) of_4/IN (l_pobj) vestibulotoxicity_8/NN
C005435_D015837 NONE edaravone_4/NN (r_nsubj) suppresses_5/VBZ (l_dobj) vestibulotoxicity_9/NN
D013307_D015837 CID streptomycin_5/NN (r_npadvmod) induced_7/VBN (r_amod) vestibulotoxicity_8/NN
D013307_D015837 CID streptomycin_5/NNS (r_npadvmod) induced_7/VBN (r_amod) vestibulotoxicity_8/NN
D013307_D015837 CID streptomycin_6/NN (r_npadvmod) induced_8/VBN (r_amod) vestibulotoxicity_9/NN
C005435_D002544 NONE Edaravone_0/NNP (r_nsubj) has_7/VBZ (l_conj) used_15/VBN (l_xcomp) treat_20/VB (l_dobj) infarction_22/NN
7189975
C004616_D012640 CID chloroprocaine_31/NN (r_compound) group_32/NN (r_pobj) of_29/IN (r_prep) %_28/NN (r_pobj) in_26/IN (r_prep) was_15/VBD (l_nsubj) dose_2/NN (l_appos) convulsions_8/NNS
C004616_D012640 CID chloroprocaine_31/NN (r_compound) group_32/NN (r_pobj) of_29/IN (r_prep) %_28/NN (r_pobj) in_26/IN (r_prep) was_15/VBD (l_prep) in_17/IN (l_pobj) %_19/NN (l_prep) of_20/IN (l_pobj) seizures_24/NNS
D008012_D012640 CID lidocaine_40/NN (r_compound) group_41/NN (r_pobj) of_38/IN (r_prep) %_37/NN (r_pobj) in_35/IN (r_conj) in_26/IN (r_prep) was_15/VBD (l_nsubj) dose_2/NN (l_appos) convulsions_8/NNS
D008012_D012640 CID lidocaine_40/NN (r_compound) group_41/NN (r_pobj) of_38/IN (r_prep) %_37/NN (r_pobj) in_35/IN (r_conj) in_26/IN (r_prep) was_15/VBD (l_prep) in_17/IN (l_pobj) %_19/NN (l_prep) of_20/IN (l_pobj) seizures_24/NNS
D002045_D012640 CID bupivacaine_21/NN (r_npadvmod) induced_23/VBN (r_amod) seizures_24/NNS (r_pobj) of_20/IN (r_prep) %_19/NN (r_pobj) in_17/IN (r_prep) was_15/VBD (l_nsubj) dose_2/NN (l_appos) convulsions_8/NNS
D002045_D012640 CID bupivacaine_21/NN (r_npadvmod) induced_23/VBN (r_amod) seizures_24/NNS
9636837
D002945_D020258 NONE cisplatin_11/NN (r_nmod) CDDP_13/NNP (r_pobj) over_10/IN (r_prep) striking_2/JJ (r_nsubj) is_15/VBZ (l_attr) rate_19/NN (l_prep) of_20/IN (l_pobj) effects_22/NNS (l_amod) neurotoxic_21/JJ
D002945_D020258 NONE CDDP_13/NNP (r_pobj) over_10/IN (r_prep) striking_2/JJ (r_nsubj) is_15/VBZ (l_attr) rate_19/NN (l_prep) of_20/IN (l_pobj) effects_22/NNS (l_amod) neurotoxic_21/JJ
D002945_D020258 NONE CDDP_23/NNP (r_pobj) by_22/IN (r_agent) caused_21/VBN (r_acl) those_20/DT (r_pobj) to_19/IN (r_prep) similar_18/JJ (r_acomp) are_15/VBP (r_conj) is_1/VBZ (l_acomp) neurotoxic_2/JJ
D002945_D020258 NONE CDDP_23/NNP (r_pobj) by_22/IN (r_agent) caused_21/VBN (r_acl) those_20/DT (r_pobj) to_19/IN (r_prep) similar_18/JJ (r_acomp) are_15/VBP (l_ccomp) is_26/VBZ (l_ccomp) induced_31/VBN (l_nsubjpass) neurotoxicity_29/NN
D016190_D020258 NONE carboplatin_4/NN (r_poss) advantages_6/NNS (r_pobj) of_3/IN (r_prep) striking_2/JJ (r_nsubj) is_15/VBZ (l_attr) rate_19/NN (l_prep) of_20/IN (l_pobj) effects_22/NNS (l_amod) neurotoxic_21/JJ
D016190_D020258 NONE CBDCA_8/NNP (r_appos) advantages_6/NNS (r_pobj) of_3/IN (r_prep) striking_2/JJ (r_nsubj) is_15/VBZ (l_attr) rate_19/NN (l_prep) of_20/IN (l_pobj) effects_22/NNS (l_amod) neurotoxic_21/JJ
D016190_D020258 NONE CBDCA_5/NNP (r_nmod) schedules_9/NNS (l_conj) association_12/NN (l_prep) with_13/IN (l_pobj) drugs_16/NNS (l_amod) neurotoxic_15/JJ
D016190_D020258 NONE CBDCA_0/NNP (r_nsubj) is_1/VBZ (l_acomp) neurotoxic_2/JJ
D016190_D020258 NONE CBDCA_0/NNP (r_nsubj) is_1/VBZ (l_conj) are_15/VBP (l_ccomp) is_26/VBZ (l_ccomp) induced_31/VBN (l_nsubjpass) neurotoxicity_29/NN
D016190_D010523 CID CBDCA_5/NNP (r_nmod) schedules_9/NNS (r_pobj) of_4/IN (r_prep) use_3/NN (r_nsubj) cause_20/VB (l_dobj) concern_22/NN (l_prep) about_23/IN (l_pobj) safety_25/NN (l_prep) with_26/IN (l_pobj) respect_27/NN (l_prep) to_28/IN (l_pobj) damage_32/NN
D016190_D010523 CID CBDCA_0/JJ (r_compound) administration_1/NN (r_nsubj) induced_2/VBD (l_dobj) neurotoxicity_7/NN
6540303
D009638_D002389 NONE norepinephrine_22/NN (r_pobj) with_21/IN (r_prep) pretreatment_20/NN (r_nsubj) did_23/VBD (r_conj) increased_8/VBD (l_dobj) duration_10/NN (l_prep) of_11/IN (l_pobj) catatonia_12/NNP
D007649_D002389 CID ketamine_5/NN (r_compound) catatonia_6/NN
D007649_D002389 CID ketamine_15/NN (r_npadvmod) induced_17/VBN (r_amod) catatonia_18/NN
D007649_D002389 CID ketamine_17/NN (r_pobj) after_16/IN (r_prep) increased_8/VBD (l_dobj) duration_10/NN (l_prep) of_11/IN (l_pobj) catatonia_12/NNP
D007649_D002389 CID ketamine_15/NN (r_compound) catatonia_16/NNP
D004298_D002389 CID dopamine_7/NN (r_pobj) with_6/IN (r_prep) pretreatment_5/NN (r_nsubj) increased_8/VBD (l_dobj) duration_10/NN (l_prep) of_11/IN (l_pobj) catatonia_12/NNP
D004298_D002389 CID dopamine_2/NN (r_nsubj) appeared_3/VBD (l_xcomp) act_5/VB (l_prep) on_6/IN (l_pobj) systems_7/NNS (l_acl) involved_10/JJ (l_prep) with_11/IN (l_pobj) induction_13/NN (l_prep) of_14/IN (l_pobj) catatonia_16/NNP
D002395_D002389 NONE catecholamines_10/NNS (r_pobj) of_9/IN (r_prep) role_8/NN (l_prep) on_14/IN (l_pobj) catatonia_18/NN
D000588_D002389 NONE amine_2/NN (r_compound) pretreatment_3/NN (l_prep) on_4/IN (l_pobj) catatonia_6/NN
19642243
D014640_D007674 NONE Vancomycin_0/NNP (r_compound) nephrotoxicity_1/NN
D014640_D007674 NONE Vancomycin_0/NNP (r_compound) nephrotoxicity_1/NN (r_nsubj) is_2/VBZ (l_conj) result_6/VB (l_prep) from_7/IN (l_pobj) coadministration_8/NN (l_prep) with_9/IN (l_pobj) agent_12/NN (l_amod) nephrotoxic_11/JJ
C096918_D000163 NONE tenofovir_8/NNS (r_pobj) on_7/IN (r_prep) patients_4/NNS (l_prep) with_5/IN (l_pobj) AIDS_6/NNP
C096918_D010019 NONE tenofovir_8/NNS (r_pobj) on_7/IN (r_prep) patients_4/NNS (r_pobj) in_3/IN (r_prep) failure_2/NN (l_advcl) receiving_10/VBG (l_prep) for_14/IN (l_pobj) osteomyelitis_15/NN
C096918_D051437 NONE Tenofovir_0/NNP (r_nsubjpass) implicated_3/VBN (l_prep) in_4/IN (l_pobj) development_6/NN (l_prep) of_7/IN (l_pobj) syndrome_9/NN (l_conj) insufficiency_12/NN
C096918_D051437 NONE tenofovir_5/NNS (r_nsubj) raise_7/VB (l_dobj) risk_9/NN (l_prep) of_10/IN (l_pobj) failure_12/NN
C096918_D058186 NONE tenofovir_8/NNS (r_pobj) on_7/IN (r_prep) patients_4/NNS (r_pobj) in_3/IN (r_prep) failure_2/NN
D014640_D000163 NONE vancomycin_12/NNP (r_amod) course_13/NN (r_dobj) receiving_10/VBG (r_advcl) failure_2/NN (l_prep) in_3/IN (l_pobj) patients_4/NNS (l_prep) with_5/IN (l_pobj) AIDS_6/NNP
D014640_D051437 NONE vancomycin_8/NNP (r_amod) therapy_9/NN (r_pobj) of_7/IN (r_prep) course_6/NN (r_pobj) after_3/IN (r_prep) developed_2/VBD (l_nsubj) failure_1/NN
D014640_D051437 NONE vancomycin_17/NNP (r_pobj) of_16/IN (r_prep) administration_15/NN (r_pobj) during_13/IN (r_prep) raise_7/VB (l_dobj) risk_9/NN (l_prep) of_10/IN (l_pobj) failure_12/NN
C096918_D005198 NONE Tenofovir_0/NNP (r_nsubjpass) implicated_3/VBN (l_prep) in_4/IN (l_pobj) development_6/NN (l_prep) of_7/IN (l_pobj) syndrome_9/NN
D014640_D058186 CID vancomycin_12/NNP (r_amod) course_13/NN (r_dobj) receiving_10/VBG (r_advcl) failure_2/NN
C418563_D051437 NONE fumarate_18/NN (r_dobj) receiving_15/VBG (r_relcl) patients_12/NNS (r_pobj) in_10/IN (r_prep) course_6/NN (r_pobj) after_3/IN (r_prep) developed_2/VBD (l_nsubj) failure_1/NN
D014640_D010019 NONE vancomycin_12/NNP (r_amod) course_13/NN (r_dobj) receiving_10/VBG (l_prep) for_14/IN (l_pobj) osteomyelitis_15/NN
7437994
11099450
D007980_D010300 NONE levodopa_33/RB (r_npadvmod) induced_35/VBN (r_amod) dyskinesias_36/NNS (r_conj) signs_31/NNS (l_poss) parkinsonian_27/NN
D007980_D010300 NONE levodopa_5/JJ (r_compound) responsiveness_6/NN (l_prep) for_7/IN (l_pobj) outcome_9/NN (l_prep) of_10/IN (l_pobj) signs_15/NNS (l_poss) parkinsonian_11/NN
D007980_D010300 NONE levodopa_5/JJ (r_compound) responsiveness_6/NN (l_prep) for_7/IN (l_pobj) outcome_9/NN (l_prep) of_10/IN (l_pobj) signs_15/NNS (l_conj) LID_17/NNP (l_conj) correlations_21/NNS (l_prep) of_22/IN (l_pobj) volume_25/NN (l_prep) with_26/IN (l_pobj) dyskinesias_27/NNS (l_conj) parkinsonian_29/NN
D007980_D010300 NONE levodopa_5/JJ (r_compound) responsiveness_6/NN (r_pobj) of_4/IN (r_prep) value_3/NN (r_nsubj) indicate_34/VBP (l_ccomp) be_42/VB (l_acomp) responsible_43/JJ (l_prep) for_44/IN (l_pobj) generation_46/NN (l_prep) of_47/IN (l_pobj) parkinsonian_48/NN
D007980_D004409 CID levodopa_33/RB (r_npadvmod) induced_35/VBN (r_amod) dyskinesias_36/NNS
D007980_D004409 CID levodopa_33/RB (r_npadvmod) induced_35/VBN (r_amod) dyskinesias_36/NNS (l_appos) LID_38/NNP
D007980_D004409 CID levodopa_8/JJ (r_compound) responsiveness_9/NN (r_pobj) between_5/IN (r_prep) correlations_4/NNS (r_dobj) found_1/VBD (l_advcl) was_45/VBD (l_attr) correlation_47/NN (l_prep) with_48/IN (l_pobj) improvement_50/NN (l_prep) in_51/IN (l_pobj) LID_52/NNP
D007980_D004409 CID levodopa_15/JJ (r_compound) responsiveness_16/NN (r_conj) responsiveness_9/NN (r_pobj) between_5/IN (r_prep) correlations_4/NNS (r_dobj) found_1/VBD (l_advcl) was_45/VBD (l_attr) correlation_47/NN (l_prep) with_48/IN (l_pobj) improvement_50/NN (l_prep) in_51/IN (l_pobj) LID_52/NNP
D007980_D004409 CID levodopa_5/JJ (r_compound) responsiveness_6/NN (l_prep) for_7/IN (l_pobj) outcome_9/NN (l_prep) of_10/IN (l_pobj) signs_15/NNS (l_conj) LID_17/NNP
D007980_D004409 CID levodopa_5/JJ (r_compound) responsiveness_6/NN (l_prep) for_7/IN (l_pobj) outcome_9/NN (l_prep) of_10/IN (l_pobj) signs_15/NNS (l_conj) LID_17/NNP (l_conj) correlations_21/NNS (l_prep) of_22/IN (l_pobj) volume_25/NN (l_prep) with_26/IN (l_pobj) dyskinesias_27/NNS
D007980_D004409 CID levodopa_5/JJ (r_compound) responsiveness_6/NN (r_pobj) of_4/IN (r_prep) value_3/NN (r_nsubj) indicate_34/VBP (l_ccomp) be_42/VB (l_acomp) responsible_43/JJ (l_prep) for_44/IN (l_pobj) signs_52/NNS (l_conj) dyskinesias_54/NNS
343678
D006514_D006509 NONE antigen_43/NN (r_nmod) donors_46/NNS (r_pobj) to_39/IN (r_prep) exposure_38/NN (r_pobj) after_34/IN (r_prep) preventing_30/VBG (r_pcomp) in_29/IN (r_prep) efficacies_28/NNS (r_dobj) assess_25/VB (r_advcl) examined_15/VBN (l_nsubjpass) globulin_3/NN (l_compound) B_1/NN
D006514_D006509 NONE antigen_43/NN (r_nmod) donors_46/NNS (r_pobj) to_39/IN (r_prep) exposure_38/NN (r_pobj) after_34/IN (r_prep) preventing_30/VBG (l_dobj) hepatitis_33/NN
D006514_D006509 NONE HBsAG)-positive_45/JJ (r_compound) donors_46/NNS (r_pobj) to_39/IN (r_prep) exposure_38/NN (r_pobj) after_34/IN (r_prep) preventing_30/VBG (r_pcomp) in_29/IN (r_prep) efficacies_28/NNS (r_dobj) assess_25/VB (r_advcl) examined_15/VBN (l_nsubjpass) globulin_3/NN (l_compound) B_1/NN
D006514_D006509 NONE HBsAG)-positive_45/JJ (r_compound) donors_46/NNS (r_pobj) to_39/IN (r_prep) exposure_38/NN (r_pobj) after_34/IN (r_prep) preventing_30/VBG (l_dobj) hepatitis_33/NN
14975762
D004317_D006333 CID doxorubicin_11/RB (r_compound) induced_13/VBN (r_pobj) from_10/IN (r_prep) myocytes_9/NNS (r_pobj) of_5/IN (r_prep) overexpression_4/NN (r_nsubj) apoptosis_14/NN (l_conj) reduces_16/VBZ (l_dobj) extent_18/NN (l_prep) of_19/IN (l_pobj) failure_22/NN
D004317_D009369 NONE Doxorubicin_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_6/NN (l_compound) tumor_5/NN
16047871
D014859_C535509 NONE Warfarin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) vasculitis_4/NN
D014859_C535509 NONE warfarin_12/NN (r_pobj) due_10/JJ (r_amod) patients_3/NNS (l_prep) with_4/IN (l_pobj) LV_8/NNP
D014859_C535509 NONE warfarin_11/JJ (r_compound) therapy_12/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) reaction_8/NN (r_attr) be_2/VB (l_nsubj) LV_0/NNP
D014859_D012871 NONE warfarin_11/NN (r_dobj) receiving_10/VBG (r_pcomp) after_9/IN (r_prep) developed_8/VBD (r_relcl) eruptions_6/NNS
D014859_D012871 NONE warfarin_21/NN (r_nsubjpass) discontinued_23/VBN (r_advcl) resolved_16/VBD (r_acl) lesions_15/NNS (r_dobj) confirming_12/VBG (r_advcl) were_6/VBD (l_nsubj) results_1/NNS (l_prep) of_2/IN (l_pobj) biopsies_5/NNS (l_compound) lesion_4/NN
D014859_D018366 CID warfarin_21/NN (r_nsubjpass) discontinued_23/VBN (r_advcl) resolved_16/VBD (r_acl) lesions_15/NNS
3015327
D007538_D009422 CID isoniazid_6/NN (r_compound) neuropathy_7/NN
D007538_D009422 CID isoniazid_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (r_pobj) by_3/IN (r_agent) caused_2/VBN (r_acl) neuropathy_1/NN
16174948
D003042_D013901 NONE Cocaine_0/NN (r_compound) use_1/NN (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) complications_7/NNS
D003042_D017542 CID cocaine_31/NN (r_compound) use_32/NN (r_pobj) with_30/IN (r_prep) associated_29/VBN (r_acl) SAH_28/NNP (l_amod) aneurysmal_27/NN
D003042_D014657 NONE Cocaine_0/NN (r_compound) use_1/NN (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) complications_7/NNS (l_prep) including_9/VBG (l_pobj) vasoconstriction_11/NN (l_conj) vasculitis_13/NN
D003042_D014657 NONE cocaine_31/NN (r_compound) use_32/NN (r_pobj) with_30/IN (r_prep) associated_29/VBN (r_acl) SAH_28/NNP (r_pobj) after_26/IN (r_prep) underwent_24/VBD (r_relcl) patients_22/NNS (r_pobj) in_21/IN (r_prep) found_20/VBN (l_nsubjpass) evidence_2/NN (l_prep) for_3/IN (l_pobj) narrowing_4/VBG (l_prep) of_5/IN (l_pobj) arteries_8/NNS (l_conj) evidence_12/NN (l_prep) for_13/IN (l_pobj) narrowing_15/NN (l_conj) vasculitis_17/NN
D003042_D013345 CID cocaine_6/NN (r_npadvmod) associated_8/VBN (r_amod) hemorrhage_10/NN
D003042_D013345 CID cocaine_12/NN (r_npadvmod) associated_14/VBN (r_amod) hemorrhage_16/NN
D003042_D013345 CID cocaine_12/NN (r_npadvmod) associated_14/VBN (r_amod) hemorrhage_16/NN (l_appos) SAH_18/NNP
D003042_D013345 CID cocaine_25/NN (r_compound) use_26/NN (r_pobj) after_24/IN (r_prep) underwent_21/VBD (r_relcl) hemorrhage_16/NN
D003042_D013345 CID cocaine_25/NN (r_compound) use_26/NN (r_pobj) after_24/IN (r_prep) underwent_21/VBD (r_relcl) hemorrhage_16/NN (l_appos) SAH_18/NNP
D003042_D013345 CID cocaine_14/NN (r_pobj) for_13/IN (r_prep) toxicology_12/NN (r_pobj) with_9/IN (r_prep) those_8/DT (r_dobj) identified_7/VBD (r_conj) screened_1/VBD (l_dobj) patients_2/NNS (l_prep) with_3/IN (l_pobj) SAH_4/NNP
D003042_D013345 CID cocaine_31/NN (r_compound) use_32/NN (r_pobj) with_30/IN (r_prep) associated_29/VBN (r_acl) SAH_28/NNP
17344330
D003932_D008133 NONE heroin_10/NN (r_compound) dependence_11/NN (r_pobj) for_9/IN (r_prep) treated_6/VBN (r_acl) patients_5/NNS (r_pobj) among_4/IN (r_prep) Syncope_0/NNP (l_conj) prolongation_3/NN
D003932_D008133 NONE heroin_15/NN (r_compound) addicts_16/NNS (r_pobj) of_14/IN (r_prep) population_13/NN (r_pobj) in_11/IN (r_prep) syncope_10/NN (r_pobj) of_9/IN (r_prep) reporting_8/NN (r_conj) prolongation_5/NN
D003932_D016171 NONE heroin_1/NN (r_compound) addicts_2/NNS (r_nsubj) faint_4/JJ (r_advcl) attribute_12/VB (l_conj) underestimate_24/VBP (l_dobj) incidence_26/NN (l_prep) of_27/IN (l_pobj) TdP_28/NNP
D008691_D008133 CID methadone_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (r_acl) patients_5/NNS (r_pobj) among_4/IN (r_prep) Syncope_0/NNP (l_conj) prolongation_3/NN
D008691_D008133 CID methadone_5/NN (r_pobj) with_4/IN (r_prep) treated_3/VBN (r_acl) subjects_2/NNS (r_pobj) Among_0/IN (r_prep) had_14/VBD (l_dobj) interval_17/NN
D008691_D008133 CID Methadone_0/NNP (r_nsubjpass) associated_2/VBN (l_prep) with_3/IN (l_pobj) prolongation_5/NN
D008691_D016171 NONE methadone_21/NN (r_compound) users_22/NNS (r_pobj) in_20/IN (r_prep) reported_19/VBN (l_nsubjpass) Prolongation_0/NN (l_prep) of_1/IN (l_pobj) interval_4/NN (l_prep) in_5/IN (l_pobj) ECG_7/NNP (l_prep) of_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) pointes_13/FW
D008691_D016171 NONE methadone_21/NN (r_compound) users_22/NNS (r_pobj) in_20/IN (r_prep) reported_19/VBN (l_nsubjpass) Prolongation_0/NN (l_prep) of_1/IN (l_pobj) interval_4/NN (l_prep) in_5/IN (l_pobj) ECG_7/NNP (l_prep) of_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) pointes_13/FW (l_appos) TdP_15/NN
D008691_D016171 NONE methadone_53/NN (r_pobj) of_52/IN (r_prep) effect_51/NN (r_pobj) by_48/IN (r_agent) caused_47/VBN (r_conj) attribute_12/VB (l_conj) underestimate_24/VBP (l_dobj) incidence_26/NN (l_prep) of_27/IN (l_pobj) TdP_28/NNP
D008691_D013575 CID methadone_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (r_acl) patients_5/NNS (r_pobj) among_4/IN (r_prep) Syncope_0/NNP
D008691_D013575 CID methadone_53/NN (r_pobj) of_52/IN (r_prep) effect_51/NN (r_pobj) by_48/IN (r_agent) caused_47/VBN (r_conj) attribute_12/VB (l_dobj) episodes_15/NNS (l_prep) of_16/IN (l_pobj) syncope_17/NN
D008691_D013575 CID methadone_9/NN (r_compound) dose_10/NN (l_conj) reporting_12/NN (l_prep) of_13/IN (l_pobj) syncope_14/NN
D008691_D013575 CID methadone_4/NN (r_compound) dose_5/NN (r_nsubjpass) associated_7/VBN (l_prep) with_8/IN (l_pobj) CI_14/NNP (l_appos) odds_21/NNS (l_prep) for_22/IN (l_pobj) syncope_23/NN
D008691_D013575 CID Methadone_0/NNP (r_nsubjpass) associated_2/VBN (l_prep) with_3/IN (l_pobj) prolongation_5/NN (l_conj) reporting_8/NN (l_prep) of_9/IN (l_pobj) syncope_10/NN
D003932_D013575 NONE heroin_10/NN (r_compound) dependence_11/NN (r_pobj) for_9/IN (r_prep) treated_6/VBN (r_acl) patients_5/NNS (r_pobj) among_4/IN (r_prep) Syncope_0/NNP
D003932_D013575 NONE heroin_1/NN (r_compound) addicts_2/NNS (r_nsubj) faint_4/JJ (r_advcl) attribute_12/VB (l_dobj) episodes_15/NNS (l_prep) of_16/IN (l_pobj) syncope_17/NN
D003932_D013575 NONE heroin_15/NN (r_compound) addicts_16/NNS (r_pobj) of_14/IN (r_prep) population_13/NN (r_pobj) in_11/IN (r_prep) syncope_10/NN
20510337
D009569_D009336 NONE oxide_35/NN (r_conj) alpha_32/NN (r_appos) factor_30/NN (l_compound) necrosis_29/NN
D015032_D009369 NONE zinc_48/NN (r_conj) selenium_46/NN (r_nmod) ions_49/NNS (r_pobj) of_45/IN (r_prep) reductions_44/NNS (r_dobj) attenuated_42/VBD (r_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) tumor_28/NN
D010984_D009369 NONE platinum_37/NN (r_compound) ion_38/NN (r_compound) concentration_39/NN (r_conj) oxide_35/NN (r_conj) alpha_32/NN (r_appos) factor_30/NN (l_compound) tumor_28/NN
D013481_D009369 NONE superoxide_15/NN (r_amod) activity_17/NN (r_conj) level_13/NN (r_dobj) compensated_3/VBD (l_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) tumor_28/NN
D012643_D009369 NONE selenium_46/NN (r_nmod) ions_49/NNS (r_pobj) of_45/IN (r_prep) reductions_44/NNS (r_dobj) attenuated_42/VBD (r_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) tumor_28/NN
D012643_D009336 NONE selenium_46/NN (r_nmod) ions_49/NNS (r_pobj) of_45/IN (r_prep) reductions_44/NNS (r_dobj) attenuated_42/VBD (r_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) necrosis_29/NN
D002945_D007674 NONE cisplatin_5/NN (r_amod) nephrotoxicity_6/NN
D002945_D007674 NONE cisplatin_8/NN (r_pobj) by_7/IN (r_agent) mediated_6/VBN (r_acl) damage_5/NN
D002945_D007674 NONE cisplatin_15/NN (r_amod) nephrotoxicity_16/NN
C024989_D007674 NONE Q10_1/NNP (r_compound) treatment_2/NN (r_nsubj) ameliorates_3/VBZ (l_dobj) nephrotoxicity_6/NN
C024989_D007674 NONE Q10_13/NNP (r_compound) treatment_14/NN (r_pobj) by_11/IN (r_agent) ameliorated_10/VBN (l_nsubjpass) damage_5/NN
C024989_D007674 NONE Q10_5/NNP (r_nsubj) represents_6/VBZ (l_dobj) option_10/NN (l_acl) protect_12/VB (l_prep) against_13/IN (l_pobj) nephrotoxicity_16/NN
D002945_D009336 NONE cisplatin_55/JJ (r_amod) administration_56/NN (r_pobj) from_54/IN (r_prep) resulted_53/VBD (r_advcl) attenuated_42/VBD (r_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) necrosis_29/NN
D002945_D009369 NONE cisplatin_55/JJ (r_amod) administration_56/NN (r_pobj) from_54/IN (r_prep) resulted_53/VBD (r_advcl) attenuated_42/VBD (r_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) tumor_28/NN
C024989_D009336 NONE Q10_1/NNP (r_nsubj) compensated_3/VBD (l_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) necrosis_29/NN
C024989_D009369 NONE Q10_1/NNP (r_nsubj) compensated_3/VBD (l_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) tumor_28/NN
D010984_D009336 NONE platinum_37/NN (r_compound) ion_38/NN (r_compound) concentration_39/NN (r_conj) oxide_35/NN (r_conj) alpha_32/NN (r_appos) factor_30/NN (l_compound) necrosis_29/NN
D002945_D058186 CID cisplatin_21/NN (r_pobj) of_20/IN (r_prep) injection_19/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_advcl) investigated_7/VBN (l_prep) in_8/IN (l_pobj) mice_9/NNS (l_prep) with_10/IN (l_pobj) injury_13/NN
C024989_D058186 NONE Q10_5/NNP (r_pobj) of_3/IN (r_prep) effect_2/NN (r_nsubjpass) investigated_7/VBN (l_prep) in_8/IN (l_pobj) mice_9/NNS (l_prep) with_10/IN (l_pobj) injury_13/NN
D013481_D009336 NONE superoxide_15/NN (r_amod) activity_17/NN (r_conj) level_13/NN (r_dobj) compensated_3/VBD (l_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) necrosis_29/NN
D005978_D009336 NONE glutathione_12/NN (r_compound) level_13/NN (r_dobj) compensated_3/VBD (l_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) necrosis_29/NN
D015032_D009336 NONE zinc_48/NN (r_conj) selenium_46/NN (r_nmod) ions_49/NNS (r_pobj) of_45/IN (r_prep) reductions_44/NNS (r_dobj) attenuated_42/VBD (r_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) necrosis_29/NN
D009569_D009369 NONE oxide_35/NN (r_conj) alpha_32/NN (r_appos) factor_30/NN (l_compound) tumor_28/NN
D005978_D009369 NONE glutathione_12/NN (r_compound) level_13/NN (r_dobj) compensated_3/VBD (l_conj) decreased_24/VBD (l_dobj) elevations_26/NNS (l_prep) of_27/IN (l_pobj) factor_30/NN (l_compound) tumor_28/NN
871943
D013390_D001049 CID succinylcholine_6/NN (r_compound) apnoea_7/NN
D013390_D001049 CID succinylcholine_10/NN (r_nsubjpass) treated_13/VBN (r_advcl) demonstrating_2/VBG (l_dobj) apnoea_5/NN
D013390_D001049 CID succinylcholine_6/NN (r_compound) apnoea_7/NN
10692744
D000086_D005862 CID Acetazolamide_0/RB (r_npadvmod) induced_2/VBN (r_amod) syndrome_4/NN
D000086_D005862 CID acetazolamide_5/NN (r_npadvmod) induced_7/VBN (r_amod) syndrome_9/NN
D000086_D007674 NONE acetazolamide_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) confusion_1/NN (r_nsubj) is_5/VBZ (l_attr) reaction_11/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) impairment_16/NN
D000086_D003221 NONE acetazolamide_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) confusion_1/NN
11058428
D013256_D013119 NONE steroid_2/NN (r_compound) myopathy_3/NN (r_nsubj) recovers_4/VBZ (l_conj) be_15/VB (l_attr) recording_18/NN (l_cc) of_30/IN (l_pobj) protection_32/NN (l_relcl) methylprednisolone_34/NN (l_dobj) offers_35/VBZ (l_prep) to_36/IN (l_pobj) injury_40/NN
D013256_D013119 NONE steroid_26/NN (r_compound) myopathy_27/NNS (r_pobj) from_24/IN (r_prep) recovery_23/NN (r_pobj) of_19/IN (r_prep) recording_18/NN (l_cc) of_30/IN (l_pobj) protection_32/NN (l_relcl) methylprednisolone_34/NN (l_dobj) offers_35/VBZ (l_prep) to_36/IN (l_pobj) injury_40/NN
D008775_D009135 CID methylprednisolone_19/NN (r_nsubj) cause_21/VB (r_acl) possibility_10/NN (l_prep) myopathy_14/NNS
D008775_D009135 CID methylprednisolone_34/NN (r_relcl) protection_32/NN (r_pobj) of_30/IN (r_cc) recording_18/NN (r_attr) be_15/VB (r_conj) recovers_4/VBZ (l_nsubj) myopathy_3/NN
D008775_D009135 CID methylprednisolone_34/NN (r_relcl) protection_32/NN (r_pobj) of_30/IN (r_cc) recording_18/NN (l_prep) of_19/IN (l_pobj) recovery_23/NN (l_prep) from_24/IN (l_pobj) myopathy_27/NNS
D008775_D009135 CID methylprednisolone_14/NN (r_nsubj) cause_19/VB (l_ccomp) myopathy_22/NNS
D008775_D013119 NONE methylprednisolone_3/NN (r_nsubj) do_5/VB (l_dobj) harm_7/NN (l_prep) for_8/IN (l_pobj) injury_11/NN
D008775_D013119 NONE methylprednisolone_16/NN (r_nsubj) became_17/VBD (l_prep) Because_0/IN (l_pobj) Studies_8/NNP (l_compound) Injury_7/NNP
D008775_D013119 NONE methylprednisolone_16/NN (r_nsubj) became_17/VBD (l_attr) standard_19/NN (l_prep) for_22/IN (l_pobj) injury_27/NN
D008775_D013119 NONE methylprednisolone_34/NN (l_dobj) offers_35/VBZ (l_prep) to_36/IN (l_pobj) injury_40/NN
D000305_D009135 NONE corticosteroid_13/NN (r_pobj) of_11/IN (r_prep) possibility_10/NN (l_prep) myopathy_14/NNS
D000305_D009135 NONE corticosteroid_21/NN (r_nsubj) myopathy_22/NNS
D013256_D009135 NONE steroid_2/NN (r_compound) myopathy_3/NN
D013256_D009135 NONE steroid_2/NN (r_compound) myopathy_3/NN (r_nsubj) recovers_4/VBZ (l_conj) be_15/VB (l_attr) recording_18/NN (l_prep) of_19/IN (l_pobj) recovery_23/NN (l_prep) from_24/IN (l_pobj) myopathy_27/NNS
D013256_D009135 NONE steroid_26/NN (r_compound) myopathy_27/NNS (r_pobj) from_24/IN (r_prep) recovery_23/NN (r_pobj) of_19/IN (r_prep) recording_18/NN (r_attr) be_15/VB (r_conj) recovers_4/VBZ (l_nsubj) myopathy_3/NN
D013256_D009135 NONE steroid_26/NN (r_compound) myopathy_27/NNS
2886572
D004837_D006973 CID epinephrine_7/NN (r_npadvmod) induced_9/VBN (r_amod) rats_11/NNS (l_amod) hypertensive_10/JJ
8546130
D017291_D020258 NONE clarithromycin_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubj) facilitated_28/VBN (l_dobj) appearance_30/NN (l_prep) of_31/IN (l_pobj) effect_35/NN (l_amod) neurotoxic_33/JJ
D000535_D007676 NONE aluminum_23/NN (r_compound) intoxication_24/NN (r_pobj) with_21/IN (r_prep) combination_1/NN (l_prep) of_2/IN (l_pobj) dose_6/NN (l_prep) in_9/IN (l_pobj) face_10/NN (l_prep) of_11/IN (l_pobj) failure_14/NN
D017291_D006212 CID Clarithromycin_0/NN (r_npadvmod) associated_2/VBN (r_amod) hallucinations_4/NNS
D017291_D006212 CID clarithromycin_16/NN (r_appos) antibiotic_14/NN (r_pobj) with_10/IN (r_prep) association_9/NN (r_pobj) in_8/IN (r_prep) occurring_7/VBG (r_acl) hallucinations_6/NNS
D017291_D007676 NONE Clarithromycin_0/NN (r_npadvmod) associated_2/VBN (r_amod) hallucinations_4/NNS (l_prep) in_5/IN (l_pobj) patient_7/NN (l_prep) with_8/IN (l_pobj) failure_11/NN
D017291_D007676 NONE clarithromycin_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (l_prep) in_9/IN (l_pobj) face_10/NN (l_prep) of_11/IN (l_pobj) failure_14/NN
D000535_D020258 NONE aluminum_23/NN (r_compound) intoxication_24/NN (r_pobj) with_21/IN (r_prep) combination_1/NN (r_nsubj) facilitated_28/VBN (l_dobj) appearance_30/NN (l_prep) of_31/IN (l_pobj) effect_35/NN (l_amod) neurotoxic_33/JJ
D018942_D006212 NONE macrolide_13/NN (r_amod) antibiotic_14/NN (r_pobj) with_10/IN (r_prep) association_9/NN (r_pobj) in_8/IN (r_prep) occurring_7/VBG (r_acl) hallucinations_6/NNS
8441146
D006046_D000741 CID gold_12/NN (r_pobj) by_11/IN (r_agent) caused_10/VBN (r_relcl) anemia_7/NN
D010396_D000741 CID penicillamine_19/NN (r_conj) case_15/NN (r_pobj) in_13/IN (r_prep) caused_10/VBN (r_relcl) anemia_7/NN
16192988
D008694_D006948 NONE METH_8/NNP (r_npadvmod) induced_10/VBN (r_amod) hyperactivity_11/NN
D008694_D001523 CID Methamphetamine_0/NN (r_nsubj) causes_1/VBZ (l_dobj) alterations_2/NNS (l_relcl) display_16/VBP (l_dobj) aggressiveness_18/NN
D008694_D001523 CID methamphetamine_18/NN (r_pobj) in_17/IN (r_prep) common_16/JJ (r_acomp) are_15/VBP (r_conj) reported_4/VBN (l_nsubjpass) behaviors_1/NNS
D008694_D001523 CID methamphetamine_18/NN (r_pobj) in_17/IN (r_prep) common_16/JJ (r_acomp) are_15/VBP (r_conj) reported_4/VBN (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_relcl) suffer_8/VBP (l_prep) from_9/IN (l_pobj) disorders_12/NNS
D008694_D001523 CID METH_20/NN (r_nmod) abusers_22/NNS (r_appos) methamphetamine_18/NN (r_pobj) in_17/IN (r_prep) common_16/JJ (r_acomp) are_15/VBP (r_conj) reported_4/VBN (l_nsubjpass) behaviors_1/NNS
D008694_D001523 CID METH_20/NN (r_nmod) abusers_22/NNS (r_appos) methamphetamine_18/NN (r_pobj) in_17/IN (r_prep) common_16/JJ (r_acomp) are_15/VBP (r_conj) reported_4/VBN (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_relcl) suffer_8/VBP (l_prep) from_9/IN (l_pobj) disorders_12/NNS
D008694_D001523 CID METH_13/NNP (r_pobj) of_12/IN (r_prep) injections_11/NNS (r_nsubj) increased_15/VBD (l_dobj) aggressiveness_16/NN
D008694_D001523 CID METH_8/NNP (r_npadvmod) induced_10/VBN (r_amod) hyperactivity_11/NN (r_pobj) to_7/IN (r_prep) secondary_6/JJ (r_acomp) was_4/VBD (l_nsubj) increase_1/NN (l_prep) in_2/IN (l_pobj) aggressiveness_3/NN
2894433
D005680_D001919 NONE GABA_38/NNP (r_compound) chloride_40/NN (r_compound) complex_43/NN (r_pobj) with_34/IN (r_prep) associated_33/VBN (r_acl) sites_32/NNS (r_pobj) to_31/IN (r_prep) binding_30/VBG (r_pcomp) by_29/IN (r_prep) blocks_26/NNS (r_appos) picrotoxin_22/NN (r_pobj) of_21/IN (r_prep) dose_20/NN (r_pobj) with_17/IN (r_prep) pretreatment_14/NN (r_pobj) by_13/IN (r_agent) antagonized_12/VBN (l_nsubjpass) enhancement_4/NN (l_prep) of_5/IN (l_pobj) bradycardia_10/NN
D005680_D001919 NONE GABA_10/NNP (r_compound) chloride_12/NN (r_compound) complex_15/NN (r_pobj) through_6/IN (r_prep) acts_5/VBZ (l_advcl) facilitate_22/VB (l_dobj) bradycardia_24/NN
D003975_D001919 CID Diazepam_0/NNP (r_nsubj) facilitates_1/VBZ (l_dobj) bradycardia_3/NN
D003975_D001919 CID diazepam_6/NN (r_pobj) with_5/IN (r_prep) pretreatment_1/NN (r_nsubj) enhance_21/VB (l_dobj) bradycardia_27/NN
D003975_D001919 CID diazepam_3/NN (r_compound) enhancement_4/NN (l_prep) of_5/IN (l_pobj) bradycardia_10/NN
D003975_D001919 CID diazepam_4/NN (r_nsubj) acts_5/VBZ (l_advcl) facilitate_22/VB (l_dobj) bradycardia_24/NN
D010852_D001919 NONE picrotoxin_22/NN (r_pobj) of_21/IN (r_prep) dose_20/NN (r_pobj) with_17/IN (r_prep) pretreatment_14/NN (r_pobj) by_13/IN (r_agent) antagonized_12/VBN (l_nsubjpass) enhancement_4/NN (l_prep) of_5/IN (l_pobj) bradycardia_10/NN
D004837_D001919 CID adrenaline_12/NN (r_pobj) of_11/IN (r_prep) infusion_10/NN (r_pobj) by_8/IN (r_agent) produced_5/VBN (l_nsubjpass) bradycardia_3/NN
D004837_D001919 CID adrenaline_14/NN (r_npadvmod) induced_16/VBN (r_amod) effect_18/NN (r_pobj) in_12/IN (r_prep) change_11/NN (r_dobj) causing_9/VBG (r_advcl) pretreatment_1/NN (r_nsubj) enhance_21/VB (l_dobj) bradycardia_27/NN
D004837_D001919 CID adrenaline_23/NN (r_npadvmod) induced_25/VBN (r_amod) bradycardia_27/NN
D004837_D001919 CID adrenaline_6/NN (r_npadvmod) induced_8/VBN (r_amod) bradycardia_10/NN
D002712_D001919 NONE chloride_27/NN (r_compound) channels_28/NNS (r_dobj) blocks_26/NNS (r_appos) picrotoxin_22/NN (r_pobj) of_21/IN (r_prep) dose_20/NN (r_pobj) with_17/IN (r_prep) pretreatment_14/NN (r_pobj) by_13/IN (r_agent) antagonized_12/VBN (l_nsubjpass) enhancement_4/NN (l_prep) of_5/IN (l_pobj) bradycardia_10/NN
D002712_D001919 NONE chloride_40/NN (r_compound) complex_43/NN (r_pobj) with_34/IN (r_prep) associated_33/VBN (r_acl) sites_32/NNS (r_pobj) to_31/IN (r_prep) binding_30/VBG (r_pcomp) by_29/IN (r_prep) blocks_26/NNS (r_appos) picrotoxin_22/NN (r_pobj) of_21/IN (r_prep) dose_20/NN (r_pobj) with_17/IN (r_prep) pretreatment_14/NN (r_pobj) by_13/IN (r_agent) antagonized_12/VBN (l_nsubjpass) enhancement_4/NN (l_prep) of_5/IN (l_pobj) bradycardia_10/NN
D002712_D001919 NONE chloride_12/NN (r_compound) complex_15/NN (r_pobj) through_6/IN (r_prep) acts_5/VBZ (l_advcl) facilitate_22/VB (l_dobj) bradycardia_24/NN
D001569_D001919 NONE benzodiazepine_36/JJ (r_amod) complex_43/NN (r_pobj) with_34/IN (r_prep) associated_33/VBN (r_acl) sites_32/NNS (r_pobj) to_31/IN (r_prep) binding_30/VBG (r_pcomp) by_29/IN (r_prep) blocks_26/NNS (r_appos) picrotoxin_22/NN (r_pobj) of_21/IN (r_prep) dose_20/NN (r_pobj) with_17/IN (r_prep) pretreatment_14/NN (r_pobj) by_13/IN (r_agent) antagonized_12/VBN (l_nsubjpass) enhancement_4/NN (l_prep) of_5/IN (l_pobj) bradycardia_10/NN
D001569_D001919 NONE benzodiazepine_8/JJ (r_amod) complex_15/NN (r_pobj) through_6/IN (r_prep) acts_5/VBZ (l_advcl) facilitate_22/VB (l_dobj) bradycardia_24/NN
18356633
D000617_D009369 NONE aminoglycoside_17/NN (r_pobj) with_15/IN (r_prep) treatment_14/NN (r_dobj) required_13/VBD (r_relcl) disorder_11/NN
D000617_D009503 NONE aminoglycoside_3/NN (l_acl) used_5/VBN (l_xcomp) provide_7/VB (l_dobj) treatment_13/NN (l_prep) for_14/IN (l_pobj) neutropenia_16/NN
D000617_D006402 NONE aminoglycoside_17/NN (r_pobj) with_15/IN (r_prep) treatment_14/NN (r_dobj) required_13/VBD (r_relcl) disorder_11/NN
D000583_D007674 CID amikacin_3/JJ (r_amod) nephrotoxicity_4/NN
D000583_D007674 CID amikacin_2/RB (r_npadvmod) associated_4/VBN (r_amod) nephrotoxicity_5/NN
D000583_D007674 CID amikacin_17/JJ (r_prep) via_16/IN (r_prep) evaluation_13/NN (r_conj) creatinine_11/NN (r_pobj) in_9/IN (r_prep) increase_8/NN (r_pobj) of_6/IN (r_prep) means_5/NNS (r_pobj) by_4/IN (r_prep) occurrence_1/NN (l_prep) of_2/IN (l_pobj) nephrotoxicity_3/NN
D000583_D007239 NONE Amikacin_0/NNP (r_nsubj) is_1/VBZ (l_attr) aminoglycoside_3/NN (l_acl) used_5/VBN (l_xcomp) provide_7/VB (l_dobj) treatment_13/NN (l_prep) for_14/IN (l_pobj) neutropenia_16/NN (l_conj) infections_20/NNS
D000617_D007239 NONE aminoglycoside_3/NN (l_acl) used_5/VBN (l_xcomp) provide_7/VB (l_dobj) treatment_13/NN (l_prep) for_14/IN (l_pobj) neutropenia_16/NN (l_conj) infections_20/NNS
D000583_D009503 NONE Amikacin_0/NNP (r_nsubj) is_1/VBZ (l_attr) aminoglycoside_3/NN (l_acl) used_5/VBN (l_xcomp) provide_7/VB (l_dobj) treatment_13/NN (l_prep) for_14/IN (l_pobj) neutropenia_16/NN
D000583_D009369 NONE amikacin_27/JJ (r_pobj) to_20/IN (r_prep) randomized_19/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_2/IN (l_pobj) diagnosis_4/NN (l_amod) consistent_5/JJ (l_prep) with_6/IN (l_pobj) disorder_11/NN
D003404_D007674 NONE creatinine_11/NN (r_pobj) in_9/IN (r_prep) increase_8/NN (r_pobj) of_6/IN (r_prep) means_5/NNS (r_pobj) by_4/IN (r_prep) occurrence_1/NN (l_prep) of_2/IN (l_pobj) nephrotoxicity_3/NN
D000583_D006402 NONE amikacin_27/JJ (r_pobj) to_20/IN (r_prep) randomized_19/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_2/IN (l_pobj) diagnosis_4/NN (l_amod) consistent_5/JJ (l_prep) with_6/IN (l_pobj) disorder_11/NN
12139551
D008787_D006323 CID metoclopramide_4/NN (r_compound) case_7/NN (r_pobj) after_2/IN (r_prep) arrest_1/NN
D008787_D006323 CID metoclopramide_4/NN (r_compound) case_7/NN (l_acl) causing_14/VBG (l_dobj) episodes_16/NNS (l_prep) of_17/IN (l_pobj) arrest_19/NN
D008787_D006323 CID metoclopramide_13/NN (r_pobj) of_12/IN (r_prep) injections_11/NNS (r_pobj) of_8/IN (r_prep) case_7/NN (r_pobj) after_2/IN (r_prep) arrest_1/NN
D008787_D006323 CID metoclopramide_13/NN (r_pobj) of_12/IN (r_prep) injections_11/NNS (r_pobj) of_8/IN (r_prep) case_7/NN (l_acl) causing_14/VBG (l_dobj) episodes_16/NNS (l_prep) of_17/IN (l_pobj) arrest_19/NN
D008787_D006323 CID metoclopramide_8/NN (r_pobj) of_7/IN (r_prep) injection_6/NN (r_nsubjpass) followed_11/VBN (l_agent) by_12/IN (l_pobj) asystole_13/NN
D008787_D006323 CID metoclopramide_3/JJ (r_dobj) received_2/VBD (r_ccomp) is_24/VBZ (l_advcl) followed_37/VBN (l_agent) by_38/IN (l_pobj) asystole_39/NN
D008787_D006323 CID metoclopramide_30/NN (r_pobj) of_29/IN (r_prep) administration_28/NN (r_nsubj) was_31/VBD (r_ccomp) is_24/VBZ (l_advcl) followed_37/VBN (l_agent) by_38/IN (l_pobj) asystole_39/NN
D008787_D006323 CID metoclopramide_10/NN (r_pobj) by_9/IN (r_agent) caused_8/VBN (r_acl) episodes_4/NNS (l_prep) of_5/IN (l_pobj) arrest_7/NN
19289093
D002809_D007022 CID sulfate_19/NN (r_nmod) derivative_23/NN (l_relcl) elicit_26/VB (l_dobj) response_29/NN (l_amod) hypotensive_28/JJ
D006493_D007022 NONE heparin_8/JJ (r_compound) products_9/NNS (r_pobj) of_7/IN (r_prep) lots_6/NNS (r_pobj) of_4/IN (r_prep) number_3/NN (r_nsubjpass) found_11/VBN (l_xcomp) contaminated_14/VBN (l_prep) with_15/IN (l_pobj) derivative_23/NN (l_relcl) elicit_26/VB (l_dobj) response_29/NN (l_amod) hypotensive_28/JJ
D006493_D007022 NONE heparin_3/JJ (r_compound) products_4/NNS (r_dobj) Using_0/VBG (r_advcl) showed_12/VBD (l_ccomp) produces_16/VBZ (l_dobj) hypotension_20/NN
8384253
D014750_D008228 NONE vincristine_10/NN (r_pobj) with_9/IN (r_prep) treated_8/VBN (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) Lymphoma_7/NNP
D014750_D008228 NONE vincristine_37/NN (r_pobj) of_36/IN (r_prep) effects_35/NNS (r_dobj) evaluate_31/VB (r_acl) order_29/NN (r_pobj) in_28/IN (r_prep) investigated_27/VBN (r_parataxis) treated_8/VBN (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) Lymphoma_7/NNP
D014750_D009422 NONE vincristine_8/NN (r_pobj) with_4/IN (r_prep) are_17/VBP (l_nsubj) signs_11/NNS (l_conj) symptoms_13/NNS (l_prep) of_14/IN (l_pobj) neuropathy_16/NN
D014750_D009422 NONE vincristine_15/NN (r_compound) neuropathy_16/NN
3732088
D011188_D003327 NONE potassium_2/NN (r_conj) Diuretics_0/NNS (l_prep) in_5/IN (l_pobj) disease_8/NN
D002752_D006973 NONE chlorthalidone_43/NN (r_pobj) on_36/IN (r_prep) period_35/NN (r_conj) measured_6/VBN (l_prep) in_7/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) hypertension_12/NN
D011188_D003324 NONE potassium_25/NN (r_npadvmod) conserving_27/VBG (r_amod) diuretic_28/JJ (r_amod) amiloride_30/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) of_21/IN (r_prep) weeks_20/NNS (r_pobj) after_18/IN (r_prep) known_14/VBN (l_dobj) disease_17/NN
D011188_D003324 NONE potassium_38/NN (r_npadvmod) losing_40/VBG (r_amod) chlorthalidone_43/NN (r_pobj) on_36/IN (r_prep) period_35/NN (r_conj) measured_6/VBN (l_conj) known_14/VBN (l_dobj) disease_17/NN
D011188_D001145 NONE potassium_2/NN (l_conj) arrhythmias_4/NNS
D011188_D001145 NONE potassium_9/NN (r_pobj) in_7/IN (r_prep) changes_6/NNS (r_nsubj) alter_11/VB (l_dobj) tendency_13/NN (l_prep) towards_14/IN (l_pobj) arrhythmias_16/NNS
D000584_D018879 NONE amiloride_2/NN (r_compound) treatment_3/NN (r_pobj) to_1/IN (r_prep) Compared_0/VBN (r_prep) associated_9/VBN (l_prep) with_10/IN (l_pobj) frequency_13/NN (l_prep) of_14/IN (l_pobj) beats_17/NNS
D002752_D003324 NONE chlorthalidone_43/NN (r_pobj) on_36/IN (r_prep) period_35/NN (r_conj) measured_6/VBN (l_conj) known_14/VBN (l_dobj) disease_17/NN
D000584_D003324 NONE amiloride_30/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) of_21/IN (r_prep) weeks_20/NNS (r_pobj) after_18/IN (r_prep) known_14/VBN (l_dobj) disease_17/NN
D011188_D006973 NONE potassium_2/NN (r_conj) Diuretics_0/NNS (l_prep) in_5/IN (l_pobj) disease_8/NN (l_amod) hypertensive_6/JJ
D011188_D006973 NONE potassium_25/NN (r_npadvmod) conserving_27/VBG (r_amod) diuretic_28/JJ (r_amod) amiloride_30/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) of_21/IN (r_prep) weeks_20/NNS (r_pobj) after_18/IN (r_prep) known_14/VBN (r_conj) measured_6/VBN (l_prep) in_7/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) hypertension_12/NN
D011188_D006973 NONE potassium_38/NN (r_npadvmod) losing_40/VBG (r_amod) chlorthalidone_43/NN (r_pobj) on_36/IN (r_prep) period_35/NN (r_conj) measured_6/VBN (l_prep) in_7/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) hypertension_12/NN
D000584_D006973 NONE amiloride_30/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) of_21/IN (r_prep) weeks_20/NNS (r_pobj) after_18/IN (r_prep) known_14/VBN (r_conj) measured_6/VBN (l_prep) in_7/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) hypertension_12/NN
D002752_D018879 CID chlorthalidone_6/NN (r_compound) phase_7/NN (r_nsubjpass) associated_9/VBN (l_prep) with_10/IN (l_pobj) frequency_13/NN (l_prep) of_14/IN (l_pobj) beats_17/NNS
D011188_D017202 NONE potassium_6/NN (r_npadvmod) losing_8/VBG (r_amod) therapy_10/NN (r_nsubj) increase_12/VB (l_dobj) excitability_15/NN (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) disease_21/NN
D011188_D017202 NONE potassium_28/NN (r_compound) concentrations_29/NNS (r_pobj) in_26/IN (r_prep) falls_25/VBZ (l_advcl) increase_12/VB (l_dobj) excitability_15/NN (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) disease_21/NN
11226639
C032232_D053608 NONE barbiturate_5/NN (r_npadvmod) induced_7/VBN (r_amod) narcosis_8/NN
C032232_D053608 NONE barbiturate_9/NN (r_compound) narcosis_10/NN
C032232_D053608 NONE barbiturate_14/NN (r_compound) narcosis_15/NN
C032232_D053608 NONE barbiturate_16/JJ (r_compound) mechanism_17/NN (r_pobj) for_14/IN (r_prep) specific_13/JJ (r_acomp) be_12/VB (r_xcomp) seems_10/VBZ (l_nsubj) action_4/NN (l_prep) of_5/IN (l_pobj) melatonin_6/NN (l_prep) on_7/IN (l_pobj) narcosis_9/NN
D003975_D053608 CID diazepam_15/NN (r_npadvmod) induced_17/VBN (r_conj) ketamine-_13/NNS (r_nmod) narcosis_18/NN
D008550_D053608 CID melatonin_3/NN (l_prep) on_4/IN (l_pobj) narcosis_8/NN
D008550_D053608 CID Melatonin_0/NNP (r_nsubj) affects_1/VBZ (l_conj) is_11/VBZ (l_ccomp) influence_17/VB (l_dobj) narcosis_21/NN
D008550_D053608 CID Melatonin_0/NNP (r_nsubjpass) found_20/VBN (l_punct) ,_11/, (l_punct) affected_4/VBN (l_prep) in_5/IN (l_pobj) narcosis_10/NN
D008550_D053608 CID melatonin_7/NN (r_pobj) of_6/IN (r_prep) dose_5/NN (r_nsubj) caused_12/VBD (l_conj) produced_20/VBD (l_dobj) reduction_23/NN (l_prep) of_24/IN (l_pobj) duration_26/NN (l_prep) of_27/IN (l_pobj) narcosis_28/NN
D008550_D053608 CID Melatonin_0/NNP (r_nsubj) influenced_5/VBD (l_dobj) duration_7/NN (l_conj) latency_11/NN (l_prep) of_12/IN (l_pobj) narcosis_18/NN
D008550_D053608 CID melatonin_6/NN (l_prep) on_7/IN (l_pobj) narcosis_9/NN
D007649_D053608 CID ketamine-_13/NNS (r_nmod) narcosis_18/NN
8677458
D007069_D064420 NONE ifosfamide_8/NN (r_pobj) of_7/IN (r_prep) toxicity_6/NN
D007069_D014839 NONE ifosfamide_33/RB (r_advmod) induced_35/VBN (r_amod) emesis_36/NN
D015080_D064420 NONE mesna_15/NN (r_dobj) administering_14/VBG (r_pcomp) by_13/IN (r_agent) prevented_12/VBN (r_relcl) toxicity_6/NN
D007069_D006470 CID ifosfamide_7/RB (r_advmod) induced_9/VBN (r_amod) cystitis_11/NN
D007069_D006470 CID ifosfamide_8/NN (r_pobj) of_7/IN (r_prep) toxicity_6/NN (r_attr) is_2/VBZ (l_nsubj) cystitis_1/NN
D015080_D003556 CID mesna_4/NN (r_pobj) of_3/IN (r_prep) administration_2/NN (l_relcl) prevent_6/VB (l_dobj) cystitis_11/NN
D015080_D003556 CID mesna_15/NN (r_dobj) administering_14/VBG (r_pcomp) by_13/IN (r_agent) prevented_12/VBN (r_relcl) toxicity_6/NN (r_attr) is_2/VBZ (l_nsubj) cystitis_1/NN
D015080_D014839 NONE mesna_19/NN (r_compound) concentrations_20/NNS (l_prep) as_23/IN (l_prep) in_24/IN (l_pobj) patient_26/NN (l_relcl) experiences_31/VBZ (l_dobj) emesis_36/NN
D015080_D014839 NONE mesna_29/NN (r_dobj) taking_27/VBG (r_acl) patient_26/NN (l_relcl) experiences_31/VBZ (l_dobj) emesis_36/NN
D015080_D006470 CID mesna_4/NN (r_pobj) of_3/IN (r_prep) administration_2/NN (l_relcl) prevent_6/VB (l_dobj) cystitis_11/NN
D015080_D006470 CID mesna_15/NN (r_dobj) administering_14/VBG (r_pcomp) by_13/IN (r_agent) prevented_12/VBN (r_relcl) toxicity_6/NN (r_attr) is_2/VBZ (l_nsubj) cystitis_1/NN
D007069_D003556 CID ifosfamide_7/RB (r_advmod) induced_9/VBN (r_amod) cystitis_11/NN
D007069_D003556 CID ifosfamide_8/NN (r_pobj) of_7/IN (r_prep) toxicity_6/NN (r_attr) is_2/VBZ (l_nsubj) cystitis_1/NN
10091616
D001058_D004409 CID apomorphine_69/NN (r_pobj) of_68/IN (r_prep) dose_67/NN (r_pobj) of_63/IN (r_prep) administration_62/NN (r_pobj) following_61/VBG (r_prep) worsening_55/VBG (r_pobj) on_53/IN (r_prep) tasks_52/NNS (r_dobj) speaking_49/VBG (r_dep) evaluate_16/VB (r_advcl) included_11/VBN (l_nsubjpass) patients_1/NNS (l_relcl) had_3/VBD (l_prep) with_7/IN (l_pcomp) disabling_8/VBG (l_dobj) dyskinesia_9/NN
D001058_D004409 CID apomorphine_69/NN (r_pobj) of_68/IN (r_prep) dose_67/NN (r_pobj) of_63/IN (r_prep) administration_62/NN (r_pobj) following_61/VBG (r_prep) worsening_55/VBG (l_prep) of_56/IN (l_pobj) dyskinesia_60/JJ
D007980_D004409 CID levodopa_2/NN (r_npadvmod) induced_4/VBN (r_amod) dyskinesias_5/NNS
D001058_D010300 NONE apomorphine_69/NN (r_pobj) of_68/IN (r_prep) dose_67/NN (r_pobj) of_63/IN (r_prep) administration_62/NN (r_pobj) following_61/VBG (r_prep) worsening_55/VBG (r_pobj) on_53/IN (r_prep) tasks_52/NNS (r_dobj) speaking_49/VBG (r_dep) evaluate_16/VB (r_advcl) included_11/VBN (l_nsubjpass) patients_1/NNS (l_relcl) had_3/VBD (l_dobj) disease_6/NN
19135948
C107135_D006086 NONE everolimus_8/NN (r_pobj) with_7/IN (r_prep) prophylaxis_6/VBN (l_compound) disease_5/NN
D016559_D006086 NONE tacrolimus_10/NN (r_conj) everolimus_8/NN (r_pobj) with_7/IN (r_prep) prophylaxis_6/VBN (l_compound) disease_5/NN
D016559_D009190 NONE tacrolimus_8/NN (r_conj) everolimus_6/NN (r_pobj) of_5/IN (r_prep) combination_4/NN (l_prep) with_19/IN (l_pobj) syndrome_22/NN
D016559_D009190 NONE tacrolimus_8/NN (r_conj) everolimus_6/NN (r_pobj) of_5/IN (r_prep) combination_4/NN (l_prep) with_19/IN (l_pobj) syndrome_22/NN (l_appos) leukemia_33/NN (l_nmod) MDS_24/NNP
D016559_D014652 CID tacrolimus_10/NN (r_conj) everolimus_8/NN (r_pobj) with_7/IN (r_prep) prophylaxis_6/VBN (r_nsubjpass) associated_12/VBN (l_conj) microangiopathy_22/NN
D016559_D015470 NONE tacrolimus_8/NN (r_conj) everolimus_6/NN (r_pobj) of_5/IN (r_prep) combination_4/NN (l_prep) with_19/IN (l_pobj) syndrome_22/NN (l_appos) leukemia_33/NN
D016559_D015470 NONE tacrolimus_8/NN (r_conj) everolimus_6/NN (r_pobj) of_5/IN (r_prep) combination_4/NN (l_prep) with_19/IN (l_pobj) syndrome_22/NN (l_appos) leukemia_33/NN (l_appos) AML_35/NNP
C107135_D009190 NONE everolimus_6/NN (r_pobj) of_5/IN (r_prep) combination_4/NN (l_prep) with_19/IN (l_pobj) syndrome_22/NN
C107135_D009190 NONE everolimus_6/NN (r_pobj) of_5/IN (r_prep) combination_4/NN (l_prep) with_19/IN (l_pobj) syndrome_22/NN (l_appos) leukemia_33/NN (l_nmod) MDS_24/NNP
D008727_D006086 NONE methotrexate_5/NNP (r_pobj) with_4/IN (r_prep) combined_3/VBN (r_acl) inhibitor_2/NN (r_nsubj) is_6/VBZ (l_attr) prophylaxis_9/NN (l_prep) for_10/IN (l_pobj) disease_16/NN
D008727_D006086 NONE methotrexate_5/NNP (r_pobj) with_4/IN (r_prep) combined_3/VBN (r_acl) inhibitor_2/NN (r_nsubj) is_6/VBZ (l_attr) prophylaxis_9/NN (l_prep) for_10/IN (l_pobj) disease_16/NN (l_appos) GVHD_18/NNP
C107135_D015470 NONE everolimus_6/NN (r_pobj) of_5/IN (r_prep) combination_4/NN (l_prep) with_19/IN (l_pobj) syndrome_22/NN (l_appos) leukemia_33/NN
C107135_D015470 NONE everolimus_6/NN (r_pobj) of_5/IN (r_prep) combination_4/NN (l_prep) with_19/IN (l_pobj) syndrome_22/NN (l_appos) leukemia_33/NN (l_appos) AML_35/NNP
C107135_D006504 CID everolimus_8/NN (r_pobj) with_7/IN (r_prep) prophylaxis_6/VBN (r_nsubjpass) associated_12/VBN (l_prep) with_13/IN (l_pobj) incidence_16/NN (l_prep) of_17/IN (l_pobj) syndrome_20/NN
C107135_D014652 CID everolimus_8/NN (r_pobj) with_7/IN (r_prep) prophylaxis_6/VBN (r_nsubjpass) associated_12/VBN (l_conj) microangiopathy_22/NN
D016559_D006504 CID tacrolimus_10/NN (r_conj) everolimus_8/NN (r_pobj) with_7/IN (r_prep) prophylaxis_6/VBN (r_nsubjpass) associated_12/VBN (l_prep) with_13/IN (l_pobj) incidence_16/NN (l_prep) of_17/IN (l_pobj) syndrome_20/NN
16563323
D005045_D011537 NONE etomidate_10/NN (l_prep) without_12/IN (l_pobj) effects_14/NNS (l_prep) as_16/IN (l_pobj) sedation_17/NN (l_conj) apnea_19/NN (l_conj) nausea_21/NN (l_conj) pruritus_24/NN
C071741_D009207 NONE Remifentanil_0/NNP (r_compound) pretreatment_1/NN (r_nsubj) reduces_2/VBZ (l_dobj) myoclonus_3/NN
C071741_D009207 NONE remifentanil_13/NN (r_nmod) kg_17/NNS (r_pobj) with_12/IN (r_prep) pretreatment_11/NN (l_conj) effect_20/NN (l_prep) on_23/IN (l_pobj) incidence_25/NN (l_prep) of_26/IN (l_pobj) myoclonus_27/NN
C071741_D009207 NONE remifentanil_9/NN (r_compound) group_10/NN (r_pobj) in_7/IN (r_prep) lower_6/JJR (r_acomp) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) myoclonus_3/NN
C071741_D009207 NONE remifentanil_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (l_appos) myoclonus_8/NN
C071741_D011537 NONE remifentanil_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) etomidate_10/NN (l_prep) without_12/IN (l_pobj) effects_14/NNS (l_prep) as_16/IN (l_pobj) sedation_17/NN (l_conj) apnea_19/NN (l_conj) nausea_21/NN (l_conj) pruritus_24/NN
D005045_D009325 NONE etomidate_10/NN (l_prep) without_12/IN (l_pobj) effects_14/NNS (l_prep) as_16/IN (l_pobj) sedation_17/NN (l_conj) apnea_19/NN (l_conj) nausea_21/NN
C071741_D009325 NONE remifentanil_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) etomidate_10/NN (l_prep) without_12/IN (l_pobj) effects_14/NNS (l_prep) as_16/IN (l_pobj) sedation_17/NN (l_conj) apnea_19/NN (l_conj) nausea_21/NN
D005045_D001049 NONE etomidate_10/NN (l_prep) without_12/IN (l_pobj) effects_14/NNS (l_prep) as_16/IN (l_pobj) sedation_17/NN (l_conj) apnea_19/NN
C071741_D001049 NONE remifentanil_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) etomidate_10/NN (l_prep) without_12/IN (l_pobj) effects_14/NNS (l_prep) as_16/IN (l_pobj) sedation_17/NN (l_conj) apnea_19/NN
D005045_D009207 CID etomidate_5/NN (r_advcl) reduces_2/VBZ (l_dobj) myoclonus_3/NN
D005045_D009207 CID etomidate_32/NN (r_pobj) with_31/IN (r_prep) induction_30/NN (r_amod) anesthesia_29/NN (r_pobj) after_28/IN (r_prep) effect_20/NN (l_prep) on_23/IN (l_pobj) incidence_25/NN (l_prep) of_26/IN (l_pobj) myoclonus_27/NN
D005045_D009207 CID etomidate_16/NN (r_advcl) associated_8/VBN (l_prep) with_9/IN (l_pobj) incidence_12/NN (l_prep) of_13/IN (l_pobj) myoclonus_14/NN
D005045_D009207 CID etomidate_10/NN (l_nsubj) Pretreatment_0/NN (l_appos) myoclonus_8/NN
D005045_D009207 CID etomidate_9/NN (r_advcl) increased_2/VBD (l_dobj) incidence_3/NN (l_prep) of_4/IN (l_pobj) myoclonus_5/NN
16574713
D018817_D008569 CID MDMA_12/NNP (r_compound) users_13/NNS (r_pobj) in_10/IN (r_prep) observed_9/VBN (l_nsubjpass) evidence_4/NN (l_prep) of_5/IN (l_pobj) impairment_7/NN
D018817_D008569 CID MDMA_4/NNP (r_pobj) of_3/IN (r_prep) use_2/NN (l_prep) in_5/IN (l_pobj) quantities_6/NNS (l_relcl) considered_10/VBN (l_oprd) associated_16/VBN (l_prep) with_17/IN (l_pobj) functioning_20/VBG
D018817_D008569 CID MDMA_4/NNP (r_pobj) of_3/IN (r_prep) use_2/NN (r_nsubj) lead_28/VB (l_prep) to_29/IN (l_pobj) impairments_33/NNS
D018817_D008569 CID MDMA_25/NNP (r_compound) use_26/NN (r_pobj) of_24/IN (r_prep) use_23/NN (r_nsubj) lead_28/VB (l_nsubj) use_2/NN (l_prep) in_5/IN (l_pobj) quantities_6/NNS (l_relcl) considered_10/VBN (l_oprd) associated_16/VBN (l_prep) with_17/IN (l_pobj) functioning_20/VBG
D018817_D008569 CID MDMA_25/NNP (r_compound) use_26/NN (r_pobj) of_24/IN (r_prep) use_23/NN (r_nsubj) lead_28/VB (l_prep) to_29/IN (l_pobj) impairments_33/NNS
D018817_D020258 NONE 3,4-methylenedioxymethamphetamine_1/CD (r_nsubjpass) shown_9/VBN (r_advcl) known_26/VBN (l_prep) about_27/IN (l_pobj) consequences_32/NNS (l_prep) of_33/IN (l_pobj) lesions_39/NNS
D018817_D020258 NONE MDMA_3/NNP (r_nsubjpass) shown_9/VBN (r_advcl) known_26/VBN (l_prep) about_27/IN (l_pobj) consequences_32/NNS (l_prep) of_33/IN (l_pobj) lesions_39/NNS
D018817_D020258 NONE ecstasy_5/NN (r_conj) MDMA_3/NNP (r_nsubjpass) shown_9/VBN (r_advcl) known_26/VBN (l_prep) about_27/IN (l_pobj) consequences_32/NNS (l_prep) of_33/IN (l_pobj) lesions_39/NNS
D018817_D020258 NONE MDMA_34/NNP (r_npadvmod) induced_36/VBN (r_amod) lesions_39/NNS
D012701_D020258 NONE serotonin_13/NN (r_dobj) damage_11/VB (r_xcomp) shown_9/VBN (r_advcl) known_26/VBN (l_prep) about_27/IN (l_pobj) consequences_32/NNS (l_prep) of_33/IN (l_pobj) lesions_39/NNS
D012701_D020258 NONE 5-HT_15/CD (r_nmod) neurons_17/NNS (r_appos) serotonin_13/NN (r_dobj) damage_11/VB (r_xcomp) shown_9/VBN (r_advcl) known_26/VBN (l_prep) about_27/IN (l_pobj) consequences_32/NNS (l_prep) of_33/IN (l_pobj) lesions_39/NNS
D012701_D020258 NONE 5-HT_37/CD (r_nummod) lesions_39/NNS
D012701_D020258 NONE 5-HT_44/CD (r_nsubjpass) involved_46/VBN (r_relcl) functions_41/NNS (r_pobj) on_40/IN (r_prep) lesions_39/NNS
4069770
D005839_D001002 NONE gentamicin_2/NN (r_compound) concentration_3/NN (r_nsubj) reached_5/VBN (l_advcl) developed_10/VBD (l_nsubj) anuria_9/NN
D010406_D058186 NONE penicillin_28/NN (r_conj) therapy_16/NN (r_pobj) after_15/IN (r_prep) died_10/VBD (l_prep) of_11/IN (l_pobj) failure_14/NN
D005839_D007674 NONE Gentamicin_0/NNP (r_amod) nephropathy_1/NN
D005839_D058186 CID gentamicin_18/NN (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) after_15/IN (r_prep) died_10/VBD (l_prep) of_11/IN (l_pobj) failure_14/NN
1928887
D002216_D062787 NONE captopril_6/NN (r_compound) overdose_7/NN
D002216_D062787 NONE captopril_7/NN (r_compound) overdose_8/NN
D009270_D007022 NONE Naloxone_0/NN (r_compound) reversal_1/NN (l_prep) of_2/IN (l_pobj) hypotension_3/NN
D009270_D007022 NONE naloxone_3/NN (r_appos) antagonist_2/NN (r_nsubjpass) shown_6/VBN (l_xcomp) block_8/VB (l_conj) reverse_10/VB (l_dobj) actions_13/NNS (l_amod) hypotensive_12/JJ
D009270_D007022 NONE naloxone_22/NN (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) with_18/IN (r_prep) resolved_16/VBD (r_ccomp) report_1/VBP (l_advcl) manifested_10/VBN (l_agent) by_11/IN (l_pobj) hypotension_13/NN
D009270_D007022 NONE naloxone_17/NN (r_pobj) with_16/IN (r_prep) treated_15/VBN (r_acl) hypotension_14/NN
D009270_D007022 NONE naloxone_7/NN (l_prep) in_8/IN (l_pobj) reversal_10/NN (l_prep) of_11/IN (l_pobj) hypotension_12/NN
D009270_D062787 NONE Naloxone_0/NN (r_compound) reversal_1/NN (l_prep) due_4/IN (l_pobj) overdose_7/NN
D009270_D062787 NONE naloxone_22/NN (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) with_18/IN (r_prep) resolved_16/VBD (r_ccomp) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) overdose_8/NN
D002216_D007022 NONE captopril_6/NN (r_compound) overdose_7/NN (r_pobj) due_4/IN (r_prep) reversal_1/NN (l_prep) of_2/IN (l_pobj) hypotension_3/NN
D002216_D007022 NONE captopril_15/NN (r_pobj) of_14/IN (r_prep) actions_13/NNS (l_amod) hypotensive_12/JJ
D002216_D007022 NONE captopril_7/NN (r_compound) overdose_8/NN (r_pobj) of_4/IN (r_prep) case_3/NN (r_dobj) report_1/VBP (l_advcl) manifested_10/VBN (l_agent) by_11/IN (l_pobj) hypotension_13/NN
D002216_D007022 NONE captopril_11/NN (r_npadvmod) induced_13/VBN (r_amod) hypotension_14/NN
D002216_D007022 NONE captopril_15/NN (r_pobj) from_14/IN (r_prep) resulting_13/VBG (r_acl) hypotension_12/NN
15638391
D006220_D006966 CID haloperidol_16/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (l_nsubj) process_1/NN (l_prep) of_2/IN (l_pobj) cells_4/NNS (l_prep) of_5/IN (l_pobj) lobe_10/NN (l_prep) in_11/IN (l_pobj) hyperprolactinemia_13/NN
D006220_D006966 CID haloperidol_15/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_advcl) was_5/VBD (l_xcomp) examine_7/VB (l_dobj) influence_9/NN (l_prep) of_10/IN (l_pobj) hyperprolactinemia_11/NN
D006220_D006966 CID HAL_17/NNP (r_appos) haloperidol_15/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_advcl) was_5/VBD (l_xcomp) examine_7/VB (l_dobj) influence_9/NN (l_prep) of_10/IN (l_pobj) hyperprolactinemia_11/NN
2709684
D005839_D009956 NONE gentamicin_8/NN (r_compound) ARF_10/NNP (r_dobj) prevent_7/VB (l_conj) day_34/NN (l_conj) score_39/NN (l_compound) necrosis_38/NN
D013311_D003920 CID streptozotocin_3/NNS (r_npadvmod) induced_5/VBN (r_amod) diabetes_6/NN (r_compound) mellitus_7/NN
D013311_D003920 CID streptozotocin_3/NNS (r_npadvmod) induced_5/VBN (r_amod) diabetes_6/NN (r_compound) mellitus_7/NN (l_appos) DM_9/NNP
D005947_D003920 NONE glucose_21/NN (r_compound) reabsorption_22/NN (r_pobj) of_19/IN (r_prep) blockage_18/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) rats_11/NNS (l_amod) diabetic_10/JJ
D013311_D006029 NONE streptozotocin_3/NNS (r_npadvmod) induced_5/VBN (r_amod) diabetes_6/NN (r_compound) mellitus_7/NN (r_pobj) with_2/IN (r_prep) rats_1/NNS (r_nsubj) have_11/VBP (l_dobj) diuresis_15/NN (l_appos) glycosuria_17/NN
D005839_D007674 NONE gentamicin_7/NN (r_compound) nephrotoxicity_8/NN
D005839_D007674 NONE gentamicin_3/NN (r_amod) nephrotoxicity_4/NN
D005839_D007674 NONE gentamicin_11/NN (r_pobj) of_10/IN (r_prep) doses_1/NNS (l_amod) Nephrotoxic_0/JJ
D010695_D007674 NONE Phlorizin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) glycosuria_3/NN (r_nsubj) prevent_6/VB (l_dobj) nephrotoxicity_8/NN
D010695_D007674 NONE phlorizin_24/NN (r_pobj) with_23/IN (r_prep) reabsorption_22/NN (r_pobj) of_19/IN (r_prep) blockage_18/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) rats_11/NNS (r_pobj) in_7/IN (r_prep) studied_6/VBN (l_nsubjpass) protection_1/NN (l_prep) from_2/IN (l_pobj) nephrotoxicity_4/NN
D010695_D007674 NONE P_26/NN (r_appos) phlorizin_24/NN (r_pobj) with_23/IN (r_prep) reabsorption_22/NN (r_pobj) of_19/IN (r_prep) blockage_18/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) rats_11/NNS (r_pobj) in_7/IN (r_prep) studied_6/VBN (l_nsubjpass) protection_1/NN (l_prep) from_2/IN (l_pobj) nephrotoxicity_4/NN
D010695_D007674 NONE P_4/NN (r_nsubj) induced_5/VBD (l_conj) CCr_33/IN (l_nsubj) evidence_27/NN (l_prep) of_28/IN (l_pobj) dysfunction_30/NN
D010695_D058186 NONE P_4/NN (r_nsubj) prevent_7/VB (l_dobj) ARF_10/NNP
D010695_D058186 NONE P_21/NN (r_appos) ARF_10/NNP
D010695_D009956 NONE P_4/NN (r_nsubj) induced_5/VBD (l_conj) CCr_33/IN (l_dobj) score_49/NN (l_compound) necrosis_48/NN
D010695_D009956 NONE P_4/NN (r_nsubj) prevent_7/VB (l_conj) day_34/NN (l_conj) score_39/NN (l_compound) necrosis_38/NN
D010695_D009956 NONE P_21/NN (r_appos) ARF_10/NNP (r_dobj) prevent_7/VB (l_conj) day_34/NN (l_conj) score_39/NN (l_compound) necrosis_38/NN
D005839_D003920 NONE gentamicin_41/NN (r_npadvmod) induced_43/VBN (r_amod) failure_46/NN (r_pobj) to_40/IN (r_prep) resistance_39/NN (r_pobj) for_37/IN (r_prep) responsible_36/JJ (r_acomp) be_35/VB (r_ccomp) suggested_29/VBN (l_advcl) have_11/VBP (l_nsubj) rats_1/NNS (l_prep) with_2/IN (l_pobj) mellitus_7/NN
D005839_D003920 NONE gentamicin_41/NN (r_npadvmod) induced_43/VBN (r_amod) failure_46/NN (r_pobj) to_40/IN (r_prep) resistance_39/NN (r_pobj) for_37/IN (r_prep) responsible_36/JJ (r_acomp) be_35/VB (r_ccomp) suggested_29/VBN (l_advcl) have_11/VBP (l_nsubj) rats_1/NNS (l_prep) with_2/IN (l_pobj) mellitus_7/NN (l_appos) DM_9/NNP
D005839_D003920 NONE gentamicin_3/NN (r_amod) nephrotoxicity_4/NN (r_pobj) from_2/IN (r_prep) protection_1/NN (r_nsubjpass) studied_6/VBN (l_prep) in_7/IN (l_pobj) rats_11/NNS (l_amod) diabetic_10/JJ
D005839_D003920 NONE gentamicin_23/NN (r_conj) P_21/NN (r_appos) II_19/NNP (l_conj) III_27/NNP (l_acl) gentamicin_29/NN (l_conj) IV_34/NNP (l_appos) DM_37/NNP
D005839_D003920 NONE gentamicin_29/NN (l_conj) IV_34/NNP (l_appos) DM_37/NNP
D005839_D003920 NONE gentamicin_39/NN (r_conj) DM_37/NNP
D010695_D006029 NONE Phlorizin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) glycosuria_3/NN
D010695_D006029 NONE P_13/NN (r_nmod) animals_15/NNS (r_pobj) of_11/IN (r_prep) that_10/DT (r_pobj) to_9/IN (r_prep) degree_8/NN (r_pobj) in_7/IN (r_prep) similar_6/JJ (r_amod) glycosuria_4/NN
D010695_D006029 NONE P_4/NN (r_nsubj) induced_5/VBD (l_dobj) glycosuria_10/NN
D005947_D007674 NONE glucose_21/NN (r_compound) reabsorption_22/NN (r_pobj) of_19/IN (r_prep) blockage_18/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) rats_11/NNS (r_pobj) in_7/IN (r_prep) studied_6/VBN (l_nsubjpass) protection_1/NN (l_prep) from_2/IN (l_pobj) nephrotoxicity_4/NN
D013311_D058186 NONE streptozotocin_3/NNS (r_npadvmod) induced_5/VBN (r_amod) diabetes_6/NN (r_compound) mellitus_7/NN (r_pobj) with_2/IN (r_prep) rats_1/NNS (r_nsubj) have_11/VBP (r_advcl) suggested_29/VBN (l_ccomp) be_35/VB (l_acomp) responsible_36/JJ (l_prep) for_37/IN (l_pobj) resistance_39/NN (l_prep) to_40/IN (l_pobj) failure_46/NN
D013311_D058186 NONE streptozotocin_3/NNS (r_npadvmod) induced_5/VBN (r_amod) diabetes_6/NN (r_compound) mellitus_7/NN (r_pobj) with_2/IN (r_prep) rats_1/NNS (r_nsubj) have_11/VBP (r_advcl) suggested_29/VBN (l_ccomp) be_35/VB (l_acomp) responsible_36/JJ (l_prep) for_37/IN (l_pobj) resistance_39/NN (l_prep) to_40/IN (l_pobj) failure_46/NN (l_appos) ARF_48/NNP
D005839_D006029 NONE gentamicin_7/NN (r_compound) nephrotoxicity_8/NN (r_dobj) prevent_6/VB (l_nsubj) glycosuria_3/NN
D005839_D006029 NONE gentamicin_41/NN (r_npadvmod) induced_43/VBN (r_amod) failure_46/NN (r_pobj) to_40/IN (r_prep) resistance_39/NN (r_pobj) for_37/IN (r_prep) responsible_36/JJ (r_acomp) be_35/VB (r_ccomp) suggested_29/VBN (l_advcl) have_11/VBP (l_dobj) diuresis_15/NN (l_appos) glycosuria_17/NN
D010695_D003920 NONE phlorizin_24/NN (r_pobj) with_23/IN (r_prep) reabsorption_22/NN (r_pobj) of_19/IN (r_prep) blockage_18/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) rats_11/NNS (l_amod) diabetic_10/JJ
D010695_D003920 NONE P_26/NN (r_appos) phlorizin_24/NN (r_pobj) with_23/IN (r_prep) reabsorption_22/NN (r_pobj) of_19/IN (r_prep) blockage_18/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) rats_11/NNS (l_amod) diabetic_10/JJ
D010695_D003920 NONE P_13/NN (r_nmod) animals_15/NNS (r_pobj) of_11/IN (r_prep) that_10/DT (r_pobj) to_9/IN (r_prep) degree_8/NN (r_pobj) in_7/IN (r_prep) similar_6/JJ (r_amod) glycosuria_4/NN (r_pobj) with_2/IN (r_prep) rats_1/NNS (l_compound) DM_0/NNP
D010695_D003920 NONE P_3/NN (r_nsubj) received_6/VBD (l_conj) II_19/NNP (l_conj) III_27/NNP (l_acl) gentamicin_29/NN (l_conj) IV_34/NNP (l_appos) DM_37/NNP
D010695_D003920 NONE P_7/NN (r_dobj) received_6/VBD (l_conj) II_19/NNP (l_conj) III_27/NNP (l_acl) gentamicin_29/NN (l_conj) IV_34/NNP (l_appos) DM_37/NNP
D010695_D003920 NONE P_21/NN (r_appos) II_19/NNP (l_conj) III_27/NNP (l_acl) gentamicin_29/NN (l_conj) IV_34/NNP (l_appos) DM_37/NNP
D005839_D058186 CID gentamicin_41/NN (r_npadvmod) induced_43/VBN (r_amod) failure_46/NN
D005839_D058186 CID gentamicin_41/NN (r_npadvmod) induced_43/VBN (r_amod) failure_46/NN (l_appos) ARF_48/NNP
D005839_D058186 CID gentamicin_8/NN (r_compound) ARF_10/NNP
20635749
D000638_D009230 CID amiodarone_6/NN (r_pobj) on_5/IN (l_pcomp) presenting_7/VBG (l_prep) with_8/IN (l_pobj) coma_10/NN
D000638_D009230 CID amiodarone_10/NN (r_npadvmod) induced_12/VBN (r_amod) hypothyroidism_13/NN (r_pobj) to_9/IN (r_prep) coma_7/NN
D000638_D009230 CID amiodarone_19/NN (r_compound) therapy_20/NN (r_pobj) during_16/IN (r_prep) report_12/NN (l_prep) of_13/IN (l_pobj) coma_15/NN
D000638_D006333 NONE amiodarone_6/NN (r_pobj) on_5/IN (r_prep) patient_4/NN (l_compound) failure_3/NN
D000638_D006333 NONE amiodarone_10/NN (r_npadvmod) induced_12/VBN (r_amod) hypothyroidism_13/NN (r_pobj) to_9/IN (r_prep) coma_7/NN (l_prep) in_14/IN (l_pobj) patient_16/NN (l_prep) with_17/IN (l_pobj) failure_21/NN
D000638_D006333 NONE amiodarone_10/NN (r_npadvmod) induced_12/VBN (r_amod) hypothyroidism_13/NN (r_pobj) to_9/IN (r_prep) coma_7/NN (l_prep) in_14/IN (l_pobj) patient_16/NN (l_prep) with_17/IN (l_pobj) failure_21/NN (l_appos) CHF_23/NNP
D000638_D006333 NONE amiodarone_4/NN (r_pobj) on_3/IN (r_prep) Patients_0/NNS (l_prep) with_1/IN (l_pobj) CHF_2/NNP
D000638_D006333 NONE amiodarone_13/NN (l_prep) among_14/IN (l_pobj) patients_16/NNS (l_compound) CHF_15/NNP
D000638_D003128 CID amiodarone_6/NN (r_pobj) on_5/IN (l_pcomp) presenting_7/VBG (l_prep) with_8/IN (l_pobj) coma_10/NN
D000638_D003128 CID amiodarone_10/NN (r_npadvmod) induced_12/VBN (r_amod) hypothyroidism_13/NN (r_pobj) to_9/IN (r_prep) coma_7/NN
D000638_D003128 CID amiodarone_19/NN (r_compound) therapy_20/NN (r_pobj) during_16/IN (r_prep) report_12/NN (l_prep) of_13/IN (l_pobj) coma_15/NN
D000638_D007037 CID amiodarone_10/NN (r_npadvmod) induced_12/VBN (r_amod) hypothyroidism_13/NN
D000638_D007037 CID amiodarone_4/NN (r_pobj) on_3/IN (r_prep) Patients_0/NNS (r_nsubj) suffer_6/VB (l_dobj) morbidity_8/NN (l_prep) from_11/IN (l_pobj) hypothyroidism_12/NN
9758264
D005492_D000014 NONE acid_6/NN (r_npadvmod) containing_8/VBG (r_amod) supplementation_10/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (r_dobj) study_1/VB (l_prep) in_18/IN (l_pobj) order_19/NN (l_acl) determine_21/VB (l_dobj) rate_23/NN (l_prep) of_24/IN (l_pobj) defects_27/NNS
D005492_D001327 NONE acid_35/NN (r_pobj) of_33/IN (r_prep) dose_25/NN (r_nsubj) triggered_36/VBD (l_ccomp) damage_15/VB (l_nsubj) disease_6/NN
D005492_D001327 NONE acid_9/NN (r_pobj) of_7/IN (r_prep) mg_5/NN (r_appos) dose_1/NN (l_prep) without_19/IN (l_pobj) disease_22/NN
D005492_D008180 CID acid_4/NN (r_pobj) of_2/IN (r_prep) activity_1/NN (r_nsubj) induces_7/VBZ (l_dobj) SLE_8/NNP
D005492_D008180 CID acid_11/NN (r_appos) SLE_8/NNP
D005492_D008180 CID acid_35/NN (r_pobj) of_33/IN (r_prep) dose_25/NN (r_nsubj) triggered_36/VBD (l_ccomp) damage_15/VB (l_nsubj) disease_6/NN (l_appos) lupus_12/NN
D005492_D004827 NONE acid_4/NN (r_pobj) of_2/IN (r_prep) activity_1/NN (r_nsubj) induces_7/VBZ (l_dobj) SLE_8/NNP (l_appos) acid_11/NN (l_conj) epilepsy_13/NN
D005492_D004827 NONE acid_11/NN (l_conj) epilepsy_13/NN
D005492_D004827 NONE acid_6/NN (r_npadvmod) containing_8/VBG (r_amod) supplementation_10/NN (l_prep) in_11/IN (l_pobj) women_13/NNS (l_amod) epileptic_12/JJ
D005492_D004827 NONE acid_6/NN (r_npadvmod) containing_8/VBG (r_amod) supplementation_10/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (r_dobj) study_1/VB (l_prep) in_18/IN (l_pobj) order_19/NN (l_acl) determine_21/VB (l_dobj) rate_23/NN (l_prep) of_24/IN (l_pobj) defects_27/NNS (l_conj) effects_33/NNS (l_amod) related_31/VBN (l_npadvmod) epilepsy_29/NN
D005492_D004827 NONE acid_7/NN (r_pobj) with_4/IN (r_prep) women_3/NNS (l_amod) epileptic_2/JJ
D005492_D004827 NONE acid_7/NN (l_appos) effects_21/NNS (l_amod) related_19/VBN (l_npadvmod) epilepsy_17/NN
D005492_D004827 NONE acid_14/NN (r_conj) carbamazepine_10/NN (r_pobj) by_9/IN (r_agent) treated_7/VBN (l_nsubjpass) woman_5/NN (l_amod) epileptic_4/JJ
D005492_D004827 NONE acid_35/NN (r_pobj) of_33/IN (r_prep) dose_25/NN (r_nsubj) triggered_36/VBD (l_ccomp) damage_15/VB (l_nsubj) disease_6/NN (l_poss) patient_3/NN (l_amod) epileptic_1/JJ
D005492_D004827 NONE acid_9/NN (r_pobj) of_7/IN (r_prep) mg_5/NN (r_appos) dose_1/NN (l_prep) in_11/IN (l_pobj) women_16/NNS (l_amod) epileptic_15/JJ
D005492_D004827 NONE acid_9/NN (r_pobj) of_7/IN (r_prep) mg_5/NN (r_appos) dose_1/NN (r_nsubj) increase_26/VB (l_dobj) risk_28/NN (l_prep) for_29/IN (l_pobj) seizures_31/NNS
D005492_D012640 CID acid_35/NN (r_pobj) of_33/IN (r_prep) dose_25/NN (r_nsubj) triggered_36/VBD (l_dobj) cluster_38/NN (l_prep) of_39/IN (l_pobj) seizures_40/NNS
D002220_D004827 NONE carbamazepine_10/NN (r_pobj) by_9/IN (r_agent) treated_7/VBN (l_nsubjpass) woman_5/NN (l_amod) epileptic_4/JJ
12842176
D000431_D064420 NONE ethanol_35/NN (r_conj) PB_33/NNP (r_nmod) isoenzymes_38/NNS (r_pobj) by_32/IN (r_agent) formed_31/VBN (r_acl) metabolites_30/NNS (r_conj) lindane_25/NN (r_nsubjpass) involved_40/VBN (l_prep) in_41/IN (l_pobj) toxicity_44/NN
C018021_D064420 NONE chloride_12/NN (r_compound) incidence_13/NN (r_pobj) by_10/IN (r_agent) blocked_9/VBN (r_advcl) increased_17/VBN (l_advcl) indicating_23/VBG (l_ccomp) involved_40/VBN (l_prep) in_41/IN (l_pobj) toxicity_44/NN
D008748_D012640 NONE 3-methylcholanthrene_9/NN (r_pobj) of_8/IN (r_prep) pretreatment_7/NN (r_nsubj) produce_21/VB (r_advcl) induced_30/VBN (l_dobj) convulsions_31/NNS
D008748_D012640 NONE 3-methylcholanthrene_9/NN (r_pobj) of_8/IN (r_prep) pretreatment_7/NN (r_nsubj) produce_21/VB (r_advcl) induced_30/VBN (r_ccomp) shown_4/VBN (r_ccomp) increased_57/VBD (l_advcl) induced_62/VBN (l_dobj) convulsions_63/NNS
D008748_D012640 NONE MC_11/NNP (r_pobj) of_8/IN (r_prep) pretreatment_7/NN (r_nsubj) produce_21/VB (r_advcl) induced_30/VBN (l_dobj) convulsions_31/NNS
D008748_D012640 NONE MC_11/NNP (r_pobj) of_8/IN (r_prep) pretreatment_7/NN (r_nsubj) produce_21/VB (r_advcl) induced_30/VBN (r_ccomp) shown_4/VBN (r_ccomp) increased_57/VBD (l_advcl) induced_62/VBN (l_dobj) convulsions_63/NNS
D001556_D012640 CID lindane_29/NN (r_pobj) of_28/IN (r_prep) incidence_27/NN (r_pobj) in_25/IN (r_prep) effect_24/NN (r_dobj) produce_21/VB (r_advcl) induced_30/VBN (l_dobj) convulsions_31/NNS
D001556_D012640 CID lindane_29/NN (r_pobj) of_28/IN (r_prep) incidence_27/NN (r_pobj) in_25/IN (r_prep) effect_24/NN (r_dobj) produce_21/VB (r_advcl) induced_30/VBN (r_ccomp) shown_4/VBN (r_ccomp) increased_57/VBD (l_advcl) induced_62/VBN (l_dobj) convulsions_63/NNS
D001556_D012640 CID lindane_61/NN (r_pobj) of_60/IN (r_prep) incidence_59/NN (r_dobj) increased_57/VBD (l_ccomp) shown_4/VBN (l_ccomp) induced_30/VBN (l_dobj) convulsions_31/NNS
D001556_D012640 CID lindane_61/NN (r_pobj) of_60/IN (r_prep) incidence_59/NN (r_dobj) increased_57/VBD (l_advcl) induced_62/VBN (l_dobj) convulsions_63/NNS
D001556_D012640 CID lindane_7/NN (r_pobj) of_6/IN (r_prep) metabolism_5/NN (r_nsubjpass) blocked_9/VBN (l_agent) by_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) convulsions_15/NNS
D001556_D012640 CID lindane_22/NN (r_pobj) with_21/IN (r_prep) treated_20/VBN (r_acl) animals_19/NNS (r_pobj) in_18/IN (r_prep) increased_17/VBN (l_advcl) blocked_9/VBN (l_agent) by_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) convulsions_15/NNS
D001556_D012640 CID lindane_25/NN (r_nsubjpass) involved_40/VBN (r_ccomp) indicating_23/VBG (r_advcl) increased_17/VBN (l_advcl) blocked_9/VBN (l_agent) by_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) convulsions_15/NNS
D001556_D020258 NONE lindane_2/NN (r_pobj) of_1/IN (r_prep) Effect_0/NN (r_nsubj) induced_16/VBN (l_dobj) neurotoxicity_17/NN
D001556_D020258 NONE lindane_15/NN (r_pobj) in_14/IN (r_prep) modulation_13/NN (r_pobj) of_11/IN (r_prep) influence_10/NN (r_nsubj) induced_16/VBN (l_dobj) neurotoxicity_17/NN
D000431_D012640 NONE ethanol_46/NN (r_conj) inducer_41/NN (r_appos) phenobarbital_35/JJ (r_pobj) with_34/IN (r_prep) pretreatment_33/NN (r_conj) convulsions_31/NNS
D000431_D012640 NONE ethanol_46/NN (r_conj) inducer_41/NN (r_appos) phenobarbital_35/JJ (r_pobj) with_34/IN (r_prep) pretreatment_33/NN (r_conj) convulsions_31/NNS (r_dobj) induced_30/VBN (r_ccomp) shown_4/VBN (r_ccomp) increased_57/VBD (l_advcl) induced_62/VBN (l_dobj) convulsions_63/NNS
D000431_D012640 NONE ethanol_35/NN (r_conj) PB_33/NNP (r_nmod) isoenzymes_38/NNS (r_pobj) by_32/IN (r_agent) formed_31/VBN (r_acl) metabolites_30/NNS (r_conj) lindane_25/NN (r_nsubjpass) involved_40/VBN (r_ccomp) indicating_23/VBG (r_advcl) increased_17/VBN (l_advcl) blocked_9/VBN (l_agent) by_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) convulsions_15/NNS
D001556_D064420 NONE lindane_7/NN (r_pobj) of_6/IN (r_prep) metabolism_5/NN (r_nsubjpass) blocked_9/VBN (r_advcl) increased_17/VBN (l_advcl) indicating_23/VBG (l_ccomp) involved_40/VBN (l_prep) in_41/IN (l_pobj) toxicity_44/NN
D001556_D064420 NONE lindane_22/NN (r_pobj) with_21/IN (r_prep) treated_20/VBN (r_acl) animals_19/NNS (r_pobj) in_18/IN (r_prep) increased_17/VBN (l_advcl) indicating_23/VBG (l_ccomp) involved_40/VBN (l_prep) in_41/IN (l_pobj) toxicity_44/NN
D001556_D064420 NONE lindane_25/NN (r_nsubjpass) involved_40/VBN (l_prep) in_41/IN (l_pobj) toxicity_44/NN
C018021_D012640 NONE chloride_12/NN (r_compound) incidence_13/NN (l_prep) of_14/IN (l_pobj) convulsions_15/NNS
D010634_D012640 NONE phenobarbital_35/JJ (r_pobj) with_34/IN (r_prep) pretreatment_33/NN (r_conj) convulsions_31/NNS
D010634_D012640 NONE phenobarbital_35/JJ (r_pobj) with_34/IN (r_prep) pretreatment_33/NN (r_conj) convulsions_31/NNS (r_dobj) induced_30/VBN (r_ccomp) shown_4/VBN (r_ccomp) increased_57/VBD (l_advcl) induced_62/VBN (l_dobj) convulsions_63/NNS
7102237
D009020_D001049 NONE morphine_6/NN (r_conj) scopolamine_4/NN (r_pobj) with_3/IN (r_prep) premedicated_2/VBN (r_acl) patients_1/NNS (r_pobj) In_0/IN (r_prep) was_28/VBD (l_advcl) occurred_57/VBD (l_nsubj) apnoea_56/NN
D013874_D001049 CID thiopentone_36/NN (r_pobj) of_35/IN (r_prep) that_34/DT (r_pobj) than_33/IN (r_prep) onset_32/NN (r_pobj) in_31/IN (r_prep) slower_30/JJR (r_acomp) was_28/VBD (l_advcl) occurred_57/VBD (l_nsubj) apnoea_56/NN
D008874_D001049 CID midazolam_24/JJ (r_pobj) of_23/IN (r_prep) effect_22/NN (r_nsubj) was_28/VBD (l_advcl) occurred_57/VBD (l_nsubj) apnoea_56/NN
D008874_D001049 CID midazolam_50/JJ (r_amod) group_51/NN (r_pobj) in_48/IN (r_prep) found_47/VBN (r_conj) was_28/VBD (l_advcl) occurred_57/VBD (l_nsubj) apnoea_56/NN
D008874_D001049 CID midazolam_62/JJ (r_amod) group_63/NN (r_pobj) in_60/IN (r_prep) occurred_57/VBD (l_nsubj) apnoea_56/NN
D009567_D001049 NONE nitrazepam_11/NN (r_amod) mg_10/IN (r_conj) scopolamine_4/NN (r_pobj) with_3/IN (r_prep) premedicated_2/VBN (r_acl) patients_1/NNS (r_pobj) In_0/IN (r_prep) was_28/VBD (l_advcl) occurred_57/VBD (l_nsubj) apnoea_56/NN
D012601_D001049 NONE scopolamine_4/NN (r_pobj) with_3/IN (r_prep) premedicated_2/VBN (r_acl) patients_1/NNS (r_pobj) In_0/IN (r_prep) was_28/VBD (l_advcl) occurred_57/VBD (l_nsubj) apnoea_56/NN
9270571
C095427_D020734 NONE A-86929_0/NNS (l_dep) study_4/NN (l_prep) in_5/IN (l_pobj) monkeys_10/NNS (l_amod) parkinsonian_6/JJ
C095427_D020734 NONE A-86929_3/NNS (r_punct) was_4/VBD (l_acomp) efficacious_6/JJ (l_prep) in_7/IN (l_pcomp) alleviating_8/VBG (l_dobj) parkinsonism_12/NN
D004298_D010300 NONE dopamine_4/NN (r_pobj) of_3/IN (r_prep) utility_2/NN (l_appos) agonists_10/NNS (l_prep) in_11/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) disease_17/NN
D004298_D010300 NONE dopamine_4/NN (r_pobj) of_3/IN (r_prep) utility_2/NN (l_appos) agonists_10/NNS (l_prep) in_11/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) disease_17/NN (l_appos) PD_19/NNP
D004298_D010300 NONE DA_6/NNP (r_nmod) agonists_10/NNS (l_prep) in_11/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) disease_17/NN
D004298_D010300 NONE DA_6/NNP (r_nmod) agonists_10/NNS (l_prep) in_11/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) disease_17/NN (l_appos) PD_19/NNP
D004298_D010300 NONE DA_1/NNP (r_compound) D1_2/NN (r_compound) agents_4/NNS (r_nsubj) are_23/VBP (l_attr) tools_26/NNS (l_prep) in_27/IN (l_pobj) PD_28/NNP
D007980_D004409 CID levodopa_20/RB (r_npadvmod) induced_22/VBN (r_amod) dyskinesias_23/NNS
D007980_D004409 CID levodopa_20/RB (r_npadvmod) induced_22/VBN (r_amod) dyskinesias_23/NNS (r_dobj) conducted_2/VBD (l_advcl) evaluate_25/VB (l_dobj) effects_30/NNS (l_amod) locomotor_27/NN (l_conj) dyskinetic_29/JJ
D007980_D004409 CID levodopa_14/NN (r_pobj) as_13/IN (r_prep) alleviating_8/VBG (r_pcomp) in_7/IN (r_prep) efficacious_6/JJ (r_acomp) was_4/VBD (l_conj) was_19/VBD (l_acomp) likely_21/JJ (l_xcomp) reproduce_23/VB (l_dobj) dyskinesias_28/NNS
D007980_D004409 CID levodopa_25/RB (r_npadvmod) induced_27/VBN (r_amod) dyskinesias_28/NNS
D007980_D004409 CID levodopa_40/NN (r_pobj) of_39/IN (r_prep) challenge_38/NN (r_pobj) with_33/IN (r_prep) than_32/IN (r_prep) reproduce_23/VB (l_dobj) dyskinesias_28/NNS
D015632_D020734 CID MPTP_9/NNP (r_npadvmod) induced_11/VBN (r_amod) parkinsonism_12/NN
D004298_D004409 NONE DA_62/NNP (r_compound) agonist_65/NN (r_appos) doses_35/NNS (r_pobj) with_33/IN (r_prep) challenge_32/NN (r_pobj) on_31/IN (r_prep) effects_30/NNS (r_dobj) evaluate_25/VB (r_advcl) conducted_2/VBD (l_dobj) dyskinesias_23/NNS
D004298_D004409 NONE DA_62/NNP (r_compound) agonist_65/NN (r_appos) doses_35/NNS (r_pobj) with_33/IN (r_prep) challenge_32/NN (r_pobj) on_31/IN (r_prep) effects_30/NNS (l_amod) locomotor_27/NN (l_conj) dyskinetic_29/JJ
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12/CD (r_pobj) in_10/IN (r_prep) study_9/NN (r_dobj) conducted_2/VBD (l_dobj) dyskinesias_23/NNS
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12/CD (r_pobj) in_10/IN (r_prep) study_9/NN (r_dobj) conducted_2/VBD (l_advcl) evaluate_25/VB (l_dobj) effects_30/NNS (l_amod) locomotor_27/NN (l_conj) dyskinetic_29/JJ
D015632_D004409 NONE MPTP)-exposed_14/VBN (r_amod) monkeys_16/NNS (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12/CD (r_pobj) in_10/IN (r_prep) study_9/NN (r_dobj) conducted_2/VBD (l_dobj) dyskinesias_23/NNS
D015632_D004409 NONE MPTP)-exposed_14/VBN (r_amod) monkeys_16/NNS (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12/CD (r_pobj) in_10/IN (r_prep) study_9/NN (r_dobj) conducted_2/VBD (l_advcl) evaluate_25/VB (l_dobj) effects_30/NNS (l_amod) locomotor_27/NN (l_conj) dyskinetic_29/JJ
D015632_D004409 NONE MPTP_9/NNP (r_npadvmod) induced_11/VBN (r_amod) parkinsonism_12/NN (r_dobj) alleviating_8/VBG (r_pcomp) in_7/IN (r_prep) efficacious_6/JJ (r_acomp) was_4/VBD (l_conj) was_19/VBD (l_acomp) likely_21/JJ (l_xcomp) reproduce_23/VB (l_dobj) dyskinesias_28/NNS
C095427_D010300 NONE A-86929_13/NNS (r_punct) agents_4/NNS (r_nsubj) are_23/VBP (l_attr) tools_26/NNS (l_prep) in_27/IN (l_pobj) PD_28/NNP
D007980_D020734 NONE levodopa_7/NN (r_npadvmod) primed_9/VBN (r_amod) monkeys_10/NNS (l_amod) parkinsonian_6/JJ
D007980_D020734 NONE levodopa_14/NN (r_pobj) as_13/IN (r_prep) alleviating_8/VBG (l_dobj) parkinsonism_12/NN
D007980_D020734 NONE levodopa_25/RB (r_npadvmod) induced_27/VBN (r_amod) dyskinesias_28/NNS (r_dobj) reproduce_23/VB (r_xcomp) likely_21/JJ (r_acomp) was_19/VBD (r_conj) was_4/VBD (l_acomp) efficacious_6/JJ (l_prep) in_7/IN (l_pcomp) alleviating_8/VBG (l_dobj) parkinsonism_12/NN
D007980_D020734 NONE levodopa_40/NN (r_pobj) of_39/IN (r_prep) challenge_38/NN (r_pobj) with_33/IN (r_prep) than_32/IN (r_prep) reproduce_23/VB (r_xcomp) likely_21/JJ (r_acomp) was_19/VBD (r_conj) was_4/VBD (l_acomp) efficacious_6/JJ (l_prep) in_7/IN (l_pcomp) alleviating_8/VBG (l_dobj) parkinsonism_12/NN
C416545_D004409 NONE LY-171555_16/NNP (r_conj) levodopa_14/NN (r_pobj) as_13/IN (r_prep) alleviating_8/VBG (r_pcomp) in_7/IN (r_prep) efficacious_6/JJ (r_acomp) was_4/VBD (l_conj) was_19/VBD (l_acomp) likely_21/JJ (l_xcomp) reproduce_23/VB (l_dobj) dyskinesias_28/NNS
C416545_D004409 NONE LY-171555_35/NNP (r_amod) challenge_38/NN (r_pobj) with_33/IN (r_prep) than_32/IN (r_prep) reproduce_23/VB (l_dobj) dyskinesias_28/NNS
C416545_D020734 NONE LY-171555_16/NNP (r_conj) levodopa_14/NN (r_pobj) as_13/IN (r_prep) alleviating_8/VBG (l_dobj) parkinsonism_12/NN
C416545_D020734 NONE LY-171555_35/NNP (r_amod) challenge_38/NN (r_pobj) with_33/IN (r_prep) than_32/IN (r_prep) reproduce_23/VB (r_xcomp) likely_21/JJ (r_acomp) was_19/VBD (r_conj) was_4/VBD (l_acomp) efficacious_6/JJ (l_prep) in_7/IN (l_pcomp) alleviating_8/VBG (l_dobj) parkinsonism_12/NN
C095427_D004409 NONE A-86929_44/NNS (r_punct) ,_57/, (r_punct) doses_35/NNS (r_pobj) with_33/IN (r_prep) challenge_32/NN (r_pobj) on_31/IN (r_prep) effects_30/NNS (r_dobj) evaluate_25/VB (r_advcl) conducted_2/VBD (l_dobj) dyskinesias_23/NNS
C095427_D004409 NONE A-86929_44/NNS (r_punct) ,_57/, (r_punct) doses_35/NNS (r_pobj) with_33/IN (r_prep) challenge_32/NN (r_pobj) on_31/IN (r_prep) effects_30/NNS (l_amod) locomotor_27/NN (l_conj) dyskinetic_29/JJ
C095427_D004409 NONE 10-diol_55/JJ (r_punct) )_56/-RRB- (r_punct) ,_57/, (r_punct) doses_35/NNS (r_pobj) with_33/IN (r_prep) challenge_32/NN (r_pobj) on_31/IN (r_prep) effects_30/NNS (r_dobj) evaluate_25/VB (r_advcl) conducted_2/VBD (l_dobj) dyskinesias_23/NNS
C095427_D004409 NONE 10-diol_55/JJ (r_punct) )_56/-RRB- (r_punct) ,_57/, (r_punct) doses_35/NNS (r_pobj) with_33/IN (r_prep) challenge_32/NN (r_pobj) on_31/IN (r_prep) effects_30/NNS (l_amod) locomotor_27/NN (l_conj) dyskinetic_29/JJ
C095427_D004409 NONE A-86929_3/NNS (r_punct) was_4/VBD (l_conj) was_19/VBD (l_acomp) likely_21/JJ (l_xcomp) reproduce_23/VB (l_dobj) dyskinesias_28/NNS
8586822
D018738_D006973 NONE hexamethonium_6/NN (r_pobj) of_2/IN (r_prep) infusion_1/NN (r_nsubj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) decline_11/NN (l_relcl) eliminated_15/VBD (l_dobj) increase_22/NN (l_prep) in_23/IN (l_pobj) MAP_24/NNP
D002216_D006973 NONE captopril_12/FW (r_npadvmod) treated_14/VBN (l_dobj) rats_17/NNS (l_amod) hypertensive_16/JJ
D002216_D006973 NONE captopril_8/FW (r_npadvmod) treated_10/VBN (l_dobj) rats_13/NNS (l_amod) hypertensive_12/JJ
D002216_D006973 NONE captopril_8/FW (r_npadvmod) treated_10/VBN (r_relcl) hypothesis_3/NN (r_dobj) test_1/VB (r_advcl) contributes_22/VBZ (l_prep) to_24/IN (l_pobj) effect_27/NN (l_amod) hypertensive_26/JJ
D017673_D006973 CID chloride_31/NN (r_compound) supplementation_32/NN (r_pobj) of_28/IN (r_prep) effect_27/NN (r_pobj) to_24/IN (r_prep) contributes_22/VBZ (l_advcl) test_1/VB (l_dobj) hypothesis_3/NN (l_relcl) treated_10/VBN (l_dobj) rats_13/NNS (l_amod) hypertensive_12/JJ
D017673_D006973 CID chloride_31/NN (r_compound) supplementation_32/NN (r_pobj) of_28/IN (r_prep) effect_27/NN (l_amod) hypertensive_26/JJ
D017673_D006973 CID chloride_19/NN (r_npadvmod) induced_21/VBN (r_amod) increase_22/NN (l_prep) in_23/IN (l_pobj) MAP_24/NNP
9431903
D009020_D013035 CID morphine_14/NN (r_compound) administration_15/NN (r_pobj) by_11/IN (r_agent) evoked_10/VBN (r_acl) spasm_9/NN
D009020_D013035 CID morphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D009020_D013035 CID morphine_9/NN (r_compound) administration_10/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_nsubjpass) spasm_3/NN
D009020_D013035 CID morphine_19/NN (r_conj) prostigmine_14/NN (r_parataxis) administration_10/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_nsubjpass) spasm_3/NN
D009020_D013035 CID morphine_3/NN (r_compound) provocation_4/NN (r_nsubj) caused_5/VBD (l_advcl) indicating_97/VBG (l_dobj) spasm_100/NN
D009020_D013035 CID morphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D009020_D046628 CID morphine_14/NN (r_compound) administration_15/NN (r_pobj) by_11/IN (r_agent) evoked_10/VBN (r_acl) spasm_9/NN
D009020_D046628 CID morphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D009020_D046628 CID morphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) sphincter_17/NN (r_pobj) on_10/IN (r_prep) trinitrate_9/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (r_nsubjpass) evaluated_22/VBN (l_prep) with_27/IN (l_pobj) sphincter_28/NN (l_prep) of_29/IN (l_pobj) dyskinesia_31/NN
D009020_D046628 CID morphine_9/NN (r_compound) administration_10/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_nsubjpass) spasm_3/NN
D009020_D046628 CID morphine_19/NN (r_conj) prostigmine_14/NN (r_parataxis) administration_10/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_nsubjpass) spasm_3/NN
D009020_D046628 CID morphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D009020_D046628 CID morphine_12/NN (r_pobj) of_11/IN (r_prep) effect_10/NN (r_dobj) overcome_6/VB (r_xcomp) able_4/JJ (r_acomp) is_3/VBZ (r_advcl) be_16/VB (l_prep) in_19/IN (l_pobj) treatment_21/NN (l_prep) of_22/IN (l_pobj) sphincter_23/NN (l_prep) of_24/IN (l_pobj) dyskinesia_26/NN
D009388_D046628 CID prostigmine_12/JJ (r_compound) morphine_14/NN (r_compound) administration_15/NN (r_pobj) by_11/IN (r_agent) evoked_10/VBN (r_acl) spasm_9/NN
D009388_D046628 CID prostigmine_12/JJ (r_compound) morphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D009388_D046628 CID prostigmine_12/JJ (r_compound) morphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) sphincter_17/NN (r_pobj) on_10/IN (r_prep) trinitrate_9/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (r_nsubjpass) evaluated_22/VBN (l_prep) with_27/IN (l_pobj) sphincter_28/NN (l_prep) of_29/IN (l_pobj) dyskinesia_31/NN
D009388_D046628 CID prostigmine_7/JJ (r_compound) morphine_9/NN (r_compound) administration_10/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_nsubjpass) spasm_3/NN
D009388_D046628 CID prostigmine_14/NN (r_parataxis) administration_10/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_nsubjpass) spasm_3/NN
D005996_D046628 NONE trinitrate_3/NN (l_prep) on_4/IN (l_pobj) sphincter_6/NN (l_prep) of_7/IN (l_pobj) spasm_9/NN
D005996_D046628 NONE trinitrate_9/NN (l_prep) on_10/IN (l_pobj) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D005996_D046628 NONE trinitrate_9/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (r_nsubjpass) evaluated_22/VBN (l_prep) with_27/IN (l_pobj) sphincter_28/NN (l_prep) of_29/IN (l_pobj) dyskinesia_31/NN
D005996_D046628 NONE trinitrate_11/NN (l_prep) on_12/IN (l_pobj) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D005996_D046628 NONE trinitrate_2/NN (r_nsubj) is_3/VBZ (r_advcl) be_16/VB (l_prep) in_19/IN (l_pobj) treatment_21/NN (l_prep) of_22/IN (l_pobj) sphincter_23/NN (l_prep) of_24/IN (l_pobj) dyskinesia_26/NN
D005996_D013035 NONE trinitrate_3/NN (l_prep) on_4/IN (l_pobj) sphincter_6/NN (l_prep) of_7/IN (l_pobj) spasm_9/NN
D005996_D013035 NONE trinitrate_9/NN (l_prep) on_10/IN (l_pobj) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D005996_D013035 NONE trinitrate_11/NN (l_prep) on_12/IN (l_pobj) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D009388_D013035 CID prostigmine_12/JJ (r_compound) morphine_14/NN (r_compound) administration_15/NN (r_pobj) by_11/IN (r_agent) evoked_10/VBN (r_acl) spasm_9/NN
D009388_D013035 CID prostigmine_12/JJ (r_compound) morphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) sphincter_17/NN (l_prep) of_18/IN (l_pobj) spasm_20/NN
D009388_D013035 CID prostigmine_7/JJ (r_compound) morphine_9/NN (r_compound) administration_10/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_nsubjpass) spasm_3/NN
D009388_D013035 CID prostigmine_14/NN (r_parataxis) administration_10/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_nsubjpass) spasm_3/NN
D009388_D013035 CID Prostigmine_1/JJ (r_compound) morphine_3/NN (r_compound) provocation_4/NN (r_nsubj) caused_5/VBD (l_advcl) indicating_97/VBG (l_dobj) spasm_100/NN
1255900
D006493_D013924 NONE heparin_8/JJ (r_compound) therapy_9/NN (r_pobj) of_7/IN (r_prep) initiation_6/NN (l_prep) for_10/IN (l_pobj) thrombophlebitis_13/NN
6794356
D008094_D001282 NONE lithium_18/NN (r_compound) level_19/NN (r_conj) failure_12/NN (r_conj) flutter_8/JJ
D008094_D001282 NONE lithium_26/NN (r_compound) compounds_27/NNS (r_pobj) to_25/IN (r_prep) exposed_24/VBN (r_acl) infants_23/NNS (r_pobj) among_22/IN (r_prep) disease_21/NN (r_pobj) with_19/IN (r_prep) patient_18/NN (r_dobj) described_17/VBN (r_conj) is_1/VBZ (l_attr) patient_4/NN (l_relcl) manifest_7/VB (l_dobj) regurgitation_9/NN (l_conj) flutter_12/NN
D008094_D014262 NONE lithium_18/NN (r_compound) level_19/NN (r_conj) failure_12/NN (r_conj) flutter_8/JJ (r_conj) regurgitation_5/NN
D008094_D014262 NONE lithium_26/NN (r_compound) compounds_27/NNS (r_pobj) to_25/IN (r_prep) exposed_24/VBN (r_acl) infants_23/NNS (r_pobj) among_22/IN (r_prep) disease_21/NN (r_pobj) with_19/IN (r_prep) patient_18/NN (r_dobj) described_17/VBN (r_conj) is_1/VBZ (l_attr) patient_4/NN (l_relcl) manifest_7/VB (l_dobj) regurgitation_9/NN
D008094_D006333 NONE lithium_18/NN (r_compound) level_19/NN (r_conj) failure_12/NN
D016651_D006331 NONE carbonate_1/NN (r_nsubj) be_3/VB (l_prep) in_6/IN (l_pobj) incidence_9/NN (l_prep) of_10/IN (l_pobj) disease_13/NN
D016651_D064420 NONE carbonate_5/NN (r_compound) toxicity_6/NN
D008094_D006331 NONE lithium_26/NN (r_compound) compounds_27/NNS (r_pobj) to_25/IN (r_prep) exposed_24/VBN (r_acl) infants_23/NNS (r_pobj) among_22/IN (r_prep) disease_21/NN
D016651_D014262 NONE carbonate_5/NN (r_compound) toxicity_6/NN (r_conj) regurgitation_2/NN
9867728
D005277_D006349 NONE fenfluramine_8/NN (r_pobj) of_7/IN (r_prep) users_6/NNS (r_pobj) among_5/IN (r_prep) disease_4/NN
D005277_D006349 NONE fenfluramine_16/NN (r_pobj) of_15/IN (r_prep) users_14/NNS (r_pobj) of_13/IN (r_prep) %_12/NN (r_nsubj) had_19/VBD (l_dobj) disease_21/NN
D005277_D006349 NONE fenfluramine_13/NN (r_pobj) of_12/IN (r_prep) users_11/NNS (r_pobj) among_10/IN (r_prep) abnormalities_9/NNS
D005277_D006349 NONE fenfluramine_18/JJ (r_compound) phentermine_20/NN (r_dobj) receiving_17/VBG (r_acl) patients_1/NNS (r_nsubj) developed_21/VBD (l_dobj) disease_24/NN
D010645_D006349 NONE phentermine_20/NN (r_dobj) receiving_17/VBG (r_acl) patients_1/NNS (r_nsubj) developed_21/VBD (l_dobj) disease_24/NN
D020372_D006349 NONE dexfenfluramine_10/NN (r_conj) fenfluramine_8/NN (r_pobj) of_7/IN (r_prep) users_6/NNS (r_pobj) among_5/IN (r_prep) disease_4/NN
D020372_D006349 NONE dexfenfluramine_18/NN (r_conj) fenfluramine_16/NN (r_pobj) of_15/IN (r_prep) users_14/NNS (r_pobj) of_13/IN (r_prep) %_12/NN (r_nsubj) had_19/VBD (l_dobj) disease_21/NN
D020372_D006349 NONE dexfenfluramine_15/NN (r_conj) fenfluramine_13/NN (r_pobj) of_12/IN (r_prep) users_11/NNS (r_pobj) among_10/IN (r_prep) abnormalities_9/NNS
2564649
D011224_D009127 NONE prazosin_32/NN (r_pobj) with_25/IN (r_prep) lesions_18/NNS (r_pobj) by_15/IN (r_agent) reduced_14/VBN (r_conj) antagonized_11/VBN (l_nsubjpass) rigidity_4/NN
D005283_D009127 CID fentanyl_8/NN (r_npadvmod) induced_10/VBN (r_amod) rigidity_12/NN
D005283_D009127 CID fentanyl_17/NN (r_compound) anesthesia_18/NN (r_pobj) with_13/IN (r_prep) associated_12/VBN (r_relcl) effect_9/NN (r_attr) is_3/VBZ (l_nsubj) rigidity_2/NN
D005283_D009127 CID fentanyl_10/NN (r_pobj) by_9/IN (r_prep) rigidity_8/NN
625456
D017693_D006934 CID bicarbonate_27/NN (r_compound) powders_28/NNS (r_pobj) of_20/IN (r_prep) amounts_19/NNS (r_dobj) consumed_17/VBN (r_relcl) patients_13/NNS (r_pobj) in_12/IN (r_prep) reported_11/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) hypercalcaemia_4/NN
D017693_D053040 CID bicarbonate_27/NN (r_compound) powders_28/NNS (r_pobj) of_20/IN (r_prep) amounts_19/NNS (r_dobj) consumed_17/VBN (r_relcl) patients_13/NNS (r_pobj) in_12/IN (r_prep) reported_11/VBN (l_nsubjpass) two_6/CD (l_prep) of_7/IN (l_pobj) nephrolithiasis_9/NN
D002119_D006934 CID ate_24/VBN (r_amod) sodium_26/NN (r_compound) powders_28/NNS (r_pobj) of_20/IN (r_prep) amounts_19/NNS (r_dobj) consumed_17/VBN (r_relcl) patients_13/NNS (r_pobj) in_12/IN (r_prep) reported_11/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) hypercalcaemia_4/NN
D002119_D053040 CID ate_24/VBN (r_amod) sodium_26/NN (r_compound) powders_28/NNS (r_pobj) of_20/IN (r_prep) amounts_19/NNS (r_dobj) consumed_17/VBN (r_relcl) patients_13/NNS (r_pobj) in_12/IN (r_prep) reported_11/VBN (l_nsubjpass) two_6/CD (l_prep) of_7/IN (l_pobj) nephrolithiasis_9/NN
326460
D001539_D007008 CID bendrofluazide_2/NN (r_advmod) induced_4/VBN (r_amod) hypokalemia_5/NN
D001539_D007008 CID bendrofluazide_17/NN (r_amod) treatment_18/NN (r_pobj) of_13/IN (r_prep) hypokalemia_12/NN
D013999_D007008 NONE timolol_7/NN (r_pobj) by_6/IN (r_prep) Amelioration_0/NN (l_prep) of_1/IN (l_pobj) hypokalemia_5/NN
D013999_D007008 NONE timolol_6/NN (r_appos) drug_4/NN (r_nsubj) tended_8/VBD (l_xcomp) correct_10/VB (l_dobj) hypokalemia_12/NN
9205462
D013629_D017093 CID tamoxifen_2/NN (r_npadvmod) induced_4/VBN (r_amod) dysfunction_6/NN
D013629_D017093 CID tamoxifen_20/NN (r_compound) metabolism_21/NN (r_pobj) in_19/IN (r_prep) alterations_18/NNS (r_pobj) because_16/IN (r_prep) be_8/VB (l_nsubj) Patients_0/NNS (l_prep) with_1/IN (l_pobj) dysfunction_6/NN
D013629_D001943 NONE tamoxifen_9/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (l_prep) for_10/IN (l_pobj) carcinoma_18/NN
D013629_C537296 CID tamoxifen_9/NN (r_compound) use_10/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) ovary_5/NN
D013629_D009369 NONE tamoxifen_8/NN (r_compound) use_9/NN (l_conj) tumors_12/NNS
D013629_D006106 NONE tamoxifen_2/NN (r_npadvmod) induced_4/VBN (r_amod) dysfunction_6/NN (r_pobj) with_1/IN (r_prep) Patients_0/NNS (r_nsubj) be_8/VB (l_prep) at_9/IN (l_pobj) risk_11/NN (l_prep) for_12/IN (l_pobj) tumors_15/NNS
D013629_D006106 NONE tamoxifen_20/NN (r_compound) metabolism_21/NN (r_pobj) in_19/IN (r_prep) alterations_18/NNS (r_pobj) because_16/IN (r_prep) be_8/VB (l_prep) at_9/IN (l_pobj) risk_11/NN (l_prep) for_12/IN (l_pobj) tumors_15/NNS
D004967_D001943 NONE estrogen_13/NN (r_compound) carcinoma_18/NN
17241657
C107044_D012640 NONE 21_15/CD (r_nummod) /-)-SM_14/SYM (r_conj) UMB24_10/NNP (r_pobj) with_9/IN (r_prep) pretreatment_4/NN (r_nsubj) attenuated_17/VBN (l_dobj) convulsions_21/NNS
D003042_D012640 CID cocaine_21/NN (r_pobj) of_20/IN (r_prep) actions_19/NNS (l_amod) convulsive_11/JJ
D003042_D012640 CID cocaine_18/NN (r_npadvmod) induced_20/VBN (r_amod) convulsions_21/NNS
C519696_D012640 NONE UMB24_10/NNP (r_pobj) with_9/IN (r_prep) pretreatment_4/NN (r_nsubj) attenuated_17/VBN (l_dobj) convulsions_21/NNS
9545159
D020117_D006973 NONE cisapride_14/NN (r_dobj) taking_13/VBG (l_prep) for_31/IN (l_pobj) hypertension_32/NN
D004110_D005764 NONE diltiazem_20/NN (r_conj) disorder_18/NN
D004110_D006973 NONE diltiazem_20/NN (r_conj) disorder_18/NN (r_pobj) for_15/IN (r_prep) taking_13/VBG (l_prep) for_31/IN (l_pobj) hypertension_32/NN
D020117_D005764 NONE cisapride_14/NN (r_dobj) taking_13/VBG (l_prep) for_15/IN (l_pobj) disorder_18/NN
D020117_D008133 CID cisapride_7/NN (r_compound) diltiazem_9/NN (r_compound) interaction_10/NN (r_pobj) to_6/IN (r_prep) related_5/VBN (r_acl) interval_4/NN
D004110_D008133 CID diltiazem_9/NN (r_compound) interaction_10/NN (r_pobj) to_6/IN (r_prep) related_5/VBN (r_acl) interval_4/NN
D004917_D016171 CID erythromycin_20/NNP (r_pobj) with_19/IN (r_prep) administration_18/NN (r_pobj) after_16/IN (r_prep) reported_15/VBN (l_nsubjpass) torsades_5/NNS (l_dobj) pointes_7/FW
D004917_D016757 CID erythromycin_20/NNP (r_pobj) with_19/IN (r_prep) administration_18/NN (r_pobj) after_16/IN (r_prep) reported_15/VBN (l_nsubjpass) torsades_5/NNS (l_dobj) pointes_7/FW (l_conj) death_12/NN
D001393_D016757 CID azole_22/JJ (r_amod) agents_24/NNS (r_conj) erythromycin_20/NNP (r_pobj) with_19/IN (r_prep) administration_18/NN (r_pobj) after_16/IN (r_prep) reported_15/VBN (l_nsubjpass) torsades_5/NNS (l_dobj) pointes_7/FW (l_conj) death_12/NN
D020117_D015835 NONE Cisapride_0/NNP (r_nsubjpass) prescribed_13/VBN (l_prep) for_14/IN (l_pobj) treatment_16/NN (l_prep) of_17/IN (l_pobj) disorders_20/NNS
D004917_D008133 CID erythromycin_20/NNP (r_pobj) with_19/IN (r_prep) administration_18/NN (r_pobj) after_16/IN (r_prep) reported_15/VBN (l_nsubjpass) torsades_5/NNS (l_nsubj) Prolongation_0/NN (l_prep) of_1/IN (l_pobj) interval_3/NN
D001393_D016171 CID azole_22/JJ (r_amod) agents_24/NNS (r_conj) erythromycin_20/NNP (r_pobj) with_19/IN (r_prep) administration_18/NN (r_pobj) after_16/IN (r_prep) reported_15/VBN (l_nsubjpass) torsades_5/NNS (l_dobj) pointes_7/FW
D001393_D008133 CID azole_22/JJ (r_amod) agents_24/NNS (r_conj) erythromycin_20/NNP (r_pobj) with_19/IN (r_prep) administration_18/NN (r_pobj) after_16/IN (r_prep) reported_15/VBN (l_nsubjpass) torsades_5/NNS (l_nsubj) Prolongation_0/NN (l_prep) of_1/IN (l_pobj) interval_3/NN
21294084
D010406_D004827 NONE penicillin_12/NN (r_npadvmod) induced_14/VBN (r_amod) model_16/NN (r_pobj) in_11/IN (r_prep) discharges_10/NNS (l_amod) epileptic_9/JJ
D010406_D004827 NONE penicillin_12/NN (r_npadvmod) induced_14/VBN (r_amod) model_16/NN (l_compound) epilepsy_15/NN
D010406_D004827 NONE penicillin_17/NN (r_npadvmod) induced_19/VBN (r_amod) model_21/NN (r_pobj) in_16/IN (r_prep) activity_15/NN (l_amod) epileptic_14/JJ
D010406_D004827 NONE penicillin_17/NN (r_npadvmod) induced_19/VBN (r_amod) model_21/NN (l_compound) epilepsy_20/NN
D010406_D004827 NONE penicillin_7/NN (r_npadvmod) induced_9/VBN (r_amod) activity_12/NN (l_amod) epileptic_11/JJ
3969369
D013739_D009369 NONE testosterone_6/NN (r_pobj) with_5/IN (r_prep) implanted_4/VBN (r_acl) rats_2/NNS (r_nsubj) developed_12/VBD (r_ccomp) developed_30/VBN (l_dobj) tumors_32/NNS
D013739_D009369 NONE testosterone_6/NN (r_pobj) with_5/IN (r_prep) implanted_4/VBN (r_acl) rats_2/NNS (r_nsubj) developed_12/VBD (r_ccomp) developed_30/VBN (l_conj) %_36/NN (l_advcl) included_39/VBD (l_dobj) tumors_41/NNS
D013739_D011471 CID testosterone_6/NN (r_pobj) with_5/IN (r_prep) implanted_4/VBN (r_acl) rats_2/NNS (r_nsubj) developed_12/VBD (l_dobj) incidence_15/NN (l_prep) of_16/IN (l_pobj) cancer_18/NN
D013739_D011471 CID testosterone_4/NN (r_npadvmod) treated_6/VBN (r_amod) rats_8/NNS (l_relcl) fed_11/VBN (l_dobj) diet_14/NN (l_relcl) supplemented_18/VBN (l_dobj) fat_26/NN (l_conj) cancer_30/NN
D013739_D063646 NONE testosterone_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_7/IN (l_pobj) carcinogenesis_9/NN
D013739_D011472 CID testosterone_9/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (l_advcl) developed_10/VBD (l_dobj) prostatitis_12/NN
19203554
D013256_D002637 NONE steroid_32/NN (r_compound) therapy_33/NN (r_dobj) initiated_31/VBD (l_advcl) resulted_5/VBD (l_prep) in_6/IN (l_pobj) improvements_7/NNS (l_prep) in_8/IN (l_pobj) fever_9/NN (l_appos) eyes_12/NNS (l_conj) pain_15/NN
D013256_D005334 NONE steroid_32/NN (r_compound) therapy_33/NN (r_dobj) initiated_31/VBD (l_advcl) resulted_5/VBD (l_prep) in_6/IN (l_pobj) improvements_7/NNS (l_prep) in_8/IN (l_pobj) fever_9/NN
D012460_D005128 NONE sulphasalazine_22/JJ (r_compound) treatment_23/NN (r_pobj) of_21/IN (r_prep) restarting_20/VBG (r_pcomp) after_19/IN (r_prep) developed_8/VBD (l_dobj) eyes_10/NNS
D012460_D005128 NONE sulphasalazine_3/NN (r_compound) treatment_4/NN (r_pobj) of_2/IN (r_prep) cessation_1/NN (r_nsubj) resulted_5/VBD (l_prep) in_6/IN (l_pobj) improvements_7/NNS (l_prep) in_8/IN (l_pobj) fever_9/NN (l_appos) eyes_12/NNS
D012460_D002637 NONE sulphasalazine_3/NN (r_compound) treatment_4/NN (r_pobj) of_2/IN (r_prep) cessation_1/NN (r_nsubj) resulted_5/VBD (l_prep) in_6/IN (l_pobj) improvements_7/NNS (l_prep) in_8/IN (l_pobj) fever_9/NN (l_appos) eyes_12/NNS (l_conj) pain_15/NN
D013256_D005128 NONE steroid_32/NN (r_compound) therapy_33/NN (r_dobj) initiated_31/VBD (l_advcl) resulted_5/VBD (l_prep) in_6/IN (l_pobj) improvements_7/NNS (l_prep) in_8/IN (l_pobj) fever_9/NN (l_appos) eyes_12/NNS
D012460_D003093 NONE sulphasalazine_22/JJ (r_compound) treatment_23/NN (r_pobj) of_21/IN (r_prep) restarting_20/VBG (r_pcomp) after_19/IN (r_prep) developed_8/VBD (l_nsubj) woman_4/NN (l_prep) with_5/IN (l_pobj) colitis_7/NN
D012460_D010996 CID sulphasalazine_22/JJ (r_compound) treatment_23/NN (r_pobj) of_21/IN (r_prep) restarting_20/VBG (r_pcomp) after_19/IN (r_prep) developed_8/VBD (l_dobj) eyes_10/NNS (l_conj) effusion_13/NN
D012460_D010996 CID sulphasalazine_3/NN (r_compound) treatment_4/NN (r_pobj) of_2/IN (r_prep) cessation_1/NN (r_nsubj) resulted_5/VBD (l_prep) in_6/IN (l_pobj) improvements_7/NNS (l_prep) in_8/IN (l_pobj) fever_9/NN (l_appos) eyes_12/NNS (l_conj) pain_15/NN (l_conj) titer_17/NN (l_prep) of_18/IN (l_pobj) protein_22/NN (l_prep) of_25/IN (l_pobj) effusions_28/NNS
D012460_D010996 CID sulphasalazine_3/NN (r_compound) treatment_4/NN (r_pobj) of_2/IN (r_prep) cessation_1/NN (r_nsubj) resulted_5/VBD (r_advcl) initiated_31/VBD (l_conj) increased_45/VBD (l_conj) remained_56/VBD (l_nsubj) effusion_55/NN
D012460_D005334 CID sulphasalazine_3/NN (r_compound) treatment_4/NN (r_pobj) of_2/IN (r_prep) cessation_1/NN (r_nsubj) resulted_5/VBD (l_prep) in_6/IN (l_pobj) improvements_7/NNS (l_prep) in_8/IN (l_pobj) fever_9/NN
D013256_D010996 NONE steroid_32/NN (r_compound) therapy_33/NN (r_dobj) initiated_31/VBD (l_advcl) resulted_5/VBD (l_prep) in_6/IN (l_pobj) improvements_7/NNS (l_prep) in_8/IN (l_pobj) fever_9/NN (l_appos) eyes_12/NNS (l_conj) pain_15/NN (l_conj) titer_17/NN (l_prep) of_18/IN (l_pobj) protein_22/NN (l_prep) of_25/IN (l_pobj) effusions_28/NNS
D013256_D010996 NONE steroid_32/NN (r_compound) therapy_33/NN (r_dobj) initiated_31/VBD (l_conj) increased_45/VBD (l_conj) remained_56/VBD (l_nsubj) effusion_55/NN
D013256_D010996 NONE steroid_3/NN (r_compound) therapy_4/NN (r_pobj) after_2/IN (r_prep) disappeared_9/VBD (l_nsubj) effusion_8/NN
D012460_D005921 NONE sulphasalazine_10/JJ (r_compound) treatment_11/NN (r_dobj) restarting_9/VBG (r_pcomp) after_8/IN (r_prep) antibody-(PR3-ANCA_3/NNS (l_appos) glomerulonephritis_7/NN
D012460_D005921 NONE sulphasalazine_4/NN (r_nsubj) induce_6/VB (l_dobj) glomerulonephritis_11/NN
D012460_D001745 NONE sulphasalazine_22/JJ (r_compound) treatment_23/NN (r_pobj) of_21/IN (r_prep) restarting_20/VBG (r_pcomp) after_19/IN (r_prep) developed_8/VBD (l_dobj) eyes_10/NNS (l_conj) effusion_13/NN (l_conj) eosinophilia_15/NN (l_conj) abnormalities_18/NNS
D012460_D004802 NONE sulphasalazine_22/JJ (r_compound) treatment_23/NN (r_pobj) of_21/IN (r_prep) restarting_20/VBG (r_pcomp) after_19/IN (r_prep) developed_8/VBD (l_dobj) eyes_10/NNS (l_conj) effusion_13/NN (l_conj) eosinophilia_15/NN
1636026
D014527_D058186 NONE acid_21/NN (r_pobj) of_19/IN (r_prep) distribution_18/NN (r_dobj) altering_15/VBG (r_pcomp) by_13/IN (r_prep) likely_12/JJ (r_advcl) causes_4/VBZ (l_dobj) declines_6/NNS (l_prep) in_7/IN (l_pobj) function_9/NN
D013496_D058186 CID suprofen_1/NN (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) development_7/NN (l_prep) of_8/IN (l_pobj) failure_11/NN
D013496_D058186 CID suprofen_3/VB (r_nsubj) causes_4/VBZ (l_dobj) declines_6/NNS (l_prep) in_7/IN (l_pobj) function_9/NN
D014527_D007674 NONE acid_39/NN (r_pobj) of_37/IN (r_prep) dL_36/NN (r_pobj) of_32/IN (r_prep) addition_31/NN (r_pobj) without_29/IN (r_conj) with_27/IN (r_prep) buffer_26/NN (r_pobj) with_22/IN (r_prep) perfused_21/VBN (r_acl) kidney_20/NN (r_pobj) in_15/IN (r_prep) compared_14/VBN (l_nsubjpass) effects_3/NNS (l_amod) nephrotoxic_2/JJ
D013496_D007674 NONE suprofen_12/NN (r_pobj) of_11/IN (r_prep) mg_10/NN (r_nsubjpass) compared_14/VBN (l_nsubjpass) effects_3/NNS (l_amod) nephrotoxic_2/JJ
15974569
D005557_D010146 NONE formalin_17/NN (r_npadvmod) induced_19/VBN (r_amod) licking_21/NN (r_pobj) of_16/IN (r_prep) reversal_15/NN (r_appos) models_11/NNS (l_prep) of_12/IN (l_pobj) pain_13/NN
D007608_D010146 NONE kainate_7/NN (r_compound) antagonists_9/NNS (r_compound) actives_10/NNS (l_prep) in_11/IN (l_pobj) models_14/NNS (l_prep) of_15/IN (l_pobj) pain_16/NN
D002211_D010146 NONE capsaicin_30/NN (r_npadvmod) induced_32/VBN (r_amod) hyperalgesia_34/NN (r_conj) hyperalgesia_27/NN (r_conj) reversal_15/NN (r_appos) models_11/NNS (l_prep) of_12/IN (l_pobj) pain_13/NN
D002351_D010146 NONE carrageenan_23/NN (r_npadvmod) induced_25/VBN (r_amod) hyperalgesia_27/NN (r_conj) reversal_15/NN (r_appos) models_11/NNS (l_prep) of_12/IN (l_pobj) pain_13/NN
D002351_D006930 CID carrageenan_23/NN (r_npadvmod) induced_25/VBN (r_amod) hyperalgesia_27/NN
D002351_D006930 CID carrageenan_23/NN (r_npadvmod) induced_25/VBN (r_amod) hyperalgesia_27/NN (l_conj) hyperalgesia_34/NN
D005557_D006930 NONE formalin_17/NN (r_npadvmod) induced_19/VBN (r_amod) licking_21/NN (r_pobj) of_16/IN (r_prep) reversal_15/NN (l_conj) hyperalgesia_27/NN
D005557_D006930 NONE formalin_17/NN (r_npadvmod) induced_19/VBN (r_amod) licking_21/NN (r_pobj) of_16/IN (r_prep) reversal_15/NN (l_conj) hyperalgesia_27/NN (l_conj) hyperalgesia_34/NN
D002211_D006930 CID capsaicin_30/NN (r_npadvmod) induced_32/VBN (r_amod) hyperalgesia_34/NN (r_conj) hyperalgesia_27/NN
D002211_D006930 CID capsaicin_30/NN (r_npadvmod) induced_32/VBN (r_amod) hyperalgesia_34/NN
10328196
D020123_D005334 NONE sirolimus_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubj) include_5/VBP (l_dobj) fever_6/NN
D020123_D019559 CID sirolimus_5/NN (r_pobj) of_4/IN (r_prep) administration_3/NN (r_dobj) following_2/VBG (r_prep) toxicity_1/NN (l_appos) association_13/NN (l_prep) of_14/IN (l_pobj) syndrome_17/NN
D020123_D019559 CID rapamycin_8/VBZ (r_appos) toxicity_1/NN (l_appos) association_13/NN (l_prep) of_14/IN (l_pobj) syndrome_17/NN
D020123_D019559 CID sirolimus_14/NN (r_nmod) cells_17/NNS (r_pobj) with_12/IN (r_prep) treatment_11/NN (r_pobj) following_10/VBG (r_acl) syndrome_9/NN
D020123_D019559 CID sirolimus_8/NN (r_npadvmod) induced_10/VBN (r_amod) syndrome_13/NN
D020123_D019559 CID sirolimus_32/NN (r_npadvmod) treated_34/VBN (r_amod) patient_35/NN (r_pobj) with_29/IN (r_prep) compared_28/VBN (r_prep) had_14/VBD (l_nsubj) specimen_3/NN (l_prep) from_4/IN (l_pobj) patient_6/NN (l_prep) with_7/IN (l_pobj) syndrome_13/NN
D020123_D019559 CID sirolimus_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubj) include_5/VBP (l_dobj) fever_6/NN (l_conj) anemia_8/NN (l_conj) syndrome_13/NN
D020123_D011565 NONE sirolimus_5/NN (r_pobj) of_4/IN (r_prep) administration_3/NN (r_dobj) following_2/VBG (r_prep) toxicity_1/NN (l_prep) for_10/IN (l_pobj) psoriasis_11/NN
D020123_D011565 NONE rapamycin_8/VBZ (r_appos) toxicity_1/NN (l_prep) for_10/IN (l_pobj) psoriasis_11/NN
D020123_D011565 NONE sirolimus_14/NN (r_nmod) cells_17/NNS (r_pobj) with_12/IN (r_prep) treatment_11/NN (r_pobj) following_10/VBG (r_acl) syndrome_9/NN (r_dobj) developed_5/VBD (l_nsubj) individuals_2/NNS (l_prep) with_3/IN (l_pobj) psoriasis_4/NN
D020123_D011565 NONE sirolimus_8/NN (r_npadvmod) induced_10/VBN (r_amod) syndrome_13/NN (r_pobj) with_7/IN (r_prep) patient_6/NN (r_pobj) from_4/IN (r_prep) specimen_3/NN (r_nsubj) had_14/VBD (l_prep) compared_28/VBN (l_prep) with_29/IN (l_pobj) patient_35/NN (l_prep) with_36/IN (l_pobj) psoriasis_37/NN
D020123_D011565 NONE sirolimus_32/NN (r_npadvmod) treated_34/VBN (r_amod) patient_35/NN (l_prep) with_36/IN (l_pobj) psoriasis_37/NN
D020123_D011565 NONE sirolimus_30/NN (r_pobj) of_29/IN (r_prep) presence_28/NN (r_pobj) in_26/IN (r_prep) did_20/VBD (r_advcl) apoptosis_18/NN (r_oprd) exhibit_11/VB (r_xcomp) tended_9/VBD (r_ccomp) Activated_0/VBN (l_dobj) cells_4/NNS (l_prep) from_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) psoriasis_8/NN
D003907_D011565 NONE dexamethasone_15/NN (r_npadvmod) induced_17/VBN (r_conj) spontaneous_13/JJ (r_amod) apoptosis_18/NN (r_oprd) exhibit_11/VB (r_xcomp) tended_9/VBD (r_ccomp) Activated_0/VBN (l_dobj) cells_4/NNS (l_prep) from_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) psoriasis_8/NN
D020123_D064420 NONE sirolimus_5/NN (r_pobj) of_4/IN (r_prep) administration_3/NN (r_dobj) following_2/VBG (r_prep) toxicity_1/NN
D020123_D064420 NONE rapamycin_8/VBZ (r_appos) toxicity_1/NN
D020123_D000740 NONE sirolimus_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubj) include_5/VBP (l_dobj) fever_6/NN (l_conj) anemia_8/NN
3431591
C031662_D008654 NONE 3717_6/CD (r_nummod) CB_5/NNP (r_pobj) with_4/IN (r_prep) studies_3/NNS (r_pobj) In_0/IN (r_prep) seen_11/VBN (l_prep) in_12/IN (l_pobj) cancer_14/NN (l_conj) cancer_17/NN (l_conj) hepatoma_19/NN (l_conj) mesothelioma_22/NN
C031662_D006528 NONE 3717_6/CD (r_nummod) CB_5/NNP (r_pobj) with_4/IN (r_prep) studies_3/NNS (r_pobj) In_0/IN (r_prep) seen_11/VBN (l_prep) in_12/IN (l_pobj) cancer_14/NN (l_conj) cancer_17/NN (l_conj) hepatoma_19/NN
C031662_D010051 NONE 3717_6/CD (r_nummod) CB_5/NNP (r_pobj) with_4/IN (r_prep) studies_3/NNS (r_pobj) In_0/IN (r_prep) seen_11/VBN (l_prep) in_12/IN (l_pobj) cancer_14/NN (l_conj) cancer_17/NN
C031662_D001943 NONE 3717_6/CD (r_nummod) CB_5/NNP (r_pobj) with_4/IN (r_prep) studies_3/NNS (r_pobj) In_0/IN (r_prep) seen_11/VBN (l_prep) in_12/IN (l_pobj) cancer_14/NN
C031662_D064420 NONE 3717_1/CD (r_nummod) CB_0/NN (r_nsubj) is_6/VBZ (l_attr) inhibitor_11/NN (l_relcl) mediated_21/VBN (l_nsubjpass) cytotoxicity_19/NN
C031662_D064420 NONE acid_4/NN (r_appos) CB_0/NN (r_nsubj) is_6/VBZ (l_attr) inhibitor_11/NN (l_relcl) mediated_21/VBN (l_nsubjpass) cytotoxicity_19/NN
C031662_D064420 NONE 3717_28/CD (r_nummod) CB_27/NNP (r_pobj) than_26/IN (r_prep) potent_25/JJ (r_amod) 26-_17/NNPS (r_attr) are_16/VBP (l_conj) be_39/VB (l_attr) determinant_42/NN (l_prep) of_43/IN (l_pobj) cytotoxicity_46/NN
C031662_D064420 NONE 3717_45/CD (r_nummod) cytotoxicity_46/NN
17194457
D012701_D001523 NONE 5-HT_16/CD (r_pobj) with_13/IN (r_prep) users_12/NNS (r_nsubj) be_18/VB (l_acomp) prone_20/JJ (l_xcomp) exhibit_22/VB (l_dobj) behavior_24/NN
-1_D001523 NONE PCPA_3/NNP (r_pobj) to_2/IN (r_prep) exposure_1/NN (r_nsubj) decreased_6/VBD (l_conj) increased_10/VBN (l_dobj) irritability_11/NN
-1_D001523 NONE PCPA_3/NNP (r_pobj) to_2/IN (r_prep) exposure_1/NN (r_nsubj) decreased_6/VBD (l_conj) had_13/VBD (l_dobj) effect_15/NN (l_prep) on_16/IN (l_pobj) behavior_18/NN (l_conj) preference_21/NN (l_conj) aggression_24/NN
D013739_D001523 CID T_0/NNP (r_nsubj) had_2/VBD (l_dobj) effect_4/NN (l_prep) on_5/IN (l_pobj) locomotion_6/NN (l_conj) irritability_8/NN
D013739_D001523 CID T_0/NNP (r_nsubj) had_2/VBD (l_conj) preference_16/NN (l_conj) aggression_18/NN
3115150
D015760_D009127 CID alfentanil_3/NN (r_npadvmod) induced_5/VBN (r_amod) rigidity_7/NN
D015760_D009127 CID alfentanil_29/NN (r_advcl) attenuated_14/VBD (l_dobj) rigidity_17/NN
D015760_D009127 CID alfentanil_15/NNS (r_pobj) by_14/IN (r_agent) produced_13/VBN (r_acl) rigidity_12/NN
D015760_D009127 CID alfentanil_19/NNS (r_pobj) by_18/IN (r_agent) followed_17/VBN (l_prep) Despite_0/IN (l_pobj) absence_2/NN (l_prep) of_3/IN (l_pobj) rigidity_4/NN
D015760_D009127 CID alfentanil_35/NN (r_advmod) receiving_34/VBG (r_acl) animals_33/NNS (r_nsubj) were_32/VBD (r_advcl) responsive_27/JJ (r_conj) flaccid_23/JJ (r_conj) motionless_21/JJ (r_acomp) were_20/VBD (l_csubj) followed_17/VBN (l_prep) Despite_0/IN (l_pobj) absence_2/NN (l_prep) of_3/IN (l_pobj) rigidity_4/NN
D012701_D009127 NONE serotonin_9/NN (r_compound) antagonist_11/NN (r_appos) pretreatment_1/NN (r_nsubj) attenuated_14/VBD (l_dobj) rigidity_17/NN
D012701_D009127 NONE serotonin_3/NN (r_compound) antagonists_4/NNS (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) be_6/VB (l_acomp) useful_8/JJ (l_prep) in_9/IN (l_pcomp) attenuating_10/VBG (l_dobj) rigidity_14/NN
D002707_D009127 NONE Chlordiazepoxide_0/VB (r_nsubj) failed_7/VBD (l_xcomp) influence_10/VB (l_dobj) rigidity_12/NN
D012701_D002318 NONE serotonin_3/NN (r_compound) antagonists_4/NNS (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) be_6/VB (l_advcl) be_20/VB (l_xcomp) assess_23/VB (l_dobj) interaction_25/NN (l_prep) of_26/IN (l_pobj) CNS_29/NNP (l_conj) cardiovascular_31/JJ (l_conj) depression_35/NN
D007650_D009127 NONE Ketanserin_0/JJ (r_compound) pretreatment_1/NN (r_nsubj) reverses_2/VBZ (l_dobj) rigidity_7/NN
D007650_D009127 NONE ketanserin_3/NN (r_pobj) with_2/IN (r_prep) pretreatment_1/NN (r_nsubj) attenuated_14/VBD (l_dobj) rigidity_17/NN
D007650_D009127 NONE ketanserin_9/JJ (r_dobj) received_8/VBD (r_relcl) animals_6/NNS (r_nsubj) followed_17/VBN (l_prep) Despite_0/IN (l_pobj) absence_2/NN (l_prep) of_3/IN (l_pobj) rigidity_4/NN
D012701_D012131 NONE serotonin_3/NN (r_compound) antagonists_4/NNS (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) be_6/VB (l_advcl) be_20/VB (l_xcomp) assess_23/VB (l_dobj) interaction_25/NN (l_prep) of_26/IN (l_pobj) CNS_29/NNP (l_conj) cardiovascular_31/JJ (l_conj) depression_35/NN
20304337
D003042_-1 NONE cocaine_8/NN (r_pobj) to_7/IN (r_prep) exposed_6/VBN (l_nsubj) dysgenesis_1/NN
16960342
D019259_D006509 NONE lamivudine_17/NN (r_amod) monotherapy_18/NN (r_pobj) with_16/IN (r_prep) treatment_15/NN (r_pobj) after_14/IN (r_prep) improvement_2/NN (l_prep) of_3/IN (l_pobj) patient_5/NN (l_prep) with_6/IN (l_pobj) cirrhosis_13/NN (l_amod) related_12/VBN (l_npadvmod) virus_10/NN (l_compound) B_9/NNP
D019259_D005355 NONE lamivudine_17/NN (r_amod) monotherapy_18/NN (r_pobj) with_16/IN (r_prep) treatment_15/NN (r_pobj) after_14/IN (r_prep) improvement_2/NN (l_prep) of_3/IN (l_pobj) patient_5/NN (l_prep) with_6/IN (l_pobj) cirrhosis_13/NN
D019259_D005355 NONE lamivudine_3/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (l_prep) to_4/IN (l_pobj) patients_5/NNS (l_prep) with_6/IN (l_pobj) cirrhosis_10/NN
8888541
D012701_D005334 NONE serotonin_3/NN (r_nmod) receptors_5/NNS (r_pobj) of_2/IN (r_prep) stimulation_1/NN (r_nsubj) causes_6/VBZ (l_dobj) syndrome_8/NN (l_prep) of_9/IN (l_pobj) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN (l_conj) salivation_20/NN (l_conj) confusion_22/NN (l_conj) agitation_24/NN (l_conj) hyperthermia_26/NN
D012701_D005334 NONE serotonin_10/NN (r_compound) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN (l_conj) salivation_20/NN (l_conj) confusion_22/NN (l_conj) agitation_24/NN (l_conj) hyperthermia_26/NN
D012701_D012798 NONE serotonin_3/NN (r_nmod) receptors_5/NNS (r_pobj) of_2/IN (r_prep) stimulation_1/NN (r_nsubj) causes_6/VBZ (l_dobj) syndrome_8/NN (l_prep) of_9/IN (l_pobj) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN (l_conj) salivation_20/NN
D012701_D012798 NONE serotonin_10/NN (r_compound) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN (l_conj) salivation_20/NN
D012701_D009127 NONE serotonin_3/NN (r_nmod) receptors_5/NNS (r_pobj) of_2/IN (r_prep) stimulation_1/NN (r_nsubj) causes_6/VBZ (l_dobj) syndrome_8/NN (l_prep) of_9/IN (l_pobj) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN
D012701_D009127 NONE serotonin_10/NN (r_compound) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN
C047426_D020230 CID venlafaxine_3/NNP (r_compound) tranylcypromine_5/NN (r_compound) interaction_6/NN (r_pobj) from_2/IN (r_prep) syndrome_1/NN
C047426_D020230 CID venlafaxine_3/NNP (r_compound) MAOI_5/NNP (r_compound) interaction_6/NN (l_relcl) resulted_8/VBD (l_prep) in_9/IN (l_pobj) syndrome_12/NN
C047426_D003866 NONE venlafaxine_3/NNP (r_compound) MAOI_5/NNP (r_compound) interaction_6/NN (l_relcl) resulted_8/VBD (l_prep) in_13/IN (l_pobj) male_18/NN (l_relcl) taking_21/VBG (l_dobj) tranylcypromine_22/NN (l_prep) for_23/IN (l_pobj) depression_24/NN
D003975_D009127 NONE diazepam_4/NN (r_pobj) of_3/IN (r_prep) mg_2/NN (r_pobj) After_0/IN (r_prep) remained_7/VBD (l_acomp) tremulous_8/JJ (l_prep) with_9/IN (l_pobj) rigidity_11/NN
D012701_D003221 NONE serotonin_3/NN (r_nmod) receptors_5/NNS (r_pobj) of_2/IN (r_prep) stimulation_1/NN (r_nsubj) causes_6/VBZ (l_dobj) syndrome_8/NN (l_prep) of_9/IN (l_pobj) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN (l_conj) salivation_20/NN (l_conj) confusion_22/NN
D012701_D003221 NONE serotonin_10/NN (r_compound) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN (l_conj) salivation_20/NN (l_conj) confusion_22/NN
D014191_D020230 CID tranylcypromine_5/NN (r_compound) interaction_6/NN (r_pobj) from_2/IN (r_prep) syndrome_1/NN
D014191_D020230 CID tranylcypromine_22/NN (r_dobj) taking_21/VBG (r_relcl) male_18/NN (r_pobj) in_13/IN (r_prep) resulted_8/VBD (l_prep) in_9/IN (l_pobj) syndrome_12/NN
D012701_D011595 NONE serotonin_3/NN (r_nmod) receptors_5/NNS (r_pobj) of_2/IN (r_prep) stimulation_1/NN (r_nsubj) causes_6/VBZ (l_dobj) syndrome_8/NN (l_prep) of_9/IN (l_pobj) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN (l_conj) salivation_20/NN (l_conj) confusion_22/NN (l_conj) agitation_24/NN
D012701_D011595 NONE serotonin_10/NN (r_compound) excess_11/NN (l_relcl) consists_13/VBZ (l_prep) of_14/IN (l_pcomp) shivering_15/VBG (l_conj) rigidity_18/NN (l_conj) salivation_20/NN (l_conj) confusion_22/NN (l_conj) agitation_24/NN
D014191_D003866 NONE tranylcypromine_22/NN (l_prep) for_23/IN (l_pobj) depression_24/NN
1504402
D007741_D004342 CID dilevalol_7/NN (r_npadvmod) associated_9/VBN (r_amod) hepatitis_10/NN (r_pobj) for_6/IN (r_prep) mechanism_5/NN (r_pobj) as_3/IN (r_prep) reaction_2/NN (l_nmod) Hypersensitivity_0/NN
D007741_D056486 CID dilevalol_7/NN (r_npadvmod) associated_9/VBN (r_amod) hepatitis_10/NN
D007741_D056486 CID dilevalol_7/VB (l_conj) serum_10/VB (l_prep) in_19/IN (l_pobj) case_21/NN (l_prep) of_22/IN (l_pobj) injury_27/NN
D007741_D056486 CID dilevalol_15/JJ (r_compound) antigens_16/NNS (r_dobj) containing_11/VBG (r_xcomp) serum_10/VB (l_prep) in_19/IN (l_pobj) case_21/NN (l_prep) of_22/IN (l_pobj) injury_27/NN
D007741_D056486 CID dilevalol_23/NN (r_npadvmod) induced_25/VBN (r_amod) injury_27/NN
D007741_D056486 CID dilevalol_10/NN (r_npadvmod) induced_12/VBN (r_amod) injury_14/NN
D007741_D056486 CID dilevalol_16/JJ (r_compound) antigens_17/NNS (r_dobj) containing_11/VBG (r_acl) sera_10/NN (r_pobj) to_9/IN (r_prep) sensitization_8/NN (r_pobj) of_6/IN (r_prep) detection_5/NN (r_dobj) allowed_3/VBD (l_advcl) suggesting_19/VBG (l_dobj) involvement_21/NN (l_prep) of_22/IN (l_pobj) mechanism_25/NN (l_prep) in_26/IN (l_pobj) injury_31/NN
D007741_D056486 CID dilevalol_27/NN (r_npadvmod) induced_29/VBN (r_amod) injury_31/NN
18161408
D002996_D013927 NONE CC_9/NN (r_pobj) of_8/IN (r_prep) complication_7/NN (r_attr) be_2/VB (l_nsubj) Thrombosis_0/NN
D002996_D013923 CID CC_17/NN (r_pobj) with_16/IN (r_prep) induction_15/NN (r_pobj) after_13/IN (r_prep) reported_12/VBN (r_relcl) complication_8/NN (r_attr) is_1/VBZ (l_nsubj) Thromboembolism_0/NN
D002996_D002637 NONE CC_12/NN (r_dobj) received_11/VBN (l_conj) presented_17/VBD (l_prep) with_18/IN (l_pobj) pain_20/NN
D002996_D009203 CID citrate_7/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) infarction_1/NN
D002996_D009203 CID CC_13/NN (l_conj) infarction_16/NN
1300436
D005665_D051437 NONE furosemide_9/NN (r_npadvmod) treated_11/VBN (r_amod) group_12/NN (r_pobj) in_7/IN (r_prep) loss_6/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (l_nsubjpass) failure_1/NN
D005665_D007674 NONE furosemide_4/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (l_prep) in_5/IN (l_pobj) nephropathy_7/NN
D005665_D007674 NONE furosemide_11/NN (r_pobj) of_10/IN (r_prep) efficacy_9/NN (r_dobj) determine_7/VB (l_prep) in_12/IN (l_pobj) addition_13/NN (l_prep) in_17/IN (l_pobj) prevention_19/NN (l_prep) of_20/IN (l_pobj) nephropathy_22/NN
D005665_D007674 NONE Furosemide_0/NNP (r_nsubj) be_2/VB (l_prep) in_4/IN (l_pobj) prevention_6/NN (l_prep) of_7/IN (l_pobj) nephropathy_9/NN
D005665_D015431 NONE furosemide_9/NN (r_npadvmod) treated_11/VBN (r_amod) group_12/NN (r_pobj) in_7/IN (r_prep) loss_6/NN
D003404_D058186 NONE creatinine_46/NN (r_pobj) in_44/IN (r_prep) rise_43/NN (r_pobj) with_41/IN (r_prep) deteriorated_26/VBD
D005665_D058186 CID furosemide_32/NN (r_pobj) with_31/IN (r_prep) pretreated_30/VBN (r_acl) group_29/NN (r_pobj) in_27/IN (r_prep) deteriorated_26/VBD
8012887
D006493_D013927 CID heparin_7/NN (r_npadvmod) induced_9/VBN (r_amod) thrombosis_11/NN
D006493_D013927 CID heparin_6/NN (r_npadvmod) induced_8/VBN (r_amod) thrombosis_9/NN
D006493_D013927 CID heparin_14/JJ (r_pobj) with_13/IN (r_prep) patients_12/NNS (r_pobj) in_11/IN (r_prep) used_3/VBN (l_prep) for_5/IN (l_pobj) prophylaxis_6/NN (l_prep) against_7/IN (l_pobj) development_8/NN (l_prep) of_9/IN (l_pobj) thrombosis_10/NN
D006493_D013927 CID heparin_14/JJ (r_pobj) with_13/IN (r_prep) patients_12/NNS (r_pobj) in_11/IN (r_prep) used_3/VBN (l_conj) defined_39/VBN (l_auxpass) is_36/VBZ (l_nsubj) success_27/NN (l_prep) in_28/IN (l_pobj) patients_29/NNS (l_relcl) developed_32/VBN (l_dobj) syndrome_35/NN (l_compound) thrombosis_34/NN
D006493_D013927 CID heparin_23/NN (r_pobj) to_22/IN (r_prep) reexposure_21/NN (r_dobj) require_19/VBP (r_relcl) aggregation_17/NN (r_dobj) induced_15/VBN (r_advcl) used_3/VBN (l_prep) for_5/IN (l_pobj) prophylaxis_6/NN (l_prep) against_7/IN (l_pobj) development_8/NN (l_prep) of_9/IN (l_pobj) thrombosis_10/NN
D006493_D013927 CID heparin_23/NN (r_pobj) to_22/IN (r_prep) reexposure_21/NN (r_dobj) require_19/VBP (r_relcl) aggregation_17/NN (r_dobj) induced_15/VBN (r_advcl) used_3/VBN (l_conj) defined_39/VBN (l_auxpass) is_36/VBZ (l_nsubj) success_27/NN (l_prep) in_28/IN (l_pobj) patients_29/NNS (l_relcl) developed_32/VBN (l_dobj) syndrome_35/NN (l_compound) thrombosis_34/NN
D006493_D013927 CID heparin_14/NN (r_npadvmod) induced_16/VBN (r_amod) thrombosis_17/NN
D006493_D001791 NONE heparin_14/JJ (r_pobj) with_13/IN (r_prep) patients_12/NNS (r_pobj) in_11/IN (r_prep) used_3/VBN (l_advcl) induced_15/VBN (l_dobj) aggregation_17/NN
D006493_D001791 NONE heparin_23/NN (r_pobj) to_22/IN (r_prep) reexposure_21/NN (r_dobj) require_19/VBP (r_relcl) aggregation_17/NN
8665051
D013256_D001284 NONE steroids_14/NNS (r_pobj) of_13/IN (r_prep) doses_12/NNS (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_nsubj) induced_15/VBD (r_ccomp) conclude_1/VBP (r_ccomp) induced_30/VBD (l_dobj) atrophy_34/NN
D013256_D001284 NONE steroids_29/NNS (r_pobj) of_28/IN (r_prep) types_27/NNS (r_nsubj) induced_30/VBD (l_dobj) atrophy_34/NN
D013256_D001284 NONE steroid_50/NN (r_nsubj) caused_51/VBD (l_ccomp) induced_30/VBD (l_dobj) atrophy_34/NN
D013256_D013746 NONE steroid_8/NN (r_compound) groups_9/NNS (r_pobj) in_6/IN (r_prep) prolonged_5/VBN (l_conj) was_16/VBD (l_advcl) were_24/VBD (l_nsubj) tensions_23/NNS (l_compound) tetanic_22/JJ
D008775_D013746 NONE M_19/NNP (r_pobj) with_18/IN (r_prep) was_16/VBD (l_advcl) were_24/VBD (l_nsubj) tensions_23/NNS (l_compound) tetanic_22/JJ
D014221_D000855 CID triamcinolone_24/NN (r_conj) methylprednisolone_18/NN (r_appos) C_15/NNP (r_pobj) of_12/IN (r_prep) injection_11/NN (r_dobj) receive_9/VB (r_xcomp) assigned_7/VBN (l_conj) showed_46/VBD (l_dobj) reduction_49/NN (l_prep) of_50/IN (l_pobj) intake_52/NN
D014221_D000855 CID T_26/NNP (r_appos) triamcinolone_24/NN (r_conj) methylprednisolone_18/NN (r_appos) C_15/NNP (r_pobj) of_12/IN (r_prep) injection_11/NN (r_dobj) receive_9/VB (r_xcomp) assigned_7/VBN (l_conj) showed_46/VBD (l_dobj) reduction_49/NN (l_prep) of_50/IN (l_pobj) intake_52/NN
D014221_D000855 CID T_67/NNP (r_conj) M_65/NNP (r_pobj) in_64/IN (r_prep) %_63/NN (r_appos) groups_58/NNS (r_pobj) in_53/IN (r_prep) reduction_49/NN (l_prep) of_50/IN (l_pobj) intake_52/NN
D000305_D009135 NONE corticosteroids_17/NNS (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_pobj) with_13/IN (r_prep) treated_12/VBN (r_acl) patients_11/NNS (r_pobj) in_10/IN (r_prep) occur_9/VB (l_nsubj) myopathy_7/NN
D014221_D009336 NONE T_27/NNP (r_pobj) with_26/IN (r_prep) atrophy_25/NN (r_conj) atrophy_15/NN (r_dobj) showed_11/VBD (l_advcl) revealed_32/VBD (l_dobj) pattern_36/NN (l_prep) with_37/IN (l_pobj) absence_38/NN (l_prep) of_39/IN (l_pobj) necrosis_40/NN
D013256_D000855 NONE steroid_55/NN (r_npadvmod) treated_57/VBN (r_amod) groups_58/NNS (r_pobj) in_53/IN (r_prep) reduction_49/NN (l_prep) of_50/IN (l_pobj) intake_52/NN
D013256_D009336 NONE steroid_18/NN (r_compound) groups_19/NNS (r_pobj) in_16/IN (r_prep) atrophy_15/NN (r_dobj) showed_11/VBD (l_advcl) revealed_32/VBD (l_dobj) pattern_36/NN (l_prep) with_37/IN (l_pobj) absence_38/NN (l_prep) of_39/IN (l_pobj) necrosis_40/NN
D013256_D009336 NONE steroids_14/NNS (r_pobj) of_13/IN (r_prep) doses_12/NNS (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_nsubj) induced_15/VBD (r_ccomp) conclude_1/VBP (r_ccomp) induced_30/VBD (r_ccomp) caused_51/VBD (l_dobj) necrosis_53/NN
D013256_D009336 NONE steroids_29/NNS (r_pobj) of_28/IN (r_prep) types_27/NNS (r_nsubj) induced_30/VBD (r_ccomp) caused_51/VBD (l_dobj) necrosis_53/NN
D013256_D009336 NONE steroid_50/NN (r_nsubj) caused_51/VBD (l_dobj) necrosis_53/NN
D008775_D000855 CID methylprednisolone_18/NN (r_appos) C_15/NNP (r_pobj) of_12/IN (r_prep) injection_11/NN (r_dobj) receive_9/VB (r_xcomp) assigned_7/VBN (l_conj) showed_46/VBD (l_dobj) reduction_49/NN (l_prep) of_50/IN (l_pobj) intake_52/NN
D008775_D000855 CID M_20/NNP (r_appos) methylprednisolone_18/NN (r_appos) C_15/NNP (r_pobj) of_12/IN (r_prep) injection_11/NN (r_dobj) receive_9/VB (r_xcomp) assigned_7/VBN (l_conj) showed_46/VBD (l_dobj) reduction_49/NN (l_prep) of_50/IN (l_pobj) intake_52/NN
D008775_D000855 CID M_65/NNP (r_pobj) in_64/IN (r_prep) %_63/NN (r_appos) groups_58/NNS (r_pobj) in_53/IN (r_prep) reduction_49/NN (l_prep) of_50/IN (l_pobj) intake_52/NN
D013256_D009133 NONE steroid_18/NN (r_compound) groups_19/NNS (r_pobj) in_16/IN (r_prep) atrophy_15/NN
D013256_D009133 NONE steroid_18/NN (r_compound) groups_19/NNS (r_pobj) in_16/IN (r_prep) atrophy_15/NN (l_conj) atrophy_25/NN
D013256_D009133 NONE steroids_14/NNS (r_pobj) of_13/IN (r_prep) doses_12/NNS (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_nsubj) induced_15/VBD (r_ccomp) conclude_1/VBP (r_ccomp) induced_30/VBD (r_ccomp) caused_51/VBD (r_ccomp) caused_63/VBN (l_nsubjpass) atrophy_60/NN
D013256_D009133 NONE steroids_29/NNS (r_pobj) of_28/IN (r_prep) types_27/NNS (r_nsubj) induced_30/VBD (r_ccomp) caused_51/VBD (r_ccomp) caused_63/VBN (l_nsubjpass) atrophy_60/NN
D013256_D009133 NONE steroid_50/NN (r_nsubj) caused_51/VBD (r_ccomp) caused_63/VBN (l_nsubjpass) atrophy_60/NN
D014221_D009133 CID T_27/NNP (r_pobj) with_26/IN (r_prep) atrophy_25/NN (r_conj) atrophy_15/NN
D014221_D009133 CID T_27/NNP (r_pobj) with_26/IN (r_prep) atrophy_25/NN
D014221_D009133 CID T_18/NNP (r_conj) C_16/NNP (r_appos) rats_14/NNS (r_pobj) in_12/IN (r_prep) performed_11/VBN (r_acl) study_9/NN (r_nsubj) showed_24/VBD (l_ccomp) was_28/VBD (l_nsubj) atrophy_27/NN
D014221_D009133 CID T_37/NNP (r_npadvmod) treated_39/VBN (r_amod) animals_40/NNS (r_pobj) in_36/IN (r_prep) than_35/IN (r_prep) pronounced_31/VBN (r_acomp) was_28/VBD (l_nsubj) atrophy_27/NN
18589141
D006493_D013927 NONE sodium_2/NN (r_nsubjpass) used_16/VBN (l_xcomp) prevent_24/VB (l_dobj) thrombosis_25/NN
D006493_D013927 NONE UFH_4/NNP (r_appos) sodium_2/NN (r_nsubjpass) used_16/VBN (l_xcomp) prevent_24/VB (l_dobj) thrombosis_25/NN
D006495_D013927 NONE heparin_11/NN (r_conj) sodium_2/NN (r_nsubjpass) used_16/VBN (l_xcomp) prevent_24/VB (l_dobj) thrombosis_25/NN
D006493_D013921 CID Heparin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN
D006493_D013921 CID Heparin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN
D006493_D013921 CID Heparin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN (l_appos) HIT_5/NNP
D006493_D013921 CID heparin_15/NN (r_pobj) to_14/IN (r_prep) reaction_13/NN (r_attr) is_7/VBZ (l_nsubj) thrombocytopenia_3/NN
D006493_D013921 CID heparin_15/NN (r_pobj) to_14/IN (r_prep) reaction_13/NN (r_attr) is_7/VBZ (l_nsubj) thrombocytopenia_3/NN (l_appos) HIT_5/NNP
D006493_D013921 CID 4/heparin_10/NN (r_nummod) reactive_12/JJ (r_amod) antibody_13/NN (r_nmod) positivity_18/NN (r_conj) frequencies_1/NNS (l_prep) of_2/IN (l_pobj) HIT_3/NN
D006493_D013921 CID 4/heparin_10/NN (r_nummod) reactive_12/JJ (r_amod) antibody_13/NN (r_nmod) positivity_18/NN (l_nmod) antibody_16/NN (l_nmod) HIT_15/NNP
D006493_D013921 CID UFH_7/NN (r_npadvmod) related_9/VBN (r_amod) HIT_10/NN
D006493_D001791 NONE heparin_1/NN (r_npadvmod) induced_3/VBN (r_amod) test_6/NN (l_compound) aggregation_5/NN
6732043
D000728_D020181 CID androgen_12/JJ (r_compound) administration_13/NN (r_pobj) by_10/IN (r_prep) woman_9/NN (r_pobj) in_7/IN (r_prep) syndrome_6/NN
D000728_D020181 CID androgens_36/NNS (r_dobj) administered_34/VBN (r_advcl) developed_22/VBN (l_dobj) changes_24/NNS (l_conj) syndrome_27/NN (l_prep) of_28/IN (l_pobj) apnea_31/NN
D000728_D020181 CID androgen_3/NN (r_nmod) symptoms_5/NNS (l_prep) of_6/IN (l_pobj) apnea_9/NN
D000728_D020181 CID androgen_15/NN (r_compound) therapy_16/NN (r_pobj) of_14/IN (r_prep) effect_13/NN (r_oprd) considered_9/VBN (l_nsubjpass) Development_0/NN (l_prep) of_1/IN (l_pobj) syndrome_6/NN
D000728_D012891 NONE androgens_7/NNS (r_pobj) of_6/IN (r_prep) role_5/NN (r_dobj) favored_3/VBN (l_prep) in_8/IN (l_pobj) pathogenesis_10/NN (l_prep) of_11/IN (l_pobj) apnea_13/NN
2257294
D015215_D007153 NONE azidothymidine_2/RB (r_advmod) induced_4/VBN (r_amod) suppression_6/NN (r_dobj) reverses_1/VBZ (l_prep) without_7/IN (l_pobj) impairment_8/NN (l_prep) of_9/IN (l_pobj) activity_15/NN (l_compound) virus_14/NN (l_compound) immunodeficiency_13/NN
D015215_D007153 NONE azidothymidine_17/NN (r_advmod) vitro_15/FW (r_amod) in_14/IN (r_prep) reduce_12/VB (l_dobj) inhibition_20/NN (l_prep) without_28/IN (l_pobj) impairment_29/NN (l_prep) of_30/IN (l_pobj) virus_34/NN (l_compound) immunodeficiency_33/NN
D015215_D007153 NONE AZT)-induced_19/JJ (r_compound) inhibition_20/NN (l_prep) without_28/IN (l_pobj) impairment_29/NN (l_prep) of_30/IN (l_pobj) virus_34/NN (l_compound) immunodeficiency_33/NN
D014529_D000740 NONE Urd_8/NNP (r_compound) administration_9/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) toxicities_4/NNS (r_pobj) Because_0/IN (r_prep) assessed_31/VBN (l_nsubjpass) anemia_27/NN
C034753_D007153 NONE Benzylacyclouridine_0/NN (r_nsubj) reverses_1/VBZ (l_prep) without_7/IN (l_pobj) impairment_8/NN (l_prep) of_9/IN (l_pobj) activity_15/NN (l_compound) virus_14/NN (l_compound) immunodeficiency_13/NN
D015215_D064420 NONE AZT_24/NNP (r_npadvmod) induced_26/VBN (r_amod) anemia_27/NN (r_nsubjpass) assessed_31/VBN (l_prep) Because_0/IN (l_pobj) toxicities_4/NNS
D014529_D064420 NONE Urd_8/NNP (r_compound) administration_9/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) toxicities_4/NNS
D014529_D064420 NONE Urd_3/NNP (r_compound) catabolism_4/NN (r_dobj) inhibits_2/VBZ (l_conj) increases_10/VBZ (l_prep) without_23/IN (l_pobj) toxicity_27/NN
D014529_D064420 NONE Urd_15/NNP (r_pobj) of_14/IN (r_prep) concentration_13/NN (r_dobj) increases_10/VBZ (l_prep) without_23/IN (l_pobj) toxicity_27/NN
D014529_D064420 NONE Urd_24/NNP (r_npadvmod) related_26/VBN (r_amod) toxicity_27/NN
D015215_-1 NONE AZT_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_pobj) by_6/IN (r_prep) leukopenic_5/JJ (r_conj) rendered_2/VBD (r_acl) mice_1/NNS (r_pobj) In_0/IN (r_prep) reversed_39/VBD (l_conj) increased_67/VBN (l_conj) improved_74/VBN (l_dobj) megaloblastosis_75/NN
D015215_-1 NONE AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_conj) increased_67/VBN (l_conj) improved_74/VBN (l_dobj) megaloblastosis_75/NN
D015215_-1 NONE AZT_40/NNP (r_npadvmod) induced_42/VBN (r_amod) anemia_43/NN (r_dobj) reversed_39/VBD (l_conj) increased_67/VBN (l_conj) improved_74/VBN (l_dobj) megaloblastosis_75/NN
D015215_D007970 CID AZT_24/NNP (r_npadvmod) induced_26/VBN (r_amod) anemia_27/NN (l_conj) leukopenia_29/NN
D015215_D007970 CID AZT_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_pobj) by_6/IN (r_prep) leukopenic_5/JJ
D015215_D007970 CID AZT_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_pobj) by_6/IN (r_prep) leukopenic_5/JJ (r_conj) rendered_2/VBD (r_acl) mice_1/NNS (r_pobj) In_0/IN (r_prep) reversed_39/VBD (l_dobj) anemia_43/NN (l_conj) leukopenia_45/NN
D015215_D007970 CID AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_prep) In_0/IN (l_pobj) mice_1/NNS (l_acl) rendered_2/VBD (l_conj) leukopenic_5/JJ
D015215_D007970 CID AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_dobj) anemia_43/NN (l_conj) leukopenia_45/NN
D015215_D007970 CID AZT_40/NNP (r_npadvmod) induced_42/VBN (r_amod) anemia_43/NN (r_dobj) reversed_39/VBD (l_prep) In_0/IN (l_pobj) mice_1/NNS (l_acl) rendered_2/VBD (l_conj) leukopenic_5/JJ
D015215_D007970 CID AZT_40/NNP (r_npadvmod) induced_42/VBN (r_amod) anemia_43/NN (l_conj) leukopenia_45/NN
C034753_D000740 NONE benzylacyclouridine_14/NN (r_pobj) of_13/IN (r_prep) ability_12/NN (r_nsubjpass) assessed_31/VBN (l_nsubjpass) anemia_27/NN
C034753_D000740 NONE BAU_16/NNP (r_appos) benzylacyclouridine_14/NN (r_pobj) of_13/IN (r_prep) ability_12/NN (r_nsubjpass) assessed_31/VBN (l_nsubjpass) anemia_27/NN
C034753_D000740 NONE BAU_31/NNP (r_conj) AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_prep) In_0/IN (l_pobj) mice_1/NNS (l_acl) rendered_2/VBD (l_oprd) anemic_3/JJ
C034753_D000740 NONE BAU_31/NNP (r_conj) AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_dobj) anemia_43/NN
C034753_D007970 NONE benzylacyclouridine_14/NN (r_pobj) of_13/IN (r_prep) ability_12/NN (r_nsubjpass) assessed_31/VBN (l_nsubjpass) anemia_27/NN (l_conj) leukopenia_29/NN
C034753_D007970 NONE BAU_16/NNP (r_appos) benzylacyclouridine_14/NN (r_pobj) of_13/IN (r_prep) ability_12/NN (r_nsubjpass) assessed_31/VBN (l_nsubjpass) anemia_27/NN (l_conj) leukopenia_29/NN
C034753_D007970 NONE BAU_31/NNP (r_conj) AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_prep) In_0/IN (l_pobj) mice_1/NNS (l_acl) rendered_2/VBD (l_conj) leukopenic_5/JJ
C034753_D007970 NONE BAU_31/NNP (r_conj) AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_dobj) anemia_43/NN (l_conj) leukopenia_45/NN
D014529_D007153 NONE uridine_4/NN (r_pobj) of_3/IN (r_prep) concentrations_2/NNS (r_nsubjpass) reported_10/VBN (l_xcomp) reduce_12/VB (l_dobj) inhibition_20/NN (l_prep) without_28/IN (l_pobj) impairment_29/NN (l_prep) of_30/IN (l_pobj) virus_34/NN (l_compound) immunodeficiency_33/NN
D014529_D007153 NONE Urd_6/NNP (r_appos) uridine_4/NN (r_pobj) of_3/IN (r_prep) concentrations_2/NNS (r_nsubjpass) reported_10/VBN (l_xcomp) reduce_12/VB (l_dobj) inhibition_20/NN (l_prep) without_28/IN (l_pobj) impairment_29/NN (l_prep) of_30/IN (l_pobj) virus_34/NN (l_compound) immunodeficiency_33/NN
C034753_D001855 NONE Benzylacyclouridine_0/NN (r_nsubj) reverses_1/VBZ (l_dobj) suppression_6/NN
C034753_D001855 NONE BAU_11/NNP (r_nsubj) reduced_12/VBD (l_dobj) toxicity_17/NN
D015215_D001855 CID azidothymidine_2/RB (r_advmod) induced_4/VBN (r_amod) suppression_6/NN
D015215_D001855 CID AZT_3/NNP (r_pobj) with_2/IN (r_prep) coadministered_1/VBN (r_advcl) reduced_12/VBD (l_dobj) toxicity_17/NN
D015215_D001855 CID AZT_13/NNP (r_npadvmod) induced_15/VBN (r_amod) toxicity_17/NN
C034753_D064420 NONE benzylacyclouridine_14/NN (r_pobj) of_13/IN (r_prep) ability_12/NN (r_nsubjpass) assessed_31/VBN (l_prep) Because_0/IN (l_pobj) toxicities_4/NNS
C034753_D064420 NONE BAU_16/NNP (r_appos) benzylacyclouridine_14/NN (r_pobj) of_13/IN (r_prep) ability_12/NN (r_nsubjpass) assessed_31/VBN (l_prep) Because_0/IN (l_pobj) toxicities_4/NNS
D014529_D007970 NONE Urd_8/NNP (r_compound) administration_9/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) toxicities_4/NNS (r_pobj) Because_0/IN (r_prep) assessed_31/VBN (l_nsubjpass) anemia_27/NN (l_conj) leukopenia_29/NN
C034753_-1 NONE BAU_31/NNP (r_conj) AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_conj) increased_67/VBN (l_conj) improved_74/VBN (l_dobj) megaloblastosis_75/NN
D015215_D000740 CID AZT_24/NNP (r_npadvmod) induced_26/VBN (r_amod) anemia_27/NN
D015215_D000740 CID AZT_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_pobj) by_6/IN (r_prep) leukopenic_5/JJ (r_conj) rendered_2/VBD (l_oprd) anemic_3/JJ
D015215_D000740 CID AZT_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_pobj) by_6/IN (r_prep) leukopenic_5/JJ (r_conj) rendered_2/VBD (r_acl) mice_1/NNS (r_pobj) In_0/IN (r_prep) reversed_39/VBD (l_dobj) anemia_43/NN
D015215_D000740 CID AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_prep) In_0/IN (l_pobj) mice_1/NNS (l_acl) rendered_2/VBD (l_oprd) anemic_3/JJ
D015215_D000740 CID AZT_28/NNP (r_pobj) of_27/IN (r_prep) administration_26/NN (r_nsubj) reversed_39/VBD (l_dobj) anemia_43/NN
D015215_D000740 CID AZT_40/NNP (r_npadvmod) induced_42/VBN (r_amod) anemia_43/NN (r_dobj) reversed_39/VBD (l_prep) In_0/IN (l_pobj) mice_1/NNS (l_acl) rendered_2/VBD (l_oprd) anemic_3/JJ
D015215_D000740 CID AZT_40/NNP (r_npadvmod) induced_42/VBN (r_amod) anemia_43/NN
8800187
D002122_D002318 NONE CaCl2_0/NNP (r_compound) therapy_1/NN (r_nsubj) worsen_4/VB (l_dobj) toxicity_11/NN
D002122_D001145 CID CaCl2_19/NNP (r_compound) group_20/NN (r_pobj) in_17/IN (r_prep) seizures_11/NNS (r_conj) arrhythmias_4/NNS
D002122_D064420 NONE chloride_3/NN (l_conj) therapy_6/NN (l_prep) on_7/IN (l_pobj) toxicity_9/NN
D003891_D007022 CID desipramine_6/NN (r_compound) IP_7/NNP (r_dobj) received_2/VBD (l_advcl) produce_9/VB (l_dobj) hypotension_10/NN
D002122_D012640 NONE CaCl2_19/NNP (r_compound) group_20/NN (r_pobj) in_17/IN (r_prep) seizures_11/NNS
D002122_D002493 NONE CaCl2_0/NNP (r_compound) therapy_1/NN (r_nsubj) worsen_4/VB (l_dobj) toxicity_11/NN
D003891_D001919 CID desipramine_6/NN (r_compound) IP_7/NNP (r_dobj) received_2/VBD (l_advcl) produce_9/VB (l_dobj) prolongation_13/NN (l_conj) bradycardia_16/NN
D002118_D007022 NONE calcium_7/NN (r_compound) channel_8/NN (r_compound) blockade_9/NN (l_prep) in_10/IN (l_pobj) hypotension_15/NN
D002118_D007022 NONE calcium_8/NN (r_compound) channel_9/NN (r_compound) inhibition_10/NN (l_prep) in_11/IN (l_pobj) pathogenesis_13/NN (l_prep) of_14/IN (l_pobj) hypotension_19/NN
D015761_D007022 NONE 4-aminopyridine_5/NN (r_punct) did_6/VBD (r_aux) reverse_8/VB (l_dobj) hypotension_13/NN
D002122_D007022 NONE CaCl2_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) reverse_8/VB (l_dobj) hypotension_13/NN
D002118_D062787 NONE calcium_14/NN (r_compound) channel_15/NN (r_compound) overdose_17/NN
D017693_D007022 NONE NaHCO3_0/NNP (r_nsubj) reversed_6/VBD (l_dobj) hypotension_7/NN
D003891_D064420 NONE desipramine_8/JJ (r_amod) toxicity_9/NN
D015761_D064420 NONE 4-aminopyridine_5/CD (r_compound) therapy_6/NN (l_prep) on_7/IN (l_pobj) toxicity_9/NN
19996135
D014148_D012640 CID Acid_4/NNP (r_nsubjpass) associated_6/VBN (l_prep) with_7/IN (l_pobj) seizures_10/NNS
D014148_D012640 CID TXA_19/NNP (r_compound) usage_20/NN (l_conj) seizures_22/NNS
D014148_D012640 CID TXA_9/NNP (r_compound) intraoperatively_10/NN (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_dobj) received_5/VBD (l_nsubj) patients_2/NNS (l_prep) with_3/IN (l_pobj) seizures_4/NNS
D014148_D012640 CID TXA_9/NN (r_pobj) of_5/IN (r_prep) use_4/NN (r_nsubjpass) associated_25/VBN (l_prep) with_26/IN (l_pobj) seizures_28/NNS
15517007
D003520_D012595 NONE cyclophosphamide_6/NN (r_nsubjpass) used_13/VBN (l_dobj) patients_28/NNS (l_compound) sclerosis_27/NN
D018943_D012595 NONE anthracyclines_8/NNS (r_conj) cyclophosphamide_6/NN (r_nsubjpass) used_13/VBN (l_dobj) patients_28/NNS (l_compound) sclerosis_27/NN
D018943_D006331 NONE anthracyclines_8/NNS (r_conj) cyclophosphamide_6/NN (r_nsubjpass) used_13/VBN (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) damage_21/NN
D003520_D006331 CID cyclophosphamide_6/NN (r_nsubjpass) used_13/VBN (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) damage_21/NN
D008942_D012595 NONE mitoxantrone_11/NN (r_pobj) as_10/IN (r_prep) anthracyclines_8/NNS (r_conj) cyclophosphamide_6/NN (r_nsubjpass) used_13/VBN (l_dobj) patients_28/NNS (l_compound) sclerosis_27/NN
D008942_D006331 CID mitoxantrone_11/NN (r_pobj) as_10/IN (r_prep) anthracyclines_8/NNS (r_conj) cyclophosphamide_6/NN (r_nsubjpass) used_13/VBN (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) damage_21/NN
19105845
D016642_D012640 CID hydrochloride_8/NN (r_npadvmod) induced_10/VBN (r_amod) seizures_11/NNS
D016642_D012640 CID bupropion_15/NN (r_npadvmod) induced_17/VBN (r_amod) seizures_18/NNS
D016642_D012640 CID HCl_12/NNP (r_pobj) of_10/IN (r_prep) rates_9/NNS (r_dobj) varying_5/VBG (r_pcomp) of_4/IN (r_prep) effect_3/NN (l_appos) CD50_22/NNP (l_amod) convulsive_18/JJ
D016642_D012640 CID HCl_12/NNP (r_pobj) of_10/IN (r_prep) rates_9/NNS (r_dobj) varying_5/VBG (r_pcomp) of_4/IN (r_prep) effect_3/NN (r_dobj) investigated_1/VBD (l_prep) on_25/IN (l_pobj) incidence_27/NN (l_prep) of_30/IN (l_pobj) convulsions_34/NNS
D016642_D012640 CID bupropion_31/NN (r_npadvmod) induced_33/VBN (r_amod) convulsions_34/NNS (r_pobj) of_30/IN (r_prep) incidence_27/NN (r_pobj) on_25/IN (r_prep) investigated_1/VBD (l_dobj) effect_3/NN (l_appos) CD50_22/NNP (l_amod) convulsive_18/JJ
D016642_D012640 CID bupropion_31/NN (r_npadvmod) induced_33/VBN (r_amod) convulsions_34/NNS
D016642_D012640 CID HCl_9/NNP (r_ccomp) showed_3/VBD (l_advcl) induced_15/VBD (l_dobj) convulsions_16/NNS
D016642_D012640 CID HCl_27/NNP (r_pobj) of_25/IN (r_prep) time_24/NN (r_dobj) increasing_20/VBG (r_conj) ratio_15/NN (r_nsubjpass) associated_31/VBN (l_prep) with_32/IN (l_pobj) odds_37/NNS (l_prep) of_38/IN (l_pobj) convulsions_39/NNS
D016642_D012640 CID bupropion_19/NN (r_pobj) of_18/IN (r_prep) dose_17/NN (l_amod) fixed_14/JJ (l_conj) convulsive_16/JJ
D016642_D012640 CID bupropion_19/NN (r_pobj) of_18/IN (r_prep) dose_17/NN (l_conj) risk_22/NN (l_prep) of_23/IN (l_pobj) convulsions_24/NNS
16418614
D011441_D006111 NONE PTU_0/NNP (r_npadvmod) associated_2/VBN (r_amod) vasculitis_3/NN (l_prep) in_4/IN (l_pobj) girl_6/NN (l_prep) with_7/IN (l_pobj) Syndrome_9/NNP (l_conj) disease_13/NN
D011441_D014657 CID PTU_0/NNP (r_npadvmod) associated_2/VBN (r_amod) vasculitis_3/NN
D011441_D014657 CID propylthiouracil_3/NN (r_pobj) of_2/IN (r_prep) diagnosis_1/NN (r_nsubjpass) made_8/VBN (l_nsubjpass) vasculitis_6/NN
D011441_D014657 CID PTU)-associated_5/VBN (r_amod) vasculitis_6/NN
D011441_D014657 CID PTU_37/NNP (r_pobj) of_36/IN (r_prep) withdrawal_35/NN (r_dobj) following_34/VBG (r_acl) resolution_31/NN (r_conj) detection_17/NN (r_appos) made_8/VBN (l_nsubjpass) vasculitis_6/NN
D011441_D014424 NONE PTU_0/NNP (r_npadvmod) associated_2/VBN (r_amod) vasculitis_3/NN (l_prep) in_4/IN (l_pobj) girl_6/NN (l_prep) with_7/IN (l_pobj) Syndrome_9/NNP
11022397
D014331_D008569 NONE tropicamide_8/NN (r_pobj) of_7/IN (r_prep) administration_6/NN (r_pobj) after_5/IN (r_prep) size_1/NN (r_ccomp) impairment_15/NN (l_prep) in_16/IN (l_pobj) recall_18/NN
D010862_D008569 NONE pilocarpine_10/NN (r_conj) tropicamide_8/NN (r_pobj) of_7/IN (r_prep) administration_6/NN (r_pobj) after_5/IN (r_prep) size_1/NN (r_ccomp) impairment_15/NN (l_prep) in_16/IN (l_pobj) recall_18/NN
D012601_D008569 CID scopolamine_12/NN (r_npadvmod) induced_14/VBN (r_amod) impairment_15/NN (l_prep) in_16/IN (l_pobj) recall_18/NN
D012601_D008569 CID scopolamine_11/NN (r_npadvmod) induced_13/VBN (r_amod) impairment_14/NN (r_dobj) had_9/VBD (l_dobj) recall_17/NN
6415512
D002220_D004832 CID carbamazepine_10/NN (r_compound) therapy_11/NN (r_pobj) of_9/IN (r_prep) institution_8/NN (r_dobj) following_7/VBG (r_prep) seizures_6/NNS
D002220_D004832 CID carbamazepine_11/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_conj) had_15/VBD (l_dobj) reaction_19/NN (l_acl) characterized_20/VBN (l_agent) by_21/IN (l_pobj) onset_23/NN (l_prep) of_24/IN (l_pobj) absence_28/NN (l_conj) seizures_35/NNS
D002220_D012640 NONE carbamazepine_2/NN (r_nsubjpass) discontinued_4/VBN (r_advcl) returned_10/VBD (r_ccomp) had_19/VBD (l_ccomp) resolve_24/VBP (l_nsubj) seizures_23/NNS
D002220_D012640 NONE carbamazepine_2/NN (r_nsubjpass) discontinued_4/VBN (r_advcl) returned_10/VBD (r_ccomp) had_19/VBD (l_conj) had_33/VBD (l_ccomp) persist_36/VB (l_nsubj) seizures_35/NNS
D002220_D004831 CID carbamazepine_10/NN (r_compound) therapy_11/NN (r_pobj) of_9/IN (r_prep) institution_8/NN (r_dobj) following_7/VBG (r_prep) seizures_6/NNS
D002220_D004831 CID carbamazepine_11/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_conj) had_15/VBD (l_dobj) reaction_19/NN (l_acl) characterized_20/VBN (l_agent) by_21/IN (l_pobj) onset_23/NN (l_prep) of_24/IN (l_pobj) absence_28/NN (l_conj) seizures_35/NNS
D002220_D004827 NONE carbamazepine_11/NN (l_prep) for_12/IN (l_pobj) epilepsy_13/NN
1079693
D002738_D012164 NONE chloroquine_2/NN (r_xcomp) used_1/VBD (l_conj) found_11/VBD (l_dobj) case_14/NN (l_prep) of_15/IN (l_pobj) chorioretinopathy_16/JJ
D000305_D002386 NONE corticosteroids_2/NNS (r_dobj) administered_1/VBN (r_csubjpass) used_4/VBN (r_ccomp) found_19/VBN (l_nsubjpass) number_13/NN (l_prep) of_14/IN (l_pobj) cataracts_17/NNS
D006886_D012164 CID hydroxychloroquine_4/NN (r_conj) chloroquine_2/NN (r_xcomp) used_1/VBD (l_conj) found_11/VBD (l_dobj) case_14/NN (l_prep) of_15/IN (l_pobj) chorioretinopathy_16/JJ
D000305_D014605 NONE corticosteroids_27/NNS (r_pobj) with_26/IN (r_prep) treatment_25/NN (r_pobj) of_22/IN (r_prep) months_21/NNS (r_pobj) to_17/IN (r_prep) respond_16/VB (l_nsubj) %_9/NN (l_prep) of_10/IN (l_pobj) cases_11/NNS (l_prep) of_12/IN (l_pobj) uveitis_13/NN
9549528
D007980_D006948 NONE dopa_17/NN (r_npadvmod) induced_19/VBN (r_amod) dyskinesia_22/NN (r_pobj) like_14/IN (r_prep) movement_12/NN (l_amod) hyperkinetic_9/JJ
D007980_D020734 NONE dopa_9/NN (r_npadvmod) induced_11/VBN (r_amod) dyskinesia_15/NN (r_pobj) with_6/IN (r_prep) patients_5/NNS (l_amod) parkinsonian_4/JJ
D007980_D020734 NONE dopa_42/NN (r_compound) medication_43/NN (r_pobj) on_39/IN (r_prep) patients_38/NNS (l_amod) parkinsonian_37/JJ
D007980_D020734 NONE dopa_51/NN (r_pobj) without_48/IN (r_prep) one_47/NN (r_nsubj) induced_52/VBD (r_conj) studied_2/VBN (l_dobj) flow_7/NN (l_conj) changes_11/NNS (l_acl) induced_12/VBN (l_agent) by_13/IN (l_pobj) execution_15/NN (l_prep) in_26/IN (l_pobj) cortex_32/NN (l_prep) of_33/IN (l_pobj) groups_35/NNS (l_prep) of_36/IN (l_pobj) patients_38/NNS (l_amod) parkinsonian_37/JJ
D007980_D004409 CID dopa_9/NN (r_npadvmod) induced_11/VBN (r_amod) dyskinesia_15/NN
D007980_D004409 CID dopa_42/NN (r_compound) medication_43/NN (r_pobj) on_39/IN (r_prep) patients_38/NNS (r_pobj) of_36/IN (r_prep) groups_35/NNS (r_pobj) of_33/IN (r_prep) cortex_32/NN (r_pobj) in_26/IN (r_prep) execution_15/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) changes_11/NNS (r_conj) flow_7/NN (r_dobj) studied_2/VBN (l_conj) induced_52/VBD (l_dobj) dyskinesia_53/NN
D007980_D004409 CID dopa_42/NN (r_compound) medication_43/NN (r_pobj) on_39/IN (r_prep) patients_38/NNS (r_pobj) of_36/IN (r_prep) groups_35/NNS (r_pobj) of_33/IN (r_prep) cortex_32/NN (r_pobj) in_26/IN (r_prep) execution_15/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) changes_11/NNS (r_conj) flow_7/NN (r_dobj) studied_2/VBN (l_conj) induced_52/VBD (l_dobj) dyskinesia_53/NN (l_conj) other_61/JJ (l_prep) with_62/IN (l_pobj) dyskinesia_67/NN
D007980_D004409 CID dopa_51/NN (r_pobj) without_48/IN (r_prep) one_47/NN (r_nsubj) induced_52/VBD (l_dobj) dyskinesia_53/NN
D007980_D004409 CID dopa_51/NN (r_pobj) without_48/IN (r_prep) one_47/NN (r_nsubj) induced_52/VBD (l_dobj) dyskinesia_53/NN (l_conj) other_61/JJ (l_prep) with_62/IN (l_pobj) dyskinesia_67/NN
D007980_D004409 CID dopa_17/NN (r_npadvmod) induced_19/VBN (r_amod) dyskinesia_22/NN (r_pobj) like_14/IN (r_prep) movement_12/NN
D007980_D004409 CID dopa_17/NN (r_npadvmod) induced_19/VBN (r_amod) dyskinesia_22/NN
12851669
D017373_D054556 NONE acetate_12/NN (r_pobj) on_9/IN (r_prep) women_8/NNS (r_pobj) in_7/IN (r_prep) thromboembolism_6/NN
D017373_D054556 NONE acetate_15/NN (r_pobj) on_13/IN (r_prep) women_12/NNS (r_pobj) among_11/IN (r_prep) thromboembolism_7/NN
D017373_D054556 NONE acetate_15/NN (r_pobj) on_13/IN (r_prep) women_12/NNS (r_pobj) among_11/IN (r_prep) thromboembolism_7/NN (l_appos) VTE_9/NNP
D017373_D054556 NONE CPA_19/NNP (r_nmod) EE_21/NNP (r_appos) ethinylestradiol_17/NN (r_conj) acetate_15/NN (r_pobj) on_13/IN (r_prep) women_12/NNS (r_pobj) among_11/IN (r_prep) thromboembolism_7/NN
D017373_D054556 NONE CPA_19/NNP (r_nmod) EE_21/NNP (r_appos) ethinylestradiol_17/NN (r_conj) acetate_15/NN (r_pobj) on_13/IN (r_prep) women_12/NNS (r_pobj) among_11/IN (r_prep) thromboembolism_7/NN (l_appos) VTE_9/NNP
D017373_D054556 NONE CPA_65/NNP (r_nmod) EE_67/NNP (r_pobj) on_64/IN (r_prep) women_63/NNS (r_pobj) among_61/IN (r_prep) years_60/NNS (r_pobj) per_56/IN (r_prep) range_50/NN (r_conj) range_9/NN (r_attr) was_6/VBD (l_nsubj) risk_3/NN (l_prep) of_4/IN (l_pobj) VTE_5/NNP
D017373_D054556 NONE CPA_20/NNP (r_nmod) EE_22/NNP (r_dobj) taking_19/VBG (r_acl) women_18/NNS (r_pobj) among_17/IN (r_prep) that_16/DT (r_pobj) to_15/IN (r_prep) similar_14/JJ (r_acomp) is_13/VBZ (r_ccomp) suggest_2/VBP (l_dobj) risk_5/NN (l_prep) of_6/IN (l_pobj) VTE_7/NNP
D003277_D054556 CID contraceptives_30/NNS (r_pobj) on_27/IN (r_prep) women_26/NNS (r_pobj) among_25/IN (r_conj) achieve_1/VB (l_dobj) estimates_4/NNS (l_prep) of_5/IN (l_pobj) thromboembolism_7/NN
D003277_D054556 CID contraceptives_30/NNS (r_pobj) on_27/IN (r_prep) women_26/NNS (r_pobj) among_25/IN (r_conj) achieve_1/VB (l_dobj) estimates_4/NNS (l_prep) of_5/IN (l_pobj) thromboembolism_7/NN (l_appos) VTE_9/NNP
D003277_D054556 CID COCs_32/NNPS (r_appos) contraceptives_30/NNS (r_pobj) on_27/IN (r_prep) women_26/NNS (r_pobj) among_25/IN (r_conj) achieve_1/VB (l_dobj) estimates_4/NNS (l_prep) of_5/IN (l_pobj) thromboembolism_7/NN
D003277_D054556 CID COCs_32/NNPS (r_appos) contraceptives_30/NNS (r_pobj) on_27/IN (r_prep) women_26/NNS (r_pobj) among_25/IN (r_conj) achieve_1/VB (l_dobj) estimates_4/NNS (l_prep) of_5/IN (l_pobj) thromboembolism_7/NN (l_appos) VTE_9/NNP
D003277_D054556 CID COCs_19/NNS (r_pobj) on_18/IN (r_advcl) had_15/VBN (l_dobj) VTE_16/NNP
D003277_D054556 CID COCs_24/NNS (r_pobj) on_23/IN (r_prep) women_22/NNS (r_pobj) among_20/IN (r_prep) years_19/NNS (r_pobj) per_15/IN (r_prep) 3.1_11/CD (r_npadvmod) range_28/NN (r_appos) range_9/NN (r_attr) was_6/VBD (l_nsubj) risk_3/NN (l_prep) of_4/IN (l_pobj) VTE_5/NNP
D003277_D054556 CID COCs_45/NNS (r_pobj) on_41/IN (r_prep) women_40/NNS (r_pobj) among_39/IN (r_prep) years_38/NNS (r_pobj) per_34/IN (r_prep) range_9/NN (r_attr) was_6/VBD (l_nsubj) risk_3/NN (l_prep) of_4/IN (l_pobj) VTE_5/NNP
D003277_D054556 CID COCs_12/NNS (r_pobj) on_11/IN (r_prep) women_10/NNS (r_pobj) among_8/IN (r_prep) risk_5/NN (l_prep) of_6/IN (l_pobj) VTE_7/NNP
D016912_D054556 NONE levonorgestrel_42/NN (r_npadvmod) containing_44/VBG (r_amod) COCs_45/NNS (r_pobj) on_41/IN (r_prep) women_40/NNS (r_pobj) among_39/IN (r_prep) years_38/NNS (r_pobj) per_34/IN (r_prep) range_9/NN (r_attr) was_6/VBD (l_nsubj) risk_3/NN (l_prep) of_4/IN (l_pobj) VTE_5/NNP
D004997_D054556 NONE ethinylestradiol_14/NN (r_conj) acetate_12/NN (r_pobj) on_9/IN (r_prep) women_8/NNS (r_pobj) in_7/IN (r_prep) thromboembolism_6/NN
D004997_D054556 NONE ethinylestradiol_17/NN (r_conj) acetate_15/NN (r_pobj) on_13/IN (r_prep) women_12/NNS (r_pobj) among_11/IN (r_prep) thromboembolism_7/NN
D004997_D054556 NONE ethinylestradiol_17/NN (r_conj) acetate_15/NN (r_pobj) on_13/IN (r_prep) women_12/NNS (r_pobj) among_11/IN (r_prep) thromboembolism_7/NN (l_appos) VTE_9/NNP
D004997_D054556 NONE EE_21/NNP (r_appos) ethinylestradiol_17/NN (r_conj) acetate_15/NN (r_pobj) on_13/IN (r_prep) women_12/NNS (r_pobj) among_11/IN (r_prep) thromboembolism_7/NN
D004997_D054556 NONE EE_21/NNP (r_appos) ethinylestradiol_17/NN (r_conj) acetate_15/NN (r_pobj) on_13/IN (r_prep) women_12/NNS (r_pobj) among_11/IN (r_prep) thromboembolism_7/NN (l_appos) VTE_9/NNP
D004997_D054556 NONE EE_67/NNP (r_pobj) on_64/IN (r_prep) women_63/NNS (r_pobj) among_61/IN (r_prep) years_60/NNS (r_pobj) per_56/IN (r_prep) range_50/NN (r_conj) range_9/NN (r_attr) was_6/VBD (l_nsubj) risk_3/NN (l_prep) of_4/IN (l_pobj) VTE_5/NNP
D004997_D054556 NONE EE_22/NNP (r_dobj) taking_19/VBG (r_acl) women_18/NNS (r_pobj) among_17/IN (r_prep) that_16/DT (r_pobj) to_15/IN (r_prep) similar_14/JJ (r_acomp) is_13/VBZ (r_ccomp) suggest_2/VBP (l_dobj) risk_5/NN (l_prep) of_6/IN (l_pobj) VTE_7/NNP
2533791
D017325_D006509 NONE vaccine_25/NN (r_dobj) derived_22/VBN (r_conj) treated_3/VBN (l_prep) with_4/IN (l_pobj) injections_6/NNS (l_prep) of_7/IN (l_pobj) globulin_11/NN (l_compound) B_9/NNP
11027904
D008691_D009293 NONE methadone_19/NN (r_compound) maintenance_21/NN (r_nmod) treatment_25/NN (r_pobj) in_18/IN (r_prep) stabilized_17/VBD (r_acl) sample_13/NN (l_prep) of_14/IN (l_pobj) addicts_16/NNS
D008691_D010146 NONE methadone_3/NN (r_npadvmod) maintained_5/VBN (r_amod) abusers_7/NNS (r_pobj) in_2/IN (r_prep) responses_1/NNS (l_compound) Pain_0/NN
D008691_D010146 NONE methadone_19/NN (r_compound) maintenance_21/NN (r_nmod) treatment_25/NN (r_pobj) in_18/IN (r_prep) stabilized_17/VBD (r_acl) sample_13/NN (r_pobj) in_11/IN (r_prep) tolerance_7/NN (l_compound) pain_6/NN
D020910_D010146 NONE ketorolac_48/RB (r_nmod) agents_53/NNS (r_conj) examined_23/VBN (l_prep) By_0/IN (l_pcomp) using_1/VBG (l_dobj) tolerance_13/NN (l_prep) to_14/IN (l_pobj) pain_21/NN
D004091_D010146 NONE hydromorphone_38/NN (r_parataxis) opioid_36/NN (r_pobj) of_34/IN (r_prep) doses_33/NNS (r_pobj) of_31/IN (r_prep) administration_30/NN (r_pobj) after_28/IN (r_conj) before_26/IN (r_advmod) examined_23/VBN (l_prep) By_0/IN (l_pcomp) using_1/VBG (l_dobj) tolerance_13/NN (l_prep) to_14/IN (l_pobj) pain_21/NN
17490864
D000661_D006948 CID Amphetamine_0/NN (r_npadvmod) induced_2/VBN (r_amod) hyperactivity_4/NN
7416947
D004077_D012214 NONE digoxin_10/NN (r_pobj) without_9/IN (r_prep) group_7/NN (r_pobj) of_2/IN (r_prep) patients_1/NNS (r_nsubj) were_12/VBD (l_conj) selected_29/VBN (l_prep) from_30/IN (l_pobj) patients_35/NNS (l_compound) disease_34/NN
D004077_D020018 CID digoxin_13/NN (r_pobj) of_12/IN (r_prep) administration_11/NN (r_pobj) on_7/IN (r_prep) patients_6/NNS (r_pobj) of_5/IN (r_prep) dysfunction_4/NN
6150641
D011899_D006402 NONE ranitidine_18/NN (r_conj) median_12/NN (r_conj) cimetidine_5/NN (r_pobj) of_4/IN (r_prep) doses_3/NNS (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubjpass) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
D011899_D006402 NONE ranitidine_46/NN (r_compound) therapy_47/NN (r_nsubjpass) associated_49/VBN (r_conj) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
D002927_D006402 NONE cimetidine_5/NN (r_pobj) of_4/IN (r_prep) doses_3/NNS (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubjpass) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
D002927_D006402 NONE cimetidine_60/NN (r_compound) therapy_61/NN (r_pobj) with_59/IN (r_prep) seen_58/VBN (r_advcl) level_56/NN (r_pobj) with_50/IN (r_prep) associated_49/VBN (r_conj) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
D011899_D056486 NONE ranitidine_18/NN (r_conj) median_12/NN (r_conj) cimetidine_5/NN (r_pobj) of_4/IN (r_prep) doses_3/NNS (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubjpass) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
D011899_D056486 NONE ranitidine_46/NN (r_compound) therapy_47/NN (r_nsubjpass) associated_49/VBN (r_conj) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
D002927_D007172 CID cimetidine_12/NN (r_dobj) taking_11/VBG (r_advcl) developed_5/VBD (l_dobj) changes_7/NNS (l_conj) impotence_9/NN
D002927_D007172 CID cimetidine_21/NN (r_nsubjpass) replaced_23/VBN (r_advcl) disappeared_19/VBD (r_conj) taking_11/VBG (r_advcl) developed_5/VBD (l_dobj) changes_7/NNS (l_conj) impotence_9/NN
D003404_D006402 NONE creatinine_55/NN (r_compound) level_56/NN (r_pobj) with_50/IN (r_prep) associated_49/VBN (r_conj) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
D002927_D056486 NONE cimetidine_5/NN (r_pobj) of_4/IN (r_prep) doses_3/NNS (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubjpass) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
D002927_D056486 NONE cimetidine_60/NN (r_compound) therapy_61/NN (r_pobj) with_59/IN (r_prep) seen_58/VBN (r_advcl) level_56/NN (r_pobj) with_50/IN (r_prep) associated_49/VBN (r_conj) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
D011899_D007172 NONE ranitidine_25/NN (r_pobj) by_24/IN (r_agent) replaced_23/VBN (r_advcl) disappeared_19/VBD (r_conj) taking_11/VBG (r_advcl) developed_5/VBD (l_dobj) changes_7/NNS (l_conj) impotence_9/NN
D003404_D056486 NONE creatinine_55/NN (r_compound) level_56/NN (r_pobj) with_50/IN (r_prep) associated_49/VBN (r_conj) associated_32/VBN (l_prep) with_33/IN (l_pobj) toxicity_37/NN
12852481
D001241_D005767 NONE ASA_20/NNP (r_nsubjpass) administered_22/VBN (r_advcl) compare_7/VB (r_xcomp) were_5/VBD (l_nsubj) Objectives_0/NNS (l_acl) compare_33/VB (l_conj) test_50/VB (l_dobj) hypothesis_52/NN (l_acl) confounds_57/VBZ (l_nsubj) toxicity_56/NN
D001241_D005767 NONE ASA_65/NNP (r_pobj) with_64/IN (r_prep) malformations_63/NNS (r_pobj) of_60/IN (r_prep) detection_59/NN (r_dobj) confounds_57/VBZ (l_nsubj) toxicity_56/NN
D001241_D000014 CID Aspirin_0/NNP (r_nsubj) acetylsalicylic_2/JJ (l_conj) induces_17/VBZ (l_dobj) anomalies_19/NNS
D001241_D000014 CID acid_3/NN (r_npadvmod) acetylsalicylic_2/JJ (l_conj) induces_17/VBZ (l_dobj) anomalies_19/NNS
D001241_D000014 CID ASA_5/NNP (r_appos) acid_3/NN (r_npadvmod) acetylsalicylic_2/JJ (l_conj) induces_17/VBZ (l_dobj) anomalies_19/NNS
D001241_D000014 CID ASA_20/NNP (r_nsubjpass) administered_22/VBN (r_advcl) compare_7/VB (r_xcomp) were_5/VBD (l_nsubj) Objectives_0/NNS (l_acl) compare_33/VB (l_conj) test_50/VB (l_dobj) hypothesis_52/NN (l_acl) confounds_57/VBZ (l_dobj) detection_59/NN (l_prep) of_60/IN (l_pobj) malformations_63/NNS
D001241_D000014 CID ASA_65/NNP (r_pobj) with_64/IN (r_prep) malformations_63/NNS
D001241_D000014 CID ASA_16/NNP (r_nsubj) induces_17/VBZ (r_advcl) focused_9/VBD (l_prep) on_10/IN (l_pobj) malformations_12/NNS
D001241_D000014 CID ASA_16/NNP (r_nsubj) induces_17/VBZ (l_dobj) malformations_23/NNS
D001241_D000014 CID ASA_6/NNP (r_nsubjpass) administered_8/VBN (r_advcl) were_3/VBD (l_nsubj) Variations_0/NNS (l_conj) malformations_2/NNS
D001241_D000014 CID ASA_38/NNP (r_pobj) with_37/IN (r_prep) induced_36/VBN (l_nsubjpass) malformations_17/NNS
10533019
D004110_D012131 NONE diltiazem_16/NN (r_pobj) of_14/IN (r_prep) infusion_13/NN (r_pobj) after_11/IN (r_prep) developed_5/VBD (l_prep) with_7/IN (l_pobj) arrest_10/NN
D002122_D013746 NONE chloride_12/NN (r_pobj) with_10/IN (r_prep) tetany_9/NN
D002122_D013746 NONE chloride_4/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) resolved_6/VBD (l_dobj) tetany_10/NN
D002122_D013746 NONE chloride_21/NN (r_nsubj) be_23/VB (r_conj) accompany_12/VB (l_nsubj) tetany_10/NN
D004110_D013746 CID diltiazem_6/NN (r_npadvmod) induced_8/VBN (r_amod) tetany_9/NN
D004110_D013746 CID diltiazem_16/NN (r_pobj) of_14/IN (r_prep) infusion_13/NN (r_pobj) after_11/IN (r_prep) developed_5/VBD (l_dobj) tetany_6/NN
D004110_D013746 CID diltiazem_17/NN (r_pobj) of_15/IN (r_prep) administration_14/NN (r_dobj) accompany_12/VB (l_nsubj) tetany_10/NN
19300240
D002395_D009369 NONE catecholamines_9/NNS (r_pobj) of_7/IN (r_prep) levels_6/NNS (l_acl) caused_14/VBN (l_agent) by_15/IN (l_pobj) diagnosis_17/NN (l_compound) cancer_16/NN
D005472_D015179 NONE fluorouracil_5/NN (r_pobj) with_4/IN (r_prep) underwent_1/VBD (l_prep) for_6/IN (l_pobj) cancer_9/NN
D005472_D054549 CID flourouracil_1/NN (r_npadvmod) induced_3/VBN (r_amod) syndrome_6/NN
D002395_D054549 NONE catecholamines_9/NNS (r_pobj) of_7/IN (r_prep) levels_6/NNS (r_nsubj) contributed_24/VBN (l_dobj) development_26/NN (l_prep) of_27/IN (l_pobj) ABS_28/NN
7910951
D003473_D018908 CID agents_9/NNS (r_pobj) of_5/IN (r_prep) use_4/NN (r_nsubjpass) implicated_18/VBN (l_prep) as_19/IN (l_pobj) cause_21/NN (l_prep) of_22/IN (l_pobj) weakness_25/NN
D003473_D018908 CID NMBA_13/NNP (r_appos) agents_9/NNS (r_pobj) of_5/IN (r_prep) use_4/NN (r_nsubjpass) implicated_18/VBN (l_prep) as_19/IN (l_pobj) cause_21/NN (l_prep) of_22/IN (l_pobj) weakness_25/NN
D003473_D018908 CID NMBAs_25/NNP (r_pobj) of_22/IN (r_prep) discontinuation_21/NN (r_pobj) following_19/VBG (r_prep) weakness_18/NN
D003473_D018908 CID NMBA_21/NNP (r_pobj) due_17/IN (r_prep) likely_16/JJ (r_parataxis) pathology_8/NN (r_pobj) due_6/JJ (r_acomp) is_5/VBZ (l_nsubj) weakness_1/NN
D000305_D010243 NONE corticosteroids_9/NNS (r_conj) agents_7/NNS (r_appos) neuromuscular_5/JJ (r_pobj) due_2/IN (r_prep) paralysis_1/NN
D003473_D012131 NONE NMBAs_25/NNP (r_pobj) of_22/IN (r_prep) discontinuation_21/NN (r_pobj) following_19/VBG (r_prep) weakness_18/NN (r_dobj) developed_16/VBD (r_relcl) insufficiency_14/NN
D003473_D010243 NONE agents_7/NNS (r_appos) neuromuscular_5/JJ (r_pobj) due_2/IN (r_prep) paralysis_1/NN
D000305_D018908 NONE corticosteroids_30/NNS (r_pobj) due_28/IN (r_prep) likely_27/JJ (r_parataxis) likely_16/JJ (r_parataxis) pathology_8/NN (r_pobj) due_6/JJ (r_acomp) is_5/VBZ (l_nsubj) weakness_1/NN
D003473_D009468 CID NMBA_21/NNP (r_pobj) due_17/IN (r_prep) likely_16/JJ (r_parataxis) pathology_8/NN (l_prep) at_9/IN (l_pobj) junction_13/NN
D000305_D009468 NONE corticosteroids_30/NNS (r_pobj) due_28/IN (r_prep) likely_27/JJ (r_parataxis) likely_16/JJ (r_parataxis) pathology_8/NN (l_prep) at_9/IN (l_pobj) junction_13/NN
3653576
D011692_D058186 CID aminonucleoside_30/NN (r_nmod) PAN_32/NNP (r_npadvmod) puromycin_29/NNS (l_ccomp) produced_20/VBN (l_nsubjpass) models_2/NNS (l_prep) of_3/IN (l_pobj) damage_5/NN
D011692_D058186 CID PAN_32/NNP (r_npadvmod) puromycin_29/NNS (l_ccomp) produced_20/VBN (l_nsubjpass) models_2/NNS (l_prep) of_3/IN (l_pobj) damage_5/NN
C004504_D007674 NONE BEA_6/NNP (r_conj) HCBD_4/NNP (r_pobj) by_3/IN (r_agent) produced_2/VBN (r_acl) damage_1/NN (r_nsubjpass) discriminated_8/VBN (l_prep) from_13/IN (l_pobj) damage_15/NN
C001335_D007674 NONE HCBD_4/NNP (r_pobj) by_3/IN (r_agent) produced_2/VBN (r_acl) damage_1/NN (r_nsubjpass) discriminated_8/VBN (l_prep) from_13/IN (l_pobj) damage_15/NN
C004504_D058186 CID 2-bromoethylamine_36/NN (r_punct) ._42/. (r_punct) puromycin_29/NNS (l_ccomp) produced_20/VBN (l_nsubjpass) models_2/NNS (l_prep) of_3/IN (l_pobj) damage_5/NN
C004504_D058186 CID BEA_38/NNP (r_nmod) 2-bromoethylamine_36/NN (r_punct) ._42/. (r_punct) puromycin_29/NNS (l_ccomp) produced_20/VBN (l_nsubjpass) models_2/NNS (l_prep) of_3/IN (l_pobj) damage_5/NN
C001335_D058186 CID hexachloro-1:3-butadiene_24/, (r_pobj) of_23/IN (r_prep) administration_22/NN (r_pobj) by_21/IN (r_agent) produced_20/VBN (l_nsubjpass) models_2/NNS (l_prep) of_3/IN (l_pobj) damage_5/NN
C001335_D058186 CID HCBD_26/NNP (r_appos) hexachloro-1:3-butadiene_24/, (r_pobj) of_23/IN (r_prep) administration_22/NN (r_pobj) by_21/IN (r_agent) produced_20/VBN (l_nsubjpass) models_2/NNS (l_prep) of_3/IN (l_pobj) damage_5/NN
D011692_D007674 NONE PAN_18/NNP (r_pobj) by_17/IN (r_agent) produced_16/VBN (r_acl) damage_15/NN
3686155
D001971_D007775 NONE bromocriptine_16/NN (r_dobj) received_15/VBN (l_prep) for_17/IN (l_pobj) inhibition_18/NN (l_prep) of_19/IN (l_pobj) lactation_20/NN
D001971_D010300 NONE Bromocriptine_0/NNP (r_nsubjpass) associated_7/VBN (l_prep) with_8/IN (l_pobj) psychosis_9/NN (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_acl) receiving_12/VBG (l_dobj) drug_14/NN (l_prep) for_15/IN (l_pobj) disease_18/NN
D001971_D001523 NONE bromocriptine_16/NN (r_dobj) received_15/VBN (r_advcl) seen_9/VBN (l_nsubjpass) patients_2/NNS (l_prep) with_3/IN (l_pobj) history_7/NN (l_amod) psychiatric_6/JJ
D001971_D011605 CID bromocriptine_4/NN (r_pobj) by_3/IN (r_prep) induced_2/VBN (l_nsubj) psychosis_1/NN
D001971_D011605 CID bromocriptine_16/NN (r_dobj) received_15/VBN (r_advcl) seen_9/VBN (l_prep) with_10/IN (l_pobj) psychosis_12/NN
D001971_D011605 CID Bromocriptine_0/NNP (r_nsubjpass) associated_7/VBN (l_prep) with_8/IN (l_pobj) psychosis_9/NN
D001971_D011605 CID bromocriptine_4/NN (r_nsubj) cause_6/VB (l_dobj) psychosis_7/NN
19370593
D004967_D020521 CID oestrogen_3/NN (r_nmod) HT_6/NNP (r_nsubj) increased_8/VBD (l_dobj) risk_10/NN (l_prep) of_11/IN (l_pobj) embolism_15/NN (l_appos) disease_20/NN (l_nmod) stroke_17/NN
D004967_D001943 NONE oestrogen_3/NN (r_nmod) HT_6/NNP (r_nsubj) increased_8/VBD (l_conj) increase_42/VB (l_dobj) risk_44/NN (l_prep) of_45/IN (l_pobj) cancer_47/NN
D004967_D005705 CID oestrogen_3/NN (r_nmod) HT_6/NNP (r_nsubj) increased_8/VBD (l_dobj) risk_10/NN (l_prep) of_11/IN (l_pobj) embolism_15/NN (l_appos) disease_20/NN
D004967_D054556 CID oestrogen_3/NN (r_nmod) HT_6/NNP (r_nsubj) increased_8/VBD (l_dobj) risk_10/NN (l_prep) of_11/IN (l_pobj) embolism_15/NN
7066357
D014280_D009404 NONE triacylglycerol_12/NN (r_conj) acids_10/NNS (r_pobj) of_8/IN (r_prep) level_7/NN (r_nsubj) decreased_15/VBD (l_prep) In_0/IN (l_pobj) stage_4/NN (l_amod) nephrotic_3/JJ
D011692_D009404 CID aminonucleoside_18/RB (r_advmod) induced_12/VBN (l_nsubj) Plasma_0/NN (l_prep) during_6/IN (l_pobj) development_8/NN (l_prep) of_9/IN (l_pobj) syndrome_11/NN
D011692_D009404 CID aminonucleoside_19/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) alterations_8/NNS (l_prep) of_9/IN (l_pobj) lipoproteins_11/NNS (l_acl) found_12/VBN (l_prep) in_13/IN (l_pobj) syndrome_15/NN
D011692_D009404 CID aminonucleoside_19/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) alterations_8/NNS (r_nsubj) were_20/VBD (l_acomp) due_21/JJ (l_prep) to_22/IN (l_pobj) syndrome_24/NN
D011692_D009404 CID aminonucleoside_37/NN (r_pobj) to_35/IN (r_prep) were_20/VBD (l_nsubj) alterations_8/NNS (l_prep) of_9/IN (l_pobj) lipoproteins_11/NNS (l_acl) found_12/VBN (l_prep) in_13/IN (l_pobj) syndrome_15/NN
D011692_D009404 CID aminonucleoside_37/NN (r_pobj) to_35/IN (r_prep) were_20/VBD (l_acomp) due_21/JJ (l_prep) to_22/IN (l_pobj) syndrome_24/NN
D011692_D009404 CID aminonucleoside_21/NN (l_conj) development_32/NN (l_prep) of_33/IN (l_pobj) syndrome_35/NN
D005227_D009404 NONE acids_10/NNS (r_pobj) of_8/IN (r_prep) level_7/NN (r_nsubj) decreased_15/VBD (l_prep) In_0/IN (l_pobj) stage_4/NN (l_amod) nephrotic_3/JJ
D002788_D009404 NONE esters_22/NNS (r_nsubj) remained_25/VBD (r_advcl) decreased_15/VBD (l_prep) In_0/IN (l_pobj) stage_4/NN (l_amod) nephrotic_3/JJ
1286498
D005442_D010146 NONE flumazenil_11/JJ (r_compound) group_12/NN (l_conj) pain_19/NN
D005442_D009325 CID flumazenil_11/JJ (r_compound) group_12/NN (r_pobj) in_9/IN (r_prep) vomiting_8/VBG (r_conj) nausea_6/NN
D005442_D009325 CID flumazenil_11/JJ (r_compound) group_12/NN (l_conj) pain_19/NN (l_nmod) nausea_14/NN
D005442_D014839 CID flumazenil_11/JJ (r_compound) group_12/NN (r_pobj) in_9/IN (r_prep) vomiting_8/VBG
2917114
D006024_D001919 NONE glycopyrronium_2/NN (r_pobj) of_1/IN (r_prep) Use_0/NN (l_acl) given_12/VBN (l_conj) was_19/VBD (l_acomp) sufficient_20/JJ (l_xcomp) minimize_22/VB (l_dobj) bradycardias_28/NNS
D004491_D001919 CID edrophonium_17/NN (r_pobj) before_15/IN (r_prep) min_14/NN (r_dobj) given_12/VBN (l_conj) was_19/VBD (l_acomp) sufficient_20/JJ (l_xcomp) minimize_22/VB (l_dobj) bradycardias_28/NNS
D004491_D001919 CID edrophonium_25/NN (r_npadvmod) induced_27/VBN (r_amod) bradycardias_28/NNS
8911359
D003520_D001749 CID Cyclophosphamide_0/NN (r_nmod) cancer_3/NN
D003520_D001749 CID cyclophosphamide_17/NN (r_pobj) with_16/IN (l_pobj) cancer_20/NN
D003520_D001749 CID Cyclophosphamide_0/NN (r_nmod) tumor_3/NN
D003520_D014523 NONE cyclophosphamide_13/NN (r_pobj) of_12/IN (r_prep) etiology_7/NN (r_pobj) of_5/IN (r_prep) knowledge_4/NN (r_dobj) gained_3/VBD (l_dobj) cancer_16/NN
20727411
D016202_D012559 NONE aspartate_8/NNP (r_nmod) receptor_12/NN (r_nsubjpass) implicated_15/VBN (l_prep) in_16/IN (l_pobj) pathophysiology_18/NN (l_prep) of_19/IN (l_pobj) schizophrenia_20/NN
D016202_D012559 NONE NMDA_10/NNP (r_nmod) receptor_12/NN (r_nsubjpass) implicated_15/VBN (l_prep) in_16/IN (l_pobj) pathophysiology_18/NN (l_prep) of_19/IN (l_pobj) schizophrenia_20/NN
D016202_D012559 NONE NMDA_13/NNP (r_compound) antagonist_15/NN (r_compound) ketamine_16/NN (r_pobj) of_8/IN (r_prep) dose_7/NN (r_nsubj) leads_17/VBZ (l_prep) to_18/IN (l_pobj) symptoms_20/NNS (l_amod) similar_21/JJ (l_prep) to_22/IN (l_pobj) those_23/DT (l_acl) observed_24/VBN (l_prep) in_25/IN (l_pobj) schizophrenia_26/NN
D016202_D012559 NONE NMDA_10/NNP (r_compound) dysfunction_12/NN (l_prep) in_13/IN (l_pobj) pathophysiology_15/NN (l_prep) of_16/IN (l_pobj) schizophrenia_17/NN
D007649_D011605 CID Ketamine_0/NN (r_nsubj) elicited_1/VBD (l_dobj) psychosis_2/NN
-1_D011605 NONE ketamine_5/NN (r_pobj) of_2/IN (r_prep) correlates_1/NNS (r_nsubj) induced_6/VBD (l_dobj) psychosis_7/NN
D007649_D012559 NONE ketamine_16/NN (r_pobj) of_8/IN (r_prep) dose_7/NN (r_nsubj) leads_17/VBZ (l_prep) to_18/IN (l_pobj) symptoms_20/NNS (l_amod) similar_21/JJ (l_prep) to_22/IN (l_pobj) those_23/DT (l_acl) observed_24/VBN (l_prep) in_25/IN (l_pobj) schizophrenia_26/NN
D007649_D012559 NONE ketamine_5/NN (r_nsubj) exacerbates_6/VBZ (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) schizophrenia_3/NN
D007649_D012559 NONE Ketamine_0/NN (r_nsubj) induces_1/VBZ (l_dobj) changes_3/NNS (l_prep) in_4/IN (l_pobj) subjects_6/NNS (l_amod) similar_7/JJ (l_prep) to_8/IN (l_pobj) those_9/DT (l_acl) observed_10/VBN (l_prep) in_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) schizophrenia_14/NN
D007649_D018754 NONE ketamine_5/NN (r_nsubj) exacerbates_6/VBZ (l_advcl) supporting_13/VBG (l_dobj) hypothesis_15/NN (l_prep) of_16/IN (l_pobj) dysfunction_19/NN
11860278
D004298_D004827 NONE Dopamine_0/NNP (r_nsubj) plays_12/VBZ (l_prep) in_16/IN (l_pobj) control_18/NN (l_prep) of_19/IN (l_pobj) seizures_21/NNS
D004298_D004827 NONE DA_2/NNP (r_appos) Dopamine_0/NNP (r_nsubj) plays_12/VBZ (l_prep) in_16/IN (l_pobj) control_18/NN (l_prep) of_19/IN (l_pobj) seizures_21/NNS
D004298_D004827 NONE DA_11/NNP (r_compound) receptors_12/NNS (r_pobj) of_10/IN (r_prep) role_9/NN (l_prep) in_13/IN (l_pobj) occurrence_15/NN (l_prep) of_16/IN (l_pobj) death_22/NN (l_amod) induced_19/VBN (l_npadvmod) epilepsy_17/NN
D018698_D012640 NONE glutamate_14/NN (r_pobj) by_12/IN (r_agent) induced_11/VBN (r_acl) seizures_10/NNS
D010862_D020258 NONE pilocarpine_18/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) mice_12/NNS (r_pobj) in_9/IN (r_prep) seizures_6/NNS (l_conj) neurotoxicity_8/NN
D010862_D012640 CID pilocarpine_18/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) mice_12/NNS (r_pobj) in_9/IN (r_prep) seizures_6/NNS
D010862_D012640 CID pilocarpine_2/NN (r_npadvmod) induced_4/VBN (r_amod) seizures_5/NNS
D000109_D012640 NONE acetylcholine_16/NN (r_conj) glutamate_14/NN (r_pobj) by_12/IN (r_agent) induced_11/VBN (r_acl) seizures_10/NNS
D007608_D012640 CID KA_23/NNP (r_pobj) to_22/IN (r_prep) comparison_21/NN (r_pobj) in_20/IN (r_prep) death_12/NN (r_pobj) in_7/IN (r_prep) result_6/VBP (l_nsubj) seizures_5/NNS
7647582
D004737_D004342 NONE enflurane_10/NN (l_conj) isoflurane_12/RB (l_prep) with_13/IN (l_pobj) hypersensitivity_15/NN
D004737_D004342 NONE enflurane_11/NN (r_nsubj) produce_15/VB (l_dobj) condition_18/NN (l_compound) hypersensitivity_17/NN
D014269_D056486 NONE trifluoroacetyl_11/JJ (r_compound) adduct_12/NN (r_appos) product_9/NN (r_pobj) to_3/IN (r_prep) response_2/NN (r_nsubjpass) detected_16/VBN (l_prep) on_17/IN (l_pobj) patients_20/NNS (l_compound) hepatitis_19/NN
D007530_D004342 NONE isoflurane_12/RB (l_prep) with_13/IN (l_pobj) hypersensitivity_15/NN
D007530_D004342 NONE isoflurane_13/NN (r_conj) enflurane_11/NN (r_nsubj) produce_15/VB (l_dobj) condition_18/NN (l_compound) hypersensitivity_17/NN
D007530_D056486 CID isoflurane_6/RB (r_conj) enflurane_4/NN (r_conj) anesthetics_2/NNS (r_nsubjpass) associated_10/VBN (l_prep) with_11/IN (l_pobj) injury_17/NN
D007530_D056486 CID isoflurane_13/NN (r_conj) enflurane_11/NN (r_nsubj) produce_15/VB (l_dobj) condition_18/NN (l_amod) similar_19/JJ (l_prep) to_20/IN (l_pobj) that_21/DT (l_prep) of_22/IN (l_pobj) hepatitis_24/NN
D006221_D056486 CID halothane_25/NN (r_relcl) exposure_23/NN (r_pobj) following_21/VBG (r_agent) associated_10/VBN (l_prep) with_11/IN (l_pobj) injury_17/NN
D006221_D056486 CID Halothane_0/NNP (r_compound) hepatitis_1/NN
D006221_D056486 CID halothane_18/NN (r_amod) patients_20/NNS (l_compound) hepatitis_19/NN
D006221_D056486 CID halothane_23/NN (r_compound) hepatitis_24/NN
D006221_D056486 CID halothane_30/NN (r_advcl) produce_15/VB (l_dobj) condition_18/NN (l_amod) similar_19/JJ (l_prep) to_20/IN (l_pobj) that_21/DT (l_prep) of_22/IN (l_pobj) hepatitis_24/NN
D004737_D056486 CID enflurane_4/NN (r_conj) anesthetics_2/NNS (r_nsubjpass) associated_10/VBN (l_prep) with_11/IN (l_pobj) injury_17/NN
D004737_D056486 CID enflurane_11/NN (r_nsubj) produce_15/VB (l_dobj) condition_18/NN (l_amod) similar_19/JJ (l_prep) to_20/IN (l_pobj) that_21/DT (l_prep) of_22/IN (l_pobj) hepatitis_24/NN
D006221_D004342 NONE halothane_18/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) hypersensitivity_15/NN
D006221_D004342 NONE halothane_23/NN (r_compound) hepatitis_24/NN (r_pobj) of_22/IN (r_prep) that_21/DT (r_pobj) to_20/IN (r_prep) similar_19/JJ (r_amod) condition_18/NN (l_compound) hypersensitivity_17/NN
D006221_D004342 NONE halothane_30/NN (r_advcl) produce_15/VB (l_dobj) condition_18/NN (l_compound) hypersensitivity_17/NN
16364460
D016713_D000647 NONE ritanserin_2/NN (r_pobj) of_1/IN (r_prep) Microinjection_0/NN (r_nsubj) improves_9/VBZ (l_dobj) amnesia_13/NN
D016713_D000647 NONE ritanserin_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (l_prep) on_8/IN (l_pobj) amnesia_14/NN
D016713_D000647 NONE ritanserin_6/NN (r_pobj) of_5/IN (r_prep) microinjection_4/NN (r_nsubj) improves_14/VBZ (l_dobj) amnesia_19/NN
D012601_D000647 CID scopolamine_10/NN (r_npadvmod) induced_12/VBN (r_amod) amnesia_13/NN
D012601_D000647 CID scopolamine_9/NN (r_nmod) amnesia_14/NN
D012601_D000647 CID scopolamine_16/NN (r_npadvmod) induced_18/VBN (r_amod) amnesia_19/NN
3708922
D005839_D064420 NONE gentamicin_16/NN (r_pobj) as_15/IN (r_prep) potential_12/NN (r_pobj) with_9/IN (r_prep) administration_2/NN (r_nsubj) aggravate_38/VB (l_ccomp) induced_41/VBN (l_dobj) toxicity_42/NN
D000666_D064420 NONE B_24/NN (r_conj) gentamicin_16/NN (r_pobj) as_15/IN (r_prep) potential_12/NN (r_pobj) with_9/IN (r_prep) administration_2/NN (r_nsubj) aggravate_38/VB (l_ccomp) induced_41/VBN (l_dobj) toxicity_42/NN
D016572_D064420 NONE CSA_4/NNP (r_pobj) of_3/IN (r_prep) administration_2/NN (r_nsubj) aggravate_38/VB (l_ccomp) induced_41/VBN (l_dobj) toxicity_42/NN
D016572_D064420 NONE CSA_40/NNP (r_dobj) aggravate_38/VB (l_ccomp) induced_41/VBN (l_dobj) toxicity_42/NN
D005839_D007674 NONE gentamicin_16/NN (r_pobj) as_15/IN (r_prep) potential_12/NN (l_amod) nephrotoxic_11/JJ
D005839_D007674 NONE Gentamicin_0/NNP (r_nsubj) increased_7/VBD (l_dobj) nephrotoxicity_9/NN
D000666_D007674 NONE B_24/NN (r_conj) gentamicin_16/NN (r_pobj) as_15/IN (r_prep) potential_12/NN (l_amod) nephrotoxic_11/JJ
D016572_D007674 CID cyclosporine_1/NN (r_compound) nephrotoxicity_2/NN
D016572_D007674 CID cyclosporine_3/NN (r_pobj) of_2/IN (l_conj) in_9/IN (l_pobj) combination_10/NN (l_prep) with_11/IN (l_pobj) chemotherapeutics_13/NNS (l_prep) in_14/IN (l_pobj) development_16/NN (l_prep) of_17/IN (l_pobj) toxicity_19/NN
D016572_D007674 CID CSA_5/NNP (r_appos) cyclosporine_3/NN (r_pobj) of_2/IN (l_conj) in_9/IN (l_pobj) combination_10/NN (l_prep) with_11/IN (l_pobj) chemotherapeutics_13/NNS (l_prep) in_14/IN (l_pobj) development_16/NN (l_prep) of_17/IN (l_pobj) toxicity_19/NN
D016572_D007674 CID CSA_4/NNP (r_pobj) of_3/IN (r_prep) administration_2/NN (l_prep) with_9/IN (l_pobj) potential_12/NN (l_amod) nephrotoxic_11/JJ
D016572_D007674 CID CSA_40/NNP (r_dobj) aggravate_38/VB (l_nsubj) administration_2/NN (l_prep) with_9/IN (l_pobj) potential_12/NN (l_amod) nephrotoxic_11/JJ
D016572_D007674 CID CSA_8/NNP (r_compound) nephrotoxicity_9/NN
D016572_D007674 CID CSA_6/NNP (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) nephrotoxicity_3/NN
D007654_D064420 NONE ketoconazole_26/NN (r_conj) B_24/NN (r_conj) gentamicin_16/NN (r_pobj) as_15/IN (r_prep) potential_12/NN (r_pobj) with_9/IN (r_prep) administration_2/NN (r_nsubj) aggravate_38/VB (l_ccomp) induced_41/VBN (l_dobj) toxicity_42/NN
D007654_D007674 NONE ketoconazole_26/NN (r_conj) B_24/NN (r_conj) gentamicin_16/NN (r_pobj) as_15/IN (r_prep) potential_12/NN (l_amod) nephrotoxic_11/JJ
15579441
D011692_D000860 CID aminonucleoside_15/NN (r_advmod) induced_17/VBN (r_amod) syndrome_19/NN (r_appos) puromycin_14/NNS (r_pobj) in_12/IN (r_prep) identify_8/VB (l_dobj) hypoxia_11/NN
D011692_D000860 CID aminonucleoside_15/NN (r_advmod) induced_17/VBN (r_amod) syndrome_19/NN (l_conj) hypoxia_24/NN
D011692_D000860 CID aminonucleoside_21/NN (r_compound) model_22/NN (r_pobj) in_18/IN (r_prep) reaching_13/VBG (r_advcl) increased_7/VBD (l_nsubj) Expression_0/NN (l_prep) of_1/IN (l_pobj) transgene_6/NN (l_amod) responsive_5/JJ (l_npadvmod) hypoxia_3/NN
D011692_D009404 CID aminonucleoside_15/NN (r_advmod) induced_17/VBN (r_amod) syndrome_19/NN
2907585
D002065_D002375 NONE buspirone_5/NN (r_appos) drug_3/NN (r_nsubj) reverses_7/VBZ (l_dobj) catalepsy_8/NN
D002065_D002375 NONE buspirone_8/NN (r_pobj) of_7/IN (r_prep) analogues_6/NNS (r_pobj) of_2/IN (r_prep) series_1/NN (r_nsubjpass) tested_14/VBN (l_conj) induced_21/VBN (l_dobj) catalepsy_22/NN
D006220_D002375 CID haloperidol_11/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) catalepsy_8/NN
D006220_D002375 CID haloperidol_20/NN (r_dobj) reverse_19/VB (r_acl) ability_17/NN (r_pobj) for_15/IN (r_prep) tested_14/VBN (l_conj) induced_21/VBN (l_dobj) catalepsy_22/NN
D012701_D002375 NONE 5-hydroxytryptamine1a_6/CD (r_compound) receptors_7/NNS (r_pobj) for_5/IN (r_prep) affinity_4/NN (r_pobj) with_2/IN (r_prep) drugs_1/NNS (r_nsubj) were_8/VBD (l_acomp) able_9/JJ (l_xcomp) reverse_11/VB (l_dobj) catalepsy_12/NN
D012701_D002375 NONE 5-HT_5/CD (r_compound) receptors_6/NNS (r_pobj) of_3/IN (r_prep) inhibition_2/NN (r_nsubj) inhibited_8/VBN (l_conj) potentiated_10/VBN (l_dobj) reversal_11/NN (l_prep) of_12/IN (l_pobj) catalepsy_13/NN
-1_D002375 NONE piperazine_10/NN (r_nmod) drugs_12/NNS (r_pobj) by_6/IN (r_prep) Reversal_0/NN (l_prep) of_1/IN (l_pobj) catalepsy_5/NN
-1_D002375 NONE piperazine_5/NN (r_compound) analogues_6/NNS (r_pobj) of_2/IN (r_prep) series_1/NN (r_nsubjpass) tested_14/VBN (l_conj) induced_21/VBN (l_dobj) catalepsy_22/NN
D058825_D002375 NONE agonists_12/NNS (r_conj) buspirone_8/NN (r_pobj) of_7/IN (r_prep) analogues_6/NNS (r_pobj) of_2/IN (r_prep) series_1/NN (r_nsubjpass) tested_14/VBN (l_conj) induced_21/VBN (l_dobj) catalepsy_22/NN
7421734
D004967_D006689 NONE estrogens_16/NNS (r_dobj) received_14/VBD (r_conj) had_1/VBD (l_dobj) failure_3/NN (l_prep) after_4/IN (l_pobj) irradiation_6/NN (l_prep) for_9/IN (l_pobj) disease_11/NN
D004967_D016889 CID estrogens_16/NNS (r_dobj) received_14/VBD (l_npadvmod) treatment_19/NN (l_acl) implicated_20/VBN (l_prep) in_21/IN (l_pobj) development_23/NN (l_prep) of_24/IN (l_pobj) cancer_26/NN
D004967_D016889 CID estrogens_4/NNS (r_pobj) on_2/IN (r_prep) women_1/NNS (r_nsubj) increased_14/VBN (l_dobj) risk_15/NN (l_prep) of_16/IN (l_pobj) carcinoma_18/NN
D004967_D009369 NONE estrogens_4/NNS (r_pobj) on_2/IN (r_prep) women_1/NNS (r_nsubj) increased_14/VBN (l_nsubj) therapy_10/NN (l_compound) cancer_9/NN
D004967_D010049 NONE estrogens_16/NNS (r_dobj) received_14/VBD (r_conj) had_1/VBD (l_dobj) failure_3/NN
D004967_D010049 NONE estrogens_4/NNS (l_prep) for_5/IN (l_pobj) failure_7/NN
16116131
D001058_D004409 NONE apomorphine_46/NN (r_compound) infusion_47/NN (r_pobj) by_44/IN (r_agent) induced_43/VBN (r_acl) state_42/NN (l_amod) dyskinetic_41/JJ
D007980_D004409 CID levodopa_7/RB (r_npadvmod) induced_9/VBN (r_amod) dyskinesia_10/NN
D001058_D010300 NONE apomorphine_46/NN (r_compound) infusion_47/NN (r_pobj) by_44/IN (r_agent) induced_43/VBN (r_acl) state_42/NN (r_pobj) of_39/IN (r_prep) modification_38/NN (r_pobj) in_36/IN (r_prep) result_35/VB (r_ccomp) investigated_28/VBN (l_advcl) Using_0/VBG (l_parataxis) rTMS_6/NN (l_prep) over_8/IN (l_pobj) area_12/NN (l_prep) in_16/IN (l_pobj) group_18/NN (l_prep) of_19/IN (l_pobj) patients_20/NNS (l_prep) with_21/IN (l_pobj) disease_24/NN
11999899
D016291_D002375 NONE MK-801_16/NNP (r_punct) produced_2/VBD (l_dobj) tremor_3/NN (l_conj) catalepsy_5/NN
D016291_D002375 NONE MK-801_17/NNP (r_punct) induced_6/VBN (l_dobj) increases_7/NNS (l_prep) in_8/IN (l_pobj) tremor_9/NN (l_conj) catalepsy_11/NN
D016291_D002375 NONE MK-801_33/NNP (r_punct) injection_38/NN (r_nsubj) min_40/NN (r_nsubj) reversed_44/VBD (r_advcl) produced_13/VBD (l_conj) increases_26/NNS (l_prep) in_27/IN (l_pobj) tremor_28/NN (l_conj) catalepsy_30/NN
D016202_D014202 NONE NMDA_5/NNP (r_pobj) by_4/IN (r_agent) produced_3/VBN (r_acl) blockage_2/NN (r_nsubj) restore_7/VB (l_dobj) signs_9/NNS (l_prep) as_12/IN (l_pobj) movements_15/NNS (l_conj) protrusions_18/NNS (l_conj) catalepsy_20/NN (l_conj) tremor_22/NN
D012110_D004409 CID Reserpine_0/NN (r_nsubj) produced_15/VBD (l_dobj) increases_16/NNS (l_prep) in_17/IN (l_pobj) dyskinesia_19/NN (l_relcl) are_30/VBP (l_attr) signs_31/NNS (l_amod) indicative_32/JJ (l_prep) of_33/IN (l_pobj) dyskinesia_35/NN
D012110_D004409 CID reserpine_4/NN (r_nsubj) produces_5/VBZ (l_dobj) movements_9/NNS
D012110_D004409 CID reserpine_4/NN (r_nsubj) produces_5/VBZ (l_dobj) movements_9/NNS (l_relcl) related_13/VBN (l_conj) considered_22/VBN (l_prep) as_23/IN (l_pobj) signs_30/NNS (l_compound) dsykinesia_29/NN
D016291_D010300 NONE MK-801_16/NNP (r_punct) produced_2/VBD (l_dobj) tremor_3/NN (l_relcl) are_8/VBP (l_attr) signs_9/NNS (l_amod) suggestive_10/JJ (l_prep) of_11/IN (l_pobj) disease_14/NN
D012110_D010300 NONE Reserpine_0/NN (r_nsubj) produced_2/VBD (l_dobj) tremor_3/NN (l_relcl) are_8/VBP (l_attr) signs_9/NNS (l_amod) suggestive_10/JJ (l_prep) of_11/IN (l_pobj) disease_14/NN
D012110_D010300 NONE reserpine_4/NN (r_nsubj) produces_5/VBZ (l_dobj) movements_9/NNS (l_relcl) related_13/VBN (l_conj) considered_22/VBN (l_prep) as_23/IN (l_pobj) signs_30/NNS (l_amod) parkinsonian_24/JJ
D012110_D014202 CID Reserpine_0/NN (r_nsubj) produced_2/VBD (l_dobj) tremor_3/NN
D012110_D014202 CID reserpine_11/NN (r_npadvmod) treated_13/VBN (r_amod) mice_14/NNS (r_pobj) in_10/IN (r_prep) increase_7/NN (l_prep) of_8/IN (l_pobj) tremor_9/NN
D012110_D014202 CID reserpine_5/NN (r_nsubj) induced_6/VBN (l_dobj) increases_7/NNS (l_prep) in_8/IN (l_pobj) tremor_9/NN
D012110_D014202 CID reserpine_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) catalepsy_7/NN (l_conj) tremor_9/NN
D012110_D014202 CID reserpine_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (l_acl) produced_13/VBD (l_conj) increases_26/NNS (l_prep) in_27/IN (l_pobj) tremor_28/NN
D012110_D014202 CID reserpine_48/NN (r_pobj) of_47/IN (r_prep) effects_46/NNS (r_dobj) reversed_44/VBD (r_advcl) produced_13/VBD (l_conj) increases_26/NNS (l_prep) in_27/IN (l_pobj) tremor_28/NN
D016291_D014202 NONE MK-801_16/NNP (r_punct) produced_2/VBD (l_dobj) tremor_3/NN
D016291_D014202 NONE MK-801_2/NNP (r_punct) produced_4/VBD (l_dobj) increase_7/NN (l_prep) of_8/IN (l_pobj) tremor_9/NN
D016291_D014202 NONE MK-801_17/NNP (r_punct) induced_6/VBN (l_dobj) increases_7/NNS (l_prep) in_8/IN (l_pobj) tremor_9/NN
D016291_D014202 NONE MK-801_33/NNP (r_punct) injection_38/NN (r_nsubj) min_40/NN (r_nsubj) reversed_44/VBD (r_advcl) produced_13/VBD (l_conj) increases_26/NNS (l_prep) in_27/IN (l_pobj) tremor_28/NN
D012110_D009069 NONE Reserpine_0/NN (r_nsubj) produced_15/VBD (l_dobj) increases_16/NNS (l_prep) in_17/IN (l_pobj) dyskinesia_19/NN
D012110_D009069 NONE Reserpine_0/NN (r_nsubj) administered_6/VBN (r_ccomp) produce_29/VB (l_dobj) dyskinesia_31/NN
D016202_D002375 NONE NMDA_5/NNP (r_pobj) by_4/IN (r_agent) produced_3/VBN (r_acl) blockage_2/NN (r_nsubj) restore_7/VB (l_dobj) signs_9/NNS (l_prep) as_12/IN (l_pobj) movements_15/NNS (l_conj) protrusions_18/NNS (l_conj) catalepsy_20/NN
D012110_D002375 CID Reserpine_0/NN (r_nsubj) produced_2/VBD (l_dobj) tremor_3/NN (l_conj) catalepsy_5/NN
D012110_D002375 CID reserpine_25/NN (r_pobj) by_24/IN (r_agent) induced_23/VBN (r_acl) movements_17/NNS (l_conj) protrusions_20/NNS (l_conj) catalepsy_22/NN
D012110_D002375 CID reserpine_5/NN (r_nsubj) induced_6/VBN (l_dobj) increases_7/NNS (l_prep) in_8/IN (l_pobj) tremor_9/NN (l_conj) catalepsy_11/NN
D012110_D002375 CID reserpine_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) catalepsy_7/NN
D012110_D002375 CID reserpine_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (l_acl) produced_13/VBD (l_conj) increases_26/NNS (l_prep) in_27/IN (l_pobj) tremor_28/NN (l_conj) catalepsy_30/NN
D012110_D002375 CID reserpine_48/NN (r_pobj) of_47/IN (r_prep) effects_46/NNS (r_dobj) reversed_44/VBD (r_advcl) produced_13/VBD (l_conj) increases_26/NNS (l_prep) in_27/IN (l_pobj) tremor_28/NN (l_conj) catalepsy_30/NN
D001058_D009069 NONE apomophine_15/JJ (r_amod) injection_16/NN (r_pobj) by_14/IN (r_agent) followed_13/VBN (r_conj) administered_6/VBN (r_ccomp) produce_29/VB (l_dobj) dyskinesia_31/NN
15042318
D004317_C535648 NONE doxorubicin_34/NN (r_npadvmod) based_36/VBN (r_amod) chemotherapy_37/NN (r_pobj) of_33/IN (r_prep) cycle_32/NN (r_pobj) following_30/VBG (r_prep) fibrillation_29/NN (r_conj) form_20/NN (r_appos) dystrophy_15/NN (l_nmod) lymphoma_12/NN
D004317_D009136 NONE doxorubicin_34/NN (r_npadvmod) based_36/VBN (r_amod) chemotherapy_37/NN (r_pobj) of_33/IN (r_prep) cycle_32/NN (r_pobj) following_30/VBG (r_prep) fibrillation_29/NN (r_conj) form_20/NN (l_prep) of_21/IN (l_pobj) dystrophy_24/NN
D004317_D009223 NONE doxorubicin_34/NN (r_npadvmod) based_36/VBN (r_amod) chemotherapy_37/NN (r_pobj) of_33/IN (r_prep) cycle_32/NN (r_pobj) following_30/VBG (r_prep) fibrillation_29/NN (r_conj) form_20/NN (r_appos) dystrophy_15/NN
D004317_D001281 CID doxorubicin_34/NN (r_npadvmod) based_36/VBN (r_amod) chemotherapy_37/NN (r_pobj) of_33/IN (r_prep) cycle_32/NN (r_pobj) following_30/VBG (r_prep) fibrillation_29/NN
12231232
D006220_D009127 CID Haloperidol_0/NN (r_nsubj) induced_6/VBD (l_dobj) rigidity_11/NN
D006220_D009127 CID haloperidol_11/NN (r_npadvmod) induced_13/VBN (r_amod) rigidity_15/NN
D006220_D010300 NONE Haloperidol_0/NN (r_nsubj) induced_6/VBD (l_dobj) rigidity_11/NN (l_amod) parkinsonian_7/JJ
C095756_D009127 NONE AIDA_0/NNP (r_nsubj) diminished_9/VBD (l_dobj) rigidity_15/NN
12180796
D009569_D001167 NONE oxide_21/NN (r_compound) synthase_22/NN (r_pobj) of_19/IN (r_prep) type_18/NN (r_pobj) of_16/IN (r_prep) expressions_15/NNS (r_pobj) for_14/IN (r_prep) examined_12/VBN (r_conj) induced_1/VBN (l_nsubj) Arteritis_0/NNP
D013806_D009369 NONE theophylline_9/NN (r_conj) fenoldopam_7/NN (r_npadvmod) induced_1/VBN (l_conj) examined_12/VBN (l_prep) for_14/IN (l_pobj) expressions_15/NNS (l_prep) of_16/IN (l_pobj) type_18/NN (l_prep) of_19/IN (l_pobj) synthase_22/NN (l_appos) factor_30/NN (l_conj) beta1_39/NNP (l_compound) factor_37/NN (l_compound) tumor_35/NN
D013806_D001167 CID theophylline_14/NN (r_conj) fenoldopam_12/NN (r_pobj) by_11/IN (r_prep) rats_10/NNS (r_pobj) in_9/IN (r_prep) induced_8/VBN (l_nsubj) beta1_0/NNP (l_prep) in_6/IN (l_pobj) arteritis_7/NN
D013806_D001167 CID theophylline_9/NN (r_conj) fenoldopam_7/NN (r_npadvmod) induced_1/VBN (l_nsubj) Arteritis_0/NNP
D018818_D001167 CID fenoldopam_12/NN (r_pobj) by_11/IN (r_prep) rats_10/NNS (r_pobj) in_9/IN (r_prep) induced_8/VBN (l_nsubj) beta1_0/NNP (l_prep) in_6/IN (l_pobj) arteritis_7/NN
D018818_D001167 CID fenoldopam_7/NN (r_npadvmod) induced_1/VBN (l_nsubj) Arteritis_0/NNP
D018818_D009369 NONE fenoldopam_7/NN (r_npadvmod) induced_1/VBN (l_conj) examined_12/VBN (l_prep) for_14/IN (l_pobj) expressions_15/NNS (l_prep) of_16/IN (l_pobj) type_18/NN (l_prep) of_19/IN (l_pobj) synthase_22/NN (l_appos) factor_30/NN (l_conj) beta1_39/NNP (l_compound) factor_37/NN (l_compound) tumor_35/NN
D009569_D009369 NONE oxide_7/NN (l_appos) factor_15/NN (l_conj) growth_21/NN (l_compound) tumor_20/NN
D009569_D009369 NONE oxide_21/NN (r_compound) synthase_22/NN (l_appos) factor_30/NN (l_conj) beta1_39/NNP (l_compound) factor_37/NN (l_compound) tumor_35/NN
2722224
D006854_D016534 NONE hydrocortisone_7/NN (r_pobj) with_6/IN (r_prep) pressure_5/NN (r_dobj) resting_3/VBG (r_pcomp) in_2/IN (r_prep) rise_1/NN (r_nsubjpass) associated_9/VBN (l_prep) with_10/IN (l_pobj) output_14/NN
D006854_D006973 CID Hydrocortisone_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) hypertension_3/NN
D006854_D006973 CID hydrocortisone_7/NN (r_pobj) with_6/IN (r_prep) pressure_5/NN
7710775
D009599_D007511 NONE nitroprusside_4/NN (r_acl) drug_3/NN (r_pobj) of_0/IN (r_prep) min_13/NN (l_prep) during_15/IN (l_pobj) ischemia_16/NN
D008315_D007022 NONE malondialdehyde_23/NN (r_pobj) in_19/IN (r_prep) was_24/VBD (r_advcl) min_13/NN (l_prep) of_0/IN (l_pobj) drug_3/NN (l_amod) hypotensive_2/JJ
D009705_D007511 NONE nucleosides_12/NNS (r_conj) oxypurines_10/NNS (r_pobj) of_8/IN (r_prep) increase_7/NN (r_nsubjpass) observed_14/VBN (l_prep) During_0/IN (l_pobj) ischemia_1/NN
D009705_D007511 NONE nucleosides_13/NNS (r_conj) oxypurines_10/NNS (r_conj) malondialdehyde_8/NN (r_pobj) of_7/IN (r_prep) determination_6/NN (r_nsubjpass) used_20/VBN (l_xcomp) monitor_22/VB (l_dobj) alterations_25/NNS (l_acl) occurring_28/VBG (l_prep) during_29/IN (l_pobj) phenomena_31/NNS (l_amod) ischemic_30/JJ
D008315_D007511 NONE malondialdehyde_1/NN (r_nsubj) increased_23/VBD (l_prep) after_24/IN (l_pobj) min_26/NN (l_prep) of_27/IN (l_pobj) ischemia_28/NN
D008315_D007511 NONE malondialdehyde_23/NN (r_pobj) in_19/IN (r_prep) was_24/VBD (r_advcl) min_13/NN (l_prep) during_15/IN (l_pobj) ischemia_16/NN
D008315_D007511 NONE malondialdehyde_8/NN (r_pobj) of_7/IN (r_prep) determination_6/NN (r_nsubjpass) used_20/VBN (l_xcomp) monitor_22/VB (l_dobj) alterations_25/NNS (l_acl) occurring_28/VBG (l_prep) during_29/IN (l_pobj) phenomena_31/NNS (l_amod) ischemic_30/JJ
D009599_D007022 NONE nitroprusside_4/NN (r_acl) drug_3/NN (l_amod) hypotensive_2/JJ
D008315_D002545 CID malondialdehyde_4/NN (r_pobj) of_2/IN (r_prep) dependence_1/NN (r_nsubj) oxypurines_6/NNS (l_conj) nucleosides_9/NNS (l_prep) during_10/IN (l_pobj) ischemia_13/NN
D001241_D007511 NONE acetylsalicylate_4/VBP (l_prep) before_7/IN (l_pobj) ischemia_8/NN
-1_D002545 NONE oxypurines_6/NNS (l_conj) nucleosides_9/NNS (l_prep) during_10/IN (l_pobj) ischemia_13/NN
D009705_D002545 NONE nucleosides_9/NNS (l_prep) during_10/IN (l_pobj) ischemia_13/NN
-1_D007511 NONE oxypurines_10/NNS (r_pobj) of_8/IN (r_prep) increase_7/NN (r_nsubjpass) observed_14/VBN (l_prep) During_0/IN (l_pobj) ischemia_1/NN
-1_D007511 NONE oxypurines_10/NNS (r_conj) malondialdehyde_8/NN (r_pobj) of_7/IN (r_prep) determination_6/NN (r_nsubjpass) used_20/VBN (l_xcomp) monitor_22/VB (l_dobj) alterations_25/NNS (l_acl) occurring_28/VBG (l_prep) during_29/IN (l_pobj) phenomena_31/NNS (l_amod) ischemic_30/JJ
2716967
D009020_D000699 NONE morphine_7/NN (r_conj) ketamine_5/NN (r_nsubj) induced_8/VBN (l_dobj) analgesia_9/NN
D009020_D000699 NONE morphine_26/NN (r_pobj) to_25/IN (r_prep) tolerance_24/NN (r_dobj) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN
D009020_D000699 NONE morphine_31/NN (r_pobj) with_30/IN (r_prep) pretreatment_29/NN (r_nsubj) induce_34/VB (r_advcl) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN
D009020_D000699 NONE morphine_53/NN (r_pobj) to_51/IN (r_prep) attributed_50/VBN (l_ccomp) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN
D009270_D002375 NONE Naloxone_0/NN (r_nsubj) inhibited_1/VBD (l_dobj) effects_5/NNS (l_amod) cataleptic_4/JJ
D009270_D002375 NONE naloxone_36/NN (r_pobj) for_35/IN (r_prep) ID50_34/NNP (r_conj) asymmetry_24/NN (r_conj) differences_16/NNS (r_conj) catalepsy_14/NN
D009020_D009127 NONE morphine_21/NN (r_conj) ketamine_19/NN (r_pobj) of_18/IN (r_prep) predominance_17/NN (r_dobj) reflected_14/VBD (l_nsubj) Latency_0/NN (l_prep) to_1/IN (l_pobj) loss_3/NN (l_prep) of_4/IN (l_pobj) reflex_6/NN (l_conj) rigidity_8/NN
D009270_D009127 NONE naloxone_36/NN (r_pobj) for_35/IN (r_prep) ID50_34/NNP (r_conj) asymmetry_24/NN (r_conj) differences_16/NNS (l_prep) in_17/IN (l_pobj) latency_18/NN (l_conj) rigidity_20/NN
D007649_D009127 NONE ketamine_19/NN (r_pobj) of_18/IN (r_prep) predominance_17/NN (r_dobj) reflected_14/VBD (l_nsubj) Latency_0/NN (l_prep) to_1/IN (l_pobj) loss_3/NN (l_prep) of_4/IN (l_pobj) reflex_6/NN (l_conj) rigidity_8/NN
D007649_D002375 CID ketamine_5/NN (r_pobj) of_4/IN (r_prep) combinations_3/NNS (r_pobj) by_2/IN (r_agent) induced_1/VBN (l_nsubj) Catalepsy_0/NNP
D007649_D002375 CID ketamine_5/NN (r_nsubj) induced_8/VBN (l_dobj) analgesia_9/NN (l_conj) catalepsy_11/NN
D007649_D002375 CID ketamine_5/NN (r_nsubj) induced_8/VBN (r_ccomp) demonstrated_2/VBD (l_advcl) induce_34/VB (l_conj) augmented_42/VBD (l_dobj) response_45/NN (l_amod) cataleptic_44/JJ
D007649_D002375 CID ketamine_20/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_nsubj) produced_21/VBD (r_amod) tolerance_24/NN (r_dobj) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN (l_conj) catalepsy_11/NN
D007649_D002375 CID ketamine_20/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_nsubj) produced_21/VBD (r_amod) tolerance_24/NN (r_dobj) demonstrated_2/VBD (l_advcl) induce_34/VB (l_conj) augmented_42/VBD (l_dobj) response_45/NN (l_amod) cataleptic_44/JJ
D007649_D002375 CID ketamine_39/NN (r_pobj) to_38/IN (r_prep) tolerance_37/NN (r_dobj) induce_34/VB (r_advcl) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN (l_conj) catalepsy_11/NN
D007649_D002375 CID ketamine_39/NN (r_pobj) to_38/IN (r_prep) tolerance_37/NN (r_dobj) induce_34/VB (l_conj) augmented_42/VBD (l_dobj) response_45/NN (l_amod) cataleptic_44/JJ
D009020_D002375 CID morphine_7/NN (r_conj) ketamine_5/NN (r_pobj) of_4/IN (r_prep) combinations_3/NNS (r_pobj) by_2/IN (r_agent) induced_1/VBN (l_nsubj) Catalepsy_0/NNP
D009020_D002375 CID morphine_7/NN (r_conj) ketamine_5/NN (r_nsubj) induced_8/VBN (l_dobj) analgesia_9/NN (l_conj) catalepsy_11/NN
D009020_D002375 CID morphine_7/NN (r_conj) ketamine_5/NN (r_nsubj) induced_8/VBN (r_ccomp) demonstrated_2/VBD (l_advcl) induce_34/VB (l_conj) augmented_42/VBD (l_dobj) response_45/NN (l_amod) cataleptic_44/JJ
D009020_D002375 CID morphine_26/NN (r_pobj) to_25/IN (r_prep) tolerance_24/NN (r_dobj) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN (l_conj) catalepsy_11/NN
D009020_D002375 CID morphine_26/NN (r_pobj) to_25/IN (r_prep) tolerance_24/NN (r_dobj) demonstrated_2/VBD (l_advcl) induce_34/VB (l_conj) augmented_42/VBD (l_dobj) response_45/NN (l_amod) cataleptic_44/JJ
D009020_D002375 CID morphine_31/NN (r_pobj) with_30/IN (r_prep) pretreatment_29/NN (r_nsubj) induce_34/VB (r_advcl) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN (l_conj) catalepsy_11/NN
D009020_D002375 CID morphine_31/NN (r_pobj) with_30/IN (r_prep) pretreatment_29/NN (r_nsubj) induce_34/VB (l_conj) augmented_42/VBD (l_dobj) response_45/NN (l_amod) cataleptic_44/JJ
D009020_D002375 CID morphine_53/NN (r_pobj) to_51/IN (r_prep) attributed_50/VBN (l_ccomp) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN (l_conj) catalepsy_11/NN
D009020_D002375 CID morphine_53/NN (r_pobj) to_51/IN (r_prep) attributed_50/VBN (l_ccomp) demonstrated_2/VBD (l_advcl) induce_34/VB (l_conj) augmented_42/VBD (l_dobj) response_45/NN (l_amod) cataleptic_44/JJ
D007649_D000699 NONE ketamine_5/NN (r_nsubj) induced_8/VBN (l_dobj) analgesia_9/NN
D007649_D000699 NONE ketamine_20/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_nsubj) produced_21/VBD (r_amod) tolerance_24/NN (r_dobj) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN
D007649_D000699 NONE ketamine_39/NN (r_pobj) to_38/IN (r_prep) tolerance_37/NN (r_dobj) induce_34/VB (r_advcl) demonstrated_2/VBD (l_ccomp) induced_8/VBN (l_dobj) analgesia_9/NN
11524350
C037663_D006323 CID ropivacaine_17/NN (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_pobj) than_12/IN (r_prep) smaller_11/JJR (r_acomp) were_10/VBD (l_nsubj) doses_2/NNS (l_relcl) produced_6/VBD (l_dobj) dysrhythmias_7/NNS (l_conj) asystole_9/NN
C037663_D006323 CID ropivacaine_13/NN (r_pobj) of_12/IN (r_prep) that_11/DT (r_pobj) between_10/IN (r_prep) intermediate_9/JJ (r_acomp) is_8/VBZ (l_advcl) administered_17/VBN (l_conj) appears_29/VBZ (l_nsubj) arrest_28/NN
C037663_D006323 CID ropivacaine_24/NN (r_npadvmod) induced_26/VBN (r_amod) arrest_28/NN
C476513_D006323 CID levobupivacaine_4/NN (r_pobj) of_3/IN (r_prep) doses_2/NNS (l_relcl) produced_6/VBD (l_dobj) dysrhythmias_7/NNS (l_conj) asystole_9/NN
C476513_D006323 CID levobupivacaine_7/NN (r_pobj) of_6/IN (r_prep) toxicity_5/NN (r_nsubj) is_8/VBZ (l_advcl) administered_17/VBN (l_conj) appears_29/VBZ (l_nsubj) arrest_28/NN
C476513_D006323 CID levobupivacaine_42/NN (r_conj) bupivacaine_40/NN (r_pobj) by_39/IN (r_agent) induced_38/VBN (r_acl) that_37/DT (r_pobj) than_36/IN (r_prep) susceptible_33/JJ (r_acomp) be_31/VB (r_xcomp) appears_29/VBZ (l_nsubj) arrest_28/NN
D002045_D012640 NONE bupivacaine_18/NN (r_pobj) of_17/IN (r_prep) those_16/DT (r_pobj) than_15/IN (r_prep) larger_14/JJR (r_acomp) were_13/VBD (r_conj) were_10/VBD (l_nsubj) seizures_9/NNS
C476513_D001145 CID levobupivacaine_4/NN (r_pobj) of_3/IN (r_prep) doses_2/NNS (l_relcl) produced_6/VBD (l_dobj) dysrhythmias_7/NNS
C037663_D012640 CID ropivacaine_6/VBP (r_conj) levobupivacaine_4/NN (r_pobj) of_3/IN (r_prep) doses_2/NNS (r_nsubj) were_10/VBD (l_nsubj) seizures_9/NNS
D002045_D006323 NONE bupivacaine_26/NN (r_pobj) of_25/IN (r_prep) those_24/DT (r_pobj) than_23/IN (r_prep) larger_22/JJR (r_acomp) were_21/VBD (r_conj) were_10/VBD (l_nsubj) doses_2/NNS (l_relcl) produced_6/VBD (l_dobj) dysrhythmias_7/NNS (l_conj) asystole_9/NN
D002045_D006323 NONE bupivacaine_15/NN (r_conj) ropivacaine_13/NN (r_pobj) of_12/IN (r_prep) that_11/DT (r_pobj) between_10/IN (r_prep) intermediate_9/JJ (r_acomp) is_8/VBZ (l_advcl) administered_17/VBN (l_conj) appears_29/VBZ (l_nsubj) arrest_28/NN
D002045_D006323 NONE bupivacaine_40/NN (r_pobj) by_39/IN (r_agent) induced_38/VBN (r_acl) that_37/DT (r_pobj) than_36/IN (r_prep) susceptible_33/JJ (r_acomp) be_31/VB (r_xcomp) appears_29/VBZ (l_nsubj) arrest_28/NN
D002045_D001145 NONE bupivacaine_26/NN (r_pobj) of_25/IN (r_prep) those_24/DT (r_pobj) than_23/IN (r_prep) larger_22/JJR (r_acomp) were_21/VBD (r_conj) were_10/VBD (l_nsubj) doses_2/NNS (l_relcl) produced_6/VBD (l_dobj) dysrhythmias_7/NNS
D002045_D064420 NONE bupivacaine-_5/DT (r_nmod) rats_13/NNS (r_pobj) in_4/IN (r_prep) toxicity_1/NN
D002045_D064420 NONE bupivacaine_6/NN (r_pobj) of_5/IN (r_prep) toxicity_4/NN
D002045_D064420 NONE bupivacaine_15/NN (r_conj) ropivacaine_13/NN (r_pobj) of_12/IN (r_prep) that_11/DT (r_pobj) between_10/IN (r_prep) intermediate_9/JJ (r_acomp) is_8/VBZ (l_nsubj) toxicity_5/NN
D002045_D064420 NONE bupivacaine_40/NN (r_pobj) by_39/IN (r_agent) induced_38/VBN (r_acl) that_37/DT (r_pobj) than_36/IN (r_prep) susceptible_33/JJ (r_acomp) be_31/VB (r_xcomp) appears_29/VBZ (r_conj) administered_17/VBN (r_advcl) is_8/VBZ (l_nsubj) toxicity_5/NN
C476513_D012640 CID levobupivacaine_4/NN (r_pobj) of_3/IN (r_prep) doses_2/NNS (r_nsubj) were_10/VBD (l_nsubj) seizures_9/NNS
C476513_D064420 NONE levobupivacaine-_7/JJ (r_conj) bupivacaine-_5/DT (r_nmod) rats_13/NNS (r_pobj) in_4/IN (r_prep) toxicity_1/NN
C476513_D064420 NONE levobupivacaine_8/NN (r_conj) toxicity_4/NN
C476513_D064420 NONE levobupivacaine_7/NN (r_pobj) of_6/IN (r_prep) toxicity_5/NN
C476513_D064420 NONE levobupivacaine_42/NN (r_conj) bupivacaine_40/NN (r_pobj) by_39/IN (r_agent) induced_38/VBN (r_acl) that_37/DT (r_pobj) than_36/IN (r_prep) susceptible_33/JJ (r_acomp) be_31/VB (r_xcomp) appears_29/VBZ (r_conj) administered_17/VBN (r_advcl) is_8/VBZ (l_nsubj) toxicity_5/NN
C037663_D064420 NONE ropivacaine_10/NN (r_npadvmod) infused_12/VBN (r_conj) levobupivacaine-_7/JJ (r_conj) bupivacaine-_5/DT (r_nmod) rats_13/NNS (r_pobj) in_4/IN (r_prep) toxicity_1/NN
C037663_D064420 NONE ropivacaine_11/NN (r_conj) levobupivacaine_8/NN (r_conj) toxicity_4/NN
C037663_D064420 NONE ropivacaine_13/NN (r_pobj) of_12/IN (r_prep) that_11/DT (r_pobj) between_10/IN (r_prep) intermediate_9/JJ (r_acomp) is_8/VBZ (l_nsubj) toxicity_5/NN
C037663_D064420 NONE ropivacaine_24/NN (r_npadvmod) induced_26/VBN (r_amod) arrest_28/NN (r_nsubj) appears_29/VBZ (r_conj) administered_17/VBN (r_advcl) is_8/VBZ (l_nsubj) toxicity_5/NN
C037663_D001145 CID ropivacaine_17/NN (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_pobj) than_12/IN (r_prep) smaller_11/JJR (r_acomp) were_10/VBD (l_nsubj) doses_2/NNS (l_relcl) produced_6/VBD (l_dobj) dysrhythmias_7/NNS
7263204
D007213_D000741 CID indomethacin_5/NN (r_pobj) due_3/IN (r_amod) anemia_2/NN
D007213_D000741 CID indomethacin_1/NN (r_nsubjpass) implicated_4/VBN (l_prep) as_5/IN (l_pobj) cause_8/NN (l_prep) of_9/IN (l_pobj) anemia_11/NN
D007213_D000741 CID indomethacin_16/NN (r_conj) allopurinol_14/NN (r_pobj) than_13/IN (r_prep) other_12/JJ (r_amod) drugs_11/NNS (r_nsubjpass) given_18/VBN (r_relcl) described_7/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) anemia_5/NN
D007213_D000741 CID indomethacin_6/NN (r_pobj) with_5/IN (r_prep) test_4/NN (r_nsubj) substantiates_10/VBZ (l_dobj) role_13/NN (l_prep) in_17/IN (l_pcomp) causing_18/VBG (l_dobj) anemia_20/NN
D000493_D000741 NONE allopurinol_14/NN (r_pobj) than_13/IN (r_prep) other_12/JJ (r_amod) drugs_11/NNS (r_nsubjpass) given_18/VBN (r_relcl) described_7/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) anemia_5/NN
2422478
D015116_D007022 NONE 5,7-dihydroxytryptamine_53/CD (r_appos) neurotoxin_52/NN (r_pobj) by_49/IN (r_agent) abolished_48/VBN (r_conj) caused_26/VBD (l_dobj) hypotension_29/NN
D015116_D007022 NONE 5,7-DHT_55/NNP (r_appos) 5,7-dihydroxytryptamine_53/CD (r_appos) neurotoxin_52/NN (r_pobj) by_49/IN (r_agent) abolished_48/VBN (r_conj) caused_26/VBD (l_dobj) hypotension_29/NN
D015116_D007022 NONE 5,7-DHT_5/CD (r_pobj) of_4/IN (r_prep) injection_3/NN (r_nsubj) affect_23/VB (l_dobj) hypotension_25/NN
D012701_D006973 NONE serotonin_19/NN (r_compound) group_21/NN (r_pobj) of_15/IN (r_prep) area_14/NN (r_pobj) into_12/IN (r_prep) microinjection_9/NN (r_conj) rats_7/NNS (l_amod) hypertensive_2/JJ
D012701_D006973 NONE serotonin_51/NN (r_compound) neurotoxin_52/NN (r_pobj) by_49/IN (r_agent) abolished_48/VBN (r_conj) caused_26/VBD (l_prep) In_0/IN (l_pobj) rats_7/NNS (l_amod) hypertensive_2/JJ
D008750_D020521 NONE methyldopa_11/NN (r_pobj) of_10/IN (r_prep) microinjection_9/NN (r_conj) rats_7/NNS (l_amod) prone_6/JJ (l_npadvmod) stroke_4/NN
D015116_D020521 NONE 5,7-dihydroxytryptamine_53/CD (r_appos) neurotoxin_52/NN (r_pobj) by_49/IN (r_agent) abolished_48/VBN (r_conj) caused_26/VBD (l_prep) In_0/IN (l_pobj) rats_7/NNS (l_amod) prone_6/JJ (l_npadvmod) stroke_4/NN
D015116_D020521 NONE 5,7-DHT_55/NNP (r_appos) 5,7-dihydroxytryptamine_53/CD (r_appos) neurotoxin_52/NN (r_pobj) by_49/IN (r_agent) abolished_48/VBN (r_conj) caused_26/VBD (l_prep) In_0/IN (l_pobj) rats_7/NNS (l_amod) prone_6/JJ (l_npadvmod) stroke_4/NN
D008750_D007022 CID methyldopa_13/NN (r_pobj) of_12/IN (r_prep) effect_11/NN (l_amod) hypotensive_10/JJ
D008750_D007022 CID methyldopa_10/NN (r_pobj) of_9/IN (r_prep) microinjection_8/NN (r_nsubj) elicits_23/VBZ (l_dobj) response_26/NN (l_amod) hypotensive_25/JJ
D008750_D007022 CID methyldopa_11/NN (r_pobj) of_10/IN (r_prep) microinjection_9/NN (r_conj) rats_7/NNS (r_pobj) In_0/IN (r_prep) caused_26/VBD (l_dobj) hypotension_29/NN
D008750_D007022 CID methyldopa_14/NN (r_npadvmod) induced_16/VBN (r_amod) hypotension_17/NN
D008750_D007022 CID methyldopa_14/NN (r_npadvmod) induced_16/VBN (r_amod) hypotension_17/NN (r_dobj) mediate_12/VBP (r_relcl) cells_10/NNS (r_pobj) unlike_6/IN (r_prep) contribute_30/VB (l_prep) to_31/IN (l_pobj) action_34/NN (l_amod) hypotensive_33/JJ
D008750_D007022 CID methyldopa_36/NN (r_pobj) of_35/IN (r_prep) action_34/NN (r_pobj) to_31/IN (r_prep) contribute_30/VB (l_prep) unlike_6/IN (l_pobj) cells_10/NNS (l_relcl) mediate_12/VBP (l_dobj) hypotension_17/NN
D008750_D007022 CID methyldopa_36/NN (r_pobj) of_35/IN (r_prep) action_34/NN (l_amod) hypotensive_33/JJ
D012701_D007022 NONE serotonin_2/NN (r_compound) nerves_3/NNS (r_nsubjpass) involved_8/VBN (l_prep) in_9/IN (l_pobj) effect_11/NN (l_amod) hypotensive_10/JJ
D012701_D007022 NONE serotonin_18/NN (r_compound) neurons_19/NNS (r_pobj) of_15/IN (r_prep) cells_14/NNS (r_pobj) onto_11/IN (r_prep) microinjection_8/NN (r_nsubj) elicits_23/VBZ (l_dobj) response_26/NN (l_amod) hypotensive_25/JJ
D012701_D007022 NONE serotonin_19/NN (r_compound) group_21/NN (r_pobj) of_15/IN (r_prep) area_14/NN (r_pobj) into_12/IN (r_prep) microinjection_9/NN (r_conj) rats_7/NNS (r_pobj) In_0/IN (r_prep) caused_26/VBD (l_dobj) hypotension_29/NN
D012701_D007022 NONE serotonin_51/NN (r_compound) neurotoxin_52/NN (r_pobj) by_49/IN (r_agent) abolished_48/VBN (r_conj) caused_26/VBD (l_dobj) hypotension_29/NN
D012701_D007022 NONE serotonin_15/NN (r_compound) projections_16/NNS (r_dobj) descending_14/VBG (r_pcomp) of_12/IN (r_prep) lesion_11/NN (r_dobj) produce_7/VB (r_relcl) injection_3/NN (r_nsubj) affect_23/VB (l_dobj) hypotension_25/NN
D012701_D007022 NONE serotonin_24/NN (r_compound) cells_26/NNS (r_nsubj) contribute_30/VB (l_prep) unlike_6/IN (l_pobj) cells_10/NNS (l_relcl) mediate_12/VBP (l_dobj) hypotension_17/NN
D012701_D007022 NONE serotonin_24/NN (r_compound) cells_26/NNS (r_nsubj) contribute_30/VB (l_prep) to_31/IN (l_pobj) action_34/NN (l_amod) hypotensive_33/JJ
D012701_D020521 NONE serotonin_19/NN (r_compound) group_21/NN (r_pobj) of_15/IN (r_prep) area_14/NN (r_pobj) into_12/IN (r_prep) microinjection_9/NN (r_conj) rats_7/NNS (l_amod) prone_6/JJ (l_npadvmod) stroke_4/NN
D012701_D020521 NONE serotonin_51/NN (r_compound) neurotoxin_52/NN (r_pobj) by_49/IN (r_agent) abolished_48/VBN (r_conj) caused_26/VBD (l_prep) In_0/IN (l_pobj) rats_7/NNS (l_amod) prone_6/JJ (l_npadvmod) stroke_4/NN
D008750_D006973 NONE methyldopa_11/NN (r_pobj) of_10/IN (r_prep) microinjection_9/NN (r_conj) rats_7/NNS (l_amod) hypertensive_2/JJ
D015116_D006973 NONE 5,7-dihydroxytryptamine_53/CD (r_appos) neurotoxin_52/NN (r_pobj) by_49/IN (r_agent) abolished_48/VBN (r_conj) caused_26/VBD (l_prep) In_0/IN (l_pobj) rats_7/NNS (l_amod) hypertensive_2/JJ
D015116_D006973 NONE 5,7-DHT_55/NNP (r_appos) 5,7-dihydroxytryptamine_53/CD (r_appos) neurotoxin_52/NN (r_pobj) by_49/IN (r_agent) abolished_48/VBN (r_conj) caused_26/VBD (l_prep) In_0/IN (l_pobj) rats_7/NNS (l_amod) hypertensive_2/JJ
8686832
D000431_D010146 NONE alcohol_27/NN (r_compound) intake_28/NN (r_pobj) to_24/IN (r_prep) admitted_23/VBD (r_acl) pain_22/NN (r_pobj) without_21/IN (r_prep) pain_10/NN
D000431_D010146 NONE alcohol_27/NN (r_compound) intake_28/NN (r_pobj) to_24/IN (r_prep) admitted_23/VBD (r_acl) pain_22/NN
D008012_D001416 CID lignocaine_11/NN (r_dobj) involving_7/VBG (r_acl) anaesthesia_6/NN (r_pobj) after_4/IN (r_prep) pain_3/NN
D008012_D001416 CID lignocaine_14/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (l_nsubjpass) Leg_0/NNP (l_conj) pain_3/NN
15531665
D019207_D003920 NONE carotene_29/NN (r_conj) E_24/NN (r_pobj) of_20/IN (r_prep) intakes_19/NNS (r_conj) duration_14/NN (r_conj) type_8/NN (l_prep) of_9/IN (l_pobj) medication_11/NN (l_compound) diabetes_10/NN
D019207_D003920 NONE carotene_29/NN (r_conj) E_24/NN (r_pobj) of_20/IN (r_prep) intakes_19/NNS (r_conj) duration_14/NN (l_prep) of_15/IN (l_pobj) diabetes_16/NNS
D014810_D003920 NONE E_24/NN (r_pobj) of_20/IN (r_prep) intakes_19/NNS (r_conj) duration_14/NN (r_conj) type_8/NN (l_prep) of_9/IN (l_pobj) medication_11/NN (l_compound) diabetes_10/NN
D014810_D003920 NONE E_24/NN (r_pobj) of_20/IN (r_prep) intakes_19/NNS (r_conj) duration_14/NN (l_prep) of_15/IN (l_pobj) diabetes_16/NNS
D019207_D002318 NONE carotene_29/NN (r_conj) E_24/NN (r_pobj) of_20/IN (r_prep) intakes_19/NNS (r_conj) duration_14/NN (r_conj) type_8/NN (r_appos) factors_6/NNS (l_compound) risk_5/NN (l_compound) disease_4/NN
D019207_D002318 NONE carotene_29/NN (l_appos) risks_34/NNS (l_prep) of_35/IN (l_pobj) mortality_39/NN (l_compound) disease_38/NN
D001205_D002318 CID C_3/NN (r_nsubj) increase_4/VB (l_dobj) risk_7/NN (l_compound) disease_6/NN
D001205_D002318 CID C_10/NN (r_compound) intake_11/NN (l_prep) from_14/IN (l_pobj) disease_16/NN
D001205_D002318 CID C_6/NN (r_compound) intake_7/NN (l_prep) from_10/IN (l_pobj) disease_13/NN
D001205_D002318 CID C_63/NN (r_compound) intake_64/NN (r_pobj) of_60/IN (r_prep) quintiles_59/NNS (r_pobj) across_58/IN (r_prep) 1.0_41/CD (r_attr) were_40/VBD (l_nsubj) adjustment_1/NN (l_prep) for_2/IN (l_pobj) factors_6/NNS (l_compound) risk_5/NN (l_compound) disease_4/NN
D001205_D002318 CID C_63/NN (r_compound) intake_64/NN (r_pobj) of_60/IN (r_prep) quintiles_59/NNS (r_pobj) across_58/IN (r_prep) 1.0_41/CD (r_attr) were_40/VBD (l_nsubj) adjustment_1/NN (l_prep) for_2/IN (l_pobj) factors_6/NNS (l_appos) type_8/NN (l_conj) duration_14/NN (l_conj) intakes_19/NNS (l_prep) of_20/IN (l_pobj) E_24/NN (l_conj) carotene_29/NN (l_appos) risks_34/NNS (l_prep) of_35/IN (l_pobj) mortality_39/NN (l_compound) disease_38/NN
D001205_D002318 CID C_1/NN (r_compound) intake_2/NN (r_nsubj) was_3/VBD (l_acomp) unrelated_4/JJ (l_prep) to_5/IN (l_pobj) mortality_6/NN (l_prep) from_7/IN (l_pobj) disease_9/NN
D001205_D002318 CID C_3/NN (r_compound) intake_4/NN (r_nsubjpass) associated_8/VBN (l_prep) with_9/IN (l_pobj) risk_12/NN (l_prep) of_13/IN (l_pobj) mortality_16/NN (l_compound) disease_15/NN
D001205_D050197 NONE C_12/NN (r_pobj) of_10/IN (r_prep) intake_9/NN (r_nsubj) promote_17/VB (l_dobj) atherosclerosis_18/NN
D014810_D002318 NONE E_24/NN (r_pobj) of_20/IN (r_prep) intakes_19/NNS (r_conj) duration_14/NN (r_conj) type_8/NN (r_appos) factors_6/NNS (l_compound) risk_5/NN (l_compound) disease_4/NN
D014810_D002318 NONE E_24/NN (l_conj) carotene_29/NN (l_appos) risks_34/NNS (l_prep) of_35/IN (l_pobj) mortality_39/NN (l_compound) disease_38/NN
D005492_D002318 NONE folate_21/NN (r_nmod) E_24/NN (r_pobj) of_20/IN (r_prep) intakes_19/NNS (r_conj) duration_14/NN (r_conj) type_8/NN (r_appos) factors_6/NNS (l_compound) risk_5/NN (l_compound) disease_4/NN
D005492_D002318 NONE folate_21/NN (r_nmod) E_24/NN (l_conj) carotene_29/NN (l_appos) risks_34/NNS (l_prep) of_35/IN (l_pobj) mortality_39/NN (l_compound) disease_38/NN
D001205_D020521 NONE C_6/NN (r_compound) intake_7/NN (r_pobj) between_4/IN (r_prep) relation_3/NN (r_dobj) studied_1/VBD (l_dep) disease_22/NN (l_conj) stroke_30/NN
D001205_D003324 NONE C_6/NN (r_compound) intake_7/NN (r_pobj) between_4/IN (r_prep) relation_3/NN (r_dobj) studied_1/VBD (l_dep) disease_22/NN
D001205_D003920 NONE C_3/NN (r_nsubj) increase_4/VB (l_dobj) risk_7/NN (l_prep) in_8/IN (l_pobj) women_9/NNS (l_prep) with_10/IN (l_pobj) diabetes_11/NNS
D001205_D003920 NONE C_12/NN (r_pobj) of_10/IN (r_prep) intake_9/NN (l_prep) in_13/IN (l_pobj) persons_15/NNS (l_amod) diabetic_14/JJ
D001205_D003920 NONE C_6/NN (r_compound) intake_7/NN (r_pobj) between_4/IN (r_prep) relation_3/NN (r_dobj) studied_1/VBD (l_dep) disease_22/NN (l_conj) stroke_30/NN (l_prep) in_36/IN (l_pobj) women_39/NNS (l_relcl) reported_41/VBD (l_xcomp) being_42/VBG (l_acomp) diabetic_43/JJ
D001205_D003920 NONE C_63/NN (r_compound) intake_64/NN (r_pobj) of_60/IN (r_prep) quintiles_59/NNS (r_pobj) across_58/IN (r_prep) 1.0_41/CD (r_attr) were_40/VBD (l_nsubj) adjustment_1/NN (l_prep) for_2/IN (l_pobj) factors_6/NNS (l_appos) type_8/NN (l_prep) of_9/IN (l_pobj) medication_11/NN (l_compound) diabetes_10/NN
D001205_D003920 NONE C_63/NN (r_compound) intake_64/NN (r_pobj) of_60/IN (r_prep) quintiles_59/NNS (r_pobj) across_58/IN (r_prep) 1.0_41/CD (r_attr) were_40/VBD (l_nsubj) adjustment_1/NN (l_prep) for_2/IN (l_pobj) factors_6/NNS (l_appos) type_8/NN (l_conj) duration_14/NN (l_prep) of_15/IN (l_pobj) diabetes_16/NNS
D001205_D003920 NONE C_3/NN (r_compound) intake_4/NN (r_nsubjpass) associated_8/VBN (l_prep) with_9/IN (l_pobj) risk_12/NN (l_prep) of_13/IN (l_pobj) mortality_16/NN (l_prep) in_17/IN (l_pobj) women_19/NNS (l_prep) with_20/IN (l_pobj) diabetes_21/NNS
D005492_D003920 NONE folate_21/NN (r_nmod) E_24/NN (r_pobj) of_20/IN (r_prep) intakes_19/NNS (r_conj) duration_14/NN (r_conj) type_8/NN (l_prep) of_9/IN (l_pobj) medication_11/NN (l_compound) diabetes_10/NN
D005492_D003920 NONE folate_21/NN (r_nmod) E_24/NN (r_pobj) of_20/IN (r_prep) intakes_19/NNS (r_conj) duration_14/NN (l_prep) of_15/IN (l_pobj) diabetes_16/NNS
4090988
D000082_D001744 NONE paracetamol_7/NN (r_npadvmod) treated_9/VBN (r_amod) rats_10/NNS (r_pobj) of_6/IN (r_prep) %_5/NN (r_nsubj) developed_11/VBD (l_dobj) hyperplasia_12/NN (l_prep) of_13/IN (l_pobj) epithelium_16/NN (l_relcl) was_19/VBD (l_acomp) coincident_21/JJ (l_prep) with_22/IN (l_pobj) presence_24/NN (l_prep) of_25/IN (l_pobj) calculi_27/NNS
D000082_D009369 NONE paracetamol_12/JJ (r_compound) feeding_13/NN (r_dobj) following_11/VBG (r_prep) arose_10/VBD (l_nsubj) yield_2/NN (l_prep) of_3/IN (l_pobj) tumours_4/NNS
D000082_D010212 NONE paracetamol_11/RB (r_npadvmod) treated_13/VBN (r_amod) groups_14/NNS (r_pobj) in_9/IN (r_prep) developed_8/VBN (l_nsubj) Papillomas_0/NNP
D000082_D006965 CID paracetamol_7/NN (r_npadvmod) treated_9/VBN (r_amod) rats_10/NNS (r_pobj) of_6/IN (r_prep) %_5/NN (r_nsubj) developed_11/VBD (l_dobj) hyperplasia_12/NN
D000082_D001749 CID paracetamol_2/NN (l_prep) of_3/IN (l_pobj) tumours_7/NNS
D000082_D001749 CID paracetamol_11/RB (r_npadvmod) treated_13/VBN (r_amod) groups_14/NNS (r_pobj) in_9/IN (r_prep) developed_8/VBN (l_conj) bore_19/VBD (l_dobj) carcinomas_21/NNS
D000082_D008113 CID paracetamol_2/NN (l_prep) of_3/IN (l_pobj) tumours_7/NNS
D000082_D008113 CID paracetamol_8/NN (r_npadvmod) treated_10/VBN (r_amod) rats_11/NNS (r_pobj) of_7/IN (r_prep) livers_6/NNS (r_pobj) of_4/IN (r_prep) study_3/NN (r_nsubj) revealed_12/VBD (l_dobj) changes_14/NNS (l_relcl) resemble_19/VBP (l_dobj) those_20/DT (l_relcl) result_22/NN (l_prep) from_23/IN (l_pobj) exposure_24/NN (l_prep) to_25/IN (l_pobj) variety_27/NN (l_prep) of_28/IN (l_pobj) hepatocarcinogens_30/NNS
10743694
591536
D006493_D013927 NONE heparin_24/JJ (r_compound) therapy_25/NN (r_pobj) of_23/IN (r_prep) initiation_22/NN (r_pobj) after_20/IN (r_prep) occurring_15/VBG (r_pcomp) by_7/IN (l_pobj) thrombi_11/NN
D006493_D007511 NONE heparin_24/JJ (r_compound) therapy_25/NN (r_pobj) of_23/IN (r_prep) initiation_22/NN (r_pobj) after_20/IN (r_prep) occurring_15/VBG (r_pcomp) by_7/IN (l_pobj) thrombi_11/NN (l_prep) with_12/IN (l_pobj) ischemia_14/NN
D006493_D013923 NONE heparin_6/JJ (r_compound) therapy_7/NN (r_dobj) receiving_4/VBG (r_acl) patients_3/NNS (r_pobj) in_2/IN (r_prep) thromboembolism_1/NN
D006493_D013923 NONE heparin_13/NN (r_npadvmod) induced_15/VBN (r_amod) thrombocytopenia_16/NN (r_pobj) with_12/IN (r_prep) associated_11/VBN (r_acl) complication_10/NN (r_appos) thromboembolism_1/NN
D006493_D013923 NONE heparin_8/JJ (r_compound) therapy_9/NN (r_pobj) of_6/IN (r_prep) complication_5/NN (r_attr) is_2/VBZ (l_nsubj) thromboembolism_1/NN
D006493_D013923 NONE heparin_8/VBN (r_npadvmod) induced_10/VBN (r_amod) aggregation_12/NN (r_attr) is_7/VBZ (l_nsubj) factor_2/NN (l_acl) relating_3/VBG (l_dobj) thromboembolism_4/NN
D006493_D001157 CID heparin_24/JJ (r_compound) therapy_25/NN (r_pobj) of_23/IN (r_prep) initiation_22/NN (r_pobj) after_20/IN (r_prep) occurring_15/VBG (r_pcomp) by_7/IN (r_prep) occlusion_6/NN
D006493_D001791 NONE heparin_8/VBN (r_npadvmod) induced_10/VBN (r_amod) aggregation_12/NN
D006493_D013921 CID heparin_6/JJ (r_compound) therapy_7/NN (r_dobj) receiving_4/VBG (r_acl) patients_3/NNS (r_pobj) in_2/IN (r_prep) thromboembolism_1/NN (l_appos) complication_10/NN (l_acl) associated_11/VBN (l_prep) with_12/IN (l_pobj) thrombocytopenia_16/NN
D006493_D013921 CID heparin_13/NN (r_npadvmod) induced_15/VBN (r_amod) thrombocytopenia_16/NN
D006493_D013921 CID heparin_24/JJ (r_compound) therapy_25/NN (r_pobj) of_23/IN (r_prep) initiation_22/NN (r_pobj) after_20/IN (r_prep) occurring_15/VBG (r_pcomp) by_7/IN (r_prep) occlusion_6/NN (l_acl) preceded_27/VBN (l_agent) by_28/IN (l_pobj) thrombocytopenia_30/NN
D006493_D013921 CID heparin_8/VBN (r_npadvmod) induced_10/VBN (r_amod) aggregation_12/NN (r_attr) is_7/VBZ (l_nsubj) factor_2/NN (l_acl) relating_3/VBG (l_dobj) thromboembolism_4/NN (l_conj) thrombocytopenia_6/NN
12760988
D013390_D010149 CID succinylcholine_3/NN (r_pobj) after_2/IN (r_prep) myalgia_1/NN
D013390_D010149 CID succinylcholine_6/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) effect_3/NN (r_nsubj) is_7/VBZ (l_attr) myalgia_9/NN
D013390_D010149 CID succinylcholine_6/NN (r_pobj) before_5/IN (r_punct) IMPLICATIONS_0/NNS (r_nsubj) was_7/VBD (l_acomp) effective_9/JJ (l_prep) in_10/IN (l_pcomp) decreasing_11/VBG (l_dobj) incidence_13/NN (l_conj) severity_16/NN (l_prep) of_17/IN (l_pobj) myalgia_22/NN
D013390_D010149 CID succinylcholine_18/NN (r_npadvmod) induced_20/VBN (r_amod) myalgia_22/NN
D013390_D010149 CID succinylcholine_11/NN (r_pobj) after_10/IN (r_prep) prevent_7/VB (l_dobj) myalgia_9/NN
D003907_D063806 NONE dexamethasone_18/NN (r_conj) saline_16/NN (r_pobj) with_15/IN (r_prep) pretreated_14/VBN (r_acl) patients_13/NNS (r_pobj) in_11/IN (r_prep) determined_10/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_4/IN (l_pobj) myalgia_8/NN
D003907_D063806 NONE dexamethasone_18/NN (r_compound) group_19/NN (r_pobj) in_16/IN (r_prep) patients_15/NNS (r_nsubj) complained_20/VBD (r_acl) groups_12/NNS (r_pobj) between_9/IN (r_prep) differ_7/VB (l_nsubj) Incidence_0/NN (l_conj) severity_2/NN (l_prep) of_3/IN (l_pobj) myalgia_4/NN
D003907_D063806 NONE dexamethasone_18/NN (r_compound) group_19/NN (r_pobj) in_16/IN (r_prep) patients_15/NNS (r_nsubj) complained_20/VBD (l_prep) of_21/IN (l_pobj) myalgia_22/NN
D003907_D063806 NONE dexamethasone_18/NN (r_compound) group_19/NN (r_pobj) in_16/IN (r_prep) patients_15/NNS (r_nsubj) complained_20/VBD (l_conj) reported_36/VBN (l_nsubjpass) myalgia_34/NN
D013390_D063806 CID succinylcholine_5/NN (r_npadvmod) associated_7/VBN (r_amod) myalgia_8/NN
D013390_D063806 CID succinylcholine_20/NN (r_pobj) before_19/IN (r_prep) pretreated_14/VBN (r_acl) patients_13/NNS (r_pobj) in_11/IN (r_prep) determined_10/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_4/IN (l_pobj) myalgia_8/NN
D013390_D063806 CID succinylcholine_12/NN (r_npadvmod) associated_14/VBN (r_amod) myalgia_15/NN
D003907_D010149 NONE dexamethasone_4/NN (r_pobj) of_3/IN (r_prep) Administration_2/NN (r_appos) IMPLICATIONS_0/NNS (r_nsubj) was_7/VBD (l_acomp) effective_9/JJ (l_prep) in_10/IN (l_pcomp) decreasing_11/VBG (l_dobj) incidence_13/NN (l_conj) severity_16/NN (l_prep) of_17/IN (l_pobj) myalgia_22/NN
D003907_D010149 NONE dexamethasone_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) is_3/VBZ (l_acomp) justified_5/VBN (l_xcomp) prevent_7/VB (l_dobj) myalgia_9/NN
17965424
D004008_D004487 NONE diclofenac_28/NNP (r_pobj) with_27/IN (r_prep) compared_26/VBN (r_prep) were_13/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) discontinuations_3/NNS (l_prep) for_4/IN (l_pobj) AEs_12/NNS (l_amod) related_7/VBN (l_conj) related_11/VBN (l_npadvmod) oedema_9/NN
D004008_D004487 NONE diclofenac_28/NNP (r_pobj) with_27/IN (r_prep) compared_26/VBN (r_prep) were_13/VBD (l_dep) p<0.001_37/VB (l_prep) for_38/IN (l_pobj) hypertension_39/NN (l_conj) p<0.01_41/NN (l_prep) for_42/IN (l_pobj) oedema_43/NN
C422649_D005767 NONE etoricoxib_12/NN (r_pobj) with_11/IN (r_prep) lower_10/JJR (r_acomp) was_8/VBD (l_nsubj) rate_3/NN (l_amod) due_4/IN (l_pcomp) to_5/IN (l_pobj) AEs_7/NNS
C422649_D005767 NONE Etoricoxib_0/NNP (r_nsubj) demonstrated_3/VBD (l_dobj) risk_7/NN (l_prep) for_8/IN (l_pcomp) discontinuing_9/VBG (l_prep) due_11/IN (l_pcomp) to_12/IN (l_pobj) AEs_14/NNS
C422649_D005767 NONE Etoricoxib_0/NNP (r_nsubj) demonstrated_3/VBD (l_advcl) common_27/JJ (l_prep) than_28/IN (l_pobj) discontinuations_29/NNS (l_prep) from_30/IN (l_pobj) AEs_32/NNS
C422649_D005767 NONE etoricoxib_38/NN (r_pobj) with_37/IN (r_prep) higher_36/JJR (r_acomp) were_34/VBD (l_ccomp) demonstrated_3/VBD (l_dobj) risk_7/NN (l_prep) for_8/IN (l_pcomp) discontinuing_9/VBG (l_prep) due_11/IN (l_pcomp) to_12/IN (l_pobj) AEs_14/NNS
C422649_D005767 NONE etoricoxib_38/NN (r_pobj) with_37/IN (r_prep) higher_36/JJR (r_acomp) were_34/VBD (l_ccomp) demonstrated_3/VBD (l_advcl) common_27/JJ (l_prep) than_28/IN (l_pobj) discontinuations_29/NNS (l_prep) from_30/IN (l_pobj) AEs_32/NNS
C422649_D006973 CID etoricoxib_17/NN (r_pobj) with_16/IN (r_prep) higher_15/JJR (r_acomp) were_13/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) discontinuations_3/NNS (l_prep) for_4/IN (l_pobj) AEs_12/NNS (l_amod) related_7/VBN (l_npadvmod) hypertension_5/NN
C422649_D006973 CID etoricoxib_17/NN (r_pobj) with_16/IN (r_prep) higher_15/JJR (r_acomp) were_13/VBD (l_dep) p<0.001_37/VB (l_prep) for_38/IN (l_pobj) hypertension_39/NN
D004008_D001172 NONE sodium_15/NN (r_compound) tolerability_17/NN (r_pobj) vs_13/IN (r_prep) etoricoxib_12/NN (r_pobj) of_10/IN (r_prep) results_9/NNS (r_appos) tolerability_1/NN (l_prep) of_2/IN (l_pobj) etoricoxib_3/NN (l_prep) in_4/IN (l_pobj) patients_7/NNS (l_compound) arthritis_6/NN
D004008_D001172 NONE diclofenac_22/NN (r_conj) etoricoxib_20/NN (r_pobj) of_19/IN (r_prep) tolerability_14/NN (r_dobj) compare_8/VB (l_prep) in_23/IN (l_pobj) patients_24/NNS (l_prep) with_25/IN (l_pobj) arthritis_27/NN
D004008_D001172 NONE diclofenac_22/NN (r_conj) etoricoxib_20/NN (r_pobj) of_19/IN (r_prep) tolerability_14/NN (r_dobj) compare_8/VB (l_prep) in_23/IN (l_pobj) patients_24/NNS (l_prep) with_25/IN (l_pobj) arthritis_27/NN (l_appos) RA_29/NNP
D004008_D001172 NONE diclofenac_28/NN (r_nmod) mg_30/NN (r_compound) twice_31/RB (r_conj) enrolled_15/VBN (l_nsubjpass) years_9/NNS (l_acl) diagnosed_11/VBD (l_prep) with_12/IN (l_pobj) RA_13/NNP
C422649_D004487 CID etoricoxib_17/NN (r_pobj) with_16/IN (r_prep) higher_15/JJR (r_acomp) were_13/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) discontinuations_3/NNS (l_prep) for_4/IN (l_pobj) AEs_12/NNS (l_amod) related_7/VBN (l_conj) related_11/VBN (l_npadvmod) oedema_9/NN
C422649_D004487 CID etoricoxib_17/NN (r_pobj) with_16/IN (r_prep) higher_15/JJR (r_acomp) were_13/VBD (l_dep) p<0.001_37/VB (l_prep) for_38/IN (l_pobj) hypertension_39/NN (l_conj) p<0.01_41/NN (l_prep) for_42/IN (l_pobj) oedema_43/NN
C422649_D001172 NONE etoricoxib_3/NN (l_prep) in_4/IN (l_pobj) patients_7/NNS (l_compound) arthritis_6/NN
C422649_D001172 NONE etoricoxib_12/NN (r_pobj) of_10/IN (r_prep) results_9/NNS (r_appos) tolerability_1/NN (l_prep) of_2/IN (l_pobj) etoricoxib_3/NN (l_prep) in_4/IN (l_pobj) patients_7/NNS (l_compound) arthritis_6/NN
C422649_D001172 NONE etoricoxib_20/NN (r_pobj) of_19/IN (r_prep) tolerability_14/NN (r_dobj) compare_8/VB (l_prep) in_23/IN (l_pobj) patients_24/NNS (l_prep) with_25/IN (l_pobj) arthritis_27/NN
C422649_D001172 NONE etoricoxib_20/NN (r_pobj) of_19/IN (r_prep) tolerability_14/NN (r_dobj) compare_8/VB (l_prep) in_23/IN (l_pobj) patients_24/NNS (l_prep) with_25/IN (l_pobj) arthritis_27/NN (l_appos) RA_29/NNP
C422649_D001172 NONE etoricoxib_18/RB (r_dobj) received_17/VBN (r_conj) enrolled_15/VBN (l_nsubjpass) years_9/NNS (l_acl) diagnosed_11/VBD (l_prep) with_12/IN (l_pobj) RA_13/NNP
D004008_D005767 CID diclofenac_14/NNP (r_pobj) than_13/IN (r_prep) etoricoxib_12/NN (r_pobj) with_11/IN (r_prep) lower_10/JJR (r_acomp) was_8/VBD (l_nsubj) rate_3/NN (l_amod) due_4/IN (l_pcomp) to_5/IN (l_pobj) AEs_7/NNS
D004008_D005767 CID diclofenac_17/NNP (r_nmod) Discontinuations_20/NNS (r_pobj) with_16/IN (r_prep) compared_15/VBN (r_prep) discontinuing_9/VBG (l_prep) due_11/IN (l_pcomp) to_12/IN (l_pobj) AEs_14/NNS
D004008_D005767 CID diclofenac_17/NNP (r_nmod) Discontinuations_20/NNS (r_pobj) with_16/IN (r_prep) compared_15/VBN (r_prep) discontinuing_9/VBG (r_pcomp) for_8/IN (r_prep) risk_7/NN (r_dobj) demonstrated_3/VBD (l_advcl) common_27/JJ (l_prep) than_28/IN (l_pobj) discontinuations_29/NNS (l_prep) from_30/IN (l_pobj) AEs_32/NNS
D004008_D006973 NONE diclofenac_28/NNP (r_pobj) with_27/IN (r_prep) compared_26/VBN (r_prep) were_13/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) discontinuations_3/NNS (l_prep) for_4/IN (l_pobj) AEs_12/NNS (l_amod) related_7/VBN (l_npadvmod) hypertension_5/NN
D004008_D006973 NONE diclofenac_28/NNP (r_pobj) with_27/IN (r_prep) compared_26/VBN (r_prep) were_13/VBD (l_dep) p<0.001_37/VB (l_prep) for_38/IN (l_pobj) hypertension_39/NN
2343592
C044650_D006259 NONE cilastatin_32/NN (r_pobj) of_29/IN (r_prep) doses_28/NNS (r_dobj) receiving_26/VBG (r_advcl) developed_23/VBN (r_conj) head_15/NN (l_dobj) trauma_16/NN
C044650_D012640 CID cilastatin_32/NN (r_pobj) of_29/IN (r_prep) doses_28/NNS (r_dobj) receiving_26/VBG (r_advcl) developed_23/VBN (l_dobj) seizures_24/NNS
C044650_D020521 NONE cilastatin_32/NN (r_pobj) of_29/IN (r_prep) doses_28/NNS (r_dobj) receiving_26/VBG (r_advcl) developed_23/VBN (r_conj) head_15/NN (l_nsubj) patients_2/NNS (l_prep) with_3/IN (l_pobj) history_5/NN (l_prep) of_6/IN (l_pobj) accident_10/NN
C044650_D020521 NONE cilastatin_32/NN (r_pobj) of_29/IN (r_prep) doses_28/NNS (r_dobj) receiving_26/VBG (r_advcl) developed_23/VBN (r_conj) head_15/NN (l_nsubj) patients_2/NNS (l_prep) with_3/IN (l_pobj) history_5/NN (l_prep) of_6/IN (l_pobj) accident_10/NN (l_appos) CVA_12/NNP
D047090_D012640 NONE lactam_10/NN (r_compound) antibiotics_11/NNS (r_pobj) of_6/IN (r_prep) doses_5/NNS (r_dobj) received_3/VBN (l_prep) without_12/IN (l_pobj) evidence_13/NN (l_prep) of_14/IN (l_pobj) activity_16/NN (l_compound) seizure_15/NN
C044650_D007674 NONE cilastatin_32/NN (r_pobj) of_29/IN (r_prep) doses_28/NNS (r_dobj) receiving_26/VBG (r_advcl) developed_23/VBN (l_nsubj) evidence_19/NN (l_prep) of_20/IN (l_pobj) disease_22/NN
D010672_D012640 NONE phenytoin_8/NN (r_pobj) of_7/IN (r_prep) doses_6/NNS (r_pobj) with_4/IN (r_prep) controlled_3/VBN (l_nsubjpass) seizures_1/NNS
D015378_D012640 NONE imipenem_3/NN (r_compound) therapy_4/NN (r_pobj) with_2/IN (r_prep) activity_1/NN (l_compound) Seizure_0/NN
18541230
D011692_D007674 NONE aminonucleoside_1/RB (r_advmod) induced_3/VBN (r_amod) dysfunction_5/NN
D011692_D006402 NONE aminonucleoside_6/NN (r_advmod) induced_8/VBN (r_amod) abnormalities_10/NNS
D011692_D006949 NONE aminonucleoside_1/RB (r_advmod) induced_3/VBN (r_amod) dysfunction_5/NN (l_conj) hyperlipidemia_7/NN
D011692_D009401 CID aminonucleoside_6/JJ (r_amod) nephrosis_7/NN
D011692_D009401 CID aminonucleoside_18/RB (r_advmod) induced_20/VBN (r_amod) nephrosis_21/NN
D011692_D009404 NONE aminonucleoside_18/RB (r_advmod) induced_20/VBN (r_amod) nephrosis_21/NN (l_relcl) is_24/VBZ (l_attr) model_27/NN (l_prep) of_28/IN (l_pobj) syndrome_31/NN
D011692_D009404 NONE aminonucleoside_14/RB (r_advmod) induced_16/VBN (r_amod) syndrome_18/NN
3137399
D016685_D066126 NONE C._12/NNP (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) study_2/NN (l_prep) on_3/IN (l_pobj) dependency_6/NN (l_prep) of_7/IN (l_pobj) cardiotoxicity_8/NN
D016685_D066126 NONE C_3/NNP (r_nsubjpass) suggested_9/VBN (l_xcomp) be_11/VB (l_acomp) cardiotoxic_12/JJ
D016685_D066126 NONE MMC_5/NN (r_appos) C_3/NNP (r_nsubjpass) suggested_9/VBN (l_xcomp) be_11/VB (l_acomp) cardiotoxic_12/JJ
D016685_D066126 NONE MMC_16/NN (r_npadvmod) related_18/VBN (r_amod) cardiotoxicity_19/NN
D004317_D006333 CID doxorubicin_17/NN (r_conj) MMC_11/NNP (r_pobj) after_7/IN (r_prep) developed_4/VBD (l_dobj) failure_6/NN
D004317_D066126 NONE doxorubicin_21/NN (r_dobj) following_20/VBG (r_pcomp) given_19/VBN (r_conj) combined_16/VBN (r_advcl) suggested_9/VBN (l_xcomp) be_11/VB (l_acomp) cardiotoxic_12/JJ
D004317_D066126 NONE doxorubicin_47/NN (r_pobj) with_46/IN (r_prep) treated_45/VBN (r_acl) patients_38/NNS (r_pobj) in_37/IN (r_prep) is_20/VBZ (l_nsubj) cardiotoxicity_19/NN
D016685_D006333 CID MMC_11/NNP (r_pobj) after_7/IN (r_prep) developed_4/VBD (l_dobj) failure_6/NN
3131282
C009166_D063646 NONE acetate_6/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (l_amod) carcinogenic_2/JJ
C009166_D017573 NONE RA_7/NNP (r_punct) co_8/NNP (r_punct) -_9/HYPH (r_punct) administered_10/VBN (r_punct) at_11/IN (r_prep) given_2/VBN (r_acl) rats_1/NNS (r_pobj) In_0/IN (r_prep) showed_23/VBD (l_dobj) effect_29/NN (l_prep) on_30/IN (l_pobj) development_32/NN (l_prep) of_33/IN (l_pobj) hyperplasia_39/NN
D002083_D002277 NONE BHA_5/NNP (r_dobj) given_2/VBN (r_acl) groups_1/NNS (r_pobj) In_0/IN (r_prep) observed_16/VBN (l_conj) increased_35/VBD (l_dobj) incidence_37/NN (l_appos) papilloma_44/NN (l_conj) carcinoma_46/NN
D002083_D002277 NONE BHA_5/NNP (r_dobj) given_2/VBN (r_acl) groups_1/NNS (r_pobj) In_0/IN (r_prep) observed_16/VBN (l_conj) increased_35/VBD (l_prep) to_48/IN (l_pobj) %_50/NN (l_appos) rats_55/NNS (l_prep) with_56/IN (l_pobj) carcinoma_57/NN
D002083_D002277 NONE BHA_5/NNP (r_dobj) given_2/VBN (r_acl) groups_1/NNS (r_pobj) In_0/IN (r_prep) observed_16/VBN (l_conj) increased_35/VBD (l_prep) from_59/IN (l_pobj) %_61/NN (l_appos) rat_66/NN (l_prep) with_67/IN (l_pobj) carcinoma_68/NN
C009166_D013274 NONE acetate_6/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (l_prep) on_7/IN (l_pobj) carcinogenesis_9/NN
C009166_D013274 NONE acetate_6/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (r_nsubjpass) examined_19/VBN (l_nsubjpass) tumorigenesis_17/NN
C009166_D013274 NONE RA_8/NNP (r_appos) acetate_6/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (r_nsubjpass) examined_19/VBN (l_nsubjpass) tumorigenesis_17/NN
C009166_D013274 NONE RA_27/NNP (r_nsubj) increased_35/VBD (l_dobj) incidence_37/NN (l_prep) of_38/IN (l_pobj) tumors_40/NNS
C009166_D013274 NONE RA_74/NNP (r_npadvmod) free_76/JJ (r_amod) water_77/NN (r_dobj) given_73/VBN (r_acl) group_72/NN (r_pobj) in_70/IN (r_prep) from_59/IN (r_prep) increased_35/VBD (l_dobj) incidence_37/NN (l_prep) of_38/IN (l_pobj) tumors_40/NNS
C009166_D013274 NONE RA_4/NNP (r_nsubj) acted_5/VBD (l_dobj) carcinogenesis_15/NN
D002083_D010212 NONE BHA_5/NNP (r_dobj) given_2/VBN (r_acl) groups_1/NNS (r_pobj) In_0/IN (r_prep) observed_16/VBN (l_conj) increased_35/VBD (l_dobj) incidence_37/NN (l_appos) papilloma_44/NN
C009166_D002277 NONE RA_27/NNP (r_nsubj) increased_35/VBD (l_dobj) incidence_37/NN (l_appos) papilloma_44/NN (l_conj) carcinoma_46/NN
C009166_D002277 NONE RA_27/NNP (r_nsubj) increased_35/VBD (l_prep) to_48/IN (l_pobj) %_50/NN (l_appos) rats_55/NNS (l_prep) with_56/IN (l_pobj) carcinoma_57/NN
C009166_D002277 NONE RA_27/NNP (r_nsubj) increased_35/VBD (l_prep) from_59/IN (l_pobj) %_61/NN (l_appos) rat_66/NN (l_prep) with_67/IN (l_pobj) carcinoma_68/NN
C009166_D002277 NONE RA_74/NNP (r_npadvmod) free_76/JJ (r_amod) water_77/NN (r_dobj) given_73/VBN (r_acl) group_72/NN (r_pobj) in_70/IN (r_prep) from_59/IN (r_prep) increased_35/VBD (l_dobj) incidence_37/NN (l_appos) papilloma_44/NN (l_conj) carcinoma_46/NN
C009166_D002277 NONE RA_74/NNP (r_npadvmod) free_76/JJ (r_amod) water_77/NN (r_dobj) given_73/VBN (r_acl) group_72/NN (r_pobj) in_70/IN (r_prep) from_59/IN (r_prep) increased_35/VBD (l_prep) to_48/IN (l_pobj) %_50/NN (l_appos) rats_55/NNS (l_prep) with_56/IN (l_pobj) carcinoma_57/NN
C009166_D002277 NONE RA_74/NNP (r_npadvmod) free_76/JJ (r_amod) water_77/NN (r_dobj) given_73/VBN (r_acl) group_72/NN (r_pobj) in_70/IN (r_prep) from_59/IN (l_pobj) %_61/NN (l_appos) rat_66/NN (l_prep) with_67/IN (l_pobj) carcinoma_68/NN
D002083_D063646 NONE hydroxyanisole_17/NN (r_pobj) with_15/IN (r_prep) induced_14/VBN (l_nsubj) effect_3/NN (l_amod) carcinogenic_2/JJ
D002083_D013274 CID hydroxyanisole_17/NN (r_pobj) with_15/IN (r_prep) induced_14/VBN (l_nsubj) effect_3/NN (l_prep) on_7/IN (l_pobj) carcinogenesis_9/NN
D002083_D013274 CID hydroxyanisole_12/NN (r_pobj) on_10/IN (r_prep) effect_3/NN (r_nsubjpass) examined_19/VBN (l_nsubjpass) tumorigenesis_17/NN
D002083_D013274 CID BHA)-induced_14/JJ (r_amod) rat_15/NN (r_compound) tumorigenesis_17/NN
D002083_D013274 CID BHA_5/NNP (r_dobj) given_2/VBN (r_acl) groups_1/NNS (r_pobj) In_0/IN (r_prep) observed_16/VBN (l_conj) increased_35/VBD (l_dobj) incidence_37/NN (l_prep) of_38/IN (l_pobj) tumors_40/NNS
D002083_D013274 CID BHA_13/NNP (r_compound) carcinogenesis_15/NN
D002083_D017573 NONE BHA_5/NNP (r_dobj) given_2/VBN (r_acl) rats_1/NNS (r_pobj) In_0/IN (r_prep) showed_23/VBD (l_dobj) effect_29/NN (l_prep) on_30/IN (l_pobj) development_32/NN (l_prep) of_33/IN (l_pobj) hyperplasia_39/NN
D002083_D017573 NONE BHA_35/NNP (r_npadvmod) induced_37/VBN (r_amod) hyperplasia_39/NN
C009166_D009369 NONE RA_17/NN (r_pobj) with_14/IN (r_prep) rats_9/NNS (r_pobj) in_7/IN (r_prep) induced_6/VBN (l_nsubjpass) Tumors_0/NNS
C009166_D009369 NONE RA_29/NNP (r_compound) administration_32/NN (r_punct) ._33/. (r_punct) induced_6/VBN (l_nsubjpass) Tumors_0/NNS
C009166_D010212 NONE RA_27/NNP (r_nsubj) increased_35/VBD (l_dobj) incidence_37/NN (l_appos) papilloma_44/NN
C009166_D010212 NONE RA_74/NNP (r_npadvmod) free_76/JJ (r_amod) water_77/NN (r_dobj) given_73/VBN (r_acl) group_72/NN (r_pobj) in_70/IN (r_prep) from_59/IN (r_prep) increased_35/VBD (l_dobj) incidence_37/NN (l_appos) papilloma_44/NN
C009166_D010212 NONE RA_17/NN (r_pobj) with_14/IN (r_prep) rats_9/NNS (r_pobj) in_7/IN (r_prep) induced_6/VBN (l_nsubjpass) Tumors_0/NNS (l_appos) papillomas_3/NNS
C009166_D010212 NONE RA_29/NNP (r_compound) administration_32/NN (r_punct) ._33/. (r_punct) induced_6/VBN (l_nsubjpass) Tumors_0/NNS (l_appos) papillomas_3/NNS
3762968
D013835_D014899 NONE pyrophosphate_42/NN (r_pobj) for_40/IN (r_prep) Km_39/NNP (r_appos) abnormality_36/NN (r_dobj) had_34/VBD (r_ccomp) delineate_29/VB (r_acl) order_27/NN (r_pobj) in_26/IN (r_prep) studied_1/VBD (l_prep) from_10/IN (l_pobj) fibroblasts_11/NNS (l_prep) of_12/IN (l_pobj) patient_15/NN (l_relcl) developed_17/VBD (l_dobj) encephalopathy_20/NN
D013835_D014899 NONE TPP_44/NNP (r_appos) pyrophosphate_42/NN (r_pobj) for_40/IN (r_prep) Km_39/NNP (r_appos) abnormality_36/NN (r_dobj) had_34/VBD (r_ccomp) delineate_29/VB (r_acl) order_27/NN (r_pobj) in_26/IN (r_prep) studied_1/VBD (l_prep) from_10/IN (l_pobj) fibroblasts_11/NNS (l_prep) of_12/IN (l_pobj) patient_15/NN (l_relcl) developed_17/VBD (l_dobj) encephalopathy_20/NN
D013835_D014899 NONE TPP_30/NNP (r_pobj) for_29/IN (r_prep) Km_28/NNP (r_pobj) by_26/IN (r_agent) determined_25/VBN (r_advcl) had_21/VBD (l_nsubj) patient_7/NN (l_prep) with_14/IN (l_pobj) history_16/NN (l_prep) of_17/IN (l_pobj) encephalopathy_20/NN
D013835_D003920 NONE pyrophosphate_42/NN (r_pobj) for_40/IN (r_prep) Km_39/NNP (r_appos) abnormality_36/NN (r_dobj) had_34/VBD (r_ccomp) delineate_29/VB (r_acl) order_27/NN (r_pobj) in_26/IN (r_prep) studied_1/VBD (l_prep) from_10/IN (l_pobj) fibroblasts_11/NNS (l_prep) of_12/IN (l_pobj) patient_15/NN (l_amod) diabetic_14/JJ
D013835_D003920 NONE TPP_44/NNP (r_appos) pyrophosphate_42/NN (r_pobj) for_40/IN (r_prep) Km_39/NNP (r_appos) abnormality_36/NN (r_dobj) had_34/VBD (r_ccomp) delineate_29/VB (r_acl) order_27/NN (r_pobj) in_26/IN (r_prep) studied_1/VBD (l_prep) from_10/IN (l_pobj) fibroblasts_11/NNS (l_prep) of_12/IN (l_pobj) patient_15/NN (l_amod) diabetic_14/JJ
D013835_D003920 NONE TPP_30/NNP (r_pobj) for_29/IN (r_prep) Km_28/NNP (r_pobj) by_26/IN (r_agent) determined_25/VBN (r_advcl) had_21/VBD (l_nsubj) patient_7/NN (l_conj) one_9/CD (l_prep) of_10/IN (l_pobj) kindreds_13/NNS (l_amod) diabetic_12/JJ
D013835_D020915 NONE pyrophosphate_42/NN (r_pobj) for_40/IN (r_prep) Km_39/NNP (r_appos) abnormality_36/NN (r_dobj) had_34/VBD (l_advcl) reported_50/VBN (l_prep) in_51/IN (l_pobj) syndrome_56/NN
D013835_D020915 NONE TPP_44/NNP (r_appos) pyrophosphate_42/NN (r_pobj) for_40/IN (r_prep) Km_39/NNP (r_appos) abnormality_36/NN (r_dobj) had_34/VBD (l_advcl) reported_50/VBN (l_prep) in_51/IN (l_pobj) syndrome_56/NN
D014042_D020915 NONE tolazamide_24/NN (r_pobj) with_23/IN (r_prep) treated_22/VBN (r_advcl) developed_17/VBD (r_relcl) patient_15/NN (r_pobj) of_12/IN (r_prep) fibroblasts_11/NNS (r_pobj) from_10/IN (r_prep) studied_1/VBD (l_prep) in_26/IN (l_pobj) order_27/NN (l_acl) delineate_29/VB (l_ccomp) had_34/VBD (l_advcl) reported_50/VBN (l_prep) in_51/IN (l_pobj) syndrome_56/NN
D014042_D020915 NONE tolazamide_15/NN (r_npadvmod) induced_17/VBN (r_amod) encephalopathy_20/NN (r_pobj) with_14/IN (r_prep) patient_13/NN (r_conj) syndrome_10/NN
D014042_D014899 CID tolazamide_3/NN (r_npadvmod) induced_5/VBN (r_amod) encephalopathy_8/NN
D014042_D014899 CID tolazamide_24/NN (r_pobj) with_23/IN (r_prep) treated_22/VBN (r_advcl) developed_17/VBD (l_dobj) encephalopathy_20/NN
D014042_D014899 CID tolazamide_15/NN (r_npadvmod) induced_17/VBN (r_amod) encephalopathy_20/NN
D013831_D020915 NONE thiamine_3/NN (r_npadvmod) dependent_5/JJ (r_amod) enzyme_6/NN (r_dobj) studied_1/VBD (l_prep) in_26/IN (l_pobj) order_27/NN (l_acl) delineate_29/VB (l_ccomp) had_34/VBD (l_advcl) reported_50/VBN (l_prep) in_51/IN (l_pobj) syndrome_56/NN
D013831_D003920 NONE thiamine_3/NN (r_npadvmod) dependent_5/JJ (r_amod) enzyme_6/NN (r_dobj) studied_1/VBD (l_prep) from_10/IN (l_pobj) fibroblasts_11/NNS (l_prep) of_12/IN (l_pobj) patient_15/NN (l_amod) diabetic_14/JJ
D013831_D014899 NONE thiamine_3/NN (r_npadvmod) dependent_5/JJ (r_amod) enzyme_6/NN (r_dobj) studied_1/VBD (l_prep) from_10/IN (l_pobj) fibroblasts_11/NNS (l_prep) of_12/IN (l_pobj) patient_15/NN (l_relcl) developed_17/VBD (l_dobj) encephalopathy_20/NN
D014042_D003920 NONE tolazamide_24/NN (r_pobj) with_23/IN (r_prep) treated_22/VBN (r_advcl) developed_17/VBD (r_relcl) patient_15/NN (l_amod) diabetic_14/JJ
7072798
D002701_D005128 NONE chloramphenicol_11/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_acl) toxicity_6/NN
D002701_D002386 NONE chloramphenicol_22/NN (r_pobj) with_21/IN (r_prep) therapy_20/NN (r_dobj) beginning_18/VBG (r_conj) undergoing_14/VBG (l_dobj) extraction_16/NN (l_compound) cataract_15/NN
D002701_D001855 NONE chloramphenicol_13/NN (r_pobj) with_12/IN (r_prep) treatment_11/NN (r_pobj) after_9/IN (r_prep) report_4/NN (r_attr) was_1/VBD (l_advcl) reported_29/VBN (l_nsubjpass) cases_20/NNS (l_prep) of_21/IN (l_pobj) hypoplasia_25/NN
D002701_D000741 CID chloramphenicol_8/NN (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) following_3/VBG (r_prep) anemia_2/NN
D002701_D000741 CID chloramphenicol_22/NN (r_pobj) with_21/IN (r_prep) therapy_20/NN (r_dobj) beginning_18/VBG (r_conj) undergoing_14/VBG (r_pcomp) after_13/IN (r_prep) died_5/VBD (l_prep) of_6/IN (l_pobj) anemia_8/NN
D002701_D000741 CID chloramphenicol_13/NN (r_acl) response_11/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (l_nsubjpass) pattern_1/NN (l_prep) of_2/IN (l_pobj) anemia_5/NN
D002701_D000741 CID chloramphenicol_13/NN (r_pobj) with_12/IN (r_prep) treatment_11/NN (r_pobj) after_9/IN (r_prep) report_4/NN (l_prep) of_5/IN (l_pobj) anemia_8/NN
12745515
D016642_D012892 NONE bupropion_9/NN (r_conj) deprivation_4/NN
D016642_D012892 NONE bupropion_12/NN (r_compound) use_13/NN (l_conj) deprivation_16/NN
D016642_D012892 NONE bupropion_11/NN (r_npadvmod) associated_13/VBN (r_amod) seizures_14/NNS (r_pobj) of_10/IN (r_prep) risk_9/NN (r_pobj) to_7/IN (r_prep) add_6/VB (l_nsubj) deprivation_4/NN
D016642_D012640 CID bupropion_9/NN (r_conj) deprivation_4/NN (r_pobj) with_2/IN (r_prep) associated_1/VBN (r_acl) Seizure_0/NN
D016642_D012640 CID bupropion_12/NN (r_compound) use_13/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_acl) seizure_6/NN
D016642_D012640 CID bupropion_4/NN (r_compound) use_5/NN (r_pobj) of_3/IN (r_prep) weeks_2/NNS (r_pobj) After_0/IN (r_prep) experienced_9/VBD (l_dobj) seizure_14/NN
D016642_D012640 CID bupropion_11/NN (r_npadvmod) associated_13/VBN (r_amod) seizures_14/NNS
11752998
D000241_D006930 NONE adenosine_34/NN (r_amod) doses_35/NNS (r_pobj) with_32/IN (r_prep) trial_31/NN (r_appos) trials_21/NNS (r_pobj) in_19/IN (r_prep) studied_18/VBN (l_conj) obtained_59/VBN (l_conj) determined_85/VBN (l_nsubjpass) ratings_66/NNS (l_prep) in_67/IN (l_pobj) response_68/NN (l_prep) to_69/IN (l_pobj) stimuli_72/NNS (l_conj) areas_74/NNS (l_prep) of_75/IN (l_pobj) hyperalgesia_77/NN
D000241_D006930 NONE adenosine_34/NN (r_amod) doses_35/NNS (r_pobj) with_32/IN (r_prep) trial_31/NN (r_appos) trials_21/NNS (r_pobj) in_19/IN (r_prep) studied_18/VBN (l_conj) obtained_59/VBN (l_conj) determined_85/VBN (l_nsubjpass) ratings_66/NNS (l_prep) in_67/IN (l_pobj) response_68/NN (l_prep) to_69/IN (l_pobj) stimuli_72/NNS (l_conj) areas_74/NNS (l_prep) of_75/IN (l_pobj) hyperalgesia_77/NN (l_conj) allodynia_79/NN
D000241_D006930 NONE adenosine_52/NN (r_pobj) of_51/IN (r_prep) trial_50/NN (r_conj) doses_35/NNS (r_pobj) with_32/IN (r_prep) trial_31/NN (r_appos) trials_21/NNS (r_pobj) in_19/IN (r_prep) studied_18/VBN (l_conj) obtained_59/VBN (l_conj) determined_85/VBN (l_nsubjpass) ratings_66/NNS (l_prep) in_67/IN (l_pobj) response_68/NN (l_prep) to_69/IN (l_pobj) stimuli_72/NNS (l_conj) areas_74/NNS (l_prep) of_75/IN (l_pobj) hyperalgesia_77/NN
D000241_D006930 NONE adenosine_52/NN (r_pobj) of_51/IN (r_prep) trial_50/NN (r_conj) doses_35/NNS (r_pobj) with_32/IN (r_prep) trial_31/NN (r_appos) trials_21/NNS (r_pobj) in_19/IN (r_prep) studied_18/VBN (l_conj) obtained_59/VBN (l_conj) determined_85/VBN (l_nsubjpass) ratings_66/NNS (l_prep) in_67/IN (l_pobj) response_68/NN (l_prep) to_69/IN (l_pobj) stimuli_72/NNS (l_conj) areas_74/NNS (l_prep) of_75/IN (l_pobj) hyperalgesia_77/NN (l_conj) allodynia_79/NN
D000241_D006930 NONE Adenosine_0/NNP (r_nsubj) produced_1/VBD (l_prep) to_7/IN (l_pobj) stimulation_13/NN (l_conj) hyperalgesia_17/NN
D000241_D006930 NONE Adenosine_0/NNP (r_nsubj) produced_1/VBD (l_prep) to_7/IN (l_pobj) stimulation_13/NN (l_conj) hyperalgesia_17/NN (l_conj) allodynia_19/NN
D000241_D010146 NONE adenosine_34/NN (r_amod) doses_35/NNS (r_pobj) with_32/IN (r_prep) trial_31/NN (r_appos) trials_21/NNS (r_pobj) in_19/IN (r_prep) studied_18/VBN (l_conj) obtained_59/VBN (l_conj) determined_85/VBN (l_nsubjpass) ratings_66/NNS (l_compound) pain_65/NN
D000241_D010146 NONE adenosine_52/NN (r_pobj) of_51/IN (r_prep) trial_50/NN (r_conj) doses_35/NNS (r_pobj) with_32/IN (r_prep) trial_31/NN (r_appos) trials_21/NNS (r_pobj) in_19/IN (r_prep) studied_18/VBN (l_conj) obtained_59/VBN (l_conj) determined_85/VBN (l_nsubjpass) ratings_66/NNS (l_compound) pain_65/NN
D000241_D010146 NONE Adenosine_0/NNP (r_nsubj) produced_1/VBD (l_dobj) effect_3/NN (l_prep) on_4/IN (l_pobj) report_6/NN (l_compound) pain_5/NN
D002211_D010146 NONE capsaicin_82/NN (r_compound) injection_83/NN (r_pobj) after_80/IN (r_prep) stimuli_72/NNS (r_pobj) to_69/IN (r_prep) response_68/NN (r_pobj) in_67/IN (r_prep) ratings_66/NNS (l_compound) pain_65/NN
D002211_D010146 NONE capsaicin_22/NN (r_compound) injection_23/NN (r_pobj) from_20/IN (r_prep) allodynia_19/NN (r_conj) hyperalgesia_17/NN (r_conj) stimulation_13/NN (r_pobj) to_7/IN (r_prep) produced_1/VBD (l_dobj) effect_3/NN (l_prep) on_4/IN (l_pobj) report_6/NN (l_compound) pain_5/NN
D000241_D004342 NONE adenosine_4/NN (r_pobj) of_2/IN (r_prep) studies_1/NNS (r_nsubj) suggest_5/VBP (l_conj) suggests_34/VBZ (l_ccomp) be_37/VB (l_acomp) effective_38/JJ (l_prep) in_39/IN (l_pobj) states_41/NNS (l_compound) hypersensitivity_40/NN
D000241_D004342 NONE adenosine_33/NN (r_pobj) of_32/IN (r_prep) formulation_31/NN (r_pobj) with_28/IN (r_prep) volunteers_25/NNS (r_pobj) in_24/IN (r_prep) studies_23/NNS (r_nsubj) suggests_34/VBZ (l_ccomp) be_37/VB (l_acomp) effective_38/JJ (l_prep) in_39/IN (l_pobj) states_41/NNS (l_compound) hypersensitivity_40/NN
D000241_D004342 NONE adenosine_15/NN (r_pobj) of_14/IN (r_prep) formulation_13/NN (r_pobj) of_10/IN (r_prep) efficacy_9/NN (r_pobj) for_8/IN (r_prep) screen_7/VB (l_advcl) using_21/VBG (l_dobj) stimulation_25/NN (l_conj) hypersensitivity_31/NN
D000241_D004342 NONE adenosine_7/NN (l_prep) of_8/IN (l_pobj) hypersensitivity_9/NN
D000241_D059787 NONE adenosine_4/NN (r_pobj) of_2/IN (r_prep) studies_1/NNS (r_nsubj) suggest_5/VBP (l_ccomp) be_8/VB (l_acomp) effective_9/JJ (l_prep) in_10/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) pain_17/NN
D000241_D059787 NONE adenosine_33/NN (r_pobj) of_32/IN (r_prep) formulation_31/NN (r_pobj) with_28/IN (r_prep) volunteers_25/NNS (r_pobj) in_24/IN (r_prep) studies_23/NNS (r_nsubj) suggests_34/VBZ (r_conj) suggest_5/VBP (l_ccomp) be_8/VB (l_acomp) effective_9/JJ (l_prep) in_10/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) pain_17/NN
D002211_D004342 NONE capsaicin_27/NN (r_npadvmod) evoked_29/VBN (r_amod) hypersensitivity_31/NN
D002211_D004342 NONE capsaicin_20/NN (r_compound) injection_21/NN (r_pobj) after_18/IN (r_prep) reflect_13/VB (r_xcomp) presumed_11/VBN (r_advcl) show_2/VBP (l_dobj) inhibition_4/NN (l_prep) by_5/IN (l_pobj) adenosine_7/NN (l_prep) of_8/IN (l_pobj) hypersensitivity_9/NN
D000241_D009437 NONE adenosine_27/NN (r_pobj) of_26/IN (r_prep) residence_25/NN (r_pobj) due_22/JJ (r_acomp) is_20/VBZ (r_conj) is_5/VBZ (l_acomp) consistent_6/JJ (l_prep) with_7/IN (l_pcomp) observed_9/VBN (l_prep) in_10/IN (l_pobj) reports_12/NNS (l_prep) of_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) pain_18/NN
D002211_D006930 CID capsaicin_82/NN (r_compound) injection_83/NN (r_pobj) after_80/IN (r_prep) stimuli_72/NNS (l_conj) areas_74/NNS (l_prep) of_75/IN (l_pobj) hyperalgesia_77/NN
D002211_D006930 CID capsaicin_82/NN (r_compound) injection_83/NN (r_pobj) after_80/IN (r_prep) stimuli_72/NNS (l_conj) areas_74/NNS (l_prep) of_75/IN (l_pobj) hyperalgesia_77/NN (l_conj) allodynia_79/NN
D002211_D006930 CID capsaicin_22/NN (r_compound) injection_23/NN (r_pobj) from_20/IN (r_prep) allodynia_19/NN (r_conj) hyperalgesia_17/NN
D002211_D006930 CID capsaicin_22/NN (r_compound) injection_23/NN (r_pobj) from_20/IN (r_prep) allodynia_19/NN
D000241_D059350 NONE adenosine_4/NN (r_pobj) of_2/IN (r_prep) studies_1/NNS (r_nsubj) suggest_5/VBP (l_ccomp) be_8/VB (l_acomp) effective_9/JJ (l_prep) in_10/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) pain_17/NN
D000241_D059350 NONE adenosine_33/NN (r_pobj) of_32/IN (r_prep) formulation_31/NN (r_pobj) with_28/IN (r_prep) volunteers_25/NNS (r_pobj) in_24/IN (r_prep) studies_23/NNS (r_nsubj) suggests_34/VBZ (r_conj) suggest_5/VBP (l_ccomp) be_8/VB (l_acomp) effective_9/JJ (l_prep) in_10/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) pain_17/NN
16629641
D012254_D000740 NONE ribavirin_8/RB (r_npadvmod) induced_10/VBN (r_amod) hemolysis_11/NN (r_pobj) of_7/IN (r_prep) result_6/NN (r_pobj) as_4/IN (r_prep) decrease_2/VBP (l_conj) be_17/VB (l_nsubj) anemia_15/NN
D012254_D000740 NONE ribavirin_1/RB (r_npadvmod) associated_3/VBN (r_amod) anemia_4/NN
D012254_D000740 NONE ribavirin_8/RB (r_npadvmod) associated_10/VBN (r_amod) anemia_11/NN
D012254_D002318 NONE ribavirin_8/RB (r_npadvmod) induced_10/VBN (r_amod) hemolysis_11/NN (r_pobj) of_7/IN (r_prep) result_6/NN (r_pobj) as_4/IN (r_prep) decrease_2/VBP (l_conj) be_17/VB (l_conj) comorbid_29/VBN (l_dobj) disorders_33/NNS
D007372_D006526 NONE interferon_12/NN (r_pobj) with_10/IN (r_prep) therapy_9/NN (r_attr) is_7/VBZ (l_nsubj) treatment_3/NN (l_prep) for_4/IN (l_pobj) infection_6/NN
D012254_D000743 CID ribavirin_8/NN (r_pobj) of_7/IN (r_prep) prodrug_6/NN (r_appos) Viramidine_0/NNP (r_nsubj) has_10/VBZ (l_dobj) potential_12/NN (l_acl) maintain_14/VB (l_advcl) decreasing_21/VBG (l_dobj) risk_23/NN (l_prep) of_24/IN (l_pobj) anemia_26/NN
D012254_D000743 CID ribavirin_19/RB (r_pobj) of_18/IN (r_prep) efficacy_17/NN (r_dobj) maintain_14/VB (l_advcl) decreasing_21/VBG (l_dobj) risk_23/NN (l_prep) of_24/IN (l_pobj) anemia_26/NN
D012254_D006461 NONE ribavirin_8/RB (r_npadvmod) induced_10/VBN (r_amod) hemolysis_11/NN
D012254_D007674 NONE ribavirin_8/RB (r_npadvmod) induced_10/VBN (r_amod) hemolysis_11/NN (r_pobj) of_7/IN (r_prep) result_6/NN (r_pobj) as_4/IN (r_prep) decrease_2/VBP (l_conj) be_17/VB (l_conj) comorbid_29/VBN (l_dobj) disorders_33/NNS
D012254_D006526 NONE ribavirin_14/NN (r_conj) interferon_12/NN (r_pobj) with_10/IN (r_prep) therapy_9/NN (r_attr) is_7/VBZ (l_nsubj) treatment_3/NN (l_prep) for_4/IN (l_pobj) infection_6/NN
D012254_D006526 NONE ribavirin_8/RB (r_npadvmod) induced_10/VBN (r_amod) hemolysis_11/NN (r_pobj) of_7/IN (r_prep) result_6/NN (r_pobj) as_4/IN (r_prep) decrease_2/VBP (l_conj) be_17/VB (l_prep) in_19/IN (l_pobj) patients_20/NNS (l_prep) with_21/IN (l_pobj) infection_23/NN
C026956_D000743 NONE Viramidine_0/NNP (r_nsubj) has_10/VBZ (l_dobj) potential_12/NN (l_acl) maintain_14/VB (l_advcl) decreasing_21/VBG (l_dobj) risk_23/NN (l_prep) of_24/IN (l_pobj) anemia_26/NN
D012254_D019698 NONE ribavirin_8/NN (r_pobj) of_7/IN (r_prep) prodrug_6/NN (r_appos) Viramidine_0/NNP (r_nsubj) has_10/VBZ (l_dobj) potential_12/NN (l_acl) maintain_14/VB (l_advcl) decreasing_21/VBG (l_dobj) risk_23/NN (l_prep) of_24/IN (l_pobj) anemia_26/NN (l_prep) in_27/IN (l_pobj) patients_28/NNS (l_prep) with_29/IN (l_pobj) C._32/NNP
D012254_D019698 NONE ribavirin_19/RB (r_pobj) of_18/IN (r_prep) efficacy_17/NN (r_dobj) maintain_14/VB (l_advcl) decreasing_21/VBG (l_dobj) risk_23/NN (l_prep) of_24/IN (l_pobj) anemia_26/NN (l_prep) in_27/IN (l_pobj) patients_28/NNS (l_prep) with_29/IN (l_pobj) C._32/NNP
C026956_D019698 NONE Viramidine_0/NNP (r_nsubj) has_10/VBZ (l_dobj) potential_12/NN (l_acl) maintain_14/VB (l_advcl) decreasing_21/VBG (l_dobj) risk_23/NN (l_prep) of_24/IN (l_pobj) anemia_26/NN (l_prep) in_27/IN (l_pobj) patients_28/NNS (l_prep) with_29/IN (l_pobj) C._32/NNP
20558148
D018698_D002375 NONE glutamate_11/NN (r_compound) antagonists_14/NNS (r_pobj) of_10/IN (r_prep) microinjections_9/NNS (r_pobj) with_6/IN (r_prep) challenged_5/VBN (l_nsubjpass) catalepsy_3/NN
D018698_D002375 NONE glutamate_4/NN (r_npadvmod) mediated_6/VBN (r_amod) mechanisms_7/NNS (l_prep) in_8/IN (l_pobj) circuits_11/NNS (l_prep) at_12/IN (l_pobj) catalepsy_20/NN
D016291_D002375 NONE MK-801_16/NNP (r_punct) microl_22/NN (r_dobj) challenged_5/VBN (l_nsubjpass) catalepsy_3/NN
D016291_D002375 NONE MK-801_7/NNP (r_punct) and_8/CC (r_cc) microinjection_5/NN (r_dobj) showed_2/VBD (l_ccomp) attenuated_17/VBD (l_dobj) catalepsy_19/NN
D006220_D002375 CID haloperidol_12/NN (r_npadvmod) induced_14/VBN (r_amod) catalepsy_15/NN
D006220_D002375 CID haloperidol_25/NN (r_appos) blocker_24/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) catalepsy_18/NN
D006220_D002375 CID Haloperidol_0/NN (r_npadvmod) induced_2/VBN (r_amod) catalepsy_3/NN
D006220_D002375 CID haloperidol_15/NN (r_pobj) of_14/IN (r_prep) injections_13/NNS (r_pobj) to_11/IN (r_prep) previous_10/JJ (r_amod) AP7_9/RB (r_conj) microinjection_5/NN (r_dobj) showed_2/VBD (l_ccomp) attenuated_17/VBD (l_dobj) catalepsy_19/NN
D006220_D002375 CID haloperidol_17/NN (r_npadvmod) induced_19/VBN (r_amod) catalepsy_20/NN
D004298_D002375 NONE dopamine_22/NN (r_compound) receptor_23/NN (r_compound) blocker_24/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) catalepsy_18/NN
D000596_D002375 NONE acid_9/NN (r_npadvmod) mediated_11/VBN (r_amod) mechanisms_12/NNS (r_pobj) of_6/IN (r_prep) influence_5/NN (l_prep) on_16/IN (l_pobj) catalepsy_18/NN
D016202_D002375 NONE NMDA_4/NNP (r_compound) receptors_5/NNS (r_pobj) by_3/IN (r_agent) mediated_2/VBN (r_acl) neurotransmission_1/NN (r_nsubj) modulate_11/VB (l_dobj) catalepsy_15/NN
D016202_D002375 NONE NMDA_12/NNP (r_compound) receptor_13/NN (r_compound) antagonists_14/NNS (r_pobj) of_10/IN (r_prep) microinjections_9/NNS (r_pobj) with_6/IN (r_prep) challenged_5/VBN (l_nsubjpass) catalepsy_3/NN
D016202_D002375 NONE NMDA_37/NNP (r_compound) receptor_38/NN (r_pobj) of_35/IN (r_prep) microl_22/NN (r_dobj) challenged_5/VBN (l_nsubjpass) catalepsy_3/NN
D016202_D002375 NONE aspartate_46/NNP (r_nmod) NMDA_48/NNP (r_appos) receptor_38/NN (r_pobj) of_35/IN (r_prep) microl_22/NN (r_dobj) challenged_5/VBN (l_nsubjpass) catalepsy_3/NN
D016202_D002375 NONE NMDA_48/NNP (r_appos) receptor_38/NN (r_pobj) of_35/IN (r_prep) microl_22/NN (r_dobj) challenged_5/VBN (l_nsubjpass) catalepsy_3/NN
C031231_D002375 NONE AP7_25/RB (r_conj) microl_22/NN (r_dobj) challenged_5/VBN (l_nsubjpass) catalepsy_3/NN
C031231_D002375 NONE AP7_9/RB (r_conj) microinjection_5/NN (r_dobj) showed_2/VBD (l_ccomp) attenuated_17/VBD (l_dobj) catalepsy_19/NN
11009181
D001058_D004409 NONE apomorphine_13/NN (r_compound) infusions_14/NNS (r_pobj) with_10/IN (r_prep) monotherapy_9/NN (r_nsubjpass) associated_16/VBN (l_prep) with_17/IN (l_pobj) reductions_19/NNS (l_prep) of_20/IN (l_pobj) dyskinesias_25/NNS
D001058_D001523 NONE apomorphine_6/NN (r_compound) treatment_7/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_nsubjpass) related_9/VBN (l_advcl) play_20/VBP (l_nsubj) sedation_16/NN (l_conj) complications_19/NNS (l_amod) psychiatric_18/JJ
D007980_D004409 CID levodopa_22/NN (r_npadvmod) induced_24/VBN (r_amod) dyskinesias_25/NNS
D001058_D010300 NONE Apomorphine_0/NNP (l_appos) therapy_4/NN (l_prep) for_5/IN (l_pobj) disease_8/NN
D001058_D010300 NONE Apomorphine_0/NNP (r_nsubj) was_1/VBD (l_attr) drug_5/NN (l_acl) used_7/VBN (l_xcomp) treat_9/VB (l_dobj) symptoms_10/NNS (l_prep) of_11/IN (l_pobj) disease_14/NN
D001058_D010300 NONE apomorphine_24/NN (r_pobj) of_23/IN (r_prep) administration_22/NN (r_pobj) by_20/IN (r_prep) treating_15/VBG (l_dobj) disease_19/NN
D001058_D010300 NONE apomorphine_8/NN (r_compound) treatment_9/NN (l_prep) in_10/IN (l_pobj) disease_14/NN
1969772
D004298_D007022 NONE dopamine-1_4/NNS (r_punct) agonist_9/NN (l_relcl) causes_11/VBZ (l_conj) preserves_23/VBZ (l_prep) during_29/IN (l_pobj) hypotension_31/NN
D009599_D007022 CID nitroprusside_26/RB (r_advmod) induced_28/VBN (r_amod) hypotension_29/NN (r_pobj) during_24/IN (r_prep) decreased_18/VBD (r_conj) increased_6/VBD (l_prep) during_7/IN (l_pobj) hypotension_11/NN
D009599_D007022 CID nitroprusside_26/RB (r_advmod) induced_28/VBN (r_amod) hypotension_29/NN
D009599_D007022 CID nitroprusside_1/NN (r_nsubj) is_2/VBZ (l_attr) vasodilator_10/NN (l_relcl) produce_13/VB (l_prep) during_22/IN (l_pobj) hypotension_24/NN
D012964_D007022 NONE sodium_25/NN (r_amod) hypotension_29/NN (r_pobj) during_24/IN (r_prep) decreased_18/VBD (r_conj) increased_6/VBD (l_prep) during_7/IN (l_pobj) hypotension_11/NN
D012964_D007022 NONE sodium_25/NN (r_amod) hypotension_29/NN
D018818_D007022 CID fenoldopam_9/NN (r_pobj) with_8/IN (r_prep) induced_7/VBN (l_nsubj) Preservation_0/NN (l_prep) during_5/IN (l_pobj) hypotension_6/NN
D018818_D007022 CID fenoldopam_3/NN (r_relcl) hypothesis_1/NN (r_nsubjpass) used_6/VBN (l_xcomp) induce_8/VB (l_dobj) hypotension_9/NN
D018818_D007022 CID fenoldopam_8/NN (r_npadvmod) induced_10/VBN (r_amod) hypotension_11/NN
D018818_D007022 CID fenoldopam_8/NN (r_npadvmod) induced_10/VBN (r_amod) hypotension_11/NN (r_pobj) during_7/IN (r_prep) increased_6/VBD (l_conj) decreased_18/VBD (l_prep) during_24/IN (l_pobj) hypotension_29/NN
7337133
D000082_D017093 CID acetaminophen_9/NN (r_compound) overdose_10/NN (r_pobj) in_8/IN (r_prep) failure_7/NN
D000082_D017093 CID acetaminophen_6/RB (r_advmod) induced_8/VBN (r_amod) failure_11/NN
D000082_D062787 NONE acetaminophen_9/NN (r_compound) overdose_10/NN
D000082_D001929 CID acetaminophen_9/NN (r_compound) overdose_10/NN (r_pobj) in_8/IN (r_prep) failure_7/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) edema_2/NN
D000082_D001929 CID acetaminophen_6/RB (r_advmod) induced_8/VBN (r_amod) failure_11/NN (r_pobj) with_4/IN (r_prep) patient_3/NN (r_dobj) present_1/VBP (l_prep) with_13/IN (l_pobj) signs_14/NNS (l_prep) of_17/IN (l_pobj) edema_19/NN
9226773
D008094_D018500 CID lithium_5/NN (r_compound) therapy_6/NN (r_dobj) following_4/VBG (r_prep) insipidus_3/NN
D008094_D018500 CID lithium_9/NN (r_npadvmod) induced_11/VBN (r_amod) insipidus_14/NN
D008094_D018500 CID lithium_17/NN (r_compound) therapy_18/NN (r_nsubjpass) discontinued_21/VBN (r_conj) diagnosed_6/VBN (l_xcomp) have_8/VB (l_dobj) insipidus_14/NN
D008094_D018500 CID lithium_8/NN (r_pobj) of_7/IN (r_prep) cessation_6/NN (r_pobj) despite_5/IN (r_prep) polyuric_4/JJ (r_conj) thirsty_2/JJ (r_acomp) remained_1/VBD (l_conj) showed_13/VBD (l_ccomp) have_16/VB (l_prep) with_24/IN (l_pobj) evidence_26/NN (l_prep) of_27/IN (l_pobj) insipidus_30/NN
D008094_D018500 CID Lithium_0/NN (r_nsubj) induced_1/VBD (l_dobj) insipidus_4/NN
D008094_D018500 CID lithium_24/NN (r_nsubjpass) stopped_26/VBN (r_advcl) be_8/VB (r_xcomp) considered_6/VBN (l_csubjpass) induced_1/VBD (l_dobj) insipidus_4/NN
D008094_D018500 CID lithium_14/NN (r_npadvmod) induced_16/VBN (r_amod) insipidus_19/NN
D008094_D011141 CID lithium_8/NN (r_pobj) of_7/IN (r_prep) cessation_6/NN (r_pobj) despite_5/IN (r_prep) polyuric_4/JJ
D008094_D011141 CID Lithium_0/NN (r_nsubj) induced_1/VBD (r_csubjpass) considered_6/VBN (l_xcomp) be_8/VB (l_acomp) reversible_9/JJ (l_prep) on_10/IN (l_pobj) cessation_11/NN (l_prep) of_12/IN (l_pobj) therapy_13/NN (l_conj) polyuria_15/NN
D008094_D011141 CID lithium_24/NN (r_nsubjpass) stopped_26/VBN (r_advcl) be_8/VB (l_acomp) reversible_9/JJ (l_prep) on_10/IN (l_pobj) cessation_11/NN (l_prep) of_12/IN (l_pobj) therapy_13/NN (l_conj) polyuria_15/NN
D014667_D011141 NONE vasopressin_21/NN (r_compound) secretion_22/NN (r_conj) thirst_19/NN (r_dobj) have_16/VB (r_ccomp) showed_13/VBD (r_conj) remained_1/VBD (l_acomp) thirsty_2/JJ (l_conj) polyuric_4/JJ
D014667_D018500 NONE vasopressin_21/NN (r_compound) secretion_22/NN (r_conj) thirst_19/NN (r_dobj) have_16/VB (l_prep) with_24/IN (l_pobj) evidence_26/NN (l_prep) of_27/IN (l_pobj) insipidus_30/NN
15580403
D012254_D000743 CID ribavirin_16/NN (r_conj) interferon_14/NN (r_pobj) of_13/IN (r_prep) therapy_12/NN (r_pobj) of_9/IN (r_prep) events_8/NNS (r_pobj) of_4/IN (r_prep) one_3/CD (r_attr) is_2/VBZ (l_nsubj) anemia_1/NN
D012254_D000743 CID ribavirin_2/RB (r_npadvmod) related_4/VBN (r_amod) anemia_6/NN
D012254_D000740 NONE ribavirin_9/NN (r_pobj) of_8/IN (r_prep) reduction_7/NN (r_pobj) with_6/IN (r_prep) patients_5/NNS (r_nsubj) continue_12/VB (l_advcl) decreased_24/VBD (l_conj) occurred_33/VBD (l_nsubj) effects_32/NNS (l_amod) related_29/VBN (l_npadvmod) anemia_27/NN
D007372_D019698 NONE interferon_13/NN (r_pobj) of_12/IN (r_prep) therapy_11/NN (l_prep) for_16/IN (l_pobj) C._19/NNP
D007372_D006461 NONE interferon_13/NN (r_pobj) of_12/IN (r_prep) therapy_11/NN (r_pobj) during_9/IN (r_prep) hemolysis_8/NN
D012254_D019698 NONE ribavirin_3/JJ (r_compound) reduction_4/NN (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) hemolysis_8/NN (l_prep) during_9/IN (l_pobj) therapy_11/NN (l_prep) for_16/IN (l_pobj) C._19/NNP
D012254_D019698 NONE ribavirin_15/RB (r_conj) interferon_13/NN (r_pobj) of_12/IN (r_prep) therapy_11/NN (l_prep) for_16/IN (l_pobj) C._19/NNP
D012254_D006461 NONE ribavirin_3/JJ (r_compound) reduction_4/NN (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) hemolysis_8/NN
D012254_D006461 NONE ribavirin_15/RB (r_conj) interferon_13/NN (r_pobj) of_12/IN (r_prep) therapy_11/NN (r_pobj) during_9/IN (r_prep) hemolysis_8/NN
D012254_D006461 NONE ribavirin_13/JJ (r_compound) reduction_14/NN (l_prep) in_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) hemolysis_18/NN
D007372_D000743 CID interferon_14/NN (r_pobj) of_13/IN (r_prep) therapy_12/NN (r_pobj) of_9/IN (r_prep) events_8/NNS (r_pobj) of_4/IN (r_prep) one_3/CD (r_attr) is_2/VBZ (l_nsubj) anemia_1/NN
11078231
D004280_D000788 CID dobutamine_4/NN (r_nsubj) provoke_6/VB (l_prep) in_9/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) angina_15/NN
D004280_D017202 NONE dobutamine_8/NN (r_compound) stress_9/NN (r_compound) echocardiography_10/RB (r_pobj) during_7/IN (r_prep) spasm_6/NN (r_pobj) due_2/IN (r_amod) ischemia_1/NN
D004280_D017202 NONE Dobutamine_0/NNP (r_nsubj) stress_1/NN (r_nsubj) is_6/VBZ (l_attr) test_12/NN (l_prep) for_13/IN (l_pobj) ischemia_15/NN
D004280_D017202 NONE dobutamine_19/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (l_nsubjpass) ischemia_11/NN
D000109_D023921 NONE acetylcholine_8/NN (r_pobj) of_7/IN (r_prep) injection_6/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_conj) documented_17/VBN (l_nsubjpass) stenosis_15/NN
D004280_D003329 CID dobutamine_8/NN (r_compound) stress_9/NN (r_compound) echocardiography_10/RB (r_pobj) during_7/IN (r_prep) spasm_6/NN
D004280_D003329 CID dobutamine_19/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (l_nsubjpass) ischemia_11/NN (l_amod) due_12/IN (l_pcomp) to_13/IN (l_pobj) spasm_15/NN
D004280_D003329 CID dobutamine_4/NN (r_nsubj) provoke_6/VB (l_dobj) spasm_8/NN
3300918
D004876_D008881 CID ergot_6/NN (r_pobj) of_5/IN (r_prep) history_4/NN (r_pobj) of_2/IN (r_prep) discussion_1/NN (r_nsubj) includes_7/VBZ (l_dobj) discovery_10/NN (l_appos) epidemics_13/NNS (l_relcl) caused_19/VBN (l_prep) through_20/IN (l_pobj) ages_22/NNS (l_conj) role_28/NN (l_prep) in_29/IN (l_pobj) management_31/NN (l_prep) of_32/IN (l_pobj) headache_34/NN
D004876_D008881 CID ergot_13/NN (r_compound) preparations_14/NNS (r_nsubj) continue_15/VBP (l_xcomp) play_17/VB (l_dobj) role_20/NN (l_prep) in_21/IN (l_pobj) therapy_23/NN (l_compound) migraine_22/NN
D002118_D004881 NONE calcium_4/NN (r_compound) channel_5/NN (r_compound) blockers_6/NNS (r_pobj) of_3/IN (r_prep) advent_2/NN (r_pobj) Despite_0/IN (r_prep) continue_15/VBP (l_advcl) persists_34/VBZ (l_nsubj) danger_28/NN (l_prep) of_29/IN (l_pobj) fire_33/NN
D002118_D008881 NONE calcium_4/NN (r_compound) channel_5/NN (r_compound) blockers_6/NNS (r_pobj) of_3/IN (r_prep) advent_2/NN (r_pobj) Despite_0/IN (r_prep) continue_15/VBP (l_xcomp) play_17/VB (l_dobj) role_20/NN (l_prep) in_21/IN (l_pobj) therapy_23/NN (l_compound) migraine_22/NN
D008784_D014652 CID methysergide_20/NN (r_pobj) of_19/IN (r_prep) ingestion_18/NN (r_pobj) to_16/IN (r_prep) described_14/VBN (l_nsubjpass) case_2/NN (l_prep) of_3/IN (l_pobj) vasospasm_5/NN
D004876_D004881 NONE ergot_13/NN (r_compound) preparations_14/NNS (r_nsubj) continue_15/VBP (l_advcl) persists_34/VBZ (l_nsubj) danger_28/NN (l_prep) of_29/IN (l_pobj) fire_33/NN
D004876_D005734 NONE ergot_6/NN (r_pobj) of_5/IN (r_prep) history_4/NN (r_pobj) of_2/IN (r_prep) discussion_1/NN (r_nsubj) includes_7/VBZ (l_dobj) discovery_10/NN (l_appos) epidemics_13/NNS (l_prep) of_14/IN (l_pobj) gangrene_15/NN
2051906
D001379_D008107 NONE azathioprine_30/NN (r_amod) therapy_31/NN (r_pobj) of_29/IN (r_prep) initiation_28/NN (r_pobj) after_27/IN (r_prep) developed_17/VBD (l_nsubj) patient_4/NN (l_prep) with_6/IN (l_conj) without_10/IN (l_pobj) evidence_12/NN (l_prep) of_13/IN (l_pobj) disease_15/NN
D001379_D017285 NONE azathioprine_30/NN (r_amod) therapy_31/NN (r_pobj) of_29/IN (r_prep) initiation_28/NN (r_pobj) after_27/IN (r_prep) developed_17/VBD (l_nsubj) patient_4/NN (l_prep) with_6/IN (l_pobj) polymyositis_8/NN
D001379_D002779 CID azathioprine_7/JJ (r_amod) therapy_8/NN (r_pobj) following_6/VBG (r_prep) cholestasis_1/NN
D001379_D002779 CID azathioprine_7/JJ (r_amod) therapy_8/NN (r_pobj) following_6/VBG (r_prep) cholestasis_1/NN (l_prep) with_2/IN (l_pobj) injury_5/NN
D001379_D002779 CID azathioprine_30/NN (r_amod) therapy_31/NN (r_pobj) of_29/IN (r_prep) initiation_28/NN (r_pobj) after_27/IN (r_prep) developed_17/VBD (l_dobj) features_21/NNS (l_prep) of_22/IN (l_pobj) cholestasis_24/NN
D001379_D002779 CID azathioprine_12/RB (r_advmod) induced_14/VBN (r_amod) cholestasis_15/NN
D001379_D002779 CID azathioprine_12/RB (r_advmod) induced_14/VBN (r_amod) cholestasis_15/NN (l_acl) associated_16/VBN (l_prep) with_17/IN (l_pobj) evidence_19/NN (l_prep) of_20/IN (l_pobj) injury_23/NN
3084782
D006046_D009393 NONE gold_32/NN (r_compound) thiosulphate_33/NN (r_pobj) due_30/IN (r_prep) between_28/IN (r_prep) found_5/VBN (l_prep) between_6/IN (l_pobj) nephritis_7/NN
-1_D009393 NONE thiosulphate_33/NN (r_pobj) due_30/IN (r_prep) between_28/IN (r_prep) found_5/VBN (l_prep) between_6/IN (l_pobj) nephritis_7/NN
D008625_D001172 NONE Tiopronin_17/NNP (r_npadvmod) related_18/VBN (r_amod) group_20/NN (r_pobj) for_15/IN (r_prep) except_14/IN (r_prep) patients_11/NNS (l_prep) with_12/IN (l_pobj) RA_13/NNP
D010396_D009393 NONE Penicillamine_17/NN (r_appos) Tiopronin_12/NNP (r_pobj) to_11/IN (r_pcomp) due_10/IN (r_prep) found_5/VBN (l_prep) between_6/IN (l_pobj) nephritis_7/NN
-1_D003872 NONE thiosulphate_33/NN (r_pobj) due_30/IN (r_prep) between_28/IN (r_prep) found_5/VBN (l_prep) between_6/IN (l_pobj) nephritis_7/NN (l_conj) dermatitis_9/NN
-1_D003872 NONE thiosulphate_33/NN (r_pobj) due_30/IN (r_prep) between_28/IN (l_pobj) dermatitis_29/NN
D008625_D009393 CID Tiopronin_12/NNP (r_pobj) to_11/IN (r_pcomp) due_10/IN (r_prep) found_5/VBN (l_prep) between_6/IN (l_pobj) nephritis_7/NN
D008625_D009393 CID Tiopronin_17/NNP (r_npadvmod) related_18/VBN (r_amod) group_20/NN (l_compound) nephritis_19/NN
D006046_D003872 CID gold_32/NN (r_compound) thiosulphate_33/NN (r_pobj) due_30/IN (r_prep) between_28/IN (r_prep) found_5/VBN (l_prep) between_6/IN (l_pobj) nephritis_7/NN (l_conj) dermatitis_9/NN
D006046_D003872 CID gold_32/NN (r_compound) thiosulphate_33/NN (r_pobj) due_30/IN (r_prep) between_28/IN (l_pobj) dermatitis_29/NN
D008625_D003872 CID Tiopronin_12/NNP (r_pobj) to_11/IN (r_pcomp) due_10/IN (r_prep) found_5/VBN (l_prep) between_6/IN (l_pobj) nephritis_7/NN (l_conj) dermatitis_9/NN
D008625_D003872 CID Tiopronin_12/NNP (r_pobj) to_11/IN (r_pcomp) due_10/IN (r_prep) found_5/VBN (l_prep) between_28/IN (l_pobj) dermatitis_29/NN
D010396_D003872 NONE Penicillamine_17/NN (r_appos) Tiopronin_12/NNP (r_pobj) to_11/IN (r_pcomp) due_10/IN (r_prep) found_5/VBN (l_prep) between_6/IN (l_pobj) nephritis_7/NN (l_conj) dermatitis_9/NN
D010396_D003872 NONE Penicillamine_17/NN (r_appos) Tiopronin_12/NNP (r_pobj) to_11/IN (r_pcomp) due_10/IN (r_prep) found_5/VBN (l_prep) between_28/IN (l_pobj) dermatitis_29/NN
3962737
D000638_D013610 NONE Amiodarone_0/NNP (r_nsubj) proved_2/VBN (l_prep) in_5/IN (l_pobj) treatment_7/NN (l_prep) of_8/IN (l_pobj) tachyarrhythmias_12/NNS
D000638_D002779 CID amiodarone_7/NN (r_compound) treatment_8/NN (r_appos) patient_1/NN (l_prep) with_2/IN (l_pobj) hepatitis_4/NN
D000638_D002779 CID amiodarone_19/NN (r_pobj) of_18/IN (r_prep) hepatotoxicity_17/NN (r_pobj) of_15/IN (r_prep) review_14/NN (r_nsubjpass) given_21/VBN (r_conj) presented_10/VBN (l_nsubjpass) patient_1/NN (l_prep) with_2/IN (l_pobj) hepatitis_4/NN
D000638_D002779 CID amiodarone_12/NN (r_compound) treatment_13/NN (r_pobj) to_11/IN (r_pcomp) due_10/IN (l_pobj) alterations_18/NNS (l_acl) resembling_19/VBG (l_dobj) hepatitis_21/NN (l_appos) cirrhosis_27/NN (l_nmod) hepatitis_24/NN
D000638_D006519 NONE amiodarone_12/NN (r_compound) treatment_13/NN (r_pobj) to_11/IN (r_pcomp) due_10/IN (l_pobj) alterations_18/NNS (l_acl) resembling_19/VBG (l_dobj) hepatitis_21/NN
D000638_D008103 CID amiodarone_12/NN (r_compound) treatment_13/NN (r_pobj) to_11/IN (r_pcomp) due_10/IN (l_pobj) alterations_18/NNS (l_acl) resembling_19/VBG (l_dobj) hepatitis_21/NN (l_appos) cirrhosis_27/NN (l_prep) of_28/IN (l_pobj) liver_30/NN
D000638_D056486 CID amiodarone_2/NN (r_pobj) of_1/IN (r_prep) Hepatotoxicity_0/NN
D000638_D056486 CID amiodarone_7/NN (r_compound) treatment_8/NN (r_appos) patient_1/NN (l_prep) with_2/IN (l_pobj) hepatitis_4/NN
D000638_D056486 CID amiodarone_7/NN (r_compound) treatment_8/NN (r_appos) patient_1/NN (r_nsubjpass) presented_10/VBN (l_conj) given_21/VBN (l_nsubjpass) review_14/NN (l_prep) of_15/IN (l_pobj) hepatotoxicity_17/NN
D000638_D056486 CID amiodarone_19/NN (r_pobj) of_18/IN (r_prep) hepatotoxicity_17/NN (r_pobj) of_15/IN (r_prep) review_14/NN (r_nsubjpass) given_21/VBN (r_conj) presented_10/VBN (l_nsubjpass) patient_1/NN (l_prep) with_2/IN (l_pobj) hepatitis_4/NN
D000638_D056486 CID amiodarone_19/NN (r_pobj) of_18/IN (r_prep) hepatotoxicity_17/NN
D000638_D056486 CID amiodarone_12/NN (r_compound) treatment_13/NN (r_pobj) to_11/IN (r_pcomp) due_10/IN (r_prep) exists_6/VBZ (l_prep) of_7/IN (l_pobj) injury_9/NN
D000638_D056486 CID amiodarone_12/NN (r_compound) treatment_13/NN (r_pobj) to_11/IN (r_pcomp) due_10/IN (l_pobj) alterations_18/NNS (l_acl) resembling_19/VBG (l_dobj) hepatitis_21/NN (l_appos) cirrhosis_27/NN (l_nmod) hepatitis_24/NN
D000638_D005234 CID amiodarone_12/NN (r_compound) treatment_13/NN (l_prep) including_15/VBG (l_pobj) steatosis_16/NN
9228650
C049860_D000647 CID NIK-247_2/NNP (l_prep) on_3/IN (l_pobj) cholinesterase_4/NN (l_conj) amnesia_9/NN
C049860_D000647 CID NIK-247_3/NNP (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) examined_15/VBN (l_nsubjpass) amnesia_10/NN
C049860_D000647 CID NIK-247_4/NNP (r_nsubj) improves_16/VBZ (l_dobj) amnesia_20/NN
C049860_D000544 NONE NIK-247_4/NNP (r_nsubj) be_6/VB (l_attr) drug_9/NN (l_prep) for_10/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) disease_16/NN
D013619_D000647 CID tacrine_27/NN (r_appos) inhibitors_26/NNS (r_pobj) of_20/IN (r_prep) those_19/DT (r_pobj) with_18/IN (r_prep) compared_17/VBN (r_conj) examined_15/VBN (l_nsubjpass) amnesia_10/NN
C076946_D000647 CID E-2020_29/NNS (r_conj) tacrine_27/NN (r_appos) inhibitors_26/NNS (r_pobj) of_20/IN (r_prep) those_19/DT (r_pobj) with_18/IN (r_prep) compared_17/VBN (r_conj) examined_15/VBN (l_nsubjpass) amnesia_10/NN
D012601_D000647 CID scopolamine_6/NN (r_npadvmod) induced_8/VBN (r_amod) amnesia_9/NN
D012601_D000647 CID scopolamine_7/NN (r_npadvmod) induced_9/VBN (r_amod) amnesia_10/NN
D012601_D000647 CID scopolamine_14/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) amnesia_11/NN
D012601_D000647 CID scopolamine_17/NN (r_npadvmod) induced_19/VBN (r_amod) amnesia_20/NN
11694026
C012655_D014581 NONE nimesulide_2/NN (r_pobj) of_1/IN (r_prep) Tolerability_0/DT (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) angioedema_13/NN (l_nmod) urticaria_11/NN
C012655_D014581 NONE nimesulide_9/NN (r_pobj) of_8/IN (r_prep) tolerability_5/NN (r_dobj) investigated_4/VBD (l_prep) in_12/IN (l_pobj) number_16/NN (l_prep) of_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) history_25/NN (l_prep) of_26/IN (l_pobj) angioedema_32/NN (l_nmod) urticaria_30/NN
C012655_D014581 NONE nimesulide_10/NN (r_pobj) with_9/IN (r_prep) procedure_8/NN (r_nsubjpass) applied_14/VBN (l_prep) with_18/IN (l_pobj) history_20/NN (l_prep) of_21/IN (l_pobj) angioedema_27/NN (l_nmod) urticaria_25/NN
C012655_D014581 NONE nimesulide_10/NN (r_pobj) of_9/IN (r_prep) tolerability_8/NN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_relcl) experienced_16/VBD (l_dobj) angioedema_19/NNP (l_nmod) urticaria_17/NN
D000894_D000799 CID NSAID_8/NNP (r_npadvmod) induced_10/VBN (r_amod) urticaria_11/NN (r_nmod) angioedema_13/NN
D000894_D000799 CID NSAID_27/NNP (r_npadvmod) induced_29/VBN (r_amod) urticaria_30/NN (r_nmod) angioedema_32/NN
D000894_D000799 CID NSAID_22/NNP (r_npadvmod) induced_24/VBN (r_amod) urticaria_25/NN (r_nmod) angioedema_27/NN
D000894_D000799 CID NSAID_21/NNP (r_npadvmod) induced_23/VBN (r_amod) urticaria_24/NN (r_nmod) angioedema_26/NN
D000894_D000799 CID NSAID_21/NNP (r_npadvmod) induced_23/VBN (r_amod) urticaria_24/NN (r_nmod) angioedema_26/NN (l_conj) angioedema_28/NN
D000894_D000799 CID NSAIDs_22/NNS (r_pobj) by_21/IN (r_agent) caused_20/VBN (r_acl) angioedema_19/NNP
D000894_D000799 CID NSAID_29/NNP (r_npadvmod) induced_31/VBN (r_amod) angioedema_32/NN
C012655_D000799 CID nimesulide_2/NN (r_pobj) of_1/IN (r_prep) Tolerability_0/DT (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) angioedema_13/NN
C012655_D000799 CID nimesulide_9/NN (r_pobj) of_8/IN (r_prep) tolerability_5/NN (r_dobj) investigated_4/VBD (l_prep) in_12/IN (l_pobj) number_16/NN (l_prep) of_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) history_25/NN (l_prep) of_26/IN (l_pobj) angioedema_32/NN
C012655_D000799 CID nimesulide_10/NN (r_pobj) with_9/IN (r_prep) procedure_8/NN (r_nsubjpass) applied_14/VBN (l_prep) with_18/IN (l_pobj) history_20/NN (l_prep) of_21/IN (l_pobj) angioedema_27/NN
C012655_D000799 CID nimesulide_10/NN (r_pobj) of_9/IN (r_prep) tolerability_8/NN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_relcl) experienced_16/VBD (l_dobj) angioedema_19/NNP
D000082_D000799 CID paracetamol_4/NN (r_conj) nimesulide_2/NN (r_pobj) of_1/IN (r_prep) Tolerability_0/DT (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) angioedema_13/NN
D000082_D000799 CID paracetamol_11/NN (r_conj) nimesulide_9/NN (r_pobj) of_8/IN (r_prep) tolerability_5/NN (r_dobj) investigated_4/VBD (l_prep) in_12/IN (l_pobj) number_16/NN (l_prep) of_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) history_25/NN (l_prep) of_26/IN (l_pobj) angioedema_32/NN
D000082_D000799 CID paracetamol_12/NNP (r_conj) nimesulide_10/NN (r_pobj) with_9/IN (r_prep) procedure_8/NN (r_nsubjpass) applied_14/VBN (l_prep) with_18/IN (l_pobj) history_20/NN (l_prep) of_21/IN (l_pobj) angioedema_27/NN
D000082_D000799 CID paracetamol_12/NN (r_conj) nimesulide_10/NN (r_pobj) of_9/IN (r_prep) tolerability_8/NN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_relcl) experienced_16/VBD (l_dobj) angioedema_19/NNP
D000894_D014581 NONE NSAID_8/NNP (r_npadvmod) induced_10/VBN (r_amod) urticaria_11/NN
D000894_D014581 NONE NSAID_27/NNP (r_npadvmod) induced_29/VBN (r_amod) urticaria_30/NN
D000894_D014581 NONE NSAID_22/NNP (r_npadvmod) induced_24/VBN (r_amod) urticaria_25/NN
D000894_D014581 NONE NSAID_21/NNP (r_npadvmod) induced_23/VBN (r_amod) urticaria_24/NN (r_nmod) angioedema_26/NN (r_pobj) of_20/IN (r_prep) history_19/NN (r_pobj) with_17/IN (r_prep) subjects_16/NNS (r_pobj) of_15/IN (r_prep) %_14/NN (r_conj) history_8/NN (l_prep) of_9/IN (l_pobj) urticaria_11/NN
D000894_D014581 NONE NSAID_21/NNP (r_npadvmod) induced_23/VBN (r_amod) urticaria_24/NN
D000894_D014581 NONE NSAID_21/NNP (r_npadvmod) induced_23/VBN (r_amod) urticaria_24/NN (r_nmod) angioedema_26/NN (r_pobj) of_20/IN (r_prep) history_19/NN (l_prep) with_31/IN (l_conj) without_33/IN (l_pobj) urticaria_35/NN
D000894_D014581 NONE NSAIDs_22/NNS (r_pobj) by_21/IN (r_agent) caused_20/VBN (r_acl) angioedema_19/NNP (l_nmod) urticaria_17/NN
D000894_D014581 NONE NSAID_29/NNP (r_npadvmod) induced_31/VBN (r_amod) angioedema_32/NN (r_pobj) of_28/IN (r_prep) history_27/NN (r_pobj) by_25/IN (r_prep) increased_13/VBN (l_agent) by_14/IN (l_pobj) history_16/NN (l_prep) of_17/IN (l_pobj) urticaria_19/NN
D000082_D014581 NONE paracetamol_4/NN (r_conj) nimesulide_2/NN (r_pobj) of_1/IN (r_prep) Tolerability_0/DT (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) angioedema_13/NN (l_nmod) urticaria_11/NN
D000082_D014581 NONE paracetamol_11/NN (r_conj) nimesulide_9/NN (r_pobj) of_8/IN (r_prep) tolerability_5/NN (r_dobj) investigated_4/VBD (l_prep) in_12/IN (l_pobj) number_16/NN (l_prep) of_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) history_25/NN (l_prep) of_26/IN (l_pobj) angioedema_32/NN (l_nmod) urticaria_30/NN
D000082_D014581 NONE paracetamol_12/NNP (r_conj) nimesulide_10/NN (r_pobj) with_9/IN (r_prep) procedure_8/NN (r_nsubjpass) applied_14/VBN (l_prep) with_18/IN (l_pobj) history_20/NN (l_prep) of_21/IN (l_pobj) angioedema_27/NN (l_nmod) urticaria_25/NN
D000082_D014581 NONE paracetamol_12/NN (r_conj) nimesulide_10/NN (r_pobj) of_9/IN (r_prep) tolerability_8/NN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_relcl) experienced_16/VBD (l_dobj) angioedema_19/NNP (l_nmod) urticaria_17/NN
2004
D010640_D005117 NONE phenothiazines_16/NNS (r_dobj) receiving_15/VBG (r_acl) patients_14/NNS (r_pobj) to_13/IN (r_prep) complications_12/NNS
D008012_D001145 NONE lidocaine_8/NN (r_pobj) of_7/IN (r_prep) administration_6/NN (r_pobj) to_4/IN (r_prep) responded_3/VBD (l_nsubj) arrhythmias_2/NNS
D011433_D001145 NONE propranolol_27/NN (r_pobj) of_26/IN (r_prep) instances_22/NNS (r_pobj) in_20/IN (r_prep) required_19/VBN (l_ccomp) responded_3/VBD (l_nsubj) arrhythmias_2/NNS
D002746_D013617 NONE Thorazine_7/NN (r_dobj) receiving_6/VBG (r_acl) patient_5/NN (r_pobj) in_3/IN (r_prep) developed_2/VBN (l_nsubj) tachycardia_1/NN
D002746_D013617 NONE chlorpromazine_9/NN (r_appos) Thorazine_7/NN (r_dobj) receiving_6/VBG (r_acl) patient_5/NN (r_pobj) in_3/IN (r_prep) developed_2/VBN (l_nsubj) tachycardia_1/NN
D013881_D017180 CID Mellaril_8/NNP (r_nsubj) appeared_12/VBD (l_xcomp) be_14/VB (l_acomp) responsible_15/JJ (l_prep) for_16/IN (l_pobj) cases_18/NNS (l_prep) of_19/IN (l_pobj) tachycardia_21/NN
D013881_D017180 CID thioridazine_10/NNP (r_appos) Mellaril_8/NNP (r_nsubj) appeared_12/VBD (l_xcomp) be_14/VB (l_acomp) responsible_15/JJ (l_prep) for_16/IN (l_pobj) cases_18/NNS (l_prep) of_19/IN (l_pobj) tachycardia_21/NN
D000639_D002037 CID Elavil_5/NNP (r_conj) Aventyl_0/NNP (r_nsubj) block_14/NN
D000639_D002037 CID amitriptyline_7/FW (r_appos) Elavil_5/NNP (r_conj) Aventyl_0/NNP (r_nsubj) block_14/NN
D009661_D002037 CID Aventyl_0/NNP (r_nsubj) block_14/NN
D009661_D002037 CID nortriptyline_2/NN (r_appos) Aventyl_0/NNP (r_nsubj) block_14/NN
8600333
D004317_D001859 NONE doxorubicin_27/NN (r_pobj) including_26/VBG (r_prep) both_25/DT (r_appos) protocol_23/NN (r_pobj) to_17/IN (r_prep) according_16/VBG (r_prep) treated_15/VBN (r_relcl) survivors_8/NNS (l_prep) of_9/IN (l_pobj) tumors_12/NNS
C053519_D001859 NONE protocol_23/NN (r_pobj) to_17/IN (r_prep) according_16/VBG (r_prep) treated_15/VBN (r_relcl) survivors_8/NNS (l_prep) of_9/IN (l_pobj) tumors_12/NNS
D004317_D066126 NONE doxorubicin_3/NN (r_npadvmod) induced_5/VBN (r_compound) cardiotoxicity_6/NN
11302406
D015725_D016171 CID Fluconazole_0/NNP (r_npadvmod) induced_2/VBN (r_amod) torsade_3/NN (r_nmod) pointes_5/FW
D015725_D016171 CID fluconazole_5/NN (r_advmod) associated_7/VBN (r_amod) pointes_10/FW
D015725_D016171 CID fluconazole_5/NN (r_advmod) associated_7/VBN (r_amod) pointes_10/FW (l_appos) TDP_12/NNP
D015725_D016171 CID fluconazole_5/NN (r_advmod) associated_7/VBN (r_amod) pointes_10/FW (r_pobj) of_4/IN (r_prep) case_3/NN (r_dobj) present_1/VB (l_conj) discuss_15/VB (l_dobj) role_18/NN (l_prep) in_19/IN (l_pcomp) causing_20/VBG (l_dobj) TDP_21/NNP
D015725_D016171 CID fluconazole_16/NN (r_poss) role_18/NN (r_dobj) discuss_15/VB (r_conj) present_1/VB (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) pointes_10/FW
D015725_D016171 CID fluconazole_16/NN (r_poss) role_18/NN (r_dobj) discuss_15/VB (r_conj) present_1/VB (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) pointes_10/FW (l_appos) TDP_12/NNP
D015725_D016171 CID fluconazole_16/NN (r_poss) role_18/NN (l_prep) in_19/IN (l_pcomp) causing_20/VBG (l_dobj) TDP_21/NNP
D015725_D016171 CID fluconazole_21/NN (r_dobj) commencing_19/VBG (r_pcomp) after_18/IN (r_prep) glabrata_8/NNS (l_xcomp) isolated_9/VBN (l_prep) from_10/IN (l_pobj) abscess_13/NN (l_acl) developed_14/VBD (l_dobj) TDP_15/NNP
D015725_D016171 CID fluconazole_33/NN (r_pobj) of_32/IN (r_prep) initiation_31/NN (r_pobj) between_29/IN (r_prep) association_28/NN (r_attr) was_25/VBD (r_relcl) factors_6/NNS (l_prep) for_7/IN (l_pobj) TDP_8/NNP
D015725_D016171 CID fluconazole_33/NN (l_conj) TDP_35/NNP
D015725_D016171 CID fluconazole_4/NN (r_nsubjpass) discontinued_6/VBN (r_advcl) resolved_2/VBD (l_nsubj) TDP_1/NNP
D015725_D016171 CID fluconazole_14/NN (r_pobj) of_13/IN (r_prep) use_12/NN (l_conj) development_17/NN (l_prep) of_18/IN (l_pobj) TDP_19/NNP
D015725_D016171 CID fluconazole_5/NN (r_ccomp) aware_3/JJ (r_acomp) be_2/VB (l_conj) cause_13/VB (l_advcl) leading_20/VBG (l_prep) to_21/IN (l_pobj) TDP_22/NNP
D015725_D003324 NONE fluconazole_33/NN (r_pobj) of_32/IN (r_prep) initiation_31/NN (r_pobj) between_29/IN (r_prep) association_28/NN (r_attr) was_25/VBD (r_relcl) factors_6/NNS (l_prep) including_10/VBG (l_pobj) disease_13/NN
D015725_D018879 NONE fluconazole_4/NN (r_nsubjpass) discontinued_6/VBN (r_advcl) resolved_2/VBD (r_ccomp) continued_12/VBD (l_xcomp) have_14/VB (l_dobj) contractions_17/NNS
D015725_D018879 NONE fluconazole_22/NN (r_dobj) suggests_21/VBZ (l_csubj) followed_9/VBN (l_nsubj) disappearance_2/NN (l_conj) contractions_8/NNS
D011188_D003866 NONE potassium_10/NN (r_compound) currents_11/NNS (r_dobj) activating_7/VBG (r_pcomp) of_5/IN (r_prep) depression_4/NN
D015725_D008133 NONE fluconazole_5/NN (r_ccomp) aware_3/JJ (r_acomp) be_2/VB (l_conj) cause_13/VB (l_dobj) prolongation_14/NN (l_prep) of_15/IN (l_pobj) interval_18/NN
D015725_D006333 NONE fluconazole_33/NN (r_pobj) of_32/IN (r_prep) initiation_31/NN (r_pobj) between_29/IN (r_prep) association_28/NN (r_attr) was_25/VBD (r_relcl) factors_6/NNS (l_prep) including_10/VBG (l_pobj) disease_13/NN (l_amod) cardiomyopathy_15/NN (l_conj) failure_19/NN
D015725_D009202 NONE fluconazole_33/NN (r_pobj) of_32/IN (r_prep) initiation_31/NN (r_pobj) between_29/IN (r_prep) association_28/NN (r_attr) was_25/VBD (r_relcl) factors_6/NNS (l_prep) including_10/VBG (l_pobj) disease_13/NN (l_amod) cardiomyopathy_15/NN
D015725_D001145 NONE fluconazole_7/NN (r_nsubjpass) administered_9/VBN (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_relcl) are_13/VBP (l_prep) at_14/IN (l_pobj) risk_15/NN (l_prep) for_16/IN (l_pobj) arrhythmias_18/NNS
D015725_D017180 NONE fluconazole_4/NN (r_nsubjpass) discontinued_6/VBN (r_advcl) resolved_2/VBD (r_ccomp) continued_12/VBD (l_conj) tachycardia_21/NN
D015725_D017180 NONE fluconazole_4/NN (r_nsubjpass) discontinued_6/VBN (r_advcl) resolved_2/VBD (r_ccomp) continued_12/VBD (l_conj) tachycardia_21/NN (l_appos) NSVT_23/NNP
D015725_D017180 NONE fluconazole_22/NN (r_dobj) suggests_21/VBZ (l_csubj) followed_9/VBN (l_nsubj) disappearance_2/NN (l_prep) of_3/IN (l_pobj) NSVT_4/NNP
16596970
D010862_D013226 CID Pilocarpine_0/NN (r_nsubj) induced_4/VBN (l_advmod) epilepticus_6/NN
D010862_D013226 CID Pilocarpine_0/NN (r_nsubj) induced_4/VBN (r_ccomp) resulted_12/VBD (l_nsubj) epilepticus_9/NN
D010862_D012640 NONE Pilocarpine_0/NNP (r_amod) seizures_1/NNS
D010862_D012640 NONE Pilocarpine_0/NN (r_nsubj) induced_4/VBN (r_ccomp) resulted_12/VBD (l_prep) in_13/IN (l_pobj) loss_16/NN (l_conj) seizures_19/NNS
D010862_D012640 NONE Pilocarpine_0/NN (r_nsubj) induced_4/VBN (r_ccomp) resulted_12/VBD (l_advcl) had_24/VBD (l_dobj) loss_27/NN (l_conj) seizures_30/NNS
D010862_D001308 CID Pilocarpine_0/NNP (r_amod) seizures_1/NNS (r_nsubj) cause_2/IN (l_dobj) impairment_6/NN (l_prep) in_7/IN (l_pobj) discrimination_10/NN
12042105
C052342_D004827 NONE Topiramate_0/NNP (r_nsubj) is_1/VBZ (l_attr) medication_6/NN (l_relcl) becoming_9/VBG (l_prep) because_13/IN (l_pobj) efficacy_16/NN (l_prep) in_17/IN (l_pcomp) treating_18/VBG (l_dobj) seizures_20/NNS
C052342_D053040 CID Topiramate_0/NNP (r_npadvmod) induced_2/VBN (r_amod) nephrolithiasis_3/NN
C052342_D053040 CID topiramate_7/RB (r_npadvmod) induced_9/VBN (r_amod) nephrolithiasis_10/NN
C020243_D053040 NONE phosphate_29/NN (r_compound) nephrolithiasis_30/NN
8617710
D006220_D003072 CID haloperidol_14/NN (r_pobj) with_13/IN (r_prep) impairment_12/NN
D006220_D003072 CID haloperidol_13/NN (r_pobj) of_12/IN (r_prep) administration_11/NN (r_pobj) after_10/IN (r_prep) observed_5/VBN (l_nsubjpass) Impairment_0/NN (l_prep) of_1/IN (l_pobj) function_3/NN
D006220_D003072 CID Haloperidol_0/NNP (r_nsubj) produced_1/VBD (l_dobj) profile_4/NN (l_prep) of_5/IN (l_pobj) impairment_7/NN
D020280_D003072 NONE sertraline_4/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (l_prep) on_5/IN (l_pobj) sensitization_9/NN (l_prep) of_10/IN (l_pobj) impairment_12/NN
D020280_D003072 NONE sertraline_14/NN (r_compound) administration_15/NN (r_pobj) by_12/IN (r_agent) worsened_11/VBN (r_relcl) profile_4/NN (l_prep) of_5/IN (l_pobj) impairment_7/NN
18201582
C084178_D006973 NONE telmisartan_32/NN (r_pobj) of_31/IN (r_prep) combination_30/NN (l_prep) with_41/IN (l_pobj) hypertension_44/NN
C084178_D006973 NONE telmisartan_23/NNP (r_pobj) of_22/IN (r_prep) combination_18/NN (r_pobj) of_12/IN (r_prep) efficacy_9/NN (r_dobj) evaluate_7/VB (l_conj) amlodipine_27/NN (l_prep) compared_33/VBN (l_prep) with_34/IN (l_pobj) amlodipine_35/NN (l_appos) monotherapy_37/NN (l_prep) in_41/IN (l_pobj) patients_44/NNS (l_prep) with_45/IN (l_pobj) hypertension_48/NN
D017311_D006973 NONE amlodipine_34/NN (r_conj) telmisartan_32/NN (r_pobj) of_31/IN (r_prep) combination_30/NN (l_prep) with_41/IN (l_pobj) hypertension_44/NN
D017311_D006973 NONE amlodipine_36/NN (r_pobj) versus_35/IN (r_prep) telmisartan_32/NN (r_pobj) of_31/IN (r_prep) combination_30/NN (l_prep) with_41/IN (l_pobj) hypertension_44/NN
D017311_D006973 NONE amlodipine_27/NN (l_prep) compared_33/VBN (l_prep) with_34/IN (l_pobj) amlodipine_35/NN (l_appos) monotherapy_37/NN (l_prep) in_41/IN (l_pobj) patients_44/NNS (l_prep) with_45/IN (l_pobj) hypertension_48/NN
D017311_D006973 NONE amlodipine_35/NN (l_appos) monotherapy_37/NN (l_prep) in_41/IN (l_pobj) patients_44/NNS (l_prep) with_45/IN (l_pobj) hypertension_48/NN
6695415
D002110_D020521 NONE caffeine_7/NN (r_nsubj) lead_9/VB (l_prep) to_10/IN (l_pobj) stroke_11/NN
D002110_D002543 CID caffeine_8/NN (r_pobj) with_7/IN (r_prep) combination_6/NN (r_pobj) in_5/IN (r_prep) associated_2/VBN (r_acl) hemorrhage_1/NN
D002110_D002543 CID caffeine_6/NN (r_nsubj) lead_8/VB (l_prep) to_9/IN (l_pobj) hemorrhage_11/NN
D010665_D006973 CID PPA_5/NNP (r_nmod) caffeine_7/NN (r_nsubj) lead_9/VB (l_prep) in_12/IN (l_pobj) rats_16/NNS (l_amod) normotensive_13/NN (l_conj) hypertensive_15/JJ
D010665_D006973 CID PPA_2/NNP (r_nmod) caffeine_4/NN (r_compound) administration_5/NN (r_nsubj) lead_10/NN (l_prep) to_11/IN (l_pobj) hypertension_13/NN
D010665_D006973 CID PPA_2/NNP (r_nmod) caffeine_4/NN (r_compound) administration_5/NN (r_nsubj) lead_10/NN (l_prep) to_11/IN (l_pobj) hypertension_13/NN (l_prep) in_14/IN (l_pobj) animals_20/NNS (l_amod) normotensive_17/NN (l_conj) hypertensive_19/JJ
D010665_D006973 CID PPA_4/NNP (r_nmod) caffeine_6/NN (r_nsubj) lead_8/VB (l_prep) to_9/IN (l_pobj) hemorrhage_11/NN (l_prep) in_12/IN (l_pobj) animals_15/NNS (l_amod) hypertensive_14/JJ
D010665_D020521 CID Phenylpropanolamine_0/NNP (r_nsubj) is_4/VBZ (l_attr) drug_6/NN (l_relcl) associated_10/VBN (l_prep) with_11/IN (l_pobj) effects_14/NNS (l_prep) including_15/VBG (l_pobj) stroke_16/NN
D010665_D020521 CID PPA_2/NNP (r_appos) Phenylpropanolamine_0/NNP (r_nsubj) is_4/VBZ (l_attr) drug_6/NN (l_relcl) associated_10/VBN (l_prep) with_11/IN (l_pobj) effects_14/NNS (l_prep) including_15/VBG (l_pobj) stroke_16/NN
D010665_D020521 CID PPA_5/NNP (r_nmod) caffeine_7/NN (r_nsubj) lead_9/VB (l_prep) to_10/IN (l_pobj) stroke_11/NN
D002110_D006973 CID caffeine_7/NN (r_nsubj) lead_9/VB (l_prep) in_12/IN (l_pobj) rats_16/NNS (l_amod) normotensive_13/NN (l_conj) hypertensive_15/JJ
D002110_D006973 CID caffeine_4/NN (r_compound) administration_5/NN (r_nsubj) lead_10/NN (l_prep) to_11/IN (l_pobj) hypertension_13/NN
D002110_D006973 CID caffeine_4/NN (r_compound) administration_5/NN (r_nsubj) lead_10/NN (l_prep) to_11/IN (l_pobj) hypertension_13/NN (l_prep) in_14/IN (l_pobj) animals_20/NNS (l_amod) normotensive_17/NN (l_conj) hypertensive_19/JJ
D002110_D006973 CID caffeine_6/NN (r_nsubj) lead_8/VB (l_prep) to_9/IN (l_pobj) hemorrhage_11/NN (l_prep) in_12/IN (l_pobj) animals_15/NNS (l_amod) hypertensive_14/JJ
D010665_D002543 CID phenylpropanolamine_4/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) hemorrhage_1/NN
D010665_D002543 CID PPA_4/NNP (r_nmod) caffeine_6/NN (r_nsubj) lead_8/VB (l_prep) to_9/IN (l_pobj) hemorrhage_11/NN
15686794
D000638_D017116 CID amiodarone_8/NN (r_pobj) of_7/IN (r_prep) administration_6/NN (r_pobj) during_4/IN (r_prep) pain_3/NN
D000638_D017116 CID amiodarone_28/NN (r_compound) loading_29/NN (r_pobj) of_26/IN (r_prep) initiation_25/NN (r_pobj) after_24/IN (r_prep) experienced_14/VBD (l_dobj) pain_20/NN
D000638_D001281 NONE Amiodarone_0/NNP (r_nsubj) represents_1/VBZ (l_dobj) drug_5/NN (l_prep) for_6/IN (l_pobj) cardioversion_7/NN (l_prep) of_8/IN (l_pobj) fibrillation_13/NN
D000638_D001281 NONE Amiodarone_0/NNP (r_nsubj) represents_1/VBZ (l_dobj) drug_5/NN (l_prep) for_6/IN (l_pobj) cardioversion_7/NN (l_prep) of_8/IN (l_pobj) fibrillation_13/NN (l_appos) AF_15/NNP
D000638_D001281 NONE amiodarone_28/NN (r_compound) loading_29/NN (r_pobj) of_26/IN (r_prep) initiation_25/NN (r_pobj) after_24/IN (r_prep) experienced_14/VBD (r_relcl) fibrillation_11/NN
6111982
D010042_D001145 CID ouabain_11/JJ (r_compound) arrhythmia_12/NN
D010869_D001145 NONE pindolol_8/NN (l_xcomp) inhibiting_9/VBG (l_dobj) arrhythmia_12/NN
D011433_D001145 NONE propranolol_6/NN (l_conj) pindolol_8/NN (l_xcomp) inhibiting_9/VBG (l_dobj) arrhythmia_12/NN
12101159
D004110_D062787 CID diltiazem_5/NN (r_compound) overdose_6/NN
D004110_D062787 CID diltiazem_15/NN (r_pobj) of_14/IN (r_prep) g_13/NN (r_pobj) including_9/VBG (r_prep) overdose_8/NN
D004110_D062787 CID diltiazem_16/NN (r_compound) overdose_17/NN
D004110_D062787 CID diltiazem_11/NN (r_compound) overdose_12/NN
D009566_D062787 NONE nitrate_22/NN (r_conj) aspirin_19/NN (r_conj) paracetamol_17/JJ (r_conj) diltiazem_15/NN (r_pobj) of_14/IN (r_prep) g_13/NN (r_pobj) including_9/VBG (r_prep) overdose_8/NN
D002118_D062787 NONE calcium_13/NN (r_pobj) with_9/IN (r_prep) resuscitation_8/NN (r_dep) Delayed_0/VBN (l_dobj) arrest_3/NN (l_prep) after_4/IN (l_pobj) overdose_6/NN
D002118_D062787 NONE calcium_12/NN (r_compound) therapy_13/NN (l_prep) in_14/IN (l_pobj) overdose_17/NN
D000431_D062787 NONE alcohol_25/NN (r_conj) nitrate_22/NN (r_conj) aspirin_19/NN (r_conj) paracetamol_17/JJ (r_conj) diltiazem_15/NN (r_pobj) of_14/IN (r_prep) g_13/NN (r_pobj) including_9/VBG (r_prep) overdose_8/NN
D002118_D006323 NONE calcium_13/NN (r_pobj) with_9/IN (r_prep) resuscitation_8/NN (r_dep) Delayed_0/VBN (l_dobj) arrest_3/NN (l_amod) asystolic_1/JJ
D002118_D006323 NONE calcium_13/NN (r_pobj) with_9/IN (r_prep) resuscitation_8/NN (r_dep) Delayed_0/VBN (l_dobj) arrest_3/NN
D002118_D006323 NONE calcium_12/NN (r_compound) therapy_13/NN (r_pobj) for_7/IN (r_prep) role_6/NN (l_prep) with_20/IN (l_pobj) onset_22/NN (l_prep) of_23/IN (l_pobj) asystole_24/NN
D001241_D062787 NONE aspirin_19/NN (r_conj) paracetamol_17/JJ (r_conj) diltiazem_15/NN (r_pobj) of_14/IN (r_prep) g_13/NN (r_pobj) including_9/VBG (r_prep) overdose_8/NN
D004110_D006323 CID diltiazem_5/NN (r_compound) overdose_6/NN (r_pobj) after_4/IN (r_prep) arrest_3/NN (l_amod) asystolic_1/JJ
D004110_D006323 CID diltiazem_5/NN (r_compound) overdose_6/NN (r_pobj) after_4/IN (r_prep) arrest_3/NN
D004110_D006323 CID diltiazem_16/NN (r_compound) overdose_17/NN (r_pobj) in_14/IN (r_prep) therapy_13/NN (r_pobj) for_7/IN (r_prep) role_6/NN (l_prep) with_20/IN (l_pobj) onset_22/NN (l_prep) of_23/IN (l_pobj) asystole_24/NN
D004110_D006323 CID diltiazem_11/NN (r_compound) overdose_12/NN (r_pobj) after_10/IN (r_prep) cases_6/NNS (l_prep) of_7/IN (l_pobj) arrest_9/NN
D000082_D062787 NONE paracetamol_17/JJ (r_conj) diltiazem_15/NN (r_pobj) of_14/IN (r_prep) g_13/NN (r_pobj) including_9/VBG (r_prep) overdose_8/NN
D007547_D062787 NONE isosorbide_21/JJ (r_compound) nitrate_22/NN (r_conj) aspirin_19/NN (r_conj) paracetamol_17/JJ (r_conj) diltiazem_15/NN (r_pobj) of_14/IN (r_prep) g_13/NN (r_pobj) including_9/VBG (r_prep) overdose_8/NN
16725121
D003042_D012640 CID cocaine_21/NN (r_pobj) by_20/IN (r_agent) induce_19/VB (r_acl) seizures_18/NNS
D003042_D012640 CID cocaine_18/NN (r_npadvmod) induced_20/VBN (r_amod) convulsions_21/NNS (r_pobj) of_17/IN (r_prep) that_16/DT (r_dobj) decreased_15/VBD (r_conj) increased_4/VBD (l_dobj) incidence_6/NN (l_prep) of_7/IN (l_pobj) appearance_8/NN (l_prep) of_9/IN (l_pobj) convulsions_13/NNS
D003042_D012640 CID cocaine_18/NN (r_npadvmod) induced_20/VBN (r_amod) convulsions_21/NNS
D003042_D012640 CID cocaine_16/NN (r_conj) lidocaine_14/NN (r_pobj) of_13/IN (r_prep) activity_12/NN (l_amod) convulsive_11/JJ
D003042_D012640 CID cocaine_19/NN (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) from_15/IN (r_prep) resulting_14/VBG (r_acl) kindling_13/VBG (r_pobj) from_12/IN (r_prep) distinct_11/JJ (r_amod) mechanism_10/NN (r_dobj) have_8/VB (l_nsubj) sensitization_3/NN (l_prep) of_4/IN (l_pobj) seizures_6/NNS
D009638_D012640 NONE norepinephrine_4/NN (r_amod) function_6/NN (r_pobj) of_3/IN (r_prep) regulation_2/NN (l_acl) induced_7/VBN (l_xcomp) linking_13/VBG (l_prep) to_14/IN (l_pobj) alteration_16/NN (l_prep) of_17/IN (l_pobj) sensitivity_18/NN (l_prep) of_19/IN (l_pobj) convulsions_25/NNS
D009638_D012640 NONE norepinephrine_2/NN (r_compound) transporter_3/NN (r_nmod) function_7/NN (l_prep) by_8/IN (l_pobj) inhibition_10/NN (l_prep) in_13/IN (l_pobj) relation_14/NN (l_prep) to_15/IN (l_pobj) sensitization_16/NN (l_prep) to_17/IN (l_pobj) seizures_18/NNS
D003891_D012640 NONE desipramine_12/NN (r_pobj) of_11/IN (r_prep) administration_10/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (l_xcomp) linking_13/VBG (l_prep) to_14/IN (l_pobj) alteration_16/NN (l_prep) of_17/IN (l_pobj) sensitivity_18/NN (l_prep) of_19/IN (l_pobj) convulsions_25/NNS
D003891_D012640 NONE desipramine_3/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) increased_4/VBD (l_dobj) incidence_6/NN (l_prep) of_7/IN (l_pobj) appearance_8/NN (l_prep) of_9/IN (l_pobj) convulsions_13/NNS
D003891_D012640 NONE desipramine_3/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) increased_4/VBD (l_conj) decreased_15/VBD (l_dobj) that_16/DT (l_prep) of_17/IN (l_pobj) convulsions_21/NNS
D003891_D012640 NONE desipramine_6/NN (r_pobj) with_5/IN (r_prep) lidocaine_4/NN (r_pobj) of_3/IN (r_prep) administration_2/NN (r_nsubj) reversed_7/VBD (l_dobj) changes_9/NNS (l_prep) of_10/IN (l_pobj) activity_12/NN (l_amod) convulsive_11/JJ
D003891_D012640 NONE desipramine_22/NN (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) changes_9/NNS (l_prep) of_10/IN (l_pobj) activity_12/NN (l_amod) convulsive_11/JJ
D003891_D012640 NONE desipramine_15/NN (r_pobj) of_14/IN (r_prep) administration_13/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) regulation_6/NN (r_nsubj) be_17/VB (l_acomp) relevant_18/JJ (l_prep) to_19/IN (l_pobj) sensitization_23/NN (l_prep) of_24/IN (l_pobj) convulsions_26/NNS
D003891_D012640 NONE desipramine_20/NN (r_advmod) induced_22/VBN (r_amod) sensitization_23/NN (l_prep) of_24/IN (l_pobj) convulsions_26/NNS
D003891_D012640 NONE Desipramine_0/NN (r_nsubj) induced_2/VBN (r_amod) sensitization_3/NN (l_prep) of_4/IN (l_pobj) seizures_6/NNS
D008012_D012640 CID lidocaine_10/NN (r_npadvmod) induced_12/VBN (r_amod) convulsions_13/NNS
D008012_D012640 CID lidocaine_10/NN (r_npadvmod) induced_12/VBN (r_amod) convulsions_13/NNS (r_pobj) of_9/IN (r_prep) appearance_8/NN (r_pobj) of_7/IN (r_prep) incidence_6/NN (r_dobj) increased_4/VBD (l_conj) decreased_15/VBD (l_dobj) that_16/DT (l_prep) of_17/IN (l_pobj) convulsions_21/NNS
D008012_D012640 CID lidocaine_4/NN (r_pobj) of_3/IN (r_prep) administration_2/NN (r_nsubj) reversed_7/VBD (l_dobj) changes_9/NNS (l_prep) of_10/IN (l_pobj) activity_12/NN (l_amod) convulsive_11/JJ
D008012_D012640 CID lidocaine_14/NN (r_pobj) of_13/IN (r_prep) activity_12/NN (l_amod) convulsive_11/JJ
D008012_D012640 CID lidocaine_25/NN (r_compound) convulsions_26/NNS
D008012_D012640 CID lidocaine_5/NN (r_compound) seizures_6/NNS
7651879
D001569_D012131 NONE benzodiazepine_3/JJ (r_amod) antagonist_5/NN (l_acl) used_6/VBD (l_xcomp) reverse_8/VB (l_dobj) sedation_9/NN (l_conj) depression_12/NN
D001569_D012131 NONE benzodiazepines_15/NNS (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) sedation_9/NN (l_conj) depression_12/NN
D005442_D012640 CID flumazenil_2/JJ (r_compound) administration_3/NN (r_pobj) after_1/IN (r_prep) Seizure_0/NN
D005442_D012640 CID flumazenil_19/JJ (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) following_15/VBG (r_acl) patient_14/NN (r_pobj) in_11/IN (r_prep) seizure_10/NN
D005442_D012131 NONE Flumazenil_0/NNP (r_nsubj) is_1/VBZ (l_attr) antagonist_5/NN (l_acl) used_6/VBD (l_xcomp) reverse_8/VB (l_dobj) sedation_9/NN (l_conj) depression_12/NN
1355091
D011224_D007024 CID prazosin_9/NN (r_npadvmod) pretreated_11/VBN (r_amod) conscious_12/JJ (r_amod) rats_15/NNS (r_pobj) in_7/IN (r_prep) blockade_6/NN (r_pobj) following_3/VBG (r_prep) occurs_2/VBZ (l_nsubj) hypotension_1/NN
D011224_D007024 CID prazosin_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) hypotension_9/NN
D011224_D007024 CID prazosin_22/NN (r_pobj) of_21/IN (r_prep) dosing_20/NN (r_pobj) after_18/IN (r_conj) to_16/IN (r_prep) prior_15/RB (r_advmod) performed_13/VBN (r_advcl) produce_9/VB (l_dobj) hypotension_11/NN
C014282_D001919 CID cirazoline_9/NN (r_pobj) to_5/IN (r_prep) bradycardia_4/NNS
C014282_D001919 CID cirazoline_7/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (l_amod) bradycardia_4/NN
C056299_D001919 CID Abbott-53693_22/NNP (r_appos) responses_2/NNS (l_conj) bradycardia_4/NNS
C056299_D001919 CID Abbott-53693_9/NNP (r_pobj) of_8/IN (r_prep) effects_7/NNS (r_nsubj) were_10/VBD (l_conj) was_22/VBD (l_nsubj) bradycardia_21/NN
D011224_D006973 NONE prazosin_9/NN (r_npadvmod) pretreated_11/VBN (r_amod) conscious_12/JJ (r_amod) rats_15/NNS (l_amod) hypertensive_14/JJ
D011224_D006973 NONE prazosin_7/NN (r_compound) treatment_8/NN (r_nsubj) alters_9/VBZ (l_prep) for_14/IN (l_pobj) control_16/NN (l_prep) in_21/IN (l_pobj) rats_25/NNS (l_amod) hypertensive_24/JJ
D009638_D001919 CID noradrenaline_33/NN (r_conj) responses_2/NNS (l_conj) bradycardia_4/NNS
D009638_D001919 CID noradrenaline_7/NN (r_npadvmod) induced_9/VBN (r_amod) effect_11/NN (r_dobj) accompanied_5/VBD (r_relcl) bradycardia_3/NN
D011224_D001919 NONE prazosin_51/NN (r_compound) pretreatment_52/NN (r_pobj) without_49/IN (r_conj) with_47/IN (r_prep) determined_43/VBN (l_nsubjpass) responses_2/NNS (l_conj) bradycardia_4/NNS
D011224_D001919 NONE prazosin_12/NN (r_pobj) in_10/IN (r_prep) abolished_9/VBN (l_nsubjpass) pressor_2/NN (l_conj) effects_5/NNS (l_amod) bradycardia_4/NN
D011224_D001919 NONE prazosin_28/NN (r_compound) treatment_29/NN (r_pobj) with_26/IN (r_prep) SHR_25/NNP (r_pobj) in_24/IN (r_prep) greater_23/JJR (r_acomp) was_22/VBD (l_nsubj) bradycardia_21/NN
D011224_D001919 NONE prazosin_20/NN (r_compound) treatment_21/NN (r_pobj) without_18/IN (r_conj) with_16/IN (r_prep) similar_15/JJ (r_acomp) was_14/VBD (l_nsubj) bradycardia_3/NN
D015016_D007024 NONE rauwolscine_33/JJ (r_pobj) with_32/IN (r_prep) treated_31/VBN (r_acl) SHR_30/NN (r_pobj) in_28/IN (r_conj) induced_7/VBN (l_dobj) hypotension_9/NN
10565806
C076029_D001714 CID olanzapine_6/NN (r_pobj) by_5/IN (r_prep) induced_4/VBN (l_nsubj) Hypomania_0/NNP
C076029_D001714 CID olanzapine_28/JJ (r_compound) treatment_29/NN (r_pobj) of_27/IN (r_prep) introduction_26/NN (r_pobj) after_24/IN (r_prep) developed_21/VBD (l_dobj) hypomania_22/NN
C076029_D011618 NONE olanzapine_28/JJ (r_compound) treatment_29/NN (r_pobj) of_27/IN (r_prep) introduction_26/NN (r_pobj) after_24/IN (r_prep) developed_21/VBD (r_relcl) disorder_14/NN
3703509
D011241_D053609 NONE prednisone_5/NN (r_pobj) to_3/IN (r_prep) exposure_2/NN (r_pobj) Following_0/VBG (r_prep) developed_9/VBD (l_dobj) lethargy_10/NN
D011241_D006970 NONE prednisone_5/NN (r_pobj) to_3/IN (r_prep) exposure_2/NN (r_pobj) Following_0/VBG (r_prep) developed_9/VBD (l_advcl) increasing_12/VBG (l_dobj) somnolence_13/NN
D019344_D007662 NONE lactate_13/NN (r_compound) level_14/NN (r_pobj) without_9/IN (r_prep) present_4/JJ (l_prep) in_5/IN (l_pobj) one_6/CD (l_conj) ketosis_8/NN
D011241_D011141 NONE prednisone_5/NN (r_pobj) to_3/IN (r_prep) exposure_2/NN (r_pobj) Following_0/VBG (r_prep) developed_9/VBD (l_advcl) increasing_12/VBG (l_dobj) somnolence_13/NN (l_conj) polydipsia_15/NN (l_conj) polyphagia_17/NN (l_conj) polyuria_20/NN
D011241_D006963 NONE prednisone_5/NN (r_pobj) to_3/IN (r_prep) exposure_2/NN (r_pobj) Following_0/VBG (r_prep) developed_9/VBD (l_advcl) increasing_12/VBG (l_dobj) somnolence_13/NN (l_conj) polydipsia_15/NN (l_conj) polyphagia_17/NN
D011241_D059606 NONE prednisone_5/NN (r_pobj) to_3/IN (r_prep) exposure_2/NN (r_pobj) Following_0/VBG (r_prep) developed_9/VBD (l_advcl) increasing_12/VBG (l_dobj) somnolence_13/NN (l_conj) polydipsia_15/NN
D019344_D000140 NONE lactate_13/NN (r_compound) level_14/NN (r_pobj) without_9/IN (r_prep) present_4/JJ (r_acomp) was_3/VBD (l_nsubj) acidosis_2/NN
19940105
C507346_D010300 NONE AMN082_1/NNP (r_nsubjpass) tested_15/VBN (l_prep) in_16/IN (l_pobj) models_19/NNS (l_prep) of_20/IN (l_pobj) PD_21/NNP
C507346_D010300 NONE AMN082_18/NNP (r_nsubj) reverses_19/VBZ (l_prep) In_0/IN (l_pobj) task_4/NN (l_acl) used_6/VBN (l_xcomp) evaluate_8/VB (l_dobj) symptoms_11/NNS (l_prep) of_12/IN (l_pobj) patients_14/NNS (l_compound) PD_13/NNP
C507346_D010300 NONE AMN082_3/NNP (r_pobj) of_2/IN (r_prep) doses_1/NNS (r_nsubj) have_11/VBP (l_dobj) effect_13/NN (l_prep) on_14/IN (l_pobj) models_17/NNS (l_prep) of_18/IN (l_pobj) PD_19/NNP
D018698_D010300 NONE glutamate_1/NN (r_nmod) subtype_4/NN (r_nsubj) modulates_5/VBZ (l_prep) in_8/IN (l_pobj) models_10/NNS (l_prep) of_11/IN (l_pobj) disease_14/NN
D018698_D010300 NONE glutamate_1/NN (r_nmod) receptors_5/NNS (r_nsubj) modulate_6/VBP (l_conj) represent_15/VBP (l_dobj) targets_18/NNS (l_prep) for_19/IN (l_pobj) treatment_21/NN (l_prep) of_22/IN (l_pobj) disease_25/NN
D018698_D010300 NONE glutamate_1/NN (r_nmod) receptors_5/NNS (r_nsubj) modulate_6/VBP (l_conj) represent_15/VBP (l_dobj) targets_18/NNS (l_prep) for_19/IN (l_pobj) treatment_21/NN (l_prep) of_22/IN (l_pobj) disease_25/NN (l_appos) PD_27/NNP
C507346_D002375 NONE AMN082_20/NNP (r_pobj) of_19/IN (r_prep) administration_12/NN (r_dobj) intrastriatal_11/JJ (r_csubj) reverses_21/VBZ (l_dobj) catalepsy_25/NN
C507346_D002375 NONE AMN082_3/NNP (r_nsubj) reduces_4/VBZ (l_dobj) duration_6/NN (l_prep) of_7/IN (l_pobj) catalepsy_11/NN
D016627_D018476 NONE 6-OHDA_31/CD (r_advmod) lesioned_33/VBN (r_amod) rats_34/NNS (r_pobj) of_29/IN (r_prep) cue_28/NN (r_pobj) to_26/IN (r_prep) respond_25/VB (r_xcomp) reverses_19/VBZ (l_prep) In_0/IN (l_pobj) task_4/NN (l_acl) used_6/VBN (l_xcomp) evaluate_8/VB (l_dobj) symptoms_11/NNS (l_amod) akinetic_10/JJ
D006220_D002375 CID haloperidol_22/NN (r_npadvmod) induced_24/VBN (r_amod) catalepsy_25/NN
D006220_D002375 CID haloperidol_8/NN (r_npadvmod) induced_10/VBN (r_amod) catalepsy_11/NN
D016627_D010300 NONE 6-OHDA_31/CD (r_advmod) lesioned_33/VBN (r_amod) rats_34/NNS (r_pobj) of_29/IN (r_prep) cue_28/NN (r_pobj) to_26/IN (r_prep) respond_25/VB (r_xcomp) reverses_19/VBZ (l_prep) In_0/IN (l_pobj) task_4/NN (l_acl) used_6/VBN (l_xcomp) evaluate_8/VB (l_dobj) symptoms_11/NNS (l_prep) of_12/IN (l_pobj) patients_14/NNS (l_compound) PD_13/NNP
C507346_D018476 NONE AMN082_18/NNP (r_nsubj) reverses_19/VBZ (l_prep) In_0/IN (l_pobj) task_4/NN (l_acl) used_6/VBN (l_xcomp) evaluate_8/VB (l_dobj) symptoms_11/NNS (l_amod) akinetic_10/JJ
11705128
D012254_D000743 CID ribavirin_3/RB (r_npadvmod) induced_5/VBN (r_amod) anemia_7/NN
D012254_D000743 CID ribavirin_11/RB (r_npadvmod) induced_13/VBN (l_dobj) anemia_15/NN
D012254_D000743 CID ribavirin_11/RB (r_npadvmod) induced_13/VBN (l_dobj) anemia_15/NN (l_appos) RIHA_17/NNP
D012254_D000743 CID ribavirin_14/JJ (r_compound) dosage_15/NN (r_pobj) of_12/IN (r_prep) reduction_9/NN (r_attr) is_8/VBZ (l_nsubj) standard_1/NN (l_prep) for_4/IN (l_pobj) management_5/NN (l_prep) of_6/IN (l_pobj) RIHA_7/NNP
D012254_D000743 CID ribavirin_7/NN (r_pobj) of_6/IN (r_prep) dose_5/NN (l_conj) incidence_10/NN (l_prep) of_11/IN (l_pobj) RIHA_12/NNP
D012254_D019698 NONE ribavirin_19/RB (r_conj) interferon_15/NN (r_pobj) with_14/IN (r_prep) therapy_13/NN (r_pobj) of_11/IN (r_prep) efficacy_6/NN (r_dobj) demonstrated_4/VBN (l_prep) compared_20/VBN (l_prep) with_21/IN (l_pobj) monotherapy_25/NN (l_prep) in_26/IN (l_pobj) treatment_28/NN (l_prep) of_29/IN (l_pobj) C_32/NNP
D012254_D019698 NONE ribavirin_19/RB (r_conj) interferon_15/NN (r_pobj) with_14/IN (r_prep) therapy_13/NN (r_pobj) of_11/IN (r_prep) efficacy_6/NN (r_dobj) demonstrated_4/VBN (l_prep) compared_20/VBN (l_prep) with_21/IN (l_pobj) monotherapy_25/NN (l_prep) in_26/IN (l_pobj) treatment_28/NN (l_prep) of_29/IN (l_pobj) C_32/NNP (l_appos) CHC_34/NNP
D016898_D019698 NONE alpha_24/NN (r_compound) monotherapy_25/NN (l_prep) in_26/IN (l_pobj) treatment_28/NN (l_prep) of_29/IN (l_pobj) C_32/NNP
D016898_D019698 NONE alpha_24/NN (r_compound) monotherapy_25/NN (l_prep) in_26/IN (l_pobj) treatment_28/NN (l_prep) of_29/IN (l_pobj) C_32/NNP (l_appos) CHC_34/NNP
D012254_D006526 NONE ribavirin_3/RB (r_npadvmod) induced_5/VBN (r_amod) anemia_7/NN (l_prep) in_8/IN (l_pobj) treatment_10/NN (l_prep) of_11/IN (l_pobj) C_13/NNP
133615
D003276_D001778 CID contraceptive_6/NN (r_amod) therapy_7/NN (r_pobj) of_4/IN (r_prep) complications_3/NNS (l_prep) in_8/IN (l_pobj) relationship_9/NN (l_prep) to_10/IN (l_pobj) levels_12/NNS (l_prep) of_13/IN (l_pobj) factors_16/NNS (l_compound) coagulation_15/NN
D003276_D013923 NONE contraceptive_6/NN (r_amod) therapy_7/NN (r_pobj) of_4/IN (r_prep) complications_3/NNS (l_amod) Thromboembolic_0/JJ
20683499
C029036_D008569 NONE crocin_3/NNS (l_prep) in_4/IN (l_pobj) impairment_14/NN
D013311_D003072 CID STZ_20/NNP (r_compound) icv_22/NN (r_pobj) by_19/IN (r_agent) caused_18/VBN (r_acl) deficits_17/NNS
C029036_D003072 NONE crocin_8/NNS (r_pobj) of_7/IN (r_prep) effectiveness_6/NN (l_prep) in_13/IN (l_pcomp) antagonizing_14/VBG (l_dobj) deficits_17/NNS
D013311_D000544 CID streptozocin_11/NNS (r_npadvmod) induced_13/VBN (r_amod) model_14/NN (l_prep) of_15/IN (l_pobj) disease_19/NN
D013311_D000544 CID streptozocin_20/NNP (r_appos) effect_6/NN (l_prep) of_7/IN (l_pobj) crocins_8/NNS (l_prep) on_9/IN (l_pobj) disease_13/NN
D013311_D000544 CID STZ_22/NNP (r_appos) streptozocin_20/NNP (r_appos) effect_6/NN (l_prep) of_7/IN (l_pobj) crocins_8/NNS (l_prep) on_9/IN (l_pobj) disease_13/NN
D013311_D000544 CID STZ_10/NNP (r_compound) icv_12/NN (r_pobj) with_9/IN (r_prep) injected_8/VBN (l_prep) In_0/IN (l_pobj) groups_4/NNS (l_compound) disease_3/NN
D013311_D000544 CID STZ_28/NNP (r_compound) icv_30/NN (r_compound) application_31/NN (r_nsubjpass) repeated_33/VBN (l_ccomp) injected_8/VBN (l_prep) In_0/IN (l_pobj) groups_4/NNS (l_compound) disease_3/NN
D013311_D000544 CID STZ_20/NNP (r_compound) icv_22/NN (r_pobj) by_19/IN (r_agent) caused_18/VBN (l_prep) in_23/IN (l_pobj) rats_24/NNS (l_conj) potential_27/NN (l_prep) in_28/IN (l_pobj) treatment_30/NN (l_prep) of_31/IN (l_pobj) diseases_33/NNS (l_prep) as_35/IN (l_pobj) disease_38/NN
C029036_D000544 NONE crocin_9/NNS (l_prep) on_10/IN (l_pobj) model_14/NN (l_prep) of_15/IN (l_pobj) disease_19/NN
C029036_D000544 NONE crocins_8/NNS (l_prep) on_9/IN (l_pobj) disease_13/NN
C029036_D000544 NONE crocin_8/NNS (r_pobj) of_7/IN (r_prep) effectiveness_6/NN (l_prep) in_13/IN (l_pcomp) antagonizing_14/VBG (l_dobj) deficits_17/NNS (l_acl) caused_18/VBN (l_prep) in_23/IN (l_pobj) rats_24/NNS (l_conj) potential_27/NN (l_prep) in_28/IN (l_pobj) treatment_30/NN (l_prep) of_31/IN (l_pobj) diseases_33/NNS (l_prep) as_35/IN (l_pobj) disease_38/NN
D013311_D008569 NONE STZ_17/NNP (r_npadvmod) injected_19/VBN (r_amod) group_20/NN (r_pobj) in_15/IN (r_prep) impairment_14/NN
D013311_D019636 NONE STZ_20/NNP (r_compound) icv_22/NN (r_pobj) by_19/IN (r_agent) caused_18/VBN (l_prep) in_23/IN (l_pobj) rats_24/NNS (l_conj) potential_27/NN (l_prep) in_28/IN (l_pobj) treatment_30/NN (l_prep) of_31/IN (l_pobj) diseases_33/NNS
C029036_D007859 NONE crocin_3/NNS (l_prep) in_4/IN (l_pobj) impairment_14/NN
C029036_D019636 NONE crocin_8/NNS (r_pobj) of_7/IN (r_prep) effectiveness_6/NN (l_prep) in_13/IN (l_pcomp) antagonizing_14/VBG (l_dobj) deficits_17/NNS (l_acl) caused_18/VBN (l_prep) in_23/IN (l_pobj) rats_24/NNS (l_conj) potential_27/NN (l_prep) in_28/IN (l_pobj) treatment_30/NN (l_prep) of_31/IN (l_pobj) diseases_33/NNS
D013311_D007859 NONE STZ_17/NNP (r_npadvmod) injected_19/VBN (r_amod) group_20/NN (r_pobj) in_15/IN (r_prep) impairment_14/NN
2339463
D015119_D020225 NONE acid_22/NN (r_compound) therapy_23/NN (r_pobj) with_17/IN (r_prep) associated_16/VBN (r_acl) thrombosis_15/NN
D015119_D008595 NONE acid_22/NN (r_compound) therapy_23/NN (l_prep) for_24/IN (l_pobj) menorrhagia_25/NN
D015119_D013923 NONE acid_15/NN (r_pobj) with_11/IN (r_prep) treatment_10/NN (r_pobj) during_9/IN (r_prep) reported_8/VBN (l_nsubjpass) risk_2/NN (l_prep) of_3/IN (l_pobj) disease_5/NN
D015119_D020227 NONE acid_22/NN (r_compound) therapy_23/NN (r_pobj) with_17/IN (r_prep) associated_16/VBN (r_acl) thrombosis_15/NN
D015119_D012851 NONE acid_15/NN (l_appos) thrombosis_19/NN
10193809
D011692_D011507 CID aminonucleoside_1/NN (r_amod) Puromycin_0/NNP (r_nsubjpass) administered_6/VBN (l_advcl) induce_12/VB (l_dobj) proteinuria_13/NN
D011692_D011507 CID PAN_3/NNP (r_appos) aminonucleoside_1/NN (r_amod) Puromycin_0/NNP (r_nsubjpass) administered_6/VBN (l_advcl) induce_12/VB (l_dobj) proteinuria_13/NN
16844102
D003676_D009422 NONE DFO_7/NNP (r_conj) TC_5/NNP (r_nsubj) ameliorate_8/VB (l_dobj) damage_14/NN
D024502_D005334 NONE TC_2/NNP (r_nsubj) attenuated_5/VBD (l_dobj) hyperthermia_10/NN
D008694_D020258 NONE methamphetamine_8/NN (r_npadvmod) induced_10/VBN (r_amod) neurotoxicity_11/NN
D008694_D020258 NONE Methamphetamine_0/NN (l_appos) neurotoxicity_4/NN
D008694_D020258 NONE MA)-induced_2/VBN (r_amod) neurotoxicity_4/NN
D008694_D020258 NONE MA_34/NNP (r_npadvmod) induced_36/VBN (r_amod) neurotoxicity_37/NN
D010100_D020258 NONE oxygen_19/NN (r_compound) species_20/NNS (r_pobj) of_17/IN (r_prep) scavenger_16/NN (r_appos) tocopherol_8/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) on_32/IN (l_pobj) neurotoxicity_37/NN
D007501_D020258 NONE iron_29/NN (r_compound) chelator_30/NN (r_appos) tocopherol_8/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) on_32/IN (l_pobj) neurotoxicity_37/NN
D024502_D009422 NONE TC_5/NNP (r_nsubj) ameliorate_8/VB (l_dobj) damage_14/NN
D024502_D020258 NONE tocopherol_4/NN (l_conj) deferoxamine_6/NN (l_prep) on_7/IN (l_pobj) neurotoxicity_11/NN
D024502_D020258 NONE tocopherol_8/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) on_32/IN (l_pobj) neurotoxicity_37/NN
D024502_D020258 NONE TC_12/NNP (r_appos) tocopherol_8/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) on_32/IN (l_pobj) neurotoxicity_37/NN
D008694_D005334 CID MA_7/NNP (r_npadvmod) induced_9/VBN (r_amod) hyperthermia_10/NN
D008694_D009422 CID MA_10/NNP (r_npadvmod) induced_12/VBN (r_amod) damage_14/NN
D003676_D020258 NONE deferoxamine_6/NN (l_prep) on_7/IN (l_pobj) neurotoxicity_11/NN
D003676_D020258 NONE deferoxamine_23/NN (r_nmod) DFO_25/NNP (r_conj) scavenger_16/NN (r_appos) tocopherol_8/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) on_32/IN (l_pobj) neurotoxicity_37/NN
D003676_D020258 NONE DFO_25/NNP (r_conj) scavenger_16/NN (r_appos) tocopherol_8/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) on_32/IN (l_pobj) neurotoxicity_37/NN
D003676_D005334 NONE DFO_4/NNP (r_conj) TC_2/NNP (r_nsubj) attenuated_5/VBD (l_dobj) hyperthermia_10/NN
7197363
D001058_D009069 NONE apomorphine_10/NN (r_npadvmod) induced_12/VBN (r_amod) aggressiveness_13/NN (l_conj) twitches_19/NNS
D001058_D009069 NONE apomorphine_7/NN (r_npadvmod) induced_9/VBN (r_amod) aggressiveness_10/NN (r_dobj) increased_6/VBD (l_conj) twitches_35/NNS
D011814_D009069 CID quipazine_15/NN (r_npadvmod) induced_17/VBN (r_amod) head_18/NN (r_compound) twitches_19/NNS
D011814_D009069 CID quipazine_31/NN (r_pobj) of_28/IN (r_prep) completing_27/VBG (r_pcomp) after_26/IN (r_prep) increased_22/VBN (r_conj) reduced_13/VBN (r_conj) increased_6/VBD (l_conj) twitches_35/NNS
D011814_D001523 NONE quipazine_15/NN (r_npadvmod) induced_17/VBN (r_amod) head_18/NN (r_compound) twitches_19/NNS (r_conj) aggressiveness_13/NN
D011814_D001523 NONE quipazine_31/NN (r_pobj) of_28/IN (r_prep) completing_27/VBG (r_pcomp) after_26/IN (r_prep) increased_22/VBN (r_conj) reduced_13/VBN (r_conj) increased_6/VBD (l_dobj) aggressiveness_10/NN
D001058_D012892 NONE apomorphine_10/NN (r_npadvmod) induced_12/VBN (r_amod) aggressiveness_13/NN (r_pobj) on_9/IN (r_prep) effects_1/NNS (l_prep) of_2/IN (l_pobj) deprivation_5/NN
D001058_D012892 NONE apomorphine_10/NN (r_npadvmod) induced_12/VBN (r_amod) aggressiveness_13/NN (r_pobj) on_9/IN (r_prep) effects_1/NNS (l_prep) of_2/IN (l_pobj) deprivation_5/NN (l_appos) REMD_7/NNP
D001058_D012892 NONE apomorphine_7/NN (r_npadvmod) induced_9/VBN (r_amod) aggressiveness_10/NN (r_dobj) increased_6/VBD (l_nsubj) hr_3/NN (l_prep) of_4/IN (l_pobj) REMD_5/NNP
D001058_D012892 NONE apomorphine_7/NN (r_npadvmod) induced_9/VBN (r_amod) aggressiveness_10/NN (r_dobj) increased_6/VBD (l_conj) reduced_13/VBN (l_prep) after_16/IN (l_pcomp) completing_17/VBG (l_prep) of_18/IN (l_pobj) REMD_19/NNP
D001058_D012892 NONE apomorphine_7/NN (r_npadvmod) induced_9/VBN (r_amod) aggressiveness_10/NN (r_dobj) increased_6/VBD (l_conj) reduced_13/VBN (l_conj) increased_22/VBN (l_prep) after_26/IN (l_pcomp) completing_27/VBG (l_prep) of_28/IN (l_pobj) quipazine_31/NN (l_nmod) REMD_29/NNP
D001058_D001523 CID apomorphine_10/NN (r_npadvmod) induced_12/VBN (r_amod) aggressiveness_13/NN
D001058_D001523 CID apomorphine_7/NN (r_npadvmod) induced_9/VBN (r_amod) aggressiveness_10/NN
D011814_D012892 NONE quipazine_15/NN (r_npadvmod) induced_17/VBN (r_amod) head_18/NN (r_compound) twitches_19/NNS (r_conj) aggressiveness_13/NN (r_pobj) on_9/IN (r_prep) effects_1/NNS (l_prep) of_2/IN (l_pobj) deprivation_5/NN
D011814_D012892 NONE quipazine_15/NN (r_npadvmod) induced_17/VBN (r_amod) head_18/NN (r_compound) twitches_19/NNS (r_conj) aggressiveness_13/NN (r_pobj) on_9/IN (r_prep) effects_1/NNS (l_prep) of_2/IN (l_pobj) deprivation_5/NN (l_appos) REMD_7/NNP
D011814_D012892 NONE quipazine_31/NN (r_pobj) of_28/IN (r_prep) completing_27/VBG (r_pcomp) after_26/IN (r_prep) increased_22/VBN (r_conj) reduced_13/VBN (r_conj) increased_6/VBD (l_nsubj) hr_3/NN (l_prep) of_4/IN (l_pobj) REMD_5/NNP
D011814_D012892 NONE quipazine_31/NN (r_pobj) of_28/IN (r_prep) completing_27/VBG (r_pcomp) after_26/IN (r_prep) increased_22/VBN (r_conj) reduced_13/VBN (l_prep) after_16/IN (l_pcomp) completing_17/VBG (l_prep) of_18/IN (l_pobj) REMD_19/NNP
D011814_D012892 NONE quipazine_31/NN (l_nmod) REMD_29/NNP
8111719
D007069_D006212 CID ifosfamide_2/RB (r_advmod) induced_4/VBN (r_amod) neurotoxicity_5/NN (r_conj) Hallucinations_0/NNS
D007069_D006212 CID ifosfamide_16/NN (r_pobj) of_15/IN (r_prep) effect_14/NN (r_attr) are_7/VBP (l_nsubj) Hallucinations_0/NNS
D007069_D006212 CID ifosfamide_3/RB (r_npadvmod) induced_5/VBN (r_amod) hallucinations_6/NNS
D007069_D006212 CID ifosfamide_6/RB (r_npadvmod) induced_8/VBN (r_amod) hallucinations_9/NNS
D007069_D006212 CID ifosfamide_7/RB (r_npadvmod) induced_9/VBN (r_amod) hallucinations_10/NNS
D007069_D020258 NONE ifosfamide_2/RB (r_advmod) induced_4/VBN (r_amod) neurotoxicity_5/NN
D007069_D020258 NONE ifosfamide_16/NN (r_pobj) of_15/IN (r_prep) effect_14/NN (r_attr) are_7/VBP (l_nsubj) Hallucinations_0/NNS (l_prep) as_1/IN (l_pobj) symptom_3/NN (l_prep) of_4/IN (l_pobj) neurotoxicity_6/NN
D007069_D020258 NONE ifosfamide_7/RB (r_npadvmod) induced_9/VBN (r_amod) hallucinations_10/NNS (l_relcl) occur_14/VB (l_prep) without_15/IN (l_pobj) signs_17/NNS (l_prep) of_18/IN (l_pobj) neurotoxicity_19/NN
D006220_D011595 NONE haloperidol_12/NN (r_appos) neuroleptics_8/NNS (l_amod) marked_3/JJ (l_auxpass) becomes_2/VBZ (l_nsubj) agitation_1/NN
6892185
D010830_D004830 CID eserine_55/NN (r_conj) carbachol_53/NN (r_pobj) by_52/IN (r_agent) produced_51/VBN (r_acl) convulsions_50/NNS
D010830_D004830 CID eserine_17/NN (r_conj) carbachol_15/NN (r_pobj) by_14/IN (r_agent) evoked_13/VBN (r_acl) mydriasis_5/NN (l_conj) tremor_7/NN (l_conj) convulsions_12/NNS
D010830_D004830 CID eserine_32/NN (r_conj) carbachol_30/NN (r_pobj) by_29/IN (r_agent) caused_28/VBN (r_acl) dissociate_8/VB (l_prep) from_13/IN (l_pobj) phenomena_17/NNS (l_prep) as_19/IN (l_pobj) mydriasis_20/NN (l_conj) tremor_22/NN (l_conj) convulsions_27/NNS
D010830_D014202 CID eserine_55/NN (r_conj) carbachol_53/NN (r_pobj) by_52/IN (r_agent) produced_51/VBN (r_acl) convulsions_50/NNS (r_conj) tremor_45/NN
D010830_D014202 CID eserine_17/NN (r_conj) carbachol_15/NN (r_pobj) by_14/IN (r_agent) evoked_13/VBN (r_acl) mydriasis_5/NN (l_conj) tremor_7/NN
D010830_D014202 CID eserine_32/NN (r_conj) carbachol_30/NN (r_pobj) by_29/IN (r_agent) caused_28/VBN (r_acl) dissociate_8/VB (l_prep) from_13/IN (l_pobj) phenomena_17/NNS (l_prep) as_19/IN (l_pobj) mydriasis_20/NN (l_conj) tremor_22/NN
D002217_D015878 CID carbachol_53/NN (r_pobj) by_52/IN (r_agent) produced_51/VBN (r_acl) convulsions_50/NNS (r_conj) tremor_45/NN (r_conj) mydriasis_43/NN
D002217_D015878 CID carbachol_15/NN (r_pobj) by_14/IN (r_agent) evoked_13/VBN (r_acl) mydriasis_5/NN
D002217_D015878 CID carbachol_30/NN (r_pobj) by_29/IN (r_agent) caused_28/VBN (r_acl) dissociate_8/VB (l_prep) from_13/IN (l_pobj) phenomena_17/NNS (l_prep) as_19/IN (l_pobj) mydriasis_20/NN
D002122_D004830 NONE chloride_4/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubj) injected_5/VBD (l_advcl) fighting_26/VBG (l_conj) mydriasis_43/NN (l_conj) tremor_45/NN (l_conj) convulsions_50/NNS
D002122_D004830 NONE chloride_24/NN (r_pobj) by_22/IN (r_agent) changed_21/VBN (l_nsubjpass) mydriasis_5/NN (l_conj) tremor_7/NN (l_conj) convulsions_12/NNS
D002122_D004830 NONE chloride_5/NN (r_nsubj) dissociate_8/VB (l_prep) from_13/IN (l_pobj) phenomena_17/NNS (l_prep) as_19/IN (l_pobj) mydriasis_20/NN (l_conj) tremor_22/NN (l_conj) convulsions_27/NNS
D002122_D014202 NONE chloride_4/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubj) injected_5/VBD (l_advcl) fighting_26/VBG (l_conj) mydriasis_43/NN (l_conj) tremor_45/NN
D002122_D014202 NONE chloride_24/NN (r_pobj) by_22/IN (r_agent) changed_21/VBN (l_nsubjpass) mydriasis_5/NN (l_conj) tremor_7/NN
D002122_D014202 NONE chloride_5/NN (r_nsubj) dissociate_8/VB (l_prep) from_13/IN (l_pobj) phenomena_17/NNS (l_prep) as_19/IN (l_pobj) mydriasis_20/NN (l_conj) tremor_22/NN
D002217_D004830 CID carbachol_53/NN (r_pobj) by_52/IN (r_agent) produced_51/VBN (r_acl) convulsions_50/NNS
D002217_D004830 CID carbachol_15/NN (r_pobj) by_14/IN (r_agent) evoked_13/VBN (r_acl) mydriasis_5/NN (l_conj) tremor_7/NN (l_conj) convulsions_12/NNS
D002217_D004830 CID carbachol_30/NN (r_pobj) by_29/IN (r_agent) caused_28/VBN (r_acl) dissociate_8/VB (l_prep) from_13/IN (l_pobj) phenomena_17/NNS (l_prep) as_19/IN (l_pobj) mydriasis_20/NN (l_conj) tremor_22/NN (l_conj) convulsions_27/NNS
D002217_D014202 CID carbachol_53/NN (r_pobj) by_52/IN (r_agent) produced_51/VBN (r_acl) convulsions_50/NNS (r_conj) tremor_45/NN
D002217_D014202 CID carbachol_15/NN (r_pobj) by_14/IN (r_agent) evoked_13/VBN (r_acl) mydriasis_5/NN (l_conj) tremor_7/NN
D002217_D014202 CID carbachol_30/NN (r_pobj) by_29/IN (r_agent) caused_28/VBN (r_acl) dissociate_8/VB (l_prep) from_13/IN (l_pobj) phenomena_17/NNS (l_prep) as_19/IN (l_pobj) mydriasis_20/NN (l_conj) tremor_22/NN
D010830_D015878 CID eserine_55/NN (r_conj) carbachol_53/NN (r_pobj) by_52/IN (r_agent) produced_51/VBN (r_acl) convulsions_50/NNS (r_conj) tremor_45/NN (r_conj) mydriasis_43/NN
D010830_D015878 CID eserine_17/NN (r_conj) carbachol_15/NN (r_pobj) by_14/IN (r_agent) evoked_13/VBN (r_acl) mydriasis_5/NN
D010830_D015878 CID eserine_32/NN (r_conj) carbachol_30/NN (r_pobj) by_29/IN (r_agent) caused_28/VBN (r_acl) dissociate_8/VB (l_prep) from_13/IN (l_pobj) phenomena_17/NNS (l_prep) as_19/IN (l_pobj) mydriasis_20/NN
D002122_D015878 NONE chloride_4/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubj) injected_5/VBD (l_advcl) fighting_26/VBG (l_conj) mydriasis_43/NN
D002122_D015878 NONE chloride_24/NN (r_pobj) by_22/IN (r_agent) changed_21/VBN (l_nsubjpass) mydriasis_5/NN
D002122_D015878 NONE chloride_5/NN (r_nsubj) dissociate_8/VB (l_prep) from_13/IN (l_pobj) phenomena_17/NNS (l_prep) as_19/IN (l_pobj) mydriasis_20/NN
2790457
D008012_D012640 CID lidocaine_13/NN (r_conj) cocaine_11/NN (r_pobj) by_10/IN (r_agent) kindled_9/VBN (r_acl) seizures_8/NNS
D008012_D012640 CID lidocaine-_8/NN (r_nmod) seizures_13/NNS
D008012_D012640 CID lidocaine-_8/NN (r_nmod) seizures_13/NNS (r_pobj) of_6/IN (r_prep) development_5/NN (r_dobj) inhibited_3/VBD (l_conj) had_16/VBD (l_dobj) effect_18/NN (l_prep) on_19/IN (l_pobj) seizures_25/NNS
D008012_D012640 CID lidocaine_18/NN (r_npadvmod) kindled_20/VBN (r_amod) seizures_26/NNS
D008012_D012640 CID lidocaine-_17/NN (r_nmod) seizures_22/NNS
D003042_D012640 CID cocaine_11/NN (r_pobj) by_10/IN (r_agent) kindled_9/VBN (r_acl) seizures_8/NNS
D003042_D012640 CID cocaine_10/NN (r_npadvmod) induced_12/VBN (r_conj) lidocaine-_8/NN (r_nmod) seizures_13/NNS
D003042_D012640 CID cocaine_10/NN (r_npadvmod) induced_12/VBN (r_conj) lidocaine-_8/NN (r_nmod) seizures_13/NNS (r_pobj) of_6/IN (r_prep) development_5/NN (r_dobj) inhibited_3/VBD (l_conj) had_16/VBD (l_dobj) effect_18/NN (l_prep) on_19/IN (l_pobj) seizures_25/NNS
D003042_D012640 CID cocaine_13/NN (r_npadvmod) injected_15/VBN (r_amod) rats_16/NNS (r_pobj) in_11/IN (r_prep) mortality_10/NN (l_amod) related_9/VBN (l_npadvmod) seizure_7/NN
D003042_D012640 CID cocaine_23/NN (r_npadvmod) induced_25/VBN (r_amod) seizures_26/NNS
D003042_D012640 CID cocaine_19/NN (r_npadvmod) kindled_21/VBN (r_amod) seizures_22/NNS
D002220_D012640 NONE carbamazepine_1/NN (r_nsubj) inhibits_2/VBZ (l_dobj) development_4/NN (l_prep) of_5/IN (l_pobj) seizures_8/NNS
D002220_D012640 NONE carbamazepine_3/NN (l_appos) treatment_7/NN (l_prep) on_8/IN (l_pobj) seizures_13/NNS
D002220_D012640 NONE CBZ_5/NNP (r_nmod) treatment_7/NN (l_prep) on_8/IN (l_pobj) seizures_13/NNS
D002220_D012640 NONE CBZ_30/NNP (r_compound) administration_31/NN (r_pobj) of_29/IN (r_prep) methods_28/NNS (r_pobj) under_26/IN (r_conj) in_18/IN (r_prep) evaluated_17/VBN (l_nsubjpass) effects_1/NNS (l_prep) of_2/IN (l_pobj) carbamazepine_3/NN (l_appos) treatment_7/NN (l_prep) on_8/IN (l_pobj) seizures_13/NNS
D002220_D012640 NONE CBZ_2/NN (r_nsubj) inhibited_3/VBD (l_dobj) development_5/NN (l_prep) of_6/IN (l_pobj) seizures_13/NNS
D002220_D012640 NONE CBZ_2/NN (r_nsubj) inhibited_3/VBD (l_conj) had_16/VBD (l_dobj) effect_18/NN (l_prep) on_19/IN (l_pobj) seizures_25/NNS
D002220_D012640 NONE CBZ_1/NN (r_nsubj) decreased_3/VBD (l_dobj) incidence_5/NN (l_prep) of_6/IN (l_pobj) mortality_10/NN (l_amod) related_9/VBN (l_npadvmod) seizure_7/NN
D002220_D012640 NONE CBZ_1/NN (r_nsubj) had_13/VBD (l_dobj) effect_15/NN (l_prep) on_16/IN (l_pobj) seizures_26/NNS
D002220_D012640 NONE CBZ_4/NNP (r_pobj) of_3/IN (r_prep) injection_2/NN (r_nsubj) was_10/VBD (l_prep) without_11/IN (l_pobj) effect_12/NN (l_prep) on_13/IN (l_pobj) development_15/NN (l_prep) of_16/IN (l_pobj) seizures_22/NNS
D002220_D012640 NONE CBZ_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) depending_5/VBG (l_prep) upon_6/IN (l_pobj) stage_7/NN (l_prep) of_8/IN (l_pobj) development_10/NN (l_compound) seizure_9/NN
D002220_D012640 NONE CBZ_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubj) suggest_11/VBP (l_ccomp) underlie_15/VBP (l_dobj) development_17/NN (l_prep) versus_18/IN (l_pobj) maintenance_19/NN (l_prep) of_20/IN (l_pobj) seizures_25/NNS
8494478
D002939_D009369 NONE Ciprofloxacin_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) nephrotoxicity_3/NN (l_prep) in_4/IN (l_pobj) patients_5/NNS (l_prep) with_6/IN (l_pobj) cancer_7/NN
D002939_D009369 NONE ciprofloxacin_13/NNS (r_pobj) with_12/IN (r_prep) treatment_11/NN (r_dobj) followed_10/VBD (r_relcl) failure_8/NN (r_dobj) developed_5/VBD (r_relcl) patients_1/NNS (l_prep) with_2/IN (l_pobj) cancer_3/NN
D002939_D058186 CID ciprofloxacin_13/NNS (r_pobj) with_12/IN (r_prep) treatment_11/NN (r_dobj) followed_10/VBD (r_relcl) failure_8/NN
D002939_D058186 CID ciprofloxacin_18/NNS (r_npadvmod) induced_20/VBN (r_amod) failure_23/NN
D002939_D007674 NONE Ciprofloxacin_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) nephrotoxicity_3/NN
D002939_D007674 NONE ciprofloxacin_3/NNS (r_pobj) with_2/IN (r_prep) associated_1/VBN (r_acl) Nephrotoxicity_0/NN
15858223
D014635_D009336 CID VPA_6/NNP (r_compound) results_8/NNS (l_advcl) measured_14/VBN (l_agent) by_15/IN (l_pobj) levels_16/NNS (l_relcl) precedes_21/VBZ (l_dobj) onset_23/NN (l_prep) of_24/IN (l_pobj) necrosis_25/NN
D014635_D005234 CID VPA_6/NNP (r_compound) results_8/NNS (l_advcl) measured_14/VBN (l_agent) by_15/IN (l_pobj) levels_16/NNS (l_relcl) precedes_21/VBZ (l_dobj) onset_23/NN (l_prep) of_24/IN (l_pobj) necrosis_25/NN (l_conj) steatosis_27/NN
D014635_D056486 CID acid_14/NN (r_compound) metabolite_15/NN (r_amod) levels_16/NNS (r_conj) toxicity_10/NN
D014635_D056486 CID VPA_9/NNP (r_npadvmod) associated_11/VBN (r_amod) stress_13/NN (l_conj) hepatotoxicity_15/NN
D014635_D056486 CID VPA_27/NNP (r_pobj) with_26/IN (r_prep) treated_24/VBN (l_advcl) determine_1/VB (l_ccomp) was_4/VBD (l_attr) relationship_7/NN (l_prep) between_8/IN (l_pobj) stress_13/NN (l_conj) hepatotoxicity_15/NN
C075750_D005234 NONE 15-F(2t)-IsoP_18/CD (r_pobj) of_17/IN (r_prep) levels_16/NNS (l_relcl) precedes_21/VBZ (l_dobj) onset_23/NN (l_prep) of_24/IN (l_pobj) necrosis_25/NN (l_conj) steatosis_27/NN
C075750_D009336 NONE 15-F(2t)-IsoP_18/CD (r_pobj) of_17/IN (r_prep) levels_16/NNS (l_relcl) precedes_21/VBZ (l_dobj) onset_23/NN (l_prep) of_24/IN (l_pobj) necrosis_25/NN
D005978_D056486 NONE glutathione_11/NN (r_compound) transferase_14/NNP (r_pobj) of_8/IN (r_prep) levels_7/NNS (r_pobj) on_5/IN (r_prep) based_4/VBN (r_prep) evaluated_3/VBN (l_nsubjpass) toxicity_1/NN
19923525
D005996_D007022 CID nitroglycerin_6/NN (r_npadvmod) induced_8/VBN (r_amod) hypotension_9/NN
D005996_D007022 CID nitroglycerin_14/NN (r_pobj) of_13/IN (r_prep) onset_12/NN (r_pobj) at_10/IN (r_prep) administered_9/VBN (r_acl) hypothesis_3/NN (r_dobj) tested_1/VBD (r_ccomp) preserve_19/VB (l_nsubj) hypotension_17/NN
D005996_D007022 CID NTG)-induced_16/JJ (r_amod) hypotension_17/NN
D005996_D007022 CID NTG_25/NNP (r_appos) saline_23/NN (r_pobj) with_22/IN (r_prep) injected_21/VBN (r_acl) those_20/DT (r_pobj) with_19/IN (r_prep) compared_18/VBN (r_prep) showed_5/VBD (r_conj) subjected_1/VBN (l_prep) to_2/IN (l_pobj) episodes_4/NNS (l_amod) hypotensive_3/JJ
D005996_D007022 CID NTG_31/NNP (r_dobj) delayed_30/VBN (r_conj) showed_5/VBD (r_conj) subjected_1/VBN (l_prep) to_2/IN (l_pobj) episodes_4/NNS (l_amod) hypotensive_3/JJ
D005996_D007022 CID NTG_9/NNP (r_pobj) of_8/IN (r_prep) injection_7/NN (r_nsubj) produced_13/VBD (l_conj) had_30/VBD (l_advcl) delayed_27/VBN (l_dobj) hypotension_29/NN
D005996_D007022 CID NTG_13/NNP (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_acl) memory_10/NN (r_pobj) of_6/IN (r_prep) consolidation_5/NN (r_pobj) in_4/IN (r_prep) disruption_3/NN (r_dobj) attenuated_1/VBD (l_conj) improve_17/VB (l_prep) in_19/IN (l_pobj) absence_21/NN (l_prep) of_22/IN (l_pobj) hypotension_23/NN
D009553_D007022 NONE Nimodipine_0/NNP (r_nsubj) prevents_1/VBZ (l_dobj) impairment_3/NN (l_acl) caused_4/VBN (l_agent) by_5/IN (l_pobj) hypotension_9/NN
D009553_D007022 NONE nimodipine_5/NN (r_nsubj) administered_9/VBN (r_acl) hypothesis_3/NN (r_dobj) tested_1/VBD (r_ccomp) preserve_19/VB (l_nsubj) hypotension_17/NN
D009553_D007022 NONE NIMO_7/NNP (r_appos) nimodipine_5/NN (r_nsubj) administered_9/VBN (r_acl) hypothesis_3/NN (r_dobj) tested_1/VBD (r_ccomp) preserve_19/VB (l_nsubj) hypotension_17/NN
D009553_D007022 NONE NIMO_27/NN (r_conj) NTG_25/NNP (r_appos) saline_23/NN (r_pobj) with_22/IN (r_prep) injected_21/VBN (r_acl) those_20/DT (r_pobj) with_19/IN (r_prep) compared_18/VBN (r_prep) showed_5/VBD (r_conj) subjected_1/VBN (l_prep) to_2/IN (l_pobj) episodes_4/NNS (l_amod) hypotensive_3/JJ
D009553_D007022 NONE NIMO_0/NN (r_advmod) attenuated_1/VBD (l_conj) improve_17/VB (l_prep) in_19/IN (l_pobj) absence_21/NN (l_prep) of_22/IN (l_pobj) hypotension_23/NN
D009553_D007022 NONE NIMO_4/NNP (r_pobj) of_3/IN (r_prep) effect_2/NN (r_nsubj) been_7/VBN (l_acomp) attributable_8/JJ (l_prep) to_9/IN (l_pobj) preservation_11/NN (l_prep) during_15/IN (l_pobj) hypotension_16/NN
D005996_D008569 CID nitroglycerin_6/NN (r_npadvmod) induced_8/VBN (r_amod) hypotension_9/NN (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) impairment_3/NN
D002118_D007022 NONE calcium_13/NN (r_compound) homeostasis_14/NN (r_pobj) of_12/IN (r_prep) preservation_11/NN (l_prep) during_15/IN (l_pobj) hypotension_16/NN
D009553_D008569 NONE Nimodipine_0/NNP (r_nsubj) prevents_1/VBZ (l_dobj) impairment_3/NN
17263743
D001418_D004827 NONE baclofen_28/JJ (r_compound) pump_29/NN (r_pobj) of_26/IN (r_prep) placement_25/NN (r_pobj) for_24/IN (r_prep) presented_23/VBD (r_relcl) restlessness_20/NN (r_pobj) for_19/IN (r_prep) receiving_17/VBG (r_advcl) present_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) child_9/NN (l_prep) with_10/IN (l_pobj) disorder_15/NN
D003000_D006323 CID clonidine_15/NN (r_pobj) after_13/IN (r_prep) anesthesia_12/NN (r_pobj) of_11/IN (r_prep) induction_10/NN (r_dobj) undergoing_8/VBG (r_acl) arrest_1/NN
D003000_D006323 CID clonidine_6/NN (r_npadvmod) associated_8/VBN (r_amod) arrest_10/NN
D003000_D011595 NONE clonidine_18/NN (r_dobj) receiving_17/VBG (l_prep) for_19/IN (l_pobj) restlessness_20/NN
C009250_D002547 NONE sevoflurane_9/NN (r_amod) induction_10/NN (r_dobj) undergoing_8/VBG (r_acl) arrest_1/NN (l_prep) in_2/IN (l_pobj) child_4/NN (l_prep) with_5/IN (l_pobj) palsy_7/JJ
C009250_D006323 NONE sevoflurane_9/NN (r_amod) induction_10/NN (r_dobj) undergoing_8/VBG (r_acl) arrest_1/NN
D001418_D002547 NONE baclofen_28/JJ (r_compound) pump_29/NN (r_pobj) of_26/IN (r_prep) placement_25/NN (r_pobj) for_24/IN (r_prep) presented_23/VBD (r_relcl) restlessness_20/NN (r_pobj) for_19/IN (r_prep) receiving_17/VBG (r_advcl) present_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) child_9/NN (l_prep) with_10/IN (l_pobj) disorder_15/NN (l_nmod) palsy_12/JJ
D003000_D004827 NONE clonidine_18/NN (r_dobj) receiving_17/VBG (r_advcl) present_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) child_9/NN (l_prep) with_10/IN (l_pobj) disorder_15/NN
D001418_D011595 NONE baclofen_28/JJ (r_compound) pump_29/NN (r_pobj) of_26/IN (r_prep) placement_25/NN (r_pobj) for_24/IN (r_prep) presented_23/VBD (r_relcl) restlessness_20/NN
D003000_D002547 NONE clonidine_15/NN (r_pobj) after_13/IN (r_prep) anesthesia_12/NN (r_pobj) of_11/IN (r_prep) induction_10/NN (r_dobj) undergoing_8/VBG (r_acl) arrest_1/NN (l_prep) in_2/IN (l_pobj) child_4/NN (l_prep) with_5/IN (l_pobj) palsy_7/JJ
D003000_D002547 NONE clonidine_18/NN (r_dobj) receiving_17/VBG (r_advcl) present_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) child_9/NN (l_prep) with_10/IN (l_pobj) disorder_15/NN (l_nmod) palsy_12/JJ
D003000_D001008 NONE clonidine_16/NN (r_pobj) of_15/IN (r_prep) doses_14/NNS (r_dobj) administered_12/VBD (l_advcl) reduce_26/VB (l_dobj) anxiety_27/NN
16157917
C047781_D009207 CID Lamotrigine_0/NNP (l_acl) associated_1/VBD (l_prep) with_2/IN (l_pobj) exacerbation_3/NN (l_conj) myoclonus_7/NN
C047781_D009207 CID lamotrigine_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_advcl) experienced_15/VBD (l_dobj) exacerbation_16/NN (l_conj) appearance_20/NN (l_prep) of_21/IN (l_pobj) jerks_23/NNS
C047781_D009207 CID lamotrigine_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_advcl) experienced_15/VBD (l_dobj) exacerbation_16/NN (l_conj) appearance_20/NN (l_prep) of_21/IN (l_pobj) jerks_23/NNS (l_appos) MJ_25/NNP
C047781_D009207 CID LTG_13/NNP (r_appos) lamotrigine_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_advcl) experienced_15/VBD (l_dobj) exacerbation_16/NN (l_conj) appearance_20/NN (l_prep) of_21/IN (l_pobj) jerks_23/NNS
C047781_D009207 CID LTG_13/NNP (r_appos) lamotrigine_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_advcl) experienced_15/VBD (l_dobj) exacerbation_16/NN (l_conj) appearance_20/NN (l_prep) of_21/IN (l_pobj) jerks_23/NNS (l_appos) MJ_25/NNP
C047781_D009207 CID LTG_4/NNP (r_nsubj) exacerbated_5/VBD (l_dobj) MJ_6/NNP
C047781_D009207 CID LTG_3/NNP (r_compound) dose_4/NN (r_nsubjpass) decreased_6/VBN (r_advcl) disappeared_1/VBD (l_nsubj) MJ_0/NNP
C047781_D009207 CID LTG_4/NNP (r_nsubj) exacerbated_5/VBD (l_dobj) MJ_6/NNP
C047781_D009207 CID LTG_4/NNP (r_nsubj) exacerbated_5/VBD (l_prep) with_15/IN (l_pobj) status_17/NN
C047781_D009207 CID LTG_22/NNP (r_compound) withdrawal_23/NN (r_pobj) after_21/IN (r_prep) ceased_20/VBD (r_relcl) status_17/NN (r_pobj) with_15/IN (r_prep) exacerbated_5/VBD (l_dobj) MJ_6/NNP
C047781_D009207 CID LTG_22/NNP (r_compound) withdrawal_23/NN (r_pobj) after_21/IN (r_prep) ceased_20/VBD (r_relcl) status_17/NN
C047781_C562694 NONE Lamotrigine_0/NNP (l_acl) associated_1/VBD (l_prep) with_2/IN (l_pobj) exacerbation_3/NN (l_prep) in_8/IN (l_pobj) epilepsies_11/NNS
C047781_C562694 NONE lamotrigine_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) epilepsies_5/NNS
C047781_C562694 NONE lamotrigine_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) epilepsies_5/NNS (l_appos) IGE_7/NNP
C047781_C562694 NONE LTG_13/NNP (r_appos) lamotrigine_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) epilepsies_5/NNS
C047781_C562694 NONE LTG_13/NNP (r_appos) lamotrigine_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) epilepsies_5/NNS (l_appos) IGE_7/NNP
8766220
D004308_D059350 NONE hydrochloride_10/NN (r_dobj) dosulepine_9/JJ (l_prep) in_11/IN (l_pobj) patient_14/NN (l_prep) with_15/IN (l_pobj) pain_17/NN
D017374_-1 NONE paroxetine_7/NN (r_pobj) with_6/IN (r_prep) association_5/NN (r_pobj) in_4/IN (r_prep) initiated_3/VBN (l_conj) dosulepine_9/JJ (l_prep) in_11/IN (l_pobj) patient_14/NN (l_amod) tetraparetic_13/JJ
D004308_-1 NONE hydrochloride_10/NN (r_dobj) dosulepine_9/JJ (l_prep) in_11/IN (l_pobj) patient_14/NN (l_amod) tetraparetic_13/JJ
D014147_D009369 NONE Tramadol_0/NNP (r_nsubj) is_1/VBZ (l_attr) opioid_4/NN (l_prep) with_5/IN (l_pobj) effects_6/NNS (l_relcl) used_14/VBN (l_xcomp) treat_16/VB (l_dobj) pain_18/NN (l_compound) cancer_17/NN
D017374_D059350 NONE paroxetine_7/NN (r_pobj) with_6/IN (r_prep) association_5/NN (r_pobj) in_4/IN (r_prep) initiated_3/VBN (l_conj) dosulepine_9/JJ (l_prep) in_11/IN (l_pobj) patient_14/NN (l_prep) with_15/IN (l_pobj) pain_17/NN
D014147_D006212 CID tramadol_9/NN (r_pobj) of_8/IN (r_prep) intake_7/NN (r_pobj) after_3/IN (r_prep) Nightmares_0/NNS (l_conj) hallucinations_2/NNS
D014147_D006212 CID tramadol_25/NN (r_conj) drugs_23/NNS (r_pobj) of_19/IN (r_prep) withdrawal_18/NN (r_pobj) after_16/IN (r_prep) stopped_15/VBD (r_relcl) hallucinations_12/NNS
D014147_D010146 NONE Tramadol_0/NNP (r_nsubj) is_1/VBZ (l_attr) opioid_4/NN (l_prep) with_5/IN (l_pobj) effects_6/NNS (l_relcl) used_14/VBN (l_xcomp) treat_16/VB (l_dobj) pain_18/NN
D014147_D010146 NONE Tramadol_0/NNP (r_nsubj) is_1/VBZ (l_attr) opioid_4/NN (l_prep) with_5/IN (l_pobj) effects_6/NNS (l_relcl) used_14/VBN (l_xcomp) treat_16/VB (l_dobj) pain_18/NN (l_conj) pain_23/NN
19761039
D012110_D004409 CID reserpine_17/NN (r_npadvmod) induced_19/VBN (r_amod) dyskinesia_21/JJ
D012110_D004409 CID reserpine_16/NN (r_npadvmod) induced_18/VBN (r_amod) dyskinesia_20/JJ
D010936_D004409 NONE sinensis_7/NN (r_pobj) of_4/IN (r_prep) extract_3/NN (r_pobj) of_1/IN (r_prep) Effect_0/NN (r_nsubjpass) studied_15/VBN (l_prep) on_16/IN (l_pobj) dyskinesia_21/JJ
D010936_D004409 NONE sinensis_10/NN (r_nsubj) had_11/VBD (l_dobj) role_14/NN (l_prep) against_15/IN (l_pobj) dyskinesia_20/JJ
16720068
D000525_D014202 NONE alprazolam_7/NN (r_compound) treatment_8/NN (r_conj) paroxetine_5/NN (r_pobj) of_4/IN (r_prep) day_3/NN (r_pobj) On_0/IN (r_prep) exhibited_12/VBD (l_dobj) retardation_15/NN (l_conj) disorientation_17/NN (l_conj) rigidity_22/NN (l_prep) with_23/IN (l_pobj) tremors_24/NNS
D017374_D009459 CID paroxetine_9/NN (r_pobj) with_8/IN (r_prep) treatment_7/NN (r_pobj) to_5/IN (r_prep) related_4/VBN (r_acl) syndrome_3/NN
D017374_D009459 CID paroxetine_24/NN (r_pobj) after_22/IN (r_prep) occur_21/VB (r_ccomp) demonstrating_14/VBG (r_advcl) presented_2/VBN (l_prep) with_3/IN (l_pobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) syndrome_8/NN
D017374_D009459 CID paroxetine_24/NN (r_pobj) after_22/IN (r_prep) occur_21/VB (r_ccomp) demonstrating_14/VBG (r_advcl) presented_2/VBN (l_prep) with_3/IN (l_pobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) syndrome_8/NN (l_appos) NMS_10/NNP
D017374_D009459 CID paroxetine_24/NN (r_pobj) after_22/IN (r_prep) occur_21/VB (l_nsubj) symptoms_19/NNS (l_amod) like_18/JJ (l_npadvmod) NMS_16/NNP
D000525_D009459 CID alprazolam_11/NN (r_conj) paroxetine_9/NN (r_pobj) with_8/IN (r_prep) treatment_7/NN (r_pobj) to_5/IN (r_prep) related_4/VBN (r_acl) syndrome_3/NN
D000525_D009459 CID alprazolam_26/NN (r_compound) treatment_27/NN (r_conj) paroxetine_24/NN (r_pobj) after_22/IN (r_prep) occur_21/VB (r_ccomp) demonstrating_14/VBG (r_advcl) presented_2/VBN (l_prep) with_3/IN (l_pobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) syndrome_8/NN
D000525_D009459 CID alprazolam_26/NN (r_compound) treatment_27/NN (r_conj) paroxetine_24/NN (r_pobj) after_22/IN (r_prep) occur_21/VB (r_ccomp) demonstrating_14/VBG (r_advcl) presented_2/VBN (l_prep) with_3/IN (l_pobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) syndrome_8/NN (l_appos) NMS_10/NNP
D000525_D009459 CID alprazolam_26/NN (r_compound) treatment_27/NN (r_conj) paroxetine_24/NN (r_pobj) after_22/IN (r_prep) occur_21/VB (l_nsubj) symptoms_19/NNS (l_amod) like_18/JJ (l_npadvmod) NMS_16/NNP
D000525_D011596 NONE alprazolam_7/NN (r_compound) treatment_8/NN (r_conj) paroxetine_5/NN (r_pobj) of_4/IN (r_prep) day_3/NN (r_pobj) On_0/IN (r_prep) exhibited_12/VBD (l_dobj) retardation_15/NN
D017374_D009127 NONE paroxetine_5/NN (r_pobj) of_4/IN (r_prep) day_3/NN (r_pobj) On_0/IN (r_prep) exhibited_12/VBD (l_dobj) retardation_15/NN (l_conj) disorientation_17/NN (l_conj) rigidity_22/NN
D000525_D009127 NONE alprazolam_7/NN (r_compound) treatment_8/NN (r_conj) paroxetine_5/NN (r_pobj) of_4/IN (r_prep) day_3/NN (r_pobj) On_0/IN (r_prep) exhibited_12/VBD (l_dobj) retardation_15/NN (l_conj) disorientation_17/NN (l_conj) rigidity_22/NN
D017374_D011596 NONE paroxetine_5/NN (r_pobj) of_4/IN (r_prep) day_3/NN (r_pobj) On_0/IN (r_prep) exhibited_12/VBD (l_dobj) retardation_15/NN
D017374_D014202 NONE paroxetine_5/NN (r_pobj) of_4/IN (r_prep) day_3/NN (r_pobj) On_0/IN (r_prep) exhibited_12/VBD (l_dobj) retardation_15/NN (l_conj) disorientation_17/NN (l_conj) rigidity_22/NN (l_prep) with_23/IN (l_pobj) tremors_24/NNS
17923537
D005446_D009798 CID acetonide_21/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_acl) patients_14/NNS (r_pobj) in_13/IN (r_prep) incidence_3/NN (l_prep) of_6/IN (l_pobj) pressure_9/NN
D005446_D009798 CID FA_23/NNP (r_nmod) implant_26/NN (r_appos) acetonide_21/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_acl) patients_14/NNS (r_pobj) in_13/IN (r_prep) incidence_3/NN (l_prep) of_6/IN (l_pobj) pressure_9/NN
D005446_D014605 NONE acetonide_9/NN (r_compound) implants_10/NNS (r_pobj) with_7/IN (r_prep) treated_6/VBN (r_acl) pressure_1/NN (l_prep) in_2/IN (l_pobj) patients_3/NNS (l_prep) with_4/IN (l_pobj) uveitis_5/NN
D005446_D014605 NONE acetonide_21/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_acl) patients_14/NNS (l_prep) with_15/IN (l_pobj) uveitis_16/NN
D005446_D014605 NONE FA_23/NNP (r_nmod) implant_26/NN (r_appos) acetonide_21/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_acl) patients_14/NNS (l_prep) with_15/IN (l_pobj) uveitis_16/NN
458486
D063325_D010300 NONE Tiapride_0/NNP (l_appos) movements_18/NNS (l_prep) in_19/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) disease_26/NN
C037689_D010300 NONE benzamide_4/RB (r_amod) derivative_5/JJ (r_amod) movements_18/NNS (l_prep) in_19/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) disease_26/NN
D007980_D010300 NONE levodopa_12/NN (r_npadvmod) induced_14/VBN (r_amod) peak_15/NN (r_nmod) movements_18/NNS (l_prep) in_19/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) disease_26/NN
D007980_D004421 NONE levodopa_5/NN (r_npadvmod) induced_7/VBN (l_prep) of_10/IN (l_pobj) dystonia_17/NN
D007980_D004409 CID levodopa_2/NN (r_npadvmod) induced_4/VBN (r_amod) movements_6/NNS
D007980_D004409 CID levodopa_12/NN (r_npadvmod) induced_14/VBN (r_amod) peak_15/NN (r_nmod) movements_18/NNS
D007980_D004409 CID levodopa_8/RB (r_npadvmod) induced_10/VBN (r_amod) dyskinesias_11/NNS
D008787_D010300 NONE metoclopramide_9/NN (r_pobj) to_8/IN (r_prep) related_7/JJ (r_acl) derivative_5/JJ (r_amod) movements_18/NNS (l_prep) in_19/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) disease_26/NN
D004298_D004409 NONE dopamine_21/NN (r_compound) receptors_22/NNS (r_pobj) of_20/IN (r_prep) group_19/NN (r_pobj) of_16/IN (r_prep) overstimulation_15/NN (r_pobj) by_14/IN (r_agent) caused_13/VBN (l_nsubjpass) dyskinesias_11/NNS
D063325_D004409 NONE Tiapride_0/NNP (l_prep) in_1/IN (l_pobj) movements_6/NNS
D063325_D004409 NONE Tiapride_0/NNP (l_appos) movements_18/NNS
D063325_D004421 NONE Tiapride_0/NNP (r_nsubj) had_1/VBD (l_advcl) induced_7/VBN (l_prep) of_10/IN (l_pobj) dystonia_17/NN
D008787_D004409 NONE metoclopramide_9/NN (r_pobj) to_8/IN (r_prep) related_7/JJ (r_acl) derivative_5/JJ (r_amod) movements_18/NNS
C037689_D004409 NONE benzamide_4/RB (r_amod) derivative_5/JJ (r_amod) movements_18/NNS
2435991
C032151_D001145 NONE cibenzoline_4/NN (r_pobj) of_3/IN (r_prep) concentrations_2/NNS (l_prep) on_5/IN (l_pobj) arrhythmias_8/NNS
C032151_D001145 NONE cibenzoline_20/NN (r_pobj) of_19/IN (r_prep) effects_18/NNS (r_nsubjpass) examined_22/VBN (l_advcl) Using_0/VBG (l_dobj) arrhythmias_15/NNS
C032151_D001145 NONE cibenzoline_20/NN (r_pobj) of_19/IN (r_prep) effects_18/NNS (r_nsubjpass) examined_22/VBN (l_conj) determined_34/VBN (l_nsubjpass) concentration_28/NN (l_prep) for_29/IN (l_pobj) model_32/NN (l_compound) arrhythmia_31/NN
C032151_D001145 NONE Cibenzoline_0/NNP (r_nsubj) suppressed_1/VBD (l_dobj) arrhythmias_4/NNS
C032151_D001145 NONE Cibenzoline_0/NNP (r_nsubj) suppressed_1/VBD (l_conj) induced_14/VBN (l_nsubj) concentrations_11/NNS (l_prep) for_12/IN (l_pobj) arrhythmias_13/NNS
C032151_D001145 NONE cibenzoline_1/NN (r_nsubj) had_2/VBD (l_advcl) given_19/VBN (l_prep) to_20/IN (l_pobj) dogs_24/NNS (l_compound) arrhythmia_23/NN
D004837_D001145 CID adrenaline_10/RB (r_npadvmod) induced_12/VBN (r_conj) digitalis-_7/NN (r_conj) ligation-_5/JJ (r_nmod) arrhythmias_15/NNS
D004837_D001145 CID adrenaline_10/RB (r_npadvmod) induced_12/VBN (r_conj) digitalis-_7/NN (r_conj) ligation-_5/JJ (r_nmod) arrhythmias_15/NNS (r_dobj) Using_0/VBG (r_advcl) examined_22/VBN (l_conj) determined_34/VBN (l_nsubjpass) concentration_28/NN (l_prep) for_29/IN (l_pobj) model_32/NN (l_compound) arrhythmia_31/NN
D004837_D001145 CID adrenaline_27/NN (r_conj) digitalis_24/NN (r_conj) ligation_22/NN (r_appos) ligation_18/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_conj) suppressed_1/VBD (l_dobj) arrhythmias_4/NNS
D004837_D001145 CID adrenaline_27/NN (r_conj) digitalis_24/NN (r_conj) ligation_22/NN (r_appos) ligation_18/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (l_nsubj) concentrations_11/NNS (l_prep) for_12/IN (l_pobj) arrhythmias_13/NNS
D004837_D001145 CID adrenaline_3/NN (r_npadvmod) induced_5/VBN (r_amod) arrhythmia_6/NN
D004837_D001145 CID adrenaline_3/NN (r_npadvmod) induced_5/VBN (r_amod) arrhythmia_6/NN (r_pobj) for_2/IN (r_prep) concentration_1/NN (r_nsubj) was_7/VBD (l_acomp) higher_9/JJR (l_prep) than_10/IN (l_pobj) those_11/DT (l_prep) for_12/IN (l_pobj) types_15/NNS (l_prep) of_16/IN (l_pobj) arrhythmias_17/NNS
D004071_D001145 CID digitalis-_7/NN (r_conj) ligation-_5/JJ (r_nmod) arrhythmias_15/NNS
D004071_D001145 CID digitalis-_7/NN (r_conj) ligation-_5/JJ (r_nmod) arrhythmias_15/NNS (r_dobj) Using_0/VBG (r_advcl) examined_22/VBN (l_conj) determined_34/VBN (l_nsubjpass) concentration_28/NN (l_prep) for_29/IN (l_pobj) model_32/NN (l_compound) arrhythmia_31/NN
D004071_D001145 CID digitalis_24/NN (r_conj) ligation_22/NN (r_appos) ligation_18/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_conj) suppressed_1/VBD (l_dobj) arrhythmias_4/NNS
D004071_D001145 CID digitalis_24/NN (r_conj) ligation_22/NN (r_appos) ligation_18/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (l_nsubj) concentrations_11/NNS (l_prep) for_12/IN (l_pobj) arrhythmias_13/NNS
C032151_D007022 NONE cibenzoline_1/NN (r_nsubj) had_2/VBD (l_dobj) effects_10/NNS (l_nmod) node_8/NN (l_amod) hypotensive_5/JJ
C032151_D003866 NONE cibenzoline_1/NN (r_nsubj) had_2/VBD (l_dobj) effects_10/NNS (l_amod) depressive_9/JJ
7161250
D006220_D010302 CID haloperidol_10/NN (r_pobj) of_9/IN (r_prep) doses_8/NNS (r_pobj) at_6/IN (r_prep) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) parkinsonism_3/NN
D001569_D017109 NONE benzodiazepine_5/JJ (r_amod) lorazepam_6/NN (r_pobj) by_3/IN (r_agent) controlled_2/VBN (l_nsubjpass) Akathisia_0/NNP
D008140_D017109 NONE lorazepam_6/NN (r_pobj) by_3/IN (r_agent) controlled_2/VBN (l_nsubjpass) Akathisia_0/NNP
9630698
D006220_D009127 CID haloperidol_5/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_nsubjpass) rigidity_1/NN
D006220_D009127 CID haloperidol_34/NN (r_advmod) induced_36/VBN (r_amod) rigidity_38/NN
D005998_D009127 NONE glycine_8/NN (r_compound) site_9/NN (r_compound) antagonist_10/NN (r_appos) acid_1/NN (r_nsubj) injected_12/VBN (l_conj) decreased_31/VBD (l_dobj) rigidity_38/NN
C066192_D009127 NONE acid_1/NN (r_nsubj) injected_12/VBN (l_conj) decreased_31/VBD (l_dobj) rigidity_38/NN
C066192_D009127 NONE 5,7-DCKA_3/CD (r_appos) acid_1/NN (r_nsubj) injected_12/VBN (l_conj) decreased_31/VBD (l_dobj) rigidity_38/NN
1628552
D002738_D001766 CID Chloroquine_0/NNP (r_nsubj) related_1/VBD (l_dobj) block_4/NN (l_prep) with_5/IN (l_pobj) blindness_6/NN
D002738_D002037 CID chloroquine_5/NN (r_amod) retinopathy_6/NN (r_pobj) of_4/IN (r_prep) features_3/NNS (r_dobj) revealed_2/VBD (r_ccomp) revealed_10/VBD (l_dobj) features_11/NNS (l_conj) block_19/NN (l_prep) with_20/IN (l_pobj) pattern_25/NN (l_compound) block_24/NN
D002738_D006333 CID chloroquine_5/NN (r_amod) retinopathy_6/NN (r_pobj) of_4/IN (r_prep) features_3/NNS (r_dobj) revealed_2/VBD (r_ccomp) revealed_10/VBD (l_dobj) features_11/NNS (l_prep) of_12/IN (l_pobj) failure_14/NN
D002738_D006333 CID chloroquine_15/NN (r_amod) discontinuation_16/NN (r_dobj) following_14/VBG (r_prep) resolved_12/VBD (l_nsubj) failure_11/NN
D002738_D015354 NONE chloroquine_9/NN (r_amod) ingestion_10/NN (r_pobj) of_7/IN (r_prep) history_6/NN (r_pobj) with_5/IN (r_prep) woman_4/NN (r_nsubj) presented_11/VBN (l_prep) with_12/IN (l_pobj) deterioration_14/NN (l_prep) of_15/IN (l_pobj) vision_16/NN
D002738_D004244 CID chloroquine_9/NN (r_amod) ingestion_10/NN (r_pobj) of_7/IN (r_prep) history_6/NN (r_pobj) with_5/IN (r_prep) woman_4/NN (r_nsubj) presented_11/VBN (l_prep) with_12/IN (l_pobj) deterioration_14/NN (l_conj) fatiguability_19/NN (l_conj) dyspnoea_21/NN (l_conj) dizziness_23/NN
D002738_D012164 CID chloroquine_5/NN (r_amod) retinopathy_6/NN
D002738_D005221 CID chloroquine_9/NN (r_amod) ingestion_10/NN (r_pobj) of_7/IN (r_prep) history_6/NN (r_pobj) with_5/IN (r_prep) woman_4/NN (r_nsubj) presented_11/VBN (l_prep) with_12/IN (l_pobj) deterioration_14/NN (l_conj) fatiguability_19/NN
D002738_D013575 CID chloroquine_9/NN (r_amod) ingestion_10/NN (r_pobj) of_7/IN (r_prep) history_6/NN (r_pobj) with_5/IN (r_prep) woman_4/NN (r_nsubj) presented_11/VBN (l_prep) with_12/IN (l_pobj) deterioration_14/NN (l_conj) fatiguability_19/NN (l_conj) dyspnoea_21/NN (l_conj) dizziness_23/NN (l_acl) progressing_24/VBG (l_prep) to_25/IN (l_pobj) attacks_27/NNS
D002738_D006327 NONE Chloroquine_0/NNP (r_nsubj) related_1/VBD (l_dobj) block_4/NN
D002738_D006327 NONE chloroquine_5/NN (r_amod) retinopathy_6/NN (r_pobj) of_4/IN (r_prep) features_3/NNS (r_dobj) revealed_2/VBD (r_ccomp) revealed_10/VBD (l_dobj) features_11/NNS (l_conj) block_19/NN
D002738_D006327 NONE chloroquine_15/NN (r_amod) discontinuation_16/NN (r_dobj) following_14/VBG (r_prep) resolved_12/VBD (r_conj) treated_4/VBN (l_nsubjpass) block_2/NN
D002738_D004417 CID chloroquine_9/NN (r_amod) ingestion_10/NN (r_pobj) of_7/IN (r_prep) history_6/NN (r_pobj) with_5/IN (r_prep) woman_4/NN (r_nsubj) presented_11/VBN (l_prep) with_12/IN (l_pobj) deterioration_14/NN (l_conj) fatiguability_19/NN (l_conj) dyspnoea_21/NN
20735774
D000082_D017114 CID paracetamol_10/NN (r_npadvmod) induced_12/VBN (r_amod) failure_15/NN
D000082_D017114 CID paracetamol_8/NN (r_npadvmod) induced_10/VBN (r_amod) failure_13/NN
D000082_D017114 CID paracetamol_5/NN (r_advmod) induced_7/VBN (r_nmod) increases_11/VBZ (l_nsubj) failure_10/NN
D000082_D017114 CID paracetamol_16/RB (r_npadvmod) induced_18/VBN (r_amod) injury_20/NN (r_nsubj) caused_22/VBN (l_dobj) failure_26/NN
D000082_D017114 CID paracetamol_16/RB (r_npadvmod) induced_18/VBN (r_amod) injury_20/NN (r_nsubj) caused_22/VBN (r_relcl) patients_14/NNS (r_pobj) for_11/IN (r_prep) higher_10/JJR (r_acomp) were_8/VBD (l_conj) was_46/VBD (l_conj) died_58/VBD (l_nsubj) survivors_53/NNS (l_prep) of_54/IN (l_pobj) failure_57/NN
D000082_D017114 CID Paracetamol_0/NNP (r_npadvmod) induced_2/VBN (r_amod) failure_5/NN
D000082_D056486 NONE paracetamol_9/NN (r_npadvmod) induced_11/VBN (r_amod) injury_14/NN
D000082_D056486 NONE paracetamol_16/RB (r_npadvmod) induced_18/VBN (r_amod) injury_20/NN
D000082_D008107 NONE paracetamol_16/RB (r_npadvmod) induced_18/VBN (r_amod) injury_20/NN (r_nsubj) caused_22/VBN (r_relcl) patients_14/NNS (r_pobj) for_11/IN (r_prep) higher_10/JJR (r_acomp) were_8/VBD (l_conj) was_46/VBD (l_conj) died_58/VBD (l_prep) of_59/IN (l_pobj) disease_61/NN
7905523
C059896_D015658 NONE deoxynojirimycin_10/NNP (l_conj) zidovudine_15/NN (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) infection_20/NN
C059896_D015658 NONE SC-48334_12/NNP (r_appos) deoxynojirimycin_10/NNP (l_conj) zidovudine_15/NN (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) infection_20/NN
D015215_D015658 NONE zidovudine_15/NN (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) infection_20/NN
C059896_D007153 NONE SC-48334_2/VBP (r_nmod) level_7/NN (r_nsubj) was_16/VBD (l_prep) below_17/IN (l_pobj) concentration_22/NN (l_prep) for_23/IN (l_pobj) virus_26/NN (l_compound) immunodeficiency_25/NN
7565311
D016190_D058186 CID carboplatin_6/NN (r_compound) chemotherapy_7/NN (r_pobj) in_3/IN (r_prep) failure_2/NN
D016190_D058186 CID Carboplatin_0/NNP (r_nsubjpass) reported_3/VBN (l_xcomp) cause_5/VB (l_dobj) failure_8/NN
D016190_D018233 NONE carboplatin_15/NN (r_pobj) with_11/IN (r_prep) treated_10/VBN (l_prep) for_16/IN (l_pobj) rhabdomyosarcoma_20/NN
18674790
D004317_D007674 NONE doxorubicin_7/NN (r_nmod) kg_9/NNS (r_appos) dose_3/NN (l_acl) administered_13/VBN (l_prep) on_14/IN (l_pobj) day_15/NN (l_nummod) 43_16/CD (l_prep) of_17/IN (l_pobj) regimen_21/NN (l_acl) led_22/VBD (l_prep) to_23/IN (l_pobj) cardiotoxicity_25/NN (l_conj) dysfunction_28/NN (l_conj) peroxidation_31/NN (l_conj) mortality_36/NN (l_prep) in_44/IN (l_pobj) absence_46/NN (l_prep) of_47/IN (l_pobj) toxicity_53/NN
D000255_D066126 NONE ATP_21/NNP (r_compound) generation_22/NN (r_dobj) downregulating_18/VBG (r_pcomp) by_16/IN (r_prep) sensitized_10/JJ (l_prep) to_11/IN (l_pobj) cardiotoxicity_15/NN
D000255_D009765 NONE ATP_99/NNP (r_compound) levels_100/NNS (r_pobj) in_97/IN (r_prep) drop_96/NN (r_conj) decreased_82/VBD (r_ccomp) revealed_2/VBD (l_ccomp) sensitized_7/VBN (l_nsubjpass) rats_5/NNS (l_compound) OB_4/NNP
D000255_D009765 NONE ATP_99/NNP (r_compound) levels_100/NNS (r_pobj) in_97/IN (r_prep) drop_96/NN (r_conj) decreased_82/VBD (l_nsubj) stress_16/NN (l_acl) activated_35/VBN (l_dobj) oxidation_56/NN (l_appos) heart_64/NN (l_prep) versus_67/IN (l_pobj) heart_74/NN (l_prep) in_75/IN (l_pobj) OB_76/NNP
D000255_D009765 NONE ATP_104/NNP (r_nmod) ADP_106/NNP (r_compound) ratio_107/NN (r_pobj) by_102/IN (r_agent) accompanied_101/VBN (r_acl) drop_96/NN (r_conj) decreased_82/VBD (r_ccomp) revealed_2/VBD (l_ccomp) sensitized_7/VBN (l_nsubjpass) rats_5/NNS (l_compound) OB_4/NNP
D000255_D009765 NONE ATP_104/NNP (r_nmod) ADP_106/NNP (r_compound) ratio_107/NN (r_pobj) by_102/IN (r_agent) accompanied_101/VBN (r_acl) drop_96/NN (r_conj) decreased_82/VBD (l_nsubj) stress_16/NN (l_acl) activated_35/VBN (l_dobj) oxidation_56/NN (l_appos) heart_64/NN (l_prep) versus_67/IN (l_pobj) heart_74/NN (l_prep) in_75/IN (l_pobj) OB_76/NNP
D000255_D009765 NONE ATP_21/NNP (r_compound) generation_22/NN (r_dobj) downregulating_18/VBG (r_pcomp) by_16/IN (r_prep) sensitized_10/JJ (r_acomp) are_8/VBP (l_nsubj) rats_7/NNS (l_amod) obese_6/JJ
D004317_D009765 NONE doxorubicin_11/RB (r_npadvmod) induced_13/VBN (r_compound) cardiotoxicity_14/NN (r_pobj) to_10/IN (r_prep) sensitive_9/JJ (r_acomp) are_7/VBP (l_nsubj) rats_6/NNS (l_amod) obese_5/JJ
D004317_D009765 NONE doxorubicin_40/RB (r_npadvmod) induced_42/VBN (r_compound) cardiotoxicity_43/NN (r_pobj) to_39/IN (r_prep) sensitizes_38/VBZ (l_nsubj) intervention_10/NN (l_prep) by_11/IN (l_pcomp) feeding_12/VBG (l_dobj) diet_17/NN (l_relcl) induces_23/VBZ (l_dobj) obesity_24/NN
D004317_D009765 NONE doxorubicin_7/NN (r_nmod) kg_9/NNS (r_appos) dose_3/NN (l_acl) administered_13/VBN (l_prep) on_14/IN (l_pobj) day_15/NN (l_nummod) 43_16/CD (l_prep) of_17/IN (l_pobj) regimen_21/NN (l_acl) led_22/VBD (l_prep) to_23/IN (l_pobj) cardiotoxicity_25/NN (l_conj) dysfunction_28/NN (l_conj) peroxidation_31/NN (l_conj) mortality_36/NN (l_prep) in_37/IN (l_pobj) rats_43/NNS (l_amod) obese_39/JJ
D004317_D009765 NONE doxorubicin_7/NN (r_nmod) kg_9/NNS (r_appos) dose_3/NN (l_acl) administered_13/VBN (l_prep) on_14/IN (l_pobj) day_15/NN (l_nummod) 43_16/CD (l_prep) of_17/IN (l_pobj) regimen_21/NN (l_acl) led_22/VBD (l_prep) to_23/IN (l_pobj) cardiotoxicity_25/NN (l_conj) dysfunction_28/NN (l_conj) peroxidation_31/NN (l_conj) mortality_36/NN (l_prep) in_37/IN (l_pobj) rats_43/NNS (l_nmod) OB_41/NNP
D004317_D009765 NONE Doxorubicin_0/NNP (r_compound) toxicokinetics_1/NNS (r_compound) studies_2/NNS (r_nsubj) revealed_3/VBD (l_dobj) change_5/NN (l_conj) hearts_27/NNS (l_compound) OB_26/NNP
D004317_D009765 NONE doxorubicin_9/NN (r_pobj) of_8/IN (r_prep) accumulation_7/NN (r_pobj) in_6/IN (r_prep) change_5/NN (l_conj) hearts_27/NNS (l_compound) OB_26/NNP
D004317_D009765 NONE doxorubicin_109/NN (r_compound) administration_110/NN (r_pobj) after_108/IN (r_prep) ratio_107/NN (r_pobj) by_102/IN (r_agent) accompanied_101/VBN (r_acl) drop_96/NN (r_conj) decreased_82/VBD (r_ccomp) revealed_2/VBD (l_ccomp) sensitized_7/VBN (l_nsubjpass) rats_5/NNS (l_compound) OB_4/NNP
D004317_D009765 NONE doxorubicin_109/NN (r_compound) administration_110/NN (r_pobj) after_108/IN (r_prep) ratio_107/NN (r_pobj) by_102/IN (r_agent) accompanied_101/VBN (r_acl) drop_96/NN (r_conj) decreased_82/VBD (l_nsubj) stress_16/NN (l_acl) activated_35/VBN (l_dobj) oxidation_56/NN (l_appos) heart_64/NN (l_prep) versus_67/IN (l_pobj) heart_74/NN (l_prep) in_75/IN (l_pobj) OB_76/NNP
D004317_D009765 NONE doxorubicin_12/RB (r_npadvmod) induced_14/VBN (r_amod) cardiotoxicity_15/NN (r_pobj) to_11/IN (r_prep) sensitized_10/JJ (r_acomp) are_8/VBP (l_nsubj) rats_7/NNS (l_amod) obese_6/JJ
D004317_D056486 NONE doxorubicin_7/NN (r_nmod) kg_9/NNS (r_appos) dose_3/NN (l_acl) administered_13/VBN (l_prep) on_14/IN (l_pobj) day_15/NN (l_nummod) 43_16/CD (l_prep) of_17/IN (l_pobj) regimen_21/NN (l_acl) led_22/VBD (l_prep) to_23/IN (l_pobj) cardiotoxicity_25/NN (l_conj) dysfunction_28/NN (l_conj) peroxidation_31/NN (l_conj) mortality_36/NN (l_prep) in_44/IN (l_pobj) absence_46/NN (l_prep) of_47/IN (l_pobj) toxicity_53/NN
D000249_D009765 NONE AMP_84/NN (r_compound) alpha2_86/NN (r_compound) kinase_88/NN (r_dobj) decreased_82/VBD (r_ccomp) revealed_2/VBD (l_ccomp) sensitized_7/VBN (l_nsubjpass) rats_5/NNS (l_compound) OB_4/NNP
D000249_D009765 NONE AMP_84/NN (r_compound) alpha2_86/NN (r_compound) kinase_88/NN (r_dobj) decreased_82/VBD (l_nsubj) stress_16/NN (l_acl) activated_35/VBN (l_dobj) oxidation_56/NN (l_appos) heart_64/NN (l_prep) versus_67/IN (l_pobj) heart_74/NN (l_prep) in_75/IN (l_pobj) OB_76/NNP
D004041_D066126 NONE fat_1/JJ (r_amod) rats_6/NNS (r_nsubj) are_7/VBP (l_acomp) sensitive_9/JJ (l_prep) to_10/IN (l_pobj) cardiotoxicity_14/NN
D004041_D066126 NONE fat_16/JJ (r_amod) diet_17/NN (r_dobj) feeding_12/VBG (r_pcomp) by_11/IN (r_prep) intervention_10/NN (r_nsubj) sensitizes_38/VBZ (l_prep) to_39/IN (l_pobj) cardiotoxicity_43/NN
D004041_D009765 CID fat_1/JJ (r_amod) rats_6/NNS (l_amod) obese_5/JJ
D004041_D009765 CID fat_16/JJ (r_amod) diet_17/NN (l_relcl) induces_23/VBZ (l_dobj) obesity_24/NN
D004317_D066126 NONE doxorubicin_11/RB (r_npadvmod) induced_13/VBN (r_compound) cardiotoxicity_14/NN
D004317_D066126 NONE doxorubicin_4/NN (r_pobj) by_3/IN (r_prep) chemotherapy_2/NN (r_nsubjpass) limited_9/VBN (l_prep) due_10/IN (l_pobj) life_12/NN (l_acl) threatening_13/VBG (l_dobj) cardiotoxicity_14/NN
D004317_D066126 NONE Adriamycin_6/NNP (r_punct) )_7/-RRB- (r_punct) is_8/VBZ (r_auxpass) limited_9/VBN (l_prep) due_10/IN (l_pobj) life_12/NN (l_acl) threatening_13/VBG (l_dobj) cardiotoxicity_14/NN
D004317_D066126 NONE doxorubicin_12/RB (r_npadvmod) induced_14/VBN (r_amod) cardiotoxicity_15/NN
D004317_D066126 NONE doxorubicin_40/RB (r_npadvmod) induced_42/VBN (r_compound) cardiotoxicity_43/NN
D004317_D066126 NONE doxorubicin_7/NN (r_nmod) kg_9/NNS (r_appos) dose_3/NN (l_acl) administered_13/VBN (l_prep) on_14/IN (l_pobj) day_15/NN (l_nummod) 43_16/CD (l_prep) of_17/IN (l_pobj) regimen_21/NN (l_acl) led_22/VBD (l_prep) to_23/IN (l_pobj) cardiotoxicity_25/NN
D004317_D066126 NONE doxorubicin_12/RB (r_npadvmod) induced_14/VBN (r_amod) cardiotoxicity_15/NN
C010013_D009765 NONE doxorubicinol_11/NN (r_conj) doxorubicin_9/NN (r_pobj) of_8/IN (r_prep) accumulation_7/NN (r_pobj) in_6/IN (r_prep) change_5/NN (l_conj) hearts_27/NNS (l_compound) OB_26/NNP
D000244_D009765 NONE ADP_106/NNP (r_compound) ratio_107/NN (r_pobj) by_102/IN (r_agent) accompanied_101/VBN (r_acl) drop_96/NN (r_conj) decreased_82/VBD (r_ccomp) revealed_2/VBD (l_ccomp) sensitized_7/VBN (l_nsubjpass) rats_5/NNS (l_compound) OB_4/NNP
D000244_D009765 NONE ADP_106/NNP (r_compound) ratio_107/NN (r_pobj) by_102/IN (r_agent) accompanied_101/VBN (r_acl) drop_96/NN (r_conj) decreased_82/VBD (l_nsubj) stress_16/NN (l_acl) activated_35/VBN (l_dobj) oxidation_56/NN (l_appos) heart_64/NN (l_prep) versus_67/IN (l_pobj) heart_74/NN (l_prep) in_75/IN (l_pobj) OB_76/NNP
D004317_D006331 CID doxorubicin_7/NN (r_nmod) kg_9/NNS (r_appos) dose_3/NN (l_acl) administered_13/VBN (l_prep) on_14/IN (l_pobj) day_15/NN (l_nummod) 43_16/CD (l_prep) of_17/IN (l_pobj) regimen_21/NN (l_acl) led_22/VBD (l_prep) to_23/IN (l_pobj) cardiotoxicity_25/NN (l_conj) dysfunction_28/NN
3120485
783197
D004071_D003324 NONE glycosides_4/NNS (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubj) are_11/VBP (l_prep) of_12/IN (l_pobj) interest_14/NN (l_prep) in_15/IN (l_pobj) presence_17/NN (l_prep) of_18/IN (l_pobj) disease_22/NN
D010042_D006333 NONE ouabain_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_prep) on_12/IN (l_pobj) parameters_19/NNS (l_prep) without_29/IN (l_pobj) failure_33/NN
D010042_D006333 NONE ouabain_26/JJ (r_compound) administration_27/NN (r_pobj) after_25/IN (r_prep) falls_24/VBZ (r_conj) conclude_1/VBP (l_ccomp) left_18/VBD (l_nsubj) patients_4/NNS (l_prep) with_5/IN (l_pobj) disease_9/NN (l_relcl) are_11/VBP (l_prep) in_13/IN (l_pobj) failure_17/NN
D010100_D003324 NONE oxygen_5/NN (r_compound) supply_6/NN (l_conj) demand_8/NN (l_prep) in_9/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) disease_15/NN
D010100_D003324 NONE oxygen_7/NN (r_compound) supply_8/NN (r_pobj) on_5/IN (r_prep) glycosides_4/NNS (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubj) are_11/VBP (l_prep) of_12/IN (l_pobj) interest_14/NN (l_prep) in_15/IN (l_pobj) presence_17/NN (l_prep) of_18/IN (l_pobj) disease_22/NN
D010042_D003324 NONE ouabain_2/NN (l_prep) on_3/IN (l_pobj) supply_6/NN (l_conj) demand_8/NN (l_prep) in_9/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) disease_15/NN
D010042_D003324 NONE ouabain_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_prep) on_12/IN (l_pobj) parameters_19/NNS (l_prep) in_20/IN (l_pobj) patients_22/NNS (l_prep) with_23/IN (l_pobj) disease_28/NN
D010042_D003324 NONE ouabain_26/JJ (r_compound) administration_27/NN (r_pobj) after_25/IN (r_prep) falls_24/VBZ (r_conj) conclude_1/VBP (l_ccomp) left_18/VBD (l_nsubj) patients_4/NNS (l_prep) with_5/IN (l_pobj) disease_9/NN
D010042_D002303 CID ouabain_26/JJ (r_compound) administration_27/NN (r_pobj) after_25/IN (r_prep) falls_24/VBZ
20533999
D004298_D009461 NONE DA_13/NNP (r_compound) deficits_14/NNS (r_dobj) have_10/VB (r_xcomp) engineered_8/VBN (l_conj) develop_15/VBP (l_dobj) deficits_20/NNS
D004298_D064420 NONE dopamine_5/NN (r_nsubj) mediates_9/VBZ (l_dobj) methamphetamine_10/NN (l_acl) METH)-induced_12/JJ (l_dobj) toxicity_13/NN
D004298_D064420 NONE dopamine_5/NN (r_nsubj) mediates_9/VBZ (l_advcl) decrease_26/NN (l_dobj) toxicity_27/NN
D004298_D064420 NONE dopamine_5/NN (r_nsubj) mediates_9/VBZ (l_advcl) decrease_26/NN (l_advcl) enhance_35/VB (l_dobj) toxicity_36/NN
D004298_D064420 NONE DA_7/NNP (r_appos) dopamine_5/NN (r_nsubj) mediates_9/VBZ (l_dobj) methamphetamine_10/NN (l_acl) METH)-induced_12/JJ (l_dobj) toxicity_13/NN
D004298_D064420 NONE DA_7/NNP (r_appos) dopamine_5/NN (r_nsubj) mediates_9/VBZ (l_advcl) decrease_26/NN (l_dobj) toxicity_27/NN
D004298_D064420 NONE DA_7/NNP (r_appos) dopamine_5/NN (r_nsubj) mediates_9/VBZ (l_advcl) decrease_26/NN (l_advcl) enhance_35/VB (l_dobj) toxicity_36/NN
D004298_D064420 NONE DA_24/NNP (r_compound) neurotransmission_25/NN (r_pobj) with_23/IN (r_prep) interfere_22/VBP (r_relcl) drugs_20/NNS (r_nsubj) decrease_26/NN (r_advcl) mediates_9/VBZ (l_dobj) methamphetamine_10/NN (l_acl) METH)-induced_12/JJ (l_dobj) toxicity_13/NN
D004298_D064420 NONE DA_24/NNP (r_compound) neurotransmission_25/NN (r_pobj) with_23/IN (r_prep) interfere_22/VBP (r_relcl) drugs_20/NNS (r_nsubj) decrease_26/NN (l_dobj) toxicity_27/NN
D004298_D064420 NONE DA_24/NNP (r_compound) neurotransmission_25/NN (r_pobj) with_23/IN (r_prep) interfere_22/VBP (r_relcl) drugs_20/NNS (r_nsubj) decrease_26/NN (l_advcl) enhance_35/VB (l_dobj) toxicity_36/NN
D004298_D064420 NONE DA_33/NNP (r_compound) neurotransmission_34/NN (r_dobj) increase_32/VBP (r_relcl) drugs_30/NNS (r_nsubj) enhance_35/VB (r_advcl) decrease_26/NN (r_advcl) mediates_9/VBZ (l_dobj) methamphetamine_10/NN (l_acl) METH)-induced_12/JJ (l_dobj) toxicity_13/NN
D004298_D064420 NONE DA_33/NNP (r_compound) neurotransmission_34/NN (r_dobj) increase_32/VBP (r_relcl) drugs_30/NNS (r_nsubj) enhance_35/VB (r_advcl) decrease_26/NN (l_dobj) toxicity_27/NN
D004298_D064420 NONE DA_33/NNP (r_compound) neurotransmission_34/NN (r_dobj) increase_32/VBP (r_relcl) drugs_30/NNS (r_nsubj) enhance_35/VB (l_dobj) toxicity_36/NN
D008694_D064420 NONE methamphetamine_10/NN (l_acl) METH)-induced_12/JJ (l_dobj) toxicity_13/NN
D008694_D064420 NONE methamphetamine_10/NN (r_dobj) mediates_9/VBZ (l_advcl) decrease_26/NN (l_dobj) toxicity_27/NN
D008694_D064420 NONE methamphetamine_10/NN (r_dobj) mediates_9/VBZ (l_advcl) decrease_26/NN (l_advcl) enhance_35/VB (l_dobj) toxicity_36/NN
D008694_D064420 NONE METH)-induced_12/JJ (l_dobj) toxicity_13/NN
D008694_D064420 NONE METH)-induced_12/JJ (r_acl) methamphetamine_10/NN (r_dobj) mediates_9/VBZ (l_advcl) decrease_26/NN (l_dobj) toxicity_27/NN
D008694_D064420 NONE METH)-induced_12/JJ (r_acl) methamphetamine_10/NN (r_dobj) mediates_9/VBZ (l_advcl) decrease_26/NN (l_advcl) enhance_35/VB (l_dobj) toxicity_36/NN
D008694_D009461 NONE METH_16/NN (r_npadvmod) induced_18/VBN (r_amod) deficits_20/NNS
D007980_D020258 NONE dihydroxyphenylalanine_11/NN (r_pobj) of_8/IN (r_prep) ability_7/NN (l_acl) reverse_13/VB (l_dobj) effect_16/NN (l_prep) of_17/IN (l_pobj) tyrosine_24/NN (l_prep) on_25/IN (l_pobj) neurotoxicity_30/NN
D008694_D020258 CID methamphetamine_8/NN (r_npadvmod) induced_10/VBN (r_amod) neurotoxicity_11/NN
D008694_D020258 CID METH_26/NNP (r_npadvmod) induced_28/VBN (r_amod) neurotoxicity_30/NN
D008694_D020258 CID METH_15/NNP (r_compound) neurotoxicity_16/NN
D008694_D020258 CID METH_25/NNP (r_pobj) of_24/IN (r_prep) effects_23/NNS (r_nsubjpass) preserved_27/VBN (r_advcl) long_19/RB (r_advmod) develop_14/VBP (l_dobj) neurotoxicity_16/NN
D008694_D020258 CID METH_15/NNP (r_npadvmod) induced_17/VBN (r_amod) neurotoxicity_19/NN
D019805_D020258 NONE tyrosine_24/NN (l_prep) on_25/IN (l_pobj) neurotoxicity_30/NN
D004298_D020258 NONE Dopamine_0/NN (r_nsubj) is_1/VBZ (l_acomp) essential_3/JJ (l_prep) for_4/IN (l_pobj) development_6/NN (l_prep) of_7/IN (l_pobj) neurotoxicity_11/NN
D004298_D020258 NONE DA_29/NNP (r_compound) neurotoxicity_30/NN
D004298_D020258 NONE DA_13/NN (r_pobj) in_11/IN (r_prep) deficient_10/JJ (r_acomp) be_9/VB (r_xcomp) engineered_7/VBN (l_conj) develop_14/VBP (l_dobj) neurotoxicity_16/NN
D004298_D020258 NONE DA_7/NNP (r_nsubj) is_8/VBZ (l_acomp) essential_10/JJ (l_prep) for_11/IN (l_pobj) development_13/NN (l_prep) of_14/IN (l_pobj) neurotoxicity_19/NN
D004298_D020258 NONE DA_26/JJ (r_pobj) of_25/IN (r_prep) independent_24/JJ (r_amod) mechanisms_23/NNS (r_nsubj) warrant_27/NN (r_ccomp) suggest_21/VBP (r_conj) is_8/VBZ (l_acomp) essential_10/JJ (l_prep) for_11/IN (l_pobj) development_13/NN (l_prep) of_14/IN (l_pobj) neurotoxicity_19/NN
8988571
D003042_D003693 CID cocaine_4/NN (r_compound) use_5/NN (r_dobj) following_3/VBG (r_acl) delirium_2/NN
D003042_D003693 CID cocaine_15/NN (r_compound) toxicity_16/NN (r_pobj) of_14/IN (r_prep) mechanisms_13/NNS (r_pobj) for_12/IN (r_prep) evidence_11/NN (r_dobj) provide_9/VBP (l_dep) delirium_2/NN
D003042_D003693 CID cocaine_7/NN (r_npadvmod) induced_9/VBN (r_amod) delirium_11/NN
D003042_D003693 CID cocaine_7/NN (r_npadvmod) induced_9/VBN (r_amod) delirium_11/NN (l_appos) EDDs_13/NNP
D003042_D003693 CID cocaine_5/NN (r_npadvmod) related_7/VBN (r_amod) deaths_8/NNS (r_pobj) of_3/IN (r_prep) registry_2/NN (r_pobj) From_0/IN (r_prep) compared_23/VBN (l_nsubjpass) EDDs_21/NNS
D003042_D003693 CID cocaine_5/NN (r_npadvmod) related_7/VBN (r_amod) deaths_8/NNS (r_pobj) of_3/IN (r_prep) registry_2/NN (r_pobj) From_0/IN (r_prep) compared_23/VBN (l_prep) with_24/IN (l_pobj) victims_26/NNS (l_prep) without_31/IN (l_pobj) delirium_33/NN
D003042_D003693 CID cocaine_29/NN (r_compound) overdose_30/NN (r_pobj) of_27/IN (r_prep) victims_26/NNS (r_pobj) with_24/IN (r_prep) compared_23/VBN (l_nsubjpass) EDDs_21/NNS
D003042_D003693 CID cocaine_29/NN (r_compound) overdose_30/NN (r_pobj) of_27/IN (r_prep) victims_26/NNS (l_prep) without_31/IN (l_pobj) delirium_33/NN
D003042_D003693 CID cocaine_4/NN (r_pobj) of_3/IN (r_prep) concentrations_2/NNS (r_dobj) had_1/VBD (l_nsubj) EDDs_0/NNS
D003042_D003693 CID cocaine_11/NN (r_compound) use_12/NN (r_nsubj) disrupts_13/VBZ (r_acl) hypothesis_8/NN (r_pobj) with_6/IN (r_prep) consistent_5/JJ (r_acomp) are_3/VBP (l_advcl) precipitate_26/VB (l_dobj) agitation_27/NN (l_conj) delirium_29/NN
D003042_D003693 CID cocaine_22/NN (r_compound) use_23/NN (r_pobj) with_20/IN (r_prep) coupled_19/VBN (r_advcl) precipitate_26/VB (l_dobj) agitation_27/NN (l_conj) delirium_29/NN
D003042_D064420 NONE cocaine_4/NN (r_compound) use_5/NN (r_dobj) following_3/VBG (r_acl) delirium_2/NN (r_dep) provide_9/VBP (l_dobj) evidence_11/NN (l_prep) for_12/IN (l_pobj) mechanisms_13/NNS (l_prep) of_14/IN (l_pobj) toxicity_16/NN
D003042_D064420 NONE cocaine_15/NN (r_compound) toxicity_16/NN
D003042_D012206 CID cocaine_11/NN (r_compound) use_12/NN (r_nsubj) disrupts_13/VBZ (r_acl) hypothesis_8/NN (r_pobj) with_6/IN (r_prep) consistent_5/JJ (r_acomp) are_3/VBP (l_advcl) precipitate_26/VB (l_dobj) agitation_27/NN (l_conj) delirium_29/NN (l_conj) thermoregulation_32/NN (l_conj) rhabdomyolysis_34/NN
D003042_D012206 CID cocaine_22/NN (r_compound) use_23/NN (r_pobj) with_20/IN (r_prep) coupled_19/VBN (r_advcl) precipitate_26/VB (l_dobj) agitation_27/NN (l_conj) delirium_29/NN (l_conj) thermoregulation_32/NN (l_conj) rhabdomyolysis_34/NN
D003042_D003645 CID cocaine_11/NN (r_compound) use_12/NN (r_nsubj) disrupts_13/VBZ (r_acl) hypothesis_8/NN (r_pobj) with_6/IN (r_prep) consistent_5/JJ (r_acomp) are_3/VBP (l_advcl) precipitate_26/VB (l_dobj) agitation_27/NN (l_conj) delirium_29/NN (l_conj) thermoregulation_32/NN (l_conj) rhabdomyolysis_34/NN (l_conj) death_38/NN
D003042_D003645 CID cocaine_22/NN (r_compound) use_23/NN (r_pobj) with_20/IN (r_prep) coupled_19/VBN (r_advcl) precipitate_26/VB (l_dobj) agitation_27/NN (l_conj) delirium_29/NN (l_conj) thermoregulation_32/NN (l_conj) rhabdomyolysis_34/NN (l_conj) death_38/NN
C005618_D003693 NONE benzoylecgonine_6/NN (r_conj) cocaine_4/NN (r_pobj) of_3/IN (r_prep) concentrations_2/NNS (r_dobj) had_1/VBD (l_nsubj) EDDs_0/NNS
D003042_D062787 NONE cocaine_5/NN (r_npadvmod) related_7/VBN (r_amod) deaths_8/NNS (r_pobj) of_3/IN (r_prep) registry_2/NN (r_pobj) From_0/IN (r_prep) compared_23/VBN (l_prep) with_24/IN (l_pobj) victims_26/NNS (l_prep) of_27/IN (l_pobj) overdose_30/NN
D003042_D062787 NONE cocaine_29/NN (r_compound) overdose_30/NN
D003042_D011595 NONE cocaine_11/NN (r_compound) use_12/NN (r_nsubj) disrupts_13/VBZ (r_acl) hypothesis_8/NN (r_pobj) with_6/IN (r_prep) consistent_5/JJ (r_acomp) are_3/VBP (l_advcl) precipitate_26/VB (l_dobj) agitation_27/NN
D003042_D011595 NONE cocaine_22/NN (r_compound) use_23/NN (r_pobj) with_20/IN (r_prep) coupled_19/VBN (r_advcl) precipitate_26/VB (l_dobj) agitation_27/NN
20466178
D016559_D012393 NONE tacrolimus_19/NN (r_compound) ointment_20/NN (r_dobj) using_13/VBG (r_advcl) developed_6/VBD (l_dobj) eruptions_11/NNS (l_amod) like_9/JJ (l_npadvmod) rosacea_7/NN
C117268_D003872 CID pimecrolimus_9/NN (r_conj) tacrolimus_7/NN (r_pobj) as_6/IN (r_prep) immunomodulators_4/NNS (r_pobj) of_3/IN (r_prep) use_2/NN (r_nsubjpass) regarded_12/VBN (l_prep) as_13/IN (l_pobj) cause_16/NN (l_prep) of_17/IN (l_pobj) dermatitis_19/NN
D016559_D003875 NONE tacrolimus_19/NN (r_compound) ointment_20/NN (r_dobj) using_13/VBG (r_advcl) developed_6/VBD (l_dobj) eruptions_11/NNS
D016559_D005148 NONE tacrolimus_19/NN (r_compound) ointment_20/NN (r_dobj) using_13/VBG (l_prep) for_21/IN (l_pobj) dermatitis_23/NN
D016559_D003872 NONE tacrolimus_5/NN (r_compound) treatment_6/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) dermatitis_1/NN
D016559_D003872 NONE tacrolimus_19/NN (r_compound) ointment_20/NN (r_dobj) using_13/VBG (r_advcl) developed_6/VBD (l_dobj) eruptions_11/NNS (l_compound) dermatitis_10/NN
D016559_D003872 NONE tacrolimus_7/NN (r_pobj) as_6/IN (r_prep) immunomodulators_4/NNS (r_pobj) of_3/IN (r_prep) use_2/NN (r_nsubjpass) regarded_12/VBN (l_prep) as_13/IN (l_pobj) cause_16/NN (l_prep) of_17/IN (l_pobj) dermatitis_19/NN
8514073
D003975_D010146 NONE diazepam_18/NN (r_compound) group_19/NN (r_pobj) in_16/IN (r_prep) patients_15/NNS (r_pobj) of_14/IN (r_prep) %_8/NN (r_pobj) in_6/IN (r_prep) occurred_5/VBD (l_nsubj) Pain_0/NN
D000431_D014652 NONE alcohol_19/NN (r_compound) use_20/NN (r_conj) time_14/NN (r_conj) site_11/NN (r_conj) use_7/NN (r_appos) Smoking_0/NN (r_nsubj) had_27/VBD (l_dobj) effect_29/NN (l_prep) on_30/IN (l_pobj) incidence_32/NN (l_prep) of_33/IN (l_pobj) complications_35/NNS
D003975_D014652 CID diazepam_5/NN (r_pobj) versus_4/FW (r_prep) midazolam_3/FW (r_pobj) of_2/IN (r_prep) complications_1/NNS
D003975_D014652 CID diazepam_14/NN (r_pobj) with_13/IN (r_prep) than_12/IN (r_prep) midazolam_11/DT (r_pobj) with_10/IN (r_prep) associated_9/VBN (l_nsubjpass) complications_7/NNS
D003975_D014652 CID diazepam_12/NN (r_pobj) of_11/IN (r_prep) injection_10/NN (r_pobj) after_8/IN (r_prep) evaluated_2/VBD (l_dobj) incidence_4/NN (l_prep) of_5/IN (l_pobj) complications_7/NNS
D003975_D014652 CID diazepam_8/NN (r_pobj) with_7/IN (r_prep) frequent_6/JJ (r_acomp) were_4/VBD (l_nsubj) complications_3/NNS
D000431_D010146 NONE alcohol_19/NN (r_compound) use_20/NN (l_conj) pain_23/NN
D008874_D014652 CID midazolam_3/FW (r_pobj) of_2/IN (r_prep) complications_1/NNS
D008874_D014652 CID midazolam_11/DT (r_pobj) with_10/IN (r_prep) associated_9/VBN (l_nsubjpass) complications_7/NNS
D008874_D014652 CID midazolam_14/NN (r_conj) diazepam_12/NN (r_pobj) of_11/IN (r_prep) injection_10/NN (r_pobj) after_8/IN (r_prep) evaluated_2/VBD (l_dobj) incidence_4/NN (l_prep) of_5/IN (l_pobj) complications_7/NNS
D008874_D014652 CID midazolam_17/NNP (r_pobj) with_16/IN (r_prep) than_15/IN (r_prep) 22_10/CD (r_npadvmod) were_4/VBD (l_nsubj) complications_3/NNS
D008874_D010146 NONE midazolam_32/JJ (r_amod) group_33/NN (r_pobj) in_30/IN (r_prep) %_23/NN (r_pobj) with_21/IN (r_prep) compared_20/VBN (r_prep) occurred_5/VBD (l_nsubj) Pain_0/NN
9098464
D012701_D062788 NONE serotonin_17/NN (r_compound) inhibitor_19/NN (r_appos) hydrochloride_13/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) effects_7/NNS (r_appos) model_2/NN (l_prep) of_3/IN (l_pobj) adenomyosis_4/NN
D012701_D062788 NONE serotonin_17/NN (r_compound) inhibitor_19/NN (r_appos) hydrochloride_13/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (l_prep) on_21/IN (l_pobj) induction_23/NN (l_compound) adenomyosis_22/NN
D012701_D006966 NONE serotonin_17/NN (r_compound) inhibitor_19/NN (r_appos) hydrochloride_13/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) effects_7/NNS (l_prep) of_8/IN (l_pobj) hyperprolactinemia_9/NN
D012701_D006966 NONE serotonin_3/NN (r_compound) inhibitor_5/NN (r_appos) Fluoxetine_0/NNP (r_nsubjpass) given_8/VBN (l_advcl) produce_17/VB (l_dobj) hyperprolactinemia_18/NN
D005473_D062788 CID hydrochloride_13/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) effects_7/NNS (r_appos) model_2/NN (l_prep) of_3/IN (l_pobj) adenomyosis_4/NN
D005473_D062788 CID hydrochloride_13/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (l_prep) on_21/IN (l_pobj) induction_23/NN (l_compound) adenomyosis_22/NN
D005473_D062788 CID fluoxetine_9/NN (r_nsubj) caused_16/VBD (l_dobj) hyperprolactinemia_17/NN (l_conj) effects_20/NNS (l_prep) with_21/IN (l_pobj) respect_22/NN (l_prep) to_23/IN (l_pobj) adenomyosis_24/NN
D005473_D062788 CID fluoxetine_14/NN (r_dobj) receiving_13/VBG (r_acl) group_12/NN (r_pobj) within_9/IN (r_prep) revealed_2/VBD (l_dobj) cases_4/NNS (l_prep) of_5/IN (l_pobj) adenomyosis_6/NN
D005473_D006966 CID hydrochloride_13/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) effects_7/NNS (l_prep) of_8/IN (l_pobj) hyperprolactinemia_9/NN
D005473_D006966 CID fluoxetine_9/NN (r_nsubj) caused_16/VBD (l_dobj) hyperprolactinemia_17/NN
D005473_D006966 CID Fluoxetine_0/NNP (r_nsubjpass) given_8/VBN (l_advcl) produce_17/VB (l_dobj) hyperprolactinemia_18/NN
7803371
D003915_D003072 CID dextromethorphan_8/NN (r_pobj) of_7/IN (r_prep) abuse_6/NN (r_pobj) from_2/IN (r_prep) deterioration_1/NN
D003915_D003072 CID DM_13/NN (r_pobj) of_12/IN (r_prep) use_11/NN (r_pobj) from_9/IN (r_prep) resulting_8/VBG (r_acl) deterioration_7/NN
85485
C012282_D006528 NONE chlorophenoxyisobutyrate_31/NN (r_appos) alpha_27/NN (r_appos) ethyl_25/NN (r_pobj) to_24/IN (r_prep) respond_23/VB (l_advcl) were_5/VBD (l_nsubj) most_1/JJS (l_prep) of_2/IN (l_pobj) hepatomas_4/NNS
D001556_D017093 NONE hexachloride_17/NN (r_pobj) by_11/IN (r_prep) induced_8/VBN (l_nsubj) Peroxisomes_0/NNS (l_prep) in_1/IN (l_pobj) lesions_7/NNS
D001556_D006528 CID hexachloride_15/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) Changes_0/NNS (l_prep) in_1/IN (l_pobj) peroxisomes_2/NNS (l_prep) in_3/IN (l_pobj) liver_5/NN (l_conj) hepatoma_7/NN
D001556_D006528 CID hexachloride_17/NN (r_pobj) by_11/IN (r_prep) induced_8/VBN (l_nsubj) Peroxisomes_0/NNS (l_prep) in_1/IN (l_pobj) hepatomas_2/NNS
C012282_D009369 NONE chlorophenoxyisobutyrate_31/NN (r_appos) alpha_27/NN (r_appos) ethyl_25/NN (r_pobj) to_24/IN (r_prep) respond_23/VB (l_advcl) were_5/VBD (l_attr) tumors_9/NNS
C012282_D009369 NONE chlorophenoxyisobutyrate_31/NN (r_appos) alpha_27/NN (r_appos) ethyl_25/NN (r_pobj) to_24/IN (r_prep) respond_23/VB (l_nsubj) cells_20/NNS (l_compound) tumor_19/NN
15276120
D014859_D006470 CID warfarin_3/RB (r_npadvmod) associated_5/VBN (r_amod) hemorrhage_6/NN
D014859_D006470 CID warfarin_4/RB (r_npadvmod) related_6/VBN (r_amod) bleeding_7/NN
921394
D007649_D013610 CID ketamine_18/NN (r_npadvmod) induced_20/VBN (r_amod) tachycardia_21/NN
D007649_D003866 NONE ketamine_2/NN (r_pobj) of_1/IN (r_prep) Injections_0/NNS (l_dep) mg_10/NN (l_prep) into_11/IN (l_pobj) artery_13/NN (l_acl) produced_14/VBD (l_dobj) depression_16/NN
9326871
D018942_D005759 NONE macrolides_31/NNS (r_pobj) with_28/IN (r_prep) experience_27/NN (l_prep) including_11/VBG (l_pobj) gastroenteritis_12/JJ
D017291_D001145 NONE clarithromycin_14/NN (r_pobj) of_13/IN (r_prep) doses_12/NNS (r_pobj) after_9/IN (r_prep) occurred_8/VBD (r_relcl) dysrhythmias_6/NNS
D018942_D066126 NONE macrolides_20/NNS (r_pobj) with_17/IN (r_prep) reported_16/VBN (r_conj) demonstrated_3/VBN (l_nsubjpass) Cardiotoxicity_0/NN
D004917_D005759 CID erythromycin_7/NNP (r_pobj) of_6/IN (r_prep) profile_5/NN (r_nsubjpass) established_9/VBN (r_advcl) recorded_35/VBN (l_nsubjpass) experience_27/NN (l_prep) including_11/VBG (l_pobj) gastroenteritis_12/JJ
D017291_D017180 CID Clarithromycin_0/NN (r_npadvmod) induced_2/VBN (r_amod) tachycardia_4/NN
D004917_D066126 NONE erythromycin_11/NNP (r_pobj) of_10/IN (r_prep) administration_9/NN (r_pobj) after_4/IN (r_prep) demonstrated_3/VBN (l_nsubjpass) Cardiotoxicity_0/NN
3950060
D000583_D007674 CID amikacin_10/JJ (r_dobj) receiving_9/VBG (r_acl) patients_8/NNS (r_pobj) in_7/IN (r_prep) nephrotoxicity_3/NN
D000583_D007674 CID amikacin_6/JJ (r_pobj) with_5/IN (r_prep) treated_4/VBN (r_acl) patients_3/NNS (r_pobj) from_1/IN (r_prep) Data_0/NNS (r_nsubjpass) analyzed_8/VBN (l_prep) for_9/IN (l_pobj) factors_10/NNS (l_acl) associated_11/VBN (l_prep) with_12/IN (l_pobj) nephrotoxicity_13/NN
11912119
D007980_D010300 NONE levodopa_3/RB (r_npadvmod) induced_5/VBN (r_amod) dyskinesias_6/NNS (l_prep) in_7/IN (l_pobj) disease_10/NN
D007980_D010300 NONE levodopa_18/NN (r_compound) therapy_19/NN (r_pobj) of_17/IN (r_prep) complications_16/NNS (r_pobj) to_14/IN (r_prep) relationship_13/NN (r_conj) disease_10/NN
D007980_D010300 NONE levodopa_23/VB (r_npadvmod) induced_25/VBN (r_amod) dyskinesias_26/NNS (r_pobj) to_22/IN (r_prep) assessed_1/VBD (l_prep) in_7/IN (l_pobj) disease_10/NN
D007980_D010300 NONE levodopa_23/NN (r_npadvmod) induced_25/VBN (r_amod) dyskinesias_26/NNS (r_pobj) without_22/IN (r_conj) with_9/IN (r_prep) studied_1/VBD (l_dobj) groups_3/NNS (l_prep) of_4/IN (l_pobj) patients_8/NNS (l_compound) disease_7/NN
D007980_D010300 NONE levodopa_23/NN (r_npadvmod) induced_25/VBN (r_amod) dyskinesias_26/NNS (r_pobj) without_22/IN (r_conj) with_9/IN (l_pobj) disease_13/NN
D007980_D010300 NONE levodopa_23/NN (r_npadvmod) induced_25/VBN (r_amod) dyskinesias_26/NNS (l_appos) LID_32/NNP (l_compound) disease_30/NN
D007980_D010300 NONE levodopa_28/RB (r_dobj) assessed_24/VBN (l_nsubjpass) score_2/NN (l_prep) of_3/IN (l_pobj) Scale_10/NNP (l_compound) Rating_9/NNP (l_compound) Disease_8/NNP
D007980_D010300 NONE levodopa_21/NN (r_pobj) by_20/IN (r_agent) increased_19/VBN (l_prep) In_0/IN (l_pobj) disease_3/NN
D007980_D004409 CID levodopa_3/RB (r_npadvmod) induced_5/VBN (r_amod) dyskinesias_6/NNS
D007980_D004409 CID levodopa_18/NN (r_compound) therapy_19/NN (r_pobj) of_17/IN (r_prep) complications_16/NNS (r_pobj) to_14/IN (r_prep) relationship_13/NN (r_conj) disease_10/NN (r_pobj) in_7/IN (r_prep) assessed_1/VBD (l_prep) to_22/IN (l_pobj) dyskinesias_26/NNS
D007980_D004409 CID levodopa_18/NN (r_compound) therapy_19/NN (r_pobj) of_17/IN (r_prep) complications_16/NNS (r_pobj) to_14/IN (r_prep) relationship_13/NN (r_conj) disease_10/NN (r_pobj) in_7/IN (r_prep) assessed_1/VBD (l_prep) to_22/IN (l_pobj) dyskinesias_26/NNS (l_appos) LID_28/NNP
D007980_D004409 CID levodopa_23/VB (r_npadvmod) induced_25/VBN (r_amod) dyskinesias_26/NNS
D007980_D004409 CID levodopa_23/VB (r_npadvmod) induced_25/VBN (r_amod) dyskinesias_26/NNS (l_appos) LID_28/NNP
D007980_D004409 CID levodopa_23/NN (r_npadvmod) induced_25/VBN (r_amod) dyskinesias_26/NNS (r_pobj) without_22/IN (r_conj) with_9/IN (l_pobj) disease_13/NN (l_conj) LID_15/NNP
D007980_D004409 CID levodopa_23/NN (r_npadvmod) induced_25/VBN (r_amod) dyskinesias_26/NNS
D007980_D004409 CID levodopa_23/NN (r_npadvmod) induced_25/VBN (r_amod) dyskinesias_26/NNS (l_appos) LID_32/NNP
D007980_D004409 CID levodopa_28/RB (r_dobj) assessed_24/VBN (l_nsubjpass) score_2/NN (l_prep) of_3/IN (l_pobj) Scale_10/NNP (l_appos) score_14/NN (l_compound) dyskinesia_13/JJ
D007980_D004409 CID levodopa_21/NN (r_pobj) by_20/IN (r_agent) increased_19/VBN (l_prep) In_0/IN (l_pobj) disease_3/NN (l_conj) LID_5/NNP
20042557
D015742_D003693 CID propofol_39/NN (r_amod) sedation_40/NN (r_pobj) with_38/IN (r_prep) anesthesia_37/NN (r_pobj) under_35/IN (r_prep) repair_34/NN (r_dobj) underwent_31/VBD (r_relcl) delirium_26/NN
D015742_D003693 CID propofol_4/NN (r_amod) sedation_5/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) decreased_6/VBD (l_dobj) prevalence_8/NN (l_prep) of_9/IN (l_pobj) delirium_11/NN
D015742_D006620 NONE propofol_39/NN (r_amod) sedation_40/NN (r_pobj) with_38/IN (r_prep) anesthesia_37/NN (r_pobj) under_35/IN (r_prep) repair_34/NN (l_compound) fracture_33/NN
D015742_D003704 NONE propofol_39/NN (r_amod) sedation_40/NN (r_pobj) with_38/IN (r_prep) anesthesia_37/NN (r_pobj) under_35/IN (r_prep) repair_34/NN (r_dobj) underwent_31/VBD (r_relcl) delirium_26/NN (l_conj) dementia_29/NN
D015742_D011183 CID propofol_4/NN (r_amod) sedation_5/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) decreased_6/VBD (l_dobj) prevalence_8/NN (l_prep) of_9/IN (l_pobj) delirium_11/NN
2004015
D015215_C565469 NONE azidothymidine_8/NN (r_advmod) treated_9/VBN (l_dobj) mice_11/NNS (l_amod) immunodeficient_10/JJ
D015215_D045262 NONE AZT_12/NNP (r_pobj) in_11/IN (r_prep) observed_10/VBN (r_acl) degree_7/NN (r_pobj) for_5/IN (r_prep) inappropriate_4/JJ (r_acomp) was_3/VBD (l_nsubj) reticulocytosis_2/NN
D015215_D000163 NONE AZT_28/NNP (r_npadvmod) induced_30/VBN (r_amod) anaemia_31/NN (r_nsubj) is_32/VBZ (r_ccomp) determine_26/VB (r_xcomp) used_2/VBN (l_dobj) model_5/NN (l_prep) of_6/IN (l_pobj) AIDS_7/NNP
D015215_D007239 NONE AZT_28/NNP (r_npadvmod) induced_30/VBN (r_amod) anaemia_31/NN (r_nsubj) is_32/VBZ (r_ccomp) determine_26/VB (r_xcomp) used_2/VBN (l_dobj) model_5/NN (l_prep) of_6/IN (l_pobj) AIDS_7/NNP (l_appos) infection_9/NN
D015215_D007938 NONE AZT_28/NNP (r_npadvmod) induced_30/VBN (r_amod) anaemia_31/NN (r_nsubj) is_32/VBZ (r_ccomp) determine_26/VB (r_xcomp) used_2/VBN (l_dobj) model_5/NN (l_prep) of_6/IN (l_pobj) AIDS_7/NNP (l_appos) infection_9/NN (l_prep) of_10/IN (l_pobj) mice_13/NNS (l_prep) with_14/IN (l_pobj) leukaemia_19/NN
C030299_D000740 NONE phenylhydrazine_22/NN (r_npadvmod) treated_26/VBD (r_conj) observed_6/VBD (l_conj) were_11/VBD (l_acomp) appropriate_12/JJ (l_prep) for_13/IN (l_pobj) degree_15/NN (l_prep) of_16/IN (l_pobj) anaemia_17/NN
C030299_D000740 NONE PHZ_24/NNP (r_nsubj) treated_26/VBD (r_conj) observed_6/VBD (l_conj) were_11/VBD (l_acomp) appropriate_12/JJ (l_prep) for_13/IN (l_pobj) degree_15/NN (l_prep) of_16/IN (l_pobj) anaemia_17/NN
C030299_D000740 NONE PHZ_19/NNP (r_conj) AZT_17/NNP (r_nsubj) treated_20/VBD (l_prep) with_22/IN (l_pobj) degrees_24/NNS (l_prep) of_25/IN (l_pobj) anaemia_26/NN
D015215_D000740 CID 3'-azido-3'dideoxythymidine_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) anaemia_1/NN
D015215_D000740 CID AZT_6/NNP (r_appos) 3'-azido-3'dideoxythymidine_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) anaemia_1/NN
D015215_D000740 CID AZT_28/NNP (r_npadvmod) induced_30/VBN (r_amod) anaemia_31/NN
D015215_D000740 CID AZT_0/NNP (r_nsubj) produced_1/VBD (l_dobj) anaemia_2/NN
D015215_D000740 CID AZT_15/NNP (r_pobj) in_14/IN (r_prep) e_13/NNP (r_pobj) of_6/IN (r_prep) number_5/NN (r_nsubj) treated_16/VBD (l_prep) Despite_0/IN (l_pobj) anaemia_2/NN
D015215_D000740 CID AZT_8/NNP (r_pobj) in_7/IN (r_prep) observed_6/VBD (l_conj) were_11/VBD (l_acomp) appropriate_12/JJ (l_prep) for_13/IN (l_pobj) degree_15/NN (l_prep) of_16/IN (l_pobj) anaemia_17/NN
D015215_D000740 CID AZT_17/NNP (r_nsubj) treated_20/VBD (l_prep) with_22/IN (l_pobj) degrees_24/NNS (l_prep) of_25/IN (l_pobj) anaemia_26/NN
D015215_D000740 CID AZT_12/NNP (r_pobj) in_11/IN (r_prep) observed_10/VBN (r_acl) degree_7/NN (l_prep) of_8/IN (l_pobj) anaemia_9/NN
D015215_D000740 CID AZT_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) anaemia_4/NN
15096016
D007980_D018476 NONE levodopa_20/RB (r_npadvmod) induced_22/VBN (r_amod) dyskinesias_23/NNS (r_dobj) improving_19/VBG (r_pcomp) in_18/IN (r_prep) be_17/VB (r_xcomp) seems_15/VBZ (l_ccomp) improves_2/VBZ (l_dobj) bradykinesia_3/JJ
D007980_D009127 NONE levodopa_20/RB (r_npadvmod) induced_22/VBN (r_amod) dyskinesias_23/NNS (r_dobj) improving_19/VBG (r_pcomp) in_18/IN (r_prep) be_17/VB (r_xcomp) seems_15/VBZ (l_ccomp) improves_2/VBZ (l_dobj) bradykinesia_3/JJ (l_conj) rigidity_5/NN
D007980_D004409 CID levodopa_20/RB (r_npadvmod) induced_22/VBN (r_amod) dyskinesias_23/NNS
6293644
D006220_D006948 NONE haloperidol_7/NN (r_npadvmod) induced_9/VBN (r_amod) catalepsy_10/NN (r_pobj) of_6/IN (r_prep) potentiation_5/NN (l_conj) prevention_14/NN (l_prep) of_15/IN (l_pobj) hyperactivity_19/NN
D006220_D002375 CID haloperidol_7/NN (r_npadvmod) induced_9/VBN (r_amod) catalepsy_10/NN
D001058_D006948 CID apomorphine_16/NN (r_npadvmod) induced_18/VBN (r_amod) hyperactivity_19/NN
D001058_D002375 NONE apomorphine_16/NN (r_npadvmod) induced_18/VBN (r_amod) hyperactivity_19/NN (r_pobj) of_15/IN (r_prep) prevention_14/NN (r_conj) potentiation_5/NN (l_prep) of_6/IN (l_pobj) catalepsy_10/NN
12691807
D007980_D008538 NONE levodopa_10/NN (r_npadvmod) induced_12/VBN (r_amod) dystonia_14/NN
D007980_D008538 NONE levodopa_10/NN (r_npadvmod) induced_12/VBN (r_amod) dystonia_14/NN (l_appos) OMD_16/NNP
D007980_D010300 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NNS (r_nsubjpass) reported_6/VBN (l_prep) in_7/IN (l_pobj) disease_10/NN
D007980_D019578 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NNS (r_nsubjpass) reported_6/VBN (l_prep) in_7/IN (l_pobj) disease_10/NN (l_conj) atrophy_14/NN
D007980_D004421 CID Levodopa_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) dystonia_4/NN
D007980_D004409 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NNS
D007980_D013494 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (l_dobj) dystonia_4/NN (l_prep) in_5/IN (l_pobj) palsy_8/JJ
D007980_D013494 NONE levodopa_10/NN (r_npadvmod) induced_12/VBN (r_amod) dystonia_14/NN (r_pobj) of_8/IN (r_prep) case_7/NN (l_prep) in_18/IN (l_pobj) patient_21/NN (l_compound) PSP_20/NNP
D007980_D013494 NONE levodopa_10/NN (r_npadvmod) induced_12/VBN (r_amod) dystonia_14/NN (r_pobj) of_8/IN (r_prep) case_7/NN (r_dobj) describe_4/VBP (l_advcl) highlight_23/VB (l_dobj) importance_25/NN (l_prep) of_26/IN (l_pcomp) recognizing_27/VBG (l_dobj) complication_31/NN (l_prep) in_32/IN (l_pobj) management_34/NN (l_prep) of_35/IN (l_pobj) PSP_36/NNP
11467664
D008687_D007565 NONE hydrochloride_1/NN (r_nsubjpass) discontinued_3/VBN (l_conj) resolved_10/VBN (l_nsubj) jaundice_9/NN
D008687_D007565 NONE metformin_12/NN (r_pobj) of_11/IN (r_prep) initiation_10/NN (r_pobj) after_8/IN (r_prep) onset_2/NN (l_prep) of_3/IN (l_pobj) jaundice_5/NN
D008687_D007565 NONE metformin_23/NN (r_npadvmod) associated_25/VBN (r_amod) hepatotoxicity_26/NN (r_pobj) of_22/IN (r_prep) example_21/NN (r_dobj) represents_19/VBZ (r_ccomp) believe_15/VBP (l_prep) Given_0/VBN (l_pobj) onset_2/NN (l_prep) of_3/IN (l_pobj) jaundice_5/NN
D008687_D041781 CID metformin_7/NN (r_pobj) of_6/IN (r_prep) use_5/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) jaundice_1/NN
D008687_D041781 CID hydrochloride_15/NN (r_pobj) with_13/IN (r_prep) treatment_12/NN (r_pobj) of_11/IN (r_prep) initiation_10/NN (r_pobj) after_9/IN (r_prep) developed_5/VBD (l_dobj) jaundice_7/NN
D008687_D056486 NONE metformin_12/NN (r_pobj) of_11/IN (r_prep) initiation_10/NN (r_pobj) after_8/IN (r_prep) onset_2/NN (r_pobj) Given_0/VBN (r_prep) believe_15/VBP (l_ccomp) represents_19/VBZ (l_dobj) example_21/NN (l_prep) of_22/IN (l_pobj) hepatotoxicity_26/NN
D008687_D056486 NONE metformin_23/NN (r_npadvmod) associated_25/VBN (r_amod) hepatotoxicity_26/NN
8841157
D000804_D006973 NONE II_5/CD (r_compound) antagonist_6/NN (l_prep) for_7/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) hypertension_12/NN
D017311_D004487 CID amlodipine_13/NN (r_compound) group_14/NN (r_pobj) in_11/IN (r_prep) was_8/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) edema_7/NN
D017311_D004487 CID amlodipine_38/NN (r_pobj) for_35/IN (r_prep) %_34/NN (r_npadvmod) was_8/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) edema_7/NN
D017311_D004487 CID amlodipine_47/NN (r_conj) %_41/NN (r_conj) %_34/NN (r_npadvmod) was_8/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) edema_7/NN
D017311_D004487 CID amlodipine_54/NN (r_pobj) for_51/IN (r_prep) %_50/NN (r_appos) %_34/NN (r_npadvmod) was_8/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) edema_7/NN
C081489_D004487 CID valsartan_31/NN (r_pobj) for_28/IN (r_prep) %_27/NN (r_appos) dose_19/NN (r_pobj) at_17/IN (r_prep) was_8/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) edema_7/NN
C081489_D004487 CID valsartan_43/NN (r_pobj) for_42/IN (r_prep) %_41/NN (r_conj) %_34/NN (r_npadvmod) was_8/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) edema_7/NN
D017311_D006973 NONE amlodipine_23/NN (r_pobj) against_22/IN (r_prep) safety_21/NN (r_conj) efficacy_19/NN (r_pobj) of_17/IN (r_prep) study_16/NN (r_appos) Valsartan_0/NNP (l_appos) antagonist_6/NN (l_prep) for_7/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) hypertension_12/NN
D017311_D006973 NONE amlodipine_31/NN (r_conj) valsartan_27/NN (r_dobj) receive_24/VB (r_advcl) allocated_14/VBN (l_nsubjpass) outpatients_6/NNS (l_prep) with_7/IN (l_pobj) hypertension_11/NN
D017311_D006973 NONE amlodipine_11/NN (l_prep) in_12/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) hypertension_19/NN
C081489_D006973 NONE Valsartan_0/NNP (l_appos) antagonist_6/NN (l_prep) for_7/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) hypertension_12/NN
C081489_D006973 NONE valsartan_27/NN (r_dobj) receive_24/VB (r_advcl) allocated_14/VBN (l_nsubjpass) outpatients_6/NNS (l_prep) with_7/IN (l_pobj) hypertension_11/NN
C081489_D006973 NONE valsartan_4/NN (r_nsubj) is_5/VBZ (l_acomp) effective_9/JJ (l_prep) as_10/IN (l_pobj) amlodipine_11/NN (l_prep) in_12/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) hypertension_19/NN
6203632
D007545_D006984 NONE ISO_8/NN (r_pobj) to_7/IN (r_prep) response_6/NN (r_nsubj) shows_9/VBZ (l_dobj) phase_13/NN (l_amod) hypertrophic_12/JJ
D007545_D006332 CID isoproterenol_2/NN (r_npadvmod) induced_4/VBN (r_amod) hypertrophy_6/NN
D007545_D006332 CID isoproterenol_17/NN (r_pobj) of_16/IN (r_prep) injections_15/NNS (r_pobj) following_12/VBG (r_prep) studied_6/VBN (l_nsubjpass) development_1/NN (l_prep) of_2/IN (l_pobj) hypertrophy_4/NN
D007545_D006332 CID ISO_19/NN (r_appos) injections_15/NNS (r_pobj) following_12/VBG (r_prep) studied_6/VBN (l_nsubjpass) development_1/NN (l_prep) of_2/IN (l_pobj) hypertrophy_4/NN
17366349
C092292_D012559 NONE ziprasidone_34/NNP (r_pobj) of_31/IN (r_prep) dose_30/NN (r_pobj) with_25/IN (r_prep) treatment_24/NN (r_pobj) of_23/IN (r_prep) days_22/NNS (r_pobj) after_20/IN (r_prep) developed_14/VBD (r_relcl) schizophrenia_12/NN
C092292_D009459 CID ziprasidone_5/NN (r_pobj) by_4/IN (r_prep) induced_3/VBN (l_nsubj) syndrome_2/NN
C092292_D009459 CID ziprasidone_16/NN (r_pobj) of_15/IN (r_prep) use_14/NN (r_pobj) with_12/IN (r_prep) associated_11/VBN (r_acl) syndrome_7/NN
C092292_D009459 CID ziprasidone_16/NN (r_pobj) of_15/IN (r_prep) use_14/NN (r_pobj) with_12/IN (r_prep) associated_11/VBN (r_acl) syndrome_7/NN (l_appos) NMS_9/NNP
C092292_D009459 CID ziprasidone_14/NN (r_pobj) like_13/IN (r_prep) drugs_12/NNS (l_nmod) NMS_8/NNP
C092292_D009459 CID ziprasidone_34/NNP (r_pobj) of_31/IN (r_prep) dose_30/NN (r_pobj) with_25/IN (r_prep) treatment_24/NN (r_pobj) of_23/IN (r_prep) days_22/NNS (r_pobj) after_20/IN (r_prep) developed_14/VBD (l_dobj) signs_15/NNS (l_prep) of_18/IN (l_pobj) NMS_19/NNP
C092292_D009459 CID ziprasidone_3/NNP (r_xcomp) due_1/IN (r_amod) NMS_0/NNP
15867025
D006514_D006509 CID antigen_42/NN (r_npadvmod) positive_44/JJ (r_amod) mothers_45/NNS (r_pobj) to_38/IN (r_prep) born_37/VBN (r_relcl) infants_34/NNS (r_pobj) to_33/IN (r_prep) administration_27/NN (r_conj) dose_22/NN (r_conj) screening_8/NN (l_prep) for_9/IN (l_pobj) B_11/NNP
D006514_D006509 CID antigen_42/NN (r_npadvmod) positive_44/JJ (r_amod) mothers_45/NNS (r_pobj) to_38/IN (r_prep) born_37/VBN (r_relcl) infants_34/NNS (r_pobj) to_33/IN (r_prep) administration_27/NN (r_conj) dose_22/NN (l_nsubj) administration_15/NN (l_prep) of_16/IN (l_pobj) birth_21/NN (l_compound) vaccine_20/NN (l_compound) B_19/NNP
D006514_D006509 CID antigen_42/NN (r_npadvmod) positive_44/JJ (r_amod) mothers_45/NNS (r_pobj) to_38/IN (r_prep) born_37/VBN (r_relcl) infants_34/NNS (r_pobj) to_33/IN (r_prep) administration_27/NN (l_prep) of_28/IN (l_pobj) globulin_32/NN (l_compound) B_30/NNP
D006514_D006509 CID antigen_9/NN (r_npadvmod) positive_11/JJ (r_amod) mothers_12/NNS (r_pobj) to_5/IN (r_prep) born_4/VBN (r_relcl) infants_1/NNS (r_nsubj) received_14/VBD (l_dobj) globulin_18/NN (l_compound) B_16/NN
D006514_D012409 NONE antigen_42/NN (r_npadvmod) positive_44/JJ (r_amod) mothers_45/NNS (r_pobj) to_38/IN (r_prep) born_37/VBN (r_relcl) infants_34/NNS (r_pobj) to_33/IN (r_prep) administration_27/NN (r_conj) dose_22/NN (r_conj) screening_8/NN (l_prep) for_9/IN (l_pobj) B_11/NNP (l_conj) rubella_13/NN
D006514_D012409 NONE antigen_42/NN (r_npadvmod) positive_44/JJ (r_amod) mothers_45/NNS (l_conj) immunity_48/NN (l_compound) rubella_47/NN
D006514_D012409 NONE antigen_42/NN (r_npadvmod) positive_44/JJ (r_amod) mothers_45/NNS (l_conj) immunity_48/NN (l_conj) administration_51/NN (l_prep) of_52/IN (l_pobj) vaccine_58/NN (l_compound) rubella_57/NN
D006514_D012409 NONE antigen_42/NN (r_npadvmod) positive_44/JJ (r_amod) mothers_45/NNS (r_pobj) to_38/IN (r_prep) born_37/VBN (l_prep) to_59/TO (l_pobj) women_62/NNS (l_compound) rubella_60/VB
6436733
D014635_D006970 CID VPA_35/NNP (r_compound) levels_37/NNS (r_nsubj) were_38/VBD (r_advcl) was_4/VBD (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_relcl) complained_14/VBD (l_prep) of_15/IN (l_pobj) drowsiness_16/NN
D014635_D004827 NONE acid_1/NN (r_nsubjpass) given_6/VBN (l_dative) to_7/IN (l_pobj) patients_10/NNS (l_amod) epileptic_9/JJ
D014635_D004827 NONE VPA_3/NNP (r_appos) acid_1/NN (r_nsubjpass) given_6/VBN (l_dative) to_7/IN (l_pobj) patients_10/NNS (l_amod) epileptic_9/JJ
D000641_D006970 CID Ammonia_0/NN (r_nsubj) was_4/VBD (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_relcl) complained_14/VBD (l_prep) of_15/IN (l_pobj) drowsiness_16/NN
D000641_D006970 CID NH3_2/NNP (r_appos) Ammonia_0/NN (r_nsubj) was_4/VBD (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_relcl) complained_14/VBD (l_prep) of_15/IN (l_pobj) drowsiness_16/NN
9041081
D000305_D009798 CID corticosteroid_25/NN (r_compound) therapy_26/NN (r_nsubjpass) discontinued_28/VBN (r_advcl) resolved_23/VBD (r_relcl) IOP_20/NNP (r_appos) pressure_18/NN
D013256_D009798 NONE steroid_13/NN (r_npadvmod) induced_15/VBN (r_amod) pressure_18/NN
D013256_D009798 NONE steroid_2/NN (r_npadvmod) induced_4/VBN (r_amod) rise_6/NN
8475949
D010419_D016171 CID isethionate_1/NN (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) tachyarrhythmias_7/NNS (l_prep) including_9/VBG (l_pobj) pointes_12/FW
D010419_D016171 CID Pentamidine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) torsade_3/NN (r_nmod) pointes_5/FW
D010419_D016171 CID pentamidine_13/NN (r_pobj) with_12/IN (r_prep) treatment_11/NN (r_pobj) of_10/IN (r_prep) days_9/NNS (r_pobj) of_7/IN (r_prep) average_6/NN (r_pobj) after_4/IN (r_prep) occurred_3/VBD (l_nsubj) pointes_2/NNS
D010419_D016171 CID pentamidine_14/NN (r_pobj) of_13/IN (r_prep) discontinuation_12/NN (r_pobj) without_11/IN (r_prep) recognized_7/VBN (r_advcl) treated_5/VBN (l_nsubjpass) pointes_2/FW
D008274_D008133 NONE magnesium_8/NN (r_compound) supplementation_9/NN (r_nsubjpass) advocated_11/VBN (l_advcl) observed_5/VBN (l_nsubjpass) prolongation_3/NN
D010419_D017180 NONE pentamidine_3/NN (l_conj) tachycardia_7/NN
D010419_D017180 NONE isethionate_1/NN (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) tachyarrhythmias_7/NNS
D010419_C537153 NONE Pentamidine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) torsade_3/NN (r_nmod) pointes_5/FW (r_nsubjpass) related_8/VBN (l_prep) to_9/IN (l_pobj) levels_12/NNS (l_conj) hypomagnesemia_14/NN
D008274_D016171 NONE magnesium_11/NN (r_compound) levels_12/NNS (r_pobj) to_9/IN (r_prep) related_8/VBN (l_nsubjpass) pointes_5/FW
D008274_C537153 NONE magnesium_11/NN (r_compound) levels_12/NNS (l_conj) hypomagnesemia_14/NN
1423339
D011433_D003704 NONE propranolol_14/JJ (r_amod) toxicity_15/NN (r_pobj) of_13/IN (r_prep) result_12/NN (r_pobj) as_10/IN (r_prep) developed_3/VBD (l_dobj) dementia_9/NN
D011433_D000647 CID propranolol_4/JJ (r_amod) toxicity_5/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) syndrome_1/NN
D011433_D064420 NONE propranolol_4/JJ (r_amod) toxicity_5/NN
D011433_D064420 NONE propranolol_14/JJ (r_amod) toxicity_15/NN
D011433_D000544 NONE propranolol_14/JJ (r_amod) toxicity_15/NN (r_pobj) of_13/IN (r_prep) result_12/NN (r_pobj) as_10/IN (r_prep) developed_3/VBD (l_dobj) dementia_9/NN (l_amod) like_7/JJ (l_npadvmod) Alzheimer_5/NNP
8480959
D003401_D009135 NONE creatine_7/NN (r_compound) kinase_8/NN (r_compound) elevations_9/NNS (r_pobj) with_6/IN (r_prep) symptoms_5/NNS (r_pobj) as_3/IN (r_prep) defined_2/VBN (r_acl) Myopathy_0/NNP
D008148_D006937 NONE lovastatin_4/NN (r_pobj) of_3/IN (r_prep) Efficacy_0/NN (l_prep) in_5/IN (l_pobj) women_7/NNS (l_prep) with_8/IN (l_pobj) hypercholesterolemia_10/NN
D008148_D006937 NONE lovastatin_7/NN (r_pobj) of_6/IN (r_prep) efficacy_3/NN (r_dobj) evaluate_1/VB (l_prep) with_10/IN (l_pobj) hypercholesterolemia_12/NN
D008148_D006937 NONE Lovastatin_0/NNP (r_nsubj) is_1/VBZ (l_conj) tolerated_7/VBN (l_prep) as_8/IN (l_pobj) therapy_9/NN (l_prep) for_10/IN (l_pobj) hypercholesterolemia_12/NN
D008148_D009135 CID lovastatin_31/NN (r_pobj) of_30/IN (r_prep) dose_29/NN (r_pobj) with_24/IN (r_prep) associated_23/VBN (r_conj) was_20/VBD (l_nsubj) Myopathy_0/NNP
17786501
D004221_D000437 NONE disulfiram_15/NN (r_pobj) of_14/IN (r_prep) use_13/NN (l_prep) for_16/IN (l_pobj) management_19/NN (l_compound) dependence_18/NN
D004221_D000437 NONE disulfiram_4/NN (r_dobj) taking_3/VBG (l_prep) for_5/IN (l_pobj) dependence_7/NN
D004221_D009901 NONE Disulfiram_0/NNP (r_npadvmod) induced_2/VBN (r_amod) optic_4/JJ (l_conj) neuropathy_7/NN
D004221_D009901 NONE disulfiram_15/NN (r_pobj) of_14/IN (r_prep) use_13/NN (r_pobj) after_11/IN (r_prep) report_3/VB (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) optic_7/JJ (l_conj) neuropathy_10/NN
D004221_D010523 NONE Disulfiram_0/NNP (r_npadvmod) induced_2/VBN (r_amod) optic_4/JJ (l_conj) neuropathy_7/NN
D004221_D010523 NONE disulfiram_15/NN (r_pobj) of_14/IN (r_prep) use_13/NN (r_pobj) after_11/IN (r_prep) report_3/VB (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) optic_7/JJ (l_conj) neuropathy_10/NN
11208990
D004317_D007674 NONE ADR_7/NNP (r_npadvmod) induced_9/VBN (r_amod) nephropathy_10/NN
D004317_D007674 NONE ADR_8/NNP (r_compound) nephropathy_10/NN
D004317_D007674 NONE ADR_13/NNP (r_compound) nephropathy_15/NN
D004317_D007674 NONE ADR_4/NNP (r_compound) nephropathy_6/NN
D010656_D007674 NONE phenylephrine_3/NN (r_nmod) responses_7/NNS (r_pobj) In_0/IN (r_prep) were_8/VBD (l_acomp) impaired_10/VBN (l_prep) in_11/IN (l_pobj) group_16/NN (l_compound) nephropathy_15/NN
D004317_D009404 CID adriamycin_25/NNS (r_pobj) of_24/IN (r_prep) injection_23/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) model_15/NN (l_prep) of_16/IN (l_pobj) syndrome_18/NN
D004317_D009404 CID ADR_27/NNP (r_appos) adriamycin_25/NNS (r_pobj) of_24/IN (r_prep) injection_23/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) model_15/NN (l_prep) of_16/IN (l_pobj) syndrome_18/NN
D004317_D009395 NONE ADR_9/NNP (r_pobj) with_8/IN (r_prep) treated_7/VBN (r_acl) rats_6/NNS (r_pobj) of_5/IN (r_prep) kidneys_4/NNS (r_pobj) of_2/IN (r_prep) examination_1/NN (r_nsubj) revealed_10/VBD (l_dobj) areas_12/NNS (l_prep) of_13/IN (l_pobj) proliferation_15/NN (l_conj) inflammation_19/NN
D009569_D009404 NONE NO_6/DT (r_intj) of_5/IN (l_pobj) association_9/NN (l_prep) with_10/IN (l_pobj) apoptosis_11/NN (l_prep) in_12/IN (l_pobj) model_15/NN (l_prep) of_16/IN (l_pobj) syndrome_18/NN
D004317_C537346 NONE ADR_9/NNP (r_pobj) with_8/IN (r_prep) treated_7/VBN (r_acl) rats_6/NNS (r_pobj) of_5/IN (r_prep) kidneys_4/NNS (r_pobj) of_2/IN (r_prep) examination_1/NN (r_nsubj) revealed_10/VBD (l_dobj) areas_12/NNS (l_prep) of_13/IN (l_pobj) proliferation_15/NN
D000109_D007674 NONE acetylcholine_5/NN (r_npadvmod) related_6/VBN (r_conj) phenylephrine_3/NN (r_nmod) responses_7/NNS (r_pobj) In_0/IN (r_prep) were_8/VBD (l_acomp) impaired_10/VBN (l_prep) in_11/IN (l_pobj) group_16/NN (l_compound) nephropathy_15/NN
D009569_D009401 NONE NO_5/UH (r_intj) between_4/IN (r_prep) interactions_3/NNS (r_nsubj) are_8/VBP (l_prep) in_10/IN (l_pobj) pathogenesis_12/NN (l_prep) of_13/IN (l_pobj) nephrosis_18/NN
D009569_D007674 NONE oxide_3/NN (r_compound) production_4/NN (r_pobj) of_1/IN (r_prep) Association_0/NN (l_conj) apoptosis_6/NN (l_prep) in_7/IN (l_pobj) model_9/NN (l_prep) of_10/IN (l_pobj) nephropathy_12/NN
D004317_D009401 NONE ADR_15/NNP (r_npadvmod) induced_17/VBN (r_amod) nephrosis_18/NN
D009573_D007674 NONE nitrite_1/NN (r_compound) levels_2/NNS (r_nsubjpass) increased_5/VBN (l_prep) in_6/IN (l_pobj) group_11/NN (l_compound) nephropathy_10/NN
9514561
D002211_D010146 CID capsaicin_5/NN (r_pobj) by_4/IN (r_agent) elicited_3/VBN (r_acl) pain_2/NN
D002211_D010146 CID capsaicin_4/NN (r_pobj) of_3/IN (r_prep) amount_2/NN (r_nsubjpass) administered_6/VBN (l_advcl) evoke_13/VB (l_dobj) sensation_17/NN (l_amod) painful_16/JJ
7282516
D004317_D009202 CID doxorubicin_9/NN (r_compound) cardiomyopathy_10/NN
D004317_D009202 CID doxorubicin_10/NN (l_nsubj) CM_3/NNP (l_amod) cardiomyopathy_1/NN
D004317_D009202 CID doxorubicin_10/NN (l_nsubj) CM_3/NNP
D004317_D009202 CID DXR_12/NN (r_appos) doxorubicin_10/NN (l_nsubj) CM_3/NNP (l_amod) cardiomyopathy_1/NN
D004317_D009202 CID DXR_12/NN (r_appos) doxorubicin_10/NN (l_nsubj) CM_3/NNP
D004317_D009202 CID Adriamycin_1/NNP (r_nsubj) provides_3/VBZ (l_dobj) opportunity_6/NN (l_acl) analyze_8/VB (l_dobj) relationships_16/NNS (l_prep) during_17/IN (l_pobj) development_18/NN (l_prep) of_19/IN (l_pobj) disease_21/NN
D004317_D009202 CID DXR_1/NNP (r_compound) CM_3/NNP
D004317_D009202 CID DXR_1/NNP (r_compound) CM_3/NNP (r_nmod) damage_5/NN
D004317_D009202 CID DXR_15/NNP (r_compound) dose_16/NN (r_appos) insult_13/NN (r_pobj) of_11/IN (r_prep) degree_10/NN (r_pobj) to_8/IN (r_prep) proportional_7/JJ (r_acomp) is_6/VBZ (l_prep) In_0/IN (l_pobj) damage_5/NN (l_nmod) CM_3/NNP
D004317_D009202 CID DXR_15/NNP (r_compound) dose_16/NN (r_appos) insult_13/NN (r_pobj) of_11/IN (r_prep) degree_10/NN (r_pobj) to_8/IN (r_prep) proportional_7/JJ (r_acomp) is_6/VBZ (l_prep) In_0/IN (l_pobj) damage_5/NN
17702969
D005473_D006976 CID fluoxetine_3/NN (r_advmod) induces_4/VBZ (l_dobj) hypertension_7/NN
D005473_D006976 CID fluoxetine_4/NN (r_amod) exposure_5/NN (r_nsubj) increases_7/VBZ (l_dobj) prevalence_9/NN (l_prep) of_10/IN (l_pobj) syndrome_14/NN
D005473_D006976 CID fluoxetine_20/NN (r_amod) effect_21/NN (r_appos) evidence_14/NN (l_prep) of_15/IN (l_pobj) hypertension_18/NN
D005473_D006976 CID fluoxetine_5/NN (r_amod) exposure_6/NN (r_nsubj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) hypertension_11/NN
D005473_D006976 CID fluoxetine_6/NN (r_amod) exposure_7/NN (r_nsubj) induces_10/VBZ (l_dobj) hypertension_12/NN
D005473_D005315 CID fluoxetine_3/NN (r_advmod) induces_4/VBZ (l_dobj) hypertension_7/NN
D005473_D005315 CID fluoxetine_5/NN (r_amod) exposure_6/NN (r_nsubj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) hypertension_11/NN
19319147
C025667_D002543 NONE PCC_5/NNP (r_nsubj) be_7/VB (l_attr) treatment_11/NN (l_prep) for_12/IN (l_pobj) ICH_15/NNP
D014859_D006470 NONE warfarin_12/RB (r_npadvmod) associated_14/VBN (r_amod) hemorrhage_16/NN (r_pobj) of_11/IN (r_prep) model_10/NN (r_pobj) in_7/IN (r_prep) reduces_4/VBZ (l_dobj) volume_6/NN (l_compound) hemorrhage_5/NN
D014859_D002543 CID warfarin_12/RB (r_npadvmod) associated_14/VBN (r_amod) hemorrhage_16/NN
D014859_D002543 CID Warfarin_0/NNP (r_npadvmod) associated_2/VBN (r_amod) hemorrhage_4/NN
D014859_D002543 CID Warfarin_0/NNP (r_npadvmod) associated_2/VBN (r_amod) hemorrhage_4/NN (l_appos) ICH_8/NNP
D014859_D020521 NONE Warfarin_0/NNP (r_npadvmod) associated_2/VBN (r_amod) hemorrhage_4/NN (r_nsubj) is_10/VBZ (l_attr) type_13/NN (l_prep) of_14/IN (l_pobj) stroke_15/NN
11704023
D013999_D009798 NONE timolol_56/NN (r_compound) solution_57/NN (r_conj) crossed_32/VBN (r_conj) randomized_30/VBN (l_nsubjpass) patients_4/NNS (l_prep) with_5/IN (l_pobj) glaucoma_10/NN (l_conj) hypertension_13/NN
D013999_D009798 NONE timolol_68/NN (r_compound) gellan_69/NN (r_conj) solution_57/NN (r_conj) crossed_32/VBN (r_conj) randomized_30/VBN (l_nsubjpass) patients_4/NNS (l_prep) with_5/IN (l_pobj) glaucoma_10/NN (l_conj) hypertension_13/NN
D013999_D005902 NONE timolol_56/NN (r_compound) solution_57/NN (r_conj) crossed_32/VBN (r_conj) randomized_30/VBN (l_nsubjpass) patients_4/NNS (l_prep) with_5/IN (l_pobj) glaucoma_10/NN
D013999_D005902 NONE timolol_68/NN (r_compound) gellan_69/NN (r_conj) solution_57/NN (r_conj) crossed_32/VBN (r_conj) randomized_30/VBN (l_nsubjpass) patients_4/NNS (l_prep) with_5/IN (l_pobj) glaucoma_10/NN
D013999_D005901 NONE timolol_6/NN (l_prep) on_9/IN (l_pobj) response_14/NN (l_prep) in_15/IN (l_pobj) patients_16/NNS (l_prep) on_17/IN (l_pobj) treatment_18/NN (l_prep) for_19/IN (l_pobj) glaucoma_20/NN
D013999_D005901 NONE timolol_11/NN (l_conj) suspension_21/NN (l_relcl) forms_23/VBZ (l_prep) on_26/IN (l_pobj) application_27/NN (l_prep) on_35/IN (l_pobj) rate_39/NN (l_prep) in_40/IN (l_pobj) patients_41/NNS (l_acl) treated_44/VBN (l_prep) for_45/IN (l_pobj) glaucoma_46/NN
D013999_D005901 NONE timolol_13/NN (r_compound) solution_14/NN (r_appos) timolol_11/NN (l_conj) suspension_21/NN (l_relcl) forms_23/VBZ (l_prep) on_26/IN (l_pobj) application_27/NN (l_prep) on_35/IN (l_pobj) rate_39/NN (l_prep) in_40/IN (l_pobj) patients_41/NNS (l_acl) treated_44/VBN (l_prep) for_45/IN (l_pobj) glaucoma_46/NN
D013999_D005901 NONE timolol_20/NN (r_compound) suspension_21/NN (l_relcl) forms_23/VBZ (l_prep) on_26/IN (l_pobj) application_27/NN (l_prep) on_35/IN (l_pobj) rate_39/NN (l_prep) in_40/IN (l_pobj) patients_41/NNS (l_acl) treated_44/VBN (l_prep) for_45/IN (l_pobj) glaucoma_46/NN
D013999_D005901 NONE timolol_32/NN (r_compound) gellan_33/NN (r_appos) conjunctiva_30/NN (r_pobj) to_28/IN (r_prep) application_27/NN (l_prep) on_35/IN (l_pobj) rate_39/NN (l_prep) in_40/IN (l_pobj) patients_41/NNS (l_acl) treated_44/VBN (l_prep) for_45/IN (l_pobj) glaucoma_46/NN
8045270
C061282_D002375 CID 21680_29/CD (r_nummod) CGS_28/NNP (r_appos) agonist_26/NN (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) responses_16/NNS (l_amod) cataleptic_15/JJ
C081198_D002375 NONE KF17837_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) ameliorated_13/VBD (l_dobj) responses_16/NNS (l_amod) cataleptic_15/JJ
C081198_D002375 NONE KF17837_0/NN (r_nsubj) reduced_2/VBD (l_dobj) catalepsy_4/NN
C081198_D010302 NONE KF17837_2/NN (r_nsubj) be_4/VB (l_attr) drug_7/NN (l_prep) in_8/IN (l_pobj) treatment_10/NN (l_prep) of_11/IN (l_pobj) parkinsonism_12/NN
D006220_D002375 CID haloperidol_7/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) catalepsy_4/NN
D012110_D002375 CID reserpine_15/NN (r_pobj) by_14/IN (r_conj) by_6/IN (r_agent) induced_5/VBN (r_acl) catalepsy_4/NN
D000241_D002375 NONE adenosine_23/NN (r_amod) agonist_26/NN (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) responses_16/NNS (l_amod) cataleptic_15/JJ
8305357
D003630_D000163 NONE daunorubicin_18/NN (r_pobj) of_16/IN (r_prep) safety_15/NN (r_conj) efficacy_13/NN (l_prep) in_22/IN (l_pobj) treatment_24/NN (l_prep) of_25/IN (l_pobj) AIDS_26/NNP
D003630_D012514 NONE daunorubicin_1/NN (l_dobj) sarcoma_6/NN
D003630_D012514 NONE daunorubicin_18/NN (r_pobj) of_16/IN (r_prep) safety_15/NN (r_conj) efficacy_13/NN (r_dobj) assess_11/VB (r_relcl) trial_9/NN (r_dobj) report_1/VBP (l_ccomp) related_27/VBD (l_dobj) sarcoma_30/NN
D003630_D012514 NONE daunorubicin_7/NN (r_nsubj) was_8/VBD (l_attr) agent_14/NN (l_prep) in_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) sarcoma_21/NN
15893386
D013390_D014313 CID Succinylcholine_0/NN (r_npadvmod) induced_2/VBN (r_amod) rigidity_5/NN
D013390_D014313 CID succinylcholine_17/NN (r_nmod) administration_21/NN (r_pobj) after_16/IN (r_prep) describe_3/VBP (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) rigidity_10/NN
D013390_D014313 CID succinylcholine_17/NN (r_nmod) administration_21/NN (r_pobj) after_16/IN (r_prep) describe_3/VBP (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) rigidity_10/NN (l_appos) jaw_12/NN (l_prep) of_13/IN (l_pobj) steel_14/NN
D013390_D014313 CID Sch_19/NNP (r_nmod) administration_21/NN (r_pobj) after_16/IN (r_prep) describe_3/VBP (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) rigidity_10/NN
D013390_D014313 CID Sch_19/NNP (r_nmod) administration_21/NN (r_pobj) after_16/IN (r_prep) describe_3/VBP (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) rigidity_10/NN (l_appos) jaw_12/NN (l_prep) of_13/IN (l_pobj) steel_14/NN
D015742_D008305 NONE propofol_5/JJ (r_amod) infusion_6/NN (r_pobj) with_4/IN (r_prep) continued_2/VBN (l_advcl) were_10/VBD (l_acomp) available_11/JJ (l_xcomp) detect_13/VB (l_conj) treat_15/VB (l_dobj) hyperthermia_17/NN
10840460
D003520_D059265 NONE Cyclophosphamide_0/NNP (r_npadvmod) induced_2/VBN (r_amod) cystitis_3/NN (l_appos) approach_12/NN (l_prep) to_13/IN (l_pobj) model_16/NN (l_prep) of_17/IN (l_pobj) pain_19/NN
D003520_D059265 NONE CP_10/NNP (r_npadvmod) induced_12/VBN (r_amod) cystitis_13/NN (r_pobj) of_9/IN (r_prep) model_8/NN (r_nsubj) be_15/VB (l_attr) model_20/NN (l_prep) of_21/IN (l_pobj) pain_24/NN
D009020_D001523 NONE Morphine_0/NNP (r_nsubj) reversed_4/VBD (l_dobj) disorders_7/NNS
D003520_D003556 CID Cyclophosphamide_0/NNP (r_npadvmod) induced_2/VBN (r_amod) cystitis_3/NN
D003520_D003556 CID Cyclophosphamide_0/NNP (r_nsubjpass) used_25/VBN (l_xcomp) induce_27/VB (l_dobj) cystitis_28/NN
D003520_D003556 CID CP_2/NNP (r_appos) Cyclophosphamide_0/NNP (r_nsubjpass) used_25/VBN (l_xcomp) induce_27/VB (l_dobj) cystitis_28/NN
D003520_D003556 CID CP_10/NNP (r_npadvmod) induced_12/VBN (r_amod) cystitis_13/NN
D009020_D004487 NONE morphine_6/NN (r_pobj) of_5/IN (r_prep) administration_4/NN (l_appos) modifications_9/NNS (l_prep) as_16/IN (l_pobj) edema_21/NN
D003520_D010146 CID CP_10/NNP (r_npadvmod) induced_12/VBN (r_amod) cystitis_13/NN (r_pobj) of_9/IN (r_prep) model_8/NN (r_nsubj) be_15/VB (l_advcl) allowing_26/VBG (l_dobj) understanding_29/NN (l_prep) of_30/IN (l_pobj) syndromes_33/NNS
D000171_D003556 NONE acrolein_22/NN (r_pobj) through_17/IN (r_prep) produce_10/VB (r_xcomp) known_8/VBN (r_acl) agent_7/NN (r_appos) Cyclophosphamide_0/NNP (r_nsubjpass) used_25/VBN (l_xcomp) induce_27/VB (l_dobj) cystitis_28/NN
12481039
D012964_D012640 NONE sodium_1/NN (r_compound) channel_2/NN (r_compound) density_3/NN (l_appos) dependence_7/NN (l_conj) susceptibility_13/NN (l_prep) to_14/IN (l_pobj) seizures_15/NNS
D012964_D012640 NONE sodium_19/NN (r_compound) channel_20/NN (r_compound) 2-subunits_22/NNS (r_dobj) lacking_18/VBG (r_pcomp) in_16/IN (r_prep) seizures_15/NNS
D010862_D012640 CID pilocarpine_17/NN (r_npadvmod) induced_19/VBN (r_amod) seizures_20/NNS (r_pobj) for_16/IN (r_prep) threshold_15/NN (r_conj) latency_13/NN (r_pobj) by_11/IN (r_agent) indicated_10/VBN (r_advcl) displayed_3/VBD (l_dobj) susceptibility_5/NN (l_prep) to_6/IN (l_pobj) seizures_7/NNS
D010862_D012640 CID pilocarpine_17/NN (r_npadvmod) induced_19/VBN (r_amod) seizures_20/NNS
3973521
2528969
16584858
C013592_D017202 NONE mangiferin_4/NN (r_pobj) of_3/IN (r_prep) role_2/NN (r_nsubjpass) analyzed_6/VBN (l_agent) by_7/IN (l_pobj) test_14/NN (l_acl) used_15/VBN (l_prep) for_16/IN (l_pobj) assay_20/NN (l_prep) of_21/IN (l_pobj) myocardium_24/NN
C013592_D006331 NONE mangiferin_8/NN (r_nsubj) exerts_9/VBZ (l_prep) due_18/IN (l_pcomp) to_19/IN (l_pobj) potential_22/NN (l_relcl) regulated_25/VBD (l_prep) against_30/IN (l_pobj) damage_32/NN
D013481_D009203 NONE superoxide_7/JJ (r_amod) dismutase_8/NN (r_pobj) as_6/IN (r_prep) enzymes_4/NNS (r_dobj) tissue_2/NN (r_nsubjpass) altered_39/VBN (l_prep) in_40/IN (l_pobj) rats_42/NNS (l_compound) MI_41/NNP
D005978_D009203 NONE glutathione_12/NN (r_compound) peroxidase_13/NN (r_conj) catalase_10/NNP (r_conj) dismutase_8/NN (r_pobj) as_6/IN (r_prep) enzymes_4/NNS (r_dobj) tissue_2/NN (r_nsubjpass) altered_39/VBN (l_prep) in_40/IN (l_pobj) rats_42/NNS (l_compound) MI_41/NNP
D005978_D009203 NONE glutathione_15/NN (r_compound) transferase_16/NN (r_conj) peroxidase_13/NN (r_conj) catalase_10/NNP (r_conj) dismutase_8/NN (r_pobj) as_6/IN (r_prep) enzymes_4/NNS (r_dobj) tissue_2/NN (r_nsubjpass) altered_39/VBN (l_prep) in_40/IN (l_pobj) rats_42/NNS (l_compound) MI_41/NNP
D005978_D009203 NONE glutathione_18/NN (r_compound) reductase_19/NN (r_compound) activities_20/NNS (r_conj) transferase_16/NN (r_conj) peroxidase_13/NN (r_conj) catalase_10/NNP (r_conj) dismutase_8/NN (r_pobj) as_6/IN (r_prep) enzymes_4/NNS (r_dobj) tissue_2/NN (r_nsubjpass) altered_39/VBN (l_prep) in_40/IN (l_pobj) rats_42/NNS (l_compound) MI_41/NNP
D005978_D009203 NONE glutathione_36/NN (r_conj) E_34/NN (r_conj) C_31/NN (r_conj) cerruloplasmin_28/NN (r_pobj) as_27/IN (r_prep) antioxidants_25/NNS (r_appos) dismutase_8/NN (r_pobj) as_6/IN (r_prep) enzymes_4/NNS (r_dobj) tissue_2/NN (r_nsubjpass) altered_39/VBN (l_prep) in_40/IN (l_pobj) rats_42/NNS (l_compound) MI_41/NNP
D007545_D006331 NONE ISPH_14/NNP (r_npadvmod) induced_16/VBN (r_amod) MI_17/NNP (r_pobj) against_13/IN (r_prep) effect_12/NN (r_dobj) exerts_9/VBZ (l_prep) due_18/IN (l_pcomp) to_19/IN (l_pobj) potential_22/NN (l_relcl) regulated_25/VBD (l_prep) against_30/IN (l_pobj) damage_32/NN
D014527_D009202 NONE acid_53/NN (r_compound) level_54/NN (r_dobj) increased_51/VBN (l_ccomp) caused_20/VBD (l_dobj) damage_22/NN
C013592_D009203 NONE mangiferin_2/NN (l_prep) on_3/IN (l_pobj) alterations_5/NNS (l_prep) in_9/IN (l_pobj) infarction_14/NN
C013592_D009203 NONE mangiferin_3/NN (r_pobj) with_2/IN (r_prep) pretreatment_1/NN (r_pobj) Upon_0/IN (r_prep) suspended_9/VBN (l_prep) given_17/VBN (l_prep) to_22/IN (l_pobj) rats_24/NNS (l_compound) MI_23/NNP
C013592_D009203 NONE mangiferin_16/JJ (r_compound) administration_17/NN (r_pobj) upon_15/IN (r_prep) rose_13/VBD (l_prep) compared_19/VBN (l_prep) to_20/IN (l_pobj) rats_25/NNS (l_compound) MI_24/NNP
C013592_D009203 NONE mangiferin_8/NN (r_nsubj) exerts_9/VBZ (l_dobj) effect_12/NN (l_prep) against_13/IN (l_pobj) MI_17/NNP
D019344_D009202 NONE lactate_36/NN (r_compound) dehydrogenase_37/NN (r_pobj) of_34/IN (r_prep) activity_33/NN (r_pobj) by_30/IN (r_agent) determined_29/VBN (r_relcl) heart_25/NN (r_pobj) in_23/IN (r_prep) damage_22/NN
D007501_D009202 NONE iron_58/NN (r_nmod) capacity_60/NN (r_conj) level_54/NN (r_dobj) increased_51/VBN (l_ccomp) caused_20/VBD (l_dobj) damage_22/NN
D003401_D009202 NONE creatine_42/NN (r_conj) caused_20/VBD (l_dobj) damage_22/NN
D007545_D009202 NONE ISPH_3/NNP (r_pobj) of_2/IN (r_prep) injection_1/NN (r_nsubj) caused_20/VBD (l_dobj) damage_22/NN
D001205_D009203 NONE C_31/NN (r_conj) cerruloplasmin_28/NN (r_pobj) as_27/IN (r_prep) antioxidants_25/NNS (r_appos) dismutase_8/NN (r_pobj) as_6/IN (r_prep) enzymes_4/NNS (r_dobj) tissue_2/NN (r_nsubjpass) altered_39/VBN (l_prep) in_40/IN (l_pobj) rats_42/NNS (l_compound) MI_41/NNP
C009591_D017202 NONE chloride_10/NN (r_nmod) test_14/NN (l_acl) used_15/VBN (l_prep) for_16/IN (l_pobj) assay_20/NN (l_prep) of_21/IN (l_pobj) myocardium_24/NN
C009591_D017202 NONE TTC_12/NNP (r_nmod) test_14/NN (l_acl) used_15/VBN (l_prep) for_16/IN (l_pobj) assay_20/NN (l_prep) of_21/IN (l_pobj) myocardium_24/NN
D014810_D009203 NONE E_34/NN (r_conj) C_31/NN (r_conj) cerruloplasmin_28/NN (r_pobj) as_27/IN (r_prep) antioxidants_25/NNS (r_appos) dismutase_8/NN (r_pobj) as_6/IN (r_prep) enzymes_4/NNS (r_dobj) tissue_2/NN (r_nsubjpass) altered_39/VBN (l_prep) in_40/IN (l_pobj) rats_42/NNS (l_compound) MI_41/NNP
D007545_D009203 CID isoproterenol_10/NN (r_npadvmod) induced_12/VBN (r_amod) infarction_14/NN
D007545_D009203 CID isoproterenol_5/NN (r_pobj) on_4/IN (r_prep) infarction_9/NN
D007545_D009203 CID isoproterenol_5/NN (r_pobj) on_4/IN (r_prep) infarction_9/NN (l_appos) MI_11/NNP
D007545_D009203 CID ISPH)-induced_7/JJ (r_amod) infarction_9/NN
D007545_D009203 CID ISPH)-induced_7/JJ (r_amod) infarction_9/NN (l_appos) MI_11/NNP
D007545_D009203 CID ISPH_21/NNP (r_npadvmod) induced_23/VBN (r_amod) rats_25/NNS (l_compound) MI_24/NNP
D007545_D009203 CID ISPH_14/NNP (r_npadvmod) induced_16/VBN (r_amod) MI_17/NNP
D004121_D009203 NONE sulphoxide_15/RB (r_pobj) of_13/IN (r_prep) ml_12/NNS (r_pobj) in_10/IN (r_prep) suspended_9/VBN (l_prep) given_17/VBN (l_prep) to_22/IN (l_pobj) rats_24/NNS (l_compound) MI_23/NNP
8106150
D008614_D004409 NONE meperidine_4/RB (r_conj) yohimbine_2/NN (r_nsubj) reduced_5/VBN (l_dobj) movements_9/NNS (l_amod) dyskinetic_8/JJ
D011433_D004409 NONE propranolol_12/NN (r_conj) methysergide_8/NN (r_conj) physostigmine_6/NN (r_conj) clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_dobj) movements_21/NNS (l_amod) dyskinetic_20/JJ
D001418_D020821 NONE Baclofen_0/NNP (r_nsubj) was_1/VBD (l_acomp) useful_3/JJ (l_prep) against_7/IN (l_pobj) form_11/NN (l_amod) dystonic_10/JJ
D016291_D020734 NONE MK-801_15/NNP (r_punct) ,_16/, (r_punct) reduced_18/VBD (l_conj) at_23/IN (l_pobj) cost_25/NN (l_prep) of_26/IN (l_pobj) return_28/NN (l_prep) of_29/IN (l_pobj) symptomatology_31/NN (l_amod) parkinsonian_30/JJ
D011433_D020734 NONE propranolol_12/NN (r_conj) methysergide_8/NN (r_conj) physostigmine_6/NN (r_conj) clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_conj) at_23/IN (l_pobj) cost_25/NN (l_prep) of_26/IN (l_pobj) return_28/NN (l_prep) of_29/IN (l_pobj) symptomatology_31/NN (l_amod) parkinsonian_30/JJ
D004298_D004409 NONE dopamine_10/NN (r_pobj) than_9/IN (r_prep) other_8/JJ (r_amod) neurotransmitters_7/NNS (r_pobj) on_6/IN (r_prep) acting_4/VBG (r_acl) agents_3/NNS (r_pobj) of_2/IN (r_prep) series_1/NN (r_nsubjpass) tested_13/VBN (l_advcl) see_21/VB (l_ccomp) modified_28/VBN (l_nsubjpass) movements_25/NNS (l_amod) dyskinetic_24/JJ
D003000_D020734 NONE clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_conj) at_23/IN (l_pobj) cost_25/NN (l_prep) of_26/IN (l_pobj) return_28/NN (l_prep) of_29/IN (l_pobj) symptomatology_31/NN (l_amod) parkinsonian_30/JJ
D001285_D002819 NONE Atropine_0/NNP (r_nsubj) converted_1/VBD (l_prep) into_5/IN (l_pobj) chorea_6/NN
D015632_D020734 CID MPTP_11/NNP (r_pobj) with_8/IN (r_prep) parkinsonian_7/NN
D008784_D004409 NONE methysergide_8/NN (r_conj) physostigmine_6/NN (r_conj) clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_dobj) movements_21/NNS (l_amod) dyskinetic_20/JJ
D010830_D020734 NONE physostigmine_6/NN (r_conj) clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_conj) at_23/IN (l_pobj) cost_25/NN (l_prep) of_26/IN (l_pobj) return_28/NN (l_prep) of_29/IN (l_pobj) symptomatology_31/NN (l_amod) parkinsonian_30/JJ
D007980_D004409 NONE dopa_7/NN (r_npadvmod) induced_9/VBN (r_amod) dyskinesias_10/NNS
D007980_D004409 NONE DOPA_19/NNP (r_pobj) with_16/IN (r_prep) combination_15/NN (r_pobj) in_14/IN (r_prep) tested_13/VBN (l_advcl) see_21/VB (l_ccomp) modified_28/VBN (l_nsubjpass) movements_25/NNS (l_amod) dyskinetic_24/JJ
D015016_D004409 NONE yohimbine_2/NN (r_nsubj) reduced_5/VBN (l_dobj) movements_9/NNS (l_amod) dyskinetic_8/JJ
D015632_D004409 NONE MPTP_12/NNP (r_npadvmod) treated_14/VBN (r_amod) monkeys_15/NNS (r_pobj) in_11/IN (r_prep) dyskinesias_10/NNS
D008784_D020734 NONE methysergide_8/NN (r_conj) physostigmine_6/NN (r_conj) clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_conj) at_23/IN (l_pobj) cost_25/NN (l_prep) of_26/IN (l_pobj) return_28/NN (l_prep) of_29/IN (l_pobj) symptomatology_31/NN (l_amod) parkinsonian_30/JJ
-1_D004409 NONE 5-MDOT_10/CD (r_conj) methysergide_8/NN (r_conj) physostigmine_6/NN (r_conj) clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_dobj) movements_21/NNS (l_amod) dyskinetic_20/JJ
D010830_D004409 NONE physostigmine_6/NN (r_conj) clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_dobj) movements_21/NNS (l_amod) dyskinetic_20/JJ
D016291_D004409 NONE MK-801_15/NNP (r_punct) ,_16/, (r_punct) reduced_18/VBD (l_dobj) movements_21/NNS (l_amod) dyskinetic_20/JJ
D001418_D004409 NONE Baclofen_0/NNP (r_nsubj) was_1/VBD (l_acomp) useful_3/JJ (l_prep) against_7/IN (l_pobj) form_11/NN (l_prep) of_12/IN (l_pobj) dyskinesia_13/NN
-1_D020734 NONE 5-MDOT_10/CD (r_conj) methysergide_8/NN (r_conj) physostigmine_6/NN (r_conj) clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_conj) at_23/IN (l_pobj) cost_25/NN (l_prep) of_26/IN (l_pobj) return_28/NN (l_prep) of_29/IN (l_pobj) symptomatology_31/NN (l_amod) parkinsonian_30/JJ
D001285_D020821 NONE Atropine_0/NNP (r_nsubj) converted_1/VBD (l_dobj) movements_4/NNS (l_amod) dystonic_3/JJ
D003000_D004409 NONE clonidine_4/NN (r_pobj) including_3/VBG (r_prep) drugs_1/NNS (r_nsubj) reduced_18/VBD (l_dobj) movements_21/NNS (l_amod) dyskinetic_20/JJ
15985056
D003907_D006606 NONE dexamethasone_2/NN (r_appos) Corticosteroids_0/NNS (r_nsubj) been_15/VBN (l_attr) agents_18/NNS (l_acl) mentioned_19/VBD (l_prep) as_25/IN (l_pcomp) associated_27/VBN (l_prep) with_28/IN (l_pobj) development_30/NN (l_prep) of_31/IN (l_pobj) hiccups_32/NNS
D017963_D010612 NONE azithromycin_11/RB (r_advmod) beginning_10/VBG (l_prep) for_12/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) pharyngitis_16/NN
D008874_D006606 NONE midazolam_9/NN (r_appos) benzodiazepines_7/NNS (r_appos) Corticosteroids_0/NNS (r_nsubj) been_15/VBN (l_attr) agents_18/NNS (l_acl) mentioned_19/VBD (l_prep) as_25/IN (l_pcomp) associated_27/VBN (l_prep) with_28/IN (l_pobj) development_30/NN (l_prep) of_31/IN (l_pobj) hiccups_32/NNS
D018942_D006606 NONE macrolide_12/NN (r_amod) antimicrobials_13/NNS (r_pobj) to_11/IN (r_prep) related_10/VBN (r_oprd) reported_9/VBN (l_nsubjpass) cases_1/NNS (l_prep) of_2/IN (l_pobj) hiccups_6/NNS
D018942_D006606 NONE macrolides_36/NNS (r_pobj) with_34/IN (r_prep) reaction_33/NN (l_conj) absence_39/NN (l_prep) of_40/IN (l_pobj) explanation_43/NN (l_prep) for_44/IN (l_pobj) hiccups_45/NNS
D018942_D006606 NONE macrolide_2/NN (r_amod) antimicrobials_3/NNS (r_nsubjpass) reported_6/VBN (l_xcomp) associated_9/VBN (l_prep) with_10/IN (l_pobj) mechanism_14/NN (l_nmod) hiccups_11/NNS
D001569_D006606 NONE benzodiazepines_7/NNS (r_appos) Corticosteroids_0/NNS (r_nsubj) been_15/VBN (l_attr) agents_18/NNS (l_acl) mentioned_19/VBD (l_prep) as_25/IN (l_pcomp) associated_27/VBN (l_prep) with_28/IN (l_pobj) development_30/NN (l_prep) of_31/IN (l_pobj) hiccups_32/NNS
D001418_D006606 CID baclofen_6/NN (r_pobj) with_5/IN (r_prep) therapy_4/NN (r_conj) Discontinuation_0/NN (r_nsubj) resolved_8/VBD (l_dobj) hiccups_9/NNS
D008775_D006606 NONE methylprednisolone_4/NN (r_conj) dexamethasone_2/NN (r_appos) Corticosteroids_0/NNS (r_nsubj) been_15/VBN (l_attr) agents_18/NNS (l_acl) mentioned_19/VBD (l_prep) as_25/IN (l_pcomp) associated_27/VBN (l_prep) with_28/IN (l_pobj) development_30/NN (l_prep) of_31/IN (l_pobj) hiccups_32/NNS
D017963_D006606 CID azithromycin_1/RB (r_advmod) associated_3/VBN (r_amod) hiccups_4/NNS
D017963_D006606 CID azithromycin_9/CD (r_amod) therapy_10/NN (r_pobj) by_8/IN (r_agent) associated_7/VBN (r_acl) hiccups_6/NNS
D017963_D006606 CID azithromycin_11/RB (r_advmod) beginning_10/VBG (r_pcomp) after_9/IN (r_prep) presented_5/VBN (l_prep) with_6/IN (l_pobj) hiccups_8/NNS
D017963_D006606 CID azithromycin_2/NNP (r_pobj) of_1/IN (r_prep) Discontinuation_0/NN (r_nsubj) resolved_8/VBD (l_dobj) hiccups_9/NNS
D017963_D006606 CID azithromycin_9/WP (r_pobj) by_8/IN (r_agent) mediated_7/VBN (r_acl) mechanism_6/NN (r_nsubj) be_11/VB (l_attr) pathogenesis_13/NN (l_prep) of_14/IN (l_pobj) hiccups_15/NNS
3934126
D014640_D007674 NONE vancomycin_20/NNP (r_appos) aminoglycoside_18/NN (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) to_14/IN (r_prep) confined_13/VBN (l_nsubjpass) nephrotoxicity_9/NN
D014640_D013924 CID vancomycin_20/NNP (r_appos) aminoglycoside_18/NN (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) to_14/IN (r_prep) confined_13/VBN (l_ccomp) occurred_1/VBD (l_nsubj) Thrombophlebitis_0/NNP
D014640_D006311 CID vancomycin_20/NNP (r_appos) aminoglycoside_18/NN (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) to_14/IN (r_prep) confined_13/VBN (l_nsubjpass) nephrotoxicity_9/NN (l_conj) ototoxicity_11/NN
D000617_D013924 NONE aminoglycoside_18/NN (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) to_14/IN (r_prep) confined_13/VBN (l_ccomp) occurred_1/VBD (l_nsubj) Thrombophlebitis_0/NNP
D014640_D007239 NONE Vancomycin_0/NNP (r_nsubj) was_1/VBD (l_acomp) curative_2/JJ (l_prep) in_3/IN (l_pobj) %_5/NN (l_prep) of_6/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) infection_11/NN
D014640_D007239 NONE vancomycin_3/NNP (r_nsubj) constitutes_8/VBZ (l_dobj) therapy_12/NN (l_prep) for_13/IN (l_pobj) infections_14/NNS
D000617_D007674 NONE aminoglycoside_18/NN (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) to_14/IN (r_prep) confined_13/VBN (l_nsubjpass) nephrotoxicity_9/NN
D000617_D006311 NONE aminoglycoside_18/NN (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) to_14/IN (r_prep) confined_13/VBN (l_nsubjpass) nephrotoxicity_9/NN (l_conj) ototoxicity_11/NN
18657397
D010406_D004827 NONE penicillin_5/NN (r_npadvmod) induced_7/VBN (r_amod) activity_9/NN
D010406_D004827 NONE Penicillin_0/NNP (r_compound) model_1/NN (r_nsubj) is_2/VBZ (l_attr) model_7/NN (l_prep) for_8/IN (l_pobj) research_10/NN (l_compound) epilepsy_9/NN
D010406_D004827 NONE penicillin_13/NN (r_npadvmod) induced_15/VBN (r_amod) activity_17/NN
D010406_D004827 NONE penicillin_7/NN (r_npadvmod) induced_9/VBN (r_amod) periods_12/NNS (l_compound) activity_11/NN
D010400_D004827 CID potassium_20/NN (r_dobj) injecting_14/VBG (r_pcomp) by_13/IN (r_prep) induced_12/VBN (l_nsubjpass) focus_10/NN (l_amod) epileptic_9/JJ
18239197
D014282_D003221 NONE trihexyphenidyl_19/NN (l_prep) on_20/IN (l_pobj) measures_21/NNS (l_acl) reflecting_22/VBG (l_dobj) sedation_23/NN (l_conj) confusion_25/NN
D014282_D003221 NONE trihexyphenidyl_32/NN (r_npadvmod) induced_34/VBN (r_amod) effects_36/NNS (r_pobj) between_31/IN (r_prep) relationship_30/NN (r_dobj) investigate_28/VB (r_conj) examine_9/VB (l_dobj) relationship_11/NN (l_conj) effects_17/NNS (l_prep) of_18/IN (l_pobj) trihexyphenidyl_19/NN (l_prep) on_20/IN (l_pobj) measures_21/NNS (l_acl) reflecting_22/VBG (l_dobj) sedation_23/NN (l_conj) confusion_25/NN
D014282_D003072 CID trihexyphenidyl_10/JJ (r_pcomp) after_9/IN (r_prep) associated_3/VBN (r_acl) slowing_2/NN
D014282_D003072 CID trihexyphenidyl_5/JJ (r_pobj) of_4/IN (r_prep) dose_3/NN (r_nsubj) resulted_6/VBD (l_prep) in_7/IN (l_pobj) ratings_10/NNS (l_prep) of_11/IN (l_pobj) slowness_13/NN
D014282_D003072 CID trihexyphenidyl_10/JJ (r_pobj) between_7/IN (r_prep) scores_6/NNS (l_prep) on_13/IN (l_pobj) ratings_14/NNS (l_prep) of_15/IN (l_pobj) slowness_17/NN
D014282_D003072 CID trihexyphenidyl_14/JJ (r_amod) challenge_16/NN (r_pobj) after_13/IN (r_prep) slowing_12/NN
10354657
D008094_D001714 NONE lithium_16/NN (r_compound) therapy_18/NN (r_dobj) receiving_15/VBG (l_nsubj) disorder_14/NN
D008094_D006934 NONE lithium_12/NN (r_compound) therapy_13/NN (r_pobj) during_11/IN (r_prep) factor_6/NN (l_prep) for_7/IN (l_pobj) hypothyroidism_8/NN (l_conj) hypercalcemia_10/NN
D008094_D013959 NONE lithium_9/NN (r_compound) therapy_10/NN (r_pobj) of_8/IN (r_prep) duration_7/NN (r_pobj) to_5/IN (r_prep) respect_4/NN (r_pobj) with_3/IN (r_prep) evaluated_2/VBN (l_parataxis) had_25/VBD (l_dobj) relative_30/NN (l_prep) with_31/IN (l_pobj) disease_33/NN
D008094_D013959 NONE lithium_22/NN (r_compound) therapy_23/NN (r_pobj) of_21/IN (r_prep) onset_20/NN (r_pobj) after_19/IN (r_prep) accelerated_12/VBN (l_nsubj) patients_1/NNS (l_acl) having_2/VBG (l_dobj) relatives_6/NNS (l_acl) affected_7/VBN (l_agent) by_8/IN (l_pobj) illness_10/NN
D008094_D013959 NONE lithium_38/NN (r_compound) therapy_39/NN (r_pobj) of_37/IN (r_prep) onset_36/NN (r_pobj) after_35/IN (r_prep) accelerated_12/VBN (l_nsubj) patients_1/NNS (l_acl) having_2/VBG (l_dobj) relatives_6/NNS (l_acl) affected_7/VBN (l_agent) by_8/IN (l_pobj) illness_10/NN
D008094_D013959 NONE lithium_12/NN (r_compound) therapy_13/NN (r_pobj) during_11/IN (r_prep) factor_6/NN (r_attr) is_3/VBZ (l_nsubj) illness_2/NN
D008094_D007037 CID lithium_22/NN (r_compound) therapy_23/NN (r_pobj) of_21/IN (r_prep) onset_20/NN (r_pobj) after_19/IN (r_prep) accelerated_12/VBN (l_dobj) onset_13/NN (l_prep) of_14/IN (l_pobj) hypothyroidism_15/NN
D008094_D007037 CID lithium_38/NN (r_compound) therapy_39/NN (r_pobj) of_37/IN (r_prep) onset_36/NN (r_pobj) after_35/IN (r_prep) accelerated_12/VBN (l_dobj) onset_13/NN (l_prep) of_14/IN (l_pobj) hypothyroidism_15/NN
D008094_D007037 CID lithium_12/NN (r_compound) therapy_13/NN (r_pobj) during_11/IN (r_prep) factor_6/NN (l_prep) for_7/IN (l_pobj) hypothyroidism_8/NN
2557556
D015232_D006930 CID E2-induced_23/VBN (r_amod) hyperalgesia_24/NN
D015124_D006930 CID monophosphate_14/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) hyperalgesia_8/NN
D009020_D006930 NONE Morphine_0/NNP (r_nsubj) alter_6/VB (l_dobj) hyperalgesia_8/NN
12109865
10524660
D009569_D010146 NONE oxide_13/NN (r_nsubjpass) involved_18/VBN (l_prep) in_19/IN (l_pobj) mechanisms_21/NNS (l_compound) pain_20/NN
D009569_D010146 NONE NO_15/NNP (r_appos) oxide_13/NN (r_nsubjpass) involved_18/VBN (l_prep) in_19/IN (l_pobj) mechanisms_21/NNS (l_compound) pain_20/NN
D009569_D010146 NONE NO_5/DT (r_nsubjpass) involved_7/VBN (l_prep) in_8/IN (l_pobj) mechanisms_11/NNS (l_compound) pain_10/NN
D005996_D008881 NONE GTN_14/NNP (r_compound) infusion_15/NN (r_advcl) was_1/VBD (l_acomp) severe_3/JJ (l_prep) in_4/IN (l_pobj) migraineurs_5/NNS
D005996_D008881 NONE GTN_5/NNP (r_npadvmod) induced_7/VBN (r_amod) headache_8/NN (r_nsubj) disappeared_10/VBD (l_advcl) peak_15/JJ (l_prep) in_13/IN (l_pobj) migraineurs_14/NNS
D005996_D020326 CID trinitrate_1/NN (r_nsubj) induces_2/VBZ (l_dobj) attacks_3/NNS (l_prep) without_6/IN (l_pobj) aura_7/NN
D009569_D020326 CID oxide_13/NN (r_nsubjpass) involved_18/VBN (l_prep) in_19/IN (l_pobj) mechanisms_21/NNS (l_prep) without_24/IN (l_pobj) aura_25/NN
D009569_D020326 CID NO_15/NNP (r_appos) oxide_13/NN (r_nsubjpass) involved_18/VBN (l_prep) in_19/IN (l_pobj) mechanisms_21/NNS (l_prep) without_24/IN (l_pobj) aura_25/NN
D009569_D006261 NONE NO_9/DT (r_intj) liberate_8/VB (r_xcomp) shown_6/VBN (r_advcl) help_16/VB (l_dobj) understanding_18/NN (l_prep) of_19/IN (l_pobj) coupling_21/NN (l_prep) between_22/IN (l_pobj) depression_25/NN (l_conj) headache_27/NN
D005996_D020325 NONE trinitrate_1/NN (r_nsubj) induces_2/VBZ (l_dobj) attacks_3/NNS (l_prep) without_6/IN (l_pobj) aura_7/NN (l_prep) in_8/IN (l_pobj) sufferers_9/NNS (l_prep) with_12/IN (l_pobj) aura_13/NN
D005996_D020325 NONE trinitrate_28/NN (r_pobj) of_26/IN (r_prep) infusion_25/NN (r_pobj) to_23/IN (r_prep) response_22/NN (r_dobj) examined_19/VBD (l_prep) In_0/IN (l_pobj) order_1/NN (l_acl) clarify_3/VB (l_ccomp) is_7/VBZ (l_acomp) true_8/JJ (l_prep) for_9/IN (l_pobj) migraine_10/NN (l_prep) with_11/IN (l_pobj) aura_12/NN
D005996_D020325 NONE trinitrate_28/NN (r_pobj) of_26/IN (r_prep) infusion_25/NN (r_pobj) to_23/IN (r_prep) response_22/NN (r_dobj) examined_19/VBD (l_parataxis) min_38/NN (l_prep) in_43/IN (l_pobj) sufferers_45/NNS (l_prep) with_48/IN (l_pobj) aura_49/NN
D005996_D020325 NONE GTN_30/NNP (r_appos) trinitrate_28/NN (r_pobj) of_26/IN (r_prep) infusion_25/NN (r_pobj) to_23/IN (r_prep) response_22/NN (r_dobj) examined_19/VBD (l_prep) In_0/IN (l_pobj) order_1/NN (l_acl) clarify_3/VB (l_ccomp) is_7/VBZ (l_acomp) true_8/JJ (l_prep) for_9/IN (l_pobj) migraine_10/NN (l_prep) with_11/IN (l_pobj) aura_12/NN
D005996_D020325 NONE GTN_30/NNP (r_appos) trinitrate_28/NN (r_pobj) of_26/IN (r_prep) infusion_25/NN (r_pobj) to_23/IN (r_prep) response_22/NN (r_dobj) examined_19/VBD (l_parataxis) min_38/NN (l_prep) in_43/IN (l_pobj) sufferers_45/NNS (l_prep) with_48/IN (l_pobj) aura_49/NN
D005996_D006261 NONE trinitrate_28/NN (r_pobj) of_26/IN (r_prep) infusion_25/NN (r_pobj) to_23/IN (r_prep) response_22/NN (l_compound) headache_21/NN
D005996_D006261 NONE GTN_30/NNP (r_appos) trinitrate_28/NN (r_pobj) of_26/IN (r_prep) infusion_25/NN (r_pobj) to_23/IN (r_prep) response_22/NN (l_compound) headache_21/NN
D005996_D006261 NONE GTN_14/NNP (r_compound) infusion_15/NN (r_advcl) was_1/VBD (l_nsubj) Headache_0/NNP
D005996_D006261 NONE GTN_5/NNP (r_npadvmod) induced_7/VBN (r_amod) headache_8/NN
D005996_D006261 NONE GTN_5/NNP (r_npadvmod) induced_7/VBN (r_amod) headache_8/NN (r_nsubj) disappeared_10/VBD (l_advcl) peak_15/JJ (l_ccomp) occurred_18/VBD (l_nsubj) intensity_17/NN (l_compound) headache_16/NN
D009569_D020325 NONE NO_5/DT (r_nsubjpass) involved_7/VBN (l_prep) in_8/IN (l_pobj) mechanisms_11/NNS (l_prep) with_14/IN (l_pobj) aura_15/NN
D009569_D020325 NONE NO_9/DT (r_intj) liberate_8/VB (r_xcomp) shown_6/VBN (r_advcl) help_16/VB (l_dobj) understanding_18/NN (l_prep) of_19/IN (l_pobj) coupling_21/NN (l_prep) between_22/IN (l_pobj) depression_25/NN (l_conj) headache_27/NN (l_prep) with_30/IN (l_pobj) aura_31/NN
D009569_D003866 NONE NO_9/DT (r_intj) liberate_8/VB (r_xcomp) shown_6/VBN (l_nsubjpass) depression_3/NN
D009569_D003866 NONE NO_9/DT (r_intj) liberate_8/VB (r_xcomp) shown_6/VBN (r_advcl) help_16/VB (l_dobj) understanding_18/NN (l_prep) of_19/IN (l_pobj) coupling_21/NN (l_prep) between_22/IN (l_pobj) depression_25/NN
11838826
D018967_D011605 NONE risperidone_27/NN (r_npadvmod) induced_29/VBN (r_amod) elevations_30/NNS (r_pobj) with_26/IN (r_prep) males_1/NNS (l_prep) with_9/IN (l_pobj) disorder_22/NN (l_conj) psychoses_24/NNS
D018967_D006966 CID risperidone_2/NN (r_npadvmod) induced_4/VBN (r_amod) hyperprolactinemia_5/NN
D018967_D006966 CID Risperidone_0/NNP (r_nsubjpass) associated_16/VBN (l_prep) with_17/IN (l_pobj) hyperprolactinemia_18/NN
D018967_D006966 CID risperidone_6/NN (r_npadvmod) induced_8/VBN (r_amod) hyperprolactinemia_9/NN
D018967_D006966 CID risperidone_10/NN (r_npadvmod) induced_12/VBN (r_amod) hyperprolactinemia_13/NN
D018967_D006966 CID risperidone_8/NN (r_npadvmod) induced_10/VBN (r_amod) hyperprolactinemia_11/NN
D004298_D006966 NONE dopamine_8/NN (r_compound) agonist_9/NN (r_pobj) with_6/IN (r_prep) hyperprolactinemia_5/NN
C047047_D001714 NONE cabergoline_55/NN (r_pobj) with_54/IN (r_prep) treated_53/VBN (l_nsubjpass) males_1/NNS (l_prep) with_9/IN (l_pobj) disorder_22/NN
D018967_D001714 NONE risperidone_27/NN (r_npadvmod) induced_29/VBN (r_amod) elevations_30/NNS (r_pobj) with_26/IN (r_prep) males_1/NNS (l_prep) with_9/IN (l_pobj) disorder_22/NN
C047047_D001523 NONE cabergoline_55/NN (r_pobj) with_54/IN (r_prep) treated_53/VBN (l_nsubjpass) males_1/NNS (l_prep) with_9/IN (l_pobj) disorder_22/NN (l_amod) Diagnostic_10/NNP (l_conj) Manual_13/NNP (l_prep) of_14/IN (l_pobj) Disorders_16/NNPS
C047047_D006966 NONE cabergoline_11/NN (r_pobj) with_10/IN (r_prep) hyperprolactinemia_9/NN
C047047_D006966 NONE cabergoline_16/NN (r_pobj) with_15/IN (r_prep) treated_14/VBN (r_acl) hyperprolactinemia_13/NN
C047047_D006966 NONE Cabergoline_0/NNP (r_nsubj) be_2/VB (l_prep) for_4/IN (l_pobj) treatment_6/NN (l_prep) of_7/IN (l_pobj) hyperprolactinemia_11/NN
C047047_D011605 NONE cabergoline_55/NN (r_pobj) with_54/IN (r_prep) treated_53/VBN (l_nsubjpass) males_1/NNS (l_prep) with_9/IN (l_pobj) disorder_22/NN (l_conj) psychoses_24/NNS
D018967_D001523 NONE risperidone_27/NN (r_npadvmod) induced_29/VBN (r_amod) elevations_30/NNS (r_pobj) with_26/IN (r_prep) males_1/NNS (l_prep) with_9/IN (l_pobj) disorder_22/NN (l_amod) Diagnostic_10/NNP (l_conj) Manual_13/NNP (l_prep) of_14/IN (l_pobj) Disorders_16/NNPS
11858397
D008787_D002037 NONE metoclopramide_5/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_prep) with_10/IN (l_pobj) block_16/NN
D008787_D002037 NONE metoclopramide_26/NN (r_pobj) of_25/IN (r_prep) administration_24/NN (r_pobj) after_20/IN (r_prep) developed_16/VBD (r_relcl) woman_7/NN (l_prep) with_8/IN (l_pobj) block_14/NN
D008787_D016171 CID metoclopramide_5/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (r_acl) pointes_2/NNS
D008787_D016171 CID metoclopramide_26/NN (r_pobj) of_25/IN (r_prep) administration_24/NN (r_pobj) after_20/IN (r_prep) developed_16/VBD (l_dobj) pointes_19/NNS
D008787_D016171 CID metoclopramide_6/NN (r_nsubj) provokes_7/VBZ (l_dobj) pointes_10/FW
D008787_D016171 CID Metoclopramide_0/NNP (r_nsubjpass) used_3/VBN (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) risk_9/NN (l_prep) of_10/IN (l_pobj) pointes_13/FW
D004917_D016171 CID erythromycin_10/NNP (r_conj) cisapride_8/RB (r_nsubjpass) given_12/VBN (r_advcl) developed_3/VBD (l_dobj) pointes_6/FW
D020117_D016171 CID cisapride_8/RB (r_nsubjpass) given_12/VBN (r_advcl) developed_3/VBD (l_dobj) pointes_6/FW
20552622
D001262_D001145 NONE atenolol_6/NN (r_pobj) with_5/IN (r_prep) resolved_2/VBD (l_nsubj) arrhythmia_1/NN
D001262_D001145 NONE atenolol_13/NN (r_pobj) with_11/IN (r_prep) week_10/NN (r_pobj) after_8/IN (r_prep) disappeared_17/VBD (l_nsubj) arrhythmia_16/NN
D001262_D013610 NONE atenolol_51/NN (r_pobj) as_50/IN (r_prep) blocker_48/NN (r_nsubj) relieve_60/VB (r_conj) swallowing_42/VBG (r_advcl) be_31/VB (l_nsubj) agonist_21/NN (l_acl) known_25/VBN (l_xcomp) induce_27/VB (l_dobj) tachycardia_28/NN
D000420_D013617 CID salbutamol_7/NN (r_pobj) by_6/IN (r_agent) triggered_5/VBN (r_acl) tachyarrhythmia_4/NN
D000420_D013617 CID Salbutamol_0/NNP (r_nsubjpass) presented_2/VBN (l_prep) as_4/IN (l_pobj) trigger_7/NN (l_prep) for_8/IN (l_pobj) SIAT_9/NNP
D000420_D013610 NONE salbutamol_23/NN (r_pobj) like_22/IN (r_prep) agonist_21/NN (l_acl) known_25/VBN (l_xcomp) induce_27/VB (l_dobj) tachycardia_28/NN
3461217
D043343_D009369 NONE TP_6/NNP (r_nsubj) acted_7/VBD (l_prep) as_8/IN (l_pobj) agent_12/NN (l_compound) enhancement_11/NN (l_compound) tumor_10/NN
D013739_D011471 NONE testosterone_21/NN (r_conj) methylurea_19/NN (r_pobj) with_12/IN (r_prep) treatments_11/NNS (r_pobj) by_10/IN (r_prep) Production_0/NN (l_prep) of_1/IN (l_pobj) cancer_4/NN
D008770_D011471 CID methylurea_19/NN (r_pobj) with_12/IN (r_prep) treatments_11/NNS (r_pobj) by_10/IN (r_prep) Production_0/NN (l_prep) of_1/IN (l_pobj) cancer_4/NN
D008770_D011471 CID methylurea_33/NN (r_pobj) with_26/IN (r_prep) treatments_25/NNS (r_pobj) following_24/VBG (r_prep) developed_15/VBD (l_dobj) PAs_22/FW (l_nmod) adenocarcinomas_20/NNS
D008770_D011471 CID methylurea_33/NN (r_pobj) with_26/IN (r_prep) treatments_25/NNS (r_pobj) following_24/VBG (r_prep) developed_15/VBD (l_dobj) PAs_22/FW
D043343_D011471 CID propionate_45/NN (r_conj) CAS_35/NN (r_appos) methylurea_33/NN (r_pobj) with_26/IN (r_prep) treatments_25/NNS (r_pobj) following_24/VBG (r_prep) developed_15/VBD (l_dobj) PAs_22/FW (l_nmod) adenocarcinomas_20/NNS
D043343_D011471 CID propionate_45/NN (r_conj) CAS_35/NN (r_appos) methylurea_33/NN (r_pobj) with_26/IN (r_prep) treatments_25/NNS (r_pobj) following_24/VBG (r_prep) developed_15/VBD (l_dobj) PAs_22/FW
D043343_D011471 CID TP_19/NNP (r_pobj) with_18/IN (r_prep) treated_16/VBN (r_advcl) developed_10/VBD (l_dobj) PA_14/NNP
D043343_D011471 CID TP_6/NNP (r_nsubj) acted_7/VBD (l_prep) with_14/IN (l_pobj) emphasis_16/NN (l_prep) on_17/IN (l_pobj) development_19/NN (l_prep) of_20/IN (l_pobj) cancer_22/NN
6402369
D013438_D008175 NONE thiol_8/JJ (r_compound) sulphonate_12/JJ (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (r_nsubjpass) tested_26/VBN (l_prep) in_27/IN (l_pobj) group_29/NN (l_prep) of_30/IN (l_pobj) patients_32/NNS (l_prep) with_33/IN (l_pobj) cancer_36/NN
D015080_D064420 NONE MESNA_7/NNP (r_compound) series_8/NN (l_conj) series_13/NN (l_prep) with_14/IN (l_pobj) respect_15/NN (l_prep) to_16/IN (l_pobj) toxicity_21/NN
D013438_D001745 NONE thiol_8/JJ (r_compound) sulphonate_12/JJ (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (l_prep) against_16/IN (l_pobj) toxicity_18/NN
D007069_D001745 CID ifosfamide_2/RB (r_advmod) induced_4/VBN (r_amod) toxicity_6/NN
D007069_D001745 CID ifosfamide_21/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) toxicity_18/NN
D007069_D001745 CID IF_23/IN (r_mark) tested_26/VBN (l_nsubjpass) effect_2/NN (l_prep) against_16/IN (l_pobj) toxicity_18/NN
D007069_D001745 CID IF_40/IN (r_mark) m2_45/NN (r_pobj) with_39/IN (r_prep) treatment_38/NN (r_pobj) under_37/IN (r_prep) cancer_36/NN (r_pobj) with_33/IN (r_prep) patients_32/NNS (r_pobj) of_30/IN (r_prep) group_29/NN (r_pobj) in_27/IN (r_prep) tested_26/VBN (l_nsubjpass) effect_2/NN (l_prep) against_16/IN (l_pobj) toxicity_18/NN
D007069_D008175 NONE ifosfamide_2/RB (r_advmod) induced_4/VBN (r_amod) toxicity_6/NN (r_pobj) of_1/IN (r_prep) Treatment_0/NN (l_prep) to_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) cancer_22/NN
D007069_D008175 NONE ifosfamide_21/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) toxicity_18/NN (r_pobj) against_16/IN (r_prep) effect_2/NN (r_nsubjpass) tested_26/VBN (l_prep) in_27/IN (l_pobj) group_29/NN (l_prep) of_30/IN (l_pobj) patients_32/NNS (l_prep) with_33/IN (l_pobj) cancer_36/NN
D007069_D008175 NONE IF_23/IN (r_mark) tested_26/VBN (l_prep) in_27/IN (l_pobj) group_29/NN (l_prep) of_30/IN (l_pobj) patients_32/NNS (l_prep) with_33/IN (l_pobj) cancer_36/NN
D007069_D008175 NONE IF_40/IN (r_mark) m2_45/NN (r_pobj) with_39/IN (r_prep) treatment_38/NN (r_pobj) under_37/IN (r_prep) cancer_36/NN
D015080_D008175 NONE sulphonate_13/JJ (r_pobj) of_10/IN (r_prep) administration_9/NN (r_pobj) by_7/IN (r_prep) toxicity_6/NN (r_pobj) of_1/IN (r_prep) Treatment_0/NN (l_prep) to_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) cancer_22/NN
D015080_D008175 NONE MESNA_15/NNP (r_appos) sulphonate_13/JJ (r_pobj) of_10/IN (r_prep) administration_9/NN (r_pobj) by_7/IN (r_prep) toxicity_6/NN (r_pobj) of_1/IN (r_prep) Treatment_0/NN (l_prep) to_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) cancer_22/NN
D015080_D008175 NONE sulphonate_12/JJ (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (r_nsubjpass) tested_26/VBN (l_prep) in_27/IN (l_pobj) group_29/NN (l_prep) of_30/IN (l_pobj) patients_32/NNS (l_prep) with_33/IN (l_pobj) cancer_36/NN
D015080_D008175 NONE MESNA_14/NNP (r_appos) sulphonate_12/JJ (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (r_nsubjpass) tested_26/VBN (l_prep) in_27/IN (l_pobj) group_29/NN (l_prep) of_30/IN (l_pobj) patients_32/NNS (l_prep) with_33/IN (l_pobj) cancer_36/NN
D015080_D001745 NONE sulphonate_13/JJ (r_pobj) of_10/IN (r_prep) administration_9/NN (r_pobj) by_7/IN (r_prep) toxicity_6/NN
D015080_D001745 NONE MESNA_15/NNP (r_appos) sulphonate_13/JJ (r_pobj) of_10/IN (r_prep) administration_9/NN (r_pobj) by_7/IN (r_prep) toxicity_6/NN
D015080_D001745 NONE sulphonate_12/JJ (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (l_prep) against_16/IN (l_pobj) toxicity_18/NN
D015080_D001745 NONE MESNA_14/NNP (r_appos) sulphonate_12/JJ (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (l_prep) against_16/IN (l_pobj) toxicity_18/NN
6292680
D018943_D009202 NONE anthracycline_11/NN (r_amod) cardiomyopathy_12/NN
D004317_D009396 NONE Doxorubicin_0/JJ (r_nsubj) cardiomyopathy_1/NN (l_prep) in_2/IN (l_pobj) children_3/NNS (l_prep) with_4/IN (l_pobj) tumor_9/NN
D004317_D009396 NONE doxorubicin_23/NN (r_pobj) of_22/IN (r_prep) dosage_21/NN (r_conj) bed_18/NN (r_pobj) to_15/IN (r_prep) irradiation_14/NN (r_pobj) after_13/IN (r_prep) experienced_9/VBD (l_nsubj) children_1/NNS (l_prep) with_2/IN (l_pobj) tumor_4/NN
D004317_D009396 NONE doxorubicin_30/NN (r_pobj) of_29/IN (r_prep) interaction_28/NN (r_pobj) to_26/IN (r_prep) include_16/VBP (l_nsubj) fields_11/VBZ (l_prep) for_12/IN (l_pobj) tumor_15/NN
D004317_D009396 NONE doxorubicin_4/NN (r_compound) dosage_5/NN (r_nsubjpass) restricted_8/VBN (l_prep) in_9/IN (l_pobj) children_10/NNS (l_prep) with_11/IN (l_pobj) tumor_13/NN
D018943_D009369 NONE anthracycline_11/NN (r_amod) cardiomyopathy_12/NN (r_dobj) experienced_9/VBD (l_prep) after_13/IN (l_pobj) irradiation_14/NN (l_prep) to_15/IN (l_pobj) bed_18/NN (l_compound) tumor_17/NN
D004317_D009202 CID Doxorubicin_0/JJ (r_nsubj) cardiomyopathy_1/NN
D004317_D009202 CID doxorubicin_23/NN (r_pobj) of_22/IN (r_prep) dosage_21/NN (r_conj) bed_18/NN (r_pobj) to_15/IN (r_prep) irradiation_14/NN (r_pobj) after_13/IN (r_prep) experienced_9/VBD (l_dobj) cardiomyopathy_12/NN
D004317_D009202 CID doxorubicin_30/NN (r_pobj) of_29/IN (r_prep) interaction_28/NN (r_pobj) to_26/IN (r_prep) include_16/VBP (r_acl) fact_8/NN (r_pobj) to_6/IN (r_prep) attributed_3/VBN (l_nsubjpass) cardiomyopathy_1/NN
D018943_D009396 NONE anthracycline_11/NN (r_amod) cardiomyopathy_12/NN (r_dobj) experienced_9/VBD (l_nsubj) children_1/NNS (l_prep) with_2/IN (l_pobj) tumor_4/NN
D004317_D009369 NONE doxorubicin_23/NN (r_pobj) of_22/IN (r_prep) dosage_21/NN (r_conj) bed_18/NN (l_compound) tumor_17/NN
6323692
D000661_D000699 NONE amphetamine_21/NN (r_npadvmod) induced_23/VBN (r_amod) activity_25/NN (r_dobj) antagonized_20/VBN (r_conj) analgesia-_12/JJ
D010433_D001259 NONE metrazol_37/NN (r_pobj) of_36/IN (r_prep) action_35/NN (r_dobj) affected_32/VBD (r_conj) analgesia-_12/JJ (l_conj) incoordination_18/NN
D000661_D001259 NONE amphetamine_21/NN (r_npadvmod) induced_23/VBN (r_amod) activity_25/NN (r_dobj) antagonized_20/VBN (r_conj) analgesia-_12/JJ (l_conj) incoordination_18/NN
D002118_D003866 NONE calcium_3/NN (r_pobj) of_1/IN (r_prep) Addition_0/NN (r_nsubj) reversed_4/VBD (l_dobj) depression_6/NN
D002118_D003866 NONE calcium_12/NN (r_npadvmod) independent_14/JJ (r_amod) release_16/NN (r_nsubjpass) blocked_21/VBN (r_conj) reversed_4/VBD (l_dobj) depression_6/NN
C018824_D001259 CID acetate_3/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) doubled_15/VBD (l_npadvmod) time_17/NN (l_relcl) remained_22/VBD (l_conj) incoordination_31/NN
C018824_D001259 CID NH4Ac_5/NNP (r_appos) acetate_3/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) doubled_15/VBD (l_npadvmod) time_17/NN (l_relcl) remained_22/VBD (l_conj) incoordination_31/NN
C018824_D001259 CID NH4Ac_36/NNP (r_compound) treatment_37/NN (r_nsubj) had_39/VBD (r_conj) remained_22/VBD (l_conj) incoordination_31/NN
C018824_D001259 CID NH4Ac_8/NNP (r_nmod) pretreatment_9/NN (r_conj) verapamil_1/NN (r_nsubj) analgesia-_12/JJ (l_conj) incoordination_18/NN
C018824_D001259 CID NH4Ac_31/NNP (r_conj) verapamil_29/NN (r_nsubj) affected_32/VBD (r_conj) analgesia-_12/JJ (l_conj) incoordination_18/NN
D003975_D001259 CID diazepam_33/NN (r_pobj) by_32/IN (r_prep) incoordination_31/NN
D003975_D001259 CID diazepam_14/NN (r_npadvmod) induced_16/VBN (r_amod) incoordination_18/NN
D014700_D001259 NONE verapamil_1/NN (r_nsubj) analgesia-_12/JJ (l_conj) incoordination_18/NN
D014700_D001259 NONE verapamil_29/NN (r_nsubj) affected_32/VBD (r_conj) analgesia-_12/JJ (l_conj) incoordination_18/NN
D000079_D003866 NONE acetaldehyde_18/NN (r_pobj) by_17/IN (r_prep) release_16/NN (r_nsubjpass) blocked_21/VBN (r_conj) reversed_4/VBD (l_dobj) depression_6/NN
D010433_D000699 NONE metrazol_37/NN (r_pobj) of_36/IN (r_prep) action_35/NN (r_dobj) affected_32/VBD (r_conj) analgesia-_12/JJ
D002118_D022124 NONE calcium_7/NN (r_compound) channel_8/NN (r_dobj) exerts_5/VBZ (l_nsubj) hyperammonemia_4/NN
D009020_D000699 NONE morphine_11/NN (r_appos) pretreatment_9/NN (r_conj) verapamil_1/NN (r_nsubj) analgesia-_12/JJ
C018824_D003866 NONE NH4Ac_23/NNPS (r_pobj) by_22/IN (r_agent) blocked_21/VBN (r_conj) reversed_4/VBD (l_dobj) depression_6/NN
D002395_D003866 NONE catecholamine_15/NN (r_compound) release_16/NN (r_nsubjpass) blocked_21/VBN (r_conj) reversed_4/VBD (l_dobj) depression_6/NN
D009020_D001259 NONE morphine_18/NN (r_npadvmod) treated_20/VBN (r_amod) mice_21/NNS (r_nsubj) remained_22/VBD (l_conj) incoordination_31/NN
D009020_D001259 NONE morphine_11/NN (r_appos) pretreatment_9/NN (r_conj) verapamil_1/NN (r_nsubj) analgesia-_12/JJ (l_conj) incoordination_18/NN
D014700_D000699 NONE verapamil_1/NN (r_nsubj) analgesia-_12/JJ
D014700_D000699 NONE verapamil_29/NN (r_nsubj) affected_32/VBD (r_conj) analgesia-_12/JJ
D003975_D000699 NONE diazepam_14/NN (r_npadvmod) induced_16/VBN (r_amod) incoordination_18/NN (r_conj) analgesia-_12/JJ
C018824_D000699 NONE NH4Ac_8/NNP (r_nmod) pretreatment_9/NN (r_conj) verapamil_1/NN (r_nsubj) analgesia-_12/JJ
C018824_D000699 NONE NH4Ac_31/NNP (r_conj) verapamil_29/NN (r_nsubj) affected_32/VBD (r_conj) analgesia-_12/JJ
11337188
D010068_D013203 NONE oxacillin_9/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (l_prep) because_13/IN (l_pobj) bacteremia_17/NN
D010068_D051437 CID oxacillin_9/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (r_relcl) man_4/NN (r_nsubj) developed_19/VBD (l_dobj) failure_21/NN
D010068_D018366 CID oxacillin_5/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) vasculitis_2/NN
D010068_D018366 CID Oxacillin_0/NNP (r_nsubjpass) included_3/VBN (l_prep) among_4/IN (l_pobj) drugs_6/NNS (l_relcl) cause_9/VB (l_dobj) vasculitis_11/NN
D010068_D011693 NONE oxacillin_9/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (r_relcl) man_4/NN (r_nsubj) developed_19/VBD (l_dobj) failure_21/NN (l_appos) lesions_29/NNS
D010068_D016470 NONE oxacillin_9/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (l_prep) because_13/IN (l_pobj) bacteremia_17/NN
9201797
D004298_D009069 NONE dopamine_5/NN (r_nmod) signs_10/NNS (l_prep) as_12/IN (l_pobj) stereotypy_13/NN (l_conj) hyperlocomotion_15/NN
D001712_D002375 NONE biperiden_30/VBN (r_conj) propranolol_28/NN (r_pobj) of_27/IN (r_prep) those_26/DT (r_pobj) with_25/IN (r_prep) compared_24/VBN (r_conj) studied_22/VBN (l_nsubjpass) effects_3/NNS (l_appos) antagonist_11/NN (l_prep) on_13/IN (l_pobj) catalepsy_17/NN
D001712_D002375 NONE biperiden_7/RB (r_conj) propranolol_5/NN (l_conj) inhibited_9/VBD (l_dobj) catalepsy_14/NN
D002354_D002375 NONE hydrochloride_5/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (l_prep) on_13/IN (l_pobj) catalepsy_17/NN
D002354_D002375 NONE carteolol_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_appos) antagonist_11/NN (l_prep) on_13/IN (l_pobj) catalepsy_17/NN
D002354_D002375 NONE Carteolol_0/NNP (l_conj) propranolol_5/NN (l_conj) inhibited_9/VBD (l_dobj) catalepsy_14/NN
D002354_D002375 NONE carteolol_5/NN (r_nsubj) improves_6/VBZ (l_dobj) catalepsy_10/NN
D004298_D002375 NONE dopamine_40/NN (r_nmod) receptor_41/NN (r_nmod) activity_43/NN (r_pobj) to_37/IN (r_pcomp) due_36/IN (r_prep) attenuating_30/VBG (r_pcomp) without_29/IN (r_prep) treatment_26/NN (r_pobj) in_24/IN (r_prep) effective_23/JJ (r_acomp) be_22/VB (r_xcomp) expected_20/VBN (r_conj) improves_6/VBZ (l_dobj) catalepsy_10/NN
D004298_D017109 NONE dopamine_40/NN (r_nmod) receptor_41/NN (r_nmod) activity_43/NN (r_pobj) to_37/IN (r_pcomp) due_36/IN (r_prep) attenuating_30/VBG (r_pcomp) without_29/IN (r_prep) treatment_26/NN (l_prep) of_27/IN (l_pobj) akathisia_28/NN
D006220_D017109 NONE haloperidol_7/NN (r_npadvmod) induced_9/VBN (r_amod) catalepsy_10/NN (r_dobj) improves_6/VBZ (l_conj) expected_20/VBN (l_xcomp) be_22/VB (l_acomp) effective_23/JJ (l_prep) in_24/IN (l_pobj) treatment_26/NN (l_prep) of_27/IN (l_pobj) akathisia_28/NN
D011433_D002375 NONE propranolol_28/NN (r_pobj) of_27/IN (r_prep) those_26/DT (r_pobj) with_25/IN (r_prep) compared_24/VBN (r_conj) studied_22/VBN (l_nsubjpass) effects_3/NNS (l_appos) antagonist_11/NN (l_prep) on_13/IN (l_pobj) catalepsy_17/NN
D011433_D002375 NONE propranolol_5/NN (l_conj) inhibited_9/VBD (l_dobj) catalepsy_14/NN
D006220_D002375 CID haloperidol_14/NN (r_npadvmod) induced_16/VBN (r_amod) catalepsy_17/NN
D006220_D002375 CID haloperidol_11/NN (r_npadvmod) induced_13/VBN (r_amod) catalepsy_14/NN
D006220_D002375 CID haloperidol_7/NN (r_npadvmod) induced_9/VBN (r_amod) catalepsy_10/NN
D002354_D017109 NONE carteolol_5/NN (r_nsubj) improves_6/VBZ (l_conj) expected_20/VBN (l_xcomp) be_22/VB (l_acomp) effective_23/JJ (l_prep) in_24/IN (l_pobj) treatment_26/NN (l_prep) of_27/IN (l_pobj) akathisia_28/NN
D002354_D009069 NONE Carteolol_0/NNP (r_nsubj) evoke_3/VB (l_dobj) signs_10/NNS (l_prep) as_12/IN (l_pobj) stereotypy_13/NN (l_conj) hyperlocomotion_15/NN
20705401
D008694_D011605 CID methamphetamine_7/NN (r_npadvmod) induced_9/VBN (r_amod) psychosis_10/NN
D008694_D011605 CID methamphetamine_3/NN (r_pobj) of_2/IN (r_prep) symptoms_1/NNS (l_appos) psychosis_6/NN
D008694_D011605 CID METH)-induced_5/JJ (r_amod) psychosis_6/NN
D008694_D011605 CID METH_17/NNP (r_npadvmod) induced_19/VBN (r_amod) psychosis_20/NN
D008694_D011605 CID METH_29/NN (r_npadvmod) induced_31/VBN (r_amod) patients_33/NNS (l_compound) psychosis_32/NN
D008694_D011605 CID METH_4/NNP (r_npadvmod) induced_6/VBN (r_amod) patients_8/NNS (l_compound) psychosis_7/NN
D008694_D011605 CID METH_32/NNP (r_npadvmod) induced_34/VBN (r_amod) patients_36/NNS (l_compound) psychosis_35/NN
D008694_D011605 CID METH_10/NNP (r_npadvmod) induced_12/VBN (r_amod) psychosis_13/NN
D012701_D012559 NONE 5-HT6_20/CD (r_nummod) receptors_21/NNS (r_nsubjpass) involved_23/VBN (r_ccomp) suggests_17/VBZ (r_conj) considered_4/VBN (l_xcomp) reflect_6/VB (l_dobj) symptoms_9/NNS (l_prep) of_10/IN (l_pobj) schizophrenia_11/NN
D012701_D011605 NONE Serotonin_0/NN (r_nmod) gene_3/NN (r_nsubjpass) associated_5/VBN (l_prep) with_6/IN (l_pobj) psychosis_10/NN
D012701_D011605 NONE 5-HT6_20/CD (r_nummod) receptors_21/NNS (r_nsubjpass) involved_23/VBN (l_prep) in_24/IN (l_pobj) pathophysiology_26/NN (l_prep) of_27/IN (l_pobj) disorders_29/NNS
D012701_D011605 NONE 5-HT6_11/CD (r_nummod) gene_12/NN (l_prep) with_16/IN (l_pobj) psychosis_20/NN
C076029_D006948 NONE olanzapine_20/NN (r_conj) clozapine_18/NN (l_conj) hyperactivity_28/NN
D003024_D006948 NONE clozapine_18/NN (l_conj) hyperactivity_28/NN
D008694_D012563 NONE methamphetamine_3/NN (r_pobj) of_2/IN (r_prep) symptoms_1/NNS (r_nsubj) are_7/VBP (l_acomp) similar_8/JJ (l_prep) to_9/IN (l_pobj) those_10/DT (l_prep) of_11/IN (l_pobj) schizophrenia_14/NN
D008694_D012563 NONE METH)-induced_5/JJ (r_amod) psychosis_6/NN (r_appos) symptoms_1/NNS (r_nsubj) are_7/VBP (l_acomp) similar_8/JJ (l_prep) to_9/IN (l_pobj) those_10/DT (l_prep) of_11/IN (l_pobj) schizophrenia_14/NN
D012701_D006948 NONE serotonin_1/NN (r_nsubjpass) targeted_9/VBN (l_agent) by_10/IN (l_pobj) antipsychotics_14/NNS (l_prep) as_17/IN (l_pobj) clozapine_18/NN (l_conj) hyperactivity_28/NN
D012701_D006948 NONE 5-HT6_4/CD (r_nummod) receptor_6/NN (r_appos) serotonin_1/NN (r_nsubjpass) targeted_9/VBN (l_agent) by_10/IN (l_pobj) antipsychotics_14/NNS (l_prep) as_17/IN (l_pobj) clozapine_18/NN (l_conj) hyperactivity_28/NN
D012701_D006948 NONE 5-HT6_39/CD (r_nummod) antagonist_41/NN (r_pobj) of_36/IN (r_prep) use_35/NN (r_pobj) with_33/IN (r_prep) corrected_32/VBN (r_conj) targeted_9/VBN (l_agent) by_10/IN (l_pobj) antipsychotics_14/NNS (l_prep) as_17/IN (l_pobj) clozapine_18/NN (l_conj) hyperactivity_28/NN
D003913_D006948 NONE amphetamine_25/NN (r_npadvmod) induced_27/VBN (r_conj) clozapine_18/NN (l_conj) hyperactivity_28/NN
12091028
D003975_D006212 NONE Diazepam_0/NNP (r_nsubj) remains_7/VBZ (l_attr) drug_12/NN (l_relcl) ketamine_14/NN (l_advcl) buffers_17/VBZ (l_conj) decreases_22/VBZ (l_dobj) duration_24/NN (l_prep) of_27/IN (l_pobj) hallucinations_31/NNS
D007649_D006212 CID ketamine_14/NN (l_advcl) buffers_17/VBZ (l_conj) decreases_22/VBZ (l_dobj) duration_24/NN (l_prep) of_27/IN (l_pobj) hallucinations_31/NNS
19274460
D003520_D009101 NONE cyclophosphamide_8/NN (r_pobj) for_6/IN (r_prep) definition_5/NN (l_prep) for_15/IN (l_pobj) induction_17/NN (l_prep) in_18/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) myeloma_23/NN
D003520_D009101 NONE cyclophosphamide_11/NN (r_pobj) of_10/IN (r_prep) dose_9/NN (r_dobj) evaluate_6/VB (l_prep) as_18/IN (l_pobj) treatment_20/NN (l_prep) before_21/IN (l_pobj) transplantation_24/NN (l_prep) for_25/IN (l_pobj) patients_27/NNS (l_prep) with_28/IN (l_pobj) myeloma_32/NN
D003520_D009101 NONE cyclophosphamide_11/NN (r_pobj) of_10/IN (r_prep) dose_9/NN (r_dobj) evaluate_6/VB (l_prep) as_18/IN (l_pobj) treatment_20/NN (l_prep) before_21/IN (l_pobj) transplantation_24/NN (l_prep) for_25/IN (l_pobj) patients_27/NNS (l_prep) with_28/IN (l_pobj) myeloma_32/NN (l_appos) MM_34/NNP
D003520_D009101 NONE cyclophosphamide_8/NN (r_pobj) with_7/IN (r_prep) combination_6/NN (r_pobj) in_5/IN (r_prep) bortezomib_4/NNS (r_nsubj) is_17/VBZ (l_attr) treatment_21/NN (l_prep) for_22/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) MM_27/NNP
C400082_D009101 NONE bortezomib_12/NNS (r_amod) dexamethasone_14/NN (r_pobj) with_11/IN (r_prep) combination_10/NN (r_pobj) in_9/IN (r_prep) definition_5/NN (l_prep) for_15/IN (l_pobj) induction_17/NN (l_prep) in_18/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) myeloma_23/NN
C400082_D009101 NONE bortezomib_15/NNS (r_pobj) with_14/IN (r_prep) combination_13/NN (r_pobj) in_12/IN (r_prep) evaluate_6/VB (l_prep) as_18/IN (l_pobj) treatment_20/NN (l_prep) before_21/IN (l_pobj) transplantation_24/NN (l_prep) for_25/IN (l_pobj) patients_27/NNS (l_prep) with_28/IN (l_pobj) myeloma_32/NN
C400082_D009101 NONE bortezomib_15/NNS (r_pobj) with_14/IN (r_prep) combination_13/NN (r_pobj) in_12/IN (r_prep) evaluate_6/VB (l_prep) as_18/IN (l_pobj) treatment_20/NN (l_prep) before_21/IN (l_pobj) transplantation_24/NN (l_prep) for_25/IN (l_pobj) patients_27/NNS (l_prep) with_28/IN (l_pobj) myeloma_32/NN (l_appos) MM_34/NNP
C400082_D009101 NONE bortezomib_4/NNS (r_nsubj) is_17/VBZ (l_attr) treatment_21/NN (l_prep) for_22/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) MM_27/NNP
D003907_D009101 NONE dexamethasone_14/NN (r_pobj) with_11/IN (r_prep) combination_10/NN (r_pobj) in_9/IN (r_prep) definition_5/NN (l_prep) for_15/IN (l_pobj) induction_17/NN (l_prep) in_18/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) myeloma_23/NN
D003907_D009101 NONE dexamethasone_17/NN (r_conj) bortezomib_15/NNS (r_pobj) with_14/IN (r_prep) combination_13/NN (r_pobj) in_12/IN (r_prep) evaluate_6/VB (l_prep) as_18/IN (l_pobj) treatment_20/NN (l_prep) before_21/IN (l_pobj) transplantation_24/NN (l_prep) for_25/IN (l_pobj) patients_27/NNS (l_prep) with_28/IN (l_pobj) myeloma_32/NN
D003907_D009101 NONE dexamethasone_17/NN (r_conj) bortezomib_15/NNS (r_pobj) with_14/IN (r_prep) combination_13/NN (r_pobj) in_12/IN (r_prep) evaluate_6/VB (l_prep) as_18/IN (l_pobj) treatment_20/NN (l_prep) before_21/IN (l_pobj) transplantation_24/NN (l_prep) for_25/IN (l_pobj) patients_27/NNS (l_prep) with_28/IN (l_pobj) myeloma_32/NN (l_appos) MM_34/NNP
D003907_D009101 NONE dexamethasone_16/NN (r_nsubj) is_17/VBZ (l_attr) treatment_21/NN (l_prep) for_22/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) MM_27/NNP
10225068
D008012_D020258 NONE lignocaine_6/NN (r_pobj) of_2/IN (r_prep) dose_1/NN (r_nsubj) ranged_8/VBD (r_ccomp) caused_21/VBN (l_agent) by_22/IN (l_pobj) neurotoxicity_24/NN
D008012_D020258 NONE lignocaine_29/NN (r_pobj) of_25/IN (r_prep) neurotoxicity_24/NN
D008012_D011128 CID lignocaine_10/NN (r_pobj) with_6/IN (r_prep) anaesthesia_5/NN (r_pobj) after_3/IN (r_prep) syndrome_2/NN
D008012_D011128 CID lignocaine_10/NN (r_pobj) with_6/IN (r_prep) anaesthesia_5/NN (r_pobj) after_3/IN (r_prep) syndrome_2/NN (l_appos) review_13/NN (l_prep) of_14/IN (l_pobj) cases_16/NNS (l_prep) of_17/IN (l_pobj) syndrome_20/NN
17049862
D004837_D001919 NONE adrenaline_15/NN (r_conj) atropine_13/NN (r_pobj) to_12/IN (r_prep) refractory_11/JJ (r_advcl) developed_6/VBD (l_dobj) bradycardia_9/NN
D001285_D001919 NONE atropine_13/NN (r_pobj) to_12/IN (r_prep) refractory_11/JJ (r_advcl) developed_6/VBD (l_dobj) bradycardia_9/NN
D010672_D001919 CID phenytoin_1/JJ (r_compound) administration_2/NN (r_pobj) Following_0/VBG (r_prep) developed_6/VBD (l_dobj) bradycardia_9/NN
D010672_D007035 NONE phenytoin_1/JJ (r_compound) administration_2/NN (r_nsubj) Is_0/VBZ (l_acomp) safe_3/JJ (l_prep) in_4/IN (l_pobj) child_7/NN (l_amod) hypothermic_6/JJ
D010672_D007035 NONE phenytoin_5/NN (l_conj) hypothermia_7/NN
D010672_D007035 NONE phenytoin_2/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (l_prep) in_3/IN (l_pobj) presence_5/NN (l_prep) of_6/IN (l_pobj) hypothermia_7/NN
D010672_D012640 NONE phenytoin_1/NN (r_nsubjpass) administered_3/VBN (l_prep) during_4/IN (l_pobj) part_7/NN (l_prep) of_8/IN (l_pobj) surgery_10/NN (l_prep) for_11/IN (l_pobj) prophylaxis_13/NN (l_compound) seizure_12/NN
10539815
D004656_D006333 NONE enalapril_26/NN (r_pobj) of_25/IN (r_prep) trial_24/NN (l_prep) for_27/IN (l_pobj) treatment_29/NN (l_prep) of_30/IN (l_pobj) CHF_31/NNP
D004656_D006333 NONE Enalapril_0/NNP (r_compound) use_1/NN (r_nsubj) caused_2/VBD (l_dobj) increase_6/NN (l_prep) in_7/IN (l_pobj) risk_9/NN (l_prep) of_10/IN (l_pobj) function_13/NN (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) CHF_17/NNP
D004656_D006333 NONE enalapril_23/JJ (r_compound) group_24/NN (r_pobj) in_21/IN (r_prep) reduced_20/VBN (r_conj) associated_2/VBN (l_prep) with_3/IN (l_pobj) risk_6/NN (l_prep) of_7/IN (l_pobj) impairment_9/NN (l_prep) in_10/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) CHF_14/NNP
D000809_D018487 NONE angiotensin_11/NN (r_npadvmod) converting_13/VBG (r_amod) enzyme_14/NN (r_compound) therapy_16/NN (r_pobj) during_10/IN (r_prep) patients_6/NNS (r_pobj) in_5/IN (r_prep) function_4/NN (r_pobj) of_1/IN (r_prep) Predictors_0/NNS (r_dep) results_18/NNS (l_prep) from_19/IN (l_pobj) studies_21/NNS (l_prep) of_22/IN (l_pobj) dysfunction_25/NN
D004656_D051437 CID enalapril_4/NN (r_pobj) to_3/IN (r_prep) assigned_2/VBN (r_acl) Patients_0/NNS (r_nsubj) had_5/VBD (l_dobj) likelihood_10/NN (l_prep) of_11/IN (l_pobj) function_14/NN
D004656_D051437 CID enalapril_9/NN (r_compound) groups_10/NNS (r_conj) placebo_7/NN (r_pobj) in_4/IN (r_prep) associated_20/VBN (l_prep) with_21/IN (l_pobj) function_24/NN
D004656_D051437 CID enalapril_23/JJ (r_compound) group_24/NN (r_pobj) in_21/IN (r_prep) more_19/RBR (r_conj) associated_3/VBN (l_prep) with_4/IN (l_pobj) risk_7/NN (l_prep) of_8/IN (l_pcomp) developing_9/VBG (l_dobj) function_12/NN
D004656_D051437 CID enalapril_26/NN (r_dep) ratio_29/NN (r_appos) group_24/NN (r_pobj) in_21/IN (r_prep) more_19/RBR (r_conj) associated_3/VBN (l_prep) with_4/IN (l_pobj) risk_7/NN (l_prep) of_8/IN (l_pcomp) developing_9/VBG (l_dobj) function_12/NN
D004656_D051437 CID enalapril_15/JJ (r_compound) group_16/NN (r_pobj) in_13/IN (r_prep) function_12/NN
D004656_D051437 CID Enalapril_0/NNP (r_compound) use_1/NN (r_nsubj) caused_2/VBD (l_dobj) increase_6/NN (l_prep) in_7/IN (l_pobj) risk_9/NN (l_prep) of_10/IN (l_pobj) function_13/NN
D004656_D051437 CID enalapril_23/JJ (r_compound) group_24/NN (r_pobj) in_21/IN (r_prep) reduced_20/VBN (r_conj) associated_2/VBN (l_prep) with_3/IN (l_pobj) risk_6/NN (l_prep) of_7/IN (l_pobj) impairment_9/NN
D000809_D051437 NONE angiotensin_11/NN (r_npadvmod) converting_13/VBG (r_amod) enzyme_14/NN (r_compound) therapy_16/NN (r_pobj) during_10/IN (r_prep) patients_6/NNS (r_pobj) in_5/IN (r_prep) function_4/NN
D000809_D051437 NONE angiotensin_1/NN (r_npadvmod) converting_3/VBG (r_amod) enzyme_4/NN (r_compound) therapy_6/NN (r_nsubj) reduces_7/VBZ (r_advcl) cause_23/VB (l_dobj) function_26/NN
D000809_D051437 NONE angiotensin_17/NN (r_npadvmod) converting_19/VBG (r_amod) enzyme_20/NN (r_compound) therapy_22/NN (r_dobj) prescribed_16/VBN (r_relcl) CHF_13/NNP (r_pobj) with_12/IN (r_prep) patients_11/NNS (r_pobj) in_10/IN (r_prep) reduction_6/NN (l_prep) in_7/IN (l_pobj) function_9/NN
D004656_D003920 NONE enalapril_9/NN (r_compound) groups_10/NNS (r_conj) placebo_7/NN (l_conj) age_12/NN (l_conj) therapy_15/NN (l_conj) diabetes_18/NNS
D004656_D003920 NONE enalapril_2/NN (r_nsubj) had_3/VBD (l_npadvmod) RR_9/NN (l_nummod) 1.33_10/CD (l_prep) compared_19/VBN (l_prep) with_20/IN (l_pobj) placebo_21/NN (l_appos) CI_28/NNP (l_prep) in_33/IN (l_pobj) patients_34/NNS (l_prep) with_35/IN (l_pobj) diabetes_36/NNS
D004656_D003920 NONE enalapril_23/JJ (r_compound) group_24/NN (r_pobj) in_21/IN (r_prep) reduced_20/VBN (r_conj) associated_2/VBN (l_nsubjpass) Diabetes_0/NN
D003404_D006973 NONE creatinine_25/NN (r_conj) fraction_22/NN (r_conj) age_18/NN (l_appos) history_38/NN (l_prep) of_39/IN (l_pobj) hypertension_40/NN
D004232_D051437 CID diuretic_14/JJ (r_amod) therapy_15/NN (r_conj) age_12/NN (r_conj) placebo_7/NN (r_pobj) in_4/IN (r_prep) associated_20/VBN (l_prep) with_21/IN (l_pobj) function_24/NN
D004232_D051437 CID Diuretic_0/JJ (r_compound) therapy_1/NN (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) risk_8/NN (l_prep) of_9/IN (l_pobj) function_12/NN
D004232_D006973 NONE diuretic_49/JJ (r_conj) antiplatelet_47/JJ (r_pobj) of_46/IN (r_prep) use_45/NN (r_conj) diabetes_42/NNS (r_conj) hypertension_40/NN
D000809_D006333 NONE angiotensin_11/NN (r_npadvmod) converting_13/VBG (r_amod) enzyme_14/NN (r_compound) therapy_16/NN (r_pobj) during_10/IN (r_prep) patients_6/NNS (l_prep) with_7/IN (l_pobj) failure_9/NN
D000809_D006333 NONE angiotensin_1/NN (r_npadvmod) converting_3/VBG (r_amod) enzyme_4/NN (r_compound) therapy_6/NN (r_nsubj) reduces_7/VBZ (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) failure_15/NN
D000809_D006333 NONE angiotensin_1/NN (r_npadvmod) converting_3/VBG (r_amod) enzyme_4/NN (r_compound) therapy_6/NN (r_nsubj) reduces_7/VBZ (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) failure_15/NN (l_appos) CHF_17/NNP
D000809_D006333 NONE angiotensin_17/NN (r_npadvmod) converting_19/VBG (r_amod) enzyme_20/NN (r_compound) therapy_22/NN (r_dobj) prescribed_16/VBN (r_relcl) CHF_13/NNP
D003404_D003920 NONE creatinine_25/NN (r_conj) fraction_22/NN (r_conj) age_18/NN (l_appos) history_38/NN (l_prep) of_39/IN (l_pobj) hypertension_40/NN (l_conj) diabetes_42/NNS
D004232_D003920 NONE diuretic_49/JJ (r_conj) antiplatelet_47/JJ (r_pobj) of_46/IN (r_prep) use_45/NN (r_conj) diabetes_42/NNS
D004232_D003920 NONE diuretic_14/JJ (r_amod) therapy_15/NN (l_conj) diabetes_18/NNS
D004656_D018487 NONE enalapril_26/NN (r_pobj) of_25/IN (r_prep) trial_24/NN (r_appos) Dysfunction_9/NNP
D003404_D051437 NONE creatinine_10/NN (r_pobj) in_8/IN (r_prep) rise_7/NN (r_pobj) as_5/IN (r_prep) defined_4/VBN (l_nsubjpass) function_2/NN
11195262
D014635_D002493 NONE VPA_30/NNP (r_pobj) of_29/IN (r_prep) administration_28/NN (r_conj) weakness_17/NN (l_prep) of_18/IN (l_pobj) system_22/NN
D014635_D004830 NONE VPA_4/NNP (r_dobj) taking_3/VBG (l_prep) for_5/IN (l_pobj) treatment_6/NN (l_prep) of_7/IN (l_pobj) convulsions_13/NNS
D014635_D007177 CID valproate_3/NN (l_prep) to_4/IN (l_pobj) syndrome_6/NN (l_prep) of_7/IN (l_pobj) secretion_9/NN (l_prep) of_10/IN (l_pobj) hormone_12/NN
D014635_D007177 CID valproate_14/NN (l_conj) developed_21/VBD (l_dobj) syndrome_23/NN (l_prep) of_24/IN (l_pobj) secretion_26/NN (l_prep) of_27/IN (l_pobj) hormone_29/NN
D014635_D007177 CID valproate_14/NN (l_conj) developed_21/VBD (l_dobj) syndrome_23/NN (l_prep) of_24/IN (l_pobj) secretion_26/NN (l_prep) of_27/IN (l_pobj) hormone_29/NN (l_appos) SIADH_31/NNP
D014635_D007177 CID VPA_16/NNP (r_npadvmod) valproate_14/NN (l_conj) developed_21/VBD (l_dobj) syndrome_23/NN (l_prep) of_24/IN (l_pobj) secretion_26/NN (l_prep) of_27/IN (l_pobj) hormone_29/NN
D014635_D007177 CID VPA_16/NNP (r_npadvmod) valproate_14/NN (l_conj) developed_21/VBD (l_dobj) syndrome_23/NN (l_prep) of_24/IN (l_pobj) secretion_26/NN (l_prep) of_27/IN (l_pobj) hormone_29/NN (l_appos) SIADH_31/NNP
D014635_D007177 CID VPA_30/NNP (r_pobj) of_29/IN (r_prep) administration_28/NN (r_conj) weakness_17/NN (r_pobj) including_15/VBG (r_prep) factors_14/NNS (r_pobj) of_13/IN (r_prep) combination_12/NN (r_pobj) of_10/IN (r_prep) result_9/NN (r_attr) be_7/VB (l_nsubj) episode_3/NN (l_prep) of_4/IN (l_pobj) SIADH_5/NNP
8638876
D004958_D002341 CID estradiol_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_nsubj) increased_18/VBD (l_dobj) thrombogenicity_20/NN (l_relcl) provided_23/VBD (l_dobj) denominator_26/NN (l_prep) for_27/IN (l_pobj) thrombosis_28/NN (l_prep) of_29/IN (l_pobj) ICA_32/NNP (l_conj) sinus_36/NN
D004958_D014839 NONE estradiol_28/NN (r_conj) progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (r_conj) developed_9/VBD (l_dobj) headache_10/NN (l_conj) nausea_12/NN (l_conj) vomiting_14/NN
D004958_D010291 NONE estradiol_28/NN (r_conj) progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (l_dobj) hemiparesis_17/NN
D004958_D009325 NONE estradiol_28/NN (r_conj) progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (r_conj) developed_9/VBD (l_dobj) headache_10/NN (l_conj) nausea_12/NN
D011374_D010291 NONE progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (l_dobj) hemiparesis_17/NN
D011374_D012851 CID progesterone_13/NN (r_conj) estradiol_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_nsubj) increased_18/VBD (l_dobj) thrombogenicity_20/NN (l_relcl) provided_23/VBD (l_dobj) denominator_26/NN (l_prep) for_27/IN (l_pobj) thrombosis_28/NN (l_prep) of_29/IN (l_pobj) ICA_32/NNP (l_conj) sinus_36/NN
D004958_D012640 NONE estradiol_28/NN (r_conj) progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (l_dobj) hemiparesis_17/NN (l_conj) seizure_19/NN
D004958_D012851 CID estradiol_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_nsubj) increased_18/VBD (l_dobj) thrombogenicity_20/NN (l_relcl) provided_23/VBD (l_dobj) denominator_26/NN (l_prep) for_27/IN (l_pobj) thrombosis_28/NN (l_prep) of_29/IN (l_pobj) ICA_32/NNP (l_conj) sinus_36/NN
D011374_D006261 NONE progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (r_conj) developed_9/VBD (l_dobj) headache_10/NN
D004958_D003920 NONE estradiol_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (l_conj) DM_17/NNP
D011374_D014839 NONE progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (r_conj) developed_9/VBD (l_dobj) headache_10/NN (l_conj) nausea_12/NN (l_conj) vomiting_14/NN
D004958_D006261 NONE estradiol_28/NN (r_conj) progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (r_conj) developed_9/VBD (l_dobj) headache_10/NN
D011374_D002341 CID progesterone_13/NN (r_conj) estradiol_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_nsubj) increased_18/VBD (l_dobj) thrombogenicity_20/NN (l_relcl) provided_23/VBD (l_dobj) denominator_26/NN (l_prep) for_27/IN (l_pobj) thrombosis_28/NN (l_prep) of_29/IN (l_pobj) ICA_32/NNP (l_conj) sinus_36/NN
D011374_D012640 NONE progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (l_dobj) hemiparesis_17/NN (l_conj) seizure_19/NN
D011374_D003920 NONE progesterone_13/NN (r_conj) estradiol_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (l_conj) DM_17/NNP
D011374_D009325 NONE progesterone_26/NN (r_pobj) of_25/IN (r_prep) use_24/NN (r_pobj) after_22/IN (r_prep) left_16/VBD (r_conj) developed_9/VBD (l_dobj) headache_10/NN (l_conj) nausea_12/NN
9579567
D013629_D016889 CID tamoxifen_9/NN (r_compound) use_10/NN (r_conj) cancer_7/NN
D013629_D016889 CID tamoxifen_4/NN (r_dobj) received_3/VBN (r_relcl) Women_0/NNS (r_nsubj) were_5/VBD (l_acomp) likely_8/JJ (l_xcomp) have_10/VB (l_dobj) cancer_12/NN
D013629_D016889 CID tamoxifen_8/NN (r_advmod) received_7/VBN (r_conj) had_2/VBD (l_dobj) cancer_4/NN
D013629_D016889 CID tamoxifen_8/NN (r_advmod) received_7/VBN (r_conj) had_2/VBD (r_relcl) Women_0/NNS (r_nsubj) had_9/VBD (l_dobj) disease_12/NN (l_conj) prognosis_15/NN (l_prep) than_16/IN (l_pobj) those_17/DT (l_prep) with_18/IN (l_pobj) cancer_20/NN
D013629_D016889 CID tamoxifen_7/NN (r_pobj) of_6/IN (r_prep) role_5/NN (l_prep) in_8/IN (l_pobj) cancer_10/NN
D013629_D016889 CID tamoxifen_7/NN (r_pobj) with_6/IN (r_prep) treated_5/VBN (r_acl) women_4/NNS (r_pobj) in_3/IN (r_prep) diagnosed_2/VBD (r_acl) cancers_1/NNS
D013629_D001943 NONE tamoxifen_1/NN (r_nsubjpass) used_4/VBN (l_prep) in_5/IN (l_pobj) treatment_8/NN (l_compound) cancer_7/NN
D013629_D001943 NONE tamoxifen_1/NN (r_nsubjpass) used_4/VBN (l_conj) proposed_12/VBN (l_prep) for_13/IN (l_pobj) prevention_15/NN (l_prep) of_16/IN (l_pobj) cancer_18/NN
D013629_D001943 NONE tamoxifen_9/NN (r_compound) use_10/NN (r_conj) cancer_7/NN (r_pobj) between_5/IN (r_prep) association_4/NN (l_acl) treated_16/VBN (l_prep) for_17/IN (l_pobj) cancer_19/NN
D013629_D001943 NONE tamoxifen_7/NN (r_pobj) of_6/IN (r_prep) role_5/NN (r_dobj) suggest_2/VBP (l_advcl) used_14/VBN (l_xcomp) proposed_17/VBN (l_prep) for_18/IN (l_pobj) prevention_21/NN (l_compound) cancer_20/NN
D013629_D001943 NONE tamoxifen_3/NN (r_dobj) receive_2/VBP (l_prep) for_4/IN (l_pobj) cancer_6/NN
D013629_D001943 NONE tamoxifen_12/NN (r_pobj) of_11/IN (r_prep) ratio_10/NN (r_pobj) of_5/IN (r_prep) evaluation_4/NN (l_prep) as_13/IN (l_pobj) treatment_16/NN (l_prep) for_17/IN (l_pobj) cancer_19/NN
D013629_D020178 NONE tamoxifen_8/NN (r_advmod) received_7/VBN (r_conj) had_2/VBD (r_relcl) Women_0/NNS (r_nsubj) had_9/VBD (l_dobj) disease_12/NN
9952311
D004317_D001919 CID ADR_10/NNP (r_pobj) with_9/IN (r_prep) mice_8/NNS (r_pobj) of_7/IN (r_prep) treatment_6/NN (r_nsubj) caused_11/VBD (l_dobj) arrhythmias_13/NNS (l_acl) characterized_14/VBN (l_agent) by_15/IN (l_pobj) bradycardia_16/NNP
D004317_D001145 NONE ADR_10/NNP (r_pobj) with_9/IN (r_prep) mice_8/NNS (r_pobj) of_7/IN (r_prep) treatment_6/NN (r_nsubj) caused_11/VBD (l_dobj) arrhythmias_13/NNS
D004317_D002318 NONE adriamycin_3/NNS (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubjpass) limited_12/VBN (l_prep) due_13/IN (l_pcomp) to_14/IN (l_pobj) toxicity_18/NN
D004317_D002318 NONE ADR_5/NNP (r_appos) adriamycin_3/NNS (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubjpass) limited_12/VBN (l_prep) due_13/IN (l_pcomp) to_14/IN (l_pobj) toxicity_18/NN
D004317_D004487 NONE ADR_10/NNP (r_pobj) with_9/IN (r_prep) mice_8/NNS (r_pobj) of_7/IN (r_prep) treatment_6/NN (r_nsubj) caused_11/VBD (l_ccomp) swelling_51/NN
D004317_D009202 NONE adriamycin_7/NNS (r_npadvmod) induced_9/VBN (r_amod) cardiomyopathy_10/NN
D004317_D028361 CID adriamycin_7/NNS (r_npadvmod) induced_9/VBN (r_amod) cardiomyopathy_10/NN (r_pobj) in_6/IN (r_prep) impairment_3/NN (l_prep) of_4/IN (l_pobj) mitochondria_5/NN
D004317_D028361 CID ADR_21/NNP (r_pobj) of_20/IN (r_prep) effects_19/NNS (r_nsubj) involve_25/VBP (l_dobj) impairment_30/NN
D004317_D009369 NONE adriamycin_3/NNS (r_pobj) of_2/IN (r_prep) use_1/NN (l_prep) in_7/IN (l_pobj) chemotherapy_9/NN (l_compound) cancer_8/NN
D004317_D009369 NONE ADR_5/NNP (r_appos) adriamycin_3/NNS (r_pobj) of_2/IN (r_prep) use_1/NN (l_prep) in_7/IN (l_pobj) chemotherapy_9/NN (l_compound) cancer_8/NN
15897593
D011034_D066126 NONE epipodophyllotoxin_7/NN (r_conj) doxorubicin_4/NN (r_conj) daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN (l_conj) toxicity_29/NN
D004317_D064420 NONE doxorubicin_41/NN (r_pobj) from_40/IN (r_prep) cytotoxicity_39/NN
D018943_D066126 NONE anthracyclines_1/NNS (r_nsubj) daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN (l_conj) toxicity_29/NN
D018943_D066126 NONE anthracycline_9/NN (r_advmod) induced_11/VBN (r_amod) cardiotoxicity_12/NN
D064730_D015431 NONE dexrazoxane_3/NN (r_npadvmod) reduced_4/VBN (r_amod) myelosuppression_5/NN (l_conj) loss_8/NN
D064730_D015431 NONE dexrazoxane_3/NN (r_npadvmod) reduced_4/VBN (r_amod) myelosuppression_5/NN (r_pobj) of_2/IN (r_prep) doses_1/NNS (r_nsubj) dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN (l_conj) loss_33/NN
D064730_D015431 NONE dexrazoxane_27/NN (l_nsubj) doses_1/NNS (l_prep) of_2/IN (l_pobj) myelosuppression_5/NN (l_conj) loss_8/NN
D064730_D015431 NONE dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN (l_conj) loss_33/NN
D003630_D066126 NONE daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN (l_conj) toxicity_29/NN
D064730_D006402 NONE dexrazoxane_12/NN (r_pobj) of_11/IN (r_prep) coadministration_10/NN (r_pobj) following_9/VBG (r_prep) toxicity_8/NN
D064730_D006402 NONE dexrazoxane_40/NN (r_dobj) doxorubicin_38/NN (r_conj) daunorubicin_35/NNS (r_conj) etoposide_33/VB (r_pobj) to_32/TO (r_prep) Sensitivity_24/NN (r_nsubjpass) determined_42/VBN (l_advcl) investigated_22/VBN (l_nsubjpass) toxicity_8/NN
D064730_D006402 NONE dexrazoxane_8/NN (r_nmod) doses_11/NNS (r_dobj) combining_7/VBG (r_acl) metastases_6/NNS (r_pobj) with_4/IN (r_prep) patients_3/NNS (r_pobj) in_2/IN (r_prep) trials_1/NNS (r_nsubj) is_14/VBZ (l_acomp) ongoing_15/JJ (l_prep) with_16/IN (l_pobj) aim_18/NN (l_prep) of_19/IN (l_pcomp) improving_20/VBG (l_prep) without_22/IN (l_pcomp) aggravating_23/VBG (l_dobj) toxicity_25/NN
D011034_D001855 NONE epipodophyllotoxin_7/NN (r_conj) doxorubicin_4/NN (r_conj) daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN
D064730_D009362 NONE dexrazoxane_8/NN (r_nmod) doses_11/NNS (r_dobj) combining_7/VBG (r_acl) metastases_6/NNS
D064730_D066126 NONE Dexrazoxane_0/NNP (r_nsubjpass) recommended_5/VBN (l_prep) for_6/IN (l_pobj) protection_7/NN (l_prep) against_8/IN (l_pobj) cardiotoxicity_12/NN
D064730_D066126 NONE ICRF-187_2/NN (r_appos) Dexrazoxane_0/NNP (r_nsubjpass) recommended_5/VBN (l_prep) for_6/IN (l_pobj) protection_7/NN (l_prep) against_8/IN (l_pobj) cardiotoxicity_12/NN
D064730_D064420 NONE dexrazoxane_3/NN (r_npadvmod) reduced_4/VBN (r_amod) myelosuppression_5/NN (r_pobj) of_2/IN (r_prep) doses_1/NNS (r_nsubj) dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN (l_conj) loss_33/NN (l_conj) cytotoxicity_39/NN
D064730_D064420 NONE dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN (l_conj) loss_33/NN (l_conj) cytotoxicity_39/NN
D004317_D066126 NONE doxorubicin_4/NN (r_conj) daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN (l_conj) toxicity_29/NN
D005047_D064420 NONE etoposide_12/RB (r_conj) daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (r_nsubj) dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN (l_conj) loss_33/NN (l_conj) cytotoxicity_39/NN
D005047_D001855 NONE etoposide_11/NN (r_advmod) protects_1/VBZ (l_prep) against_2/IN (l_pobj) myelosuppression_3/NN
D005047_D001855 NONE etoposide_8/NN (r_appos) epipodophyllotoxin_7/NN (r_conj) doxorubicin_4/NN (r_conj) daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN
D005047_D001855 NONE etoposide_12/RB (r_conj) daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (l_prep) of_2/IN (l_pobj) myelosuppression_5/NN
D005047_D001855 NONE etoposide_12/RB (r_conj) daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (r_nsubj) dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN
D005047_D006402 CID etoposide_33/VB (r_pobj) to_32/TO (r_prep) Sensitivity_24/NN (r_nsubjpass) determined_42/VBN (l_advcl) investigated_22/VBN (l_nsubjpass) toxicity_8/NN
D005047_D006402 CID etoposide_13/NN (r_pobj) of_12/IN (r_prep) doses_11/NNS (r_dobj) combining_7/VBG (r_acl) metastases_6/NNS (r_pobj) with_4/IN (r_prep) patients_3/NNS (r_pobj) in_2/IN (r_prep) trials_1/NNS (r_nsubj) is_14/VBZ (l_acomp) ongoing_15/JJ (l_prep) with_16/IN (l_pobj) aim_18/NN (l_prep) of_19/IN (l_pcomp) improving_20/VBG (l_prep) without_22/IN (l_pcomp) aggravating_23/VBG (l_dobj) toxicity_25/NN
D003630_D015431 CID daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (l_prep) of_2/IN (l_pobj) myelosuppression_5/NN (l_conj) loss_8/NN
D003630_D015431 CID daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (r_nsubj) dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN (l_conj) loss_33/NN
D003630_D064420 NONE daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (r_nsubj) dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN (l_conj) loss_33/NN (l_conj) cytotoxicity_39/NN
D005047_D066126 NONE etoposide_8/NN (r_appos) epipodophyllotoxin_7/NN (r_conj) doxorubicin_4/NN (r_conj) daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN (l_conj) toxicity_29/NN
D005047_D009362 NONE etoposide_13/NN (r_pobj) of_12/IN (r_prep) doses_11/NNS (r_dobj) combining_7/VBG (r_acl) metastases_6/NNS
D004317_D006402 CID doxorubicin_38/NN (r_conj) daunorubicin_35/NNS (r_conj) etoposide_33/VB (r_pobj) to_32/TO (r_prep) Sensitivity_24/NN (r_nsubjpass) determined_42/VBN (l_advcl) investigated_22/VBN (l_nsubjpass) toxicity_8/NN
D004317_D001855 NONE doxorubicin_16/RB (r_conj) etoposide_11/NN (r_advmod) protects_1/VBZ (l_prep) against_2/IN (l_pobj) myelosuppression_3/NN
D004317_D001855 NONE doxorubicin_4/NN (r_conj) daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN
D004317_D001855 NONE doxorubicin_41/NN (r_pobj) from_40/IN (r_prep) cytotoxicity_39/NN (r_conj) loss_33/NN (r_conj) myelosuppression_30/NN (r_dobj) dexrazoxane_27/NN (l_nsubj) doses_1/NNS (l_prep) of_2/IN (l_pobj) myelosuppression_5/NN
D004317_D001855 NONE doxorubicin_41/NN (r_pobj) from_40/IN (r_prep) cytotoxicity_39/NN (r_conj) loss_33/NN (r_conj) myelosuppression_30/NN
D064730_D001855 NONE Dexrazoxane_0/NNP (r_nsubj) protects_1/VBZ (l_prep) against_2/IN (l_pobj) myelosuppression_3/NN
D064730_D001855 NONE dexrazoxane_3/NN (r_npadvmod) reduced_4/VBN (r_amod) myelosuppression_5/NN
D064730_D001855 NONE dexrazoxane_3/NN (r_npadvmod) reduced_4/VBN (r_amod) myelosuppression_5/NN (r_pobj) of_2/IN (r_prep) doses_1/NNS (r_nsubj) dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN
D064730_D001855 NONE dexrazoxane_27/NN (l_nsubj) doses_1/NNS (l_prep) of_2/IN (l_pobj) myelosuppression_5/NN
D064730_D001855 NONE dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN
D003630_D006402 CID daunorubicin_35/NNS (r_conj) etoposide_33/VB (r_pobj) to_32/TO (r_prep) Sensitivity_24/NN (r_nsubjpass) determined_42/VBN (l_advcl) investigated_22/VBN (l_nsubjpass) toxicity_8/NN
D018943_D001855 NONE anthracyclines_1/NNS (r_nsubj) daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN
D003630_D001855 NONE daunorubicin_13/NNS (r_conj) etoposide_11/NN (r_advmod) protects_1/VBZ (l_prep) against_2/IN (l_pobj) myelosuppression_3/NN
D003630_D001855 NONE daunorubicin_2/NN (r_ccomp) limit_30/VBP (l_nsubj) myelosuppression_26/NN
D003630_D001855 NONE daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (l_prep) of_2/IN (l_pobj) myelosuppression_5/NN
D003630_D001855 NONE daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (r_nsubj) dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN
D004317_D015431 CID doxorubicin_41/NN (r_pobj) from_40/IN (r_prep) cytotoxicity_39/NN (r_conj) loss_33/NN (r_conj) myelosuppression_30/NN (r_dobj) dexrazoxane_27/NN (l_nsubj) doses_1/NNS (l_prep) of_2/IN (l_pobj) myelosuppression_5/NN (l_conj) loss_8/NN
D004317_D015431 CID doxorubicin_41/NN (r_pobj) from_40/IN (r_prep) cytotoxicity_39/NN (r_conj) loss_33/NN
D005047_D015431 CID etoposide_12/RB (r_conj) daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (l_prep) of_2/IN (l_pobj) myelosuppression_5/NN (l_conj) loss_8/NN
D005047_D015431 CID etoposide_12/RB (r_conj) daunorubicin_10/NN (r_pobj) from_9/IN (r_prep) doses_1/NNS (r_nsubj) dexrazoxane_27/NN (l_dobj) myelosuppression_30/NN (l_conj) loss_33/NN
982002
D012293_D058186 CID rifampicin_8/NNS (r_pobj) of_7/IN (r_prep) administration_6/NN (r_pobj) to_4/IN (r_prep) subsequent_3/JJ (r_amod) failure_2/NN
D012293_D051437 NONE rifampicin_12/NNS (r_pobj) of_11/IN (r_prep) administration_10/NN (r_pobj) after_7/IN (r_prep) developed_3/VBN (l_dobj) failure_6/NN
1610717
D003042_D012640 CID Cocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) seizures_4/NNS
12093990
D012254_D000740 NONE ribavirin_7/RB (r_pobj) of_5/IN (r_prep) effect_4/NN (r_nsubj) is_8/VBZ (l_attr) anemia_11/NN
D012254_D006482 NONE Ribavirin_0/NNP (r_nsubjpass) licensed_2/VBN (l_conj) is_27/VBZ (l_attr) treatment_29/NN (l_prep) for_32/IN (l_pobj) infection_33/NN (l_prep) with_34/IN (l_pobj) viruses_37/NNS
D012254_D006482 NONE ribavirin_26/RB (r_dobj) treat_22/VB (r_conj) licensed_2/VBN (l_conj) is_27/VBZ (l_attr) treatment_29/NN (l_prep) for_32/IN (l_pobj) infection_33/NN (l_prep) with_34/IN (l_pobj) viruses_37/NNS
C059262_D000257 NONE cidofovir_3/NN (r_pobj) of_2/IN (r_prep) use_1/NN (l_prep) in_4/IN (l_pobj) infection_7/NN
D012254_D000257 NONE ribavirin_1/JJ (r_compound) treatment_2/NN (l_prep) for_3/IN (l_pobj) disease_6/NN
D012254_D000257 NONE ribavirin_7/NN (r_compound) therapy_8/NN (r_pobj) with_5/IN (r_prep) experience_4/NN (l_prep) for_9/IN (l_pobj) disease_12/NN
D012254_D000257 NONE ribavirin_12/RB (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_prep) for_13/IN (l_pobj) disease_17/NN
D012254_D000257 NONE ribavirin_2/NN (r_nsubj) was_3/VBD (l_acomp) effective_5/JJ (l_prep) for_6/IN (l_pobj) children_8/NNS (l_prep) with_9/IN (l_pobj) disease_12/NN
D012254_D000257 NONE ribavirin_11/RB (r_pobj) with_9/IN (r_prep) treated_8/VBN (l_nsubj) children_3/NNS (l_prep) with_4/IN (l_pobj) disease_7/NN
D012254_D000257 NONE ribavirin_33/NN (r_pobj) as_31/IN (r_prep) therapies_28/NNS (r_pobj) of_22/IN (r_prep) trial_21/NN (r_conj) children_14/NNS (r_appos) hosts_11/NNS (r_pobj) in_9/IN (r_prep) prevalence_5/NN (l_prep) of_6/IN (l_pobj) disease_8/NN
C059262_D009503 CID cidofovir_2/NN (r_pobj) of_1/IN (r_prep) Use_0/NN (r_nsubjpass) associated_7/VBN (l_prep) with_8/IN (l_pobj) failure_11/NN (l_conj) neutropenia_13/NN
D012254_D018357 NONE Ribavirin_0/NNP (r_nsubjpass) licensed_2/VBN (l_prep) in_3/IN (l_pobj) form_5/NN (l_prep) for_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) infection_13/NN
D012254_D018357 NONE ribavirin_26/RB (r_dobj) treat_22/VB (r_conj) licensed_2/VBN (l_prep) in_3/IN (l_pobj) form_5/NN (l_prep) for_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) infection_13/NN
D012254_D006526 NONE Ribavirin_0/NNP (r_nsubjpass) licensed_2/VBN (l_conj) treat_22/VB (l_dobj) ribavirin_26/RB (l_compound) Intravenous_25/NNP (l_compound) C._24/NNP
D012254_D006526 NONE ribavirin_26/RB (l_compound) Intravenous_25/NNP (l_compound) C._24/NNP
C059262_D007674 NONE cidofovir_3/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubjpass) limited_10/VBN (r_ccomp) is_20/VBZ (l_attr) nephrotoxicity_21/NN
D012254_D007239 NONE ribavirin_2/NN (r_nsubj) was_3/VBD (r_advcl) is_22/VBZ (l_advcl) begun_29/VBN (l_prep) in_31/IN (l_pobj) course_33/NN (l_prep) of_34/IN (l_pobj) infection_36/NN
C059262_D058186 CID cidofovir_2/NN (r_pobj) of_1/IN (r_prep) Use_0/NN (r_nsubjpass) associated_7/VBN (l_prep) with_8/IN (l_pobj) failure_11/NN
761833
D007980_D001927 NONE dopa_18/NNP (r_dobj) receiving_15/VBG (r_acl) patients_14/NNS (l_amod) encephalopathic_13/JJ
D004298_D003128 NONE dopamine_3/NN (r_pobj) of_2/IN (r_prep) infusion_1/NN (r_nsubj) sufficient_4/JJ (l_conj) prevent_16/VB (l_dobj) coma_19/NN
D004298_D003128 NONE dopamine_9/NN (r_dobj) raise_6/VB (r_xcomp) sufficient_4/JJ (l_conj) prevent_16/VB (l_dobj) coma_19/NN
D004298_D003128 NONE dopamine_29/NN (r_pobj) of_28/IN (r_prep) effect_27/NN (r_pobj) by_24/IN (r_agent) accounted_22/VBN (l_nsubjpass) reduction_3/NN (l_conj) prevention_11/NN (l_prep) of_12/IN (l_pobj) coma_14/NN
D000641_D003128 NONE ammonia_2/NN (r_compound) coma_3/NN
D000641_D003128 NONE Ammonia_0/NN (r_compound) coma_1/NN
D000641_D003128 NONE ammonia_18/NN (r_compound) coma_19/NN
D000641_D003128 NONE ammonia_26/NN (r_compound) concentrations_27/NNS (r_dobj) affect_21/VB (r_conj) prevent_16/VB (l_dobj) coma_19/NN
D000641_D003128 NONE ammonia_14/NN (r_pobj) on_10/IN (r_prep) dopa_9/NN (l_conj) coma_18/NN
D000641_D003128 NONE ammonia_17/NN (r_compound) coma_18/NN
D000641_D003128 NONE ammonia_8/NN (r_pobj) in_4/IN (r_prep) reduction_3/NN (l_conj) prevention_11/NN (l_prep) of_12/IN (l_pobj) coma_14/NN
D000641_D003128 NONE ammonia_13/NN (r_compound) coma_14/NN
D000643_D003128 CID NH4CL_17/NN (r_pobj) of_14/IN (r_prep) intraperitonealinjection_13/NN (r_pobj) of_11/IN (r_prep) minutes_10/NNS (r_pobj) within_6/IN (r_prep) rats_5/NNS (r_pobj) in_4/IN (r_prep) produced_3/VBN (l_nsubjpass) coma_1/NN
D007980_D003128 NONE dopa_9/NNP (r_pobj) by_6/IN (r_prep) rats_5/NNS (r_pobj) in_4/IN (r_prep) coma_3/NN
D007980_D003128 NONE dopa_9/NN (r_pobj) with_4/IN (r_prep) prevented_3/VBN (l_nsubjpass) coma_1/NN
D007980_D003128 NONE dopa_9/NN (l_conj) coma_18/NN
D007980_D003128 NONE dopa_18/NNP (r_pobj) after_15/IN (r_prep) prevention_11/NN (l_prep) of_12/IN (l_pobj) coma_14/NN
D064751_D003128 NONE salt_19/NN (r_compound) injection_20/NN (r_pobj) before_16/IN (r_prep) prevented_3/VBN (l_nsubjpass) coma_1/NN
8278214
D009020_D009207 CID morphine_11/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (r_acl) patients_6/NNS (r_pobj) in_3/IN (r_prep) myoclonus_2/NN
D009020_D009207 CID morphine_16/NN (r_pobj) of_15/IN (r_prep) doses_14/NNS (r_conj) myoclonus_11/NN
D009020_D009207 CID morphine_27/NN (r_nsubj) plays_33/VBZ (r_ccomp) indicates_25/VBZ (l_advcl) are_17/VBP (l_nsubj) descriptions_4/NNS (l_prep) of_5/IN (l_pobj) relationship_7/NN (l_prep) between_8/IN (l_pobj) myoclonus_11/NN
D009020_D009369 NONE morphine_11/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (r_acl) patients_6/NNS (l_compound) cancer_5/NN
D009020_D009369 NONE morphine_16/NN (r_pobj) of_14/IN (r_prep) doses_13/NNS (r_pobj) with_11/IN (r_prep) treated_10/VBN (l_nsubj) patients_2/NNS (l_compound) cancer_1/NN
D009020_D006930 CID morphine_11/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (r_acl) patients_6/NNS (r_pobj) in_3/IN (r_prep) myoclonus_2/NN (r_conj) Hyperalgesia_0/NNP
D009020_D006930 CID morphine_16/NN (r_pobj) of_14/IN (r_prep) doses_13/NNS (r_pobj) with_11/IN (r_prep) treated_10/VBN (l_advcl) developed_17/VBN (l_dobj) hyperalgesia_18/NN
D009020_D006930 CID morphine_16/NN (r_pobj) of_15/IN (r_prep) doses_14/NNS (r_conj) myoclonus_11/NN (l_nmod) hyperalgesia_9/NN
D009020_D006930 CID morphine_27/NN (r_nsubj) plays_33/VBZ (r_ccomp) indicates_25/VBZ (l_advcl) are_17/VBP (l_nsubj) descriptions_4/NNS (l_prep) of_5/IN (l_pobj) relationship_7/NN (l_prep) between_8/IN (l_pobj) myoclonus_11/NN (l_nmod) hyperalgesia_9/NN
7650771
D004456_D009157 NONE iodide_12/NN (r_nmod) drops_14/NNS (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) from_7/IN (r_prep) syndrome_6/NN (r_dobj) developed_2/VBD (l_conj) presented_16/VBN (l_conj) given_24/VBN (l_dobj) diagnosis_26/NN (l_prep) of_27/IN (l_pobj) gravis_29/NN
D004456_D018908 CID iodide_12/NN (r_nmod) drops_14/NNS (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) from_7/IN (r_prep) syndrome_6/NN (r_dobj) developed_2/VBD (l_conj) presented_16/VBN (l_prep) with_17/IN (l_pobj) weakness_20/NN
D004456_D064420 NONE iodide_8/NN (r_compound) drops_10/VBZ (r_pobj) of_6/IN (r_prep) instillation_5/NN (r_pobj) from_3/IN (r_prep) resulting_2/VBG (r_acl) toxicity_1/NN
2826064
D013726_D007008 CID terbutaline_9/NN (r_npadvmod) induced_11/VBN (r_amod) hypokalemia_12/NN
D013726_D007008 CID terbutaline_4/JJ (r_compound) concentrations_5/NNS (r_pobj) of_2/IN (r_prep) spite_1/NN (r_pobj) In_0/IN (r_prep) antagonized_15/VBN (l_nsubjpass) hypokalemia_11/NN
D010096_D007008 NONE oxprenolol_8/NN (r_pobj) by_7/IN (r_prep) abolishment_6/NN (r_conj) hypokalemia_3/NN
D010096_D007008 NONE oxprenolol_6/NN (r_pobj) of_5/IN (r_prep) efficacy_4/NN (r_dobj) investigated_2/VBD (l_prep) in_7/IN (l_pcomp) antagonizing_8/VBG (l_dobj) hypokalemia_10/NN
D010096_D007008 NONE oxprenolol_7/NN (r_amod) pretreatment_8/NN (r_pobj) after_6/IN (r_prep) concentrations_5/NNS (r_pobj) of_2/IN (r_prep) spite_1/NN (r_pobj) In_0/IN (r_prep) antagonized_15/VBN (l_nsubjpass) hypokalemia_11/NN
10728962
D014667_D006333 NONE Vasopressin_0/NN (l_prep) in_1/IN (l_pobj) treatment_3/NN (l_prep) of_4/IN (l_pobj) hypotension_8/NN (l_prep) in_9/IN (l_pobj) failure_12/NN
D014667_D006333 NONE vasopressin_16/NN (r_pobj) of_15/IN (r_prep) doses_14/NNS (r_nsubj) restored_17/VBD (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) failure_5/NN
D014667_D007022 CID Vasopressin_0/NN (l_prep) in_1/IN (l_pobj) treatment_3/NN (l_prep) of_4/IN (l_pobj) hypotension_8/NN
D014667_D007022 CID vasopressin_16/NN (r_pobj) of_15/IN (r_prep) doses_14/NNS (r_nsubj) restored_17/VBD (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) failure_5/NN (l_prep) with_6/IN (l_pobj) hypotension_7/NN
D020105_D006333 NONE milrinone_5/NN (r_npadvmod) induced_7/VBN (r_amod) hypotension_8/NN (l_prep) in_9/IN (l_pobj) failure_12/NN
D020105_D006333 NONE milrinone_7/NN (l_prep) in_8/IN (l_pobj) treatment_10/NN (l_prep) of_11/IN (l_pobj) failure_14/NN
D020105_D006333 NONE milrinone_11/NN (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_pobj) after_8/IN (r_prep) hypotension_7/NN (r_pobj) with_6/IN (r_prep) failure_5/NN
D020105_D006333 NONE milrinone_26/NN (r_pobj) of_25/IN (r_prep) effect_24/NN (r_dobj) inhibiting_21/VBG (r_pcomp) without_20/IN (r_prep) restored_17/VBD (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) failure_5/NN
D020105_D007022 CID milrinone_5/NN (r_npadvmod) induced_7/VBN (r_amod) hypotension_8/NN
D020105_D007022 CID milrinone_7/NN (r_pobj) as_6/IN (r_prep) inhibitors_4/NNS (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubjpass) restricted_17/VBN (l_advcl) cause_20/VBP (l_dobj) vasodilation_21/NN (l_conj) hypotension_23/NN
D020105_D007022 CID milrinone_11/NN (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_pobj) after_8/IN (r_prep) hypotension_7/NN
D020105_D007022 CID milrinone_26/NN (r_pobj) of_25/IN (r_prep) effect_24/NN (r_dobj) inhibiting_21/VBG (r_pcomp) without_20/IN (r_prep) restored_17/VBD (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) failure_5/NN (l_prep) with_6/IN (l_pobj) hypotension_7/NN
48362
D011802_D056486 CID Quinidine_0/NN (r_compound) hepatitis_1/NN
D011802_D056486 CID quinidine_6/VBN (r_poss) hepatotoxicity_7/NN
6699841
D012459_D001172 NONE salicylates_22/NNS (r_conj) calcium_18/NN (r_conj) sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (l_prep) with_5/IN (l_pobj) arthritis_7/NN
D009288_D007681 CID naproxen_5/NN (r_pobj) due_3/IN (r_prep) necrosis_2/NN
D009288_D007681 CID naproxen_39/NN (r_compound) therapy_40/NN (r_pobj) of_38/IN (r_prep) institution_37/NN (r_pobj) after_36/IN (r_prep) developed_27/VBD (l_dobj) necrosis_30/NN
D009288_D007681 CID naproxen_39/NN (r_compound) therapy_40/NN (r_pobj) of_38/IN (r_prep) institution_37/NN (r_pobj) after_36/IN (r_prep) developed_27/VBD (l_dobj) necrosis_30/NN (l_appos) RPN_32/NNP
D005279_D007681 NONE calcium_18/NN (r_conj) sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (r_nsubj) developed_27/VBD (l_dobj) necrosis_30/NN
D005279_D007681 NONE calcium_18/NN (r_conj) sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (r_nsubj) developed_27/VBD (l_dobj) necrosis_30/NN (l_appos) RPN_32/NNP
D006046_D007681 NONE gold_24/NN (r_compound) salts_25/NNS (r_conj) salicylates_22/NNS (r_conj) calcium_18/NN (r_conj) sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (r_nsubj) developed_27/VBD (l_dobj) necrosis_30/NN
D006046_D007681 NONE gold_24/NN (r_compound) salts_25/NNS (r_conj) salicylates_22/NNS (r_conj) calcium_18/NN (r_conj) sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (r_nsubj) developed_27/VBD (l_dobj) necrosis_30/NN (l_appos) RPN_32/NNP
D013467_D001172 NONE sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (l_prep) with_5/IN (l_pobj) arthritis_7/NN
D009288_D001172 NONE naproxen_39/NN (r_compound) therapy_40/NN (r_pobj) of_38/IN (r_prep) institution_37/NN (r_pobj) after_36/IN (r_prep) developed_27/VBD (l_nsubj) man_4/NN (l_prep) with_5/IN (l_pobj) arthritis_7/NN
D005279_D001172 NONE calcium_18/NN (r_conj) sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (l_prep) with_5/IN (l_pobj) arthritis_7/NN
D006046_D001172 NONE gold_24/NN (r_compound) salts_25/NNS (r_conj) salicylates_22/NNS (r_conj) calcium_18/NN (r_conj) sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (l_prep) with_5/IN (l_pobj) arthritis_7/NN
D013467_D007681 NONE sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (r_nsubj) developed_27/VBD (l_dobj) necrosis_30/NN
D013467_D007681 NONE sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (r_nsubj) developed_27/VBD (l_dobj) necrosis_30/NN (l_appos) RPN_32/NNP
D013467_D007681 NONE sulindac_15/NN (r_pobj) of_14/IN (r_prep) advantages_13/NNS (r_dobj) discuss_11/VB (r_conj) linking_4/VBG (l_dobj) RPN_5/NNP
D013467_D007674 NONE sulindac_15/NN (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_relcl) experienced_20/VBN (l_dobj) toxicity_22/NN
D012459_D007681 NONE salicylates_22/NNS (r_conj) calcium_18/NN (r_conj) sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (r_nsubj) developed_27/VBD (l_dobj) necrosis_30/NN
D012459_D007681 NONE salicylates_22/NNS (r_conj) calcium_18/NN (r_conj) sulindac_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_relcl) man_4/NN (r_nsubj) developed_27/VBD (l_dobj) necrosis_30/NN (l_appos) RPN_32/NNP
10411803
D002511_D000743 NONE cephalosporins_5/NNS (r_conj) Second-_0/NNP (r_nsubjpass) associated_12/VBN (l_prep) with_13/IN (l_pobj) anemia_20/NN
D015313_D000743 CID cefotetan_9/NN (r_pobj) of_8/IN (r_prep) use_7/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) anemia_3/NN
D015313_D000743 CID cefotetan_8/JJ (r_appos) cephalosporins_5/NNS (r_conj) Second-_0/NNP (r_nsubjpass) associated_12/VBN (l_prep) with_13/IN (l_pobj) anemia_20/NN
D015313_D000743 CID cefotetan_9/NN (r_npadvmod) induced_11/VBN (r_amod) anemias_13/NNS
D015313_D000743 CID cefotetan_20/JJ (r_dobj) received_19/VBN (r_relcl) patients_16/NNS (r_pobj) in_15/IN (r_prep) were_14/VBD (l_nsubj) 10_3/CD (l_prep) of_4/IN (l_pobj) cases_7/NNS (l_prep) of_8/IN (l_pobj) anemias_13/NNS
6308526
D009020_D007022 CID morphine_6/NN (r_npadvmod) induced_8/VBN (r_amod) depression_12/NN (l_nmod) hypotension_9/NN
D009020_D007022 CID morphine_15/NN (r_npadvmod) induced_17/VBN (r_amod) bradycardia_18/NN (r_nsubj) was_19/VBD (r_advcl) attenuated_4/VBD (l_dobj) depression_12/NN (l_nmod) hypotension_9/NN
C024224_D001919 NONE naloxazone_2/NN (r_nsubj) attenuated_4/VBD (l_advcl) was_19/VBD (l_nsubj) bradycardia_18/NN
C024224_D002375 NONE naloxazone_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) blocked_4/VBD (l_npadvmod) analgesia_6/NN (l_conj) catalepsy_8/NN
C024224_D007022 NONE naloxazone_2/NN (r_nsubj) attenuated_4/VBD (l_dobj) depression_12/NN (l_nmod) hypotension_9/NN
D009020_D007035 CID morphine_5/NN (r_dobj) blocked_4/VBD (l_npadvmod) analgesia_6/NN (l_conj) catalepsy_8/NN (l_conj) hypothermia_10/VBN
D009020_D012131 NONE morphine_6/NN (r_npadvmod) induced_8/VBN (r_amod) depression_12/NN
D009020_D012131 NONE morphine_15/NN (r_npadvmod) induced_17/VBN (r_amod) bradycardia_18/NN (r_nsubj) was_19/VBD (r_advcl) attenuated_4/VBD (l_dobj) depression_12/NN
D009020_D000699 NONE morphine_5/NN (r_dobj) blocked_4/VBD (l_npadvmod) analgesia_6/NN
C024224_D000699 NONE naloxazone_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) blocked_4/VBD (l_npadvmod) analgesia_6/NN
C024224_D007035 NONE naloxazone_2/NN (r_pobj) with_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) blocked_4/VBD (l_npadvmod) analgesia_6/NN (l_conj) catalepsy_8/NN (l_conj) hypothermia_10/VBN
C024224_D012131 NONE naloxazone_2/NN (r_nsubj) attenuated_4/VBD (l_dobj) depression_12/NN
D009020_D002375 CID morphine_5/NN (r_dobj) blocked_4/VBD (l_npadvmod) analgesia_6/NN (l_conj) catalepsy_8/NN
D009020_D001919 CID morphine_6/NN (r_npadvmod) induced_8/VBN (r_amod) depression_12/NN (r_dobj) attenuated_4/VBD (l_advcl) was_19/VBD (l_nsubj) bradycardia_18/NN
D009020_D001919 CID morphine_15/NN (r_npadvmod) induced_17/VBN (r_amod) bradycardia_18/NN
384871
D004977_D009901 CID ethambutol_6/NN (r_nmod) treatment_9/NN (r_pobj) due_3/IN (r_prep) neuropathy_2/NN
D004977_D064420 NONE ethambutol_8/NN (r_pobj) due_6/IN (r_amod) hazards_1/NNS (l_prep) of_2/IN (l_pobj) toxicity_5/NN
D007538_D009901 CID isoniazid_8/NN (r_conj) ethambutol_6/NN (r_nmod) treatment_9/NN (r_pobj) due_3/IN (r_prep) neuropathy_2/NN
9915601
D005680_D007022 NONE acid_29/NN (r_pobj) of_24/IN (r_prep) synthesis_23/NN (r_pobj) to_21/IN (r_prep) attributed_20/VBN (r_acl) interaction_19/NN (r_appos) doses_1/NNS (l_appos) hypotension_5/NN
D005680_D007022 NONE GABA_31/NNP (r_appos) acid_29/NN (r_pobj) of_24/IN (r_prep) synthesis_23/NN (r_pobj) to_21/IN (r_prep) attributed_20/VBN (r_acl) interaction_19/NN (r_appos) doses_1/NNS (l_appos) hypotension_5/NN
D007538_D013610 NONE isoniazid_3/NN (r_pobj) of_2/IN (r_prep) doses_1/NNS (l_appos) hypotension_5/NN (l_conj) change_10/VB (l_dobj) tachycardia_14/NN
D018738_D001919 NONE hexamethonium_22/NN (r_pobj) after_21/IN (r_conj) increased_2/VBD (l_acomp) bradycardia_3/NNP
D011433_D001919 NONE propranolol_5/NN (r_advcl) increased_2/VBD (l_acomp) bradycardia_3/NNP
D002698_D001919 NONE chloralose_24/NN (r_compound) urethane_26/NN (r_pobj) with_23/IN (r_prep) anaesthetised_22/VBN (r_acl) rats_21/NNS (r_pobj) in_20/IN (r_prep) determined_19/VBN (l_nsubjpass) enhancement_7/NN (l_prep) by_8/IN (l_pobj) isoniazid_9/NN (l_prep) of_10/IN (l_pobj) bradycardia_11/NN
D003000_D001919 NONE clonidine_17/NN (r_pobj) after_16/IN (r_prep) as_15/IN (r_cc) increased_2/VBD (l_acomp) bradycardia_3/NNP
D007741_D001919 NONE labetalol_9/JJ (r_conj) pindolol_7/NN (r_conj) propranolol_5/NN (r_advcl) increased_2/VBD (l_acomp) bradycardia_3/NNP
D007538_D007022 CID isoniazid_3/NN (r_pobj) of_2/IN (r_prep) doses_1/NNS (l_appos) hypotension_5/NN
D014520_D001919 NONE urethane_26/NN (r_pobj) with_23/IN (r_prep) anaesthetised_22/VBN (r_acl) rats_21/NNS (r_pobj) in_20/IN (r_prep) determined_19/VBN (l_nsubjpass) enhancement_7/NN (l_prep) by_8/IN (l_pobj) isoniazid_9/NN (l_prep) of_10/IN (l_pobj) bradycardia_11/NN
D005680_D001919 NONE acid_29/NN (r_pobj) of_24/IN (r_prep) synthesis_23/NN (r_pobj) to_21/IN (r_prep) attributed_20/VBN (r_acl) interaction_19/NN (r_appos) doses_1/NNS (l_appos) hypotension_5/NN (l_conj) change_10/VB (l_prep) to_15/IN (l_pobj) bradycardia_16/NNP
D005680_D001919 NONE GABA_31/NNP (r_appos) acid_29/NN (r_pobj) of_24/IN (r_prep) synthesis_23/NN (r_pobj) to_21/IN (r_prep) attributed_20/VBN (r_acl) interaction_19/NN (r_appos) doses_1/NNS (l_appos) hypotension_5/NN (l_conj) change_10/VB (l_prep) to_15/IN (l_pobj) bradycardia_16/NNP
D010869_D001919 NONE pindolol_7/NN (r_conj) propranolol_5/NN (r_advcl) increased_2/VBD (l_acomp) bradycardia_3/NNP
D007538_D001919 CID isoniazid_12/NN (r_pobj) with_11/IN (r_prep) pretreated_10/VBD (r_acl) rats_9/NNS (r_pobj) in_8/IN (r_prep) antagonists_7/NNS (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) bradycardia_1/NNS
D007538_D001919 CID isoniazid_3/NN (r_pobj) of_2/IN (r_prep) doses_1/NNS (l_appos) hypotension_5/NN (l_conj) change_10/VB (l_prep) to_15/IN (l_pobj) bradycardia_16/NNP
D007538_D001919 CID isoniazid_9/NN (l_prep) of_10/IN (l_pobj) bradycardia_11/NN
D007538_D001919 CID Isoniazid_0/NNP (r_nsubj) increased_2/VBD (l_acomp) bradycardia_3/NNP
D001262_D001919 NONE atenolol_11/NN (r_conj) labetalol_9/JJ (r_conj) pindolol_7/NN (r_conj) propranolol_5/NN (r_advcl) increased_2/VBD (l_acomp) bradycardia_3/NNP
D002217_D001919 NONE carbachol_24/NN (r_conj) hexamethonium_22/NN (r_pobj) after_21/IN (r_conj) increased_2/VBD (l_acomp) bradycardia_3/NNP
D005680_D013610 NONE acid_29/NN (r_pobj) of_24/IN (r_prep) synthesis_23/NN (r_pobj) to_21/IN (r_prep) attributed_20/VBN (r_acl) interaction_19/NN (r_appos) doses_1/NNS (l_appos) hypotension_5/NN (l_conj) change_10/VB (l_dobj) tachycardia_14/NN
D005680_D013610 NONE GABA_31/NNP (r_appos) acid_29/NN (r_pobj) of_24/IN (r_prep) synthesis_23/NN (r_pobj) to_21/IN (r_prep) attributed_20/VBN (r_acl) interaction_19/NN (r_appos) doses_1/NNS (l_appos) hypotension_5/NN (l_conj) change_10/VB (l_dobj) tachycardia_14/NN
14982270
D008713_D041781 CID Methimazole_0/NN (r_npadvmod) induced_2/VBN (r_amod) jaundice_4/NN
D011433_D007565 NONE propranolol_21/NN (r_conj) receiving_13/VBG (r_pcomp) after_12/IN (r_prep) itching_9/NN (r_conj) had_5/VBD (l_dobj) jaundice_7/NN
D008713_D007565 NONE methimazole_14/NN (r_dobj) receiving_13/VBG (r_pcomp) after_12/IN (r_prep) itching_9/NN (r_conj) had_5/VBD (l_dobj) jaundice_7/NN
D008713_D006980 NONE methimazole_14/NN (r_dobj) receiving_13/VBG (l_conj) propranolol_21/NN (l_prep) for_27/IN (l_pobj) treatment_28/NN (l_prep) of_29/IN (l_pobj) hyperthyroidism_30/NN
D008713_D011537 CID methimazole_14/NN (r_dobj) receiving_13/VBG (r_pcomp) after_12/IN (r_prep) itching_9/NN
D011433_D011537 NONE propranolol_21/NN (r_conj) receiving_13/VBG (r_pcomp) after_12/IN (r_prep) itching_9/NN
D011433_D006980 NONE propranolol_21/NN (l_prep) for_27/IN (l_pobj) treatment_28/NN (l_prep) of_29/IN (l_pobj) hyperthyroidism_30/NN
D011433_D002779 NONE propranolol_8/NN (r_conj) diagnosed_5/VBN (l_nsubjpass) cholestasis_3/NN
D008713_D002779 NONE Methimazole_0/NN (r_npadvmod) induced_2/VBN (r_amod) cholestasis_3/NN
2819587
17943461
D015215_D002311 CID zidovudine_12/NNP (r_appos) component_11/NN (r_nsubj) triggers_18/VBZ (l_conj) cause_28/VB (l_dobj) disruption_30/NN (l_prep) in_31/IN (l_pobj) model_34/NN (l_prep) of_35/IN (l_pobj) DCM_36/NNP
D015215_D002311 CID 3'-azido-2',3'-deoxythymidine_14/CD (r_appos) zidovudine_12/NNP (r_appos) component_11/NN (r_nsubj) triggers_18/VBZ (l_conj) cause_28/VB (l_dobj) disruption_30/NN (l_prep) in_31/IN (l_pobj) model_34/NN (l_prep) of_35/IN (l_pobj) DCM_36/NNP
D015215_D002311 CID AZT_16/NNP (r_appos) component_11/NN (r_nsubj) triggers_18/VBZ (l_conj) cause_28/VB (l_dobj) disruption_30/NN (l_prep) in_31/IN (l_pobj) model_34/NN (l_prep) of_35/IN (l_pobj) DCM_36/NNP
D015215_D002311 CID AZT_69/NNP (r_pobj) of_68/IN (r_prep) concentrations_67/NNS (r_dobj) containing_65/VBG (r_acl) libitum_64/NN (r_dobj) received_61/VBD (l_prep) In_4/IN (l_pobj) order_5/NN (l_acl) investigate_7/VB (l_ccomp) triggers_18/VBZ (l_conj) cause_28/VB (l_dobj) disruption_30/NN (l_prep) in_31/IN (l_pobj) model_34/NN (l_prep) of_35/IN (l_pobj) DCM_36/NNP
D015215_D002311 CID AZT_3/NNP (r_npadvmod) treated_5/VBN (r_amod) FasL_6/NNPS (r_compound) mice_8/NNS (r_nsubj) developed_9/VBD (l_dobj) dilation_11/NN
D015215_D009202 CID AZT_7/NNP (r_npadvmod) induced_9/VBN (r_amod) cardiomyopathy_10/NN
19893084
D005839_D058186 CID gentamicin_12/NN (r_pcomp) by_11/IN (r_agent) induced_10/VBN (r_acl) failure_9/NN
11282081
D004110_D001281 NONE Diltiazem_0/NNP (r_nsubj) affect_3/VB (l_dobj) ERP_4/NNP (l_conj) length_8/NN (l_compound) AF_6/NNP
D004110_D001281 NONE Diltiazem_0/NNP (r_nsubj) affect_3/VB (l_dobj) ERP_4/NNP (l_conj) length_8/NN (l_conj) duration_11/NN (l_compound) AF_10/NNP
D004110_D001281 NONE diltiazem_23/NN (r_pobj) by_22/IN (r_agent) shared_21/VBN (r_conj) effect_13/NN (r_dobj) promotes_1/VBZ (l_dobj) AF_2/NNP
D002698_D001281 NONE chloralose_21/NN (r_amod) dogs_23/NNS (r_pobj) to_18/IN (r_prep) administered_16/VBD (l_advcl) evaluate_1/VB (l_dobj) mechanisms_4/NNS (l_prep) of_5/IN (l_pobj) promotion_7/NN (l_compound) AF_6/NNP
D014700_D001281 CID verapamil_2/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_3/IN (l_pobj) fibrillation_5/NN
D014700_D001281 CID verapamil_17/NN (r_dobj) administered_16/VBD (l_advcl) evaluate_1/VB (l_dobj) mechanisms_4/NNS (l_prep) of_5/IN (l_pobj) promotion_7/NN (l_compound) AF_6/NNP
D014700_D001281 CID Verapamil_1/NNP (r_nsubj) caused_2/VBD (l_dobj) promotion_4/NN (l_compound) AF_3/NNP
D014700_D001281 CID Verapamil_1/NNP (r_nsubj) caused_2/VBD (l_advcl) increasing_9/VBG (l_dobj) duration_11/NN (l_prep) of_12/IN (l_pobj) AF_13/NNP
D014700_D001281 CID verapamil_4/NN (r_nsubj) shortened_5/VBN (l_conj) accelerated_43/VBN (l_conj) decreased_47/VBD (l_dobj) length_50/NN (l_prep) of_51/IN (l_pobj) 94+/-4_54/CD (l_nmod) AF_52/NNP
D014700_D001281 CID verapamil_22/NNP (r_nmod) n=5_24/NNS (r_pobj) by_21/IN (r_agent) caused_20/VBN (r_acl) that_19/DT (r_pobj) to_18/IN (r_prep) similar_17/JJ (r_amod) acceleration_16/NN (r_dobj) produced_14/VBD (r_conj) affect_3/VB (l_dobj) ERP_4/NNP (l_conj) length_8/NN (l_compound) AF_6/NNP
D014700_D001281 CID verapamil_22/NNP (r_nmod) n=5_24/NNS (r_pobj) by_21/IN (r_agent) caused_20/VBN (r_acl) that_19/DT (r_pobj) to_18/IN (r_prep) similar_17/JJ (r_amod) acceleration_16/NN (r_dobj) produced_14/VBD (r_conj) affect_3/VB (l_dobj) ERP_4/NNP (l_conj) length_8/NN (l_conj) duration_11/NN (l_compound) AF_10/NNP
D014700_D001281 CID verapamil_7/NN (r_nsubj) failed_8/VBD (l_xcomp) promote_10/VB (l_dobj) AF_11/NNP
D014700_D001281 CID verapamil_4/NN (r_nsubj) promoted_5/VBD (l_dobj) AF_6/NNP
D014700_D001281 CID Verapamil_0/NNP (r_nsubj) promotes_1/VBZ (l_dobj) AF_2/NNP
D009020_D001281 NONE morphine_19/NN (r_npadvmod) chloralose_21/NN (r_amod) dogs_23/NNS (r_pobj) to_18/IN (r_prep) administered_16/VBD (l_advcl) evaluate_1/VB (l_dobj) mechanisms_4/NNS (l_prep) of_5/IN (l_pobj) promotion_7/NN (l_compound) AF_6/NNP
D002118_D013617 NONE Ca(2_23/NNP (r_dobj) decreases_19/VBZ (r_conj) promotes_7/VBZ (l_nsubj) tachycardia_3/NN
D002118_D001281 NONE Ca(2_23/NNP (r_dobj) decreases_19/VBZ (r_conj) promotes_7/VBZ (l_dobj) occurrence_9/NN (l_prep) of_12/IN (l_pobj) fibrillation_14/NN
D002118_D001281 NONE Ca(2_23/NNP (r_dobj) decreases_19/VBZ (r_conj) promotes_7/VBZ (l_dobj) occurrence_9/NN (l_prep) of_12/IN (l_pobj) fibrillation_14/NN (l_appos) AF_16/NNP
D002118_D001281 NONE Ca(2_11/NN (r_nmod) channel_13/NN (r_compound) blockade_14/NN (r_nsubj) promote_16/VB (l_dobj) AF_17/NNP
D002118_D001281 NONE Ca(2_11/NN (r_nmod) channel_13/NN (r_compound) blockade_14/NN (r_nsubj) promote_16/VB (l_advcl) consistent_19/JJ (l_prep) with_20/IN (l_pobj) effect_24/NN (l_compound) AF_22/NNP
D002118_D001281 NONE Ca(2_26/NNP (r_nmod) inhibition_30/NN (r_pobj) of_25/IN (r_prep) effect_24/NN (r_pobj) with_20/IN (r_prep) consistent_19/JJ (r_advcl) promote_16/VB (l_dobj) AF_17/NNP
D002118_D001281 NONE Ca(2_26/NNP (r_nmod) inhibition_30/NN (r_pobj) of_25/IN (r_prep) effect_24/NN (l_compound) AF_22/NNP
D002118_D001281 NONE Ca(2_9/NNP (r_nmod) blockers_13/NNS (r_pobj) by_8/IN (r_prep) promotion_7/NN (l_compound) AF_6/NNP
18997632
D002110_D001145 NONE caffeine_25/NN (r_compound) administration_26/NN (r_pobj) after_24/IN (r_prep) developed_14/VBD (r_relcl) disease_10/NN (l_conj) arrhythmia_12/NN
D002110_D001145 NONE caffeine_2/NN (r_nsubjpass) tolerated_6/VBN (r_advcl) be_11/VB (l_acomp) aware_12/JJ (l_prep) of_13/IN (l_pobj) potential_15/NN (l_prep) for_16/IN (l_pobj) arrhythmias_21/NNS
D002110_D006331 NONE caffeine_25/NN (r_compound) administration_26/NN (r_pobj) after_24/IN (r_prep) developed_14/VBD (r_relcl) disease_10/NN
D002110_D018879 CID caffeine_1/NN (r_nsubjpass) used_4/VBN (l_conj) tolerated_18/VBN (l_prep) from_20/IN (l_pobj) reports_22/NNS (l_prep) of_23/IN (l_pobj) ectopy_27/NN
D002110_D017180 CID caffeine_7/NN (r_compound) pretreatment_8/NN (r_pobj) to_6/IN (r_prep) related_5/VBN (r_acl) tachycardia_4/NN
D002110_D017180 CID caffeine_25/NN (r_compound) administration_26/NN (r_pobj) after_24/IN (r_prep) developed_14/VBD (l_dobj) bigeminy_16/JJ (l_conj) runs_20/NNS (l_prep) of_21/IN (l_pobj) tachycardia_23/NN
D002110_D012640 CID caffeine_1/NN (r_nsubjpass) used_4/VBN (l_xcomp) improve_6/VB (l_dobj) duration_8/NN (l_compound) seizure_7/NN
11573852
D000431_D012640 NONE alcohol_9/NN (r_compound) intake_10/NN (r_conj) history_4/NN (r_dobj) had_2/VBD (l_conj) cause_17/VB (l_dobj) seizures_18/NNS
D000431_D000437 NONE alcohol_9/NN (r_compound) intake_10/NN (r_conj) history_4/NN (l_prep) of_5/IN (l_pobj) abuse_7/NN
D016049_D012640 NONE Didanosine_0/NNP (r_nsubj) has_2/VBZ (l_dobj) potential_4/NN (l_prep) for_5/IN (l_pcomp) inducing_6/VBG (l_dobj) seizures_7/NNS
D000666_D004830 NONE B_18/NNP (r_pobj) of_16/IN (r_prep) infusion_15/NN (r_pobj) during_13/IN (r_prep) experienced_8/VBD (l_dobj) seizures_12/NNS
D000666_D012640 CID B_1/NN (r_npadvmod) induced_3/VBN (r_amod) seizures_4/NNS
D000666_D012640 CID B_16/NNP (r_compound) infusion_17/NN (r_pobj) following_14/VBG (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) episodes_6/NNS (l_prep) of_7/IN (l_pobj) activity_9/NN (l_compound) seizure_8/NN
D000666_D012640 CID B_18/NNP (r_pobj) of_16/IN (r_prep) infusion_15/NN (r_pobj) during_13/IN (r_prep) experienced_8/VBD (l_conj) stopped_28/VBN (l_nsubjpass) seizures_23/NNS
D000666_D012640 CID B_15/NNP (r_compound) administration_16/NN (r_pobj) during_13/IN (r_prep) occurred_11/VBD (r_conj) persisted_9/VBD (l_nsubj) seizures_8/NNS
D000666_D012640 CID B_8/NNP (r_nsubj) was_9/VBD (l_attr) cause_11/NN (l_prep) of_12/IN (l_pobj) seizures_14/NNS
D000666_D012640 CID B_1/NNP (r_nsubj) seems_2/VBZ (l_xcomp) be_4/VB (l_attr) cause_7/NN (l_prep) of_8/IN (l_pobj) seizures_10/NNS
D000666_D012640 CID B_11/NNP (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) seizures_7/NNS
D000666_D000163 NONE B_1/NN (r_npadvmod) induced_3/VBN (r_amod) seizures_4/NNS (l_prep) in_5/IN (l_pobj) patient_7/NN (l_prep) with_8/IN (l_pobj) AIDS_9/NNP
D000666_D000163 NONE B_16/NNP (r_compound) infusion_17/NN (r_pobj) following_14/VBG (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) episodes_6/NNS (l_prep) in_10/IN (l_pobj) patent_13/NN (l_compound) AIDS_12/NNP
D000666_D000163 NONE B_8/NNP (r_nsubj) was_9/VBD (l_attr) cause_11/NN (l_prep) of_12/IN (l_pobj) seizures_14/NNS (l_prep) in_15/IN (l_pobj) patient_18/NN (l_compound) AIDS_17/NNP
D008140_D012640 NONE lorazepam_5/NN (r_conj) phenytoin_3/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (r_pobj) Despite_0/IN (r_prep) persisted_9/VBD (l_nsubj) seizures_8/NNS
D010672_D012640 NONE phenytoin_3/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (r_pobj) Despite_0/IN (r_prep) persisted_9/VBD (l_nsubj) seizures_8/NNS
3123611
D000661_D002819 CID amphetamine_5/NN (r_npadvmod) induced_7/VBN (r_amod) chorea_8/NN
D003276_D002819 CID contraception_4/NN (r_pobj) with_2/IN (r_prep) associated_1/VBN (r_acl) Chorea_0/NNP
D003276_D002819 CID contraceptives_7/NNS (r_dobj) receiving_5/VBG (r_advcl) developed_2/VBD (l_dobj) chorea_3/NN
D003276_D002819 CID contraception_12/NN (r_pobj) after_9/IN (r_prep) had_3/VBD (l_dobj) chorea_8/NN
2320800
D007069_D007674 CID ifosfamide_5/JJ (r_compound) chemotherapy_6/NN (r_dobj) complicating_2/VBG (l_prep) in_7/IN (l_pobj) patient_11/NN (l_prep) with_12/IN (l_pobj) function_16/NN
D007069_D007674 CID Ifosfamide_0/NNP (r_nsubj) is_1/VBZ (l_attr) drug_5/NN (l_amod) nephrotoxic_4/JJ
D007069_D007674 CID Ifosfamide_0/NNP (r_nsubj) is_1/VBZ (l_attr) drug_5/NN (l_prep) with_6/IN (l_pobj) tubulopathies_8/NNS
D007069_D007674 CID ifosfamide_5/NN (r_pobj) of_4/IN (r_prep) use_3/NN (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_acl) pretreated_8/VBN (l_prep) with_9/IN (l_pobj) chemotherapy_11/NN (l_amod) nephrotoxic_10/JJ
D007069_D001943 NONE ifosfamide_5/JJ (r_compound) chemotherapy_6/NN (r_dobj) complicating_2/VBG (l_prep) in_7/IN (l_pobj) patient_11/NN (l_compound) cancer_10/NN
D007069_D001943 NONE ifosfamide_34/NN (r_pobj) after_28/IN (r_prep) day_27/NN (r_npadvmod) developed_17/VBD (l_nsubj) woman_6/NN (l_prep) with_7/IN (l_pobj) cancer_10/NN
D002945_D007022 NONE cisplatin_20/NN (r_amod) chemotherapy_21/NN (r_dobj) received_18/VBN (l_prep) with_23/IN (l_pobj) perfusion_26/NN (l_prep) due_27/IN (l_pcomp) to_28/IN (l_pobj) hypotension_30/NN
D002945_D001943 NONE cisplatin_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) woman_6/NN (l_prep) with_7/IN (l_pobj) cancer_10/NN
D007069_D001002 CID ifosfamide_5/JJ (r_compound) chemotherapy_6/NN (r_dobj) complicating_2/VBG (l_nsubj) anuria_1/NN
D007069_D001002 CID ifosfamide_34/NN (r_pobj) after_28/IN (r_prep) day_27/NN (r_npadvmod) developed_17/VBD (l_dobj) failure_22/NN (l_prep) with_23/IN (l_pobj) anuria_24/NN
D007069_D001002 CID ifosfamide_11/NN (r_xcomp) due_9/JJ (r_acomp) was_7/VBD (l_nsubj) anuria_6/NN
D007069_D007022 NONE ifosfamide_11/NN (r_xcomp) due_9/JJ (r_acomp) was_7/VBD (l_advcl) occurring_13/VBG (l_advcl) received_18/VBN (l_prep) with_23/IN (l_pobj) perfusion_26/NN (l_prep) due_27/IN (l_pcomp) to_28/IN (l_pobj) hypotension_30/NN
D002945_D051437 NONE cisplatin_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) woman_6/NN (r_nsubj) developed_17/VBD (l_dobj) failure_22/NN
D007069_D051437 NONE ifosfamide_34/NN (r_pobj) after_28/IN (r_prep) day_27/NN (r_npadvmod) developed_17/VBD (l_dobj) failure_22/NN
D002945_D001002 NONE cisplatin_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) woman_6/NN (r_nsubj) developed_17/VBD (l_dobj) failure_22/NN (l_prep) with_23/IN (l_pobj) anuria_24/NN
D002945_D001002 NONE cisplatin_20/NN (r_amod) chemotherapy_21/NN (r_dobj) received_18/VBN (r_advcl) occurring_13/VBG (r_advcl) was_7/VBD (l_nsubj) anuria_6/NN
9214597
D004967_D009369 NONE estrogen_14/NN (r_npadvmod) induced_16/VBN (r_amod) rat_17/NN (r_nmod) tumors_19/NNS (r_pobj) of_13/IN (r_prep) development_12/NN (r_pobj) during_10/IN (r_prep) receptor_9/NN (r_conj) factor_6/NN (r_pobj) of_2/IN (r_prep) expression_1/NN (r_pobj) Over_0/IN (r_prep) mediate_21/VB (l_dobj) angiogenesis_26/NN (l_compound) tumor_25/NN
D004967_D009369 NONE estrogen_22/NN (r_npadvmod) initiated_24/VBN (r_amod) angiogenesis_26/NN (l_compound) tumor_25/NN
D004967_D009369 NONE Estrogens_0/NNP (l_relcl) associated_5/VBN (l_prep) with_6/IN (l_pobj) types_8/NNS (l_prep) of_9/IN (l_pobj) cancers_13/NNS
D004967_D009369 NONE Estrogens_0/NNP (r_nsubj) induce_16/VB (l_dobj) angiogenesis_18/NN (l_compound) tumor_17/NN
D004967_D009369 NONE estrogen_9/NN (r_compound) carcinogenesis_10/NN (r_pobj) during_8/IN (r_prep) are_12/VBP (l_nsubj) details_2/NNS (l_prep) of_3/IN (l_pobj) angiogenesis_5/NN (l_compound) tumor_4/NN
D004967_D009369 NONE estrogen_5/NN (r_pobj) of_4/IN (r_prep) role_3/NN (r_dobj) elucidate_1/VB (l_prep) in_6/IN (l_pobj) regulation_8/NN (l_prep) of_9/IN (l_pobj) angiogenesis_11/NN (l_compound) tumor_10/NN
D004967_D009369 NONE estrogen_27/NN (r_pobj) of_26/IN (r_prep) regulation_25/NN (r_pobj) of_23/IN (r_prep) step_22/NN (r_pobj) in_19/IN (r_prep) play_15/VB (r_ccomp) suggest_2/VBP (l_ccomp) induced_28/VBN (l_dobj) angiogenesis_30/NN (l_compound) tumor_29/NN
D004967_D063646 NONE estrogen_9/NN (r_compound) carcinogenesis_10/NN
D004967_D010911 NONE estrogen_14/NN (r_npadvmod) induced_16/VBN (r_amod) rat_17/NN (r_nmod) tumors_19/NNS
D004967_D010911 NONE estrogen_22/NN (r_npadvmod) initiated_24/VBN (r_amod) angiogenesis_26/NN (r_dobj) mediate_21/VB (l_prep) Over_0/IN (l_pobj) expression_1/NN (l_prep) of_2/IN (l_pobj) factor_6/NN (l_conj) receptor_9/NN (l_prep) during_10/IN (l_pobj) development_12/NN (l_prep) of_13/IN (l_pobj) tumors_19/NNS
11860495
C018370_D000647 NONE sulphate_13/NN (r_pobj) of_11/IN (r_prep) effects_10/NNS (l_amod) amnesic_9/JJ
C018370_D000647 NONE PREGS_2/NNP (r_nsubj) is_3/VBZ (l_acomp) able_4/JJ (l_xcomp) reverse_6/VB (l_dobj) effects_11/NNS (l_amod) like_10/JJ (l_amod) amnesic_8/JJ
C018370_D000647 NONE PREGS_6/NNP (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_nsubjpass) tested_11/VBN (l_prep) in_12/IN (l_pobj) task_16/NN (l_acl) using_17/VBG (l_dobj) model_19/NN (l_prep) of_20/IN (l_pobj) amnesia_24/NN
C018370_D000647 NONE PREGS_10/NNP (r_pobj) of_8/IN (r_prep) ability_7/NN (l_acl) be_12/VB (l_attr) order_14/NN (l_amod) effective_18/JJ (l_prep) than_19/IN (l_pobj) enantiomer_22/NN (l_prep) in_23/IN (l_pcomp) reversing_24/VBG (l_dobj) amnesia_28/NN
D013256_D000647 NONE Steroid_0/NN (r_compound) structure_1/NN (r_nsubj) determine_5/VBP (l_dobj) effects_10/NNS (l_amod) amnesic_9/JJ
D005680_D000647 NONE GABA(A)R_15/NNP (r_compound) ligands_16/NNS (r_conj) NMDAR_13/NNP (r_pobj) of_12/IN (r_prep) effects_11/NNS (l_amod) like_10/JJ (l_amod) amnesic_8/JJ
D012601_D000647 CID scopolamine_21/NN (r_npadvmod) induced_23/VBN (r_amod) amnesia_24/NN
D012601_D000647 CID scopolamine_25/NN (r_npadvmod) induced_27/VBN (r_amod) amnesia_28/NN
2750819
D008278_D020879 CID sulfate_4/NN (r_pobj) with_2/IN (r_prep) blockade_1/NN
D008278_D020879 CID sulfate_15/NN (r_pobj) of_13/IN (r_prep) mg_12/NN (r_nsubjpass) administered_17/VBN (l_nsubjpass) patient_1/NN (l_relcl) received_3/VBD (l_dobj) tocolysis_4/NN (l_prep) with_5/IN (l_pobj) blockade_9/NN
D009543_D020879 CID nifedipine_6/NN (r_conj) sulfate_4/NN (r_pobj) with_2/IN (r_prep) blockade_1/NN
D009543_D020879 CID nifedipine_6/NN (r_nmod) blockade_9/NN
D008274_D064420 NONE magnesium_11/NN (r_pobj) of_10/IN (r_prep) toxicity_9/NN
D009543_D064420 NONE nifedipine_4/NN (r_nsubj) potentiate_7/VB (l_dobj) toxicity_9/NN
6728084
D000617_D007674 NONE aminoglycoside_3/NN (r_compound) treatment_4/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_amod) Nephrotoxic_0/JJ
D000617_D007674 NONE aminoglycosides_2/NNS (r_nsubj) act_4/VB (l_prep) as_5/IN (l_pobj) nephrotoxicants_6/NNS (l_prep) at_7/IN (l_pobj) impairment_13/NN (l_prep) of_14/IN (l_pobj) reabsorption_16/NN
18627295
D004317_D007249 NONE Doxorubicin_0/NNP (l_dobj) inflammation_4/NN
D004317_D007249 NONE DOX_17/NNP (r_compound) cardiomyopathy_18/NN (r_pobj) of_16/IN (r_prep) development_15/NN (r_pobj) during_13/IN (r_prep) elucidate_1/VB (r_advcl) studied_21/VBD (l_prep) by_29/IN (l_pcomp) investigating_30/VBG (l_dobj) inflammation_32/NN
D004317_D007249 NONE DOX_38/NNP (r_npadvmod) induced_40/VBN (r_amod) cardiomyopathy_41/NN (r_pobj) of_37/IN (r_prep) induction_36/NN (r_pobj) after_35/IN (r_prep) apoptosis_34/NN (r_conj) investigating_30/VBG (l_dobj) inflammation_32/NN
D018943_D066126 NONE anthracycline_4/NN (r_amod) doxorubicin_5/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubjpass) limited_10/VBN (l_agent) by_11/IN (l_pobj) effects_14/NNS (l_amod) cardiotoxic_13/JJ
D004317_D009202 CID Doxorubicin_0/NNP (l_dobj) inflammation_4/NN (l_amod) induced_3/VBN (l_npadvmod) cardiomyopathy_1/NN
D004317_D009202 CID DOX_17/NNP (r_compound) cardiomyopathy_18/NN
D004317_D009202 CID DOX_17/NNP (r_compound) cardiomyopathy_18/NN (r_pobj) of_16/IN (r_prep) development_15/NN (r_pobj) during_13/IN (r_prep) elucidate_1/VB (r_advcl) studied_21/VBD (l_prep) by_29/IN (l_pcomp) investigating_30/VBG (l_conj) apoptosis_34/NN (l_prep) after_35/IN (l_pobj) induction_36/NN (l_prep) of_37/IN (l_pobj) cardiomyopathy_41/NN
D004317_D009202 CID DOX_38/NNP (r_npadvmod) induced_40/VBN (r_amod) cardiomyopathy_41/NN (r_pobj) of_37/IN (r_prep) induction_36/NN (r_pobj) after_35/IN (r_prep) apoptosis_34/NN (r_conj) investigating_30/VBG (r_pcomp) by_29/IN (r_prep) studied_21/VBD (l_advcl) elucidate_1/VB (l_prep) during_13/IN (l_pobj) development_15/NN (l_prep) of_16/IN (l_pobj) cardiomyopathy_18/NN
D004317_D009202 CID DOX_38/NNP (r_npadvmod) induced_40/VBN (r_amod) cardiomyopathy_41/NN
D004317_D009202 CID DOX_8/NNP (r_pobj) in_7/IN (r_prep) is_5/VBZ (l_acl) cardiomyopathy_9/NN
D004317_D009202 CID DOX_16/NNP (r_compound) cardiomyopathy_17/NN
D004317_D006331 NONE DOX_0/NN (r_compound) control_1/NN (r_compound) mice_2/NNS (r_nsubj) showed_3/VBD (l_dobj) dysfunction_5/NN
D004317_D006331 NONE DOX_1/NNP (r_nmod) mice_4/NNS (r_pobj) In_0/IN (r_prep) improved_9/VBN (l_nsubjpass) dysfunction_7/NN
D004317_D006331 NONE DOX_12/NNP (r_compound) mice_14/NNS (r_pobj) to_11/IN (r_prep) compared_10/VBN (r_prep) improved_9/VBN (l_nsubjpass) dysfunction_7/NN
D004317_D066126 NONE doxorubicin_5/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubjpass) limited_10/VBN (l_agent) by_11/IN (l_pobj) effects_14/NNS (l_amod) cardiotoxic_13/JJ
D004317_D066126 NONE DOX_7/NNP (r_appos) doxorubicin_5/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubjpass) limited_10/VBN (l_agent) by_11/IN (l_pobj) effects_14/NNS (l_amod) cardiotoxic_13/JJ
18363626
D010100_D001919 NONE oxygen_30/NN (r_compound) saturations_31/NNS (r_conj) range_28/NN (r_pobj) of_23/IN (r_prep) %_22/NN (r_pobj) within_20/IN (r_prep) were_19/VBD (l_advcl) associated_4/VBN (l_prep) with_5/IN (l_pobj) incidence_9/NN (l_prep) of_10/IN (l_pobj) bradycardia_11/NN
D020927_D001919 CID dexmedetomidine_1/NN (r_amod) sedation_2/NN (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) incidence_9/NN (l_prep) of_10/IN (l_pobj) bradycardia_11/NN
2980315
D008794_D014693 CID metrizoate_27/NN (r_pobj) after_26/IN (r_prep) than_25/IN (r_prep) were_4/VBD (l_nsubj) Frequencies_0/NNS (l_prep) of_1/IN (l_pobj) fibrillation_3/NN
D007472_D014693 NONE iohexol_20/NN (r_conj) iopentol_14/NN (r_pobj) after_13/IN (r_prep) 0.05_11/CD (r_parataxis) were_4/VBD (l_nsubj) Frequencies_0/NNS (l_prep) of_1/IN (l_pobj) fibrillation_3/NN
C053571_D014693 NONE iopentol_14/NN (r_pobj) after_13/IN (r_prep) 0.05_11/CD (r_parataxis) were_4/VBD (l_nsubj) Frequencies_0/NNS (l_prep) of_1/IN (l_pobj) fibrillation_3/NN
3780814
D010634_D009369 NONE PB_3/NNP (r_conj) DEN_1/NNP (r_nsubj) treated_4/VBN (r_ccomp) was_9/VBD (l_conj) decreased_15/VBD (l_nsubj) incidence_14/NN (l_compound) tumor_13/NN
D010634_D063646 NONE phenobarbital_5/JJ (r_pobj) of_4/IN (r_prep) action_3/NN (l_amod) carcinogenic_2/JJ
D010634_D063646 NONE phenobarbital_13/JJ (r_pobj) of_12/IN (r_prep) effect_11/NN (l_prep) on_25/IN (l_pobj) carcinogenesis_26/NN
D010634_D063646 NONE PB_15/NNP (r_appos) phenobarbital_13/JJ (r_pobj) of_12/IN (r_prep) effect_11/NN (l_prep) on_25/IN (l_pobj) carcinogenesis_26/NN
D010634_D063646 NONE PB_15/NNP (r_conj) DEN_13/NNP (r_pobj) by_12/IN (r_conj) by_8/IN (r_agent) treated_7/VBN (l_prep) according_23/VBG (l_prep) to_24/IN (l_pobj) schedule_26/NN (l_prep) for_27/IN (l_pobj) hepatocarcinogenesis_28/NN
D010634_D063646 NONE PB_4/NNP (l_relcl) promotes_7/VBZ (l_dobj) carcinogenesis_8/NN
D004052_D009369 NONE DEN_1/NNP (r_nsubj) treated_4/VBN (r_ccomp) was_9/VBD (l_conj) decreased_15/VBD (l_nsubj) incidence_14/NN (l_compound) tumor_13/NN
D004052_D009369 NONE DEN_23/NNP (r_pobj) by_22/IN (r_agent) obtained_21/VBN (r_acl) results_20/NNS (r_pobj) with_18/IN (r_prep) compared_17/VBN (r_prep) as_16/IN (r_prep) decreased_15/VBD (l_nsubj) incidence_14/NN (l_compound) tumor_13/NN
D010634_D011230 NONE PB_22/NNP (r_nsubjpass) given_24/VBN (r_advcl) reduced_20/VBN (l_nsubjpass) number_8/NN (l_conj) size_11/NN (l_prep) of_12/IN (l_pcomp) induced_13/VBN (l_dobj) foci_17/NN
D004052_D063646 NONE diethylnitrosamine_9/NN (r_pobj) with_8/IN (r_prep) given_6/VBN (r_prep) action_3/NN (l_amod) carcinogenic_2/JJ
D004052_D063646 NONE diethylnitrosamine_33/JJ (r_pobj) with_32/IN (r_prep) administered_30/VBN (r_advcl) elucidate_9/VB (l_dobj) effect_11/NN (l_prep) on_25/IN (l_pobj) carcinogenesis_26/NN
D004052_D063646 NONE DEN_35/NNP (r_parataxis) planned_5/VBN (l_prep) in_6/IN (l_pobj) order_7/NN (l_acl) elucidate_9/VB (l_dobj) effect_11/NN (l_prep) on_25/IN (l_pobj) carcinogenesis_26/NN
D004052_D063646 NONE DEN_9/NNP (r_pobj) by_8/IN (r_agent) treated_7/VBN (l_prep) according_23/VBG (l_prep) to_24/IN (l_pobj) schedule_26/NN (l_prep) for_27/IN (l_pobj) hepatocarcinogenesis_28/NN
D004052_D063646 NONE DEN_13/NNP (r_pobj) by_12/IN (r_conj) by_8/IN (r_agent) treated_7/VBN (l_prep) according_23/VBG (l_prep) to_24/IN (l_pobj) schedule_26/NN (l_prep) for_27/IN (l_pobj) hepatocarcinogenesis_28/NN
D004052_D063646 NONE DEN_13/NNP (r_compound) treatment_14/NN (r_pobj) after_11/IN (r_prep) administered_10/VBN (r_advcl) promotes_7/VBZ (l_dobj) carcinogenesis_8/NN
D004052_D063646 NONE DEN_24/NNP (r_pobj) with_23/IN (r_prep) given_21/VBN (r_advcl) reduces_16/VBZ (l_nsubj) PB_4/NNP (l_relcl) promotes_7/VBZ (l_dobj) carcinogenesis_8/NN
D004052_D011230 CID DEN_27/NNP (r_pobj) with_26/IN (r_prep) given_24/VBN (r_advcl) reduced_20/VBN (l_nsubjpass) number_8/NN (l_conj) size_11/NN (l_prep) of_12/IN (l_pcomp) induced_13/VBN (l_dobj) foci_17/NN
6769133
D018943_D009202 NONE anthracycline_10/NN (r_amod) induced_12/VBN (r_amod) cardiomyopathy_13/NN
D004317_D015470 CID adriamycin_16/NNS (r_pobj) of_15/IN (r_prep) m2_14/CD (r_dobj) receiving_10/VBG (r_pcomp) after_9/IN (r_prep) developed_5/VBD (l_dobj) leukemia_8/NN
D004317_D007938 NONE adriamycin_4/NN (r_nsubj) is_5/VBZ (l_conj) be_20/VB (l_nsubj) leukemia_18/NN
D004317_D066126 NONE adriamycin_6/NNS (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_conj) Cardiotoxic_0/NNP
D004317_D006333 CID adriamycin_13/NNS (r_compound) dose_14/NN (r_pobj) at_9/IN (r_prep) developed_5/VBD (l_dobj) failure_8/NN
D018943_D001768 NONE anthracycline_10/NN (r_amod) induced_12/VBN (r_amod) cardiomyopathy_13/NN (r_pobj) in_8/IN (r_prep) found_7/VBN (r_acl) those_6/DT (r_dobj) resembled_5/VBD (l_nsubj) lesions_4/NNS
11847945
D007530_D002779 CID isoflurane_6/RB (r_pobj) to_5/IN (r_prep) exposure_4/NN (r_pobj) after_3/IN (r_prep) hepatitis_2/NN
D007530_D002779 CID isoflurane_14/RB (r_pobj) to_10/IN (r_prep) exposure_9/NN (r_pobj) following_8/VBG (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) hepatitis_7/NN
D007530_D002779 CID Isoflurane_0/NNP (r_nsubj) cause_8/VB (l_dobj) hepatitis_11/NN
D004177_D000699 NONE dipyrone_7/NN (l_prep) for_8/IN (l_pobj) analgesia_9/NN
D007530_D056486 CID isoflurane_6/RB (r_pobj) to_5/IN (r_prep) exposure_4/NN (r_pobj) after_3/IN (r_prep) hepatitis_2/NN
D007530_D056486 CID isoflurane_14/RB (r_pobj) to_10/IN (r_prep) exposure_9/NN (r_pobj) following_8/VBG (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) hepatitis_7/NN
D007530_D056486 CID Isoflurane_0/NNP (r_nsubj) cause_8/VB (l_dobj) hepatitis_11/NN
16710500
D004977_D009901 CID Ethambutol_0/NN (r_npadvmod) associated_2/VBN (r_amod) neuropathy_4/NN
D004977_D009901 CID ethambutol_3/NN (r_npadvmod) associated_5/VBN (r_amod) neuropathy_8/NNS
D004977_D014376 NONE Ethambutol_2/NNP (r_nsubjpass) used_4/VBN (l_prep) in_5/IN (l_pobj) treatment_7/NN (l_prep) of_8/IN (l_pobj) tuberculosis_9/NN
D004977_D014786 CID Ethambutol_2/NNP (r_nsubjpass) used_4/VBN (l_conj) associated_22/VBN (l_prep) with_23/IN (l_pobj) loss_26/NN
D004977_D014786 CID Ethambutol_0/NNP (r_compound) usage_1/NN (r_nsubjpass) associated_3/VBN (l_prep) with_4/IN (l_pobj) loss_7/NN
11185967
D000661_D012640 NONE amphetamine_18/NN (r_conj) cocaine_16/NN (l_prep) in_19/IN (l_pobj) patients_24/NNS (l_compound) seizure_23/NN
D000431_D012640 NONE alcohol_8/NN (r_npadvmod) related_10/VBN (r_amod) disorder_12/NN (l_compound) seizure_11/NN
D000431_D012640 NONE alcohol_8/NN (r_npadvmod) related_10/VBN (r_amod) disorder_12/NN (r_conj) drug_6/NN (r_pobj) of_4/IN (r_prep) history_3/NN (r_appos) demographics_1/NNS (r_nsubj) estimated_14/VBN (l_prep) from_16/IN (l_pobj) seizure_17/NN
D000431_D019969 NONE alcohol_8/NN (r_npadvmod) related_10/VBN (r_amod) disorder_12/NN (r_conj) drug_6/NN (r_pobj) of_4/IN (r_prep) history_3/NN (r_appos) demographics_1/NNS (r_nsubj) estimated_14/VBN (l_prep) from_16/IN (l_prep) to_18/IN (l_pobj) collection_20/NN (l_conj) history_22/NN (l_conj) suspicion_24/NN (l_prep) of_25/IN (l_pobj) cocaine_26/NN (l_conj) abuse_29/NN
D003042_D012640 NONE cocaine_16/NN (l_prep) in_19/IN (l_pobj) patients_24/NNS (l_compound) seizure_23/NN
D003042_D012640 NONE cocaine_9/NN (l_prep) in_12/IN (l_pobj) patients_15/NNS (l_compound) seizure_14/NN
D000431_D019970 NONE alcohol_8/NN (r_npadvmod) related_10/VBN (r_amod) disorder_12/NN (r_conj) drug_6/NN (r_pobj) of_4/IN (r_prep) history_3/NN (r_appos) demographics_1/NNS (r_nsubj) estimated_14/VBN (l_prep) from_16/IN (l_prep) to_18/IN (l_pobj) collection_20/NN (l_conj) history_22/NN (l_conj) suspicion_24/NN (l_prep) of_25/IN (l_pobj) cocaine_26/NN (l_conj) abuse_29/NN
D000662_D012640 NONE amphetamines_11/NNS (r_conj) cocaine_9/NN (l_prep) in_12/IN (l_pobj) patients_15/NNS (l_compound) seizure_14/NN
17019386
D008353_D019586 CID mannitol_5/NN (r_pobj) of_4/IN (r_prep) use_3/NN (l_acl) reduce_7/VB (l_dobj) edema_9/NN (l_conj) ICP_13/NNP
D008353_D005910 NONE mannitol_2/NN (r_pobj) of_1/IN (r_prep) Passage_0/NN (r_nsubj) gliomas_7/NNS
D008353_D005910 NONE Mannitol_2/NN (r_appos) METHODS_0/NNS (r_nsubjpass) administered_14/VBN (l_parataxis) had_22/VBD (l_dobj) glioma_24/NN
D008353_D005910 NONE mannitol_5/NN (r_amod) concentrations_6/NNS (r_nsubj) were_10/VBD (l_prep) In_0/IN (l_pobj) patients_3/NNS (l_compound) glioma_2/NN
D008353_D005910 NONE mannitol_13/NN (r_nsubj) leak_15/VB (l_prep) near_20/IN (l_pobj) gliomas_21/NNS
D008353_D008579 NONE Mannitol_2/NN (r_appos) METHODS_0/NNS (r_nsubjpass) administered_14/VBN (l_parataxis) had_22/VBD (l_dobj) glioma_24/NN (l_conj) metastases_28/NNS (l_conj) meningioma_31/NN
D008353_D008579 NONE mannitol_8/NN (r_pobj) of_7/IN (r_prep) concentrations_6/NNS (l_compound) patients_4/NNS (l_nmod) meningioma_1/NN
D008353_D004487 NONE mannitol_13/NN (r_nsubj) leak_15/VB (l_advcl) reversing_23/VBG (l_conj) aggravating_34/VBG (l_dobj) edema_36/NN
D008353_D001929 NONE mannitol_5/NN (r_pobj) of_4/IN (r_prep) use_3/NN (l_acl) reduce_7/VB (l_dobj) edema_9/NN
D008353_D009362 NONE Mannitol_2/NN (r_appos) METHODS_0/NNS (r_nsubjpass) administered_14/VBN (l_parataxis) had_22/VBD (l_dobj) glioma_24/NN (l_conj) metastases_28/NNS
D008353_D009362 NONE mannitol_8/NN (r_pobj) of_7/IN (r_prep) concentrations_6/NNS (l_compound) patients_4/NNS (l_nmod) meningioma_1/NN (l_conj) metastases_3/NNS
D008353_D001932 NONE mannitol_5/NN (r_pobj) of_4/IN (r_prep) use_3/NN (l_acl) reduce_7/VB (l_dobj) edema_9/NN (l_conj) ICP_13/NNP (l_prep) in_14/IN (l_pobj) patients_17/NNS (l_compound) tumor_16/NN
D008353_D001932 NONE mannitol_14/NN (r_pobj) of_13/IN (r_prep) passage_12/NN (r_dobj) research_9/VB (l_prep) to_20/IN (l_pobj) patients_24/NNS (l_compound) tumor_23/NN
28952
D002752_D007008 CID chlorthalidone_6/NN (r_compound) administration_7/NN (r_pobj) during_5/IN (r_prep) hypokalaemia_4/NN
D012964_D006973 NONE sodium_18/NN (r_compound) restriction_19/NN (r_pobj) of_16/IN (r_prep) influence_15/NN (r_appos) loss_2/NN (l_conj) hypokalaemia_4/NN (l_prep) during_5/IN (l_pobj) administration_7/NN (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) hypertension_12/NN
D002752_D006973 NONE chlorthalidone_6/NN (r_compound) administration_7/NN (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) hypertension_12/NN
D011188_D006973 NONE potassium_1/NN (r_compound) loss_2/NN (l_conj) hypokalaemia_4/NN (l_prep) during_5/IN (l_pobj) administration_7/NN (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) hypertension_12/NN
D011188_D006973 NONE potassium_4/NN (r_compound) loss_5/NN (r_dobj) investigate_1/VB (r_csubjpass) performed_22/VBN (l_prep) in_23/IN (l_pobj) patients_25/NNS (l_prep) with_26/IN (l_pobj) hypertension_28/NN
D012964_D007008 NONE sodium_18/NN (r_compound) restriction_19/NN (r_pobj) of_16/IN (r_prep) influence_15/NN (r_appos) loss_2/NN (l_conj) hypokalaemia_4/NN
D011188_D007008 NONE potassium_1/NN (r_compound) loss_2/NN (l_conj) hypokalaemia_4/NN
D011188_D007008 NONE potassium_4/NN (r_compound) loss_5/NN (l_conj) development_7/NN (l_prep) of_8/IN (l_pobj) hypokalaemia_9/NN
D011188_D007008 NONE potassium_4/NN (r_compound) loss_5/NN (r_dobj) investigate_1/VB (r_csubjpass) performed_22/VBN (l_prep) in_23/IN (l_pobj) patients_25/NNS (l_prep) with_26/IN (l_pobj) hypertension_28/NN (l_relcl) shown_31/VBN (l_dobj) hypokalaemia_32/NN
8742498
D000431_D056486 CID ethanol_35/NN (r_compound) consumption_36/NN (r_pobj) of_33/IN (r_prep) influence_32/NN (r_dobj) evaluates_30/VBZ (r_conj) acts_20/VBZ (l_prep) in_22/IN (l_pobj) mice_25/NNS (l_prep) with_26/IN (l_pobj) hepatitis_28/NN
D000431_D056486 CID ethanol_25/NN (r_pobj) by_24/IN (r_agent) caused_23/VBN (r_acl) exacerbation_22/NN (r_pobj) unlike_20/IN (r_prep) inhibited_37/VBN (l_nsubjpass) damage_35/NN
D000431_D056486 CID ethanol_42/NN (r_pobj) by_41/IN (r_prep) %_40/NN (r_pobj) by_38/IN (r_agent) inhibited_37/VBN (l_nsubjpass) damage_35/NN
D000431_D056486 CID ethanol_15/NN (r_nmod) mice_19/NNS (r_pobj) to_14/IN (r_dative) given_13/VBN (r_advcl) observed_8/VBN (l_nsubjpass) reduction_4/NN (l_prep) of_5/IN (l_pobj) hepatitis_6/NN
D000431_D056486 CID ethanol_14/NN (r_pobj) by_13/IN (r_prep) exacerbation_12/NN (r_conj) hepatitis_9/NN
D009536_D056486 NONE amide_10/NN (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_dobj) demonstrated_3/VBD (l_npadvmod) AAP)-hepatitis_33/NNP
D009536_D056486 NONE amide_10/NN (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_dobj) demonstrated_3/VBD (l_advcl) suggesting_35/VBG (l_ccomp) involves_43/VBZ (l_nsubj) injury_42/NN
D009536_D056486 NONE NAA_11/NNP (r_nsubjpass) given_13/VBN (r_advcl) observed_8/VBN (l_nsubjpass) reduction_4/NN (l_prep) of_5/IN (l_pobj) hepatitis_6/NN
D009536_D056486 NONE NAA_27/NNP (r_pobj) by_26/IN (r_prep) inhibition_23/NN (r_pobj) by_19/IN (r_agent) reduced_18/VBN (l_nsubjpass) hepatitis_9/NN
D009536_D056486 NONE NAA_6/NNP (r_pobj) of_5/IN (r_prep) application_4/NN (r_dobj) see_1/VBP (l_prep) in_17/IN (l_pobj) order_18/NN (l_acl) avoid_20/VB (l_dobj) damage_22/NN
D011064_D056486 NONE )_19/-RRB- (r_punct) polymerase_20/NN (r_pobj) of_15/IN (r_prep) inhibitor_14/NN (r_appos) amide_10/NN (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_dobj) demonstrated_3/VBD (l_npadvmod) AAP)-hepatitis_33/NNP
D011064_D056486 NONE )_19/-RRB- (r_punct) polymerase_20/NN (r_pobj) of_15/IN (r_prep) inhibitor_14/NN (r_appos) amide_10/NN (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_dobj) demonstrated_3/VBD (l_advcl) suggesting_35/VBG (l_ccomp) involves_43/VBZ (l_nsubj) injury_42/NN
D000082_D056486 CID acetaminophen_9/NN (r_pobj) on_8/IN (l_pobj) hepatotoxicity_10/NN
D000082_D056486 CID acetaminophen_31/NN (r_pobj) from_30/IN (r_prep) suffering_29/VBG (r_pcomp) on_27/IN (r_prep) inhibitor_14/NN (r_appos) amide_10/NN (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_dobj) demonstrated_3/VBD (l_npadvmod) AAP)-hepatitis_33/NNP
D000082_D056486 CID acetaminophen_31/NN (r_pobj) from_30/IN (r_prep) suffering_29/VBG (r_pcomp) on_27/IN (r_prep) inhibitor_14/NN (r_appos) amide_10/NN (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_dobj) demonstrated_3/VBD (l_advcl) suggesting_35/VBG (l_ccomp) involves_43/VBZ (l_nsubj) injury_42/NN
D000082_D056486 CID AAP)-hepatitis_33/NNP
D000082_D056486 CID AAP)-hepatitis_33/NNP (r_npadvmod) demonstrated_3/VBD (l_advcl) suggesting_35/VBG (l_ccomp) involves_43/VBZ (l_nsubj) injury_42/NN
D000082_D056486 CID AAP_38/NNP (r_npadvmod) induced_40/VBN (r_amod) injury_42/NN (r_nsubj) involves_43/VBZ (r_ccomp) suggesting_35/VBG (r_advcl) demonstrated_3/VBD (l_npadvmod) AAP)-hepatitis_33/NNP
D000082_D056486 CID AAP_38/NNP (r_npadvmod) induced_40/VBN (r_amod) injury_42/NN
D000082_D056486 CID AAP_27/NNP (r_compound) hepatitis_28/NN
D000082_D056486 CID AAP_17/NNP (r_pobj) of_16/IN (r_prep) presence_15/NN (r_pobj) in_13/IN (r_prep) measured_12/VBN (l_conj) inhibited_37/VBN (l_nsubjpass) damage_35/NN
D000082_D056486 CID AAP_17/NNP (r_compound) mice_19/NNS (r_pobj) to_14/IN (r_dative) given_13/VBN (r_advcl) observed_8/VBN (l_nsubjpass) reduction_4/NN (l_prep) of_5/IN (l_pobj) hepatitis_6/NN
D000082_D056486 CID AAP_6/NNP (r_npadvmod) induced_8/VBN (r_amod) hepatitis_9/NN
D000082_D056486 CID acetaminophen_16/NN (r_pobj) of_15/IN (r_prep) preparations_14/NNS (r_pobj) in_12/IN (r_prep) use_11/NN (r_pobj) for_8/IN (r_prep) as_7/IN (r_prep) see_1/VBP (l_prep) in_17/IN (l_pobj) order_18/NN (l_acl) avoid_20/VB (l_dobj) damage_22/NN
D018698_D056486 NONE glutamate_8/NN (r_compound) oxaloacetate_10/NN (r_compound) transaminase_11/NN (r_pobj) of_7/IN (r_prep) activities_6/NNS (r_pobj) as_4/IN (r_prep) quantified_3/VBN (l_nsubjpass) injuries_1/NNS
D018698_D056486 NONE glutamate_16/NN (r_npadvmod) pyruvate_18/NN (r_compound) transaminase_19/NN (r_conj) transaminase_11/NN (r_pobj) of_7/IN (r_prep) activities_6/NNS (r_pobj) as_4/IN (r_prep) quantified_3/VBN (l_nsubjpass) injuries_1/NNS
D009243_D056486 NONE NAD_5/NNP (r_compound) precursors_7/NNS (r_pobj) of_4/IN (r_prep) free_3/JJ (l_prep) on_8/IN (l_pobj) hepatotoxicity_10/NN
D009243_D056486 NONE NAD_13/NNP (l_appos) substrate_16/NN (l_relcl) acts_20/VBZ (l_prep) in_22/IN (l_pobj) mice_25/NNS (l_prep) with_26/IN (l_pobj) hepatitis_28/NN
D009243_D056486 NONE NAD_37/NNP (r_appos) substrate_36/NN (r_pobj) of_32/IN (r_prep) depletion_31/NN (r_pobj) by_29/IN (r_conj) by_26/IN (r_prep) inhibition_23/NN (r_pobj) by_19/IN (r_agent) reduced_18/VBN (l_nsubjpass) hepatitis_9/NN
D062907_D056486 NONE oxaloacetate_10/NN (r_compound) transaminase_11/NN (r_pobj) of_7/IN (r_prep) activities_6/NNS (r_pobj) as_4/IN (r_prep) quantified_3/VBN (l_nsubjpass) injuries_1/NNS
D019289_D056486 NONE pyruvate_18/NN (r_compound) transaminase_19/NN (r_conj) transaminase_11/NN (r_pobj) of_7/IN (r_prep) activities_6/NNS (r_pobj) as_4/IN (r_prep) quantified_3/VBN (l_nsubjpass) injuries_1/NNS
20331935
D013739_D006966 NONE testosterone_1/NN (r_compound) concentration_2/NN (r_nsubj) increased_3/VBD (l_conj) affected_10/VBN (l_agent) by_11/IN (l_pobj) hyperprolactinemia_12/NN
D018967_D006966 CID risperidone_12/NN (r_npadvmod) induced_14/VBN (r_amod) hyperprolactinemia_15/NN
D018967_D006966 CID risperidone_17/NN (r_pobj) with_16/IN (r_prep) treated_15/VBN (r_acl) %_6/NN (r_pobj) in_4/IN (r_prep) present_3/JJ (r_acomp) was_2/VBD (l_nsubj) Hyperprolactinemia_1/NNP
D018967_D006966 CID risperidone_8/NN (r_nsubjpass) started_12/VBN (r_advcl) occurred_6/VBD (l_conj) occurred_16/VBD (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) hyperprolactinemia_20/NN
D018967_D006966 CID risperidone_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperprolactinemia_10/NN
D018967_D050723 NONE risperidone_8/NN (r_nsubjpass) started_12/VBN (r_advcl) occurred_6/VBD (l_nsubj) fractures_3/NNS
9154656
D011692_D009404 CID nucleoside_11/NN (r_nmod) PAN_13/NNP (r_pobj) of_7/IN (r_prep) injection_6/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (l_nsubjpass) NS_0/NNP
D011692_D009404 CID PAN_13/NNP (r_pobj) of_7/IN (r_prep) injection_6/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (l_nsubjpass) NS_0/NNP
D011692_D009404 CID PAN_19/NNP (r_compound) injection_20/NN (r_pobj) after_18/IN (r_prep) observed_14/VBN (r_advcl) change_34/VB (l_advcl) established_26/VBN (l_nsubjpass) NS_23/NNP
D011692_D009404 CID PAN_22/NNP (r_pobj) by_21/IN (r_agent) induced_20/VBN (r_acl) development_15/NN (l_prep) of_16/IN (l_pobj) NS_19/NNP
D000809_D009404 NONE angiotensin_9/NN (r_compound) proteins_11/NNS (r_pobj) of_5/IN (r_prep) concentration_1/NN (r_nsubjpass) altered_13/VBN (l_prep) in_14/IN (l_pobj) rats_15/NNS (l_prep) with_16/IN (l_pobj) syndrome_18/NN
D000809_D009404 NONE angiotensin_9/NN (r_compound) proteins_11/NNS (r_pobj) of_5/IN (r_prep) concentration_1/NN (r_nsubjpass) altered_13/VBN (l_prep) in_14/IN (l_pobj) rats_15/NNS (l_prep) with_16/IN (l_pobj) syndrome_18/NN (l_appos) NS_20/NNP
6433367
D001640_D012640 CID bicuculline_35/NN (r_conj) electroshock_33/NN (r_conj) PTZ_30/NNP (r_conj) picrotoxin_26/JJ (r_conj) flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS (r_pobj) on_20/IN (r_prep) effects_14/NNS (r_nsubjpass) evaluated_37/VBN (l_advcl) investigate_1/VB (l_prep) to_9/TO (l_pobj) induction_11/NN (l_compound) seizure_10/NN
D001640_D012640 CID bicuculline_35/NN (r_conj) electroshock_33/NN (r_conj) PTZ_30/NNP (r_conj) picrotoxin_26/JJ (r_conj) flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS
D001640_D012640 CID bicuculline_26/NN (r_advmod) induced_28/VBN (r_conj) electroshock-_23/XX (r_conj) picrotoxin-_21/XX (r_conj) involved_6/VBN (l_prep) in_7/IN (l_pobj) fluorthyl-_12/NNS (l_conj) convulsions_17/NNS
D001640_D012640 CID bicuculline_26/NN (r_advmod) induced_28/VBN (r_conj) electroshock-_23/XX (r_conj) picrotoxin-_21/XX (l_pobj) convulsions_29/NNS
D011453_D012640 NONE prostaglandin_2/JJ (r_amod) inhibitors_4/NNS (r_pobj) of_1/IN (r_prep) Effect_0/NN (l_prep) on_5/IN (l_pobj) convulsions_8/NNS
D011453_D012640 NONE prostaglandins_5/NNS (r_pobj) of_4/IN (r_prep) relationship_3/NN (r_dobj) investigate_1/VB (l_prep) to_9/TO (l_pobj) induction_11/NN (l_compound) seizure_10/NN
D011453_D012640 NONE prostaglandins_5/NNS (r_pobj) of_4/IN (r_prep) relationship_3/NN (r_dobj) investigate_1/VB (r_advcl) evaluated_37/VBN (l_nsubjpass) effects_14/NNS (l_prep) on_20/IN (l_pobj) convulsions_21/NNS
D011453_D012640 NONE PGs_7/NNS (r_appos) prostaglandins_5/NNS (r_pobj) of_4/IN (r_prep) relationship_3/NN (r_dobj) investigate_1/VB (l_prep) to_9/TO (l_pobj) induction_11/NN (l_compound) seizure_10/NN
D011453_D012640 NONE PGs_7/NNS (r_appos) prostaglandins_5/NNS (r_pobj) of_4/IN (r_prep) relationship_3/NN (r_dobj) investigate_1/VB (r_advcl) evaluated_37/VBN (l_nsubjpass) effects_14/NNS (l_prep) on_20/IN (l_pobj) convulsions_21/NNS
D011453_D012640 NONE PGs_4/NNS (r_nsubjpass) involved_6/VBN (l_prep) in_7/IN (l_pobj) fluorthyl-_12/NNS (l_conj) convulsions_17/NNS
D011453_D012640 NONE PGs_4/NNS (r_nsubjpass) involved_6/VBN (l_conj) picrotoxin-_21/XX (l_pobj) convulsions_29/NNS
D005481_D012640 CID flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS (r_pobj) on_20/IN (r_prep) effects_14/NNS (r_nsubjpass) evaluated_37/VBN (l_advcl) investigate_1/VB (l_prep) to_9/TO (l_pobj) induction_11/NN (l_compound) seizure_10/NN
D005481_D012640 CID flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS
D005481_D012640 CID fluorthyl-_12/NNS (l_conj) convulsions_17/NNS
D005481_D012640 CID fluorthyl-_12/NNS (r_pobj) in_7/IN (r_prep) involved_6/VBN (l_conj) picrotoxin-_21/XX (l_pobj) convulsions_29/NNS
D010433_D012640 CID pentetrazol_28/NNP (r_nmod) PTZ_30/NNP (r_conj) picrotoxin_26/JJ (r_conj) flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS (r_pobj) on_20/IN (r_prep) effects_14/NNS (r_nsubjpass) evaluated_37/VBN (l_advcl) investigate_1/VB (l_prep) to_9/TO (l_pobj) induction_11/NN (l_compound) seizure_10/NN
D010433_D012640 CID pentetrazol_28/NNP (r_nmod) PTZ_30/NNP (r_conj) picrotoxin_26/JJ (r_conj) flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS
D010433_D012640 CID PTZ_30/NNP (r_conj) picrotoxin_26/JJ (r_conj) flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS (r_pobj) on_20/IN (r_prep) effects_14/NNS (r_nsubjpass) evaluated_37/VBN (l_advcl) investigate_1/VB (l_prep) to_9/TO (l_pobj) induction_11/NN (l_compound) seizure_10/NN
D010433_D012640 CID PTZ_30/NNP (r_conj) picrotoxin_26/JJ (r_conj) flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS
D010433_D012640 CID PTZ_14/NNP (r_npadvmod) induced_16/VBN (r_amod) convulsions_17/NNS
D010433_D012640 CID PTZ_14/NNP (r_npadvmod) induced_16/VBN (r_amod) convulsions_17/NNS (r_conj) fluorthyl-_12/NNS (r_pobj) in_7/IN (r_prep) involved_6/VBN (l_conj) picrotoxin-_21/XX (l_pobj) convulsions_29/NNS
D010852_D012640 CID picrotoxin_26/JJ (r_conj) flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS (r_pobj) on_20/IN (r_prep) effects_14/NNS (r_nsubjpass) evaluated_37/VBN (l_advcl) investigate_1/VB (l_prep) to_9/TO (l_pobj) induction_11/NN (l_compound) seizure_10/NN
D010852_D012640 CID picrotoxin_26/JJ (r_conj) flurothyl_24/JJ (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) convulsions_21/NNS
D010852_D012640 CID picrotoxin-_21/XX (r_conj) involved_6/VBN (l_prep) in_7/IN (l_pobj) fluorthyl-_12/NNS (l_conj) convulsions_17/NNS
D010852_D012640 CID picrotoxin-_21/XX (l_pobj) convulsions_29/NNS
6674249
D015119_D009336 CID acid_12/NN (r_nmod) EACA_14/NNP (r_nmod) treatment_16/NN (r_pobj) due_5/IN (r_prep) necrotizing_3/VBG (l_advmod) myopathy_4/NNS
D015119_D009336 CID EACA_14/NNP (r_nmod) treatment_16/NN (r_pobj) due_5/IN (r_prep) necrotizing_3/VBG (l_advmod) myopathy_4/NNS
D015119_D009135 CID acid_5/NN (r_nsubj) induce_9/VBP (l_dobj) myopathy_10/NNS
D015119_D009135 CID EACA_7/NNP (r_appos) acid_5/NN (r_nsubj) induce_9/VBP (l_dobj) myopathy_10/NNS
D015119_D009135 CID acid_12/NN (r_nmod) EACA_14/NNP (r_nmod) treatment_16/NN (r_pobj) due_5/IN (r_prep) necrotizing_3/VBG (l_advmod) myopathy_4/NNS
D015119_D009135 CID EACA_14/NNP (r_nmod) treatment_16/NN (r_pobj) due_5/IN (r_prep) necrotizing_3/VBG (l_advmod) myopathy_4/NNS
D015119_D013345 NONE acid_12/NN (r_nmod) EACA_14/NNP (r_nmod) treatment_16/NN (l_prep) in_17/IN (l_pobj) patient_23/NN (l_prep) with_24/IN (l_pobj) haemorrhage_26/NN
D015119_D013345 NONE acid_12/NN (r_nmod) EACA_14/NNP (r_nmod) treatment_16/NN (r_pobj) due_5/IN (r_prep) necrotizing_3/VBG (r_pcomp) of_2/IN (r_prep) case_1/NN (r_nsubjpass) described_31/VBN (l_punct) (_27/-LRB- (l_preconj) SAH_28/NNP
D015119_D013345 NONE EACA_14/NNP (r_nmod) treatment_16/NN (l_prep) in_17/IN (l_pobj) patient_23/NN (l_prep) with_24/IN (l_pobj) haemorrhage_26/NN
D015119_D013345 NONE EACA_14/NNP (r_nmod) treatment_16/NN (r_pobj) due_5/IN (r_prep) necrotizing_3/VBG (r_pcomp) of_2/IN (r_prep) case_1/NN (r_nsubjpass) described_31/VBN (l_punct) (_27/-LRB- (l_preconj) SAH_28/NNP
3670965
D012459_D012202 NONE salicylates_14/NNS (r_pobj) with_13/IN (r_prep) association_12/NN (r_pobj) of_11/IN (r_prep) lack_10/NN (r_pobj) despite_7/IN (r_prep) disappearing_4/VBG (l_nsubj) syndrome_1/NN
D001241_D012202 CID aspirin_16/JJ (r_compound) ingestion_17/NN (r_conj) salicylates_14/NNS (r_pobj) with_13/IN (r_prep) association_12/NN (r_pobj) of_11/IN (r_prep) lack_10/NN (r_pobj) despite_7/IN (r_prep) disappearing_4/VBG (l_nsubj) syndrome_1/NN
21418164
D008130_D064420 NONE CCNU_0/NNP (r_npadvmod) lomustine_2/NN (l_dobj) toxicity_4/NN
D008130_D064420 NONE lomustine_2/NN (l_dobj) toxicity_4/NN
D008130_D064420 NONE CCNU_6/NNP (r_pobj) with_5/IN (r_prep) treated_4/VBN (r_acl) dogs_3/NNS (r_pobj) Of_0/IN (r_prep) met_9/VBD (l_dobj) criteria_12/NNS (l_prep) for_13/IN (l_pobj) class_17/NN (l_prep) of_18/IN (l_pobj) toxicity_19/NN
D008130_D064420 NONE CCNU_0/NN (r_npadvmod) associated_2/VBN (r_amod) toxicity_3/NN
D008130_D034801 NONE CCNU_0/NNP (r_nsubjpass) used_2/VBN (l_prep) in_5/IN (l_pobj) treatment_7/NN (l_prep) of_8/IN (l_pobj) lymphoma_9/NN (l_conj) tumour_13/NN
D008130_D008223 NONE CCNU_0/NNP (r_nsubjpass) used_2/VBN (l_prep) in_5/IN (l_pobj) treatment_7/NN (l_prep) of_8/IN (l_pobj) lymphoma_9/NN
D008130_D008223 NONE CCNU_0/NNP (r_nsubjpass) used_2/VBN (l_prep) in_5/IN (l_pobj) treatment_7/NN (l_prep) of_8/IN (l_pobj) lymphoma_9/NN (l_conj) tumour_13/NN (l_conj) tumour_16/NN (l_conj) tumours_19/NNS (l_conj) lymphoma_22/NN
D008130_D006402 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19/JJ (r_nmod) CCNU_21/NNP (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) in_13/IN (r_prep) toxicities_12/NNS
D008130_D006402 NONE CCNU_21/NNP (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) in_13/IN (r_prep) toxicities_12/NNS
D008130_D005767 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19/JJ (r_nmod) CCNU_21/NNP (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) in_13/IN (r_prep) toxicities_12/NNS
D008130_D005767 NONE CCNU_21/NNP (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) in_13/IN (r_prep) toxicities_12/NNS
D008130_D015620 NONE CCNU_0/NNP (r_nsubjpass) used_2/VBN (l_prep) in_5/IN (l_pobj) treatment_7/NN (l_prep) of_8/IN (l_pobj) lymphoma_9/NN (l_conj) tumour_13/NN (l_conj) tumour_16/NN (l_conj) tumours_19/NNS
D008130_D056486 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19/JJ (r_nmod) CCNU_21/NNP (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) in_13/IN (r_prep) toxicities_12/NNS
D008130_D056486 NONE CCNU_21/NNP (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) in_13/IN (r_prep) toxicities_12/NNS
D000409_D064420 NONE alanine_5/NN (r_compound) transaminase_6/NN (r_nmod) concentration_10/NN (r_conj) toxicity_2/NN
D008130_D007674 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19/JJ (r_nmod) CCNU_21/NNP (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) in_13/IN (r_prep) toxicities_12/NNS
D008130_D007674 NONE CCNU_21/NNP (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) in_13/IN (r_prep) toxicities_12/NNS
D008130_D001932 NONE CCNU_0/NNP (r_nsubjpass) used_2/VBN (l_prep) in_5/IN (l_pobj) treatment_7/NN (l_prep) of_8/IN (l_pobj) lymphoma_9/NN (l_conj) tumour_13/NN (l_conj) tumour_16/NN
17074608
D014635_D001927 CID Valproate_0/NNP (r_npadvmod) induced_2/VBN (r_amod) chorea_3/NN (l_conj) encephalopathy_5/JJ
D014635_D001927 CID valproate_32/NN (r_amod) therapy_33/NN (r_pobj) of_31/IN (r_prep) initiation_30/NN (r_pobj) after_29/IN (r_prep) presentation_22/NN (l_prep) with_23/IN (l_pobj) encephalopathy_25/NN
D014635_D002819 CID Valproate_0/NNP (r_npadvmod) induced_2/VBN (r_amod) chorea_3/NN
D014635_D002819 CID valproate_32/NN (r_amod) therapy_33/NN (r_pobj) of_31/IN (r_prep) initiation_30/NN (r_pobj) after_29/IN (r_prep) presentation_22/NN (l_prep) with_23/IN (l_pobj) encephalopathy_25/NN (l_conj) chorea_27/NN
D014635_D008607 NONE valproate_32/NN (r_amod) therapy_33/NN (r_pobj) of_31/IN (r_prep) initiation_30/NN (r_pobj) after_29/IN (r_prep) presentation_22/NN (r_pobj) following_20/VBG (r_prep) found_15/VBN (r_relcl) delay_8/NN (l_conj) retardation_11/NN
D014635_D020158 NONE Valproate_0/NNP (r_npadvmod) induced_2/VBN (r_amod) chorea_3/NN (l_conj) encephalopathy_5/JJ (l_prep) in_6/IN (l_pobj) hyperglycinemia_9/NN
D014635_D020158 NONE valproate_32/NN (r_amod) therapy_33/NN (r_pobj) of_31/IN (r_prep) initiation_30/NN (r_pobj) after_29/IN (r_prep) presentation_22/NN (r_pobj) following_20/VBG (r_prep) found_15/VBN (l_xcomp) have_17/VB (l_dobj) hyperglycinemia_19/NN
D005998_D000592 NONE glycine_15/NN (r_compound) system_17/NN (r_pobj) in_13/IN (r_prep) defect_12/NN (r_nsubj) leads_18/VBZ (r_relcl) metabolism_8/NN
D005998_D000592 NONE glycine_23/NN (r_pobj) of_22/IN (r_prep) accumulation_21/NN (r_pobj) to_19/IN (r_prep) leads_18/VBZ (r_relcl) metabolism_8/NN
D014635_D007805 NONE valproate_32/NN (r_amod) therapy_33/NN (r_pobj) of_31/IN (r_prep) initiation_30/NN (r_pobj) after_29/IN (r_prep) presentation_22/NN (r_pobj) following_20/VBG (r_prep) found_15/VBN (r_relcl) delay_8/NN
D005998_D020158 NONE glycine_15/NN (r_compound) system_17/NN (r_pobj) in_13/IN (r_prep) defect_12/NN (r_nsubj) leads_18/VBZ (r_relcl) metabolism_8/NN (r_pobj) of_5/IN (r_prep) disorder_4/NN (r_attr) is_2/VBZ (l_nsubj) hyperglycinemia_1/NN
D005998_D020158 NONE glycine_23/NN (r_pobj) of_22/IN (r_prep) accumulation_21/NN (r_pobj) to_19/IN (r_prep) leads_18/VBZ (r_relcl) metabolism_8/NN (r_pobj) of_5/IN (r_prep) disorder_4/NN (r_attr) is_2/VBZ (l_nsubj) hyperglycinemia_1/NN
17285209
D000809_D007410 NONE angiotensin_3/NN (r_npadvmod) converting_5/VBG (r_amod) enzyme_6/NN (r_pobj) of_2/IN (r_prep) recognition_1/NN (r_nsubj) constitutes_19/VBZ (l_nsubj) angioedema_18/NN
D000809_D007410 NONE angiotensin_11/NN (r_compound) blocker_13/NN (r_conj) enzyme_6/NN (r_pobj) of_2/IN (r_prep) recognition_1/NN (r_nsubj) constitutes_19/VBZ (l_nsubj) angioedema_18/NN
D000809_D000799 NONE angiotensin_3/NN (r_npadvmod) converting_5/VBG (r_amod) enzyme_6/NN (r_pobj) of_2/IN (r_prep) recognition_1/NN (r_nsubj) constitutes_19/VBZ (l_nsubj) angioedema_18/NN
D000809_D000799 NONE angiotensin_11/NN (r_compound) blocker_13/NN (r_conj) enzyme_6/NN (r_pobj) of_2/IN (r_prep) recognition_1/NN (r_nsubj) constitutes_19/VBZ (l_nsubj) angioedema_18/NN
D017311_D006973 NONE amlodipine_26/NN (r_pobj) of_25/IN (r_prep) pill_24/NN (r_pobj) on_21/IN (r_prep) started_20/VBN (r_relcl) female_12/NN (l_prep) with_13/IN (l_pobj) hypertension_16/NN
C044946_D006973 NONE benazapril_28/NN (r_compound) mg._30/CD (r_appos) pill_24/NN (r_pobj) on_21/IN (r_prep) started_20/VBN (r_relcl) female_12/NN (l_prep) with_13/IN (l_pobj) hypertension_16/NN
18513945
D010121_D020521 NONE oxytocin_4/NN (r_pobj) to_3/IN (r_prep) response_2/NN (r_pobj) in_1/IN (r_prep) Hypotension_0/NN (r_nsubjpass) associated_6/VBN (l_prep) with_7/IN (l_pobj) decrease_9/NN (l_conj) increase_17/NN (l_prep) in_18/IN (l_pobj) volume_20/NN (l_compound) stroke_19/NN
D010121_D006473 NONE Oxytocin_0/NN (r_npadvmod) induced_2/VBN (r_amod) hypotension_3/NN (r_nsubjpass) attributed_10/VBN (l_prep) to_11/IN (l_pobj) loss_13/NN
D010121_D007022 CID Oxytocin_0/NN (r_nsubj) is_1/VBZ (l_attr) uterotonic_5/NN (l_relcl) cause_8/VB (l_dobj) hypotension_13/NN
D010121_D007022 CID Oxytocin_0/NN (r_npadvmod) induced_2/VBN (r_amod) hypotension_3/NN
D010121_D007022 CID oxytocin_4/NN (r_pobj) to_3/IN (r_prep) response_2/NN (r_pobj) in_1/IN (r_prep) Hypotension_0/NN
11900788
D001285_D002375 NONE atropine_3/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (l_appos) catalepsy_14/NN
D001285_D002375 NONE atropine_3/NN (r_pobj) of_2/IN (r_prep) injection_1/NN (r_nsubj) decreased_10/VBD (l_dobj) catalepsy_11/NN
D018738_D002375 NONE hexamethonium_10/NN (r_conj) mecamylamine_7/NN (r_conj) naloxone_5/NN (r_appos) administration_1/NN (l_appos) catalepsy_14/NN
D018738_D002375 NONE hexamethonium_5/NN (r_conj) atropine_3/NN (r_pobj) of_2/IN (r_prep) injection_1/NN (r_nsubj) decreased_10/VBD (l_dobj) catalepsy_11/NN
D008464_D002375 NONE mecamylamine_7/NN (r_conj) naloxone_5/NN (r_appos) administration_1/NN (l_appos) catalepsy_14/NN
D009270_D002375 NONE naloxone_5/NN (r_appos) administration_1/NN (l_appos) catalepsy_14/NN
D009270_D002375 NONE naloxone_8/NN (r_conj) hexamethonium_5/NN (r_conj) atropine_3/NN (r_pobj) of_2/IN (r_prep) injection_1/NN (r_nsubj) decreased_10/VBD (l_dobj) catalepsy_11/NN
D009020_D002375 CID morphine_3/NN (r_npadvmod) induced_5/VBN (r_amod) catalepsy_6/NN
D009020_D002375 CID morphine_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) effects_5/NNS (l_prep) on_8/IN (l_pobj) catalepsy_9/NN
D009020_D002375 CID Morphine_0/NNP (r_nsubj) induced_4/VBD (l_dobj) catalepsy_9/NN
D009020_D002375 CID morphine_20/NN (r_pobj) of_19/IN (r_prep) combination_18/NN (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) catalepsy_14/NN
D009020_D002375 CID morphine_14/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) catalepsy_11/NN
D009020_D002375 CID morphine_4/NN (r_compound) catalepsy_5/NN
D009020_D002375 CID morphine_19/NN (r_pobj) of_18/IN (r_prep) potentiation_17/NN (r_nsubjpass) mediated_26/VBN (r_conj) elicited_8/VBN (l_nsubjpass) catalepsy_5/NN
D009538_D002375 CID Nicotine_0/NN (r_compound) potentiation_1/NN (l_prep) of_2/IN (l_pobj) catalepsy_6/NN
D009538_D002375 CID nicotine_7/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (l_prep) on_8/IN (l_pobj) catalepsy_9/NN
D009538_D002375 CID nicotine_3/NN (r_conj) Morphine_0/NNP (r_nsubj) induced_4/VBD (l_dobj) catalepsy_9/NN
D009538_D002375 CID nicotine_22/NN (r_pobj) with_21/IN (r_prep) combination_18/NN (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) catalepsy_14/NN
D009538_D002375 CID nicotine_16/NN (r_conj) morphine_14/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) catalepsy_11/NN
D009538_D002375 CID nicotine_22/NN (r_pobj) by_21/IN (r_agent) induced_20/VBN (r_acl) potentiation_17/NN (r_nsubjpass) mediated_26/VBN (r_conj) elicited_8/VBN (l_nsubjpass) catalepsy_5/NN
19707748
D064704_D012640 CID levofloxacin_3/NNS (r_pobj) with_2/IN (r_prep) associated_1/VBN (r_acl) Seizures_0/NNS
D064704_D012640 CID levofloxacin_15/NNS (r_pobj) with_14/IN (r_prep) treatment_13/NN (r_dobj) initiating_12/VBG (r_pcomp) after_11/IN (r_prep) developed_8/VBD (l_dobj) seizures_9/NNS
D064704_D012640 CID levofloxacin_15/NNS (r_pobj) with_14/IN (r_prep) treatment_13/NN (r_dobj) initiating_12/VBG (r_pcomp) after_11/IN (r_prep) developed_8/VBD (r_relcl) patient_6/NN (l_prep) of_47/IN (l_pobj) seizures_51/NNS
D064704_D012640 CID levofloxacin_48/NN (r_npadvmod) induced_50/VBN (r_amod) seizures_51/NNS (r_pobj) of_47/IN (r_prep) patient_6/NN (l_relcl) developed_8/VBD (l_dobj) seizures_9/NNS
D064704_D012640 CID levofloxacin_48/NN (r_npadvmod) induced_50/VBN (r_amod) seizures_51/NNS
D064704_D012640 CID levofloxacin_3/NN (r_npadvmod) induced_5/VBN (r_amod) seizures_6/NNS
16132524
D017239_D005909 NONE paclitaxel_3/NN (r_nmod) carboplatin_5/VB (r_amod) phases_9/NNS (l_prep) for_11/IN (l_pobj) glioblastoma_13/NN
D017239_D005909 NONE paclitaxel_21/NN (r_pobj) of_20/IN (r_prep) application_19/NN (r_pobj) of_15/IN (r_prep) effects_14/NNS (r_conj) safety_8/NN (r_conj) feasibility_6/NN (r_nsubjpass) examined_31/VBN (l_prep) For_0/IN (l_pobj) recurrences_3/NNS (l_compound) glioblastoma_2/NN
D017239_D005909 NONE paclitaxel_22/NN (r_pobj) of_21/IN (r_prep) application_20/NN (r_dobj) received_17/VBD (r_conj) underwent_12/VBN (r_acl) multiforme_11/NN (l_compound) glioblastoma_10/NN
D017239_D001929 CID paclitaxel_9/NN (r_dobj) received_4/VBD (l_conj) suffered_11/VBD (l_prep) from_12/IN (l_prep) to_14/TO (l_pobj) edema_17/NN
D017239_D001929 CID paclitaxel_30/NN (r_pobj) of_27/IN (r_prep) total_26/NN (r_dobj) received_23/VBD (r_advcl) suffered_11/VBD (l_prep) from_12/IN (l_prep) to_14/TO (l_pobj) edema_17/NN
D016190_D005909 NONE carboplatin_5/VB (r_amod) phases_9/NNS (l_prep) for_11/IN (l_pobj) glioblastoma_13/NN
D016190_D005909 NONE carboplatin_23/NN (r_advmod) encapsulated_24/VBN (r_conj) effects_14/NNS (r_conj) safety_8/NN (r_conj) feasibility_6/NN (r_nsubjpass) examined_31/VBN (l_prep) For_0/IN (l_pobj) recurrences_3/NNS (l_compound) glioblastoma_2/NN
D016190_D005909 NONE carboplatin_24/VB (r_amod) phases_26/NNS (r_conj) received_17/VBD (r_conj) underwent_12/VBN (r_acl) multiforme_11/NN (l_compound) glioblastoma_10/NN
8410199
C028911_D009410 NONE violet_6/NN (r_compound) staining_7/NN (l_conj) methods_11/NNS (l_compound) degeneration_10/NN
C028911_D009410 NONE violet_6/NN (r_compound) staining_7/NN (r_pobj) including_4/VBG (r_prep) studies_2/NNS (r_nsubj) suggested_22/VBD (l_ccomp) related_36/VBN (l_prep) to_37/IN (l_pobj) loss_39/NN
D018698_D012640 NONE glutamate_2/NN (r_compound) decarboxylase_3/NN (r_nmod) neurons_7/NNS (r_pobj) of_1/IN (r_prep) Loss_0/NN (l_prep) following_13/VBG (l_pobj) seizures_17/NNS
D018698_D012640 NONE acid_10/NN (r_compound) decarboxylase_11/NN (r_nsubj) are_26/VBP (l_acomp) vulnerable_27/JJ (l_prep) to_28/IN (l_pobj) damage_32/NN (l_amod) induced_31/VBN (l_npadvmod) seizure_29/NN
D018698_D012640 NONE acid_10/NN (r_compound) decarboxylase_11/NN (r_nsubj) are_26/VBP (l_acomp) vulnerable_27/JJ (l_prep) to_28/IN (l_pobj) damage_32/NN (l_prep) in_33/IN (l_pobj) model_35/NN (l_prep) of_36/IN (l_pobj) seizures_38/NNS
D010862_D012640 CID pilocarpine_14/NN (r_npadvmod) induced_16/VBN (r_amod) seizures_17/NNS
D010862_D012640 CID pilocarpine_8/NN (r_pobj) with_7/IN (r_prep) injected_5/VBN (l_conj) studied_15/VBN (l_conj) intervals_27/NNS (l_prep) after_28/IN (l_pobj) seizures_32/NNS
D010862_D012640 CID pilocarpine_29/NN (r_npadvmod) induced_31/VBN (r_amod) seizures_32/NNS
9848575
D018943_D009202 NONE anthracycline_6/NN (r_amod) derivative_7/JJ (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_11/IN (l_pobj) heart_13/NN (l_conj) cardiomyopathy_18/NN
C055866_D066126 NONE SM-5887_11/NNP (r_pobj) of_10/IN (r_prep) potential_9/NN (l_amod) cardiotoxic_8/JJ
C055866_D066126 NONE SM-5887_11/NNP (r_pobj) of_10/IN (r_prep) potential_9/NN (l_conj) effect_16/NN (l_prep) on_19/IN (l_pobj) cardiotoxicity_23/NN
C055866_D066126 NONE SM-5887_18/NNP (r_pobj) of_17/IN (r_prep) effect_16/NN (r_conj) potential_9/NN (l_amod) cardiotoxic_8/JJ
C055866_D066126 NONE SM-5887_18/NNP (r_pobj) of_17/IN (r_prep) effect_16/NN (l_prep) on_19/IN (l_pobj) cardiotoxicity_23/NN
C055866_D066126 NONE SM-5887_8/NNP (r_nmod) cardiomyopathy_13/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (l_amod) cardiotoxic_5/JJ
C055866_D066126 NONE SM-5887_3/NNP (r_nsubj) have_6/VB (l_dobj) potential_8/NN (l_prep) of_9/IN (l_pobj) cardiotoxicity_11/NN
C055866_D066126 NONE SM-5887_3/NNP (r_nsubj) have_6/VB (l_dobj) potential_8/NN (l_prep) of_9/IN (l_pobj) cardiotoxicity_11/NN (l_conj) effect_14/NN (l_prep) on_15/IN (l_pobj) cardiotoxicity_19/NN
D004317_D009202 CID doxorubicin_15/RB (r_npadvmod) induced_17/VBN (r_amod) cardiomyopathy_18/NN
D004317_D009202 CID doxorubicin_7/NN (r_pobj) of_6/IN (r_prep) courses_5/NNS (r_dobj) received_2/VBD (r_relcl) Animals_0/NNS (r_nsubj) demonstrated_8/VBD (l_dobj) decrease_16/NN (l_prep) of_17/IN (l_pobj) pressure_19/NN (l_conj) cardiomyopathy_25/NN
D004317_D009202 CID doxorubicin_22/NN (r_pobj) of_21/IN (r_prep) courses_20/NNS (r_pobj) by_18/IN (r_agent) induced_15/VBN (l_csubjpass) examine_1/VB (l_dobj) effect_6/NN (l_prep) of_7/IN (l_pobj) cardiomyopathy_13/NN
D004317_D066126 NONE doxorubicin_28/NN (r_appos) potential_9/NN (l_amod) cardiotoxic_8/JJ
D004317_D066126 NONE doxorubicin_28/NN (r_appos) potential_9/NN (l_conj) effect_16/NN (l_prep) on_19/IN (l_pobj) cardiotoxicity_23/NN
D004317_D066126 NONE doxorubicin_22/NN (r_pobj) of_21/IN (r_prep) courses_20/NNS (r_pobj) by_18/IN (r_agent) induced_15/VBN (l_csubjpass) examine_1/VB (l_dobj) effect_6/NN (l_amod) cardiotoxic_5/JJ
D004317_D066126 NONE doxorubicin_11/NN (r_compound) treatment_12/NN (r_pobj) by_8/IN (r_agent) enhanced_7/VBN (l_nsubjpass) changes_5/NNS (l_amod) cardiotoxic_4/JJ
D004317_D066126 NONE doxorubicin_16/RB (r_npadvmod) induced_18/VBN (r_amod) cardiotoxicity_19/NN (r_pobj) on_15/IN (r_prep) effect_14/NN (r_conj) cardiotoxicity_11/NN
D004317_D066126 NONE doxorubicin_16/RB (r_npadvmod) induced_18/VBN (r_amod) cardiotoxicity_19/NN
C055866_D009202 NONE SM-5887_9/NNP (r_appos) derivative_7/JJ (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_11/IN (l_pobj) heart_13/NN (l_conj) cardiomyopathy_18/NN
C055866_D009202 NONE SM-5887_35/NNP (r_compound) administration_36/NN (r_nsubj) show_39/VB (r_advcl) demonstrated_8/VBD (l_dobj) decrease_16/NN (l_prep) of_17/IN (l_pobj) pressure_19/NN (l_conj) cardiomyopathy_25/NN
C055866_D009202 NONE SM-5887_8/NNP (r_nmod) cardiomyopathy_13/NN
C055866_D009202 NONE SM-5887_5/NNP (r_compound) treatment_6/NN (r_nsubj) progress_9/VB (l_dobj) grade_11/NN (l_prep) of_12/IN (l_pobj) cardiomyopathy_13/NN
19234905
D014635_D006423 NONE Valproate_33/NNP (r_pobj) with_32/IN (r_prep) improved_28/VBD (r_advcl) developed_18/VBN (r_conj) had_8/VBD (l_dobj) hemianopsia_12/NN
D007980_D004409 CID levodopa_55/RB (r_npadvmod) induced_57/VBN (r_amod) dyskinesias_58/NNS
19692487
D008094_D011141 NONE lithium_6/NN (r_npadvmod) induced_8/VBN (r_amod) polyuria_9/NN
D008094_D011141 NONE lithium_8/NN (r_npadvmod) induced_10/VBN (r_amod) polyuria_11/NN
D008094_D011141 NONE lithium_7/NN (r_npadvmod) induced_9/VBN (r_amod) polyuria_10/NN
D008094_D011141 NONE lithium_10/NN (r_npadvmod) induced_12/VBN (r_amod) polyuria_13/NN
D008094_D011141 NONE lithium_7/NN (r_npadvmod) induced_9/VBN (r_amod) polyuria_10/NN
D011458_D011141 NONE E_17/NN (r_appos) microsomal_15/JJ (r_pobj) in_14/IN (r_prep) deficient_13/JJ (r_pobj) in_11/IN (r_prep) polyuria_10/NN
D015232_D011141 NONE )_29/-RRB- (r_punct) PGE(2_28/NNP (r_appos) urine_27/NN (r_pobj) of_25/IN (r_prep) blockade_24/NN (r_pobj) by_21/IN (r_agent) accompanied_20/VBN (r_advcl) were_6/VBD (l_acomp) resistant_8/JJ (l_prep) to_9/IN (l_pobj) polyuria_13/NN
D015232_D011141 NONE )_5/-RRB- (r_punct) PGE(2_4/NNP (r_nsubj) mediates_6/VBZ (l_dobj) polyuria_10/NN
7053705
D013866_D054198 NONE 6-thioguanine_27/CD (r_punct) ._28/. (r_punct) disease_5/NN (l_prep) of_6/IN (l_pobj) liver_8/NN (l_acl) developed_9/VBN (l_prep) in_10/IN (l_pobj) man_15/NN (l_prep) with_16/IN (l_pobj) leukemia_19/NN
D013866_D006504 CID 6-thioguanine_7/CD (r_pobj) by_6/IN (r_agent) caused_5/VBN (r_acl) disease_4/NN
D013866_D006504 CID 6-thioguanine_27/CD (r_punct) ._28/. (r_punct) disease_5/NN (l_prep) of_6/IN (l_pobj) liver_8/NN
D013866_D006504 CID 6-thioguanine_35/CD (r_pobj) to_34/IN (r_prep) related_32/VBN (r_pobj) of_28/IN (r_prep) case_27/NN (r_attr) be_24/VB (r_conj) presented_2/VBD (l_dobj) opportunity_5/NN (l_acl) observe_7/VB (l_dobj) features_10/NNS (l_prep) of_11/IN (l_pobj) disease_18/NN
10523326
D010100_D006973 NONE oxygen_5/NN (r_compound) species_6/NNS (r_dobj) showed_2/VBD (l_conj) increased_22/VBD (l_dobj) sequestration_24/NN (l_prep) as_25/IN (l_pobj) nitrotyrosine_26/JJ (l_prep) in_27/IN (l_pobj) tissues_29/NNS (l_prep) in_30/IN (l_pobj) rats_31/NNS (l_prep) with_32/IN (l_pobj) hypertension_36/NN
C002744_D006973 NONE nitrotyrosine_26/JJ (l_prep) in_27/IN (l_pobj) tissues_29/NNS (l_prep) in_30/IN (l_pobj) rats_31/NNS (l_prep) with_32/IN (l_pobj) hypertension_36/NN
D008315_D006973 NONE MDA_8/NNP (r_compound) concentration_9/NN (r_dobj) lowered_6/VBD (r_conj) ameliorated_3/VBD (l_dobj) hypertension_4/NN
D014810_D006973 NONE E_1/NN (r_compound) supplementation_2/NN (r_nsubj) ameliorated_3/VBD (l_dobj) hypertension_4/NN
D009569_D006973 NONE oxide_1/NN (r_compound) synthase_2/NN (r_compound) expression_3/NN (l_prep) in_4/IN (l_pobj) course_6/NN (l_prep) of_7/IN (l_pobj) hypertension_11/NN
D009569_D006973 NONE NO_15/DT (r_det) metabolites_16/NNS (r_pobj) of_14/IN (r_prep) excretion_13/NN (r_dobj) showed_2/VBD (l_conj) increased_22/VBD (l_dobj) sequestration_24/NN (l_prep) as_25/IN (l_pobj) nitrotyrosine_26/JJ (l_prep) in_27/IN (l_pobj) tissues_29/NNS (l_prep) in_30/IN (l_pobj) rats_31/NNS (l_prep) with_32/IN (l_pobj) hypertension_36/NN
D009569_D006973 NONE NO_23/DT (r_det) sequestration_24/NN (l_prep) as_25/IN (l_pobj) nitrotyrosine_26/JJ (l_prep) in_27/IN (l_pobj) tissues_29/NNS (l_prep) in_30/IN (l_pobj) rats_31/NNS (l_prep) with_32/IN (l_pobj) hypertension_36/NN
D009569_D006973 NONE NO_25/DT (r_det) synthase_26/NN (r_nmod) expression_30/NN (r_pobj) due_22/IN (r_prep) is_17/VBZ (l_nsubj) reduction_8/NN (l_prep) in_12/IN (l_pobj) hypertension_16/NN
D009569_D006973 NONE NO_11/DT (r_compound) inactivation_12/NN (l_appos) inhibition_17/NN (l_conj) actions_25/NNS (l_prep) of_26/IN (l_pobj) stress_29/NN (l_acl) associated_30/VBN (l_prep) with_31/IN (l_pobj) hypertension_32/NN
D007854_D006973 CID lead_8/NN (r_npadvmod) induced_10/VBN (r_amod) hypertension_11/NN
D007854_D006973 CID lead_33/NN (r_npadvmod) induced_35/VBN (r_amod) hypertension_36/NN
D007854_D006973 CID lead_13/NN (r_npadvmod) induced_15/VBN (r_amod) hypertension_16/NN
D007854_D006973 CID lead_3/NN (r_npadvmod) induced_5/VBN (r_amod) hypertension_6/NN
D007854_D006973 CID lead_14/NN (r_npadvmod) associated_16/VBN (r_amod) inhibition_17/NN (l_conj) actions_25/NNS (l_prep) of_26/IN (l_pobj) stress_29/NN (l_acl) associated_30/VBN (l_prep) with_31/IN (l_pobj) hypertension_32/NN
11271907
D003520_D006470 CID cyclophosphamide_5/NN (r_compound) therapy_6/NN (r_pobj) to_4/IN (r_prep) secondary_3/JJ (l_amod) myocarditis_2/NN
D003520_D006470 CID cyclophosphamide_9/NN (r_compound) therapy_10/NN (r_pobj) of_8/IN (r_prep) complication_7/NN (r_attr) is_2/VBZ (l_nsubj) myocarditis_1/NN
D003520_D009205 CID cyclophosphamide_5/NN (r_compound) therapy_6/NN (r_pobj) to_4/IN (r_prep) secondary_3/JJ (l_amod) myocarditis_2/NN
D003520_D009205 CID cyclophosphamide_9/NN (r_compound) therapy_10/NN (r_pobj) of_8/IN (r_prep) complication_7/NN (r_attr) is_2/VBZ (l_nsubj) myocarditis_1/NN
6615052
D006493_D013927 NONE Heparin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN (l_conj) thrombosis_5/NN
D006493_D001791 NONE heparin_12/NN (r_pobj) to_11/IN (r_prep) resistance_10/NN (r_dobj) increased_9/VBN (r_conj) revealed_3/VBN (l_dobj) count_7/NN
D006493_D001791 NONE heparin_24/NN (r_nsubjpass) added_26/VBN (r_conj) increased_9/VBN (r_conj) revealed_3/VBN (l_dobj) count_7/NN
D006493_D001791 NONE heparin_15/JJ (l_appos) testing_19/NN (l_compound) aggregation_18/NN
D006493_D013921 CID Heparin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN
D006493_D013921 CID heparin_6/NN (r_npadvmod) induced_8/VBN (r_amod) thrombocytopenia_9/NN
D006493_D006470 CID Heparin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN (l_conj) thrombosis_5/NN (l_conj) hemorrhage_8/NN
D006493_D006470 CID heparin_17/VBN (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) in_14/IN (r_prep) events_13/NNS (r_appos) hemorrhage_6/NN
D006493_D013923 CID heparin_17/VBN (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (r_pobj) in_14/IN (r_prep) events_13/NNS (l_compound) thromboembolic_12/JJ
3780697
D005283_D009127 CID fentanyl_5/NN (r_compound) administration_6/NN (r_pobj) after_4/IN (r_prep) rigidity_3/NN
D005283_D009127 CID fentanyl_29/NN (r_pobj) of_28/IN (r_prep) dose_27/NN (r_dobj) received_24/VBD (r_relcl) patient_22/NN (r_pobj) in_19/IN (r_prep) period_18/NN (r_pobj) in_13/IN (r_prep) described_12/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) rigidity_6/NN
D005283_D012131 NONE fentanyl_29/NN (r_pobj) of_28/IN (r_prep) dose_27/NN (r_dobj) received_24/VBD (r_relcl) patient_22/NN (r_pobj) in_19/IN (r_prep) period_18/NN (r_pobj) in_13/IN (r_prep) described_12/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) rigidity_6/NN (l_acl) leading_7/VBG (l_prep) to_8/IN (l_pobj) failure_10/NN
20394767
D010433_D012021 CID PTZ_23/NNP (r_nsubj) suppressed_24/VBD (r_conj) suppressed_13/VBD (r_conj) increased_3/VBN (l_dobj) startle_5/NN
D010433_D012021 CID PTZ_23/NNP (r_nsubj) suppressed_24/VBD (r_conj) suppressed_13/VBD (l_dobj) startle_15/NN
D010433_D012021 CID PTZ_23/NNP (r_nsubj) suppressed_24/VBD (l_dobj) startle_26/NN
D015016_D012021 CID yohimbine_2/NN (r_nsubj) increased_3/VBN (l_dobj) startle_5/NN
D015016_D012021 CID yohimbine_2/NN (r_nsubj) increased_3/VBN (l_conj) suppressed_13/VBD (l_dobj) startle_15/NN
D015016_D012021 CID yohimbine_2/NN (r_nsubj) increased_3/VBN (l_conj) suppressed_13/VBD (l_conj) suppressed_24/VBD (l_dobj) startle_26/NN
C015068_D012021 CID mCPP_12/NNS (r_advcl) increased_3/VBN (l_dobj) startle_5/NN
C015068_D012021 CID mCPP_12/NNS (r_advcl) increased_3/VBN (l_conj) suppressed_13/VBD (l_dobj) startle_15/NN
C015068_D012021 CID mCPP_12/NNS (r_advcl) increased_3/VBN (l_conj) suppressed_13/VBD (l_conj) suppressed_24/VBD (l_dobj) startle_26/NN
15814210
D003907_D009422 CID dexamethasone_19/NN (r_compound) treatment_20/NN (r_pobj) after_18/IN (r_prep) dysfunction_2/NN
D003907_D009422 CID dexamethasone_19/NN (r_compound) therapy_20/NN (r_pobj) after_18/IN (r_prep) assess_7/VB (l_dobj) dysfunction_10/NN
D003907_D009422 CID dexamethasone_1/NN (r_compound) treatment_2/NN (r_pobj) After_0/IN (r_prep) showed_5/VBD (l_dobj) rate_8/NN (l_prep) of_9/IN (l_pobj) dysfunctions_12/NNS
9067481
C013440_D056486 NONE hemisuccinate_14/NN (r_conj) rigidifier_9/NN (r_pobj) as_5/IN (r_prep) use_4/NN (r_pobj) to_2/IN (r_prep) addition_1/NN (r_pobj) In_0/IN (r_prep) shown_25/VBN (l_xcomp) protect_27/VB (l_prep) from_29/IN (l_pobj) effects_32/NNS (l_amod) hepatotoxic_31/JJ
D004317_D064420 NONE adriamycin-_45/JJ (r_conj) acetaminophen-_43/NN (r_nmod) tetrachloride-_48/NN (l_appos) toxicity_55/NN
D002251_D064420 NONE tetrachloride-_48/NN (l_appos) toxicity_55/NN
D002251_D066126 NONE CCl4_31/NNP (r_nmod) CHCl3_33/NNP (l_conj) acetaminophen_35/RB (l_conj) against_39/IN (l_pobj) lethal_41/JJ (l_conj) effect_47/NN (l_amod) cardiotoxic_45/JJ
-1_D064420 NONE CS_8/NNP (r_compound) cytoprotection_9/NN (r_pobj) of_7/IN (r_prep) mechanism_6/NN (r_pobj) of_4/IN (r_prep) understanding_3/NN (r_dobj) further_1/VB (r_advmod) examined_12/VBD (l_conj) mice_16/NNS (l_dobj) abilities_19/NNS (l_prep) of_20/IN (l_pobj) CS_21/NNP (l_conj) form_28/NN (l_prep) of_29/IN (l_pobj) CS_30/NNP (l_conj) acid_35/NN (l_conj) salt_38/NN (l_prep) against_42/IN (l_pobj) tetrachloride-_48/NN (l_appos) toxicity_55/NN
-1_D064420 NONE CS_21/NNP (l_conj) form_28/NN (l_prep) of_29/IN (l_pobj) CS_30/NNP (l_conj) acid_35/NN (l_conj) salt_38/NN (l_prep) against_42/IN (l_pobj) tetrachloride-_48/NN (l_appos) toxicity_55/NN
-1_D064420 NONE CS_30/NNP (l_conj) acid_35/NN (l_conj) salt_38/NN (l_prep) against_42/IN (l_pobj) tetrachloride-_48/NN (l_appos) toxicity_55/NN
-1_D064420 NONE salt_38/NN (l_prep) against_42/IN (l_pobj) tetrachloride-_48/NN (l_appos) toxicity_55/NN
-1_D064420 NONE CSE_40/NNP (r_appos) salt_38/NN (l_prep) against_42/IN (l_pobj) tetrachloride-_48/NN (l_appos) toxicity_55/NN
D000082_D056486 CID acetaminophen_35/RB (r_conj) CHCl3_33/NNP (r_pobj) of_30/IN (r_prep) effects_29/NNS (l_amod) hepatotoxic_28/JJ
D002725_D056486 CID CHCl3_33/NNP (r_pobj) of_30/IN (r_prep) effects_29/NNS (l_amod) hepatotoxic_28/JJ
D004317_D056486 NONE adriamycin_49/NNS (r_amod) administration_50/NN (r_pobj) of_48/IN (r_prep) effect_47/NN (r_conj) lethal_41/JJ (r_pobj) against_39/IN (r_conj) acetaminophen_35/RB (r_conj) CHCl3_33/NNP (r_pobj) of_30/IN (r_prep) effects_29/NNS (l_amod) hepatotoxic_28/JJ
-1_D066126 NONE CS_13/NNP (r_nmod) kg_17/NNS (r_pobj) of_12/IN (r_prep) dose_11/NN (r_pobj) with_8/IN (r_prep) pretreatment_2/NN (r_nsubj) resulted_22/VBD (l_prep) in_23/IN (l_pobj) protection_25/NN (l_prep) against_26/IN (l_pobj) effects_29/NNS (l_prep) of_30/IN (l_pobj) CHCl3_33/NNP (l_conj) acetaminophen_35/RB (l_conj) against_39/IN (l_pobj) lethal_41/JJ (l_conj) effect_47/NN (l_amod) cardiotoxic_45/JJ
D005688_D056486 CID galactosamine_37/NN (r_conj) acetaminophen_35/RB (r_conj) CHCl3_33/NNP (r_pobj) of_30/IN (r_prep) effects_29/NNS (l_amod) hepatotoxic_28/JJ
D005688_D056486 CID galactosamine_30/NN (r_amod) hepatotoxicity_31/NN
D005688_D066126 NONE galactosamine_37/NN (r_conj) acetaminophen_35/RB (l_conj) against_39/IN (l_pobj) lethal_41/JJ (l_conj) effect_47/NN (l_amod) cardiotoxic_45/JJ
D005688_D064420 NONE galactosamine_52/NN (r_npadvmod) induced_54/VBN (r_conj) chloroform-_50/JJ (r_nmod) toxicity_55/NN
D002725_D066126 NONE CHCl3_33/NNP (l_conj) acetaminophen_35/RB (l_conj) against_39/IN (l_pobj) lethal_41/JJ (l_conj) effect_47/NN (l_amod) cardiotoxic_45/JJ
D002725_D064420 NONE chloroform-_50/JJ (r_nmod) toxicity_55/NN
D002251_D056486 CID tetrachloride_35/NN (r_advmod) effects_32/NNS (l_amod) hepatotoxic_31/JJ
D002251_D056486 CID CCl4_37/NNP (r_appos) effects_32/NNS (l_amod) hepatotoxic_31/JJ
D002251_D056486 CID CCl4_31/NNP (r_nmod) CHCl3_33/NNP (r_pobj) of_30/IN (r_prep) effects_29/NNS (l_amod) hepatotoxic_28/JJ
D000082_D066126 NONE acetaminophen_35/RB (l_conj) against_39/IN (l_pobj) lethal_41/JJ (l_conj) effect_47/NN (l_amod) cardiotoxic_45/JJ
-1_D056486 NONE salt_17/NN (r_nmod) administration_21/NN (r_conj) hemisuccinate_14/NN (r_conj) rigidifier_9/NN (r_pobj) as_5/IN (r_prep) use_4/NN (r_pobj) to_2/IN (r_prep) addition_1/NN (r_pobj) In_0/IN (r_prep) shown_25/VBN (l_xcomp) protect_27/VB (l_prep) from_29/IN (l_pobj) effects_32/NNS (l_amod) hepatotoxic_31/JJ
-1_D056486 NONE CS_19/NNP (r_nmod) administration_21/NN (r_conj) hemisuccinate_14/NN (r_conj) rigidifier_9/NN (r_pobj) as_5/IN (r_prep) use_4/NN (r_pobj) to_2/IN (r_prep) addition_1/NN (r_pobj) In_0/IN (r_prep) shown_25/VBN (l_xcomp) protect_27/VB (l_prep) from_29/IN (l_pobj) effects_32/NNS (l_amod) hepatotoxic_31/JJ
-1_D056486 NONE CS_13/NNP (r_nmod) kg_17/NNS (r_pobj) of_12/IN (r_prep) dose_11/NN (r_pobj) with_8/IN (r_prep) pretreatment_2/NN (r_nsubj) resulted_22/VBD (l_prep) in_23/IN (l_pobj) protection_25/NN (l_prep) against_26/IN (l_pobj) effects_29/NNS (l_amod) hepatotoxic_28/JJ
-1_D056486 NONE CS_3/NNP (r_compound) protection_4/NN (r_pobj) of_2/IN (r_prep) mechanism_1/NN (r_nsubj) appear_7/VB (l_xcomp) be_9/VB (l_acomp) dependent_10/JJ (l_prep) on_11/IN (l_pobj) inhibition_13/NN (l_prep) to_17/IN (l_pobj) in_23/IN (l_pobj) light_24/NN (l_prep) of_25/IN (l_pobj) protection_27/NN (l_acl) observed_28/VBN (l_prep) against_29/IN (l_pobj) hepatotoxicity_31/NN
D000082_D064420 NONE acetaminophen-_43/NN (r_nmod) tetrachloride-_48/NN (l_appos) toxicity_55/NN
C103872_D064420 NONE acid_35/NN (l_conj) salt_38/NN (l_prep) against_42/IN (l_pobj) tetrachloride-_48/NN (l_appos) toxicity_55/NN
D004317_D066126 CID adriamycin_49/NNS (r_amod) administration_50/NN (r_pobj) of_48/IN (r_prep) effect_47/NN (l_amod) cardiotoxic_45/JJ
839274
D003276_D000236 CID contraceptives_14/NNS (r_pobj) on_12/IN (r_prep) hyperplasia_5/NN (r_conj) adenomas_1/NNS
D003276_D000236 CID contraceptives_18/NNS (r_pobj) of_16/IN (r_prep) use_15/NN (r_pobj) with_13/IN (r_prep) associated_12/VBD (r_acl) one_6/CD (r_conj) cases_1/NNS (l_prep) of_2/IN (l_pobj) adenoma_4/NN
D003276_D020518 CID contraceptives_14/NNS (r_pobj) on_12/IN (r_prep) hyperplasia_5/NN
D003276_D020518 CID contraceptives_18/NNS (r_pobj) of_16/IN (r_prep) use_15/NN (r_pobj) with_13/IN (r_prep) associated_12/VBD (r_acl) one_6/CD (l_prep) of_7/IN (l_pobj) hyperplasia_10/NN
8473723
D008728_D012640 CID levomepromazine_4/JJ (r_amod) fluvoxamine_6/NN (r_compound) treatment_7/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (l_nsubj) Seizures_0/NNS
D008728_D012640 CID levomepromazine_6/JJ (r_amod) fluvoxamine_8/NN (r_nmod) seizures_12/NNS
D016666_D012640 CID fluvoxamine_6/NN (r_compound) treatment_7/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (l_nsubj) Seizures_0/NNS
D016666_D012640 CID fluvoxamine_8/NN (r_nmod) seizures_12/NNS
16820346
D003907_D006973 CID dexamethasone_4/NN (r_npadvmod) induced_6/VBN (r_amod) hypertension_7/NN
D003907_D006973 CID dexamethasone_11/NN (l_appos) hypertension_14/NN
D003907_D006973 CID dex)-induced_13/VBN (r_amod) hypertension_14/NN
D003907_D006973 CID dex_2/NN (r_npadvmod) induced_4/VBN (r_amod) hypertension_5/NN
D003907_D006973 CID dexamethasone_6/NN (r_npadvmod) induced_8/VBN (r_amod) hypertension_9/NN
C065179_D006973 NONE Atorvastatin_0/NNS (r_nsubj) prevented_1/VBD (l_conj) reversed_3/VBD (l_dobj) hypertension_7/NN
C065179_D006973 NONE atorvastatin_6/NN (r_nmod) atorva_8/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (l_prep) on_10/IN (l_pobj) dexamethasone_11/NN (l_appos) hypertension_14/NN
C065179_D006973 NONE atorva_8/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (l_prep) on_10/IN (l_pobj) dexamethasone_11/NN (l_appos) hypertension_14/NN
C065179_D006973 NONE atorva_25/NN (r_nmod) water_34/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (l_advcl) assess_1/VB (l_dobj) effects_4/NNS (l_prep) on_10/IN (l_pobj) dexamethasone_11/NN (l_appos) hypertension_14/NN
C065179_D006973 NONE Atorva_0/NN (r_nsubj) reversed_1/VBN (l_dobj) hypertension_5/NN
C065179_D006973 NONE atorvastatin_2/NN (r_nsubj) prevented_3/VBN (l_conj) reversed_5/VBN (l_dobj) hypertension_9/NN
D013481_D006973 NONE superoxide_25/RB (r_advmod) decreased_23/VBD (r_conj) reversed_1/VBN (l_dobj) hypertension_5/NN
663266
D003974_D064420 NONE Renografin_7/NNP (r_pobj) with_6/IN (r_prep) occurred_2/VBD (l_advcl) suggesting_9/VBG (l_ccomp) contribute_13/VBP (l_prep) to_14/IN (l_pobj) toxicity_15/NN
D003974_D014693 NONE Renografin_7/NNP (r_pobj) with_6/IN (r_prep) occurred_2/VBD (l_nsubj) fibrillation_1/NN
C027278_D064420 NONE %_5/NN (r_appos) toxicity_1/NN
C027278_D064420 NONE %_13/NN (r_npadvmod) compared_7/VBN (l_nsubjpass) toxicity_1/NN
D003973_D014693 NONE diatrizoate_3/JJ (r_pobj) from_2/IN (r_prep) fibrillation_1/NN
9305828
D010862_D001930 NONE pilocarpine_1/NN (r_nsubjpass) characterized_9/VBN (l_agent) by_10/IN (l_pobj) period_13/NN (l_acl) followed_17/VBN (l_agent) by_18/IN (l_pobj) seizures_21/NNS (l_conj) damage_25/NN
D010862_D001930 NONE PILO_3/NNP (r_nmod) model_5/NN (r_nsubjpass) characterized_9/VBN (l_agent) by_10/IN (l_pobj) period_13/NN (l_acl) followed_17/VBN (l_agent) by_18/IN (l_pobj) seizures_21/NNS (l_conj) damage_25/NN
D010862_D004833 CID pilocarpine_6/NN (r_amod) model_7/NN (l_prep) of_8/IN (l_pobj) epilepsy_11/NN
D010862_D004833 CID PILO_30/NNP (r_amod) model_31/NN (l_prep) of_32/IN (l_pobj) TLE_33/NNP
D010862_D012640 NONE pilocarpine_1/NN (r_nsubjpass) characterized_9/VBN (l_agent) by_10/IN (l_pobj) period_13/NN (l_acl) followed_17/VBN (l_agent) by_18/IN (l_pobj) seizures_21/NNS
D010862_D012640 NONE PILO_3/NNP (r_nmod) model_5/NN (r_nsubjpass) characterized_9/VBN (l_agent) by_10/IN (l_pobj) period_13/NN (l_acl) followed_17/VBN (l_agent) by_18/IN (l_pobj) seizures_21/NNS
D010862_D013226 NONE pilocarpine_1/NN (r_nsubjpass) characterized_9/VBN (l_agent) by_10/IN (l_pobj) period_13/NN (l_prep) of_14/IN (l_pobj) epilepticus_16/NN
D010862_D013226 NONE PILO_3/NNP (r_nmod) model_5/NN (r_nsubjpass) characterized_9/VBN (l_agent) by_10/IN (l_pobj) period_13/NN (l_prep) of_14/IN (l_pobj) epilepticus_16/NN
D010862_D004827 NONE pilocarpine_1/NN (r_nsubjpass) characterized_9/VBN (l_nsubjpass) model_5/NN (l_prep) of_6/IN (l_pobj) epilepsy_7/NN
D010862_D004827 NONE PILO_3/NNP (r_nmod) model_5/NN (l_prep) of_6/IN (l_pobj) epilepsy_7/NN
9165568
D004298_D009459 NONE dopamine_10/NN (r_compound) blockade_13/NN (r_pobj) of_9/IN (r_prep) result_8/NN (r_attr) be_6/VB (r_xcomp) thought_4/VBN (l_nsubjpass) syndrome_2/NN
D018967_D001480 NONE risperidone_14/NN (r_pobj) with_13/IN (r_prep) frequency_9/NN (l_prep) of_10/IN (l_pobj) symptoms_12/NNS
D018967_D009459 CID risperidone_4/NN (r_pobj) with_3/IN (r_prep) syndrome_2/NN
D018967_D009459 CID risperidone_12/NN (r_pobj) with_11/IN (r_prep) monotherapy_10/NN (r_pobj) after_9/IN (r_prep) developed_5/VBD (l_dobj) syndrome_8/NN
D018967_D009459 CID risperidone_11/NN (r_pobj) with_10/IN (r_prep) observed_9/VBN (r_ccomp) appears_1/VBZ (l_conj) ensure_14/VB (l_dobj) protection_15/NN (l_prep) from_16/IN (l_pobj) syndrome_19/NN
11284996
D009569_D051270 NONE oxide_6/NN (r_nsubj) induced_10/VBN (l_ccomp) associated_17/VBN (l_nsubjpass) headache_11/NN (l_prep) in_12/IN (l_pobj) headaches_14/NNS
D009569_D051270 NONE NO_8/NNP (r_intj) oxide_6/NN (r_nsubj) induced_10/VBN (l_ccomp) associated_17/VBN (l_nsubjpass) headache_11/NN (l_prep) in_12/IN (l_pobj) headaches_14/NNS
D005996_D018781 NONE trinitrate_20/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (l_prep) in_24/IN (l_pobj) patients_26/NNS (l_prep) with_27/IN (l_pobj) headache_32/NN
D005996_D018781 NONE GTN_22/NNP (r_appos) trinitrate_20/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (l_prep) in_24/IN (l_pobj) patients_26/NNS (l_prep) with_27/IN (l_pobj) headache_32/NN
D005996_D006261 CID trinitrate_20/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_acl) headache_13/NN
D005996_D006261 CID GTN_22/NNP (r_appos) trinitrate_20/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_acl) headache_13/NN
D005996_D006261 CID GTN_13/NNP (l_conj) placebo_15/NN (l_prep) over_16/IN (l_pobj) min_18/NN (l_prep) on_19/IN (l_pobj) days_24/NNS (l_amod) free_23/JJ (l_npadvmod) headache_21/NN
D005996_D006261 CID GTN_11/NNP (r_compound) day_12/NN (r_pobj) on_9/IN (r_prep) headache_8/NN
D005996_D006261 CID GTN_11/NNP (r_compound) day_12/NN (r_pobj) on_9/IN (r_prep) headache_8/NN (r_dobj) developed_4/VBD (l_conj) was_21/VBD (l_nsubj) headache_20/NN
D009569_D018781 NONE oxide_8/NN (r_npadvmod) induced_10/VBN (r_amod) headache_11/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) headache_19/NN
D009569_D018781 NONE NO_17/JJ (r_det) trinitrate_20/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (l_prep) in_24/IN (l_pobj) patients_26/NNS (l_prep) with_27/IN (l_pobj) headache_32/NN
D009569_D006261 CID oxide_8/NN (r_npadvmod) induced_10/VBN (r_amod) headache_11/NN
D009569_D006261 CID oxide_6/NN (r_nsubj) induced_10/VBN (l_ccomp) associated_17/VBN (l_nsubjpass) headache_11/NN
D009569_D006261 CID NO_8/NNP (r_intj) oxide_6/NN (r_nsubj) induced_10/VBN (l_ccomp) associated_17/VBN (l_nsubjpass) headache_11/NN
D009569_D006261 CID NO_17/JJ (r_det) trinitrate_20/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_acl) headache_13/NN
D009569_D006261 CID NO_5/RB (r_intj) induced_7/VBN (r_amod) headache_9/NN
7752389
D015320_D053201 NONE tachykinins_12/NNS (r_pobj) of_11/IN (r_prep) involvement_10/NN (r_appos) rats_8/NNS (r_pobj) in_4/IN (r_prep) hyperactivity_3/NN
D015320_D053201 NONE tachykinins_6/NNS (r_pobj) of_5/IN (r_prep) release_4/NN (r_pobj) via_3/IN (r_prep) contribute_8/VBP (l_prep) to_9/IN (l_pobj) urge_11/VB (l_conj) hyperactivity_14/NN
D015232_D053201 CID E2-induced_1/JJ (r_amod) hyperactivity_3/NN
D011453_D053201 NONE Prostanoids_0/NNS (r_nsubj) contribute_8/VBP (l_prep) to_9/IN (l_pobj) urge_11/VB (l_conj) hyperactivity_14/NN
19139001
D013467_D018256 NONE sulindac_22/NN (r_conj) difluoromethylornithine_17/NN (r_pobj) with_16/IN (r_prep) months_15/NNS (r_pobj) for_13/IN (r_prep) treatment_12/NN (r_pobj) after_11/IN (r_prep) polyps_10/NNS
D000518_D064420 NONE DFMO_10/NN (r_pobj) with_9/IN (r_prep) treatment_8/NN (r_pobj) of_7/IN (r_prep) toxicity_6/NN
D000518_D018256 NONE difluoromethylornithine_17/NN (r_pobj) with_16/IN (r_prep) months_15/NNS (r_pobj) for_13/IN (r_prep) treatment_12/NN (r_pobj) after_11/IN (r_prep) polyps_10/NNS
D000518_D018256 NONE DFMO_19/NN (r_appos) difluoromethylornithine_17/NN (r_pobj) with_16/IN (r_prep) months_15/NNS (r_pobj) for_13/IN (r_prep) treatment_12/NN (r_pobj) after_11/IN (r_prep) polyps_10/NNS
D013467_D034381 CID sulindac_14/NN (r_compound) group_15/NN (l_relcl) experienced_17/VBD (l_dobj) loss_21/NN
D000518_D034381 NONE DFMO_10/NN (r_pobj) with_9/IN (r_prep) treatment_8/NN (r_pobj) of_7/IN (r_prep) toxicity_6/NN (r_attr) is_3/VBZ (l_nsubj) loss_2/NN
D000518_D034381 NONE DFMO_12/NN (r_nmod) group_15/NN (l_relcl) experienced_17/VBD (l_dobj) loss_21/NN
D013467_D015179 NONE sulindac_15/NN (l_prep) for_16/IN (l_pobj) prevention_17/NN (l_prep) of_18/IN (l_pobj) adenomas_21/NNS
D000518_D015179 NONE difluoromethylornithine_13/NN (l_conj) sulindac_15/NN (l_prep) for_16/IN (l_pobj) prevention_17/NN (l_prep) of_18/IN (l_pobj) adenomas_21/NNS
12739036
D003520_D007674 NONE cyclophosphamide_25/NN (r_conj) azathioprine_23/NN (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) of_20/IN (r_prep) periods_19/NNS (r_dobj) undergone_18/JJ (r_conj) suffering_6/VBG (l_prep) with_14/IN (l_pobj) involvement_16/NN
D002738_D018771 NONE chloroquine_3/NN (r_amod) CQ_5/NNP (r_pobj) with_2/IN (r_prep) therapy_1/NN (r_nsubjpass) started_8/VBN (l_prep) because_9/IN (l_pobj) arthralgia_11/NN
D002738_D018771 NONE CQ_5/NNP (r_pobj) with_2/IN (r_prep) therapy_1/NN (r_nsubjpass) started_8/VBN (l_prep) because_9/IN (l_pobj) arthralgia_11/NN
D001379_D008180 NONE azathioprine_23/NN (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) of_20/IN (r_prep) periods_19/NNS (r_dobj) undergone_18/JJ (r_conj) suffering_6/VBG (l_prep) from_7/IN (l_pobj) erythematosus_10/NN
D001379_D008180 NONE azathioprine_23/NN (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) of_20/IN (r_prep) periods_19/NNS (r_dobj) undergone_18/JJ (r_conj) suffering_6/VBG (l_prep) from_7/IN (l_pobj) erythematosus_10/NN (l_appos) SLE_12/NNP
D013256_D009220 NONE steroids_10/NNS (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_conj) suspected_2/VBN (l_nsubjpass) Myositis_0/NNP
D001379_D007674 NONE azathioprine_23/NN (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) of_20/IN (r_prep) periods_19/NNS (r_dobj) undergone_18/JJ (r_conj) suffering_6/VBG (l_prep) with_14/IN (l_pobj) involvement_16/NN
D003401_D008180 NONE creatine_5/NN (r_compound) levels_7/NNS (l_prep) in_8/IN (l_pobj) erythematosus_11/NN
D003520_D008180 NONE cyclophosphamide_25/NN (r_conj) azathioprine_23/NN (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) of_20/IN (r_prep) periods_19/NNS (r_dobj) undergone_18/JJ (r_conj) suffering_6/VBG (l_prep) from_7/IN (l_pobj) erythematosus_10/NN
D003520_D008180 NONE cyclophosphamide_25/NN (r_conj) azathioprine_23/NN (r_pobj) with_22/IN (r_prep) treatment_21/NN (r_pobj) of_20/IN (r_prep) periods_19/NNS (r_dobj) undergone_18/JJ (r_conj) suffering_6/VBG (l_prep) from_7/IN (l_pobj) erythematosus_10/NN (l_appos) SLE_12/NNP
D002738_D009135 NONE chloroquine_15/NN (r_advmod) induced_17/VBN (r_amod) myopathy_18/NN
D002738_D009135 NONE chloroquine_3/NN (r_npadvmod) induced_5/VBN (r_compound) myopathy_6/NN
15075188
D012964_D011507 NONE sodium_14/NN (r_compound) excretion_15/NN (r_dobj) decreased_12/VBD (l_advcl) induced_6/VBD (l_dobj) proteinuria_8/NN
D011692_D001201 CID PAN_4/NNP (r_compound) treatment_5/NN (r_nsubj) induced_6/VBD (r_advcl) decreased_12/VBD (l_dobj) excretion_15/NN (l_conj) ascites_19/NNS
D011692_D009404 CID aminonucleoside_11/RB (r_advmod) induced_13/VBN (r_amod) syndrome_15/NN
D011692_D009404 CID PAN_38/NNP (r_npadvmod) induced_40/VBN (r_amod) syndrome_42/NN
D011692_D034141 CID PAN_4/NNP (r_compound) treatment_5/NN (r_nsubj) induced_6/VBD (l_dobj) proteinuria_8/NN (l_appos) hypoalbuminemia_10/NN
D012964_D034141 NONE sodium_14/NN (r_compound) excretion_15/NN (r_dobj) decreased_12/VBD (l_advcl) induced_6/VBD (l_dobj) proteinuria_8/NN (l_appos) hypoalbuminemia_10/NN
D012964_D009404 NONE sodium_6/NN (r_compound) retention_7/NN (r_pobj) by_5/IN (r_agent) accompanied_4/VBN (l_nsubjpass) syndrome_1/NN
D012964_D009404 NONE sodium_34/NN (r_compound) retention_35/NN (l_acl) associated_36/VBN (l_prep) with_37/IN (l_pobj) syndrome_42/NN
D012964_D001201 NONE sodium_14/NN (r_compound) excretion_15/NN (l_conj) ascites_19/NNS
D012964_D004487 NONE sodium_6/NN (r_compound) retention_7/NN (l_conj) edema_10/NN
D011692_D011507 CID PAN_4/NNP (r_compound) treatment_5/NN (r_nsubj) induced_6/VBD (l_dobj) proteinuria_8/NN
2840807
D000324_D004421 CID ACTH_10/NNP (r_nmod) stimulation_12/NN (r_pobj) after_5/IN (r_prep) syndrome_4/NN (l_amod) like_3/JJ (l_npadvmod) dystonia_1/NN
D000324_D009069 NONE ACTH_20/NNP (r_compound) terminal_23/NN (r_compound) fragments_24/NNS (r_pobj) by_18/IN (r_agent) stimulated_17/VBN (r_ccomp) is_3/VBZ (l_conj) cause_57/VB (l_ccomp) resulted_94/VBD (l_nsubj) depression_62/NN (l_relcl) resulted_74/VBD (l_prep) in_75/IN (l_pobj) duration_78/NN (l_prep) of_79/IN (l_pobj) disorder_82/NN
D000324_D003866 NONE ACTH_20/NNP (r_compound) terminal_23/NN (r_compound) fragments_24/NNS (r_pobj) by_18/IN (r_agent) stimulated_17/VBN (r_ccomp) is_3/VBZ (l_conj) cause_57/VB (l_ccomp) resulted_94/VBD (l_nsubj) depression_62/NN
D009074_D004421 CID MSH_8/NNP (r_nmod) ACTH_10/NNP (r_nmod) stimulation_12/NN (r_pobj) after_5/IN (r_prep) syndrome_4/NN (l_amod) like_3/JJ (l_npadvmod) dystonia_1/NN
18086064
D020927_D009203 NONE Dexmedetomidine_0/NNP (r_nsubjpass) associated_2/VBN (r_ccomp) mortality_14/NN (l_appos) infarction_35/NN
15930398
D015742_D000647 CID propofol_12/NN (r_pobj) with_11/IN (r_prep) sedation_10/NN (r_pobj) during_8/IN (r_prep) onset_3/NN (l_prep) of_6/IN (l_pobj) amnesia_7/NN
16600756
D015232_D053201 CID PGE2_3/NNP (r_conj) NGF_1/NNP (r_nsubjpass) increased_8/VBN (l_prep) in_9/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) OAB_12/NNP
D015232_D053201 CID PGE2_5/NNP (l_compound) OAB_3/NNP
D011464_D053201 NONE PGI2_3/NNP (r_nsubj) was_4/VBD (l_acomp) different_6/JJ (l_prep) between_7/IN (l_pobj) controls_8/NNS (l_prep) with_11/IN (l_pobj) OAB_12/NNP
D011464_D053201 NONE PGI2_5/NNP (r_conj) PGF2alpha_3/NNP (r_appos) NGF_1/NNP (r_nsubj) correlate_8/VB (l_prep) with_9/IN (l_pobj) parameters_11/NNS (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) OAB_15/NNP
D015237_D053201 CID PGF2alpha_5/NNP (r_conj) PGE2_3/NNP (r_conj) NGF_1/NNP (r_nsubjpass) increased_8/VBN (l_prep) in_9/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) OAB_12/NNP
D015237_D053201 CID PGF2alpha_3/NNP (r_appos) NGF_1/NNP (r_nsubj) correlate_8/VB (l_prep) with_9/IN (l_pobj) parameters_11/NNS (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) OAB_15/NNP
D011453_D053201 NONE prostaglandins_4/NNS (r_conj) factor_2/NN (l_prep) in_5/IN (l_pobj) urine_7/NN (l_prep) of_8/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) bladder_13/NN
D011453_D053201 NONE PGs_7/NNS (l_prep) in_8/IN (l_pobj) women_9/NNS (l_prep) with_10/IN (l_pobj) OAB_11/NNP
D011453_D053201 NONE PG_8/NNP (r_conj) NGF_6/NNP (r_pobj) between_4/IN (r_prep) correlations_3/NNS (l_conj) parameters_12/NNS (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) OAB_16/NNP
D011453_D053201 NONE PGs_2/NNS (r_conj) NGF_0/NNP (r_nsubj) have_3/VBP (l_dobj) roles_5/NNS (l_prep) in_6/IN (l_pobj) development_8/NN (l_prep) of_9/IN (l_pobj) symptoms_11/NNS (l_compound) OAB_10/NNP
3952818
D005472_D066126 NONE 5-fluorouracil_3/CD (r_punct) ._4/. (r_punct) toxicity_1/NN
D005472_D066126 NONE 5-FU_14/CD (r_pobj) to_13/IN (r_pcomp) due_12/JJ (r_prep) be_7/VB (l_attr) cause_9/NN (l_prep) of_10/IN (l_pobj) cardiotoxicity_11/NN
D005472_D066126 NONE 5-FU_14/CD (r_pobj) to_13/IN (r_pcomp) due_12/JJ (r_prep) be_7/VB (l_conj) used_23/VBN (l_prep) in_24/IN (l_pobj) prevention_26/NN (l_prep) of_29/IN (l_pobj) cardiotoxicity_31/NN
D005472_D066126 NONE 5-FU_30/CD (r_compound) cardiotoxicity_31/NN (r_pobj) of_29/IN (r_prep) prevention_26/NN (r_pobj) in_24/IN (r_prep) used_23/VBN (r_conj) be_7/VB (l_attr) cause_9/NN (l_prep) of_10/IN (l_pobj) cardiotoxicity_11/NN
D005472_D066126 NONE 5-FU_30/CD (r_compound) cardiotoxicity_31/NN
D002118_D003329 NONE calcium_18/NN (r_compound) antagonists_19/NNS (r_nsubjpass) used_23/VBN (r_conj) be_7/VB (l_nsubj) spasm_5/NN
D009543_D002637 NONE nifedipine_19/NN (r_pobj) with_18/IN (r_prep) resolved_17/VBD (l_nsubj) pain_15/NN
D005472_D003110 NONE 5-fluorouracil_18/CD (r_punct) administration_22/NN (r_pobj) after_17/IN (r_prep) presented_14/VBD (r_relcl) patient_6/NN (l_prep) with_7/IN (l_pobj) carcinoma_9/NN
D005472_D003110 NONE 5-FU_20/CD (r_nmod) administration_22/NN (r_pobj) after_17/IN (r_prep) presented_14/VBD (r_relcl) patient_6/NN (l_prep) with_7/IN (l_pobj) carcinoma_9/NN
D005472_D009362 NONE 5-fluorouracil_18/CD (r_punct) administration_22/NN (r_pobj) after_17/IN (r_prep) presented_14/VBD (r_relcl) patient_6/NN (l_prep) with_7/IN (l_pobj) carcinoma_9/NN (l_conj) metastasis_12/NN
D005472_D009362 NONE 5-FU_20/CD (r_nmod) administration_22/NN (r_pobj) after_17/IN (r_prep) presented_14/VBD (r_relcl) patient_6/NN (l_prep) with_7/IN (l_pobj) carcinoma_9/NN (l_conj) metastasis_12/NN
D005472_D002637 CID 5-fluorouracil_18/CD (r_punct) administration_22/NN (r_pobj) after_17/IN (r_prep) presented_14/VBD (l_dobj) pain_16/NN
D005472_D002637 CID 5-FU_20/CD (r_nmod) administration_22/NN (r_pobj) after_17/IN (r_prep) presented_14/VBD (l_dobj) pain_16/NN
D005472_D003329 NONE 5-FU_14/CD (r_pobj) to_13/IN (r_pcomp) due_12/JJ (r_prep) be_7/VB (l_nsubj) spasm_5/NN
D005472_D003329 NONE 5-FU_30/CD (r_compound) cardiotoxicity_31/NN (r_pobj) of_29/IN (r_prep) prevention_26/NN (r_pobj) in_24/IN (r_prep) used_23/VBN (r_conj) be_7/VB (l_nsubj) spasm_5/NN
D009543_D000788 NONE nifedipine_19/NN (r_pobj) with_18/IN (r_prep) resolved_17/VBD (r_conj) was_3/VBD (l_acomp) similar_4/JJ (l_prep) to_5/IN (l_pobj) that_6/DT (l_acl) observed_7/VBN (l_prep) in_8/IN (l_pobj) angina_11/NN
D002118_D066126 NONE calcium_18/NN (r_compound) antagonists_19/NNS (r_nsubjpass) used_23/VBN (r_conj) be_7/VB (l_attr) cause_9/NN (l_prep) of_10/IN (l_pobj) cardiotoxicity_11/NN
D002118_D066126 NONE calcium_18/NN (r_compound) antagonists_19/NNS (r_nsubjpass) used_23/VBN (l_prep) in_24/IN (l_pobj) prevention_26/NN (l_prep) of_29/IN (l_pobj) cardiotoxicity_31/NN
11583940
C063008_D007674 NONE mofetil_7/NNS (r_dobj) mycophenolate_6/VB (l_dep) have_14/VBP (l_dobj) nephrotoxicity_16/NN
D020123_D007674 NONE sirolimus_9/NN (r_conj) mofetil_7/NNS (r_dobj) mycophenolate_6/VB (l_dep) have_14/VBP (l_dobj) nephrotoxicity_16/NN
D020123_D007674 NONE rapamycin_11/NNS (r_appos) mofetil_7/NNS (r_dobj) mycophenolate_6/VB (l_dep) have_14/VBP (l_dobj) nephrotoxicity_16/NN
1415380
D011803_D006463 CID quinine_8/NN (r_pobj) of_7/IN (r_prep) ingestion_6/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) syndrome_3/NN
D011803_D006463 CID quinine_5/NN (r_compound) ingestion_6/NN (r_pobj) following_4/VBG (r_prep) syndrome_3/NN
D011803_D006463 CID Quinine_0/NN (r_npadvmod) associated_2/VBN (r_amod) syndrome_6/NN
9669632
D020117_D043183 NONE cisapride_2/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_conj) function_11/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) syndrome_17/NN
D020117_D043183 NONE cisapride_17/NN (l_prep) on_19/IN (l_pobj) motility_22/NN (l_prep) in_25/IN (l_pobj) syndrome_29/NN
D020117_D043183 NONE cisapride_17/NN (l_prep) on_19/IN (l_pobj) motility_22/NN (l_prep) in_25/IN (l_pobj) syndrome_29/NN (l_appos) IBS_31/NNP
D020117_D043183 NONE cisapride_36/NN (r_conj) before_28/IN (r_advmod) underwent_23/VBD (l_nsubj) patients_3/NNS (l_prep) with_4/IN (l_pobj) IBS_5/NNP
D020117_D043183 NONE cisapride_11/NN (r_npadvmod) treated_13/VBN (r_amod) patients_18/NNS (l_compound) IBS_17/NNP
D020117_D043183 NONE cisapride_11/NN (r_compound) therapy_12/NN (r_nmod) score_14/NN (r_advcl) had_5/VBD (l_nsubj) patients_4/NNS (l_compound) IBS_3/NNP
D020117_D043183 NONE cisapride_25/NN (r_conj) score_14/NN (r_advcl) had_5/VBD (l_nsubj) patients_4/NNS (l_compound) IBS_3/NNP
D020117_D043183 NONE Cisapride_0/NNP (r_nsubj) affects_1/VBZ (l_dobj) characteristics_4/NNS (l_conj) symptoms_7/NNS (l_prep) in_8/IN (l_pobj) IBS_9/NNP
D020117_D010146 NONE cisapride_11/NN (r_compound) therapy_12/NN (r_nmod) score_14/NN (r_advcl) had_5/VBD (l_dobj) score_9/NN (l_compound) pain_8/NN
D020117_D010146 NONE cisapride_25/NN (r_conj) score_14/NN (r_advcl) had_5/VBD (l_dobj) score_9/NN (l_compound) pain_8/NN
D020117_D003248 NONE cisapride_36/NN (r_conj) before_28/IN (r_advmod) underwent_23/VBD (l_nsubj) patients_3/NNS (l_prep) with_4/IN (l_pobj) IBS_5/NNP (l_appos) predominant_9/JJ (l_compound) constipation_7/NN
D020117_D003248 NONE cisapride_11/NN (r_npadvmod) treated_13/VBN (r_amod) patients_18/NNS (r_pobj) in_10/IN (r_prep) were_8/VBD (l_nsubj) scores_1/NNS (l_acl) relating_2/VBG (l_prep) to_3/IN (l_pobj) severity_5/NN (l_prep) of_6/IN (l_pobj) constipation_7/NN
D020117_D003248 NONE cisapride_11/NN (r_npadvmod) treated_13/VBN (r_amod) patients_18/NNS (l_amod) predominant_16/JJ (l_compound) constipation_14/NN
D020117_D003967 NONE cisapride_36/NN (r_conj) before_28/IN (r_advmod) underwent_23/VBD (l_punct) ;_14/: (l_preconj) predominant_17/JJ (l_compound) diarrhoea_15/NN
D020117_D003967 NONE cisapride_14/NN (r_nmod) groups_17/NNS (r_pobj) between_12/IN (r_prep) observed_11/VBN (l_prep) In_0/IN (l_pobj) patients_4/NNS (l_amod) predominant_3/JJ (l_npadvmod) diarrhoea_1/NN
D020117_D003967 NONE cisapride_1/NN (r_npadvmod) treated_3/VBN (r_amod) patients_7/NNS (l_amod) predominant_6/JJ (l_npadvmod) diarrhoea_4/NN
D020117_D003967 NONE cisapride_11/NN (r_compound) therapy_12/NN (r_nmod) score_14/NN (r_advcl) had_5/VBD (l_nsubj) patients_4/NNS (l_amod) predominant_2/JJ (l_npadvmod) Diarrhoea_0/NN
D020117_D003967 NONE cisapride_25/NN (r_conj) score_14/NN (r_advcl) had_5/VBD (l_nsubj) patients_4/NNS (l_amod) predominant_2/JJ (l_npadvmod) Diarrhoea_0/NN
16471092
C099041_D053201 NONE tolterodine_14/JJ (r_amod) treatment_15/NN (r_pobj) after_13/IN (r_prep) symptoms_1/NNS (l_conj) quality_3/NN (l_prep) of_4/IN (l_pobj) changes_6/NNS (l_prep) with_10/IN (l_pobj) bladder_12/NN
C099041_D053201 NONE tolterodine_22/JJ (r_amod) treatment_23/NN (r_pobj) after_21/IN (r_prep) study_3/VB (l_dobj) symptoms_6/NNS (l_conj) quality_8/NN (l_prep) of_9/IN (l_pobj) changes_11/NNS (l_prep) with_15/IN (l_pobj) bladder_17/NN
C099041_D053201 NONE tolterodine_22/JJ (r_amod) treatment_23/NN (r_pobj) after_21/IN (r_prep) study_3/VB (l_dobj) symptoms_6/NNS (l_conj) quality_8/NN (l_prep) of_9/IN (l_pobj) changes_11/NNS (l_prep) with_15/IN (l_pobj) bladder_17/NN (l_appos) OAB_19/NNP
C099041_D053201 NONE Tolterodine_0/NNP (r_nsubjpass) tolerated_3/VBN (l_conj) improved_7/VBD (l_dobj) quality_9/NN (l_prep) with_15/IN (l_pobj) OAB_16/NNP
8424298
D007530_D007022 CID isoflurane_8/NN (r_pobj) with_7/IN (r_prep) labetalol_6/NN (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) hypotension_3/NN
D007530_D007022 CID isoflurane_18/JJ (r_amod) group_21/NN (r_pobj) with_17/IN (r_prep) labetalol_16/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_acl) hypotension_13/NN
D007530_D007022 CID isoflurane_18/JJ (r_amod) group_21/NN (l_amod) hypotensive_20/JJ
D007530_D007022 CID isoflurane_9/NN (r_pobj) with_8/IN (r_prep) labetalol_7/NN (r_pobj) by_6/IN (r_prep) induced_5/VBN (l_nsubj) hypotension_4/NN
D007741_D007022 CID labetalol_6/NN (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) hypotension_3/NN
D007741_D007022 CID labetalol_16/NN (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_acl) hypotension_13/NN
D007741_D007022 CID labetalol_16/NN (l_prep) with_17/IN (l_pobj) group_21/NN (l_amod) hypotensive_20/JJ
D007741_D007022 CID labetalol_7/NN (r_pobj) by_6/IN (r_prep) induced_5/VBN (l_nsubj) hypotension_4/NN
9523850
D007505_D063806 NONE dextran_19/NN (r_pobj) of_17/IN (r_prep) infusion_16/NN (r_pobj) with_12/IN (r_prep) associated_11/VBN (r_acl) syndrome_10/NN (l_compound) myalgia_9/NN
D008775_D018771 NONE methylprednisolone_2/NN (r_pobj) of_1/IN (r_prep) Value_0/NN (l_prep) in_3/IN (l_pobj) prevention_4/NN (l_prep) of_5/IN (l_pobj) syndrome_10/NN (l_compound) myalgia_9/NN (l_compound) arthralgia_7/JJ
D008775_D018771 NONE MP_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_nsubj) reduces_11/VBZ (l_dobj) frequency_13/NN (l_prep) of_16/IN (l_pobj) syndrome_21/NN (l_compound) myalgia_20/NN (l_compound) arthralgia_18/JJ
D007505_D018771 CID dextran_19/NN (r_pobj) of_17/IN (r_prep) infusion_16/NN (r_pobj) with_12/IN (r_prep) associated_11/VBN (r_acl) syndrome_10/NN (l_compound) myalgia_9/NN (l_compound) arthralgia_7/JJ
D008775_D063806 NONE methylprednisolone_2/NN (r_pobj) of_1/IN (r_prep) Value_0/NN (l_prep) in_3/IN (l_pobj) prevention_4/NN (l_prep) of_5/IN (l_pobj) syndrome_10/NN (l_compound) myalgia_9/NN
D008775_D063806 NONE MP_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_nsubj) reduces_11/VBZ (l_dobj) frequency_13/NN (l_prep) of_16/IN (l_pobj) syndrome_21/NN (l_compound) myalgia_20/NN
8643966
D017239_D010051 NONE Paclitaxel_0/NNP (r_nsubj) demonstrated_15/VBN (l_dobj) activity_18/NN (l_prep) against_19/IN (l_pobj) types_22/NNS (l_appos) carcinoma_28/NN
D017239_D010051 NONE Taxol_2/NNP (r_appos) Paclitaxel_0/NNP (r_nsubj) demonstrated_15/VBN (l_dobj) activity_18/NN (l_prep) against_19/IN (l_pobj) types_22/NNS (l_appos) carcinoma_28/NN
D017239_D001943 NONE Paclitaxel_0/NNP (r_nsubj) demonstrated_15/VBN (l_dobj) activity_18/NN (l_prep) against_19/IN (l_pobj) types_22/NNS (l_appos) carcinoma_28/NN
D017239_D001943 NONE Taxol_2/NNP (r_appos) Paclitaxel_0/NNP (r_nsubj) demonstrated_15/VBN (l_dobj) activity_18/NN (l_prep) against_19/IN (l_pobj) types_22/NNS (l_appos) carcinoma_28/NN
D017239_D064420 NONE paclitaxel_9/NN (r_compound) infusion_10/NN (r_pobj) of_6/IN (r_prep) efficacy_3/NN (l_conj) toxicity_5/NN
D017239_D064420 NONE Paclitaxel_0/NNP (r_nsubj) is_1/VBZ (l_prep) with_12/IN (l_pobj) infusion_15/NN (l_acl) proving_16/VBG (l_oprd) effective_18/JJ (l_prep) to_19/IN (l_pobj) infusion_22/NN (l_conj) superior_24/JJ (l_prep) in_25/IN (l_pobj) terms_26/NNS (l_prep) of_27/IN (l_pobj) incidence_29/NN (l_prep) of_30/IN (l_pobj) toxicity_34/NN
D017239_D009369 NONE Paclitaxel_0/NNP (r_nsubj) demonstrated_15/VBN (l_dobj) activity_18/NN (l_prep) against_19/IN (l_pobj) types_22/NNS (l_compound) tumor_21/NN
D017239_D009369 NONE Taxol_2/NNP (r_appos) Paclitaxel_0/NNP (r_nsubj) demonstrated_15/VBN (l_dobj) activity_18/NN (l_prep) against_19/IN (l_pobj) types_22/NNS (l_compound) tumor_21/NN
D017239_D002289 NONE paclitaxel_11/NN (r_pobj) with_10/IN (r_prep) cancer_9/NN
D017239_D002289 NONE paclitaxel_6/NN (r_compound) infusions_7/NNS (l_prep) in_8/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) IIIB_15/NNS (l_conj) cancer_23/NN
D017239_D002289 NONE paclitaxel_6/NN (r_compound) infusions_7/NNS (l_prep) in_8/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) IIIB_15/NNS (l_conj) cancer_23/NN (l_appos) NSCLC_25/NNP
D017239_D002289 NONE paclitaxel_9/NN (r_compound) infusion_10/NN (l_prep) in_11/IN (l_pobj) trial_15/NN (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) IIIB_21/NNS (l_conj) NSCLC_24/NNP
D017239_D002289 NONE paclitaxel_5/NN (r_pobj) with_4/IN (r_prep) studies_3/NNS (l_acl) combined_6/VBN (l_prep) with_7/IN (l_pobj) drugs_9/NNS (l_amod) active_10/JJ (l_prep) against_11/IN (l_pobj) NSCLC_12/NNP
D017239_D002289 NONE paclitaxel_21/NN (r_dobj) comparing_20/VBG (r_acl) studies_19/NNS (r_dobj) phase_17/NN (r_conj) indicated_14/VBN (l_nsubjpass) phase_1/NN (l_dobj) studies_3/NNS (l_acl) combined_6/VBN (l_prep) with_7/IN (l_pobj) drugs_9/NNS (l_amod) active_10/JJ (l_prep) against_11/IN (l_pobj) NSCLC_12/NNP
19917396
D016559_D006332 CID tacrolimus_5/NNS (r_pobj) by_4/IN (r_agent) induced_3/VBN (r_acl) hypertrophy_2/NN
D016559_D006332 CID tacrolimus_8/NNS (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) hypertrophy_5/NN
D016559_D006332 CID tacrolimus_10/NN (r_pobj) of_9/IN (r_prep) concentration_8/NN (r_dobj) reducing_5/VBG (r_pcomp) upon_4/IN (r_prep) resolved_3/VBN (l_nsubj) hypertrophy_1/NN
D016559_D006332 CID tacrolimus_5/NN (r_nsubj) induces_6/VBZ (l_dobj) hypertrophy_9/NN
2322844
D011453_D010146 NONE prostaglandins_6/NNS (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_7/IN (l_pobj) responses_9/NNS (l_compound) pain_8/NN
D015232_D006930 CID E2_1/NNP (r_nsubj) showed_2/VBD (l_dobj) effect_5/NN (l_amod) hyperalgesic_4/JJ
D015232_D006930 CID E2-induced_3/NNP (r_amod) hyperalgesia_4/NN
D015232_D006930 CID E2_9/NNP (r_conj) D2_6/NN (r_nsubj) exert_10/VBP (l_dobj) hyperalgesia_11/NN
D015237_D010146 NONE alpha_2/NN (r_nsubj) had_3/VBD (l_dobj) effect_5/NN (l_prep) on_6/IN (l_pobj) responses_8/NNS (l_compound) pain_7/NN
D015230_D006930 CID D2_1/NN (r_nsubj) had_10/VBD (l_dobj) action_13/NN (l_amod) hyperalgesic_12/JJ
D015230_D006930 CID D2_32/NN (r_pobj) of_30/IN (r_prep) that_29/DT (r_pobj) than_28/IN (r_prep) min_26/NN (r_dobj) lasted_20/VBD (r_conj) showed_2/VBD (l_dobj) effect_5/NN (l_amod) hyperalgesic_4/JJ
D015230_D006930 CID D2_5/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (l_amod) hyperalgesic_1/JJ
D015230_D006930 CID D2_6/NN (r_nsubj) exert_10/VBP (l_dobj) hyperalgesia_11/NN
D019342_D010146 NONE acid_21/NN (r_conj) plate_18/NN (r_dobj) using_16/VBG (r_pcomp) by_15/IN (r_prep) evaluated_14/VBN (l_nsubjpass) effects_1/NNS (l_prep) on_7/IN (l_pobj) responses_9/NNS (l_compound) pain_8/NN
D011453_D006930 NONE pg_10/NN (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_pobj) at_6/IN (r_prep) effect_5/NN (l_amod) hyperalgesic_4/JJ
C053876_D006930 NONE AH6809_28/NN (r_pobj) by_27/IN (r_agent) blocked_7/VBN (l_nsubjpass) effect_2/NN (l_amod) hyperalgesic_1/JJ
C053876_D006930 NONE AH6809_8/NN (r_pobj) by_7/IN (r_agent) blocked_6/VBN (l_nsubjpass) hyperalgesia_4/NN
7604176
D017035_D009220 CID pravastatin_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) case_1/NN (l_prep) of_2/IN (l_pobj) myopathy_5/NNS
D019821_D009135 NONE simvastatin_3/NN (r_conj) lovastatin_1/NN (r_nsubjpass) associated_6/VBN (l_prep) with_7/IN (l_pobj) myopathy_9/NNS
D019821_D009135 NONE simvastatin_3/NN (r_conj) lovastatin_1/NN (r_nsubjpass) associated_6/VBN (r_advcl) represent_16/VB (l_nsubj) myopathy_14/NNS
D017035_D009135 NONE Pravastatin_0/NNP (r_npadvmod) associated_2/VBN (r_amod) myopathy_3/NN
D017035_D009135 NONE pravastatin_17/JJ (r_amod) discontinuation_18/NN (r_pobj) after_16/IN (r_prep) resolved_11/VBD (r_relcl) limbs_9/NNS (r_pobj) of_6/IN (r_prep) myopathy_5/NN
D017035_D009135 NONE pravastatin_11/RB (r_npadvmod) associated_13/VBN (r_amod) myopathy_14/NNS (r_nsubj) represent_16/VB (l_advcl) associated_6/VBN (l_prep) with_7/IN (l_pobj) myopathy_9/NNS
D017035_D009135 NONE pravastatin_11/RB (r_npadvmod) associated_13/VBN (r_amod) myopathy_14/NNS
D008148_D009135 NONE lovastatin_1/NN (r_nsubjpass) associated_6/VBN (l_prep) with_7/IN (l_pobj) myopathy_9/NNS
D008148_D009135 NONE lovastatin_1/NN (r_nsubjpass) associated_6/VBN (r_advcl) represent_16/VB (l_nsubj) myopathy_14/NNS
D017035_D006937 NONE pravastatin_2/RB (r_dobj) assumed_1/VBD (l_prep) because_9/IN (l_pobj) hypercholesterolemia_11/NN
7791169
D016595_D007674 NONE misoprostol_3/NNP (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubj) induced_6/VBD (l_dobj) dysfunction_8/NN
D016595_D007674 NONE misoprostol_2/NNP (r_pobj) of_1/IN (r_prep) Addition_0/NN (r_nsubj) minimize_4/VB (l_dobj) impairment_7/NN
D007213_D007674 CID indomethacin_5/NN (r_pobj) on_4/IN (r_prep) misoprostol_3/NNP (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubj) induced_6/VBD (l_dobj) dysfunction_8/NN
D007213_D007674 CID indomethacin_8/NN (r_nmod) dysfunction_11/NN
D016595_D010146 NONE misoprostol_2/NNP (r_pobj) of_1/IN (r_prep) Addition_0/NN (r_nsubj) minimize_4/VB (l_prep) without_8/IN (l_pcomp) affecting_9/VBG (l_dobj) control_11/NN (l_compound) pain_10/NN
16428827
D002794_D000544 NONE choline_1/NN (r_compound) acetyltransferase_2/NN (r_nsubj) is_25/VBZ (l_attr) factor_28/NN (l_prep) in_29/IN (l_pobj) treatment_31/NN (l_prep) of_32/IN (l_pobj) disease_35/NN
D002794_D000544 NONE choline_1/NN (r_compound) acetyltransferase_2/NN (r_nsubj) is_25/VBZ (l_attr) factor_28/NN (l_prep) in_29/IN (l_pobj) treatment_31/NN (l_prep) of_32/IN (l_pobj) disease_35/NN (l_appos) AD_37/NN
D002794_D000647 NONE choline_2/NN (r_compound) acetyltransferase_3/NN (r_dobj) activates_1/VBZ (l_conj) improves_10/VBZ (l_dobj) amnesia_14/NN
D012601_D007859 NONE scopolamine_12/NN (r_npadvmod) induced_14/VBN (r_amod) impairments_15/NNS (l_prep) of_16/IN (l_pobj) learning_17/NN (l_conj) memory_19/NN
D012601_D000647 CID scopolamine_16/NN (r_npadvmod) induced_18/VBN (r_amod) amnesia_19/NN
D012601_D000647 CID scopolamine_22/NN (r_npadvmod) induced_24/VBN (r_amod) amnesia_25/NN
D012601_D008569 NONE scopolamine_12/NN (r_npadvmod) induced_14/VBN (r_amod) impairments_15/NNS (l_prep) of_16/IN (l_pobj) learning_17/NN (l_conj) memory_19/NN
C004742_D007859 NONE daidzein_7/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (l_prep) from_8/IN (l_pobj) thunbergiana_10/NNS (l_prep) on_11/IN (l_pobj) impairments_15/NNS (l_prep) of_16/IN (l_pobj) learning_17/NN (l_conj) memory_19/NN
D000109_D000647 NONE acetylcholine_10/NN (r_compound) biosynthesis_11/NN (r_pobj) in_9/IN (r_prep) role_8/NN (r_dobj) play_6/VB (l_conj) ameliorates_21/VBZ (l_dobj) amnesia_25/NN
C004742_D008569 NONE daidzein_7/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (l_prep) from_8/IN (l_pobj) thunbergiana_10/NNS (l_prep) on_11/IN (l_pobj) impairments_15/NNS (l_prep) of_16/IN (l_pobj) learning_17/NN (l_conj) memory_19/NN
D000109_D000544 NONE acetylcholine_20/NN (r_nmod) ACh_22/NNS (r_pobj) of_19/IN (r_prep) production_18/NN (r_pobj) of_15/IN (r_prep) augmentation_14/NN (r_pobj) via_12/IN (r_prep) enhances_9/VBZ (r_relcl) activator_6/NN (r_appos) acetyltransferase_2/NN (r_nsubj) is_25/VBZ (l_attr) factor_28/NN (l_prep) in_29/IN (l_pobj) treatment_31/NN (l_prep) of_32/IN (l_pobj) disease_35/NN
D000109_D000544 NONE acetylcholine_20/NN (r_nmod) ACh_22/NNS (r_pobj) of_19/IN (r_prep) production_18/NN (r_pobj) of_15/IN (r_prep) augmentation_14/NN (r_pobj) via_12/IN (r_prep) enhances_9/VBZ (r_relcl) activator_6/NN (r_appos) acetyltransferase_2/NN (r_nsubj) is_25/VBZ (l_attr) factor_28/NN (l_prep) in_29/IN (l_pobj) treatment_31/NN (l_prep) of_32/IN (l_pobj) disease_35/NN (l_appos) AD_37/NN
D000109_D000544 NONE ACh_22/NNS (r_pobj) of_19/IN (r_prep) production_18/NN (r_pobj) of_15/IN (r_prep) augmentation_14/NN (r_pobj) via_12/IN (r_prep) enhances_9/VBZ (r_relcl) activator_6/NN (r_appos) acetyltransferase_2/NN (r_nsubj) is_25/VBZ (l_attr) factor_28/NN (l_prep) in_29/IN (l_pobj) treatment_31/NN (l_prep) of_32/IN (l_pobj) disease_35/NN
D000109_D000544 NONE ACh_22/NNS (r_pobj) of_19/IN (r_prep) production_18/NN (r_pobj) of_15/IN (r_prep) augmentation_14/NN (r_pobj) via_12/IN (r_prep) enhances_9/VBZ (r_relcl) activator_6/NN (r_appos) acetyltransferase_2/NN (r_nsubj) is_25/VBZ (l_attr) factor_28/NN (l_prep) in_29/IN (l_pobj) treatment_31/NN (l_prep) of_32/IN (l_pobj) disease_35/NN (l_appos) AD_37/NN
C004742_D000647 NONE Daidzein_0/NNP (r_nsubj) activates_1/VBZ (l_conj) improves_10/VBZ (l_dobj) amnesia_14/NN
C004742_D000647 NONE daidzein_2/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubjpass) shown_12/VBN (l_xcomp) reverse_15/VB (l_dobj) amnesia_19/NN
C004742_D000647 NONE daidzein_4/NN (r_nsubj) play_6/VB (l_conj) ameliorates_21/VBZ (l_dobj) amnesia_25/NN
17490790
D007501_D010300 NONE Iron_0/NN (r_compound) accumulation_1/NN (r_nsubjpass) considered_3/VBN (l_xcomp) involved_6/VBN (l_prep) in_7/IN (l_pobj) pathogenesis_9/NN (l_prep) of_10/IN (l_pobj) disease_13/NN
D007505_D009410 CID dextran_2/NN (r_nsubj) induced_3/VBD (l_dobj) degeneration_4/NN (l_prep) of_5/IN (l_pobj) neurons_7/NNS
D007505_D009410 CID dextran_66/NN (r_amod) animals_68/NNS (r_pobj) of_64/IN (r_prep) SN_63/NN (r_pobj) in_61/IN (r_prep) content_60/NN (r_conj) staining_40/NN (l_conj) detection_49/NN (l_acl) study_51/VB (l_dobj) degeneration_53/NN (l_prep) of_54/IN (l_pobj) neurons_56/NNS
D007505_D009410 CID dextran_6/NN (r_nsubj) increase_8/VB (l_dobj) level_11/NN (l_relcl) causes_19/VBZ (l_dobj) degeneration_21/NN (l_prep) of_22/IN (l_pobj) neurons_24/NNS
D007501_D009410 NONE iron_6/NN (r_compound) overload_7/NN (r_pobj) between_4/IN (r_prep) relationship_3/NN (r_dobj) demonstrate_1/VB (r_advcl) used_25/VBD (l_dobj) voltammetry_28/NN (l_conj) immunohistochemistry_35/NN (l_conj) staining_40/NN (l_conj) detection_49/NN (l_acl) study_51/VB (l_dobj) degeneration_53/NN (l_prep) of_54/IN (l_pobj) neurons_56/NNS
D007501_D009410 NONE iron_39/NN (r_compound) staining_40/NN (l_conj) detection_49/NN (l_acl) study_51/VB (l_dobj) degeneration_53/NN (l_prep) of_54/IN (l_pobj) neurons_56/NNS
D007501_D009410 NONE iron_59/NN (r_compound) content_60/NN (r_conj) staining_40/NN (l_conj) detection_49/NN (l_acl) study_51/VB (l_dobj) degeneration_53/NN (l_prep) of_54/IN (l_pobj) neurons_56/NNS
D007501_D009410 NONE iron_10/NN (r_compound) level_11/NN (l_relcl) causes_19/VBZ (l_dobj) degeneration_21/NN (l_prep) of_22/IN (l_pobj) neurons_24/NNS
D007501_D009410 NONE iron_18/NN (r_nsubj) causes_19/VBZ (l_dobj) degeneration_21/NN (l_prep) of_22/IN (l_pobj) neurons_24/NNS
D014443_D009410 NONE tyrosine_30/NN (r_det) immunohistochemistry_35/NN (l_conj) staining_40/NN (l_conj) detection_49/NN (l_acl) study_51/VB (l_dobj) degeneration_53/NN (l_prep) of_54/IN (l_pobj) neurons_56/NNS
11077455
D020888_D014786 CID vigabatrin_16/NN (r_npadvmod) attributed_18/VBN (r_amod) constriction_21/NN
D020888_D014786 CID vigabatrin_9/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_xcomp) thought_4/NN (l_nsubj) constriction_3/NN
D020888_D014786 CID vigabatrin_15/NN (r_npadvmod) attributed_17/VBN (r_amod) loss_20/NN
D020888_D014786 CID vigabatrin_9/NN (r_compound) therapy_10/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_xcomp) appears_4/VBZ (l_nsubj) constriction_3/NN
7880714
6115999
D001539_D006973 NONE bendrofluazide_3/VB (l_conj) propranolol_5/NN (l_prep) for_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) hypertension_11/NN
D001539_D006973 NONE bendrofluazide_21/NN (r_amod) groups_19/NNS (r_pobj) of_16/IN (r_prep) one_15/CD (r_pobj) to_14/IN (r_prep) allocated_13/VBN (l_nsubjpass) Participants_0/NNS (l_prep) in_1/IN (l_pobj) trial_7/NN (l_prep) for_8/IN (l_pobj) hypertension_10/NN
D001539_D006073 CID bendrofluazide_23/NN (r_amod) treatment_24/NN (r_pobj) with_22/IN (r_prep) associated_21/VBN (r_acl) tolerance_11/NN (l_prep) in_12/IN (l_pobj) men_13/NNS (l_conj) women_15/NNS (l_conj) gout_17/NN
D011433_D007172 CID propranolol_20/RB (r_dobj) taking_19/VBG (r_acl) patients_18/NNS (r_pobj) in_17/IN (r_prep) occurred_14/VBD (r_conj) show_2/VBP (l_dobj) association_4/NN (l_prep) between_5/IN (l_pobj) treatment_7/NN (l_conj) impotence_9/NN
D011433_D007172 CID propranolol_20/RB (r_dobj) taking_19/VBG (r_acl) patients_18/NNS (r_pobj) in_17/IN (r_prep) occurred_14/VBD (l_nsubj) impotence_12/NN
D011433_D006973 NONE propranolol_5/NN (l_prep) for_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) hypertension_11/NN
D011433_D006973 NONE propranolol_23/NN (r_conj) bendrofluazide_21/NN (r_amod) groups_19/NNS (r_pobj) of_16/IN (r_prep) one_15/CD (r_pobj) to_14/IN (r_prep) allocated_13/VBN (l_nsubjpass) Participants_0/NNS (l_prep) in_1/IN (l_pobj) trial_7/NN (l_prep) for_8/IN (l_pobj) hypertension_10/NN
D001539_D011928 NONE bendrofluazide_23/NN (r_amod) treatment_24/NN (r_pobj) with_22/IN (r_prep) associated_21/VBN (r_acl) tolerance_11/NN (l_conj) phenomenon_29/NN
D001539_D007172 CID bendrofluazide_6/JJ (r_amod) treatment_7/NN (l_conj) impotence_9/NN
D001539_D007172 CID bendrofluazide_6/JJ (r_amod) treatment_7/NN (r_pobj) between_5/IN (r_prep) association_4/NN (r_dobj) show_2/VBP (l_conj) occurred_14/VBD (l_nsubj) impotence_12/NN
D011433_D004417 CID propranolol_37/NN (r_dobj) taking_36/VBG (r_acl) men_33/NNS (r_pobj) in_32/IN (r_prep) phenomenon_29/NN (l_conj) dyspnoea_31/NN
D011433_D011928 CID propranolol_37/NN (r_dobj) taking_36/VBG (r_acl) men_33/NNS (r_pobj) in_32/IN (r_prep) phenomenon_29/NN
D001539_D004417 NONE bendrofluazide_23/NN (r_amod) treatment_24/NN (r_pobj) with_22/IN (r_prep) associated_21/VBN (r_acl) tolerance_11/NN (l_conj) phenomenon_29/NN (l_conj) dyspnoea_31/NN
D011433_D003316 NONE propranolol_10/NN (r_amod) group_11/NN (r_pobj) in_8/IN (r_prep) occurred_7/VBN (r_xcomp) known_4/VBN (l_nsubjpass) disease_2/NN
D001539_D018149 CID bendrofluazide_23/NN (r_amod) treatment_24/NN (r_pobj) with_22/IN (r_prep) associated_21/VBN (r_acl) tolerance_11/NN
D011433_D018149 NONE propranolol_37/NN (r_dobj) taking_36/VBG (r_acl) men_33/NNS (r_pobj) in_32/IN (r_prep) phenomenon_29/NN (r_conj) tolerance_11/NN
D011433_D006073 NONE propranolol_37/NN (r_dobj) taking_36/VBG (r_acl) men_33/NNS (r_pobj) in_32/IN (r_prep) phenomenon_29/NN (r_conj) tolerance_11/NN (l_prep) in_12/IN (l_pobj) men_13/NNS (l_conj) women_15/NNS (l_conj) gout_17/NN
12452237
D013390_D010149 CID succinylcholine_3/NN (r_dobj) reduce_2/VB (l_conj) induced_4/VBD (l_dobj) myalgia_6/NN
D013390_D010149 CID succinylcholine_4/NN (r_nsubjpass) used_6/VBN (r_advcl) proven_10/VBN (l_xcomp) be_12/VB (l_attr) agent_16/NN (l_prep) for_17/IN (l_pobj) reduction_19/NN (l_prep) of_20/IN (l_pobj) myalgia_22/NN
D013390_D063806 NONE succinylcholine_14/NN (r_npadvmod) induced_16/VBN (r_amod) myalgia_17/NN
D008012_D010149 NONE lidocaine_1/RB (r_nsubj) reduce_2/VB (l_conj) induced_4/VBD (l_dobj) myalgia_6/NN
D008012_D010149 NONE lidocaine_8/NN (r_nsubjpass) proven_10/VBN (l_xcomp) be_12/VB (l_attr) agent_16/NN (l_prep) for_17/IN (l_pobj) reduction_19/NN (l_prep) of_20/IN (l_pobj) myalgia_22/NN
D008012_D063806 NONE lidocaine_9/JJ (r_compound) pretreatment_10/NN (l_prep) on_11/IN (l_pobj) reduction_12/NN (l_prep) of_13/IN (l_pobj) myalgia_17/NN
6127992
D000319_D017202 NONE drugs_24/NNS (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) during_14/IN (r_prep) bradycardia_13/NN (r_conj) hypotension_11/NN (r_conj) failure_9/NN (r_dobj) developed_6/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) disease_5/NN
D000319_D001919 CID drugs_24/NNS (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) during_14/IN (r_prep) bradycardia_13/NN
D000319_D006333 CID drugs_24/NNS (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) during_14/IN (r_prep) bradycardia_13/NN (r_conj) hypotension_11/NN (r_conj) failure_9/NN
D014700_D017202 NONE verapamil_18/NN (r_nmod) drugs_24/NNS (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) during_14/IN (r_prep) bradycardia_13/NN (r_conj) hypotension_11/NN (r_conj) failure_9/NN (r_dobj) developed_6/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) disease_5/NN
D000319_D007022 CID drugs_24/NNS (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) during_14/IN (r_prep) bradycardia_13/NN (r_conj) hypotension_11/NN
D014700_D007022 CID verapamil_18/NN (r_nmod) drugs_24/NNS (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) during_14/IN (r_prep) bradycardia_13/NN (r_conj) hypotension_11/NN
D014700_D001919 CID verapamil_18/NN (r_nmod) drugs_24/NNS (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) during_14/IN (r_prep) bradycardia_13/NN
D014700_D006333 CID verapamil_18/NN (r_nmod) drugs_24/NNS (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) during_14/IN (r_prep) bradycardia_13/NN (r_conj) hypotension_11/NN (r_conj) failure_9/NN
33969
D001590_D012559 NONE benztropine_9/VB (l_advcl) induced_15/VBN (l_agent) by_16/IN (l_pobj) fluphenazine_17/JJ (l_amod) enanthate_18/NN (l_prep) in_19/IN (l_pobj) outpatients_22/NNS (l_amod) schizophrenic_21/JJ
D001590_D003866 CID benztropine_2/NN (r_nsubj) had_5/VBD (l_conj) treated_28/VBN (l_nsubj) anxiety_23/NN (l_conj) depression_25/NN
D011352_D004409 NONE procyclindine_17/JJ (r_compound) treatment_18/NN (r_pobj) during_16/IN (r_prep) condition_15/NN (r_pobj) to_13/IN (r_prep) compared_12/VBN (r_prep) had_5/VBD (l_dobj) increase_8/NN (l_prep) in_9/IN (l_pobj) dyskinesia_11/JJ
C084820_D012559 NONE ethopropazine_5/NN (r_pobj) In_0/IN (r_prep) compared_7/VBN (l_xcomp) benztropine_9/VB (l_advcl) induced_15/VBN (l_agent) by_16/IN (l_pobj) fluphenazine_17/JJ (l_amod) enanthate_18/NN (l_prep) in_19/IN (l_pobj) outpatients_22/NNS (l_amod) schizophrenic_21/JJ
C084820_D004409 NONE ethopropazine_27/NN (r_pobj) than_26/IN (r_mark) treated_28/VBN (r_conj) had_5/VBD (l_dobj) increase_8/NN (l_prep) in_9/IN (l_pobj) dyskinesia_11/JJ
C084820_D001008 NONE ethopropazine_27/NN (r_pobj) than_26/IN (r_mark) treated_28/VBN (l_nsubj) anxiety_23/NN
C017610_D012559 NONE enanthate_18/NN (l_prep) in_19/IN (l_pobj) outpatients_22/NNS (l_amod) schizophrenic_21/JJ
D001590_D001008 CID benztropine_2/NN (r_nsubj) had_5/VBD (l_conj) treated_28/VBN (l_nsubj) anxiety_23/NN
D011352_D001008 NONE procyclindine_17/JJ (r_compound) treatment_18/NN (r_pobj) during_16/IN (r_prep) condition_15/NN (r_pobj) to_13/IN (r_prep) compared_12/VBN (r_prep) had_5/VBD (l_conj) treated_28/VBN (l_nsubj) anxiety_23/NN
C084820_D010302 NONE Ethopropazine_0/NN (l_conj) benztropine_2/NN (l_prep) in_3/IN (l_pobj) parkinsonism_7/NN
C084820_D010302 NONE ethopropazine_5/NN (r_pobj) In_0/IN (r_prep) compared_7/VBN (l_xcomp) benztropine_9/VB (l_prep) in_10/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) parkinsonism_14/NN
C084820_D010302 NONE Ethopropazine_0/NN (r_nsubjpass) found_4/VBN (l_xcomp) be_6/VB (l_acomp) effective_8/JJ (l_prep) in_9/IN (l_pcomp) controlling_10/VBG (l_dobj) symptoms_12/NNS
C084820_D003866 NONE ethopropazine_27/NN (r_pobj) than_26/IN (r_mark) treated_28/VBN (l_nsubj) anxiety_23/NN (l_conj) depression_25/NN
D001590_D004409 CID benztropine_2/NN (r_nsubj) had_5/VBD (l_dobj) increase_8/NN (l_prep) in_9/IN (l_pobj) dyskinesia_11/JJ
D011352_D003866 NONE procyclindine_17/JJ (r_compound) treatment_18/NN (r_pobj) during_16/IN (r_prep) condition_15/NN (r_pobj) to_13/IN (r_prep) compared_12/VBN (r_prep) had_5/VBD (l_conj) treated_28/VBN (l_nsubj) anxiety_23/NN (l_conj) depression_25/NN
C017610_D010302 CID enanthate_18/NN (r_amod) fluphenazine_17/JJ (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_advcl) benztropine_9/VB (l_prep) in_10/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) parkinsonism_14/NN
D011352_D010302 NONE procyclidine_18/NN (r_pobj) as_17/IN (r_prep) efficacious_16/JJ (r_acomp) were_14/VBD (r_conj) found_4/VBN (l_xcomp) be_6/VB (l_acomp) effective_8/JJ (l_prep) in_9/IN (l_pcomp) controlling_10/VBG (l_dobj) symptoms_12/NNS
D001590_D010302 NONE benztropine_2/NN (l_prep) in_3/IN (l_pobj) parkinsonism_7/NN
D001590_D010302 NONE benztropine_9/VB (l_prep) in_10/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) parkinsonism_14/NN
D001590_D010302 NONE benztropine_2/NN (r_conj) Ethopropazine_0/NN (r_nsubjpass) found_4/VBN (l_xcomp) be_6/VB (l_acomp) effective_8/JJ (l_prep) in_9/IN (l_pcomp) controlling_10/VBG (l_dobj) symptoms_12/NNS
D001590_D010302 NONE benztropine_3/NN (r_nsubj) is_4/VBZ (l_attr) drug_8/NN (l_prep) in_11/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) symptoms_19/NNS
